| Entries |
| Document | Title | Date |
|---|
| 20100035272 | DETECTION OF NEGATIVELY CHARGED POLYMERS USING WATER-SOLUBLE, CATIONIC, POLYTHIOPHENE DERIVATIVES - Novel methods allowing for the simple optical and electrochemical detection of double-stranded oligonucleotides are disclosed. The methods are rapid, selective and versatile. Advantageously, they do not require any chemical reaction on the probes or on the analytes since they are based on different electrostatic interactions between cationic poly(3-alkoxy-4-methylthiophene) derivatives and single-stranded or double-stranded (hybridized) oligonucleotides. | 02-11-2010 |
| 20100041042 | BREEDING AND MILKING COWS FOR MILK FREE OF BETA-CASEIN A1 - A milk or other dairy product, capable of minimising the onset of disease such as coronary heart disease or enhancing the immune response is derived from animals which are substantially free of the β-casein A allele. Bulk milk can be produced by testing for and culling cows who test positive for the β-casein A allele, or by producing immunoglobulins and other immune response proteins, in cow's milk from animals not possessing the β-casein A | 02-18-2010 |
| 20100267028 | Tgfbr1 HAPLOINSUFFICIENCY MODIFIES RISK FOR CANCER - The present invention provides methods for assessing a genetic susceptibility to cancer in a subject which includes measuring allele specific expression or presence of at-risk haplotypes of TGFBR1, where a difference in expression or the presence of at-risk haplotypes is indicative of a cancer or susceptibility to a cancer. Methods to screen for agents that modify expression of TGRBR1 are also provided. | 10-21-2010 |
| 20090305295 | IDENTIFICATION OF A GENE EXPRESSION PROFILE THAT DIFFERENTIATES ISCHEMIC AND NONISCHEMIC CARDIOMYOPATHY - A method of preparing a gene expression prediction profile for distinguishing ischemic and nonischemic cardiomyopathy comprises the steps of obtaining clinical specimens from patients suffering from ischemic or nonischemic cardiomyopathy, isolating nucleic acid sequences from at least a plurality of said specimens, obtaining a gene expression level corresponding to each individual of said nucleic acid sequence by a gene expression profiling method, identifying genes having differences in gene expression by comparing the gene expression level of an ischemic specimen with the gene expression level of a nonischemic specimen, and identifying a gene expression prediction profile comprises genes identified as having differences in gene expression so that said prediction profile distinguishes ischemic and nonischemic cardiomyopathy. | 12-10-2009 |
| 20090305294 | METHOD OF ISOLATING NUCLEIC ACIDS FROM STOOL SAMPLES - The present invention relates to a method of isolating a nucleic acid molecule form a biological sample. More particularly, the present invention relates to a method of isolating ribonucleic acid molecule from a biological sample. The method of the present invention is useful in a range of applications including, but not limited to, diagnostic applications and research and development applications, to the extent that the isolation of nucleic acid molecules, and in particular ribonucleic acid molecules, is required. Most particularly, the method of the present invention provides for the isolation of ribonucleic acid molecules which are suitable for analysis by reverse transcriptase-PCR. | 12-10-2009 |
| 20090305293 | COMPOSITIONS AND METHODS TO DETECT CANDIDA ALBICANS NUCLEIC ACID - Compositions are disclosed as nucleic acid sequences that may be used as amplification oligomers, including primers, capture probes for sample preparation, and detection probes specific for | 12-10-2009 |
| 20090305291 | METHOD AND A MICRODEVICE FOR THE IDENTIFICATION AND/OR QUANTIFICATION OF AN ANALYTE IN A BIOLOGICAL SAMPLE - A method and device, based on a film of a luminescent substance, such as colloidal semiconductor nanocrystals dispersed in a polymer matrix, for conducting quantitative and real-time analyses of PCR processes or of biomolecular interactions in genomics and/or proteomics. The optical detection system is based on FRET processes between the luminescent substance (which acts as the donor in the FRET process) and a suitable fluorophore (which acts as the acceptor species) with which the DNA or other biomolecule is marked. The device is essentially composed of a reaction microchamber with a wall formed by a thin film made of polymer material, in which the nanocrystals are uniformly dispersed, or made of a photoluminescent or electroluminescent polymer. Molecular probes are chemically immobilized on the surface of the polymer film for the specific recognition of the analyte which is to be determined in real time. The film of nanocrystals is excited by radiation at low wavelength (for example, UV/blue), and the radiation in the spectral emission window characteristic of the fluorescent marker of the biomolecule is detected. The specific photophysical characteristics of FRET processes make it possible to monitor in a selective way, in real time and in quantitative mode, the biomolecular interactions, which take place in the close proximity of the surface of the film (typically at distances of <10 nanometres), thus almost completely reducing possible interference caused by background signals and by the free biomolecules in solution (which have not interacted with the corresponding recognition sites). The characteristics of the device also enable simultaneous analyses to be conducted in parallel on different biomolecules (multiplexing). | 12-10-2009 |
| 20090305290 | LATERAL FLOW NUCLEIC ACID DETECTOR - Point-of-care binding assays include at least one target nucleic acid binding in a multiplex structure with at least one sequence in a partner nucleic acid associated with a label, due to complementary base pairings between at least one sequence in the target nucleic acid and at least one sequence in the partner nucleic acid. The assays overcome the inherent deficiencies of antibody-protein antigen assays. In a preferred embodiment, color tagged nucleic acid sequences are used to bind a complementary target nucleic acid. The tagged nucleic acid sequences are preferably made from deoxyribonucleotides, ribonucleotides, or peptide nucleotides. | 12-10-2009 |
| 20090305289 | SCREENING METHOD TO IDENTIFY PROTECTIVE SUBSTANCES FOR THE TREATMENT OF NEURODEGENERATIVE AND/OR ISCHAEMIC DISEASES - The present invention relates to a screening method for the identification of protective substances which influence haemoglobin formation in neuronal, myocardial and/or skeletomuscular cells, as well as to recombinant constructs, host cells and transgenic animals for the implementation of this method. In addition, the present invention relates to a diagnostic method for the differential diagnosis of neurodegenerative and/or ischaemic diseases in mammals and the use of haemoglobin, a globin or a mutein or fusion protein thereof or a corresponding nucleic acid for the treatment of neurodegenerative and/or ischaemic diseases in mammals. The invention furthermore relates to constructs for gene therapy of such diseases. | 12-10-2009 |
| 20090305283 | CLEAVAGE OF NUCLEIC ACIDS - The present invention relates to means for the detection and characterization of nucleic acid sequences, as well as variations in nucleic acid sequences. The present invention also relates to methods for forming a nucleic acid cleavage structure on a target sequence and cleaving the nucleic acid cleavage structure in a site-specific manner. The structure-specific nuclease activity of a variety of enzymes is used to cleave the target-dependent cleavage structure, thereby indicating the presence of specific nucleic acid sequences or specific variations thereof. | 12-10-2009 |
| 20090305285 | ASYMMETRIC CYANINE COMPOUNDS, THEIR PREPARATION METHODS AND THEIR USES - Asymmetric cyanine compounds represented by general formula I are provided, wherein X, n, R | 12-10-2009 |
| 20090305281 | NOVEL INHIBITORS OF RETROVIRAL REVERSE TRANSCRIPTACE - Disclosed are nucleic acid molecules, and methods of their use, which have a specific structure including a double helical domain and a G-quadruplex domain physically connected by a linker domain which may be nucleosidic or non-nucleosidic. These aptamers demonstrate potent inhibition of phylogenetically diverse primate lentiviral reverse transcriptases, which effect is largely independent of aptamer sequence provided that the aptamer has the specified structure. | 12-10-2009 |
| 20090305288 | METHODS FOR AMPLIFYING NUCLEIC ACIDS AND FOR ANALYZING NUCLEIC ACIDS THEREWITH - An object of the present invention is to control the increase in amplification errors generated during the nucleic acid amplification and thus to obtain an amplification product having a good reproducibility. The present invention is characterized in that a target nucleic acid to be amplified is amplified through a two-stage amplification process in which the amplification only of a single strand is first performed and a strand which is complementary to its amplified product is then amplified. The amplification uses a first primer which is employed for the first-stage amplification and a second primer which is employed for the second-stage amplification. These primers are each used separately, or alternatively designed to have a different stringency and used at the same time. | 12-10-2009 |
| 20090305284 | Methods for Identifying Risk of Breast Cancer and Treatments Thereof - Provided herein are methods for identifying risk of breast cancer in a subject and/or a subject at risk of breast cancer, reagents and kits for carrying out the methods, methods for identifying candidate therapeutics for treating breast cancer, and therapeutic methods for treating breast cancer in a subject. These embodiments are based upon an analysis of polymorphic variations in nucleotide sequences within the human genome. | 12-10-2009 |
| 20090305278 | SEQUENCE DETERMINATION IN CONFINED REGIONS - A sequencing methodology is disclosed that allows a single DNA or RNA molecule or portion thereof to be sequenced directly and in substantially real time. The methodology involves engineering a polymerase and/or dNTPs with atomic and/or molecular tags that have a detectable property that is monitored by a detection system. | 12-10-2009 |
| 20090305276 | Method for Predicting Skin Sensitizing Activity of Compounds - The present invention provides methods for predicting the in vivo skin sensitizing activity of chemical compounds using a combination of mammalian cell models with multiple endpoint analysis, time and concentration response curves. The methods allow the determination of a predicted in vivo sensitization value of a compound—for example, a EC3 LLNA value, a GPMT value or a IVTI value—without the use of animals, with a high degree of accuracy. The methods involve detecting expression levels of genes implicated in skin sensitization, combining expression level data with concentration response data, conducting a computational analysis, and comparing test compound data to a database of known skin sensitizers. | 12-10-2009 |
| 20090305275 | DNAs AND PROTEINS OR PEPTIDES SPECIFIC TO BACTERIA OF THE SPECIES NEISSERIA MENINGITIDIS, PROCESS FOR OBTAINING THEM AND THEIR BIOLOGICAL USES - The DNA of the invention are characterised in that they concern the whole or pan of genes, with their reading frame, to be found in | 12-10-2009 |
| 20090305271 | In Vitro Assay Based on Camp Levels Modulated by Gi-Coupled Receptors - The present invention relates to a reliable and effective in vitro assay based on cAMP levels modulated by Gi-coupled receptors expressed in a selected cell for screening and identifying pharmaceutically effective compounds that specifically interact with and modulate the activity of a cellular receptor. | 12-10-2009 |
| 20090305277 | GENE EXPRESSION MARKERS FOR PREDICTION OF PATIENT RESPONSE TO CHEMOTHERAPY - The present invention relates to gene sets useful in assessing prognosis and/or predicting the response of cancer, e.g. colorectal cancer to chemotherapy. In addition, the invention relates to a clinically validated cancer test, e.g. colorectal test, for assessment of prognosis and/or prediction of patient response to chemotherapy, using expression analysis. The present invention accommodates the use of archived paraffin embedded biopsy material for assay of all markers in the relevant gene sets and therefore is compatible with the most widely available type of biopsy material. | 12-10-2009 |
| 20090305263 | PROBE, PROBE SET, PROBE-IMMOBILIZED CARRIER, AND GENETIC TESTING METHOD - A nucleic acid probe for classification of pathogenic bacterial species is capable of collectively detecting bacterial strains of the same species and differentially detecting them from other bacterial species. Any one of the base sequences of SEQ ID NOS. 43 to 45 or a combination of at least two of them is used for detecting the gene of an infectious disease pathogenic bacterium. | 12-10-2009 |
| 20090305262 | PROBE, PROBE SET, PROBE-IMMOBILIZED CARRIER, AND GENETIC TESTING METHOD - A nucleic acid probe for classification of pathogenic bacterial species is capable of collectively detecting bacterial strains of the same species and differentially detecting them from other bacterial species. Any one of the base sequences of SEQ ID NOS. 56 to 58 or a combination of at least two of them is used for detecting the gene of an infectious disease pathogenic bacterium. | 12-10-2009 |
| 20090305259 | Early Diagnosis of Congenital Abnormalities in the Offspring of Diabetic Mothers - The present invention relates to the identification of a series of biomarkers, the detection of which is prognostic for women at risk of becoming hyperglycemic during pregnancy and/or fetuses at risk of developing congenital anomalies as a result of maternal hyperglycemia. | 12-10-2009 |
| 20090305257 | BIOMARKERS DOWNREGULATED IN PROSTATE CANCER - Biomarkers are identified by analyzing gene expression data using support vector machines (SVM), recursive feature elimination (RFE) and/or linear ridge regression classifiers to rank genes according to their ability to separate prostate cancer from normal tissue. Proteins expressed by identified genes are detected in patient samples to screen, predict and monitor prostate cancer. | 12-10-2009 |
| 20090305256 | DNA methylation biomarkers for lung cancer - The present invention relates to the identification of novel DNA biomarkers and the use of the aberrant methylation patterns of the biomarkers to diagnose a disease or a condition (e.g., a cancer) associated therewith. In particular, the present invention relates to the use of the novel DNA biomarkers to diagnose lung cancers, e.g., squamous cell carcinomas and adenocarcinomas. | 12-10-2009 |
| 20090305253 | Methods and Compositions Related to the Modulation of Riboswitches - Disclosed herein are methods and compositions related to the detection of conformational changes and interactions with trigger molecules in riboswitches. | 12-10-2009 |
| 20090305249 | METHOD OF DETECTING CYP2A6 GENE VARIANTS - The present invention relates to methods for amplifying various regions of the CYP2A6 gene. Methods are provided for amplifying one or more fragments of the CYP2A6 gene in a single tube. The methods can identify mutations, deletion, duplication, and/or rearrangement in a sample containing the CYP2A6 gene. | 12-10-2009 |
| 20090305250 | DETERMINATION OF THE BIOLOGICAL FUNCTION OF A TARGET GENE IN A CELL - Disclosed herein is a method to determine the biological function(s) of a target gene in a cell, the steps of which involve separately culturing a first population and a second population of the cell under same culturing conditions, the first population of the cell differing from the second population of the cell in that the first population of the cell has accepted the introduction of a methylated polynucleotide; comparing the first population and the second population of the cell to determine which biological difference(s) is/are present therebetween; and determining which biological function(s) the target gene is associated with based on the determined biological difference(s) between the first population and the second population of the cell. | 12-10-2009 |
| 20090305246 | SCHIZOPHRENIA ASSOCIATED GENES AND MARKERS - The invention discloses schizophrenia-associated polymorphism located on chromosome 6q23 within the human Abelson Helper Integration Site 1 gene (AHI1), or a genomic region linked to the AHI1 gene that includes the C6orf217 gene. The invention further discloses systems and methods for diagnosing schizophrenia or predisposition to schizophrenia. | 12-10-2009 |
| 20090305248 | METHODS FOR INCREASING ACCURACY OF NUCLEIC ACID SEQUENCING - The invention provides methods for improving the fidelity of a sequencing-by-synthesis reaction by resequencing at least a portion of a nucleic acid template. | 12-10-2009 |
| 20090305254 | Method and Apparatus for Assaying Test Substance in Sample - Disclosed are a method for assaying a target substance in a sample and an apparatus for the method. The method can specifically assay the target substance in the sample without using any antibody against the target substance. The assaying method includes simultaneously or successively bringing a labeled aptamer, the target substance in the sample and a solid phase into contact together, and then measuring the label of the aptamer which has not been bound on the solid phase. The labeled aptamer has a property of binding to the target substance. The solid phase carries an oligonucleotide immobilized on it in an excess amount relative to the target substance. The oligonucleotide is hybridizable with the labeled aptamer when the labeled aptamer is in a state that it is not bound to the target substance, but is not hybridizable with the labeled aptamer when the labeled aptamer is in a state that it is bound to the target substance. | 12-10-2009 |
| 20090305239 | Methods and compositions for determing a level of biologically active serum paraoxonase - A method of determining a level of biologically active PON enzyme is provided. The method comprising determining lactonase activity of the PON enzyme, the lactonase activity being indicative of the level of biologically active PON enzyme. Also provided are novel compounds which may be used for measuring a lactonase activity of an enzyme. | 12-10-2009 |
| 20090305233 | Methods and Reagents for Polynucleotide Assembly - The present invention provides methods, compositions, and kits for polynucleotide assembly. | 12-10-2009 |
| 20090305238 | Microarray Microcard - A fluid processing device is provided that comprises a substrate including a surface and a fluid processing pathway at least partially formed in or on the surface. The fluid processing pathway can comprise a channel, a reaction region in fluid communication with the channel, a microarray in fluid communication with the channel, and optionally a deformable valve. The microarray can comprise binding and/or detection sites, and each site can comprise a binding moiety. A method and a system using the fluid processing device, are also provided. | 12-10-2009 |
| 20090305236 | METHODS OF ENRICHING FETAL CELLS - The present invention relates to methods of enriching fetal cells from a pregnant female. The present invention relates to removing, from a sample, cells that comprise at least one MHC molecule. The present invention also relates to methods that rely on using telomerase, mRNA encoding components thereof, as well as telomere length, as markers for fetal cells. Enriched fetal cells can be used in a variety of procedures including, detection of a trait of interest such as a disease trait, or a genetic predisposition thereto, gender typing and parentage testing. | 12-10-2009 |
| 20090305241 | DNA demethylases and uses thereof - Polypeptides with DNA demethylase activity as well as methods of their use are provided. | 12-10-2009 |
| 20090305234 | Specific DNAS for Epigenetic Characterisation of Cells and Tissues - The present invention provides methods, nucleic acids and molecular markers for the characterization of cells, tissues and heterogeneous mixtures of cells. Specifically, it describes particular genes and genomic regions in which DNA methylation patterns are a consistent and characteristic property of different cell types, states and stages of differentiation. The invention is useful in determining the identity, composition, quality and potency of cells and cell populations. Furthermore, the invention will be useful in monitoring the differentiation of cells. | 12-10-2009 |
| 20100035270 | Methods and Compositions for the Detection of Bovine Pregnancy - Provided herein are pregnancy specific marker genes, such as those shown in Tables I-III, and methods of detecting the same to determine bovine pregnancy. | 02-11-2010 |
| 20090311705 | METHOD OF DETERMINING EFFICIENCY OF OVUM COLLECTION IN BOVINE - The novel means by which an efficiency of ovum collection can be easily determined in bovine at gene level is disclosed. The present inventors performed the genomic linkage analysis using bovine populations with high and low efficiency of ovum collection and to identify GRIA1 gene, which encodes an ion channel protein, as a factor deeply related to an efficiency of ovum collection. Bovines having a mutation (e.g. the amino acid substitution of aa306) in GRIA1 produce significantly fewer ova on superovulatory treatment than those not having the mutation. Therefore, the efficiency of ovum collection can be determined based on the existence of a mutation in GRIA1 gene. | 12-17-2009 |
| 20100035252 | Methods for sequencing individual nucleic acids under tension - The invention provides apparatuses and methods of use thereof for sequencing nucleic acids subjected to a force, and thus considered under tension. The methods may employ but are not dependent upon incorporation of extrinsically detectably labeled nucleotides. | 02-11-2010 |
| 20090317797 | Non-Invasive, Prenatal, In-Vitro Method for Detecting the Normal Healthy Condition, the Condition of a Healthy Carrier or the Condition of a Carrier Inflicted with Cystic Fibrosis - The invention relates to a non-invasive, prenatal, in-vitro method for detecting the normal healthy condition, the condition of a healthy carrier or the condition of a carrier inflicted with cystic fibrosis, from the fetal cell(s) from a maternal sample, comprising the DNA of an individual to be tested. The invention also relates to oligonucleotide primers and to their use within the scope of a non-invasive, prenatal, in-vitro method for detecting the condition of a healthy carrier or of a carrier inflicted with cystic fibrosis. | 12-24-2009 |
| 20090291433 | Droplet-based nucleic acid amplification method and apparatus - The present invention relates to a droplet-based nucleic acid amplification method and apparatus. According to one embodiment, a method of amplifying a nucleic acid in a biological sample is provided, wherein the method includes: (a) providing a system comprising a droplet microactuator electronically coupled to and controlled by a processor capable of executing instructions, the droplet microactuator comprising: (i) a sample potentially comprising a target nucleic acid; (ii) a substrate comprising electrodes for conducting droplet operations; and (iii) one or more temperature control means arranged in proximity with one or more of the electrodes for heating a region of the droplet microactuator such that a droplet can be transported into the region for heating; (b) using droplet operations to combine on the droplet microactuator one or more amplification reagent droplets and one or more sample droplets to yield an amplification-ready droplet; and (c) thermal cycling the amplification-ready droplet sufficient to result in amplification of a target nucleic acid when present in the amplification-ready droplet. | 11-26-2009 |
| 20100190179 | Lateral Flow Methods and Devices for Detection of Nucleic Acid Binding Proteins - Methods and devices are provided for detecting the presence or absence of nucleic acid binding proteins, such as NMP22, and other proteins, in bodily fluids. | 07-29-2010 |
| 20100190175 | METHODS OF RANDOM MUTAGENESIS AND METHODS OF MODIFYING NUCLEIC ACIDS USING TRANSLESION DNA POLYMERASES - The invention is related generally to methods of amplifying or synthesizing or producing nucleic acid molecules using Translesion DNA polymerases. In particular, the invention relates to methods of introducing a random mutation into a nucleic acid and encoded polypeptide using Translesion DNA polymerases. The invention also relates to methods of introducing a modified nucleotide into a nucleic acid using Translesion DNA polymerases. The invention also relates to mutagenized and modified nucleic acid molecules and proteins produced by these methods, and to fragments or derivatives thereof. The invention also relates to vectors and host cells comprising mutagenized nucleic acid molecules, fragments, or derivatives. The invention also relates to the use of mutagenized nucleic acid molecules to produce desired polypeptides and uses of modified nucleic acid molecules to analyze samples. The invention also relates to kits or compositions or compounds for use in the invention or for carrying out the invention. | 07-29-2010 |
| 20100190172 | GENETIC POLYMORPHISMS ASSOCIATED WITH CARDIOVASCULAR DISORDERS AND DRUG RESPONSE, METHODS OF DETECTION AND USES THEREOF - The present invention is based on the discovery of genetic polymorphisms that are associated with cardiovascular disorders, particularly acute coronary events such as myocardial infarction and stroke, and genetic polymorphisms that are associated with responsiveness of an individual to treatment of cardiovascular disorders with statin. In particular, the present invention relates to nucleic acid molecules containing the polymorphisms, variant proteins encoded by such nucleic acid molecules, reagents for detecting the polymorphic nucleic acid molecules and proteins, and methods of using the nucleic acid and proteins as well as methods of using reagents for their detection. | 07-29-2010 |
| 20100190171 | MICROORGANISM CONCENTRATION PROCESS - A process for capturing or concentrating microorganisms for detection or assay comprises (a) providing a concentration agent that comprises an amorphous metal silicate and that has a surface composition having a metal atom to silicon atom ratio of less than or equal to about 0.5, as determined by X-ray photoelectron spectroscopy (XPS); (b) providing a sample comprising at least one microorganism strain; and (c) contacting the concentration agent with the sample such that at least a portion of the at least one microorganism strain is bound to or captured by the concentration agent. | 07-29-2010 |
| 20100190170 | MICROTITER PLATE MASK AND METHODS FOR ITS USE - Provided is a masking system of masks for use with multiwell plates such as microtiter plates to facilitate sample dispensing and assay accuracy, especially when dispensing more than one solution into the wells. One or more masks, adapted in size to fit snugly over a multiwell plate and the mask formed with openings each aligned with a subset of one or more wells of the plate beneath, aids the user in sample and/or reagent administration. Advantageously, the masks contain registration aids so that proper orientation with respect to the plate below is achieved; the registration aid may be a cut corner, registration peg or mark, or visual marking or stamping. | 07-29-2010 |
| 20100190169 | SINGLE NUCLEOTIDE POLYMORPHISMS PREDICTING CARDIOVASCULAR DISEASE - The present invention relates to an isolated polynucleotide encoding a Na | 07-29-2010 |
| 20100190168 | COMPETITOR MOLECULES USEFUL FOR LOWERING NONSPECIFIC ADSORPTION OF DYE LABELED NUCLEOTIDES - Methods are described which enable higher signal/noise when performing surface measurements at the single molecule level. Methods are particularly useful in the field of molecular biology when performing single molecule nucleic acid sequencing by synthesis using dye labeled nucleotides. The method employs using a competitor molecule which blocks nonspecific binding of analog molecules to the surface. | 07-29-2010 |
| 20100190166 | TISSUE REJECTION BIOMARKERS - This document relates to methods and materials involved in assessing tissue rejection (e.g., organ rejection) in mammals. For example, methods and materials involved in detecting tissue rejection (e.g., kidney rejection) are provided, as are methods and materials for distinguishing types of tissue rejection (e.g., antibody-mediated rejection versus T cell-mediated rejection) in mammals (e.g., humans). | 07-29-2010 |
| 20100190164 | DIAGNOSIS AND MONITORING OF RENAL FAILURE USING PEPTIDE BIOMARKERS - Methods for the determination of renal failure, especially chronic renal failure and acute kidney injury, by measurement of peptide or protein biomarkers are described. The methods are useful to determine stages of renal failure, especially the early stages such as stage | 07-29-2010 |
| 20100190160 | INDICATOR CELL LINES AND METHODS FOR MAKING SAME - Methods of making an indicator cell are described. The methods include, e.g., contacting a vertebrate cell comprising a functional endogenous target gene under control of an endogenous inducible promoter with a parvoviral vector comprising a construct comprising a targeting DNA sequence linked to a DNA encoding a reporter gene, wherein the construct enters the cell and undergoes homologous recombination with the target gene, thereby operably linking the reporter gene and the target gene; inducing expression of the target gene thereby causing expression of the reporter gene; and selecting the cell based on expression of the reporter gene. | 07-29-2010 |
| 20100190158 | Rapid Test for Detecting DNA Sequences - The present invention relates to an in vitro method for detecting a target DNA sequence in cells using an oligonucleotide which is labelled with a beta-D-galactopyranoside which, on hydrolysis of the glycosidic linkage, forms a water-insoluble dye. The invention relates in particular to an in vitro method for detecting a target DNA sequence from a group of DNA sequences whose members differ from one another in exactly one predetermined nucleotide position, by using an oligonucleotide which is labelled with a beta-D-galactopyranoside which, on hydrolysis of the glycosidic linkage, forms a water-insoluble dye. The invention additionally relates to the use of such an oligonucleotide in DNA hybridization methods. The invention finally relates to kits for carrying out the above methods. | 07-29-2010 |
| 20100190154 | Development of low allergen soybean seeds using molecular markers for the P34 allele - A mutation in the gene encoding the P34 protein in soybean which affects allergenicity is characterized. Soybean homozygous for a mutant allele comprising a four base pair insertion at the start codon of the gene encoding the P34 protein, exhibit significantly reduced P34 protein accumulation. Nucleic acid samples of soybean may be assayed for the presence of this insertion to detect the mutant allele, and soybean containing the allele may be selected for breeding to generate reduced P34 soybean lines. Molecular markers have been developed for detecting the presence or absence of the four base pair insertion. | 07-29-2010 |
| 20100190153 | SINGLE-MOLECULE PCR ON MICROPARTICLES IN WATER-IN-OIL EMULSIONS - Modulation of the viscosity of the oil phase of a microemulsion used for amplification of DNA on a bead increases the homogeneity of product beads and the amount of amplified DNA per bead. Moreover the number of separate microemulsion populations that can be formed in parallel is increased using multi-well plates and mixer mill disruptor machines designed to lyse biological samples. | 07-29-2010 |
| 20100190152 | Apparatus for Analysing A Sample and Assessing its Global Position - An apparatus for analysing a sample and assessing its global position, the apparatus comprising a portable sample analysing device and a global positioning device. | 07-29-2010 |
| 20100190150 | Biomarkers and methods for determining sensitivity to epidermal growth factor receptor modulators - EGFR biomarkers useful in a method for identifying a mammal that will respond therapeutically to a method of treating cancer comprising administering an EGFR modulator, wherein the method comprises (a) exposing the mammal to the EGFR modulator and (b) measuring in the mammal the level of the at least one biomarker, wherein a difference in the level of the at least one biomarker measured in (b) compared to the level of the biomarker in a mammal that has not been exposed to the EGFR modulator indicates that the mammal will respond therapeutically to the method of treating cancer. | 07-29-2010 |
| 20100028896 | ROTARY EXTRACTION CONTAINER AND METHOD OF IDENTIFYING CELL SPECIES, METHOD OF DETECTING GENE, AND AUTOMATIC NUCLEIC ACID EXTRACTOR USING THE SAME - Disclosed is a rotary extraction container enabling to safely and simply perform extraction and separation of a target substance from a sample containing plural substances. Specifically, there is disclosed a rotary extraction container enabling to simply perform extraction and separation of a nucleic acid from a biological sample or from a bio-derived sample without any risk of infection, contamination or the like, which has conventionally required cumbersome operations and a large, expensive apparatus. Further, there is disclosed a method of identifying a cell species a method of detecting a gene and an automatic nucleic acid extractor using the same. The foregoing rotary extraction container, which is a rotary extraction container to extract a target substance from a sample comprises a cylindrical container section, a rotating section and a cover section, and a solution or solid contained in any one of the small chambers of the cylindrical container section is allowed to transfer to another of the small chambers by an operation including rotation of the rotating section and the target substance is extracted from the sample by such an operation including the transfer. | 02-04-2010 |
| 20100028892 | YEAST BASED EXPRESSION OF PROTEASES AND METHODS OF USE - This disclosure generally relates to components and methods of using a high throughput screening (HTS) systems for intracellular proteases, using Caspases as a prototype. Genetic systems are disclosed for monitoring exogenous caspase activation pathways in the yeast, | 02-04-2010 |
| 20100028889 | COMPANION DIAGNOSTIC ASSAYS FOR CANCER THERAPY - Methods for identifying cancer patients eligible to receive Bcl-2 family inhibitor therapy and for monitoring patient response to Bcl-2 family inhibitor therapy comprise assessment of the expression levels of the biomarker combinations set out in TABLES 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 or 20 in a patient tissue sample. The methods of the invention allow more effective identification of patients to receive Bcl-2 family inhibitor therapy and of determination of patient response to the therapy. | 02-04-2010 |
| 20100028888 | METHODS FOR PRODUCING A PAIRED TAG FROM A NUCLEIC ACID SEQUENCE AND METHODS OF USE THEREOF - Methods for producing a paired tag from a nucleic acid sequence are provided in which the paired tag comprises the 5′ end tag and 3′ end tag of the nucleic acid sequence. In one embodiment, the nucleic acid sequence comprises two restriction endonuclease recognition sites specific for a restriction endonuclease that cleaves the nucleic acid sequence distally to the restriction endonuclease recognition sites. In another embodiment, the nucleic acid sequence further comprises restriction endonuclease recognition sites specific for a rare cutting restriction endonuclease. Methods of using paired tags are also provided. In one embodiment, paired tags are used to characterize a nucleic acid sequence. In a particular embodiment, the nucleic acid sequence is a genome. In one embodiment, the characterization of a nucleic acid sequence is karyotyping. Alternatively, in another embodiment, the characterization of a nucleic acid sequence is mapping of the sequence. In a further embodiment, a method is provided for identifying nucleic acid sequences that encode at least two interacting proteins. | 02-04-2010 |
| 20100028885 | Labelled nucleotides - Nucleosides and nucleotides are disclosed that are linked to detectable labels via a cleavable linker group. | 02-04-2010 |
| 20100028883 | METHOD FOR EVALUATION OF TISSUE PRESERVATION SOLUTION - The present invention provides a method for evaluating preservative effect of a tissue preservation solution, comprising immersing a mammalian tissue introduced with a luminescence or fluorescence labeling gene in the tissue preservation solution, measuring a luminescence or fluorescence level by the labeling gene in the tissue after immersion, and evaluating the preservative effect of the tissue preservation solution based on the luminescence or fluorescence level. | 02-04-2010 |
| 20100028884 | Detection of penicillin tolerance in group B streptococcus: single nucleotide polymorphisms in penicillin binding protein 4 - Disclosed are methods of detecting penicillin tolerance in Group B | 02-04-2010 |
| 20100028882 | METHODS FOR DIAGNOSING OSTEOARTHRITIS - Methods are disclosed for assessing risk of developing osteoarthritis. Said methods comprise determining the cellular localizations, blood or synovial fluid concentrations, sumoylation states and post-translational modifications of pituitary homeobox transcription factor 1 (pitx-1) repressor proteins, identifying mutations in genes which encode said proteins and identifying any mutations or post-translational modifications causing the nuclear accumulation or retention of said proteins. Said proteins include prohibitin (PHB-I), prohibitone (PHB-2) and B cell lymphoma-6 transcriptional repressor interacting co-repressor (BCoR). | 02-04-2010 |
| 20100028878 | Modulators of UDP-glucose ceramide glucosyltransferase for treating acne or hyperkeratinization - An in vitro method for screening candidate compounds for the preventive or curative treatment of acne, includes the determination of the capacity of a compound to modulate the expression or the activity of UDP-glucose ceramide glucosyltransferase (UGCG), and the use of modulators of the expression or activity of this enzyme for the treatment of acne or skin disorders associated with a hyperkeratinization; methods for the in vitro diagnosis or prognosis of these pathologies are also described. | 02-04-2010 |
| 20100028873 | METHODS AND MEANS FOR NUCLEIC ACID SEQUENCING - The present invention provides a nucleic acid sequencing method. The method comprises enriching a nucleic acid sample for target nucleic acids, where the nucleic acid sample is enriched through at least a first round of hybridization selection and amplification, and a second round of hybridization selection and amplification. The enriched nucleic acids are in a form convenient for sequencing with the Cantaloupe sequencing technology, which employs shotgun sequencing by hybridization (SBH) of immobilized rolling circle amplicons. | 02-04-2010 |
| 20100028862 | BACTERIAL REPLICATION SYSTEMS AND METHODS - Reconstituted bacterial replication assemblies and methods for their use are provided. | 02-04-2010 |
| 20100021916 | MICROSATELLITE-BASED FINGERPRINTING SYSTEM FOR SACCHARUM COMPLEX - This invention relates to | 01-28-2010 |
| 20100086934 | Use of non-clonal chromosomal aberrations for cancer research and clinical diagnosis - A diagnostic method of determining tumorigenicity of a tissue specimen includes the steps of determining a magnitude of genome diversity in the tissue specimen, and diagnosing a likelihood of cancer in response to said step of determining the magnitude of genome diversity. The magnitude of genome diversity includes the determination of karyotypic heterogeneity in the tissue specimen, illustratively by detecting non-clonal chromosome aberrations (NCCAs). The detection of NCCAs includes the detection the frequency of NCCAs, and the diagnosis is responsive to the step of detecting the frequency of NCCAs. Detection of NCCAs advantageously includes the further step of screening lymphocytes. Also, the step of determining the presence of elevated genome diversity includes the step of applying Spectral Karyotyping to detect translocations throughout the genome. The diagnostic method is useful to determine drug resistance of a patient. | 04-08-2010 |
| 20090298079 | HIGH AFFINITY BINDING SITE OF HGFR AND METHODS FOR IDENTIFICATION OF ANTAGONISTS THEREOF - Use of a polynucleotide encoding or a polypeptide comprising at least the extracellular IPT-3 and IPT-4 domains of hepatocyte growth factor receptor for the screening and/or development of pharmacologically active agents useful in the treatment of cancer, preferably a cancer with dysregulation of hepatocyte growth factor receptor. | 12-03-2009 |
| 20090298062 | METHOD FOR DETERMINATION OF THE LENGTH OF THE G-TAIL SEQUENCE AND KIT FOR THE METHOD - A method of measuring the length of a G tail sequence, characterized by hybridizing the G tail of an nondenatured chromosomal DNA in a sample with a labeled DNA probe having a sequence complementary to the telomere repeat sequence, measuring chemiluminescence from the hybridized DNA probe, and determining the length of the G tail sequence from the measured value, and a kit used for use in such a method. | 12-03-2009 |
| 20090298086 | PLANT FARNESYLTRANSFERASES - This invention relates to an isolated nucleic acid fragment encoding a farnesyltransferase subunit. The invention also relates to the construction of a chimeric gene encoding all or a portion of the farnesyltransferase subunit, in sense or antisense orientation, wherein expression of the chimeric gene results in production of altered levels of the farnesyltransferase subunit in a transformed host cell. | 12-03-2009 |
| 20090298061 | Diagnostic Methods for the Prediction of Therapeutic Success, Recurrence Free and Overall Survival in Cancer Therapy - Described are 12 human genes which are differentially expressed in neoplastic tissues of patients responding well to treatment as compared to patients not responding well as determined by overall survival time in the non responding cohort. Moreover, methods for prognosis of the therapeutic success in cancer therapy are described. These methods are based on determination of expression levels of particular genes which are differentially expressed in cancer patients, preferably the genes encoding VEGFC, ERBB3 and Her2/neu, prior to the onset of anti-cancer chemotherapy. These methods are particularly useful in the investigation of advanced head and neck cancer, but are useful in the investigation of other types of cancer and therapies as well. | 12-03-2009 |
| 20090298055 | PRODUCTION OF PROTEINS - The present invention is of a method of producing proteins in mammalian cells using a permanent selection in the absence of cytotoxic drugs. Specifically, the present invention can be used to produce large quantities of highly pure human proteins which are suitable for pharmaceutical applications. | 12-03-2009 |
| 20100003669 | Primer for Detection of Cytochrome P450 Hydroxylase Specific to Polyene - The present invention relates to a primer for detection of cytochrome P450 hydroxylase specific to polyene and a method for detecting a strain of bacteria which produces polyene, by using the primer. More particularly, the present invention is directed in a forward degenerate primer of following sequence (I) and a reverse degenerate primer of following sequence (II), which are complementary to conserved region which resides in the polyene-specific CYP (cytochrome P450 hydroxylose) encoding sequences: (I) 5′-TGGATCGGCGACGACCGSVYCGT-3′ and (II) 5′-CCGWASAGSAYSCCGTCOTACTT-3′, wherein S indicated Guanine or Cytosine, V indicates Adrenine, Guanine or Cytosine, Y indicates Thymine or Cytosine and W indicates Thymine or Adenine. | 01-07-2010 |
| 20100330557 | GENOMIC COORDINATE SYSTEM - A method of sample analysis is provided. In certain embodiments, the method comprises: a) site-specifically labeling a test genome with at least two different labels to produce a labeled genome labeled at a plurality of discrete sites across the genome; b) stretching a nucleic acid of the labeled genome to produce a linear pattern of the different labels along a region of a stretched nucleic acid; c) reading the labels along the region to provide a test pattern comprising a sequence of colors emitted by the labels; d) comparing the test pattern to a plurality of reference patterns obtained from a reference genome, in which the reference patterns are mapped to corresponding genomic locations in the reference genome; and e) identifying one or more reference patterns that match the test pattern, thereby mapping a location for the region in the test genome. | 12-30-2010 |
| 20100015618 | DNA FRAGMENT USED AS ATTACHED TO 5' END OF PRIMER USED IN NUCLEIC ACID AMPLIFICATION REACTION AND USE OF DNA FRAGMENT - A method is provided which enables quick, convenient, inexpensive, and high sensitivity confirmation of nucleic acid amplification after a nucleic acid amplification reaction. The DNA fragment in accordance with the present invention is a single-stranded DNA fragment containing a hairpin structure which in turn contains a bulge, wherein the DNA fragment is used as being attached to the 5′ end of a primer used in nucleic acid amplification. The nucleic acid amplification confirmation method in accordance with the present invention quantifies a hairpin primer containing the DNA fragment at its 5′ end by using bulge-binding fluorescent molecules after carrying out PCR or like nucleic acid amplification reaction using the hairpin primer. SNPs are detected quickly and conveniently at low cost and with high sensitivity by applying the nucleic acid amplification confirmation method, for example, to allele specific PCR. | 01-21-2010 |
| 20100015621 | METHOD FOR DIRECT AMPLIFICATION FROM CRUDE NUCLEIC ACID SAMPLES - The present teachings relate to improved methods, kits, and reaction mixtures for amplifying nucleic acids. In some embodiments a novel direct buffer formulation is provided which allows for the direct amplification of the nucleic acids in a crude sample with minimal sample purification. | 01-21-2010 |
| 20100015619 | METHOD OF DETECTING GENOMIC ABERRATIONS FOR PRENATAL DIAGNOSIS - This invention relates to assays used to detect and confirm genomic aberrations, such as chromosomes 13, 18, 21, X and Y aneuploidy as well as 22q11.2 deletions, for prenatal diagnosis. For the detection, combined STR markers (all tetra-nucleotide repeats) are employed to cover different chromosome regions. For the confirmation step, individual chromosome specific STR markers (tetra-nucleotide repeats) are utilized. This invention particularly relates to multiplex analysis for the presence or absence of STR markers in genomic DNA isolated from peripheral blood, amniotic fluid, cultured amniocytes, chorionic villi, or fetal cells existing in maternal blood. This invention offers an efficient approach to identify chromosomal abnormalities by using STR markers. | 01-21-2010 |
| 20100015617 | Nucleic Acid Amplification Method - Disclosed is a nucleic acid amplification method which is based on a new principle and enables to amplify a nucleic acid having a specific nucleotide sequence in a simple manner, within a short time and with efficiency. The nucleic acid amplification method comprises the steps of: (a) conducting a DNA polymerase chain reaction by using, as a template, DNA comprising a nucleotide sequence to be amplified and using a primer pair having a nucleotide sequence complementary to the nucleotide sequence to be amplified, thereby producing a linear DNA fragment; and (b) conducting a chain-substituting DNA polymerase chain reaction in a chaining manner by using cyclic single-stranded DNA comprising the same nucleotide sequence as that of at least one of the primer pair as a template and employing the 3′-terminus of the linear DNA fragment produced in step (a) as the replication origin. | 01-21-2010 |
| 20100015606 | MICROFLUIDIC DROPLET QUEUING NETWORK - A multi-port liquid bridge ( | 01-21-2010 |
| 20100015604 | Composition and method for determination of ck19 expression - Disclosed is a method for quantitative determination of CK-19 mRNA positive cells in a biological sample. The method can be used, for instance, with peripheral blood to detect cancer in a patient. In one embodiment, the method can be used to detect the cancer before initiation of adjuvant treatment, thereby providing information about therapeutic efficacy. Practice of the invention method is sensitive, reliable, and easy to perform. | 01-21-2010 |
| 20100015601 | BIOLOGICAL CONFIRMATION AND DETECTION SYSTEM - The present disclosure describes a method and apparatus for collecting samples of particles from air or other gases at one or more monitored locations, and identifying in real-time whether biological agents, such as bacterial or viral pathogens, are present in the samples. The apparatus preferably uses a liquid-assisted collector to collect the sample of particles, which are suspended in a liquid that contains dyes that detect the presence of nucleic acids. An integrated detector with a light source and a light detector detects whether there is a change in the fluorescence of the liquid, which indicates the presence of a biological agent in the sample. | 01-21-2010 |
| 20100015602 | REVERSE TRANSCRIPTION AND AMPLIFICATION OF RNA WITH SIMULTANEOUS DEGRADATION OF DNA - The invention relates to a method for processing RNA, in particular, a RNA reaction method and kits for carrying out said RNA reaction method. | 01-21-2010 |
| 20090280489 | Ig genes specific oligonucleotides and uses thereof - The present invention provides oligonucleotides for detection of rearrangement of immunoglobulin genes for identifying clonality of cells, cancer cells, hypermutation in immunoglobulin gene, antibody isotype producing cell and/or assaying B cell repertoire in a sample. The oligonucleotides disclosed in the present invention are very specific to the immunoglobulin genes. | 11-12-2009 |
| 20090275022 | STAT6 EFFECTS ON LIVESTOCK ANIMAL GROWTH - The present invention provides for selection of livestock animals, including bovines, whose genotypes based in the STAT6 gene are correlated with phenotypes reflecting desirable carcass and feedlot traits. These phenotypes include back fat (BFAT), calculated yield grade (CALCYG), cutability (CUT), hot carcass weight (HCW), dry matter intake (DMI), days on feed (DOF), back fat rate (BFAT RATE) and average daily gain (ADG), based on the knowledge of the STAT6 genotypes. The predictive value is based in part on the discovery that certain single nucleotide polymorphisms (SNPs) within the STAT6 gene are linked to phenotypes of economically these important carcass and feedlot traits. Also provided are SNPs within the STAT6 gene useful in reliably distinguishing between a | 11-05-2009 |
| 20090298072 | DNA Sequencing by Nanopore Using Modified Nucleotides - This invention provides a process for sequencing single-stranded DNA by employing a nanopore and modified nucleotides. | 12-03-2009 |
| 20110097727 | DNA MARKERS FOR MANAGEMENT OF CANCER - A method is provided for assessing allelic losses and hypermethylation of genes in CpG tumor promotor region on specific chromosomal regions in cancer patients, including melanoma, neuroblastoma breast, colorectal, and prostate cancer patients. The method relies on the evidence that free DNA and hypermethylation of genes in CpG tumor promotor region may be identified in the bone marrow, serum, plasma, and tumor tissue samples of cancer patients. Methods of melanoma, neuroblastoma, colorectal cancer, breast cancer and prostate cancer detection, staging, and prognosis are also provided. | 04-28-2011 |
| 20090246756 | Thermostable polypeptide having polynucleotide kinase activity and/or phosphatase activity - Isolated polypeptides having 5′-kinase and/or 3′-phosphatase activity and temperature optimum of at least 60° C. are described. The invention also relates to isolated nucleic acids encoding the polypeptides, nucleic acid constructs and host cells comprising the nucleic acid sequences as well as methods using the polypeptides and kits for practicing the methods. | 10-01-2009 |
| 20100003678 | SENSITIVE MAGNETIC ASSAY THROUGH AMPLICATION OF A LABEL SIGNAL - This invention relates to a device and a method for amplifying a signal generated from primary nanoparticle labels in an assay by using secondary nanoparticle labels, typically magnetic labels, wherein by binding the secondary labels to the primary labels the results in that the signal produced from the labels will be amplified. | 01-07-2010 |
| 20100003682 | Compositions, kits, and methods for identification, assessment, prevention and therapy of breast and ovarian cancer - The invention relates to newly discovered nucleic acid molecules and proteins associated with breast or ovarian cancer. Compositions, kits, and methods for detecting, characterizing, preventing, and treating human breast or ovarian cancers are provided. | 01-07-2010 |
| 20100003691 | Genetic Markers Associated with Degenerative Disc Disease and Uses Thereof - The present invention relates to novel genetic markers associated with degenerative disc disease (DDD), risk of developing DDD and risk of DDD progression, and methods and materials for determining whether a human subject has DDD, is at risk of developing DDD or is at risk of DDD progression. | 01-07-2010 |
| 20100003686 | PROCESS FOR PRODUCING TETRACYCLINE INDUCIBLE GENE EXPRESSING CELL LINE AND CONDITIONAL GENE KNOCKOUT CELL LINE, AND USES THEREOF - It is intended to provide a method of screening a so-called Tc inducible gene expressing cell line, in which the expression of a gene of interest is regulated depending on the presence/absence of a Tc compound regardless of the type of cell, easily with high efficiency. A gene-of-interest expression vector for transfecting a gene of interest into the genome of a host cell and a TA expression vector that expresses a transactivator that is switched to be bound or not to be bound to a tet operator sequence depending on the presence or absence of tetracycline are prepared. The gene-of-interest expression vector is a vector with a bicistronic regulatory sequence arranged downstream of the tet operator sequence and promoter sequence and between a gene-of-interest coding sequence and a selection marker coding sequence. These vectors are transfected into a host cell, and cell lines in which the selection marker of the gene-of-interest expression vector is expressed are selected. Thus, inducible gene expressing cell lines can be obtained in which the expression of a gene of interest can be controlled with Tc. | 01-07-2010 |
| 20100143898 | USE OF PRODUCTS OF PCR AMPLIFICATION CARRYING ELEMENTS OF SECONDARY STRUCTURE TO IMPROVE PCR-BASED NUCLEIC ACID DETECTION - Particular aspects comprise amplifying target nucleic acid using PCR and an oligonucleotide primer pair wherein at least one of the primers is designed to incorporate a 5′-specialty sequence to provide for an amplification product that intramolecularly folds into a secondary structure; and detecting the amplification product by a method comprising: providing an oligonucleotide cleavage component, hybridizing said oligonucleotide cleavage component with the amplification product to form a three-strand cleavage structure wherein two strands of the three-strand cleavage structure are provided by the secondary structure of the amplification product, cleaving 3′- or 5′-strands of the three-strand cleavage structure using a duplex-specific nuclease activity resulting in a cleavage product, and detecting the cleavage product indicative of the presence of the target nucleic acid. In certain aspects both primers incorporate a 5′-specialty sequence and detecting comprises cleaving 3′- or 5′-strands of a three-strand cleavage structure using duplex-specific nuclease to provide a cleavage product. | 06-10-2010 |
| 20100035267 | Detection of Individual T-Cell Reaction Patterns Against Tumor-Associated Antigens (TAA) in Tumor Patients as a Basis for the Individual Therapeutic Vaccination of Patients - The present invention relates to a method for identifying the preferential target antigens of antitumoural T-cells of a tumour patient, comprising: a) providing T-cells from the blood of at least one tumour patient, b) providing dendritic cell (DCs) and/or B-lymphocytes (BLCs) that are autologous for said tumour patient, wherein said DCs and BLCs were transfected beforehand with a selection of mRNAs encoding for T-cell-immunogenic tumour-associated antigens (TAA), and express these, c) contacting said T-cells with the DCs and/or BLCs, d) identifying of those T-cells that recognize antigens of the DCs and/or BLCs, and e) identifying of the preferential target antigens of antitumoural T-cells of the at least one tumour patient on the basis of the T-cells that recognize antigens of the DCs and/or BLCs. The method can furthermore comprise the expansion of the T-cells that recognize the antigens of the DCs and/or BLCs. The present invention furthermore relates to a method for producing an individualized tumour vaccine or individualized tumour therapeutic, as well as corresponding methods for treating a tumourous disease using the individualised tumour vaccine or individualised tumour therapeutic. | 02-11-2010 |
| 20100261190 | Mammalian Genes; Related Reagents and Methods - Purified genes encoding proteins from a mammal, reagents related thereto including purified proteins, specific antibodies, and nucleic acids encoding these molecules are provided. Methods of using said reagents and diagnostic kits are also provided. | 10-14-2010 |
| 20100261189 | System and method for detection of HLA Variants - A method for detecting one or more HLA sequence types is described that comprises the steps of: amplifying a plurality of first amplicons from a double stranded nucleic acid sample, wherein the first amplicons are amplified with a plurality of pairs of nucleic acid primers that define exons 2 and 3 of both strands of HLA loci from the group consisting of HLA-A, HLA-B, and HLA-C; amplifying the first amplicons to produce a plurality of populations of second amplicons, wherein each population of second amplicons is clonally amplified from one of the first amplicons; sequencing the plurality of populations of second amplicons to generate a nucleic acid sequence composition for each of the plurality of second amplicons; and detecting variation in the sequence composition from one or more of the second amplicons for one or more of the HLA loci. | 10-14-2010 |
| 20100261187 | GENETIC POLYMORPHISMS ASSOCIATED WITH CARDIOVASCULAR DISORDERS AND DRUG RESPONSE, METHODS OF DETECTION AND USES THEREOF - The present invention is based on the discovery of genetic polymorphisms that are associated with cardiovascular disorders, particularly acute coronary events such as myocardial infarction and stroke, and genetic polymorphisms that are associated with responsiveness of an individual having a cardiovascular disorder to treatment of the disorder with statin. In particular, the present invention relates to nucleic acid molecules containing the polymorphisms, variant proteins encoded by such nucleic acid molecules, reagents for detecting the polymorphic nucleic acid molecules and proteins, and methods of using the nucleic acid and proteins as well as methods of using reagents for their detection. | 10-14-2010 |
| 20100261186 | POLYMORPHISM IDENTIFICATION METHOD - The present invention is to provide a method for identifying a polymorphism with high sensitivity and high accuracy. The method of the present invention includes: performing a nucleic acid chain extension reaction and identifying the polymorphism of the nucleic acid contained in a test nucleic acid sample. The extension reaction is conducted with use of: a nucleic acid in a test nucleic acid sample as a template, a type I detection primer which hybridizes with a region including the polymorphic site of a nucleic acid whose polymorphic site nucleotide sequence consists of a first nucleotide sequence, and a polymerase having no strand displacement activity. The reaction is conducted with the presence of an inhibitory oligonucleotide which contains a nucleotide sequence complementary to the sequence of a region including the polymorphic site of a nucleic acid whose polymorphic site nucleotide sequence consisting of a second nucleotide sequence. | 10-14-2010 |
| 20100261183 | METHOD OF DETERMINING RISK FOR CANCER - A method of determining risk of cancer in a mammal is provided. The method includes analyzing the genomic DNA of the mammal and determining genomic CNV frequency or genomic structural variation. An increase in either CNV frequency or genomic structural variation in comparison to a baseline mean value is indicative of cancer. | 10-14-2010 |
| 20100261182 | PPM1E PROTEINS AND NUCLEIC ACIDS AS TARGETS FOR NEURODEGENERATIVE DISEASES | 10-14-2010 |
| 20100261174 | Determination of 5-ASA efficacy in CRC prevention and/or treatment by gene expression analysis - A method is disclosed for the determination of 5-ASA efficacy in preventing and/or treating CRC in a mammalian, which comprises the analysis of the inhibition of the β-catenin pathway in presence of 5-ASA. More in details, the method comprises measuring the expression of at least one gene involved in the regulation of the β-catenin signalling pathway, such as μ-protocadherin, E-cadherin, β-catenin, Axin1, ICAT, p21 | 10-14-2010 |
| 20100261173 | Identification Of Fat And Lean Phenotypes In Chickens Using Molecular Markers - The present invention provides methods of screening chickens to determine those more likely to have a lean or fat phenotype. The invention also provides methods of screening chickens to identify a polymorphism associated with a fat or lean phenotype. | 10-14-2010 |
| 20100261172 | INTERFERON ALPHA-INDUCED PHARMACODYNAMIC MARKERS - The present invention encompasses type-I IFN and IFNα-induced PD marker expression profiles, kits, and methods for identifying such IFNα-induced PD marker expression profiles. The type-I IFN and IFNα-induced PD marker expression profiles may also be used in, for example, methods of treating patients having a type-I IFN or IFNα-mediated disorder, methods of monitoring disease progression of patients receiving treatment with a therapeutic agent that binds to and modulates IFNα activity, identifying patients as candidates to receive a therapeutic that binds to and neutralizes IFNα activity, and in diagnosing or providing a prognosis to patients having IFNα-induced disorders. | 10-14-2010 |
| 20100261166 | METHOD FOR SPECIFICALLY AND SENSITIVELY AMPLIFYING A TARGET SEQUENCE - The present invention aims to develop a method for amplifying only a target gene while reducing the noise from a non-target gene having a similar sequence, as well as to develop a new method of quantitation based on acquisition of the signal from the amplified sequence with high precision (in high sensitivity and specificity). | 10-14-2010 |
| 20100261164 | Diagnostic detection of nucleic acids - This invention provides sensitive nucleic acid hybridization assay methods for the detection of target animal nucleic acids in a biological sample, such as acellular fluids. The methods are particularly useful in early diagnosis of animal diseases, particularly chronic illnesses. | 10-14-2010 |
| 20100124752 | Non-Invasive Fetal Genetic Screening by Digital Analysis - The present methods are exemplified by a process in which maternal blood containing fetal DNA is diluted to a nominal value of approximately 0.5 genome equivalent of DNA per reaction sample. Digital PCR is then be used to detect aneuploidy, such as the trisomy that causes Down Syndrome. Since aneuploidies do not present a mutational change in sequence, and are merely a change in the number of chromosomes, it has not been possible to detect them in a fetus without resorting to invasive techniques such as amniocentesis or chorionic villi sampling. Digital amplification allows the detection of aneuploidy using massively parallel amplification and detection methods, examining, e.g., 10,000 genome equivalents. | 05-20-2010 |
| 20100015615 | Identification and Isolation of Adult Stem Cells and Related Methods of Use - Inhibitor of DNA Binding-1 (Id-1) is a marker protein found in stem cells, including adult stem cells, which can be used an indicator of the “stem-ness” of the cells. This allows Id1 expression to be used in a method for identifying cells as potential stem cells involving the step of screening the cells for expression of Id1; and a method for isolating cells as potential stem cells comprising the step of separating cells that express Id1 from cells that do not. Expression of GFAP can be used as a secondary screen to isolate rare B1 type adult neuronal stem cells. | 01-21-2010 |
| 20100062438 | NATURAL SELECTION AND CELLULAR IMMORTALITY - The invention provides new insights into the manner in which cells evolve and age thereby providing methods for assessing and studying those processes. | 03-11-2010 |
| 20110053149 | METHYLATION DETECTION IN THE GENOMIC REGION OF A RECEPTOR PROTEINTYROSINE PHOSPHATASE GAMMA GENE FOR DETECTION AND/OR DIAGNOSIS OF A TUMOUR - The invention discloses means and methods for detecting methylation of a CpG in a region of a receptor protein tyrosine phosphatase gamma gene in samples obtained from a relevant site of an individual. The means and methods can be used to determine whether the individual is suffering from a tumor. | 03-03-2011 |
| 20090258352 | Pin1 as a marker for abnormal cell growth - Methods for the use of Pin1 as a marker of abnormal cell growth are disclosed. In one embodiment, the method includes detecting a level of Pin1 to stage an abnormal cell growth, such as breast or prostate cancer. In another embodiment, the method includes evaluating the efficacy of a treatment of an abnormal cell growth, such as cancer, by monitoring the levels of Pin1. In another embodiment, the method includes evaluating the extent of metastasis of abnormal cell growth, such as cancer. The levels of Pin1 can be protein levels or nucleic acid levels. | 10-15-2009 |
| 20090311685 | NMU-GHSR1b/NTSR1 oncogenic signaling pathway as a therapeutic target for lung cancer - The present invention relates to a method of and a kit for assessing the prognosis of lung cancer by detecting the expression level of the neuromedin U (NMU) gene in a patient-derived biological sample. The method and kit are particularly preferred for assessing the prognosis of non-small cell lung cancer (NSCLC). Furthermore, the present invention relates to a method of screening for a therapeutic agent for cancer, in particular, lung cancer, by detecting compounds that inhibit the binding of the NMU protein with the heterodimer of growth hormone secretagogue receptor 1 | 12-17-2009 |
| 20090275045 | METHOD FOR DETECTING MAMMARY CANCER CELLS - The present invention provides a novel method for detecting mammary cancer cells which uses, as an index, an expression level of a specific gene in human mammary cancer tissue (or cells). The method is characterized by including (1) measuring an expression level of a gene having a specific nucleotide sequence in human mammary cancer tissue (or cells), (2) measuring an expression level of the gene in human normal mammary gland tissue (or cells), and (3) detecting mammary cancer cells on the basis of the difference between measurement values obtained in (1) and (2). | 11-05-2009 |
| 20090275044 | METHOD FOR DETECTING HUMAN PAPILLOMAVIRUS mRNA - An in vitro method is provided for screening human female subjects to assess their risk of developing cervical carcinoma which comprises screening the subject for expression of mRNA transcripts from the E6 and optionally the L1 gene of human papillomavirus, wherein subjects positive for expression of L1 and/or E6 mRNA are scored as being at risk of developing cervical carcinoma. Kits for carrying out such methods are also provided. | 11-05-2009 |
| 20090275041 | NUCLEIC ACID AND CORRESPONDING PROTEIN ENTITLED 193P1E1B USEFUL IN TREATMENT AND DETECTION OF CANCER - A novel gene 0193P1E1B (also designated 193P1E1B) and its encoded protein, and variants thereof, are described wherein 193P1E1B exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, 193P1E1B provides a diagnostic, prognostic, prophylactic and/or therapeutic target for cancer. The 193P1E1B gene or fragment thereof, or its encoded protein, or variants thereof, or a fragment thereof, can be used to elicit a humoral or cellular immune response; antibodies or T cells reactive with 193P1E1B can be used in active or passive immunization. | 11-05-2009 |
| 20090275040 | DETECTING BCL-B EXPRESSION IN CANCER AND USES THEREOF - Provided herein are compositions and methods of detecting Bcl-B expression in cancer cells to prognose, monitor, or select therapies for cancers such as breast cancer, prostate cancer, lung cancer, or gastric cancer. | 11-05-2009 |
| 20090275037 | FLUORESCENT DOUBLE STRANDED DNA BINDING DYES - The present invention is directed to a fluorescent dye comprising a benzothiazolium moiety and a pyrimidinium moiety connected by a mono-methine bridge, characterized in that (i) the 2-position of the pyrimidine carries a substituent which starts with a C-atom and (ii) the 5- and 6-positions of the pyrimidine ring are an integral part of a further aromatic ring structure. | 11-05-2009 |
| 20090275035 | PRIMERS FOR HUMAN MITOCHONDRIAL HYPERVARIABLE REGION AND METHOD FOR DETECTING HUMAN DNA BY USING THE PRIMERS - The present invention relates to primer pairs for human mitochondrial hypervariable region and a method for detecting human DNA by using the primer pairs. | 11-05-2009 |
| 20090275036 | SYSTEMS AND METHODS FOR REAL TIME SINGLE MOLECULE SEQUENCE DETERMINATION - A sequencing methodology is disclosed that allows a single DNA or RNA molecule or portion thereof to be sequenced directly and in substantially real time. The methodology involves engineering a polymerase and/or dNTPs with atomic and/or molecular tags that have a detectable property that is monitored by a detection system. | 11-05-2009 |
| 20090275033 | Uses of BNIPXL-Beta in premature canities - The present invention concerns the use of a polypeptide comprising a sequence having at least 90% identity with all or part of BNIPXLβ, for cosmetic or therapeutic applications, in the treatment or prevention of premature canities in humans, said portion comprising at least 30 amino acids, as well as the use, for the same purpose, of a molecule comprising a RNAi sequence having at least 90% identity with all or part of the cDNA sequence of BNIPXLβ, said part comprising at least 18 nucleotides. | 11-05-2009 |
| 20090275032 | Reprogramming a cell by inducing a pluripotent gene through use of an HDAC modulator - The invention relate to methods, compositions, and kits for reprogramming a cell. In one embodiment, the invention relates to a method comprising inducing the expression of at least one gene that contributes to a cell being pluripotent or multipotent. In yet another embodiment, the method comprises inhibiting the activity of an HDAC with an HDAC inhibitor and inducing the expression of at least one gene that contributes to a cell being pluripotent or multipotent. In still another embodiment, the invention relates to a method for reprogramming comprising exposing a cell to more than one agent to inhibit more than ore type of regulatory protein. In yet another embodiment, the invention relates to a reprogrammed cell or an enriched population of reprogrammed cells that can have characteristics of an ES-like cell, which can be re- or trans-differentiated into various differentiated cell types | 11-05-2009 |
| 20090275031 | Biomolecular nano device - Methods for measuring environmental parameters using chemical recording are provided. In some embodiments, the methods include generating a polymer comprising an ordered series of chemical units, wherein the position and number of each chemical unit in the polymer is indicative of a reading of the environmental state variable at a given point in time. The presently disclosed subject matter also provides compositions that can be employed in and/or that employ the disclosed methods for recording environmental state variables. | 11-05-2009 |
| 20090275030 | CELL CALCIFICATION SUPPRESSING PROTEINS, AND GENES OF THE PROTEINS - This invention provides cell-calcification inhibitory proteins as well as genes encoding the proteins. Based on the discovery of a novel isoform gene of the c-erg gene (herein referred to as “C-11 gene”) which is an erg gene derived from chickens, the nucleotide sequence of the gene has been determined, and then the expression of a protein encoded by such gene (herein referred to as “C-11 protein”) has been confirmed. Further, it has been discovered that when the c-erg or C-11 gene is introduced into osteoblasts, the calcification of the cells is inhibited. | 11-05-2009 |
| 20090275028 | METHOD OF DETECTING TARGET NUCLEIC ACID - The present invention provides a method of detecting a target nucleic acid which includes a step of examining whether a washing step has been normally conducted. In an aspect of the invention, a monitoring nucleic acid probe to monitor the washing level is used. The probe shows a change in signal intensity by washing at a washing temperature changed in the optimum temperature range for washing the target nucleic acid and in a temperature range in the vicinity of the optimum temperature range for washing. | 11-05-2009 |
| 20090275027 | Medium scale intergration of molecular logic gates in an automaton - Compositions and methods for optically detecting the presence of a plurality of oligonucleotides in a sample, wherein each oligonucleotide to be detected comprises consecutive nucleotides having a sequence different than the remaining oligonucleotides of the plurality are provided. | 11-05-2009 |
| 20090275019 | Pancreatic Cancer Genes - The present invention provides the art with the DNA coding sequences of polynucleotides that are up-or-down-regulated in cancer and dysplasia. These polynucleotides and encoded proteins or polypeptides can be used in the diagnosis or identification of cancer and dysplasia. Inhibitors of the up-regulated polynucleotides and proteins can decrease the abnormality of cancer and dysplasia. Enhancing the expression of down-regulated polynucleotides or introducing down-regulated proteins to cells can decrease the growth and/or abnormal characteristics of cancer and dysplasia. | 11-05-2009 |
| 20090275024 | Novel centrerosome-associated protein and applications thereof - A method for diagnosing a genetic disease associated with disturbances in mitotic spindle organization or with cell division anomalies or both, which comprises demonstrating a functional alteration of the gene encoding an ASAP protein comprising at least the following steps of: obtaining DNA containing the gene encoding the ASAP protein from a biological sample; bringing said DNA into contact with a probe, and under conditions for hybridization between the DNA and the probe; and detecting the hybrid formed; and wherein the ASAP protein is selected from the group consisting of a human protein having sequence SEQ ID NO:1 and proteins having a sequence exhibiting at least 80% identity or at least 90% similarity with entire SEQ ID NO. 1. | 11-05-2009 |
| 20090275018 | Detection of hepatotoxic cyanobacteria - The present invention relates to methods and kits for the detection of toxic cyanobacteria, in particular of hepatotoxin-producing cyanobacteria. | 11-05-2009 |
| 20100009373 | METHODS AND COMPOSITIONS RELATING TO MULTIPLEX GENOMIC GAIN AND LOSS ASSAYS - Compositions and methods are provided for detecting genomic DNA gain and loss. Embodiments of inventive compositions and methods include composite nucleic acid probes which specifically hybridize to two or more genomic loci in a genomic region of a reference genome for detection of genomic gain and/or loss in a subject genome. In some embodiments, a substrate-attached composite nucleic acid probe is provided which includes a mixture of separate populations of beads having attached DNA probes wherein all of the beads are identically encoded and wherein each individual bead has exclusively DNA derived from one source, such as a particular large insert vector containing chromosomal DNA, or amplicons generated by amplification of DNA derived from a large insert vector containing chromosomal DNA. | 01-14-2010 |
| 20100009372 | METHOD FOR ESTIMATING TARGET NUCLEIC ACID RATIO - The present invention provides a method for estimating a ratio between the amount of target nucleic acid and the amount of reference nucleic acid in the examined nucleic acid samples from the PCR reaction solutions at the endpoint. | 01-14-2010 |
| 20100009375 | Silica Magnetic Particles with a High Nucleic Acid Binding Capacity - Magnetic particles for nucleic acid isolation are coated with silica and separated from impurities and nanoparticulates using a multi-step fractionation process. In each cycle of the fractionation process, the particles are stirred, sedimented, and resuspended, resulting in a decline in pH of the suspended particles. Repeating the fractionation process until the resuspended particles have dropped to a target pH in the range of about 9 to 10.5, and their zeta potential is more negative than about −40 mV, results in a purified population of particles with a high and reproducible binding capacity for nucleic acids. The silica-treated magnetic beads produced by the method offer improved sensitivity and consistency for recovery of nucleic acids in a sample. | 01-14-2010 |
| 20100009371 | SELECTION OF MARKERS - Methods of selecting a portfolio of markers for use in a diagnostic applications include defining diagnostic parameters, establishing a relationship among the parameters so that they are optimized, and selecting an optimal group of markers for the diagnostic application. The diagnostic parameters can include a measure of the relative degree of expression of a gene, a measure of the variation in the measurement of the degree of expression of the gene, and the relationship between the diagnostic and discriminating parameters can be a mean variance relationship. | 01-14-2010 |
| 20100009374 | SIRE EARLY SELECTION FOR MALE FERTILITY USING SINGLE NUCLEOTIDE POLYMORPHISMS (SNPS) OF THE DAZL GENE - Methods and materials for identifying bovine males which will produce semen which will exhibit a higher rate of successfully impregnation by either artificial insemination or natural mating. The method employs SNPs that have been identified in the bDAZL gene which are associated with enhanced (or decreased) male fertility in bovine males and haplotypes formed from such SNPs. The method herein can be used to identify male dairy or beef cattle. The method herein can be applied to bovine animals at an appropriate time and particularly at birth or in utero. The invention further provides kits for conduction assays to assess bovine male fertility/infertility. The invention additionally provides a method of breeding cattle employing the methods and materials herein. | 01-14-2010 |
| 20100009364 | Methods for diagnosis, prognosis and methods of treatment - The present invention provides an approach for the determination of the activation states of a plurality of proteins in single cells. This approach permits the rapid detection of heterogeneity in a complex cell population based on activation states, expression markers and other criteria, and the identification of cellular subsets that exhibit correlated changes in activation within the cell population. Moreover, this approach allows the correlation of cellular activities or properties. In addition, the use of modulators of cellular activation allows for characterization of pathways and cell populations. Several exemplary diseases that can be analyzed using the invention include AML, MDS, and MPN. | 01-14-2010 |
| 20100009368 | METHODS AND COMPOSITIONS FOR THE ASSESSMENT OF CARDIOVASCULAR FUNCTION AND DISORDERS - The present invention provides methods for the assessment of risk of developing acute coronary syndrome (ACS), arterial inflammation, or ACS-associated impaired vascular function, in smokers and non-smokers using analysis of genetic polymorphisms. The present invention also relates to the use of genetic polymorphisms in assessing a subject's risk of developing ACS, arterial inflammation, or ACS-associated impaired vascular function. Nucleotide probes and primers, kits, and microarrays suitable for such assessment are also provided. | 01-14-2010 |
| 20100009366 | POLYMORPHISMS IN THE HUMAN GENES FOR OCT1 AND THEIR USE IN DIAGNOSTIC AND THERAPEUTIC APPLICATIONS - The present invention relates to a polymorphic OCT1 polynucleotide. Moreover, the invention relates to genes or vectors comprising the polynucleotides of the invention and to a host cell genetically engineered with the polynucleotide or gene of the invention. Further, the invention relates to methods for producing molecular variant polypeptides or fragments thereof, methods for producing cells capable of expressing a molecular variant polypeptide and to a polypeptide or fragment thereof encoded by the polynucleotide or the gene of the invention or which is obtainable by the method or from the cells produced by the method of the invention. Furthermore, the invention relates to an antibody which binds specifically the polypeptide of the invention. Moreover, the invention relates to a transgenic non-human animal. The invention also relates to a solid support comprising one or a plurality of the above mentioned polynucleotides, genes, vectors, polypeptides, antibodies or host cells. Furthermore, methods of identifying a polymorphism, identifying and obtaining a pro-drug or drug or an inhibitor are also encompassed by the present invention. In addition, the invention relates to methods for producing of a pharmaceutical composition and to methods of diagnosing a disease. Further, the invention relates to a method of detection of the polynucleotide of the invention. Furthermore, comprised by the present invention are a diagnostic and a pharmaceutical composition. Even more, the invention relates to uses of the polynucleotides, genes, vectors, polypeptides or antibodies of the invention. Finally, the invention relates to a diagnostic kit. | 01-14-2010 |
| 20100009357 | PREDICTION OF LUNG CANCER TUMOR RECURRENCE - The invention provides methods of estimating the likelihood of lung cancer recurrence in a subject, including those afflicted with NSCLC. The methods of the invention are useful for developing a therapeutic treatment plan to prevent cancer recurrence for subjects deemed to be at high risk, and withholding treatments from those subjects deemed to be at low risk. The invention also provides methods of generating and using metagene-based prediction tree models for estimating the likelihood of lung cancer recurrence. The invention also provides reagents, such as DNA microarrays, software and computer systems useful for estimating cancer recurrence, and provides methods of conducting a diagnostic business for the prediction of cancer recurrence. | 01-14-2010 |
| 20100009358 | Compositions, kits, and methods for identification, assessment, prevention, and therapy of breast cancer - The invention relates to compositions, kits, and methods for detecting, characterizing, preventing, and treating human breast cancers. A variety of newly identified markers are provided, wherein changes in the levels of expression of one or more of the markers is correlated with the presence of breast cancer. | 01-14-2010 |
| 20100009356 | DIAGNOSIS OF CARDIOVASCULAR DISEASE - This invention relates to methods for the detection of cardiovascular disease, e.g., acute coronary syndrome, heart failure and/or pulmonary embolism, in high body mass index (BMI) individuals, e.g., with a BMI of 25-29, or 30 or above, and those with impaired renal function. | 01-14-2010 |
| 20100009350 | METHOD FOR QUANTITATIVE ANALYSIS OF TRANSCRIPTS WITH NUCLEOTIDE POLYMORPHISM AT SPECIFIC SITE - The present invention provides a quantitative method for assaying the expression ratio between alleles differed by a single nucleotide polymorphism. | 01-14-2010 |
| 20100009347 | Kit and method for detecting urothelial cancer - This invention relates to a method for detecting in vitro a urothelial cancer, comprising measuring CXCL1 protein, or expression of a gene encoding the protein, in a biological sample from a subject, and to a kit for diagnosing a urothelial cancer comprising an antibody or nucleic acid probe, which is capable of binding specifically to the CXCL1 protein or a gene encoding the protein, respectively. | 01-14-2010 |
| 20100009349 | Method for Treating a Biological Sample - The invention relates to a method for treating a biological sample, comprising the following method steps: i) preparation of a biological sample and ii) bringing the biological sample into contact with a composition, comprising: (1) 1 to 100 wt. % of at least one polyol and (2) 0 to 99 wt. % of at least one additive, wherein the total amount of components (1) and (2) is 100 wt. %. The invention further relates to biological samples obtained by said method, a method for analysis of a treated biological sample, devices for treating a biological sample, use of said devices, various kits and use of a composition. | 01-14-2010 |
| 20100009348 | Methods and Constructs for Analyzing Biological Activities of Biological Specimens and Determining States of Organism - This application provides methods of determining biological activities of a biological sample comprising, for example, comparing the profile of transcription factor activities in a cell contacted with the biological sample to a control profile, such as a profile of transcription factor activities in a cell not contacted with the biological sample. | 01-14-2010 |
| 20090311693 | METHOD FOR THE IN VITRO SCREENING OF ANTI-CANCER COMPOUNDS THAT INHIBITS SK3 ACTIVITY, AND SAID ANTI-CANCER COMPOUNDS - The present invention relates to methods for the in vitro screening of an anti-metastatic compound that inhibits activity, methods for determining in vitro the presence or absence of a metastatic cancer in a subject by quantifying SK3 activity, methods for the in vitro assessment of the progression of the metastatic property of a cancer by quantifying SK3. | 12-17-2009 |
| 20100041038 | METHOD FOR DISCRIMINATING SINGLE NUCLEOTIDE POLYMORPHISMS - A method for discriminating single nucleotide polymorphisms (SNPs) offers improved sensitivity and specificity. A test kit is also provided. The method may be for genotyping in typing assays applied to a biological sample. The method may include steps of performing a real-time amplification of the target, generating multiple copies of amplicons, in presence of at least two different labeled probes, each probe allowing real-time detection at the SNP position of both the wildtype and at least one possible mutation, assessing the discriminatory variable value(s) based on the signals of each combination of two detection probes, and discriminating between the genotypes. The methods may be for diagnostic, preventive and therapeutic applications. | 02-18-2010 |
| 20100041037 | GENETIC VARIANTS CONTRIBUTING TO RISK OF PROSTATE CANCER - The present invention is characterised by certain genetic variants being susceptibility variants for prostate cancer. The invention relates to methods of determining increased susceptibility to prostate cancer, as well as methods of determining decreased susceptibility to prostate cancer, using such variants. The invention further relates to kits for determining a susceptibility to prostate cancer. | 02-18-2010 |
| 20100041034 | METHOD FOR MANIPULATING SAMPLES WITH MAGNETIC NUCLEATION NANOPARTICLES - A method for manipulating a sample by utilizing a nucleic acid binding substance which has affinity for nucleic acid polymers. The nucleic acid binding substance is comprised of a nucleic acid binding element capable of specific binding to nucleic acid molecules and connected to a nucleation nanoparticle having paramagnetic properties. | 02-18-2010 |
| 20100041029 | SYNTHESIS OF FOUR COLOR 3'O-ALLYL, MODIFIED PHOTOCLEAVABLE FLUORESCENT NUCLEOTIDES AND RELATED METHODS - This invention provides a process for making 3′-O-allyl-dGTP-PC-Biodopy-FL-510, 3′-O-allyl-dATP-PC-ROX, 3′-O-allyl-dCTP-PC- and 3′-O-allyl-dUTP-PC-R6G, and related methods. | 02-18-2010 |
| 20100041027 | METHODS OF ASSESSING CORONARY ARTERY DISEASE - An association between the Ala allele of the P12A variant of the human PPARγ gene and development of CAD, particularly premature CAD, in individuals, and specifically in women, particularly Caucasian women, is described, as are methods of assessing or predicting the likelihood or risk that an individual, such as a woman, will develop premature CAD. Single nucleotide polymorphisms in the human resistin gene, human resistin gene variants, gender-related increase in premature coronary artery disease, methods of assessing or aiding in assessing the risk that an individual will develop premature CAD, and methods of predicting the likelihood or aiding in predicting the likelihood that an individual will develop premature CAD are described. | 02-18-2010 |
| 20100041023 | Inactivated FCV vaccines - The present invention relates to improved inactivated feline calicivirus (FCV) vaccines. The invention also provides a process for producing stabilized inactivated FCV, and the use of such stabilized inactivated FCV, in the production of FCV immunogenic compositions. The invention further provides methods of inducing an immune response in an animal of the Felidae family, preferably a cat, using the immunogenic compositions according to the invention. | 02-18-2010 |
| 20090325153 | ANALYSIS OF HETEROGENEOUS NUCLEIC ACID SAMPLES - Methods for capturing and characterizing low frequency nucleic acid molecules indicative of diseases such as cancer (e.g. adenomas or early stage cancers) are provided. In some aspects, a low complexity capture technique is combined with a high complexity analytical technique. In some aspects, samples may be analyzed using a digital analysis and/or a single molecule sequencing technique. | 12-31-2009 |
| 20100267041 | SERIAL ANALYSIS OF BIOMARKERS FOR DISEASE DIAGNOSIS - The present invention generally relates to serial analysis of biomarkers for disease diagnosis. In certain embodiments, the invention provides methods for diagnosing a disease including obtaining a sample from a subject, conducting a first assay to determine whether a first biomarker in the sample is positive or negative for a disease, and conducting a second assay to determine whether a second biomarker in the sample is positive or negative for the disease if the first assay produced a negative result. | 10-21-2010 |
| 20100143903 | Methods of Detecting and Monitoring Cancer Using 3D Analysis of Centromeres - The present application relates to a method of detecting and monitoring cancer or precancer in a cell using three-dimensional analysis to assess centromere organization. In addition, the application relates to a method and system for characterizing the 3D organization of centromeres. | 06-10-2010 |
| 20090246762 | NUCLEIC ACID TERMINATORS INCORPORATING A CATIONIC MOIETY AND METHODS FOR THEIR USE - Disclosed are methods and kits applicable to sequencing methods, such as Sanger dideoxy sequencing methods. The methods and kits disclosed utilize a cationically charged nucleic acid terminator in combination with a discriminatory polymerase. | 10-01-2009 |
| 20110159482 | METHOD FOR DETECTING MULTIPLE SMALL NUCLEIC ACIDS - The present invention discloses a method for simultaneously detecting multiple small nucleic acids, which comprises steps: mixing a specimen, fluorescent probes, and bridge nucleic acids having different lengths to form a tested liquid; hybridizing the mixed short nucleic acid molecules, probes and bridge nucleic acids; adding ligases to enable the ligations of the short nucleic acid molecules and the fluorescent probes with the bridge nucleic acids being the templates; injecting the tested liquid into a capillary, and applying a voltage to the capillary to generate an electrophoresis effect and separate the hybridization products; and using laser to induce different fluorescent rays from different reaction products, and measuring the fluorescent rays, whereby the present invention can simultaneously detect multiple types of short nucleic acid molecules in a single capillary. | 06-30-2011 |
| 20110159483 | CYANINE COMPOUNDS, COMPOSITIONS INCLUDING THESE COMPOUNDS AND THEIR USE IN CELL ANALYSIS - A compound having the general formula I or a conjugate thereof, wherein various groups are as defined in the specification. A composition includes: (i) a compound having the general formula I or a conjugate thereof; and (ii) at least one surfactant selected from cationic surfactants and nonionic surfactants. Also disclosed is a preparation method for the composition and a kit comprising the composition. Further disclosed is a method for identifying and differentiating erythroblasts, basophils and lymphocytes simultaneously using the composition according to the present disclosure. | 06-30-2011 |
| 20110159481 | Solid-phase chelators and electronic biosensors - Methods for sequencing nucleic acids are presented. Sequencing is accomplished through the chemical amplification of the products of DNA synthesis and the detection of the chemically amplified products. In embodiments of the invention, a substrate is provided having a plurality of molecules of DNA to be sequenced attached and a plurality of molecules capable of chelating pyrophosphate ions attached, the DNA molecules to be sequenced are primed, and a next complementary nucleotide is incorporated and excised a plurality of times leading to the buildup of pyrophosphate ions locally around the DNA molecule to be sequenced. Pyrophosphate ions are captured by the substrate-attached chelators and electronically detected to determine the identity of the next complementary nucleic acid in the DNA molecule to be sequenced. Additionally, devices and methods are provided for detecting biomolecules through the detection of pyrophosphate ions. | 06-30-2011 |
| 20110159478 | METHOD FOR SCREENING DRUG CANDIDATES BY USING DOMAIN PROTEIN - The present invention relates to a method for screening and discovering bioactive materials using specifically selected protein domains interacting with specific intracellular proteins, and more particularly, to (1) a screening method including confirmation of changes in biological activities by introducing a specific protein domain into microorganisms or animal and plant cells and (2) a screening method including confirmation of changes in biological activities after introducing the specific protein domains into a number of microorganisms or animal and plant cells. Via this method, according to the present invention, it is possible that the selected protein domains can be used to develop novel antibiotic agents with antimicrobial activity effective on bacteria resistant to conventional antibiotics while requiring less genetic information compared with a conventional drug which targets specific genes. | 06-30-2011 |
| 20100105028 | PROBE FOR DETECTING NUCLEIC ACIDS - The invention relates to a probe for detecting nucleic acids, to a method for producing the probe, methods for carrying out analytical reactions and test kits containing the reagents that are required for carrying out the probe-based analytical reaction. | 04-29-2010 |
| 20100330581 | METHOD FOR IN VITRO DIAGNOSIS OR PROGNOSIS OF TESTICULAR CANCER - The invention relates to a method for in vitro diagnosis or prognosis of testicular cancer which comprises a step of detecting the presence or absence of at least one expression product from at least one nucleic acid sequence selected from the sequences identified in SEQ ID NOS: 1 to 6 or from the sequences which exhibit at least 99% identity with one of the sequences identified in SEQ ID NOS: 1 to 6, to isolated nucleic acid sequences and to the use thereof as a testicular cancer marker. | 12-30-2010 |
| 20100330573 | OPTIMIZED OLIGONUCLEOTIDES AND METHODS OF USING SAME FOR THE DETECTION, ISOLATION, QUANTIFICATION, MONITORING AND SEQUENCING OF BORDETELLA - Described herein are oligonucleotides useful for detecting, isolating, quantitating, monitoring and sequencing | 12-30-2010 |
| 20100330568 | ASSAY AND METHOD FOR THE ASSESSMENT OF RESPONDERS AND NON-RESPONDERS TO NK CELL MODULATION BY IMMUNOGLOBULIN THERAPY - A method of determining a patient's susceptibility for NK cell modulation by immunoglobulins in response to a treatment of a disease or prophylaxis of a disease with immunoglobulins wherein a modulation of natural killer cells caused by said immunoglobulins is determined. | 12-30-2010 |
| 20100330567 | DNA MARKERS FOR MANAGEMENT OF CANCER - A method is provided for assessing allelic losses and hypermethylation of genes in CpG tumor promotor region on specific chromosomal regions in cancer patients, including melanoma, neuroblastoma breast, colorectal, and prostate cancer patients. The method relies on the evidence that free DNA and hypermethylation of genes in CpG tumor promotor region may be identified in the bone marrow, serum, plasma, and tumor tissue samples of cancer patients. Methods of melanoma, neuroblastoma, colorectal cancer, breast cancer and prostate cancer detection, staging, and prognosis are also provided. | 12-30-2010 |
| 20100330562 | Unique Calibrator Polynucleotides and Methods of Using in Quantitative Nucleic Acid Assays - Disclosed herein are are polynucleotides which may be used to calibrate or standardize quantitative nucleic acid assays. As disclosed, the polynucleotides comprise a sequence derived from a plant viroid polynucleotide or a bacterial or chloroplast Type II intron polynucleotide. Also disclosed are methods of making and using the polynucleotides. | 12-30-2010 |
| 20100143932 | SINGLE MOLECULE SEQUENCING OF CAPTURED NUCLEIC ACIDS - The invention provides methods and devices for detecting, enumerating or identifying target nucleic acid molecules using immobilized capture probes and single molecule sequencing techniques. | 06-10-2010 |
| 20090269772 | SYSTEMS AND METHODS FOR IDENTIFYING COMBINATIONS OF COMPOUNDS OF THERAPEUTIC INTEREST - Systems, methods, and apparatus for searching for a combination of compounds of therapeutic interest are provided. Cell-based assays are performed, each cell-based assay exposing a different sample of cells to a different compound in a plurality of compounds. From the cell-based assays, a subset of the tested compounds is selected. For each respective compound in the subset, a molecular abundance profile from cells exposed to the respective compound is measured. Targets of transcription factors and post-translational modulators of transcription factor activity are inferred from the molecular abundance profile data using information theoretic measures. This data is used to construct an interaction network. Variances in edges in the interaction network are used to determine the drug activity profile of compounds in the subset of compounds. The drug activity profiles are used to form a filter set of compound combinations from the subset of compounds. | 10-29-2009 |
| 20090269771 | METHOD OF SEQUENCING AND MAPPING TARGET NUCLEIC ACIDS - The present teachings pertain to methods, compositions, reaction mixtures, and kits for mapping a low complexity sequence to a locus in a genome. In some embodiments, the low complexity sequence can be used to determine the methylation profile of a target nucleic acid. A strand-replacing reaction results in a product containing a first strand and a second strand, which can be connected together with a stem-loop adapter to form a single strand. A sequencing reaction can compare the two strands of the product, allowing the experimentalist to both map the sequence to a locus in a reference genome, as well as ascertain the methylation profile of the original target nucleic acid. | 10-29-2009 |
| 20090269770 | METHODS FOR EVALUATION PROGNOSIS AND FOLLOW-UP OF DRUG TREATMENT OF PSYCHIATRIC DISEASES OR DISORDERS - The present invention provides methods for evaluating the pharmacological efficacy of drugs or drug candidates in treatment of psychiatric diseases or disorders, particularly schizophrenia, and for predicting the efficacy of drugs or drug combinations indicated for treatment of both positive and negative symptoms of psychiatric diseases or disorders in an individual having such a disease or disorder. In both methods, the drugs or drug candidates evaluated are assessed for their ability to produce certain changes in the expression of specific genes in peripheral mononuclear cells in blood of psychiatric patients, which are similar to the changes obtained following treatments with reference drugs or drug combinations effective against both positive and negative symptoms of psychiatric diseases or disorders. | 10-29-2009 |
| 20090269769 | Drug Discovery Methods Involving A Preclinical, In Vitro Isolated Gastrointestinal Epithelial Stem Cell-Like Progenitor Cell System - The described invention relate to systems comprising isolated human gastrointestinal segment-specific epithelial stem cell-like progenitor cells and uses thereof in drug discovery. | 10-29-2009 |
| 20090269768 | DETECTION OF HIGH GRADE DYSPLASIA IN CERVICAL CELLS - Methods of using probes and probe sets for the detection of high grade dysplasia and carcinoma in cervical cells are described. Methods of the invention include hybridizing one or more chromosomal probes to a biological sample obtained from a subject and detecting the hybridization pattern of the chromosomal probes to the sample to determine whether the subject has high grade dysplasia or carcinoma. Methods of the invention also include preliminary screening the cells for a marker associated with a risk for cancer, and preferably involves screening for HPV infected cells by in situ hybridization using an HPV probe mixture. | 10-29-2009 |
| 20090269752 | METHOD FOR SELECTING NUCLEIC ACIDS THAT BOND WITH HIGH-AFFINITY TO A TARGET - The invention relates to a method for selecting nucleic acids that bond with high affinity to a target molecule from a mixture of nucleic acids, comprising the following steps: a) loading a column with the target molecules whereby the target molecules are immobilized in said column, b) feeding the mixture of nucleic acids into a first end of the column, to create a defined volumetric flow of medium through the column, running from the first end to the second end of said column, c) immobilizing the nucleic acids to the target molecule wherein an affinity of the nucleic acids to the target molecule decreases as the distance from the first end of the column increases, d) stopping the volumetric flow of medium through the column after a defined period of time, e) cutting the column into column segments, and allocating a routing co-ordinate to each segment, and f) identifying and collecting nucleic acids that bond with a high affinity to the target molecule by desorbing the immobilized nucleic acids from at least one segment in a non-specific manner and extracting the nucleic acids, wherein the routing co-ordinate allocated a segment in step e) is allocated to the nucleic acids desorbed from that segment. | 10-29-2009 |
| 20090269759 | UNNATURAL POLYMERASE SUBSTRATES THAT CAN SUSTAIN ENZYMATIC SYNTHESIS OF DOUBLE STRANDED NUCLEIC ACIDS FROM A NUCLEIC ACID TEMPLATE AND METHODS OF USE - Nucleotide analogs that can sustain the enzymatic synthesis of double-stranded nucleic acid from a nucleic template are described. The nucleotide analogs include: (i) a base selected from the group consisting of adenine, guanine, cytosine, thymine, uracil and their analogs; (ii) a label attached to the base or analog of the base via a cleavable linker; (iii) a deoxyribose; and (iv) one or more phosphate groups. The linker and/or the label inhibits template directed polymerase incorporation of a further nucleotide substrate onto an extended primer strand. In addition, cleavage of the linker leaves a residue attached to the base which is not present in the natural nucleotide and which does not inhibit extension of the primer strand. The nucleotide analogs can therefore be used as reversible terminators in sequencing by synthesis methods without blocking the 3′ hydroxyl group. Methods of sequencing DNA using the substrates are also described. | 10-29-2009 |
| 20090269758 | Diagnostic methods and kits for functional disorders - The present invention relates to methods for the diagnosis of functional disorders in humans. A method of the invention, in certain embodiments, comprises the detection of one or more polymorphisms in mitochondrial DNA of a human. The current invention further provides kits for use in a method of the invention. | 10-29-2009 |
| 20090269757 | DIAGNOSIS KITS AND METHOD FOR DETECTING CANCER USING POLYMORPHIC MINISATELLITE - The present invention relates to a kit and a method for diagnosing cancer using polymorphic minisatellites (MS), more specifically, relates to a primer set for detecting polymorphic minisatellites MUC2-MS6 or MUC2-MS7 in the MUC2 gene, a DNA typing kit comprising said primer set, and a kit and a method for diagnosing cancer using a primer set for detecting polymorphic minisatellites MUC2-MS6, MUC2-MS7 or hTERT-VNTR 2-2. According to the present invention, DNA typing of MUC2-MS6 and MUC2-MS7 can effectively achieve the parentage identification, kinship identification or medicolegal examination, because the polymorphic minisatellites MUC2-MS6 and MUC2-MS7 are inherited through meiosis according to Mendelian genetics. In addition, the polymorphic minisatellites MUC2-MS6, MUC2-MS7 and hTERT-VNTR 2-2 can be used to predict and diagnose various cancers; such as gastric cancer, colon cancer, rectal cancer and prostate cancer etc. | 10-29-2009 |
| 20090269755 | MEANS AND METHOD FOR INDUCING EXON-SKIPPING - In the present invention means and method are provided for optimising exon-skipping using exon-internal AON. We show that skipping efficiencies are improved by targeting putative splicing regulatory sequences (ESEs) within an exon. Such double targeting may be particularly useful for exons with which efficient skipping was difficult to obtain prior to the invention. | 10-29-2009 |
| 20090269745 | RNA EXTRACTION METHOD AND RNA DETECTION METHOD - The present invention provides a method for inactivating RNase which generally presents in a sample such as biological sample (especially an excrement sample), or in a sample such as a living body-derived sample (especially an excrement-derived sample) obtained by separation of an RNA-including body therefrom or the like; a method for extracting and detecting RNA from the sample. An RNA extraction method, comprising the steps of: obtaining a mixture under a heating condition, said mixture comprising: a sample comprising an RNA-including body and RNase, and an alkaline treating reagent comprising at least a reducing agent, and having pH of 8.1 or higher, and conducting inactivation of the RNase and extraction of RNA from the RNA-including body by keeping the mixture under the heating condition. An RNA detection method, comprising conducting RNA amplification reaction by mixing a treated sample liquid comprising RNA extracted by the extraction method and an amplification reaction solution. | 10-29-2009 |
| 20090269750 | MARKER AND METHOD FOR CANCER DIAGNOSIS - The present invention relates to a diagnostic cancer marker using variation of a granulocyte colony stimulating factor (G-CSF) gene and a method for preparing the same, and more specifically, relates to a method for diagnosing cancer and/or assessing the state of cancer progression using an oligonucleotide having the 3′-terminal end of exon 2 region linked to the 5′-terminal end of exon 4 region of a G-CSF gene as a diagnostic cancer marker. According to the present invention, cancer can be quickly and exactly diagnosed using variation in a G-CSF gene expression. | 10-29-2009 |
| 20090269749 | METHOD FOR HIGH-THROUGHPUT AFLP-BASED POLYMORPHISM DETECTION - The invention relates to a method for the high throughput discovery, detection and genotyping of one or more genetic markers in one or more samples, comprising the steps of restriction endonuclease digest of DNA, adaptor-ligation, optional pre-amplification, selective amplification, pooling of the amplified products, sequencing the libraries with sufficient redundancy, clustering followed by identification of the genetic markers within the library and/or between libraries and determination of (co-) dominant genotypes of the genetic markers. | 10-29-2009 |
| 20090269748 | IDENTIFICATION OF SUBSTANCES THAT INHIBIT NEMO OLIGOMERIZATION - The present invention provides methods for screening for substances which inhibit the oligomerization of NEMO and/or IKK-related complexes and/or signaling pathways based on the interference with NEMO oligomerization | 10-29-2009 |
| 20090269746 | MICROSEQUENCER-WHOLE GENOME SEQUENCER - The method and apparatus are disclosed to support speedy sequencing of genomes of individuals. The method comprises random digestion of a stretch of DNA; adaptor ligation of adaptor DNA fragments to DNA segments produced in random digestion, each said adaptor DNA fragment containing a sequence which is complementary to a single DNA primer; PCR amplification of the ligated segments produced in adaptor ligation, utilizing a single DNA primer; distributing the ligated segments into one or more pre-defined isolated locations of a sequencing apparatus, each said location containing DNA fragments placed there for capturing a unique kind of digested DNA segments; capturing at each location a unique kind of amplified DNA segments by hybridization with the DNA fragments, dislodging captured DNA segments from DNA fragments; adding DNA sequencing reaction components into the locations; performing sequencing reactions at each location; separating the products of the sequencing reactions in the sequencing apparatus; and determining the sequences of DNA segments captured at individual locations of the sequencing apparatus. The apparatus comprises one or more isolated locations, each location has a reservoir containing DNA fragments placed there for capturing a unique kind of DNA segments from a DNA solution after dispensing the DNA solution into the reservoir; one or more channels performing DNA separation according to size, said channels being associated with one or more reservoirs; one or more gates controlling the flow of substances in the reservoirs; an optical system which induces fluorescence excitation in, and detects fluorescence emission in the channels; and a computer to produce DNA sequence data. | 10-29-2009 |
| 20090269742 | SUBSTRATE FOR IMMOBILIZING BIOPOLYMER AND METHOD OF IMMOBILIZING BIOPOLYMER BY USING THE SAME - [Problems] To immobilize a chain-type biopolymer in an elongated state at a predetermined position on a substrate. | 10-29-2009 |
| 20090269740 | Pancreatic Cancer Genes - The present invention provides the art with the DNA coding sequences of polynucleotides that are up-or-down-regulated in cancer and dysplasia. These polynucleotides and encoded proteins or polypeptides can be used in the diagnosis or identification of cancer and dysplasia. Inhibitors of the up-regulated polynucleotides and proteins can decrease the abnormality of cancer and dysplasia. Enhancing the expression of down-regulated polynucleotides or introducing down-regulated proteins to cells can decrease the growth and/or abnormal characteristics of cancer and dysplasia. | 10-29-2009 |
| 20090269738 | Method of Screening for the Presence of a Genetic Defect Associated With Deep Venous Thrombosis - The present invention relates to a method for screening an individual for the presence in his/her genome of a genetic marker that is indicative of an increased risk of deep venous thrombosis, wherein the genetic marker is haplotype 2 of the fibrinogen γ gene (FGG-H2) as given in FIG. | 10-29-2009 |
| 20090269737 | Integrated non-homogeneous nucleic acid amplification and detection - The present invention relates to an integrated method of amplifying and analyzing target nucleic acids, in which immobilized or immobilizable oligonucleotide capture probes are provided and a nucleic acid containing sample to be analyzed is added together with a reagent mixture, which mixture contains all reagents needed for amplification and subsequent analysis of said target nucleic acids. In the method amplification of the target nucleic acids, hybridization of said amplified target nucleic acids to the capture probes and separating the hybrids formed from un-reacted components, as well as the detection and measuring of the amount of labeled, hybridized target nucleic acids by means of a detectable signal, is performed in one reaction chamber. Further provided are reagent mixtures and kits for use in such methods. | 10-29-2009 |
| 20090298073 | Kidney Toxicity Biomarkers - Novel biomarkers for kidney toxicity. Said biomarkers may be useful for optimization of lead compounds, or in safety assessment. | 12-03-2009 |
| 20090291438 | Methods for Analysis of Extracelluar RNA Species - The invention provides methods and kits for enabling quantitative or qualitative analysis of extracellular RNA species in non-cellular bodily fluids including plasma and serum to detect, infer, evaluate, or monitor cancer and other neoplasia or other diseases of interest. | 11-26-2009 |
| 20100009376 | METHOD FOR MEASURING DNA METHYLATION - The present invention relates to a method of measuring the content of methylated DNA in a DNA region of interest in a genomic DNA contained in a biological specimen, and so on. | 01-14-2010 |
| 20100009377 | METHODS AND COMPOSITIONS FOR DIAGNOSING AND MONITORING AUTO IMMUNE AND CHRONIC INFLAMMATORY DISEASES - Methods of diagnosing or monitoring autoimmune and chronic inflammatory diseases, particularly systemic lupus erythematosis and rheumatoid arthritis, in a patient by detecting the expression level of one or more genes in a patient, are described. Diagnostic oligonucleotides for diagnosing or monitoring autoimmune and chronic inflammatory diseases, particularly systemic lupus erythematosis and rheumatoid arthritis and kits or systems containing the same are also described. | 01-14-2010 |
| 20090305265 | INTERLEUKIN-33 (IL-33) FOR THE DIAGNOSIS AND PROGNOSIS OF CARDIOVASCULAR DISEASE - The present invention includes methods for the use of interleukin-33 (IL-33) in the diagnosis of cardiovascular conditions including acute coronary syndrome (ACS), myocardial infarction, and/or heart failure, angina, cardiac hypertrophy, arteriosclerosis, myocarditis, pancarditis, endocarditis, stroke and/or pulmonary embolism and the determination of the severity of such conditions (prognosis). | 12-10-2009 |
| 20090305260 | PROBE, PROBE SET, PROBE-IMMOBILIZED CARRIER, AND GENETIC TESTING METHOD - A nucleic acid probe for classification of pathogenic bacterial species is capable of collectively detecting bacterial strains of the same species and differentially detecting them from other bacterial species. Any one of the base sequences of SEQ ID NOS. 59 to 61 or a combination of at least two of them is used for detecting the gene of an infectious disease pathogenic bacterium. | 12-10-2009 |
| 20090305244 | Selection, Propagation and Use of Mosaic Aneuploid Stem Cells - The distribution of cell karyotypes within a population of cells can determine the phenotype and ability of stem cells to differentiate into desired cell types, to function normally, as well as represent risk for adverse events like cancer. Therefore, determination of the aneuploid mosaic status of a cell population is useful in identifying and/or maintaining desirable traits and eliminating undesirable traits in stem cells, and for defining them at the level of their chromosomal complement. | 12-10-2009 |
| 20100015610 | DIAGNOSTIC SCREENING METHODS FOR DISORDERS OF THE ENDOPLASMIC RETICULUM-TO-GOLGI TRAFFICKING OF PROTEINS - The invention relates to methods of diagnosing Cranio-lenticulo-sutural dysplasia and other disorders that occur as a result of defective endoplasmic reticulum-to-Golgi trafficking using immunofluorescence based screening tests using antibodies against protein disulfide isomerase. | 01-21-2010 |
| 20100099111 | ANTIBODIES AGAINST A PROTEIN ENTITLED 161P2F10B - Antibodies and methods of using same against products of the gene designated 161P2F10B and its encoded protein are described wherein 161P2F10B exhibits tissue specific expression in normal adult tissue, it is aberrantly expressed in the cancers listed in Table I. Consequently, 161P2F10B provides a diagnostic, prognostic, prophylactic and/or therapeutic target for cancer. The 161P2F10B gene or fragment thereof, or its encoded protein or a fragment thereof, can be used to elicit a humoral or cellular immune response. | 04-22-2010 |
| 20090286234 | IL10 SNP ASSOCIATED WITH ACUTE REJECTION - The present invention concerns a method for the prediction of acute renal transplant rejection by detecting a poly-morphism in the promoter region of the IL 10 gene, optionally in combination with polymorphisms of the MDR1 and IMPDH2 genes which were found to be associated with this disease. | 11-19-2009 |
| 20100279294 | METHODS OF DETECTING AND GENOTYPING ESCHERICHIA COLI O157:H7 - A method for detecting and genotyping | 11-04-2010 |
| 20090305272 | METHOD OF CHARACTERIZING ENDOGENOUS POLYNUCLEOTIDE-POLYPEPTIDE INTERACTIONS - A method for characterizing an endogenous polypeptide includes introducing epitope tag-encoding polynucleotide into an endogenous locus of a somatic cell by homogenous recombination mediated knock-in so that an epitope tagged endogenous polypeptide is expressed by the cell, and characterizing the epitope tagged endogenous polypeptide using an immunoassay. | 12-10-2009 |
| 20110039263 | PLANTS HAVING ALTERED AGRONOMIC CHARACTERISTICS UNDER NITROGEN LIMITING CONDITIONS AND RELATED CONSTRUCTS AND METHODS INVOLVING GENES ENCODING LNT2 POLYPEPTIDES AND HOMOLOGS THEREOF - Isolated polynucleotides and polypeptides and recombinant DNA constructs particularly useful for altering agronomic characteristics of plants under nitrogen limiting conditions, compositions (such as plants or seeds) comprising these recombinant DNA constructs, and methods utilizing these recombinant DNA constructs. The recombinant DNA construct comprises a polynucleotide operably linked to a promoter functional in a plant, wherein said polynucleotide encodes an LNT2 polypeptide. | 02-17-2011 |
| 20100136561 | Genetic Markers for Weight Management and Methods of Use Thereof - This application relates to methods and tests that allow for the establishment of personalized weight-loss programs for a subject based upon the subject's metabolic genotype in key metabolic genes. Kits and methods are disclosed for determining a subject's metabolic genotype, which may be used to select an appropriate therapeutic/dietary regimen or lifestyle recommendation based upon the likelihood of a subject's responsiveness to certain diets and activity levels. Such a personalized weight-loss program will have obvious benefits (e.g., yield better results in terms of weight loss and weight maintenance) over traditional weight-loss programs that do not take into account genetic information. | 06-03-2010 |
| 20110014617 | Methods and Systems for Detecting Nucleic Acids - Methods and kits for detecting a target nucleic acid in a sample are described. In some embodiments, the sample to be analyzed includes a primer which hybridizes to at least a portion of the target nucleic acid, a probe having a first region which hybridizes to at least a portion of the target nucleic acid and a second region having a detectable label, a polymerase which extends the hybridized primer and an enzyme comprising nuclease activity that can cleave the hybridized hybridization probe to thereby release a labeled probe fragment. In some embodiments, the sample can then be contacted with a solid support comprising surface bound capture probes which can hybridize to the labeled probe fragment(s). These capture probes more readily bind to the probe fragment(s) than to the intact hybridization probe. The label can then be detected on the support surface. In this manner, improved discrimination between the probe fragments and the intact hybridization probes can be achieved. | 01-20-2011 |
| 20110014618 | DETECTION OF NUCLEIC ACIDS AND PROTEINS - The invention generally relates to methods for detecting a target nucleic acid and a target protein in a single assay. | 01-20-2011 |
| 20110014624 | Methods For Identifying Cells Suitable For Large-Scale Production of Recombinant Proteins - The present invention provides methods of identifying a clonal population of cells suitable for large-scale production of a protein of interest. The invention further provides methods for high-throughput screening for genetic rearrangements in the gene encoding the protein of interest, whereby the absence of a deletion in the gene encoding the protein of interest indicates that the cell is suitable for large-scale production of the protein of interest. | 01-20-2011 |
| 20110014619 | REACTION TREATMENT APPARATUS AND REACTION TREATMENT METHOD - Provided is a reaction treatment apparatus in which, in a case of mixing a plurality of solutions in a microchip used in a biochemical reaction system, an electric field generation area for changing solute concentration distribution in the solutions is provided in a solution upstream fluid path. Diffusion between the solutions is accelerated by bringing an area with a high solute concentration into contact with another solution. This may shorten a time required for mixing the solutions. | 01-20-2011 |
| 20110014622 | GENETIC REFERENCE MATERIALS - The invention provides a genetic reference standard with at least one human genetic reference sequence (having a human DNA sequence containing at least one genetic variant whose presence in the DNA of a human subject is indicative of a pathological condition, a predisposition to a pathological condition, or a predisposition to an adverse reaction to external stimuli, or is indicative of a patient's likely response to a therapeutic intervention, i.e. a variant used in pharmacogenomic analysis) cloned into a non-mammalian animal cell line. There are also provided such reference standards where the human DNA is targeted to specific location in the host genome, using homologous recombination. The invention further provides a method of detecting a genetic variant using such reference standards. | 01-20-2011 |
| 20110014625 | System and Method for Determining the Health of a Subject Using Polymorphic Risk Markers - A system and method for predicting the health of a subject comprising obtaining nucleic acid sequence data about the subject. Identifying at least one polymorphic risk marker associated with a change in promoter methylation of a gene associated with lung cancer; and predicting the health of the subject from a presence of at least one polymorphic risk marker identified and kits associated therewith. | 01-20-2011 |
| 20110014615 | METHOD FOR DIAGNOSING NON-SMALL CELL LUNG CANCERS BY tRNA-DIHYDROURIDINE SYNTHASE ACTIVITY OF URLC8 - The present invention features a method for determining t-RNA dihydrouridine-synthase activity of a polypeptide and screening for modulators of t-RNA dihydrouridine-synthase activity. The present invention further provides methods or pharmaceutical compositions for preventing and/or treating non-small cell lung cancer (NSCLC) using such modulators. Furthermore, the present invention provides methods for diagnosing non-small cell lung cancer (NSCLC) using the t-RNA dihydrouridine-synthase activity of IMS-E21 (URLC8) protein as an index. The present invention further provides methods for predicting and prognosing lung squamous-cell carcinoma (SCC). | 01-20-2011 |
| 20100075314 | CHEMICALLY-MODIFIED GOLD NANOPARTICLES AND METHODS FOR USE IN DETECTING TARGET MOLECULES - The invention provides stable bioconjugate-nanoparticle probes which are useful for detecting nucleic acids and other target analytes, e.g., proteins, and methods of preparing those probes. | 03-25-2010 |
| 20090298078 | METHOD FOR THE DETECTION OF AN ACTIVATION OF THE IMMUNE SYSTEM OR THE EXTENT OF CELL DEATH - The present invention relates to a method for the detection of an activation of the immune system, preferably in the sense of an NET formation, or the extent of cell death in a non-tumorous tissue or in a body fluid, wherein free DNA is measured in a sample from an individual. Furthermore, the invention relates to a method for the production of a kit for the detection of an activation of the immune system or the extent of cell death in an individual, comprising the packaging of a fluorescent dye and a DNA standard in at least one container. | 12-03-2009 |
| 20090298075 | COMPOSITIONS AND METHODS FOR NUCLEIC ACID SEQUENCING - Compositions and methods for nucleic acid sequencing include template constructs that comprise double stranded portions in a partially or completely contiguous constructs, to provide for redundant sequence determination through one or both of sequencing sense and antisense strands, and iteratively sequencing the entire construct multiple times. Additional sequence components are also optionally included within such template constructs. Methods are also provided for the use and preparation of these constructs as well as sequencing compositions for their application. | 12-03-2009 |
| 20090269739 | Kit for detection of telomerase reverse transcriptase nucleic acids - The invention provides compositions and methods related to human telomerase reverse transcriptase (hTRT), the catalytic protein subunit of human telomerase. The polynucleotides and polypeptides of the invention are useful for diagnosis, prognosis and treatment of human diseases, for changing the proliferative capacity of cells and organisms, and for identification and screening of compounds and treatments useful for treatment of diseases such as cancers. | 10-29-2009 |
| 20090275021 | NOVEL NUCLEOTIDE AND AMINO ACID SEQUENCES, AND ASSAYS AND METHODS OF USE THEREOF FOR DIAGNOSIS - Novel splice variants, amino acid sequences and nucleotide sequences thereof, and methods of using same. | 11-05-2009 |
| 20100075311 | CARTRIDGE SYSTEM - A cartridge system includes a reagent component for storing one or more reagents and a processing component for processing the one or more reagents in an assay. The reagent component and the processing component are configured to be coupled together to form a cartridge. The reagent component and/or the processing component include at least one compartment configured to accept waste from the assay. The reagent component does not take part in processing the reagents in the assay, except to accept waste from the processing component. In one aspect, the cartridge system further includes a sensing component with at least one sensing element for detecting an analyte. In another aspect, the cartridge system further includes a sample preparation component for preparing a sample for the assay. | 03-25-2010 |
| 20100075310 | Methods for Microorganism Detection and Identification - Methods for detecting and identifying microorganisms in a biologic sample are provided. The methods utilize identifying rRNA from microorganisms to both show the presence and identity for the majority of infectious agents present in clinical samples. The methods are preferably adapted for use in a clinical setting. | 03-25-2010 |
| 20100075309 | INTERMITTENT DETECTION DURING ANALYTICAL REACTIONS - Methods, devices, and systems for performing intermittent detection during analytical reactions are provided. Such methods facilitate collection of reaction data from disparate reaction times. Further, such methods are useful for reducing photo-induced damage of one or more reactants in an illuminated analytical reaction at a given reaction time. In preferred embodiments, the reaction mixture is subjected to at least one illuminated and non-illuminated period and allowed to proceed such that the time in which the reaction mixture is illuminated is less than a photo-induced damage threshold period. | 03-25-2010 |
| 20100075303 | METHODS FOR TARGETTED MUTAGENESIS IN GRAM-POSITIVE BACTERIA - The present invention provides a method of targeted mutagenesis in Gram-positive bacteria. In particular, the present invention provides a method that effectively integrates a suicide integrative vector into a target gene in the chromosome of a Gram-positive bacterium, resulting in inactivation of the target gene. | 03-25-2010 |
| 20090269767 | MICROFLUIDIC CHIP DEVICES AND THEIR USE - A microfluidic chip device (MCD) and its use for performing miniaturized assays on magnetic microbeads (MMs) are described. The MCD is particularly useful for carrying out miniaturized transcript analysis by aiding affinity capturing (TRAC) assays, including PCR. The MCD comprises at least one reaction chamber with sealable liquid connections and at least one fluidic pillar filter in each chamber. The fluidic pillar filter comprises rods with spacings allowing MMs to pass. The sealable liquid connections feed liquid to the reaction chamber, wherein air bubbles are removed. The liquid stream contacts the MMs, which are manipulated with a magnetic rod. The liquid connections enable trapping of the MMs behind the pillar filters or in the channel, while the liquid is changed. | 10-29-2009 |
| 20090269762 | Cotton event PV-GHGT07(1445) and compositions and methods for detection thereof - The present invention provides DNA compositions and assays for detecting the presence of the DNA compositions in PV-GHGT07(1445) cotton event based on the DNA sequence of the recombinant construct inserted into the cotton genome and of the genomic sequences flanking the insertion site. Kits and conditions useful in conducting the assays are provided. | 10-29-2009 |
| 20110003304 | METHOD AND KIT FOR DETECTION OF AUTOIMMUNE CHRONIC URTICARIA - Disclosed is a rapid, non-invasive and highly specific and sensitive diagnostic assay for the identification of individuals with autoimmune chronic urticaria, which makes use of CD203c, and in some embodiments, additional proteins, as a marker for the disease. Test kits for diagnosis of an individual suspected of having autoimmune chronic urticaria are also disclosed. Also disclosed are a method of identifying compounds useful for treating autoimmune chronic urticaria and a method of treating autoimmune chronic urticaria. | 01-06-2011 |
| 20110039261 | MOBILE RAPID TEST SYSTEM FOR NUCLEIC ACID ANALYSIS - A mobile rapid test system for nucleic acid analysis. A method comprising the steps of amplification of the nucleic acids by means of rapid-PCR technology, conversion of a double-stranded amplification product into a single-stranded DNA fragment, hybridization with a labeled probe and detection of the nucleic acids on a lateral-flow test strip. A device comprising a reaction cavity which preferably consists of a thin film, inlet and outlet openings for the reaction cavity, one or more heatable sample blocks which are connected to miniaturized cooling bodies and a window for reading off the result. The lateral-flow test strip is a component of the mobile rapid test system. Operation of the instrument system requires no external power source, but only batteries or a rechargeable battery. | 02-17-2011 |
| 20110059448 | COMPOSITIONS AND METHODS FOR DETERMINING CANCER STEM CELL SELF-RENEWAL POTENTIAL - In alternative embodiments, the invention provides compositions and methods for determining the self-renewal potential of a cancer stem cell (CSC) through analysis of the cross-talk between cell self-renewal pathways leading to deregulation and enhanced self-renewal of the CSC, or for predicting the drugability (susceptibility to a drug) of a CSC, and/or for predicting the progression of a cancer that corresponds to the CSC, the method comprising detecting and quantifying in CSCs one or more B-cell lymphoma-2 (Bcl-2) family protein isoform(s) or transcripts (mRNAs, messages) encoding one or more Bcl-2 family protein(s) or protein isoform(s) thereof. In alternative embodiments, the invention provides compositions and methods to determine and measure the levels of Wnt, glycogen synthase kinase-3 beta (GSK-3 beta), glycogen synthase kinase-3 alpha (GSK-3 alpha), and/or Sonic Hedgehog Homolog (SHH or Shh) family proteins and alternatively spliced transcripts (mRNAs), and Wnt, GSK3beta, GSK3alpha and/or Shh family protein and alternatively spliced transcript ratios in cancer cells, e.g., stem cells, e.g., CSCs, for diagnostic, drug discovery and prognostic purposes. | 03-10-2011 |
| 20110059445 | MUCOSAL GENE SIGNATURES - Infliximab (IFX) is an effective treatment for Crohn's disease (CD) and ulcerative colitis (UC) not responding to standard therapy. Thirty percent to forty percent of patients however do not improve and the response is often incomplete. We identified mucosal gene signatures predictive of response to EFX using high-density oligonucleotide arrays. Eight UC patients and twelve CD patients showed healing. In UC, only one probe set was differentially expressed in responders compared with non-responders, i.e., IL-13R(alpha)2. At PAM analysis, two probe sets, representing IL-13Ralpha2 and IL-I 1, separated IBD responders from non-responders with an overall misclassification error rate of 0.046 (2/43), with 100% sensitivity and 91.3% specificity. The IL-13R(alpha)2 probe set was a top-ranked probe set in all our analyses using both LIMMA and PAM strategies. Our gene array studies of mucosal biopsies identified IL-13R(alpha)2 in IBD as a predictor of response or non-response to IFX. | 03-10-2011 |
| 20110059435 | Methods for Beaming - Improvements on the basic method used for BEAMing increase sensitivity and increase the signal-to-noise ratio. The improvements have permitted the determination of intrinsic error rates of various DNA polymerases and have permitted the detection of rare and subtle mutations in DNA isolated from plasma of cancer patients. | 03-10-2011 |
| 20110014616 | Rapid screening of biologically active nucleases and isolation of nuclease-modified cells - Disclosed herein are methods and compositions for rapidly identifying active nucleases and cells having nuclease-mediated genomic modifications. | 01-20-2011 |
| 20110014604 | METHODS FOR SEQUENCE DETERMINATION - A sequencing methodology is disclosed that allows a single DNA or RNA molecule or portion thereof to be sequenced directly and in substantially real time. The methodology involves engineering a polymerase and/or dNTPs with atomic and/or molecular tags that have a detectable property that is monitored by a detection system. | 01-20-2011 |
| 20110014606 | Assays - A device comprising a rigid substrate, a flexible cover element at least partially covering the substrate, a first structure formed in the substrate, adapted for accommodating liquids and adapted for releasing contents of one or more cells, spores, or viruses, the contents including the target molecules, a second structure formed in the substrate, adapted for accommodating liquids and comprising at least one binding member adapted for capturing the target molecules and for determining a value indicative of the presence and/or amount of the target molecules, a micro fluidic network interconnecting at least the first structure and the second structure, and an actuator member adapted for effecting a fluid flow between the first structure and the second structure by pressing the flexible cover element against the substrate to selectively close a portion of the micro fluidic network. | 01-20-2011 |
| 20110014608 | SCREENING FOR CD93 (C1qRp)-ASSOCIATED POLYMORPHISM(S) IN THE DIAGNOSIS, PREVENTION AND TREATMENT OF AUTOIMMUNE DISEASES - This invention is directed to a marker gene for autoimmune disease. Specifically, the invention is directed to the use of a polymorph of CD93 in methods and compositions for the detection, prognosis and therapy of Type I Diabetes and systemic lupus erythematosus (SLE). | 01-20-2011 |
| 20110014614 | Method of profiling gene expression in a subject having an infectious disease - The present invention is directed to detection and measurement of gene transcripts in blood. Specifically provided is a RT-PCR analysis performed on a drop of blood for detecting, diagnosing and monitoring diseases using tissue-specific primers. The present invention also describes methods by which delineation of the sequence and/or quantitation of the expression levels of disease-associated genes allows for an immediate and accurate diagnostic/prognostic test for disease or to assess the effect of a particular treatment regimen. | 01-20-2011 |
| 20110014609 | NUCLEIC ACID SIGNAL ENHANCEMENT USING NANOPARTICLE-BASED HYBRIDIZATION - A method of enhancing signal detection through use of nanoparticle-conjugated nucleic acid probes is provided. Following chromosomal FISH hybridization of a target sequence with a genomic probe linked to a flag sequence, the flag sequence is hybridized to an anti-flag sequence conjugated to a nanoparticle. The enhanced fluorescent probe is then visualized using microscopy. | 01-20-2011 |
| 20110020795 | ANALYZING THE FMR1 GENE - A method of predicting a degree of risk of early ovarian aging of a young female. The method includes analyzing the female's FMR1 gene, wherein the FMR1 gene has a first allele and a second allele; determining the number of triple CGG repeats on each of the first and second alleles; defining a normal range of triple CGG repeats; comparing the number of triple CGG repeats on each of the first and second alleles to the normal range. If the triple CGG repeat numbers for both of the first and second alleles are within the normal range, then the female is at minimal risk for early ovarian aging. If the triple CGG repeat number for one of the first and second alleles is outside of the normal range and the other one of the first and second alleles is within the normal range, then the first and second alleles are heterozygous and the female is at increased risk for early ovarian aging. If the triple CGG repeat numbers for both of the first and second alleles are outside of the normal range, then the first and second alleles are homozygous and the female is also at an increased risk for early ovarian aging. | 01-27-2011 |
| 20110008794 | HIGH SPEED PARALLEL MOLECULAR NUCLEIC ACID SEQUENCING - A method and device is disclosed for high speed, automated sequencing of nucleic acid molecules. A nucleic acid molecule to be sequenced is exposed to a polymerase in the presence of nucleotides which are to be incorporated into a complementary nucleic acid strand. The polymerase carries a donor fluorophore, and each type of nucleotide (e.g. A, T/U, C and G) carries a distinguishable acceptor fluorophore characteristic of the particular type of nucleotide. As the polymerase incorporates individual nucleic acid molecules into a complementary strand, a laser continuously irradiates the donor fluorophore, at a wavelength that causes it to emit an emission signal (but the laser wavelength does not stimulate the acceptor fluorophore). In particular embodiments, no laser is needed if the donor fluorophore is a luminescent molecule or is stimulated by one. The emission signal from the polymerase is capable of stimulating any of the donor fluorophores (but not acceptor fluorophores), so that as a nucleotide is added by the polymerase, the acceptor fluorophore emits a signal associated with the type of nucleotide added to the complementary strand. The series of emission signals from the acceptor fluorophores is detected, and correlated with a sequence of nucleotides that correspond to the sequence of emission signals. | 01-13-2011 |
| 20110008795 | MARKER FOR DETECTION OF IL-17-PRODUCING HELPER T-CELL, AND METHOD FOR DETECTION OF IL-17-PRODUCING HELPER T-CELL - Disclosed is a polynucleotide marker or a protein marker for use in the specific detection of an IL-17-producing helper T-cell (a Th17 cell). Also disclosed is a method for detecting a Th17 cell, which is characterized by detecting the occurrence of the polynucleotide marker or the protein marker. | 01-13-2011 |
| 20110008786 | METHODS OF DETECTING AND CONTROLLING MUCOID PSEUDOMONAS BIOFILM PRODUCTION - Compositions and methods for detecting and controlling the conversion to mucoidy in | 01-13-2011 |
| 20110008780 | METHOD FOR THE DETECTION OF GENE TRANSCRIPTS IN BLOOD AND USES THEREOF - The present invention is directed to detection and measurement of gene transcripts in blood. Specifically provided is a RT-PCR analysis performed on a drop of blood for detecting, diagnosing and monitoring diseases using tissue-specific primers. The present invention also describes methods by which delineation of the sequence and/or quantitation of the expression levels of disease-associated genes allows for an immediate and accurate diagnostic/prognostic test for disease or to assess the effect of a particular treatment regimen. | 01-13-2011 |
| 20110008783 | FLUORIMETRIC PROCESS FOR EVALUATING THE INFLUENCE OF A CONDITION ON A BIOLOGICAL SAMPLE, AND APPLICATIONS THEREOF - The present invention relates to a process for determining the influence of a condition on a biological sample comprising a step consisting in establishing the kinetic profile of the fluorescence emitted, during the excitation at a suitable excitation wavelength, of a fluorescent compound bound to said biological sample, said sample having been, prior to said excitation, subjected to said condition and said process not necessitating the utilization of a fluorescence donor component and of a different fluorescence acceptor component. The present invention also relates to the various applications of such a process. | 01-13-2011 |
| 20090311701 | Organ-specific gene, method for identifying the same and use thereof - The present invention provides a method of extracting an organ- or tissue-specific highly expressed gene, including: | 12-17-2009 |
| 20090311696 | POLYMORPHISMS IN THE HUMAN CYP2B6 GENE AND THEIR USE IN DIAGNOSTIC AND THERAPEUTIC APPLICATIONS - Described are general means and methods of diagnosing and treating the phenotypic spectrum as well as the overlapping clinical characteristics with several forms of inherited abnormal expression and/or function of the CYP2B6 genes. In particular, polynucleotides of molecular variant CYP2B6 genes which, for example, are associated with insufficient metabolization and/or sensitively of drugs, and vectors comprising such polynucleotides are provided. Furthermore, host cells comprising such polynucleotides or vectors and their use for the production of variant CYP2B6 proteins are described. In addition, variant CYP2B6 proteins and antibodies specifically recognizing such proteins as well as transgenic non-human animals comprising the above-described polynucleotide or vectors are provided. Described are also methods for identifying and obtaining inhibitors for therapy of disorders related to the malfunction of the CYP2B6 gene as well as methods of diagnosing the status of such disorders. Pharmaceutical and diagnostic compositions useful for diagnosing and treating various diseases with drugs that are substrates, inhibitors or modulators of the CYP2B6 gene product are described as well. | 12-17-2009 |
| 20100081130 | Multifunctional particles providing cellular uptake and magnetic motor effect - Preparation of novel multifunctional particles and nanomaterials having a useful combination of magnetic and optical properties and biocompatibility. The internalization efficiencies in various in vitro cell studies have been investigated, and the external magnetic motor effect on the floating cells internalized with magnetic nanoparticles were clearly observed, for the first time. The particle surfaces can be derivatized with, for example, DNA or antibodies. The system is stable, versatile, and well-controlled. Novel gene delivery can be achieved using nanoparticles as a carrier. | 04-01-2010 |
| 20100081129 | Genemap of the human genes associated with crohn's disease - The present invention relates to the selection of a set of polymorphism markers for use in genome wide association studies based on linkage disequilibrium mapping. In particular, the invention relates to the fields of pharmacogenomics, diagnostics, patient therapy and the use of genetic haplotype information to predict an individual's susceptibility to Crohn's disease and/or their response to a particular drug or drugs. | 04-01-2010 |
| 20090280497 | Multiplex Detection Compositions, Methods, and Kits - The present invention generally relates to the detection of analytes, particularly biomolecules in samples. The invention also relates to compositions, methods, and kits for detecting the presence of analytes, typically in multiplex detection formats. The invention also relates to methods for determining the presence of at least one analyte in a sample, the methods employing employ single molecule detection techniques to individually detect at least one molecular complex or at least part of a molecular complex. | 11-12-2009 |
| 20090280490 | Expression Profile Algorithm and Test for Cancer Prognosis - The present invention provides a noninvasive, quantitative test for prognosis determination in cancer patients. The test relies on measurements of the tumor levels of certain messenger RNAs (mRNAs). These mRNA levels are inserted into a polynomial formula (algorithm) that yields a numerical recurrence score, which indicates recurrence risk. | 11-12-2009 |
| 20090280487 | METHODS FOR PRODUCING OLFACTORY GPCRS - The subject invention provides a method for producing an olfactory GPCR in a cell. In general, the methods involve introducing an expression cassette containing a promoter operably linked to a nucleic acid encoding an olfactory PCR into a macroglial cell, e.g., a Schwann or oligodendritic cell, and maintaining the cell under conditions suitable for production of the olfactory GPCR. Also provided is a macroglial cell containing a recombinant nucleic acid encoding an olfactory GPCR, methods of screening for modulators of olfactory GPCR activity, and a kit for producing an olfactory GPCR in a macroglial cell. The invention finds most use in research on flavors and fragrances, and, consequently, has a variety of research and industrial applications. | 11-12-2009 |
| 20090280482 | Novel nucleic acid sequences encoding adenylate kinases, alcohol dehydrogenases, ubiquitin proteases, lipases, adenylate cyclases, and GTPase activators - The invention provides isolated nucleic acids molecules that encode novel polypeptides. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing the nucleic acid molecules of the invention, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a sequence of the invention has been introduced or disrupted. The invention still further provides isolated proteins, fusion proteins, antigenic peptides and antibodies. Diagnostic methods utilizing compositions of the invention are also provided. | 11-12-2009 |
| 20100255494 | METHODS FOR PREDICTING THE RISK OF DIABETIC NEPHROPATHY USING GENETIC MARKERS AND ARRAYS CONTAINING THE SAME - A method for detecting a Chinese diabetic subject suffering from, at risk for developing, or suspected of suffering from a nephropathy. The method includes determining whether a sample from the subject has at least one of the following polymorphic sequences: an I/D genotype of an ACE gene, an M235T genotype of an AGT gene, a (CA)n-5′(z−2) genotype of an ALR2 gene, an C106T genotype of an ALR2 gene in the promoter region, a G-308A genotype of a TNF-α gene, or a complement thereof, provided that the ALR2 gene cannot be used alone, in which the presence of the polymorphic sequence indicates the subject suffering from, at risk for suffering from a nephropathy. An array for detecting a Chinese diabetic subject suffering from, or at risk for suffering from, a nephropathy. | 10-07-2010 |
| 20100255493 | Non-Invasive Fetal Genetic Screening by Digital Analysis - The present methods are exemplified by a process in which maternal blood containing fetal DNA is diluted to a nominal value of approximately 0.5 genome equivalent of DNA per reaction sample. Digital PCR is then be used to detect aneuploidy, such as the trisomy that causes Down Syndrome. Since aneuploidies do not present a mutational change in sequence, and are merely a change in the number of chromosomes, it has not been possible to detect them in a fetus without resorting to invasive techniques such as amniocentesis or chorionic villi sampling. Digital amplification allows the detection of aneuploidy using massively parallel amplification and detection methods, examining, e.g., 10,000 genome equivalents. | 10-07-2010 |
| 20100255490 | METHODS, COMPOSITIONS AND KITS FOR DETECTION AND ANALYSIS OF ANTIBIOTIC-RESISTANT BACTERIA - The present invention relates generally to detection of antibiotic-resistant bacteria in a sample. In particular, the invention provides methods, compositions and kits for detecting and analyzing methicillin-resistant | 10-07-2010 |
| 20100255484 | SAMPLE PREPARATION CONTAINER AND METHOD - A system and method for preparing and collecting samples for analyte testing. The system can include a sample preparation system and a sample collection system coupled to the sample preparation system. The sample preparation system can include at least one of a deformable self-supporting receptacle comprising a reservoir and a freestanding receptacle comprising a reservoir. The reservoir can be adapted to contain a liquid composition. The sample collection system can be positioned in fluid communication with a reservoir of the sample preparation system, and can be adapted to capture an analyte of interest. The method can include providing a fluid path defined at least partially by the sample preparation system and the sample collection system, positioning the liquid composition in a reservoir of the sample preparation system, and moving at least a portion of the liquid composition in the fluid path to the sample collection system. | 10-07-2010 |
| 20100255486 | METHOD FOR DIAGNOSING LUNG CANCERS USING GENE EXPRESSION PROFILES IN PERIPHERAL BLOOD MONONUCLEAR CELLS - Methods and compositions are provided for diagnosing lung cancer in a mammalian subject by use of three or more selected genes, e.g., a gene expression profile, from the peripheral blood mononuclear cells (PBMC) of the subject which is characteristic of disease, a stage of the disease, or enables prognosis of recurrence of disease. The gene expression profile includes three or more genes of Table I, Table II, Table III, Table IV, Table V, Table VI or Table VII herein. Detection of changes in expression in the selected genes forming the gene expression profile from that of a reference gene expression profile are correlated with non-small cell lung cancer (NSCLC). One composition for use in such diagnosis includes three or more PCR primer-probe sets, wherein each primer-probe set amplifies a different polynucleotide sequence from the gene expression profile. Another composition for similar use contains a plurality of polynucleotides immobilized on a substrate, which probes hybridize to three or more gene expression products from genes in the gene expression profile. Still another composition involves detection of the protein expression products of genes from the gene expression profile. | 10-07-2010 |
| 20100255485 | BIOMARKERS FOR THE ONSET OF NEURODEGENERATIVE DISEASES - The present invention provides a method of predicting the imminent degeneration of motoneurons in a subject, said method comprising assessing in at least one motoneuron of said subject the expression of at least one particular gene, wherein an at least two-fold upregulation of the expression of the assessed genes is indicative of the imminent degeneration of motoneurons and/or of the imminent onset of a neurodegenerative disease. Kits therefor are also provided. | 10-07-2010 |
| 20100255480 | COMPOSITION FOR ANALYZING NUCLEIC ACID - The present invention provides a firefly luciferase for inexpensive, highly accurate and highly sensitive nucleic acid analysis that uses dATP instead of an expensive reagent having low reactivity to DNA polymerase in the manner of dATPαS, a method of analyzing nucleic acid that uses that luciferase, and a kit for analyzing nucleic acid thereof. | 10-07-2010 |
| 20100255479 | DEVICES AND METHODS OF CELL CAPTURE AND ANALYSIS - The present invention provides a device for isolating target biomolecules or cells from samples, particularly biological samples. In particular, the device comprises a loading mixture, which contains the biological sample and a first binding entity that specifically binds to the target biomolecule or target cell; and a micro-channel coated with a second binding entity that binds directly or indirectly to the first binding entity. Methods of capturing, detecting, and/or evaluating target biomolecules or target cells (e.g. cancer cells) in biological samples are also disclosed. | 10-07-2010 |
| 20100255472 | BIOMARKERS FOR PROSTATE CANCER - The instant invention provides methods and compositions for the detection of prostate cancer in a subject. | 10-07-2010 |
| 20100255465 | Nucleic Acid-Polymer Particle for and Method of Tracing Movement of a Liquid - A particle ( | 10-07-2010 |
| 20090305282 | NOVEL HUMAN VIRUS CAUSING RESPIRATORY TRACT INFECTION AND USES THEREOF - The present invention provides the complete genomic sequence of a novel human coronavirus, coined as coronavirus-HKU1 (“CoV-HKU1”), isolated in Hong Kong from a patient who had a recent history of visit to Schenzhen. China. The virus belongs to the order Nidovirales of the family Coronavirdae, being a single-stranded RNA virus of positive polarity. The invention also provides the deduced amino acid sequences of the complete genome of the CoV-HKU1. The nucleotide sequences and deduced amino acid sequences of the CoV-HKU1 are useful in preventing, diagnosing and/or treating the infection by CoV-HKU1. Furthermore, the invention provides immunogenic and vaccine preparations using recombinant and chimeric forms as well as subunits of the CoV-HKU1 based on the nucleotide sequences and deduced amino acid sequences of the CoV-HKU1. | 12-10-2009 |
| 20090305292 | DNA POLYMERASE - The present invention relates to DNA polymerases. In particular the invention relates to a method for the generation of DNA polymerases exhibiting a relaxed substrate specificity. Uses of mutant polymerases produced using the methods of the invention are also described. | 12-10-2009 |
| 20090305280 | Luciferase biosensors for camp - A modified luciferase protein which is a sensor for molecules including cAMP is provided. The modified luciferase protein includes one or more heterologous amino acid sequences, at least one of which directly or indirectly interacts with cAMP. | 12-10-2009 |
| 20090305273 | NANONOZZLE DEVICE ARRAYS: THEIR PREPARATION AND USE FOR MACROMOLECULAR ANALYSIS - Constricted nanochannel devices suitable for use in analysis of macromolecular structure, including DNA sequencing, are disclosed. Also disclosed are methods for fabricating such devices and for analyzing macro-molecules using such devices. | 12-10-2009 |
| 20090305268 | METHOD OF DETERMINING AN AMOUNT OF FATTY ACID CONTENTS IN BOVINE INTRAMUSCULAR FAT ON THE BASIS OF GENOTYPE OF FATTY ACID SYNTHASE GENE AND METHOD OF DETERMINING GOODNESS OF EATING QUALITY OF BEEF ON THE BASIS OF THE RESULTS THEREOF - The present invention has an object to provide a method of determining fatty acid composition in intramuscular fat on the basis of bovine genotype, in particular a method of simply determining an amount of an oleic acid content with a high degree of accuracy, and a method of objectively determining the goodness of eating quality of beef on the basis of the results of the determination. The present invention provides a method of determining an amount of fatty acid content in bovine intramuscular fat on the basis of the genotype of fatty acid synthase determined by determining base <1> and/or base <2> described below, and a method of determining whether cattles are those from which beef with an excellent eating quality is obtained on the basis of the results thereof. | 12-10-2009 |
| 20110045483 | Diagnostic Screens for Alzheimer's Disease - The present invention relates diagnostic screens for Alzheimer's disease, and in particular to diagnostic tests based on screening for the presence of cellular changes that occur early in the pathology of Alzheimer's disease. | 02-24-2011 |
| 20110091891 | PROBE, PROBE SET, PROBE CARRIER, AND TESTING METHOD - A probe, a set of probes, and a probe carrier on which the probe or the set of probes is immobilized, are provided for classification of fungus species. The probe or the set of probes is capable of collectively detecting fungus of the same species and distinguishingly detecting those fungus from fungus of other species. The probe is an oligonucleotide probe for detecting a pathogenic fungus DNA and includes at least one of base sequences of SEQ ID NOS. 1 to 3 and mutated sequences thereof. | 04-21-2011 |
| 20110111396 | BIOMARKERS FOR MONITORING THE TREATMENT BY QUINAZOLINONE COMPOUNDS - Provided herein are the biomarkers for monitoring the treatment by quinazolinone compounds. For example, the use of SPARC, p21, and cyclin D1 mRNA levels as biomarkers to predict whether a quinazolinone compound is likely to be successful in treating certain types of cancer, such as NHL is provided. Further, the expression of these genes can be used to monitor progress of treatment effectiveness and patient compliance in cancer patients that are receiving treatment with quinazolinone compounds. | 05-12-2011 |
| 20110033860 | Method For Searching Target Base Sequence Of Rna Interference, Method For Designing Base Sequence Of Polynucleotide For Causing Rna Interference, Method For Producing Double-Stranded Polynucleotide, Method For Inhibiting Gene Expression, Base Sequence Processing Apparatus, Program For Running Base Sequence Processing Method On Computer, Recording Medium, And Base Sequence Processing System - In the present invention, a sequence segment conforming to the following rules (a) to (d) is searched from the base sequences of a target gene of RNA interference and, based on the search results, siRNA capable of causing RNAi is designed, synthesized:
| 02-10-2011 |
| 20110045489 | Polymerases for Incorporating Modified Nucleotides - Compositions and methods are provided that relate to a recombinant protein with DNA polymerase activity in which one or more amino acids are mutated compared with the corresponding wild type protein. The recombinant protein is capable of incorporating one or more modified nucleotides into a nucleic acid substrate with a specific activity greater than 200. | 02-24-2011 |
| 20110045487 | METHODS OF DIAGNOSING MYELODYSPLASTIC SYNDROME (MDS) OR LEUKEMIA USING NUCLEIC ACIDS OR FRAGMENTS ENCODING FLT3 KINASE - To provide a nucleic acid encoding a receptor protein kinase, wherein the nucleic acid has tandem duplication in a nucleotide sequence of a juxtamembrane and is useful for diagnosis of leukemia; a polypeptide encoded by the nucleic acid; an antibody capable of specifically binding to a region encoded by the nucleic acid having tandem duplication occurring in a nucleotide sequence of a juxtamembrane; a nucleic acid capable of specifically binding to the nucleic acid having tandem duplication occurring in a nucleotide sequence of a juxtamembrane; a method for detection of the nucleic acid encoding a receptor protein kinase; and a kit therefor. A nucleic acid encoding a receptor protein kinase, wherein the nucleic acid has tandem duplication in a nucleotide sequence of a juxtamembrane; a polypeptide encoded by the nucleic acid; an antibody capable of specifically binding to the portion of the polypeptide; a nucleic acid capable of specifically binding to the nucleic acid; a method for detection of the nucleic acid; and a kit for detection, | 02-24-2011 |
| 20110045481 | METHODS AND COMPOSITIONS FOR THE ASSESSMENT OF DRUG RESPONSE - The present invention provides methods for predicting or determining a subject's response to an antiplatelet agent, and methods for determining a subject's suitability to a treatment regime or intervention for a disease associated with platelet aggregation, using analysis of genetic polymorphisms. The present invention also relates to the use of genetic polymorphisms in assessing a subject's response to an antiplatelet agent. Nucleotide probes and primers, kits, and microarrays suitable for such assessment are also provided. | 02-24-2011 |
| 20110045463 | METHOD FOR MEASURING DNA METHYLATION - The present invention relates to a method of measuring the content of methylated DNA in a DNA region of interest in a genomic DNA contained in a biological specimen, and so on. | 02-24-2011 |
| 20110045462 | DIGITAL ANALYSIS OF GENE EXPRESSION - The disclosure provides methods and compositions useful for high throughput sequencing of nucleic acid sequences associated with gene expression, nucleic acid-polypeptide interactions, and/or chromosomal interactions. | 02-24-2011 |
| 20110020811 | HOST CELLS COMPRISING ALPHA 1,2 MANNOSIDASE AND CULTURE METHODS THEREOF - Improved host cells and culture methods involving overexpression of MAN1C1 activity to improve protein production are provided. | 01-27-2011 |
| 20110020806 | Rapid DNA Sequencing by Peroxidative Reaction - Disclosed is a method of polynucleic acid (e.g., DNA) sequencing which is based on the generation of pyrophosphate (PPi) that occurs when a complementary base is incorporated into a growing DNA strand being synthesized on a template. The method utilizes a cascade of enzymatic reactions catalyzed by hypoxanthine-phosphoribosyl transferase, xanthine oxidase, and peroxidase in addition to DNA polymerase and apyrase. The last chemical step in the cascade of reactions is the oxidation of a material such as an electrode or luminol by hydrogen peroxide. This generates a detectable electrical or optical signal. This method is independent of luciferase, does not require dATP analogue, and is intended to improve precision and sensitivity of DNA sequencing, and to lessen the unsynchronized polymerization. | 01-27-2011 |
| 20110020805 | MUTATIONAL ANALYSIS OF CHRONIC MYELOPROLIFERATIVE DISORDERS - The invention relates to molecular assays, reagents and kit for the mutational analysis, for diagnostic and prognostic purposes, of chronic myeloproliferative disorders, a group of neoplastic pathologies of the haemopoietic system. The invention relates to the identification of nucleic acid probes labelled with fluorochrome, allowing a quantitative assessment, in a specific and sensitive way, of mutation of MPL gene sequence and quantification of the mutated alleles of the MPL gene in Genomic DNA samples from patients with chronic myeloproliferative syndrome. | 01-27-2011 |
| 20100330555 | ACCURACY FLUORESCENCE IN-SITU HYBRIDIZATION ASSAY OF SAMPLES WITH APOPTOTIC CELLS - The present application discloses a process for improving the accuracy of fluorescence in-situ hybridization (FISH) assays in which the sample being assayed is likely to contain cells in apoptosis by excluding these cells from the evaluation of the FISH assay. This is conveniently done by labeling the cells in apoptosis by incorporating labeled nucleotides into the apoptosis typical breaks in their nuclear DNA. The present application also discloses a kit and system adapted for carrying out this process for improving the accuracy of FISH assays. | 12-30-2010 |
| 20100330553 | Chemically induced optical signals and DNA sequencing - Methods for sequencing nucleic acids are presented. Sequencing is accomplished through the chemical amplification of the products of DNA synthesis and the detection of the chemically amplified products. In embodiments of the invention, a substrate is provided having a plurality of molecules of DNA to be sequenced attached and a plurality of molecules capable of chelating pyrophosphate ions attached, the DNA molecules to be sequenced are primed, and a next complementary nucleotide is incorporated and excised a plurality of times leading to the buildup of pyrophosphate ions locally around the DNA molecule to be sequenced. Pyrophosphate ions are captured by the substrate-attached chelators and optically detected to determine the identity of the next complementary nucleic acid in the DNA molecule to be sequenced. | 12-30-2010 |
| 20100330552 | Comparative cellular deficiency diagnosis genetic deviation diagnosis procedurecellular protein output deficiency - This procedure is intended to demonstrate the genetic foundation of infirmities caused by abnormal base pair sequences and protein deficiencies (which are an expression of genetic aberrations). | 12-30-2010 |
| 20110045486 | Susceptibility Gene For Alzheimer's Disease - The invention relates to genetic screens for susceptibility to Alzheimer's disease. In particular, the invention provides genetic screens based on genotyping of the p21E2c31 A/T polymorphism and/or the p21E3+20 C/T polymorphism in the p21cip 1 gene. | 02-24-2011 |
| 20110045476 | INFLAMMATORY BOWEL DISEASE PROGNOSTICS - The methods and systems of the present invention are useful in the diagnosis of inflammatory bowel disease (IBD) and in the prognosis of IBD progression and disease complications. With the present invention, it is possible to predict outcome of disease and patients who will have a particular risk of disease complications and/or progression to surgery. | 02-24-2011 |
| 20110008796 | INDUSTRIAL METHOD FOR THE ENCAPSULATION OF BIOLOGICAL MATERIAL FOR THE PURPOSE OF STORAGE AT AMBIENT TEMPERATURE WITH A VACUUM SEAL TEST OF THE ENCAPSULATION - A method for the preparation of a sample of biological material in a container for the purpose of its storage, its recovery, and its subsequent use, includes the succession of the following stages:
| 01-13-2011 |
| 20110008792 | PROMOTERS FOR EXPRESSION IN MODIFIED VACCINIA VIRUS ANKARA - The invention concerns promoters, in particular for the expression of genes and/or coding sequences in vaccinia viruses such as Modified vaccinia virus Ankara (MVA). The invention further concerns expression cassettes comprising said promoter, vectors comprising said expression cassettes as well as pharmaceutical compositions and vaccines. | 01-13-2011 |
| 20110008793 | Maize Polymorphisms and Methods of Genotyping - Polymorphic maize DNA loci useful for genotyping between at least two varieties of maize. Sequences of the loci are useful for designing primers and probe oligonucleotides for detecting polymorphisms in maize DNA. Polymorphisms are useful for genotyping applications in maize. The polymorphic markers are useful to establish marker/trait associations, e.g. in linkage disequilibrium mapping and association studies, positional cloning and transgenic applications, marker-aided breeding and marker-assisted selection, hybrid prediction and identity by descent studies. The polymorphic markers are also useful in mapping libraries of DNA clones, e.g. for maize QTLs and genes linked to polymorphisms. | 01-13-2011 |
| 20110008787 | DETECTION PRIMERS FOR NUCLEIC ACID EXTENSION OR AMPLIFICATION REACTIONS - Disclosed are methods and compositions related to real-time PCR and other nucleic acid extension or amplification reactions. | 01-13-2011 |
| 20110008785 | METHODS FOR FORENSIC DNA QUANTITATION - Described herein are methods and devices for nucleic acid quantification and, in particular, to microfluidic methods and devices for nucleic acid quantification. In certain embodiments methods of quantifying a target nucleic acid without the need for amplification are provided. The methods involve, in some embodiments, allowing a binding agent to become immobilized with respect to the target nucleic acid. In some cases, the binding agent comprises a signaling moiety that can be used to quantify the amount of target nucleic acid. In another aspect, the quantification can be carried out rapidly. For example, in certain embodiments, the quantification can be completed within 5 minutes. In yet another aspect, samples containing a low amount of target nucleic acid can be quantified. For instance, in some cases, samples containing less than 100 nanograms per microliter may be quantified. Also described are devices and kits for performing such methods, or the like. | 01-13-2011 |
| 20110008791 | Molecular Diagnosis of Bacteremia - A highly specific assay can be used for the detection of bacteremia in the clinical setting. The ubiquitous background endogenous DNA present in all PCR reagents is eliminated using a restriction endonuclease digestion. Universal primers for eubacteria are used for detection, and specific primers or probes for bacterial species can be used for identification of species. | 01-13-2011 |
| 20110008789 | METHODS AND MATERIALS FOR TREATING INFLAMMATORY CONDITIONS - Methods and kits for treating inflammatory conditions are described that include modulating kallikrein 6 protease activity. | 01-13-2011 |
| 20110008779 | Method of profiling gene expression in a subject having disease - The present invention is directed to detection and measurement of gene transcripts in blood. Specifically provided is a RT-PCR analysis performed on a drop of blood for detecting, diagnosing and monitoring diseases using tissue-specific primers. The present invention also describes methods by which delineation of the sequence and/or quantitation of the expression levels of disease-associated genes allows for an immediate and accurate diagnostic/prognostic test for disease or to assess the effect of a particular treatment regimen. | 01-13-2011 |
| 20110008778 | Method of Generating p.degree. Cells - Described is a method of the generation of ρ° cells using a mitochondrial targeted restriction endonuclease. This method comprises (a) tranfecting cells with an expression vector containing a gene encoding a fusion protein comprising a mitochondrial targeting sequence (MTS) and a restriction endonuclease operatively linked to a suitable promoter, (b) culturing the transfected cells over a sufficient period of time; and (c) selected ρ° cells, e.g., via FACS analysis. | 01-13-2011 |
| 20110008782 | Site-specific incorporation of redox active amino acids into proteins - Compositions and methods of producing components of protein biosynthetic machinery that include orthogonal tRNAs, orthogonal aminoacyl-tRNA synthetases, and orthogonal pairs of tRNAs/synthetases, which incorporate redox active amino acids into proteins are provided. Methods for identifying these orthogonal pairs are also provided along with methods of producing proteins with redox active amino acids using these orthogonal pairs. | 01-13-2011 |
| 20110008784 | METHODS AND COMPOSITIONS FOR IDENTIFYING UNDIFFERENTIATED STEM CELLS AND ASSESSING CELL HEALTH - Disclosed herein are methods and compositions for the identification of teloRNA marks to assess the differentiation status of an individual stem cell or a population of stem cells, to diagnose whether and to what extent a stem cell or stem cell culture has already initiated cell differentiation, and to monitor the differentiation status of an individual stem cell or a stem cell culture during passage. The use of these methods and compositions to monitor the pluripotency and differentiation status of a stem cell or stem cell culture during differentiation enables the identification of undifferentiated and pluripotent stem cells prior to the initiation of differentiation. The methods and compositions can also be used to assess and maintain cell viability; to identify cells or a population of cells that are in a state of poor cell health; and to reduce cell growth or treat a diseased cell including, for example, pre-cancerous cells, cancerous cells, apoptotic cells, aging cells, cells undergoing stress, and otherwise diseased or dysfunctional cells. | 01-13-2011 |
| 20110008776 | INTEGRATED SEPARATION AND DETECTION CARTRIDGE USING MAGNETIC PARTICLES WITH BIMODAL SIZE DISTRIBUTION - The present invention relates to a device and a method for quantitative detecting of the presence or absence of a target analyte in a liquid sample, the device comprising a reaction chamber having a volume of less than 200 μl comprising an immobilization matrix capable of capturing the analyte, said immobilization matrix, preferably comprising a particulate magnetic material, having a size distribution that is at least bimodal. | 01-13-2011 |
| 20110008775 | SEQUENCING OF NUCLEIC ACIDS - The present invention relates to the field of analysis of nucleic acid sequences. More specifically, the present invention relates to the method and instrument for high throughput parallel DNA sequencing. The present invention also provides method for selection of sequences from analyte samples for enrichment of the target sequences or depletion of the selected molecules and in particular undesirable sequence templates from sequencing samples. | 01-13-2011 |
| 20110008774 | PROTEIN DISCOVERY USING INTRACELLULAR RIBOSOME DISPLAY - The present invention relates to a method of identifying a protein that binds to a target molecule and has intracellular functionality. This method includes providing a construct comprising a deoxyribonucleic acid molecule encoding the protein which binds to the target molecule, with the deoxyribonucleic acid molecule being coupled to a stall sequence. A host cell is transformed with the construct and then cultured under conditions effective to form, within the host cell, a complex of the protein whose translation has been stalled, the mRNA encoding the protein, and ribosomes. The protein in the complex is in a properly folded, active form and the complex is recovered from the cell. This method can be carried out with a cell-free extract preparation containing ribosomes instead of a host cell. The present invention also relates to a construct which includes a deoxyribonucleic acid molecule encoding a protein that binds to a target molecule and an SecM stalling sequence coupled to the deoxyribonucleic acid molecule. The deoxyribonucleic acid molecule and the SecM stalling sequence are coupled with sufficient distance between them to permit expression of their encoded protein, within the cell, in a properly folded, active form. | 01-13-2011 |
| 20110008773 | METHOD FOR THE DETERMINATION OF DATA FOR THE PREPARATION OF THE DIAGNOSIS OF PHAKOMATOSIS - The invention concerns a method for the determination of data for the preparation of presymptomatic or prenatal diagnosis of phakomatosis, in particular, a tumor suppressor gene disease, in a high-risk patient, in particular of neurofibromatosis, comprising the steps of: making available the tumor material from a person afflicted with the tumor suppressor gene disease, who is a relative of the high-risk patient; isolating tumor DNA from the tumor in the relative; isolating blood DNA from the blood of the relative; amplifying polymorphous DNA microsatellite markers from the tumor and the blood; separating the markers by length; observing the lengths of the markers; comparing the markers from the blood and the tumor; examining for a loss of alleles; optionally, comparing amplified markers from a second tumor of the relative; and amplifying polymorphous DNA microsatellite markers from the blood of an offspring and separating and observing the markers. | 01-13-2011 |
| 20110008772 | PROBES FOR DETECTING MYCOBACTERIUM TUBERCULOSIS AND MYCOBACTERIUM TUBERCULOSIS COMPLEX AND METHOD USING THE SAME - The present invention relates to a probe for detecting | 01-13-2011 |
| 20110008770 | COMPOSITIONS AND METHODS FOR REVERSE TRANSCRIPTION OF NUCLEIC ACID MOLECULES - The present invention is generally related to compositions and methods for the reverse transcription of nucleic acid molecules, especially messenger RNA molecules. Specifically, the invention relates to compositions comprising mixtures of polypeptides having reverse transcriptase (RT) activity, and to methods of producing, amplifying or sequencing nucleic acid molecules (particularly cDNA molecules) using these compositions or polypeptides, particularly at temperatures above about 55° C. The invention also relates to nucleic acid molecules produced by these methods, to vectors and host cells comprising these nucleic acid molecules, and to the use of such nucleic acid molecules to produce desired polypeptides. The invention also relates to methods for producing Rous Sarcoma Virus (RSV) and Avian Myeloblastosis Virus (AMV) RTs or other Avian Sarcoma-Leukosis Virus (ASLV) RTs (α and/or β subunits thereof), to isolated nucleic acid molecules encoding such RSV RT, AMV RT or other ASLV RT subunits, to vectors and host cells comprising these isolated nucleic acid molecules and to RSV RT, AMV RT and other ASLV RT subunits produced by these methods. The invention further relates to nucleic acid molecules encoding recombinant heterodimeric RT holoenzymes, particularly heterodimeric RSV RTs, AMV RTs or other ASLV RTs (which may be αβ RTs, ββ RTs, or α RTs), vectors (particularly baculovirus vectors) and host cells (particularly insect and yeast cells) comprising these nucleic acid molecules, methods for producing these heterodimeric RTs and heterodimeric RTs produced by these methods. The invention also relates to kits comprising the compositions, polypeptides, or RSV RTs, AMV RTs or other ASLV RTs of the invention. | 01-13-2011 |
| 20110008771 | METHOD AND MATERIALS FOR TRIGGERED RELEASE OF A BIOLOGICAL SAMPLE - The invention relates to a method for releasing a biological sample from a solid matrix substantially without disintegration of biomolecules comtained in said biological sample by at least partially transferring the solid state of said matrix into a dissolved or liquid state by changing at least one physico-chemical property of the environment of said matrix. | 01-13-2011 |
| 20110008781 | ISOTHERMAL AMPLIFICATION OF NUCLEIC ACIDS ON A SOLID SUPPORT - Methods for isothermal amplification of nucleic acid by means of a solid support are disclosed. These methods are useful for applications needing high throughput, in particular nucleic acid sequencing. | 01-13-2011 |
| 20110008777 | PD-1 MODULATION AND USES THEREOF - Reagents, kits, methods and uses thereof useful for the modulation of immune function, such as the identification of modulators of PD-1 activity, are described. Such reagents, kits, methods and uses thereof may be useful, for example, in the diagnosis, prognostication, prevention and/or treatment of immune-related diseases and/or conditions. | 01-13-2011 |
| 20100055678 | Method of profiling a cell population - The present invention relates to a method of profiling a cell population comprising a step of detecting the presence or absence of at least two biological markers in said cell population, wherein at least one of said markers is a cell surface marker, which is a sialylated N-glycan marker with structure NeuNAcα3Gal, and at least one of said markers is a mRNA marker related to glycoproteins and/or glycosynthase proteins. The invention also relates to method for purification of cord blood cell population and to a complete cell population from cord blood purified by said method. | 03-04-2010 |
| 20100068701 | CHROMOSOME LABELING METHOD - A method of sample analysis is provided. In certain embodiments, the method may involve a) contacting a genomic sample comprising a test chromosome with a plurality of sets of labeled oligonucleotide probes under in situ hybridization conditions to produce a contacted sample having an oligonucleotide binding pattern; b) imaging the contacted sample to provide an image showing the oligonucleotide binding pattern; and c) analyzing the oligonucleotide binding pattern to identify a chromosomal rearrangement in the test chromosome relative to a reference chromosome. | 03-18-2010 |
| 20100055708 | Assay for Chlamydia trachomatis by amplification and detection of Chlamydia trachomatis cytotoxin gene - A region of the | 03-04-2010 |
| 20100055680 | GENOMIC DNA LABELING AND AMPLIFICATION - Methods of amplifying genomic DNA are provided which include contacting template genomic DNA, a plurality of random primers, and a DNA polymerase, wherein the ratio of template genomic DNA to random primers is in the range of about 1:10-1:35,000,000 (w/w), inclusive, to produce a reaction mixture; and incubating the reaction mixture under isothermal conditions suitable for DNA synthesis, thereby producing amplified genomic DNA characterized by less than 10 percent gene copy number error. The template genomic DNA used in described methods can be in denatured condition and/or in non-denatured condition to achieve production of amplified genomic DNA characterized by less than 10 percent gene copy number error. In a particular option, the reaction mixture includes detectably labeled nucleotides and detectably labeled amplified genomic DNA characterized by less than 10 percent gene copy number error is produced. | 03-04-2010 |
| 20110053164 | METHODS FOR DETERMINING CANCER RESISTANCE TO HISTONE DEACETYLASE INHIBITORS - Described herein are methods and compositions for determining whether a particular cancer is resistant to or susceptible to a histone deacetylase inhibitor or to histone deacetylase inhibitors. The methods include analysis of the expression levels of at least four biomarker genes associated with response to a histone deacetylase inhibitor. Also described herein are methods and compositions for increasing the likelihood of a therapeutically effective treatment in a patient, comprising an analysis of the expression levels of at least four biomarker genes associated with response to a histone deacetylase inhibitor. Also described herein are isolated populations of nucleic acids derived from a cancer sensitive to or resistant to a histone deacetylase inhibitor. Further described are kits and indications that are optionally used in conjunction with the aforementioned methods and compositions. | 03-03-2011 |
| 20090317818 | RESTRICTION ENDONUCLEASE ENHANCED POLYMORPHIC SEQUENCE DETECTION - Provided in part herein is an improved method for the detection of specific polymorphic alleles in a mixed DNA population. The method comprises enriching the relative percentage of a given polymorphic allele that is exponentially amplifiable by PCR. Provided also are methods for selectively enriching target nucleic acid, for example, fetal nucleic acid in a maternal sample. In the case of detecting fetal nucleic acid in a maternal sample, a restriction enzyme is introduced that can discriminate between the alleles of a polymorphic site. In some embodiments, the maternal allele is digested and nucleic acid comprising the paternal allele is relatively enriched. | 12-24-2009 |
| 20110014621 | DETECTING MULTINUCLEOTIDE REPEATS - Methods of determining the length of a multinucleotide repeat region in a target nucleic acid are provided herein which include labeling amplified target nucleic acids with a target detection label independent of the number of multinucleotide repeats and a repeat-detection label proportional to the number of multinucleotide repeats, wherein the two types of labels are each independently incorporated in the amplified target nucleic acids during the amplifying or after the amplifying; binding the amplified target nucleic acids to a capture probe specific for the amplified target nucleic acids; detecting the target detection label associated with the capture probe to produce a first signal; detecting the repeat-detection label associated with the capture probe to produce a second signal; and determining a ratio of the first signal and the second signal, wherein the ratio is indicative of the length of the multinucleotide repeat region in the target nucleic acid. | 01-20-2011 |
| 20100028874 | HEPATITIS C VIRUS INFECTION BIOMARKERS - A signature set of genes associated with hepatitis C virus infection is described. | 02-04-2010 |
| 20100240039 | FHL1 MUTATIONS ASSOCIATED WITH NOVEL X-LINKED MUSCULAR MYOPATHIES - Four and a Half LIM domains protein 1 (FHL-1) mutations at positions 128 or 224 that are associated with X-linked muscular myopathy, methods of screening subjects to identify those susceptible to muscular myopathy including muscular dystrophy and cardiomyopathy and kits. | 09-23-2010 |
| 20100240031 | Method of Predicting Metastatic Potential Prognosis or Overall Survival of Cancer Patients - A method of predicting metastatic potential, prognosis or overall survival of cancer patients is provided. The method utilizes reliable markers, HIF-1α, TWIST or Snail, to predict the probability of the metastatic potential, prognosis situation or overall survival of cancer patients. Moreover, the method provided by the present invention can reach relatively higher predictability of metastatic potential, prognosis situation or overall survival as compared with the current markers. | 09-23-2010 |
| 20110039275 | Method for Predicting a Clinical Response of a Patient Suffering from or at Risk of Developing Cancer Towards a Given Mode of Treatment - The present invention relates to a method for predicting a clinical response of a patient suffering from or at risk of developing cancer, preferably colorectal cancer, towards a given mode of treatment, said method comprising the steps of: a) obtaining a biological sample from said patient; b) determining the expression level of at least SPON-2, and optionally determining the expression level of SPON-1, in said sample; c) comparing the expression level or expression levels determined in (b) with one or several reference expression levels; and d) predicting therapeutic success for said given mode of treatment in said patient or implementing therapeutic regimen in said subject from the outcome of the comparison in step (C). | 02-17-2011 |
| 20110033854 | METHODS AND COMPOSITIONS FOR LONG FRAGMENT READ SEQUENCING - The present invention is directed to methods and compositions for long fragment read sequencing. The present invention encompasses methods and compositions for preparing long fragments of genomic DNA, for processing genomic DNA for long fragment read sequencing methods, as well as software and algorithms for processing and analyzing sequence data. | 02-10-2011 |
| 20110117568 | Method for Amplifying Target Nucleic Acid Sequence, Method for Detecting Mutation Using the Same, and Reagent Used for the Same - The present invention provides a method for detecting a mutation capable of detecting a mutation with high sensitivity and high reliability in one reaction system. Using primers (Xmt) and (Xwt), a target nucleic acid sequence whose objective base to be detected is a mutant-type is amplified with amplification efficiency higher than a target nucleic acid sequence whose objective base to be detected is a normal-type. The (Xmt) is a primer that is complementary to a region including a mutant-type base in the template nucleic acid and has a base complementary to a mutant-type base at a 3′ region, and the (Xwt) is a primer that is complementary to a region including a normal-type base in the template nucleic acid and has a base complementary to a normal-type base at a 3′ region. It is preferable that amplification efficiency by the (Xmt) with reference to a mutant-type template nucleic acid is higher than that by the (Xwt) with reference to a normal-type template nucleic acid. Then, a signal value that shows a molten state of a hybridization product between the thus obtained amplification product and the probe is measured, and the presence or absence of the mutation of the objective base site is determined from a change in the signal value accompanying a change in the temperature. | 05-19-2011 |
| 20110081651 | EGFR AND KRAS MUTATIONS - The present invention relates to mutations in Epidermal Growth Factor Receptor (EGFR) and KRAS and methods of detecting such mutations as well as prognostic methods for identifying tumors that are susceptible to anticancer therapy such as chemotherapy and/or kinase inhibitor treatment. The methods involve determining the presence of a mutated EGFR gene or mutated EGFR protein and/or a mutated KRAS gene or mutated KRAS protein in a tumor sample. | 04-07-2011 |
| 20100240060 | Detection and Diagnosis of Smoking Related Cancers - Gene probes for specific regions of chromosome 3 (3p21.3) and chromosome 10 (10q22) have been found to be tools for the diagnosis and prognosis of smoking related cancers such as non-small cell lung cancer (NSCLC). For example, these probes can be used with fluorescence in situ hybridization (FISH), and used to stratify smokers into high and low risk groups, as well as determine a patients susceptibility to the development of smoking related cancers. | 09-23-2010 |
| 20090275034 | TEMPERATURE CONTROL SYSTEM - Single molecule technologies generally require sensitive optical detection and the ability to operate at multiple temperatures simultaneously in different parts of the instrument. The system for controlling the temperature of a microfluidic device and methods for controlling the temperature of sequencing reactions includes a chamber for receiving a microfluidic device, a heating control device in fluid communication with the chamber for delivering a heated fluid to the chamber to heat the microfluidic device, and a cooling control device in liquid communication with the chamber for delivering a cooled fluid to the chamber to cool the microfluidic device. A temperature control unit in liquid communication with a cooling element and/or a heating element are used to regulate temperature of sequencing substrates and objective lenses for optical detection of sequencing reactions. | 11-05-2009 |
| 20110059444 | Magnetic Detection of Small Entities - A novel detection or quantifying method for biological entities or molecules such as, but not limited to, DNA, microorganisms and pathogens, proteins and antibodies, that by themselves are target molecules or from which target molecules are extracted, comprises the steps of i) forming target molecule-dependent volume-amplified entities, ii) allowing magnetic nanoparticles to bind to said volume-amplified entities, and iii) measuring changes in dynamic magnetic response of the magnetic nanoparticles caused by the increase in hydrodynamic volume of said magnetic nanoparticles or measuring the magnetic field due to the magnetic nanoparticles as they bind to a sensor surface functionalized with a secondary capturing probe. Biosensors and kits are adapted to be used in such a method. | 03-10-2011 |
| 20110059441 | METHOF OF PRODUCING BIOACTIVE PAPER - The present disclosure relates to methods for attaching bioactive agents to paper products by contacting the paper with a solution comprising colloidal support particles where said colloidal support particles are associated with bioactive agents. In specific embodiment of the disclosure, the colloidal support particles are functionalized poly(N-isopropylacrylamide) microgels. The disclosure further covers the bioactive paper produced by this method as well as uses thereof, in particular for pathogen detection. | 03-10-2011 |
| 20110059440 | RAPID ANALYSIS OF VARIATIONS IN A GENOME - The invention provides a method useful for determining the sequence of large numbers of loci of interest on a single or multiple chromosomes. The method utilizes an oligonucleotide primer that contains a recognition site for a restriction enzyme such that digestion with the restriction enzyme generates a 5′ overhang containing the locus of interest. The 5′ overhang is used as a template to incorporate nucleotides, which can be detected. The method is especially amenable to the analysis of large numbers of sequences, such as single nucleotide polymorphisms, from one sample of nucleic acid. | 03-10-2011 |
| 20110039265 | Method of detecting tumor-associated DNA in plasma or serum - This invention relates to detection of specific extracellular nucleic acid in plasma or serum fractions of human or animal blood associated with neoplastic or proliferative disease. Specifically, the invention relates to detection of nucleic acid derived from mutant oncogenes or other tumor-associated DNA, and to those methods of detecting and monitoring extracellular mutant oncogenes or tumor-associated DNA found in the plasma or serum fraction of blood by using rapid DNA extraction followed by nucleic acid amplification with or without enrichment for mutant DNA. In particular, the invention relates to the detection, identification, or monitoring of the existence, progression or clinical status of benign, premalignant, or malignant neoplasms in human or other animals that contain a mutation that is associated with the neoplasm through detection of the mutated nucleic acid of the neoplasm in plasma or serum fractions. The invention permits the detection of extracellular, tumor-associated nucleic acid in the serum or plasma of humans or other animals recognized as having a neoplastic or proliferative disease or in individuals without any prior history or diagnosis of neoplastic or proliferative disease. The invention provides the ability to detect extracellular nucleic acid derived from genetic sequences known to be associated with neoplasia, such a oncogenes, as well as genetic sequences previously unrecognized as being associated with neoplastic or proliferative disease. The invention thereby provides methods for early identification of colorectal, pancreatic, lung, breast, bladder, ovarian, lymphoma and all other malignancies carrying tumor-related mutations of DNA and methods for monitoring cancer and other neoplastic disorders in humane and other animals. | 02-17-2011 |
| 20110091890 | TRICHOPLUSIA NI CELL LINE AND METHODS OF USE - An isolated cell from the cell line identified as TnT4. This cell may be infected with a baculovirus expression vector which may carry a heterologous nucleotide that encodes a polypeptide, such as a membrane protein, e.g., human neurotensin receptor 1. Also included is a method for using this cell line to produce a polypeptide, such as a membrane protein; and a method for identifying a cell-of-interest which expresses a protein-of-interest. | 04-21-2011 |
| 20110033846 | Concurrent Analysis of Multiple Patient Samples Using Solid Phase Addressable Multiplex Test with High Signal-to-Noise Ratio - Contemplated systems and methods allow analysis of multiple and distinct patient samples using a labeling scheme that entirely avoids carry-over of a label or reagent to the analytic platform, typically an addressable solid phase. In preferred aspects, a hybridization portion, a fluorophore, and/or a quencher are removed by a 5′-3′-exonuclease activity of a polymerase from a reporter oligonucleotide to so remove the oligonucleotide from the pool of molecules that bind to the solid phase and/or or to provide signal differentiation by removal of a fluorophore or quencher. | 02-10-2011 |
| 20090286253 | GENETIC LOCI ASSOCIATED WITH SCLEROTINIA TOLERANCE IN SOYBEAN - The invention relates to methods and compositions for identifying soybean plants that are tolerant, have improved tolerance or are susceptible to | 11-19-2009 |
| 20090286252 | NRIF3, NOVEL CO-ACTIVATOR FOR NUCLEAR HORMONE RECEPTORS - Nucleic acids encoding NRIF3 are described. Polypeptides having amino acid sequences of NRIF3 proteins are also provided. A method is also provided for isolating and cloning NRIF3 cDNA. NRIF3 is useful in development/implementation of high throughput screens to identify novel thyroid hormone receptor (TR) and retinoid X receptor (RXR) agonists and antagonists. Methods are also provided for identifying compounds that directly interfere with the interaction of NRIF3 and TR or RXR. Finally, therapies based on modulation of NRIF3 activity are disclosed. | 11-19-2009 |
| 20090286251 | Enzyme Reagents for Amplification of Polynucleotides in the Presence of Inhibitors - Compositions and methods are provided for amplifying polynucletoides from samples containing inhibitors that normally inhibit amplification using an enzyme blend containing a plurality of polymerases. The ability to amplify polynucleotides efficiently in the presence of inhibitors allows the enzyme reagent to be used in both routine amplification and real-time amplification from inhibitor-containing samples. | 11-19-2009 |
| 20090286249 | INACTIVATABLE TARGET CAPTURE OLIGOMERS FOR USE IN THE SELECTIVE HYBRIDIZATION AND CAPTURE OF TARGET NUCLEIC ACID SEQUENCES - The present invention provides compositions, kits and methods for the selective hybridization and capture of a specific target nucleic acid. The specific target nucleic acid may be present in a heterogeneous mixture of nucleic acids. Selective hybridization and capture provides a target nucleic acid that is substantially free of non-target and/or contaminating nucleic acids. Target nucleic acids that have been selectively hybridized and captured using the current invention are then used in subsequent analysis, wherein the presence of non-target and/or contaminating nucleic acids that interfere with said subsequent analysis have been substantially reduced or eliminated, thereby providing improved analysis results. The invention offers the further advantage of requiring less stringent purification and/or sterility efforts than conventionally needed in order to ensure that enzymes and other reagents used in subsequent analysis, or present in the environment in which an assay is performed, are free of bacterial or other contaminating nucleic acids. | 11-19-2009 |
| 20090286248 | Methods for Determining Drug Responsiveness - The invention provides a diagnostics assay for measuring the responsiveness to a drug by comparing the mRNA levels of a gene that responds to the drug, such as a steroid, to the MRNA levels of a gene that does not respond to the drug. Methods according to the invention are useful for predicting the ability of a patient (or a tissue, body fluid or cell sample in vitro) to respond to a drug or steroid at any stage of their treatment (i.e., before, during or after), and to monitor the patient (or a tissue, body fluid or cell) over time to assess continued responsiveness to the drug or steroid. | 11-19-2009 |
| 20090286247 | Novel nucleic acid base pair - A novel artificial nucleic acid base pair which is obtained by forming a selective base pair by introducing a group having steric hindrance (preferably a group having steric hindrance and static repulsion and a stacking effect) and can be recognized by a polymerase such as DNA polymerase; a novel artificial gene; and a method of designing nucleic acid bases so as to form a selective base pair with the use of steric hindrance, static repulsion and stacking effect at the base moiety of the nucleic acid. An artificial nucleic acid comprising these bases; a process for producing the same; a codon containing the same; a nucleic acid molecule containing the same; a process for producing a non-natural gene by using the same; a process for producing a novel protein by using the above nucleic acid molecule or non-natural gene, and the like. | 11-19-2009 |
| 20090286245 | TWO SLOW-STEP POLYMERASE ENZYME SYSTEMS AND METHODS - Compositions, kits, methods and systems for nucleotide sequencing comprising producing polymerase reactions that exhibit two kinetically observable steps within an observable phase of the polymerase reaction. Two slow step systems can be produced, for example, by selecting the appropriate polymerase enzyme, polymerase reaction conditions including cofactors, and polymerase reaction substrates including the primed template and nucleotides. | 11-19-2009 |
| 20090286244 | Fluorescent Color Markers - The invention provides a yeast-enhanced red fluorescent protein. In an embodiment of the invention, the yeast-enhanced red fluorescent protein is monomeric and is expressible in | 11-19-2009 |
| 20090286243 | Compositions and methods for spinocerebellar ataxia - Mutations in the KCNC3 (Kv3.3) voltage-gated potassium channel gene result in spinocerebellar ataxia. | 11-19-2009 |
| 20090286241 | SYSTEM AND METHOD FOR DETECTING A GENE MUTATION - A system for detecting a gene mutation encompasses a spectrum generation mechanism configured to acquire an amplified product containing the specific site sandwiched by recognition sites of a restriction enzyme by using a recognition site introduction-oriented primer, and to generate a mass spectrum of an oligonucleotide fragment, which is cut out from the amplified product by using the restriction enzyme; an area ratio calculation mechanism configured to calculate an area ratio of a peak of a wild-type sequence of the specific site and a peak of a mutation-type sequence of the specific site in the mass spectrum; and an abundance ratio calculation mechanism configured to obtain an abundance ratio of the wild-type sequence and the mutation-type sequence based on a relationship between a previously acquired area ratio and the abundance ratio of the wild-type sequence and the mutation-type sequence. | 11-19-2009 |
| 20090286240 | BIOMARKERS OVEREXPRESSED IN PROSTATE CANCER - Biomarkers are identified by analyzing gene expression data using support vector machines (SVM) to rank genes according to their ability to separate prostate cancer from normal tissue. Proteins expressed by identified genes are detected in patient samples to screen, predict and monitor prostate cancer. | 11-19-2009 |
| 20090286238 | Methods to Monitor, Diagnose and Identify Biomarkers for Psychotic Disorders - A stimulated or non-stimulated T-cell sample can be used to diagnose or monitor a psychotic disorder, to identify a biomarker, or as to test a considerate as a potential therapeutic agent. | 11-19-2009 |
| 20090286237 | Diagnostic Kits and Methods for Oesophageal Abnormalities - The invention relates to kits and methods for aiding the diagnosis of Barrett's oesophagus or Barrett's associated dysplasia. Preferred is a method comprising assaying cells from the surface of a subject's oesophagus for a non-squamous cellular marker, wherein detection of such a marker indicates increased likelihood of the presence of Barrett's or Barrett's associated dysplasia, preferably wherein said sample of cells is not directed to a particular site within the oesophagus. The invention also encompasses a method comprising sampling the cellular surface of the oesophagus of said subject. The invention also relates to a kit comprising a swallowable device comprising abrasive material capable of collecting cells from the surface of the oesophagus, together with printed instructions for its use in detection of Barrett's oesophagus or Barrett's associated dysplasia. Preferably said device comprises a capsule sponge. | 11-19-2009 |
| 20090286236 | Method for detecting cell proliferative disorders - The present invention relates to the detection of a cell proliferative disorder associated with alterations of microsatellite DNA in a sample. The microsatellite DNA can be contained within any of a variety of samples, such as urine, sputum, bile, stool, cervical tissue, saliva, tears, or cerebral spinal fluid. The invention is a method to detect an allelic imbalance by assaying microsatellite DNA. Allelic imbalance is detected by observing an abnormality in an allele, such as an increase or decrease in microsatellite DNA which is at or corresponds to an allele. An increase can be detected as the appearance of a new allele. In practicing the invention, DNA amplification methods, particularly polymerase chain reactions, are useful for amplifying the DNA. DNA analysis methods can be used to detect such a decrease or increase. The invention is also a method to detect genetic instability of microsatellite DNA. Genetic instability is detected by observing an amplification or deletion of the small, tandem repeat DNA sequences in the microsatellite DNA which is at or corresponds to an allele. The invention is also a kit for practicing these methods. | 11-19-2009 |
| 20090286235 | Mdr1 Snp in Acute Rejection - The present invention concerns a method for the prediction of acute renal transplant rejection by detecting a polymorphism in exon 26 of the MDR1 gene, optionally in combination with polymorphisms of the IMPDH2 and IL 10 genes which were found to be associated with this disease. | 11-19-2009 |
| 20110111409 | METHODS FOR DEPLETING RNA FROM NUCLEIC ACID SAMPLES - The invention relates to methods of depleting RNA from a nucleic acid sample. The RNA may be any RNA, including, but not limited to, rRNA, tRNA, and mRNA. The method is useful for depleting RNA from a nucleic acid sample obtained from a fixed paraffin-embedded tissue (FPET) sample. The method may also be used to prepare cDNA, in particular, a cDNA library for further analysis or manipulation. | 05-12-2011 |
| 20110033862 | METHODS FOR CELL GENOTYPING - Methods for cell genotyping are disclosed herein. A method for determining the genomic data of one or a small number of cells, or from fragmentary DNA, where a limited quantity of genetic data is available may include adding one or more targeted primers to a whole genome amplification of a cell, increasing the accuracy with which key alleles are measured in the context of a whole genome amplification. The genetic material from a single cell may be divided into fractions, each of which may be separately genotyped, allowing the reconstruction of the cells haplotype. The genetic material from a single cell may be divided into fractions, each of which may be separately genotyped, and the distribution of the various alleles in the different fractions may be used to determine the ploidy state of one or a plurality of chromosomes in the cell. | 02-10-2011 |
| 20110033858 | siRNA DETECTION METHOD - PolydG is added to the terminal overhangs of an siRNA. Next, a primer containing a polydC sequence added with a tag sequence is annealed and cDNA is synthesized by a reverse transcription reaction. Quantitative PCR is performed between a primer carrying the same sequence as the tag sequence, and a primer containing the same sequence as the siRNA sequence to be detected. The amount of siRNA of interest can be determined from a calibration curve produced using known amounts of short-chain dsDNA. | 02-10-2011 |
| 20100028867 | LRRTM1 Compositions and Methods of Their Use for the Diagnosis and Treatment of Cancer - Microarray analysis, confirmed by RT-PCR, demonstrated that mRNA from certain cancer tissues, for example, ovarian cancer tissue, pancreatic cancer tissue, and colorectal cancer tissue, hybridizes specifically and preferentially to LRRTM1. LRRTM1 is a leucine-rich repeat transmembrane protein overexpressed on the surface of cancer cells compared to normal tissues and thus provides a therapeutic target for treating cancer. Modulators of LRRTM1, highly expressed in cancerous as compared to normal tissues, are provided for the diagnosis and treatment of proliferative disorders such as cancer. The invention further provides methods of treating cancer with therapeutic agents directed toward LRRTM1. | 02-04-2010 |
| 20100184081 | GENETIC MARKERS FOR OBESITY - The present invention is directed to new genetic variants or polymorphisms at the perilipin locus (PLIN) including PLIN1: 6209T (allele 1)>C (allele 2); PLIN3 10171 (allele 1) A >T (allele 2); PLIN4: 11482G (allele 1)>A (allele 2); PLIN5: 13041A (allele 1)>G (allele 2) and PLIN6: 14995A (allele 1)>T (allele 2), and their use in diagnostic and prognostic applications for obesity and obesity-related diseases, such as metabolic syndrome and cardiovascular disease. | 07-22-2010 |
| 20100055687 | Mutations in the BCR-ABL tyrosine kinase associated with resistance to ST1-571 - The invention described herein relates to novel genes and their encoded proteins, termed Mutants Associated with Resistance to STI-571 (e.g., T315I Bcr-Abl), and to diagnostic and therapeutic methods and compositions useful in the management of various cancers that express MARS. The invention further provides methods for identifying molecules that bind to and/or modulate the functional activity of MARS. | 03-04-2010 |
| 20100009353 | Dye Compounds and the Use of their Labelled Conjugates - Novel rhodamine dye compounds, labelled conjugates comprising the dyes are described, together with methods for their use. The dyes and labelled conjugates are useful as molecular probes in a variety of applications, such as in assays involving staining of cells, protein binding, and analysis of nucleic acids, such as hybridization assays and nucleic acid sequencing. | 01-14-2010 |
| 20100323361 | METHODS, SYSTEMS AND KITS FOR DETECTING PROTEIN-NUCLEIC ACID INTERACTIONS - Methods, systems and kits for detecting protein-nucleic acid interactions, in particular, detecting the genomic location to near-base pair resolution at which a particular protein (e.g., transcription factor) binds includes combining steps of a convention chromatin immunoprecipitation (ChIP) assay with use of an exonuclease that digests DNA strands in the 5′-3′ or 3′-5′ direction until it reaches a bound protein including a protein crosslinked to DNA. A significant improvement of the resolution and dynamic range of the ChIP assay will increase one's ability to determine with confidence where a particular protein is binding in the genome. Importantly, proteins that inefficiently crosslink to DNA (either intrinsically or due to indirect crosslinking via another protein) and thus are very difficult to detect, are expected to be significantly detected by the kits and methods described herein. Inasmuch as most aspects of infectious diseases, inborn diseases, and cancers are rooted in the mis-expression of genes, having a better measure of the binding of proteins to genes or promoter regions will greatly enhance the ability of investigators to understand the driving molecular mechanisms behind these human maladies. | 12-23-2010 |
| 20100330551 | Novel Restriction Endonucleases, DNA Encoding These Endonucleases and Methods for Identifying New Endonucleases with the Same or Varied Specificity - Specified restriction endonucleases have been characterized for the first time by their amino acid and DNA sequences. These sequences and those with at least 90% identity thereto have been used as probes in sequence similarity analyses to identify sequence matches in a sequence database that corresponds to novel restriction endonucleases or isoschizomers. The sequence similarity analyses includes selecting a positive sequence match from any sequence producing an expectation value of less than or equal to e-02. | 12-30-2010 |
| 20090258369 | OVER-EXPRESSION AND MUTATION OF A TYROSINE KINASE RECEPTOR FGFR4 IN TUMORS - This disclosure provides tyrosine kinase protein and nucleic acid variants, particularly FGFR4 variants, which are linked to increased risk of tumor metastasis. The disclosure further provides methods of diagnosis and prognosis, and development of new therapeutic agents using these molecules and fragments thereof, and kits for employing these methods and compositions. | 10-15-2009 |
| 20100196907 | MARKERS TO PREDICT AND MONITOR RESPONSE TO AURORA KINASE B INHIBITOR THERAPY - The present invention relates to identifying the presence or absence of one or more copy number gains in the ABCB1 gene, the ABCB4 gene or combinations thereof, identifying patients eligible to receive Aurora kinase inhibitor therapy, either as monotherapy or as part of combination therapy, and monitoring patients' response to such therapy. | 08-05-2010 |
| 20090317807 | Primers for Use in Detecting Metallo-Beta-Lactamases - Oliognucleotide primers are provided that are specific for nucleic acid characteristic of certain beta-lactamases. The primers can be employed in methods to identify nucleic acid characteristic of family-specific beta-lactamase enzymes in samples, and particularly, in clinical isolates of Gram-negative bacteria. | 12-24-2009 |
| 20100184054 | BINDING OF PATHOLOGICAL FORMS OF PRION PROTEINS - A process for the selective binding of an aggregating abnormal form of a protein in the presence of the nonaggregating normal form of the protein, including contacting under selective binding conditions a material containing both the abnormal and normal forms with a binding agent which is a polyionic material having a binding avidity for the aggregating form of the protein as present in the sample. | 07-22-2010 |
| 20100151448 | Asymmetric PCR Amplification, its Special Primer and Application - The present invention discloses an asymmetric PCR amplification method, its special primer and application, aims to provide a simple, effective PCR amplification for preparation of single-stranded product. The asymmetric PCR primer of the invention comprises some PCR primer pairs, in which an unrelated nucleic acids sequence to target sequence to be detected is added onto 5′-terminal of one primer. The asymmetric PCR amplification provided includes the steps: 1) preparative denaturing; 2) repetitiously denaturing, primers annealing, extending cycles as the first stage of PCR amplification; 3) repetitiously denaturing, primer extending cycles as the second stage of PCR amplification, wherein an unrelated nucleic acids sequence to target sequence to be detected is added onto 5′-terminal of one PCR primer of each pair in extension. With the asymmetric PCR amplification of the invention, high throughput of single-stranded products can be obtained, single PCR amplification or multiple PCR amplification can be carried out. And the method can be widely used in detection of nucleic acids. | 06-17-2010 |
| 20100248253 | METHOD AND KIT FOR ASSESSING RISK OF GOUT AND HYPERURICEMIA - A method for assessing a risk of suffering from a gout of a subject is provided. The method includes steps of obtaining a nucleotide sample from the subject; determining a genetic polymorphism of one of a Urate transporter 1 (URAT1) gene and an alpha-kinase 1 (ALPK1) gene in the nucleotide sample, wherein the genetic polymorphism is associated with an occurrence of the gout; and comparing the genetic polymorphism with a predetermined genetic polymorphism so as to assess the risk of suffering from the gout of the subject. | 09-30-2010 |
| 20100248251 | Tissue Rejection - This document relates to methods and materials involved in detecting tissue rejection (e.g., organ rejection). For example, this document relates to methods and materials involved in the early detection of kidney tissue rejection. | 09-30-2010 |
| 20100248248 | Use of the Serological Assay of the Cytokine B-Lymphocyte Stimulator (Blys) as a Prognostic and Monitoring Test for Immune-Related Transfusion Reactions - The use for the serum quantification of the cytokine B-Lymphocyte Stimulator (BLyS) for the evaluation of the risk of immunization and transfusion reactions after blood transfusion, and for the monitoring of patients undergoing blood transfusion or re-transfusion in a patient that includes an initial step of taking a sample of blood from the patient, a step of analyzing the blood sample to determine the concentration of cytokine BLyS, a step of comparing the BLyS levels determined in the previous step and one or more reference values of concentration of cytokine BLyS, a step of identifying a significant deviation between the determined concentration of cytokine BLyS and the reference values of concentration of cytokine BLyS indicated in the previous step and a step of assigning a risk and/or therapeutic effectiveness with respect to the immune-mediated transfusion reactions mentioned above, based on the previous steps. | 09-30-2010 |
| 20100248250 | METHOD FOR PREPARING STOOL SAMPLE, SOLUTION FOR PREPARING STOOL SAMPLE, AND KIT FOR COLLECTING STOOL - Provided in the present invention are a method for preparing a stool sample without any need for complicated operations which is capable of efficiently recovering a nucleic acid or the like originating from mammalian cells, such as the cells exfoliated from the large intestine, in the stool; a solution for preparing a stool sample and a kit for stool collection which are used in the above method; and a method for recovering and analyzing the nucleic acid in stool using the stool sample prepared by the above method. More specifically, provided are a method for preparing a stool sample which is a method for preparing a stool sample in order to efficiently recover a nucleic acid from the stool sample, the method characterized in that the collected stool is mixed with a solution for preparing a stool sample which has a water-soluble organic solvent as an active ingredient; a solution for preparing a stool sample which is used in the method; a kit for collecting stool; a method for recovering a nucleic acid characterized by recovering a nucleic acid originating from indigenous enteric bacterium and a nucleic acid originating from an organism other than indigenous enteric bacterium at the same time from the stool sample prepared by the preparation method; and a method for analyzing a nucleic acid that analyzes the nucleic acid recovered by the method for recovering a nucleic acid. | 09-30-2010 |
| 20100248247 | BLOOD ANALYZER AND METHOD FOR DETERMINING EXISTENCE AND NONEXISTENCE OF LYMPHOBLASTS IN BLOOD SAMPLE - The invention provides a blood analyzer comprising a blood sample supply section, a sample preparation section for preparing an assay sample by mixing the blood sample with a nucleic acid-staining fluorescent dye, a light source for irradiating the assay sample, an optical detecting section for receiving fluorescence emitted from the irradiated assay sample and a controller for performing operations comprising detecting a cell group comprising lymphoblasts on the basis of the fluorescence received by the optical detecting section, and outputting an information on an appearance of the lymphoblasts in the blood sample, as well as a method for determining the existence and nonexistence of lymphoblasts in a blood sample. | 09-30-2010 |
| 20100248246 | METHODS OF ENRICHING FOR AND IDENTIFYING POLYMORPHISMS - The invention encompasses methods for enriching for and identifying a polymorphism within a nucleic acid sample either by separating a subset of a nucleic acid sample or by selectively replicating a subset of a nucleic acid sample such that the polymorphism is contained within a nucleic acid population with reduced complexity, and then identifying the polymorphism within the enriched nucleic acid sample. Methods also are disclosed for enriching for and identifying a polymorphism by contacting a nucleic acid sample that includes a subset of nucleic acid molecules having a sequence that binds to a sequence-specific binding activity with a molecule having a sequence-specific binding activity under conditions which permit specific binding, such that the subset of nucleic acid molecules bound to the activity is enriched for nucleic acid molecules having the sequence recognized by the sequence-specific binding activity, and detecting a polymorphism with respect to a reference sequence in the subset of nucleic acid molecules. | 09-30-2010 |
| 20100248243 | METHOD AND ARRANGEMENT FOR CALIBRATING A SENSOR ELEMENT - A method is disclosed for calibrating a sensor element, which has an immobilized probe oligonucleotide, via which the bonding of a target nucleic acid (Z) can be detected by the sensor. In at least one embodiment, the method includes: a) bringing the sensor element into contact with a control nucleic acid (K), the melting temperature Tm(K) of which is less than the melting temperature Tm(Z) of the target nucleic acid (Z); b) hybridizing the control nucleic acid (K) to the probe oligonucleotide at a temperature T[p]Tm(K) and detecting a negative control signal at a temperature T[n]. According to a refinement of at least one embodiment of the invention, a measuring signal of the target nucleic acid (Z) is measured at a measuring temperature T [mess], where Tm(K)| 09-30-2010 | |
| 20100248245 | INTEGRATED APPARATUS FOR CONDUCTING AND MONITORING CHEMICAL REACTIONS - Apparatus for conducting and monitoring chemical reactions comprises a base and a thermal cycler mounted on the base. A plurality of heat-conducting receptacles are mounted on the thermal cycler and in heat-communication therewith. Each receptacle comprises an opaque body defining a bore having an open end, a first window, and a second window. A cartridge is removably mounted on the receptacles. The cartridge comprises a plurality of light-transmitting reaction vessels, and conduits connected to the reaction vessels for processing and transferring fluid. The reaction vessels are received in the bores of the receptacles through the open ends of the bores. A light emitter is mounted on the base for illuminating the reaction vessels through the first windows of the reaction vessels. A light detector is mounted on the base for selectively receiving and detecting light emitted from the reaction vessels through the second windows of the receptacles. | 09-30-2010 |
| 20100248242 | PROCESS FOR CONCENTRATING NUCLEIC ACID MOLECULES - A process concentrates nucleic acid molecules to be detected of a sample on a surface, with capture molecules that specifically bind the nucleic acid molecules. A support material has a capture probe that can specifically be linked to the nucleic acid molecules to be detected to give complexes. The support material and the nucleic acid molecules of the sample are incubated to form the complexes. The complexes are moved to the surface. At least one portion of the complexes becomes bound to the capture molecules via the capture probe. | 09-30-2010 |
| 20100248241 | MUTATIONS IN THE BCR-ABL TYROSINE KINASE ASSOCIATED WITH RESISTANCE TO STI-571 - The invention described herein relates to novel genes and their encoded proteins, termed Mutants Associated with Resistance to STI-571 (e.g., T315I Bcr-Abl), and to diagnostic and therapeutic methods and compositions useful in the management of various cancers that express MARS. The invention further provides methods for identifying molecules that bind to and/or modulate the functional activity of MARS. | 09-30-2010 |
| 20100248239 | METHODS AND MATERIALS FOR DETECTING FRAGILE X MUTATIONS - This document relates to methods and materials involved in detecting Fragile X mutations and assessing the methylation state of Fragile X alleles. For example, methods and materials for detecting Fragile X alleles using polymerase chain reaction and a hybridization probe (e.g., a non-radioactively labeled hybridization probe) are provided. | 09-30-2010 |
| 20100248240 | GENE AND PROTEIN RELATING TO HEPATOCELLULAR CARCINOMA AND METHODS OF USE THEREOF - The present invention provides a novel human gene ZNFN3A1 whose expression is markedly elevated in a great majority of HCCs compared to corresponding non-cancerous liver tissues. The gene encodes a protein having a zinc finger domain as well as a SET domain and has been found to form a regulatory complex with RNA helicase and RNA polymerase. | 09-30-2010 |
| 20100248238 | Detection Of Bacteria Belonging to the Genus Campylobacter By Targeting Cytolethal Distending Toxin - Multiplex PCR primers that can amplify the cdt genes of | 09-30-2010 |
| 20100248237 | MINIATURIZED, HIGH-THROUGHPUT NUCLEIC ACID ANALYSIS - The present invention is directed to method for analyzing multiple nucleic acid molecules of interest comprising in the steps of (i) providing a plurality of beads, characterized in that each bead comprises at least two sequence specific amplification primers, further characterized in that at least one of the primers is bound to the bead via a cleavable linker, (ii) capturing the nucleic acid molecules of interest from a sample, (iii) clonally isolating the plurality of beads, (iv) cleaving the at least one primer, (v) clonally amplifying the nucleic acid thereby creating multiple amplification products, and (vi) analyzing the amplification products. | 09-30-2010 |
| 20100248235 | BIOMARKERS FOR AUTISM SPECTRUM DISORDERS - Methods of determining the risk of ASD in an individual are provided which comprise identifying the presence of one or more genomic mutations in one or more of the genes, PTCHD1, SHANK3, NFIA, DPP6, DPP10, DYPD, GPR98, PQBP1, ZNF41 and FTSJ1. | 09-30-2010 |
| 20100248236 | Evaluating Genetic Disorders - The present invention relates to genetic analysis and evaluation utilizing copy-number variants or polymorphisms. The methods utilize array comparative genomic hybridization and PCR assays to identify the significance of copy number variations in a subject or subject group. | 09-30-2010 |
| 20100248228 | Method for detecting DNA methylation in cancer cells - The present invention provides a detecting method of detecting malignant cells in a patient's specimen or a biological sample. Specifically, the inventive method includes the steps of extracting a genomic DNA, digesting said genomic DNA with one or multiple methylation sensitive restriction enzymes, and amplifying by PCR with one or multiple selected primers. The PCR can be performed in a conventional or a real-time platform. The inventive method can detect leukemia cells in 90% ALL patients at a sensitivity of up to 10 | 09-30-2010 |
| 20100248229 | INVITRO HUMAN EMBRYONIC MODEL AND A METHOD THEREOF - The present invention relates to the field of stem cells particularly development of a novel human embryonic model using human embryoid bodies obtained from the human embryonic stem cell. The novel human embryonic model disclosed thus can provide a screening assay for determining the toxic activity of the compound and/or drug. | 09-30-2010 |
| 20100248227 | DRUG-PHOSPHORYLATING ENZYME - The objects of the present invention are: elucidation of an enzyme that phosphorylates in vivo a compound such as (2R)-2-amino-2-methyl-4-[5-(5-phenylpentanoyl)thiophen-2-yl]butan-1-ol and provision of a method of phosphorylating the aforementioned compound; provision of a method of screening for a substance phosphorylated by the aforementioned enzyme; provision of a method of determining the ability of a subject to phosphorylate a test compound. | 09-30-2010 |
| 20100248226 | METHODS FOR MEASURING CELL RESPONSE TO DNA DAMAGING AGENTS USING PROMYELOCYTIC LEUKEMIA PROTEIN NUCLEAR BODIES - Methods for assessing the potential efficacy of a DNA-damaging agent as a tumour treatment or for monitoring the efficacy of such treatment by determining promyelocytic leukemia protein nuclear body (PML NB) properties of the tumour are disclosed. PML NB properties, including morphology, number and biochemical composition, of cells or tissue are assessed following exposure to a DNA-damaging agent and compared to corresponding PML NB properties of cells or tissue not exposed to the DNA-damaging agent. The difference, or lack thereof, determines the efficacy of the DNA-damaging agent as a treatment for tumours or monitoring the efficacy of such treatment. | 09-30-2010 |
| 20100248224 | DNA FRAGMENTATION ASSAY - The present invention provides methods for the detection of agents that modify the formation of DNA fragmentation in cells. The disclosed methods are configured in an assay format amendable to high throughput screening applications. | 09-30-2010 |
| 20100248223 | ASSESSING OUTCOMES FOR BREAST CANCER PATIENTS - This document provides methods and materials related to assessing the likely outcome for mammals (e.g., humans) with cancer (e.g., breast cancer). For example, methods and materials for using the ratio of HOXB13 polypeptide expression to IL-17BR polypeptide expression, CYP2D6 genotype, medication history, or combinations thereof to determine the likelihood of a breast cancer patient to experience breast cancer relapse or death are provided. | 09-30-2010 |
| 20100248221 | METHOD FOR IDENTIFICATION OF ORGANISM BY DNA TAG - The object is to provide a novel organism identification method which can be used as an alternative method to a conventional organism identification method which utilizes DNA and requires enormous labor. Developed is an organism identification method for determining whether or not an organism of interest is identical to a specific organism or a progeny thereof, which is characterized by introducing a DNA tag(s) in advance into a cell(s) of the specific organism, or a parasite or a symbiont with the specific organism, and determining whether or not the organism of interest is identical to the specific organism or a progenitor thereof based on the detection or non-detection of the DNA tag in DNA extracted from the organism of interest, or the parasite or the symbiont with the organism of interest. | 09-30-2010 |
| 20100248222 | METHOD OF FORMING SIGNAL PROBE-POLYMER - Provided are a method of forming a signal probe-polymer which makes it possible to form a polymer efficiently and quantitatively, a signal probe-polymer formed by the method, oligonucleotide probes for use in the method, and a method of detecting target analyte having high sensitivity and excellent quantitative capability. The method of forming a signal probe-polymer comprises reacting a plurality of pairs of oligonucleotide probes with each other to form a polymer, a first probe of the pair of oligonucleotide probes comprising three nucleic acid regions of X, Y, and Z regions, located in the stated order from the 5′-terminal and a second probe comprising three nucleic acid regions of X′, Y′, and Z′ regions, located in the stated order from the 5′-terminal, wherein each region of the oligonucleotide probes has a length of from 13 to 15 bases. | 09-30-2010 |
| 20100248219 | Compositions for use in identification of influenza viruses - The present invention provides oligonucleotide primers, compositions, and kits containing the same for rapid identification of viruses which are members of the influenza virus family by amplification of a segment of viral nucleic acid followed by molecular mass analysis. | 09-30-2010 |
| 20100248218 | Conjugates, and use thereof in detection methods - The invention relates to methods for the quantitative and qualitative detection of an analyte in an assay as well as appropriate reagents therefor, especially a carrier molecule to which one or several analyte-specific binding partners are bound and which is provided with additional binding points for a specific binding partner X or Y that is associated with a component of a signal-forming system. Also disclosed is the use of such a conjugate particularly in homogeneous binding tests. | 09-30-2010 |
| 20100184053 | IDENTIFICATION AND QUANTIFICATION OF ONCOGENIC HPV NUCLEIC ACIDS BY MEANS OF REAL-TIME PCR ASSAYS - Method for the identification and quantification of oncogenic HPV nucleic acids comprising: a) first line screening by means of 5 independent SYBR Green I Real-time PCR assays to determine the total viral load and to identify the presence of one or more of 13 high risk HPV genotypes in the sample; b) second line assays to be applied to samples positives for: 5 independent TaqMan Real-time PCR assays to determine the presence and the viral load of the most common oncogenic HPV types: HPV types: 16, 18, 31, 45, 33 group (including 33, 52, 58, 67 genotypes).6 independent SYBR Green I RT Real-time PCR assays to determine the presence in the sample of the oncogenic transcripts E6/E7 of HPV types 16, 18, 31, 33, 45, 58. | 07-22-2010 |
| 20100068708 | Methods for Identifying Compounds that Modulate WNT Signaling in Cancer Cells - Provided herein are methods for screening compounds for their ability to modulate Wnt signaling in cancer cells. | 03-18-2010 |
| 20090258366 | pCryptoRNAi - A vector developed to transform fungi can be used to study the expression of a gene of interest. The vector can provide for the expression of signal proteins in fungi that can be observed and/or monitored. The vector can be used to investigate the effects of RNA interference on a gene of interest in pathogenic fungi. Systems and methods of using the vector are provided. | 10-15-2009 |
| 20100203512 | METHOD FOR RENAL DISEASE DIAGNOSIS AND PROGNOSIS USING ANNEXIN A1 AND RAB23 AS MARKERS - Use of Annexin A1 or Rab23 as a biomarker for diagnosing kidney disease or assessing efficacy of kidney disease treatment. | 08-12-2010 |
| 20100330561 | Marker Gene For Detection of Tumor Promoter, and Method For Detection of Tumor Promoter - The present invention provides 27 marker genes comprising Orm1, Scarb1, Stmn1, Rad21, Nup54, Jun, Dmp1, Abi1, 6530403A03Rik, Slc2a1, Plf (Plf2, Mrpplf3), Fosl1, Chek1, Pik3r5, JunB, Vegfa, Rif1 (LOC671598), Il1rl1, Phex, Tfrc, Zfhx1b, Rad51ap1, Hells, Mcm3, Orm2, Car13 and Ccnb1, which enables the detection of a tumor promoter in a simple manner and within a short period of time in a test for predicting carcinogenicity as a tumor promoter using a cultured cell. The present invention further provide a tumor promoter detection method using at least one of the marker genes. | 12-30-2010 |
| 20090325175 | METHODs OF DETECTION AND QUANTIFICATION OF HOST CELL DNA CONTAMINATION OF PURIFIED PROTEINS - The present invention provides a novel robust, sensitive, reproducible, and accurate method of detecting and quantifying host cell genomic DNA contamination utilizing quantitative real time Polymerase Chain Reaction (qPCR), wherein the qPCR primers are complementary to the highly repetitive host cell genomic DNA sequences, e.g., Alu-equivalent sequences. The present invention is particularly useful for determining the levels of residual genomic DNA in biological products to be administered as therapeutics, e.g., therapeutic proteins. | 12-31-2009 |
| 20110065105 | Novel transcription factor-based biosensor - The present invention provides for a system comprising a BmoR transcription factor, a σ | 03-17-2011 |
| 20100081139 | METHOD FOR DETECTION OF PRESENCE OF TARGET POLYNUCLEOTIDE IN SAMPLES - A method for detecting the presence of a target polynucleotide in a sample, including providing a mixture of the sample and target binding agent and measuring a signal from the mixture, where the target binding agent is capable of assuming a first position where the target binding agent is not bound to the target polynucleotide and a second position where the target binding agent is bound to the target polynucleotide, and the intensity of the signal depends on the proportion of target binding agent in the first and second positions. The method is suitable for detecting a PCR product using a homogeneous detection method. | 04-01-2010 |
| 20100159462 | TUNABLE ELASTOMERIC NANOCHANNELS FOR NANOFLUIDIC MANIPULATION - The invention relates to tunable elastomeric nanochannels for nanofluidic manipulation. In particular, the present invention relates to nanochannels for performing biological assays. | 06-24-2010 |
| 20100184033 | METHODS TO ACCELERATE THE ISOLATION OF NOVEL CELL STRAINS FROM PLURIPOTENT STEM CELLS AND CELLS OBTAINED THEREBY - Aspects of the present invention relate to methods to differentiate pluripotent primordial stem cells, such as human embryonic stem (“hES”) cells, human embryonic germ (“hEG”) cells, human embryo-derived (“hED”) cells and human embryonal carcinoma (“hEC”) cells, to obtain subpopulations of cells from heterogeneous mixtures of cells, wherein the subpopulation of cells possess reduced differentiation potential compared to the original pluripotent stem cells and where the subpopulation is capable of being propagated 20 or more population doublings. This invention also provides novel compositions of such subpopulations of cells and methods to propagate and differentiate said cells. | 07-22-2010 |
| 20100297644 | HIGH THROUGHPUT NUCLEIC ACID SEQUENCING BY SPACING - Nucleic acid sequencing methods and related devices, products and kits are disclosed. Methods for sequencing a target nucleic acid comprise providing a daughter strand produced by a template-directed synthesis, the daughter strand comprising a plurality of subunits coupled in a sequence corresponding to a contiguous nucleotide sequence of all or a portion of the target nucleic acid, wherein the individual subunits comprise a probe and a reporter construct. The subunit encodes sequence information in its reporter construct that is less than sequence information in the corresponding portion of the target nucleic acid. The reduced information allows for reduced resolution requirements on the detection system and for increased size of resolvable reporter groups. | 11-25-2010 |
| 20110104665 | MUTANT SODIUM CHANNEL NAV 1.7 AND METHODS RELATED THERETO - Described are mutant Na | 05-05-2011 |
| 20110020828 | CE43-67B INSECTICIDAL COTTON - The present application relates an insect resistant transgenic cotton plant. In particular, it relates to a specific event, designated CE43-67B. The application also relates to polynucleotides which are characteristic of the CE43-67B event, plants comprising said polynucleotides, and methods of detecting the CE43-67B event. | 01-27-2011 |
| 20110039274 | ANALYSIS OF NUCLEIC ACID AMPLIFICATION CURVES USING WAVELET TRANSFORMATION - A method comprising acquiring amplification data proportional to an amount of nucleic acid present for each of a plurality of PCR cycles includes applying wavelet transformation to the amplification data to determine a PCR cycle corresponding to a point within a growth period of the amplification data, and updating a display A device including a control module, an analysis module and an interface module for initialization of PCR analysis of a nucleic acid sample, receiving amplification data proportional to an amount of nucleic acid present applying wavelet transformation to the amplification data to determine a PCR cycle corresponding to a point within a growth period of the amplification data, and updating a display based on the amplification data is also provided. | 02-17-2011 |
| 20110111412 | Uses of Parylene Membrane Filters - The invention provides parylene membrane filters, filter devices and methods of making them and using them in the mechanical separation of cells and particles by size. The provision of parylene membrane filters with high figures of merit and finely controlled hole sizes allows the separation of cells and particles in a variety of biological and other fluids according to sizes. | 05-12-2011 |
| 20110053146 | COMPOUNDS AND METHODS FOR DETECTING RICIN AND USES THEREOF - This application provides fluorescent probes, substrates, kits and methods for detecting the presence or absence of an enzyme, such as ricin, that catalyzes the release of adenine from a GAGA RNA tetraloop. | 03-03-2011 |
| 20100173313 | BIOMARKERS OF INFLAMMATION - Methods for the detection of DP | 07-08-2010 |
| 20110081652 | METHOD OF CLASSIFYING GENE EXPRESSION STRENGTH IN LUNG CANCER TISSUES - The present invention provides a method of confirming the gene expression, useful in the decision of a five year survival rate of a patient with lung cancer and the use of a DNA probe kit in the method. A method useful in the decision of a survival rate of a patient with non-small cell lung cancer comprising confirming the expression strength of at least one gene in lung cancer tissues isolated from the patient. | 04-07-2011 |
| 20110081653 | High Spatial Resolution Imaging of a Structure of Interest in a Specimen - In high spatial resolution imaging, a structure in a specimen is marked with a substance which, in a first electronic state, is excited by light of one wavelength to emit fluorescent light, which is also converted from its first into a second electronic state by that light, and which returns from its second into its first electronic state. The specimen is imaged onto a sensor at a spatial resolution not resolving an average spacing between neighboring molecules of the substance, and exposed to the light at such an intensity that the molecules in the first state are alternately excited to emit fluorescent light and converted into their second state, and that at least 10% of the molecules presently in their first state lie at a distance from their closest neighboring molecules in their first state which is greater than the spatial resolution of the imaging onto the sensor. | 04-07-2011 |
| 20110081655 | NUCLEIC ACID ANALYZING DEVICE AND NUCLEIC ACID ANALYZER - An object of the present invention relates to distinguishing, from a fluorophore of an unreacted substrate, a single fluorophore attached to a nucleotide that is incorporated into a probe by a nucleic acid synthesis. The present invention relates to a nucleic acid analyzing device that analyzes a nucleic acid in sample by fluorescence, wherein a localized surface plasmon is generated by illumination, and a probe for analyzing the nucleic acid in the sample is on the site where the surface plasmon is generated. According to the present invention, since it is possible to efficiently produce fluorescence intensifying effects due to the surface plasmon and to immobilize the probe to a region within the reach of the fluorescence intensifying effects, it becomes possible to measure a nucleic acid synthesis without removing unreacted nucleotide to which fluorophores are attached. | 04-07-2011 |
| 20110081650 | FREE NGAL AS A BIOMARKER FOR CANCER - Uncomplexed neutrophil gelatinase associated lipocalin (NGAL) is present at increased levels in individuals with atypical ductal hyperplasia (ADH), a major risk factor for future breast cancer development; in individuals that have ovarian cancer; and in individuals that have breast cancer, both invasive and noninvasive. Accordingly, the present invention is directed to measuring uncomplexed NGAL levels in urine as a primary screen to determine if an individual is either at risk of developing, or has developed cancer, e.g., cancer of epithelial origin including breast and ovarian cancer. | 04-07-2011 |
| 20110081648 | Methods for diagnosing peripheral neuropathy - Genes whose expression is correlated with the presence of CIDP or vasculitic neuropathy are disclosed. Probes and sets of nucleic acids and proteins specific for these genes are described, as are molecular and immunological methods for aiding in the diagnosis of these disease conditions in a subject. | 04-07-2011 |
| 20110104690 | ENGINEERED NITRILE HYDRATASE-PRODUCING BACTERIUM WITH AMIDASE GENE KOUCKED-OUT, THE CONSTRUCTION AND THE USE THEREOF - An engineered nitrile hydratase-producing bacterium and its construction method as well as its applications, wherein the engineered nitrile hydratase-producing bacterium is a mutant strain of an original nitrile hydratase-producing bacterium strain obtained by knocking-out or inhibiting the amidase gene in the original strain. The construction method of the engineered bacterium is to block the expression of the amidase gene by inserting the large fragment of a recombinant suicide plasmid carrying an amidase gene fragment into a wild-type strain through the homologous recombination between the recombinant suicide plasmid and the amidase gene of the wild-type strain. Compared to the corresponding wild-type bacterium strain, both the cell growth and the nitrile hydratase expression of the engineered nitrile hydratase-producing bacterium according to the invention are increased. In the process of catalyzing the hydration of acrylonitrile to produce acrylamide, the yield of the product, acrylamide, is significantly increased, while the yield of the by-product acrylic acid is significantly decreased. The engineered nitrile hydratase-producing bacterium of the present invention has wide application prospect in the production of acrylamide by microbiological process. | 05-05-2011 |
| 20100184079 | SOYBEAN EVENT 3560.4.3.5 AND COMPOSITIONS AND METHODS FOR THE IDENTIFICATION AND DETECTION THEREOF - Compositions and methods related to transgenic glyphosate/ALS inhibitor-tolerant soybean plants are provided. Specifically, soybean plants having a 3560.4.3.5 event which imparts tolerance to glyphosate and at least one ALS-inhibiting herbicide are provided. The soybean plant harboring the 3560.4.3.5 event at the recited chromosomal location comprises genomic/transgene junctions having at least the polynucleotide sequence of SEQ ID NO:10 and/or 11. The characterization of the genomic insertion site of the 3560.4.3.5 event provides for an enhanced breeding efficiency and enables the use of molecular markers to track the transgene insert in the breeding populations and progeny thereof. Various methods and compositions for the identification, detection, and use of the soybean 3560.4.3.5 events are provided. | 07-22-2010 |
| 20100221727 | SITE-SPECIFIC ENZYMATIC DEPOSITION OF METAL IN SITU - The present invention provides compositions, kits, assembles of articles and methodology for carrying out processes that permit biological enzymes to act directly on metals and metal particles. In particular, the invention relates to use of enzymes to selectively deposit metal to the vicinity of a target molecule. The invention also relates to linking of metals to enzyme substrates, control of enzymatic metal deposition and applications of enzymatic metal deposition to sensitively and selectively detect target molecules such as biomarkers in various biological samples, such as chromogenic immunohistochemical (IHC) detection in situ by using bright field light microscope. | 09-02-2010 |
| 20100221730 | Methods for assessing SPARC Resistance, Disease Progression, and Treatment Efficacy in Ovarian Cancer - The invention provides methods for predicting whether an ovarian cancer patient's tumor will be resistant to chemotherapy. The invention also provides methods for monitoring the effectiveness of treatment, particularly a chemotherapeutic treatment, in a patient treated for ovarian cancer. The invention further provides methods for treating ovarian cancer, by reducing chemotherapeutic drug resistance in said cells. In addition, the invention provides methods of screening compounds to identify tumor cell growth inhibitors in tumor cells resistant to conventional chemotherapeutic treatment regimes. | 09-02-2010 |
| 20100221720 | Plant artificial chromosomes, uses thereof and methods of preparing plant artificial chromosomes - Methods for preparing cell lines that contain plant artificial chromosomes, methods for preparation of plant artificial chromosomes, methods for targeted insertion of heterologous DNA into plant artificial chromosomes, and methods for delivery of plant chromosomes to selected cells and tissues are provided. In particular, plant artificial chromosomes that are substantially composed of repeated nucleic acid units of varying amounts of heterochromatin and euchromatin are provided. Also provided are methods of using plant and animal artificial chromosomes in the production of valuable transgenic plants. Methods for identifying plant genes encoding particular traits using artificial chromosomes and for producing an acrocentric plant chromosome also are provided. | 09-02-2010 |
| 20100221708 | METHOD FOR CHROMOSOME ENUMERATION - A method of sample analysis is provided. The method comprises: a) contacting a genomic sample comprising a plurality of intact chromosomes, i.e., metaphase or interphase chromosomes, with a first set of labeled oligonucleotide probes under in situ hybridization conditions to produce a contacted sample comprising labeled chromosomes, where i. each of the labeled oligonucleotide probes is complementary to a non-repetitive, unique sequence in a region that flanks the centromere of a single chromosome of the plurality of chromosomes; and ii. hybridization of the labeled oligonucleotide probes to the chromosomes produces a distinct labeling pattern for each hybridized chromosome, thereby allowing each of the labeled chromosomes to be distinguished from one another; b) imaging the hybridized chromosomes to provide an image showing the labeling pattern for each labeled chromosome; and c) enumerating a labeled chromosome based on the labeling pattern of said labeled chromosome. A composition and kits for performing the method are also provided. | 09-02-2010 |
| 20110076687 | FLUORESCENCE STANDARD, AND THE USE THEREOF - The invention concerns fluorescence standards, and in particular fluorescence standards for calibrating optical detectors. According to the invention, a fluorescent mineral or mixtures of minerals are employed for use as a fluorescence standard. The fluorescent mineral can be a naturally occurring mineral or a synthetically produced mineral. Preferred fluorescent minerals for use as fluorescence standards are corundum, fluorite, turquoise, amber, zircon, zoisite, iolite or cordierite, spinel, topaz, calcium fluorite, sphalerite or zincblende, calcite or calcspar, apatite, scheelite or calcium tungstate, willemite, feldspars, sodalite, a uranium mineral, a mineral containing Al | 03-31-2011 |
| 20110076675 | NOVEL METHODS FOR QUANTIFICATION OF MICRORNAS AND SMALL INTERFERING RNAS - The invention relates to ribonucleic acids, probes and methods for detection, quantification as well as monitoring the expression of mature microRNAs and small interfering RNAs (siRNAs). The invention furthermore relates to methods for monitoring the expression of other non-coding RNAs, mRNA splice variants, as well as detecting and quantifying RNA editing, allelic variants of single transcripts, mutations, deletions, or duplications of particular exons in transcripts, e.g., alterations associated with human disease such as cancer. The invention furthermore relates to methods for detection, quantification as well as monitoring the expression of deoxy nucleic acids. | 03-31-2011 |
| 20110076681 | Modified gene-silencing nucleic acid molecules and uses thereof - Methods and means for efficiently downregulating the expression of a target gene of interest in cell from an organism that is an animal, fungus, and protest. The invention provides chimeric nucleic acid molecules for downregulating target genes. The invention also provides modified cells and organisms comprising the chimeric nucleic acid molecules and compositions comprising the chimeric molecules. | 03-31-2011 |
| 20110076673 | Detection of bacteria - The invention relates to a method for detecting bacterial contaminations preferably in physiological samples as well as sequences of synthetic oligonucleotides used therefor. The method comprises the steps of i) extracting the nucleic acid, particularly bacterial DNA, ii) amplification by means of primers and detection by means of oligonucleotides, particularly fluorescence-marked oligonucleotides as hybridization probes, containing a sequence that is selected from among a group encompassing SEQ ID NO:5 to SEQ ID NO:35, preferably in real-time PCR, and iii) evaluation by means of fusion curve analysis. | 03-31-2011 |
| 20110076679 | 3'-O-FLUORESCENTLY MODIFIED NUCLEOTIDES AND USES THEREOF - The present invention relates to a DNA sequencing method using a nucleoside triphosphate with a fluorescent blocking group on its 3′-OH end as a reversible terminator. Further, the present invention relates to sequencing-by-synthesis method using the mono-modified reversible terminator (MRT), the novel nucleotide monomer having a reversible fluorescent blocking group removable chemically or enzymatically at its 3′-OH end. The sequencing method of the present invention facilitates sequencing of bases inserted by terminating extension of a nucleotide chain by the nucleotide monomer and then detecting fluorescence signal from 3′-OH end. At this time, after analyzing the fluorescence signal, the blocking group conjugated to the 3′-OH end can be effectively removed, indicating that a free 3′-OH functional group can be successfully restored, so that the next monomer insertion is possible, making continuous sequencing possible. | 03-31-2011 |
| 20110076689 | PRIMER FOR DETECTING TYROSINASE mRNA - The present invention provides a means and method for detecting TYR mRNA. As a primer for detecting TYP mRNA, a primer comprising a first sequence at the 5′ end side and a second sequence at the 3′ end side, wherein the first sequence has 10 to 30 nucleotides in length, and the first sequence is a sequence of a polynucleotide capable of hybridizing with a strand complementary to a first region which is a partial region of SEQ ID NO: 1; and wherein the second sequence has 10 to 30 nucleotides in length, and the second sequence is a sequence of a polynucleotide capable of hybridizing with a second region located in the 3′ end side from the first region in SEQ ID NO: 1 is used. | 03-31-2011 |
| 20110076676 | Method of Purifying RNA Binding Protein-RNA Complexes - The present invention provides methods for purifying RNA molecules interacting with an RNA binding protein (RBP), and the use of such methods to analyze a gene expression profile of a cell. The invention also provides sequences of RNA molecules that mediate binding to an RBP, proteins encoded by the sequences, a method of identifying the sequences, and the use of the sequences in a screen to identify bioactive molecules. The invention also provides RNA motifs found among the sequences and compounds that bind the RNA motifs. In addition, the invention provides methods of treating diseases associated with a function of an RNA binding protein. | 03-31-2011 |
| 20110076683 | Identification, Isolation and Elimination of Cancer Stem Cells - Isolated populations of leukemic stem cells are provided. The cells are useful for experimental evaluation, and as a source of lineage and cell specific products, and as targets for the discovery of factors or molecules that can affect them. Detection of leukemic stem cells is useful in predicting disease progression, relapse, and development of drug resistance. Proliferation of LSC may be inhibited through interfering with activation of the β-catenin pathway. Methods are provided for the clinical staging of pre-leukemia and leukemias by differential analysis of hematologic samples for the distribution of one or more hematopoietic stem or progenitor cell subsets. | 03-31-2011 |
| 20110076677 | METHOD FOR DETECTING SINGLE NUCLEOTIDE POLYMORPHISMS - A method of detecting a single nucleotide polymorphism includes providing a first template polynucleotide, a second polynucleotide comprising a first and second sequence (complementary to a first portion of the first polynucleotide), and a third polynucleotide (complementary to a second portion of the first polynucleotide). The first, second and third polynucleotides are annealed, ligated and optionally, these steps are repeated. A fourth polynucleotide, which is essentially complementary to at least a portion of the first sequence, coupled to a first indicator is then provided. A fifth and/or sixth polynucleotide is provided. The fifth polynucleotide is essentially identical to at least a portion of the second sequence of the second polynucleotide and/or to at least a portion of the third polynucleotide. The sixth polynucleotide is essentially complementary to a portion of the second sequence of the second polynucleotide. The third or fifth polynucleotides may be coupled to a second indicator. | 03-31-2011 |
| 20110076674 | RAPID EPIDEMIOLOGIC TYPING OF BACTERIA - Methods for typing a strain of an organism are provided, the methods comprising the steps of amplifying, in a single reaction mixture containing nucleic acid from the organism, dividing the reaction mixture into a plurality of sets of second-stage reaction wells, each set of second-stage reaction wells containing a different pair of second-stage primers, subjecting each of the second-stage reaction wells to amplification conditions to generate a plurality of second-stage amplicons, melting the second-stage amplicons to generate a melting curve for each second-stage amplicon, and identifying the strain of the organism from the melting curves. | 03-31-2011 |
| 20090311672 | Detection of amplicon contamination during pcr exhibiting two different annealing temperatures - A method to perform PCR reactions with one set of primers comprising sequence elements that are complementary to the target sequence and comprising sequence elements that server as tagging sequences. By conducting amplification reactions at different temperatures, the presence of contaminations arising from amplification products of previous reactions can be determined, improving reliability of the reaction and reducing the need for control reactions and reproduction of reactions. | 12-17-2009 |
| 20100184037 | DEATH ASSOCIATED PROTEIN KINASE 1 (DAPK1) AND USES THEREOF FOR THE TREATMENT OF CHRONIC LYMPOCYTIC LEUKEMIA - A method for determining susceptibility to chronic lymphocytic leukemia in a subject includes determining a loss or reduced expression of death associated protein kinase 1 (DAPK1) or fragments or functional equivalents thereof. | 07-22-2010 |
| 20100047803 | BIOMARKERS FOR ACETAMINOPHEN TOXICITY - Materials and methods for evaluating cellular responses to acetaminophen and assessing susceptibility to liver damage. | 02-25-2010 |
| 20100047801 | METHOD AND SYSTEM FOR DATA DRIVEN MANAGEMENT OF INDIVIDUAL SEEDS - A method for managing seed includes non-destructively sampling individual seeds to assist in providing evaluation data for each of the individual seeds, storing the evaluation data and seed identifiers associated with each of the individual seeds in a data store, selecting a subset of seed for planting at least partially based on the evaluation data, and planting the subset of seed. A system for management of seed on an individual seed basis includes an evaluation subsystem for evaluating individual non-destructively sampled seeds to provide evaluation data for the seeds, a selection subsystem for selecting a subset of the individual seeds at least partially based on the evaluation data, and a planting subsystem for planting the subset of individual seeds. | 02-25-2010 |
| 20100047798 | ADENOSINE A1 AND A3 RECEPTOR GENE SEQUENCE VARIATIONS FOR PREDICTING DISEASE OUTCOME AND TREATMENT OUTCOME - The present invention relates to methods for identify subjects for responsiveness to adenosine agonist treatment. Another aspect of the present invention relates to methods to predict a relative infarct size in response to ischemia reperfusion injury. In particular, the present invention relates to methods for to identify responsiveness to adenosine agonist treatment and/or relative infarct size by identifying a sequence differences such as mutations and/or polymorphisms in the human A1 adenosine receptor (A1-AR) gene that alters the stability of the A1-AR mRNA. Other aspect of the present invention relates to methods to identify responsiveness to adenosine agonist treatment and/or relative infarct size by identifying a sequence differences, such as mutations and/or polymorphisms in the human A3 adenosine receptor (A3-AR) gene that alters the A3-AR protein function. Other aspect of the present invention also relate to kits and assays to detect sequence differences in the human A1 adenosine receptor (A1-AR) gene and/or A3 adenosine receptor (A3-AR) gene. | 02-25-2010 |
| 20100047793 | METHODS TO STIMULATE BIOGENIC METHANE PRODUCTION FROM HYDROCARBON-BEARING FORMATIONS - The present invention describes methods of identifying stimulants for the biogenic production of methane in hydrocarbon-bearing formations. Methods involve the use of microbial nucleic acid sequence information for the determination of gene products that are enzymes in a variety of pathways involved in the conversion of hydrocarbons to methane. Enzymes and stimulants identified by invention methods can be used in processes for enhancing biogenic methane production, for example, by addition to coal seams and coalbed methane wells. | 02-25-2010 |
| 20100047792 | LABEL-FREE OPTICAL DETECTION METHOD - The present provides optical sensor based sensitive, label-free binding assay methods and kits for isothermal real-time detection of the binding of specific analytes (such as nucleic acids, proteins and low molecular weight antigenic or receptor binding ligands) present in low amount in different biological samples. In the binding assays of the invention, the analyte is captured at the specifically pretreated solid surface of optical biosensors in specific recognition reactions (such as hybridization, specific protein-protein interactions and receptor-ligand interactions). The specificity of the methods of the invention is further enhanced by a second specific recognition step using a padlock probe comprising an indicator sequence designed to keep the products of a subsequently performed isothermal nucleic acid amplification method (e.g. rolling circle amplification: RCA) anchored on the sensor surface, enhancing thereby the sensitivity of the detection of the specific binding of the analyte occurred on the sensor surface. | 02-25-2010 |
| 20100047790 | Sample analyser - There are provided processes for analysing a plurality of different samples. The processes comprise the steps of: a) applying the samples to a support, to which an analytical component is immobilised; and b) allowing the samples to interact with the analytical component, thus permitting analysis of the samples. The samples are applied in step a) to different areas of the support to produce a spatial arrangement of samples on the support. The spatial arrangement of the samples is maintained in step b), thus permitting the results of the analysis to be matched to individual samples. | 02-25-2010 |
| 20100047789 | METHOD OF SURFACE PLASMON RESONANCE (SPR) TO DETECT GENOMIC DISORDERS FOR POSTNATAL DIAGNOSIS - The present invention discloses using SPR technology to postnatally detect specific DNA loss or gain related to some genomic disorders. An efficient formula to make a mixed SAM that can greatly enhance the immobilization ability of the metal surface in SPR based techniques, which is good for the immobilization of DNA markers used for the identification of subtelomere imbalances and chromosome microdeletion syndromes is also disclosed. | 02-25-2010 |
| 20100047780 | TARGET AND METHOD FOR INHIBITION OF BACTERIAL RNA POLYMERASE - Target and method for inhibition of bacterial RNA polymerase disclosed are targets and methods for specific binding and inhibition of RNAP from bacterial species. | 02-25-2010 |
| 20110117553 | Methods for PCR and HLA typing using raw blood - Provided are methods for amplifying a gene or RNA or sets thereof of interest using a tandem PCR process. The primers in the first PCR or set of PCR reactions are locus-specific. The primers in the second PCR or set of PCR reactions are specific for a sub-sequence of the locus-specific primers and completely consumed during the secondary PCR amplification. For RNA amplification, the first PCR is reverse transcription and the resulting cDNA(s) provide a template for cRNA synthesis, endpoint PCR or real time PCR. Also provided is a method of allelotyping a gene or set thereof by amplifying the gene(s) using tandem PCR on DNA or RNA comprising the sample, hybridizing the resulting amplicon or sets thereof to probes with sequences of gene-associated allele variations. A detectable signal indicating hybridization corresponds to an allelotype of the gene or a set of allelotypes for the set of genes. | 05-19-2011 |
| 20100047776 | Cell-based screening assays for compounds that regulate the expresion of a tumor marker dj-1 - The present invention generally provides compositions and methods that are useful for the treatment or prevention of a neoplasm, and screening methods that can be used to detect compounds that modulate the activity of a DJ-I gene. | 02-25-2010 |
| 20100047771 | MARKERS FOR THE DIAGNOSIS OF LUNG CANCER - Disclosed is a diagnostic marker specific for lung cancer. Also, the present invention relates to a composition and a kit, comprising an agent measuring the presence of the marker, and a method of diagnosing lung cancer using the composition or kit. | 02-25-2010 |
| 20100285468 | DETECTION AND/OR QUANTIFICATION OF NUCLEIC ACIDS - The present invention provides compositions, methods, and kits for nucleic acids analyses. In particular, melting analyses are used to detect the presence or absence and to quantify nucleic acids. | 11-11-2010 |
| 20110117549 | METHOD FOR DETECTING NUCLEIC ACID, AND DEVICE OR KIT - The present invention has its object to provide a method and a device or kit for detecting a nucleic acid, which enable simple and precise visual detection of a nucleic acid amplified by a nucleic acid amplification method, without necessity of a special device. | 05-19-2011 |
| 20090298074 | Modulators of ELOVL5 for treating acne or hyperseborrhea - An in vitro method for screening candidate compounds for the preventive or curative treatment of acne, includes the determination of the capacity of a compound to modulate the expression or the activity of ELOVL5 and the use of modulators of the expression or activity of this enzyme for the treatment of acne or skin disorders associated with a hyperseborrhea; methods for the in vitro diagnosis or prognosis of these pathologies are also described. | 12-03-2009 |
| 20110070590 | Primers and Methods for Determining RhD Zygosity - Provided herein are primers comprising a nucleotide sequence complementary to a portion of a RhD gene. Also provided herein are methods of determining a RhD zygosity in a subject. Also provided are methods of detecting a weak D allele in a subject. Further provided are kits for determining an RhD zygosity. | 03-24-2011 |
| 20110070587 | System For Genetic Surveillance and Analysis - A genetic surveillance system comprises a communications network and at least one reader-analyzer instrument. The reader-analyzer instrument has a communication interface to communicate over the network. The reader-analyzer instrument is adapted to perform genetic assay analysis of a sample obtained from a member of a population and to generate detection-related data based upon the analysis. The reader-analyzer instrument is adapted to associate qualifying information with the detection-related data and to communicate the associated qualifying information and detection-related data over the network. | 03-24-2011 |
| 20110070578 | DNA analyzer - Aspects of the disclosure provide a microfluidic chip to facilitate DNA analysis. The microfluidic chip includes a first domain configured for polymerase chain reaction (PCR) amplification of DNA fragments, a dilution domain coupled to the first domain to dilute a PCR mixture received from the first domain, and a second domain that is coupled to the dilution domain so as to receive the amplified DNA fragments. The second domain includes a separation channel that is configured to perform electrophoretic separation of the amplified DNA fragments. In addition, the disclosure provides a DNA analyzer to act on the microfluidic chip to perform an integrated single chip DNA analysis. | 03-24-2011 |
| 20110070585 | INTEGRATED NUCLEIC ACID ANALYSIS - The present invention relates to an integrated method of nucleic acid analysis, and more particularly to a simplified sample pre-treatment, which renders the method more easily automated, where the sample is provided on or applied onto a solid matrix and the subsequent amplification and detection steps are performed in one single, sealed reaction vial without removing the matrix. | 03-24-2011 |
| 20110070591 | REPLICATION PROTEIN - This invention relates to a screening method for the identification of agents which modulate the activity of a DNA replication protein as a target for intervention in cancer therapy and includes agents which modulate said activity. The invention also relates to the use of the DNA replication protein, and its RNA transcripts in the prognosis and diagnosis of proliferative disease e.g., cancer. | 03-24-2011 |
| 20110070586 | Multiplex Detection Of Agricultural Pathogens - Described are kits and methods useful for detection of agricultural pathogens in a sample. Genomic sequence information from agricultural pathogens was analyzed to identify signature sequences, e.g., polynucleotide sequences useful for confirming the presence or absence of a pathogen in a sample. Primer and probe sets were designed and optimized for use in a PCR based, multiplexed Luminex assay and/or an array assay to successfully identify the presence or absence of pathogens in a sample. | 03-24-2011 |
| 20110070588 | Methods for Identifying Genomic Deletions - The genomic locus responsible for Van Buchem's disease is narrowed to an approximately 92 kb region of human chromosome 17 at 17q21. Individuals afflicted with or carriers of Van Buchem's disease exhibit a 52 kb deletion within this 92 kb region. Methods are provided that permit the differentiation between individuals homozygous for and therefore afflicted with Van Buchem's disease, individuals heterozygous for and therefore carriers of Van Buchem's disease, and individuals who are normal with respect to Van Buchem's disease. Also provided are general methodologies for the detection of a wide variety of large genomic deletions. | 03-24-2011 |
| 20110070579 | POLYKETIDE SYNTHASE-NONRIBOSOMAL PEPTIDE SYNTHETASE GENE - The objective is to provide a method for rapidly, and highly accurately performing genetic detection of the cyclopiazonic acid-producing ability in a strain belonging to genus | 03-24-2011 |
| 20110070575 | Immunomodulatory Compositions, Combinations and Methods - The invention provides immunomodulatory compositions, immunomodulatory combinations, and methods of modulating TLR7-mediated biological activity. Generally, the immunomodulatory compositions include an immunomodulatory oligonucleotide in an amount effective to reduce TLR7-mediated biological activity. In some cases, an immunomodulatory combination can further include an IRM compound. In some of these embodiments, the IRM compound can be a TLR7/8 agonist. Generally, the Imethods include contacting immune cells with an immunomodulatory composition in an amount effective to reduce TLR7-mediated biological activity. | 03-24-2011 |
| 20110059456 | System for the Cell-Specific and Development-Specific Selection of Differentiating Embryonic Stem Cells, Adult Stem Cells and Embryonic Germline Cells - The invention relates to a system for selecting differentiating embryonic or adult stem cells or embryonic germline cells in a cell-specific and development-specific manner, using a combination of resistance genes and detectable reporter genes under the common control of a cell-specific and/or development-specific promoter. | 03-10-2011 |
| 20110059451 | DETECTING FETAL CHROMOSOMAL ABNORMALITIES USING TANDEM SINGLE NUCLEOTIDE POLYMORPHISMS - The invention provides tandem single nucleotide polymorphisms and methods for their use, for example, in diagnosing Down Syndrome. | 03-10-2011 |
| 20100209923 | Probe for diagnosis of marfan syndrome and a method for screening using the probe - The purpose of this invention is to provide a probe for diagnosis of Marfan syndrome, which enables early diagnosis of Marfan syndrome, and to provide a method for screening using said probe. The invention is a probe for a Marfan Syndrome characterized by using a nucleic acid comprising following (a) or (b);
| 08-19-2010 |
| 20100209920 | Gene Expression Profiling in Biopsied Tumor Tissues - The invention concerns sensitive methods to measure mRNA levels in biopsied tumor tissues, including archived paraffin-embedded biopsy material. The invention also concerns breast cancer gene sets important in the diagnosis and treatment of breast cancer, and methods for assigning the most optimal treatment options to breast cancer patient based upon knowledge derived from gene expression studies. | 08-19-2010 |
| 20100028900 | SCREENING METHODS AND SEQUENCES RELATING THERETO - Disclosed are screening methods and sequences related thereto. Disclosed are methods for detecting mutations in the MYH gene of an individual. Also disclosed are methods of genotyping and methods of predicting for an individual the likelihood of developing certain cancers, such as colorectal cancer. | 02-04-2010 |
| 20110033856 | METHODS RELATING TO AROMATASE INHIBITOR PHARMACOGENETICS - Methods for aiding in determining therapeutic efficacy of an aromatase inhibitor in a subject are provided according to embodiments of the present invention which include detecting expression and/or function of at least one UDP-glucuronosyltransferase having activity to modify at least one aromatase inhibitor and/or metabolite of the aromatase inhibitor by glucuronidation, wherein detection of expression and/or function of the UDP-glucuronosyltransferase is correlated with therapeutic efficacy of the aromatase inhibitor in the subject. Detection of UDP-glucuronosyltransferase expression and/or function includes detection of a UDP-glucuronosyltransferase gene deletion polymorphism in the subject | 02-10-2011 |
| 20110033849 | OVINE IDENTIFICATION METHOD - The invention relates to method for identifying an ovine with a genotype indicative of one or more altered performance traits, the method including the step of detecting, in a sample derived from the ovine, the presence of at least one allele of the CP34 simple sequence repeat (SSR) marker, or at least one allele of a marker in linkage disequilibrium (LD) with CP34, wherein the presence of the allele is indicative of the altered performance traits in the ovine. | 02-10-2011 |
| 20110033861 | METHOD FOR DIAGNOSING SPINAL MUSCULAR ATROPHY - A method for diagnosing spinal muscular atrophy is provided. The method includes providing a biological sample of a subject containing a nucleotide of SMN gene, amplifying SMN exons 1, 2a, 2b, 3, 4, 5, 6, 7, and 8 by a universal multiplex PCR using the nucleotide as a template and the primers to obtain fragments of the SMN exons 1, 2a, 2b, 3, 4, 5, 6, 7, and 8, labeling the fragments of the SMN exons 1, 2a, 2b, 3, 4, 5, 6, 7, and 8 by a fluorescent primer to obtain fluorescence-labeled exon fragments, and analyzing the fluorescence-labeled exon fragments by a capillary electrophoresis. If the SMN1/SMN2 ratios in exon 7 and 8 are different, it indicates that the subject is susceptible to spinal muscular atrophy. Additionally, if the peak of certain exon fragment appears crossed, it indicates an intragenic mutation in the exon. | 02-10-2011 |
| 20100209914 | METHODS, SYSTEMS, AND KITS FOR EVALUATING MULTIPLE SCLEROSIS - The present invention provides a method for evaluating multiple sclerosis (MS), or excluding MS as a diagnosis for a patient The method comprises determining a gene expression profile for a sample from such a patient. The gene expression profile, which contains gene expression values for a plurality of genes that are differentially expressed in white blood cells of MS patients, is compared to an MS-profile and/or a non-MS profile, and classified. The invention also provides a method for monitoring treatment of an MS patient Pre-treatment and post-treatment gene expression profiles contain gene expression values for a plurality of genes that are differentially expressed upon treatment of MS patients. The expression profiles may then be compared, to identify differences between pre-treatment and post-treatment gene expression. These differences are indicative of the patient's response to treatment The invention further provides kits and systems for performing the methods of the invention. | 08-19-2010 |
| 20100209912 | METHOD FOR THE TREATMENT OF A SAMPLE CONTAINING BIOMOLECULES - The invention generally provides a method for the sample preparation for a subsequent preparation, processing or analysis method of a sample containing an at least one species of nucleic acid and/or one species of protein, whereby the method comprises the following steps: A) providing a sample which contains at least one species of a nucleic acid and/or of a protein, B) contacting the sample with a fluid or solid composition to produce a fluid sample preparation, whereby the composition contains at least a nitrogenous compound, which is selected from the group consisting of a) polyamines, b) amino acids, and oligo- and polypeptides, c) nitrogenous heterocyclic compounds, including homo- oder heteropolymers, which comprise these nitrogenous compounds, d) amines of the type R | 08-19-2010 |
| 20100209911 | Microsatellite maker combination and method for identifying Lanyu pig breed - The present invention provides a microsatellite marker combination for identifying Lanyu pig breed, and the identification method thereof. The identification method comprises the following steps: (a) providing a genomic DNA sample obtained from a pig; (b) identifying the polymorphism of microsatellite markers of said genomic DNA sample; and (c) analyzing the results obtained from step (b) to determine the phylogenetic relationship between said pig and Lanyu pig. | 08-19-2010 |
| 20100209909 | ASSAYS BASED ON DETECTION OF PHOTOBLEACHING REACTION PRODUCTS FROM DYE CATALYTIC COMPLEX - The present invention relates to the methods for assaying an analyte comprising a nucleic acid analog binding substrate in a sample, comprising reacting a catalytic complex comprising a nucleic acid analog, a nucleic acid analog specific binding substrate and a light reactive dye with a light stimulus, and detecting the presence or absence or amount of a reaction product of the catalytic complex and light stimulus. The present invention also relates to a method of assaying a nucleic acid analyte in a sample using an analyte-specific reporter complex. The present invention also relates to a method of assaying an analyte in a sample using a reporter molecule. | 08-19-2010 |
| 20100209908 | SYSTEM AND METHOD FOR NUCLEOTIDE SEQUENCE PROFILING FOR SAMPLE IDENTIFICATION - The invention includes a method of sample profiling for identification. The method includes the steps of performing less than four nucleotide-specific chemical cleavage reactions to obtain nucleotide sequence fragments, performing size separation on the fragments, detecting the fragments' separation, generating a profile based on the detection, and comparing the profile to a data base to identify the sample. | 08-19-2010 |
| 20100209907 | ISOLATED MAMMALIAN MONOCYTE CELL GENES; RELATED REAGENTS - Nucleic acids encoding various monocyte cell proteins from a primate, reagents related thereto, including specific antibodies, and purified proteins are described. Methods of using said reagents and related diagnostic kits are also provided. | 08-19-2010 |
| 20110053168 | REAGENT COMPRISING PRIMER FOR DETECTION OF mRNA FOR CYTOKERATIN-7 - Disclosed is a primer for detecting mRNA for CK7. The primer comprises a first sequence on its 5′-terminal side and a second sequence on its 3′-terminal side. The first sequence has a length of 10 to 30 nucleotides, and can hybridize with a strand complementary to a first region which is a region contained in the sequence depicted in SEQ ID NO:1. The second sequence has a length of 10 to 30 nucleotides, and can hybridize with a second region which is located on the 3′-terminal side from the first region in the sequence depicted in SEQ ID NO:1. | 03-03-2011 |
| 20110053165 | CACNB2 NUCLEIC ACID MUTATIONS AS INDICATORS OF SHORTER THAN NORMAL QT INTERVAL AND ST SEGMENT ELEVATION ASSOCIATED WITH SUDDEN CARDIAC DEATH - Previously unknown mutations of the CACNA1C and CACNB2b genes are disclosed which are involved in ion channel disruptions associated with shorter than normal QT interval and ST segment elevation syndrome. These mutations are utilized to diagnose and screen for shorter than normal QT interval and ST segment elevation syndrome, thus providing modalities for diagnosing syncope and/or sudden cardiac death and/or predicting susceptibility to syncope and/or sudden cardiac death. Nucleic acid probes are provided which selectively hybridize to the mutant nucleic acids described herein. Antibodies are provided which selectively bind to the mutant polypeptides described herein. The mutations described herein are also utilized to screen for compounds useful in treating the symptoms manifest by such mutations. | 03-03-2011 |
| 20110053163 | Biomarker - The invention relates to a process for in vitro prediction of a potentially allergenic substance wherein monocytes and/or macrophages and/or myelomonocytic cell lines are cultivated in the presence of the substance and interferon-γ, whereby productions of cytokines and/or neopterin are increased and measured. | 03-03-2011 |
| 20110053151 | MICROFLUIDIC DEVICE AND METHOD OF USING SAME - A microfluidic device comprising a plurality of reaction chambers in fluid communication with a flow channel formed in an elastomeric substrate, a vapor barrier for preventing evaporation from the plurality of reaction chambers, and a continuous phase fluid for isolation of each of the plurality of reaction chambers. | 03-03-2011 |
| 20110053155 | POLAR DYES - The present invention relates to novel polar fluorescent and quenchers dyes, and minor groove binder with enhanced polarity. The present invention further relates to methods of preparing oligonucleotide probes labeled with polar arsonate dyes under the condition of automated synthesis and method of using such probes. | 03-03-2011 |
| 20110053150 | Method and Kit for Detection/Quantification of Target RNA - [Object] It is to provide a method and a kit capable of detecting or quantifying a target RNA simply and rapidly from trace amounts of RNA in a sample, in a case such as when one or more kinds of pathogenic microorganisms are to be detected or quantified. | 03-03-2011 |
| 20110053148 | COCCIDIOSIS VACCINES - The present invention relates to hydrophilic | 03-03-2011 |
| 20110053147 | HEAT-RESISTANT DNA LIGASE WITH HIGH REACTIVITY - Thermostable DNA ligases with enhanced DNA binding activity and reaction activity are obtained. These modified thermostable DNA ligases having enhanced DNA binding activity compared to the wild type can be obtained by substituting a negatively charged amino acid (for example, the amino acid corresponding to the aspartic acid at position 540 of SEQ ID NO: 1) present at the N-terminal side of the C-terminal helix moiety of thermostable DNA ligases from thermophilic bacteria, hyperthermophilic bacteria, thermophilic archaea, or hyperthermophilic archaea, with a non-negatively charged amino acid (for example, alanine, serine, arginine, or lysine). | 03-03-2011 |
| 20100112582 | GENE ENCODING LABYRINTHIN, A MARKER FOR CANCER - A cDNA molecule that encodes a protein designated Labyrinthin (Lab) isolated and its nucleotide sequence is determined. The protein, or peptides derived from the protein, are markers useful to define novel classes of cancers. Diagnostic assays for these cancers use antibodies to Lab or nucleotide probes that hybridize with the lab gene or a fragment therefrom. Vaccines useful either to prevent recurrence of cancers in subjects who test positive for Lab (or lab), or to prevent initial occurrence of cancer, use proteins or peptides derived from Lab. Expression of Lab via immunogenic assays is used to monitor effects of cancer treatments. Antisense molecules against lab are used in treatments. Sense molecules of lab are used to restore lost lab function in diseased normal cells, for example, gland cells. | 05-06-2010 |
| 20110027797 | Method for the Diagnosis of Higher- and Lower-Grade Astrocytoma Using Biomarkers and Diagnostic Kit Thereof - Disclosed is a method of diagnosing the presence of higher grade astrocytoma/glioblastoma (GBM) or lower-grade grade astrocytoma (DA or AA) in a human subject using secreted or plasma membrane associated biomarkers, which involves the detection of the expression levels of said genes, alone or in combination, in either tumor tissue samples or body fluids and a diagnostic kit thereof. | 02-03-2011 |
| 20110027794 | Method for Synthesizing Nucleic Acids, and Application Thereof - The invention relates to a method for synthesizing a nucleic acid containing modified nucleotides. The method encompasses the following steps: a matrix strand is provided; —a primer which at least partially hybridizes on the matrix strand is provided; —nucleoside triphosphates, at least some of which are modified nucleoside triphosphates, are provided; —a polymerase activity is supplied; and—the matrix strand, the primer, and the nucleoside triphosphates are incubated so as to synthesize a nucleic acid that is substantially complementary to the matrix strand. The polymerase activity can be a reverse transcriptase activity. | 02-03-2011 |
| 20110027788 | REAGENT AND KIT FOR CLASSIFYING AND COUNTING LEUKOCYTES, THE PREPARATION THEREOF, AND PROCESS FOR CLASSIFYING AND COUNTING LEUKOCYTES - A reagent for classifying and counting leukocytes containing (1) a cyanine fluorescent dye; and (2) a glycoside compound; a reagent kit containing the reagent for classifying and counting leukocytes as well as its preparation process; and a process for classifying and counting blood cells using the reagent or kit are provided. Using the reagent, kit and/or process provided, leukocytes can be classified and counted in four groups with a high degree of differentiation and a better classification among each subpopulation of leukocytes, especially in that it successfully addresses the indistinct classification between lymphocytes and monocytes and between the eosinophils and neutrophils in a scattergram. | 02-03-2011 |
| 20110027787 | METHODS AND SYSTEMS FOR IDENTIFYING AND ISOLATING STEM CELLS AND FOR OBSERVING MITOCHONDRIAL STRUCTURE AND DISTRIBUTION IN LIVING CELLS - Methods and systems for a) identifying and isolating stem cells, b) assessing mitochondrial distribution and structure in living cells and c) performing fluorescence microscopy on living cells while the cells remain within a condition-controlled cell culture chamber. | 02-03-2011 |
| 20100068702 | Method for Detecting Disease-Related Marker Using Gastric Mucosal Lavage Fluid - The invention relates to a sample containing a gastric mucosa lavage fluid collected from a subject who has received a gastric mucus removal treatment and a method for detecting a disease-related marker using the same. By using the sample of the invention, the disease-related marker can be detected conveniently, less invasively, highly sensitively and highly accurately. | 03-18-2010 |
| 20100035242 | Methods and nucleic acids for the detection of metastasis of colon cell proliferative disorders - The invention provides methods, nucleic acids and kits for detecting metastasis of colon cell proliferative disorders. The invention discloses genomic sequences the methylation patterns of which have utility for the improved detection of metastasis of colon cell proliferative disorders, thereby enabling the improved diagnosis and treatment of patients. | 02-11-2010 |
| 20100112565 | Methods, kits, and reaction mixtures for high resolution melt genotyping - Various methods are described that provide for high resolution melt (HRM) genotyping. Some embodiments comprise providing a locus specific primer, and two allele specific primers each comprising at least one single nucleotide polymorphism (SNP) allele-hybridizable sequence, wherein at least one of the allele specific primers also comprises at least one nucleotide alteration. In some embodiments, a nucleic acid is provided comprising a SNP base located within 1-20 bases of its 3′ end. Some embodiments comprise hybridizing the locus specific primer and at least one of the allele specific primers to the nucleic acid, amplifying the hybridized nucleic acid using pyrophosphorolysis activated polymerization (PAP) PCR, and determining the melting temperature (Tm) of the resulting amplicons, for example, using HRM. In some embodiments, reaction mixtures and kits for HRM genotyping are provided. The reaction mixtures and kits can each comprise a locus specific primer, one or more allele specific primers each comprising at least one SNP allele-hybridizable sequence, and a PAP PCR enzyme, wherein at least one of the allele specific primers also comprises a nucleotide alteration, for example, a tail. | 05-06-2010 |
| 20100112584 | CYANINE COMPOUNDS AND THEIR USE IN STAINING BIOLOGICAL SAMPLES - Cyanine compounds having the general formula I for staining biological samples, wherein R | 05-06-2010 |
| 20110033864 | PROLIFERATIVE DISEASE DETECTION METHOD - In the present invention, the methylation of the genomic DNA a Zar1 gene specifically found in proliferative disease is used as a marker. Specifically, the present invention provides a method for detecting proliferative disease, which comprises detecting the methylation of the genomic DNA of a Zar1 gene in a biological sample. There is thereby provided a method for detecting proliferative disease, using a marker having a high detection rate and a low false positive rate. | 02-10-2011 |
| 20110076686 | WATER MANAGEMENT - A method for detecting and enumerating viable microorganisms in a sample suspected of containing said microorganisms comprising: (1) contacting said sample with a cell nutritive resource and a cellular proliferation inhibitor, (2) contacting said sample with at least one fluorescence labelled oligonucleotidic probe able to specifically hybridise at least one portion of ribosomal nucleic acids of said microorganisms, (3) detecting and quantifying the fluorescent signal, in which the microorganisms are of the species | 03-31-2011 |
| 20100196915 | Method of Detecting Oncogenesis of Hematopoietic Cells - Disclosed in a method of detecting cancer using IL-27 receptors. IL27R is a cytokine receptor identified as a novel oncogene from an acute myeloid leukemia patient. It induces cancer-like properties when expressed in cells and can activate a protein that causes various myeloid cell disorders. The data show cytokine receptors play unappreciated roles in mediating activation of signaling pathways in circulatory system cancers. Also method of screening for novel oncogenes using a functional, approach is disclosed using cytokine-dependent cells to screen for transforming events. | 08-05-2010 |
| 20100311061 | REAL-TIME SEQUENCING METHODS AND SYSTEMS - The present invention is generally directed to compositions, methods, and systems for performing single-molecule, real-time analysis of a variety of different biological reactions. The ability to analyze such reactions provides an opportunity to study those reactions as well as to potentially identify factors and/or approaches for impacting such reactions, e.g., to either enhance or inhibit such reactions. In certain preferred embodiments, RNA templates are used in single-molecule real-time sequencing reactions. | 12-09-2010 |
| 20110070576 | VITRO DIAGNOSTIC KIT FOR IDENTIFICATION OF HUMAN PAPILLOMAVIRUS IN CLINICAL SAMPLES - A method and kit for detection and typing of HPV in a sample are described, as is a reaction vessel for use in the method. Universal HPV primers are used to amplify a sample by PCR; the amplified sample is then hybridised to an array of HPV type-specific probes to determine the HPV type. | 03-24-2011 |
| 20110033855 | METHOD FOR QUANTIFYING TARGET NUCLEIC ACID MOLECULES AND KIT FOR QUANTIFYING TARGET NUCLEIC ACID MOLECULES - The present invention is to provide a method for highly sensitively and precisely quantifying nucleic acid molecules in a sample. The method for quantifying target nucleic acid molecules in a nucleic acid-containing sample comprises: (a) preparing a sample solution comprising a nucleic acid-containing sample, a first nucleic acid molecule probe comprising a sequence complementary to the target nucleic acid molecule and conjugated with a first marker, and a second nucleic acid molecule probe comprising a sequence complementary to the first nucleic acid molecule probe and conjugated with a second marker; (b) denaturing nucleic acid molecules in this sample solution; (c) hybridizing them; (d) forming a covalent bond between two nucleic acid strands in the hybrid under a same condition, regarding the temperature and the salt concentration, as that of the hybrid formation; and (e) quantifying the target nucleic acid molecules by detecting a time course change in an optical characteristic of the first marker or the second marker in the sample solution, wherein an optical characteristic of at least either one of the first marker and the second marker is changed depending on whether or not the first nucleic acid molecule probe and the second nucleic acid molecule probe are hybridized. | 02-10-2011 |
| 20110065110 | Method For The Extraction And Purification Of Nucleic Acids On A Membrane - The invention relates to a method for the extraction and detection of nucleic acids on a membrane, making it possible to identify the microorganisms present in low concentration in a liquid or gaseous medium, as well as a novel lysis composition comprising guanidium chloride and between 0.1 and 1% N-Lauroyl-Sarcosine (NLS) making it possible to implement this method. | 03-17-2011 |
| 20110081654 | TRANSCRIPTIONAL PROFILING OF STEM CELLS AND THEIR MULTILINEAGE DIFFERENTIATION - The present invention concerns methods of screening cells for differentiation or de-differentiation, and/or for status as a pluripotent or multipotent (e.g., “stem”) cell, by detecting the differential expression (e.g., upregulation, downregulation) of genes. | 04-07-2011 |
| 20100267044 | GENETICALLY ENGINEERED BIOLOGICAL INDICATOR - The disclosed technology relates to a genetically engineered biological indicator, comprising: at least one test organism and at least one reporter gene suitable for producing an indicator enzyme, the reporter gene being taken up by the test organism; and at least one repressor gene that inhibits expression of the reporter gene until the reporter gene is exposed to at least one inducer. A process and an apparatus for using the biological indicator are disclosed. | 10-21-2010 |
| 20100267033 | Methods and Compositions For Detecting Autoimmune Disorders - The invention provides methods and compositions useful for detecting autoimmune disorders. | 10-21-2010 |
| 20100267022 | MONOCYTE-DERIVED NUCLEIC ACIDS AND RELATED COMPOSITIONS AND METHODS - Nucleic acids encoding various monocyte-derived proteins and related compositions, including purified proteins and specific antibodies are described. Methods of using such composition are also provided. | 10-21-2010 |
| 20100248252 | METHODS FOR ANALYSIS OF MOLECULAR EVENTS - Methods and compositions are provided for detecting the presence of nucleic acid sequence variants in a subpopulation of nucleic acid molecules in a biological sample. These methods are particularly useful for identifying individuals with mutations indicative of cancer. | 09-30-2010 |
| 20110097728 | MATERIALS AND METHOD FOR ASSAYING FOR METHYLATION OF CpG ISLANDS ASSOCIATED WITH GENES IN THE EVALUATION OF CANCER - Provided are methods, reagents, and kits for evaluating cancer, such as prostate cancer, in a subject. Disclosed methods of evaluating cancer include methods of diagnosing cancer, methods of prognosticating cancer and methods of assessing the efficacy of cancer treatment. The methods include assaying a biological sample for methylation of a CpG island associated with specified genes. Provided reagents and kits include primers suitable for amplifying at least a portion of a target CpG islands associated with specified genes. | 04-28-2011 |
| 20100261185 | LABELED ENZYME COMPOSITIONS, METHODS AND SYSTEMS - Disclosed herein are conjugates comprising a biomolecule linked to a label that have biological activity and are useful in a wide variety of biological applications. For example, provided herein are labeled polymerase conjugates including a polymerase linked to one or more labels, wherein the conjugate has polymerase activity. Such conjugates can exhibit enhanced biological activity and/or superior detectability as compared to conventional labeled polymerases. Also disclosed herein are improved methods for preparing such conjugates, and methods and systems for using such conjugates in biological applications such as nucleotide incorporation, primer extension and single molecule sequencing. | 10-14-2010 |
| 20110086343 | METHOD FOR THE SCREENING OF BACTERIAL ISOLATES - Present invention relates to a method to determine the genotype of organisms by RAPD analysis and more specifically, to establish the relatedness of individual organisms across and within species. RAPD uses genotypic information of an organism to give an organism specific DNA fragment of different sizes. The present invention provide methods and a set of oligonucleotide primers for performing amplification and other enzymatic reactions on nucleic acid molecules that have been collected directly as environmental DNA or DNA derived form pure isolates. More specifically, the present invention relates to a novel method of genetic analysis using a set of sub-sequence, which occurs as inverted repeats in different genome with different frequencies. All bacterial cultures used in this study have been isolated from activated biomass collected from effluent treatment plants. The bacteria have been sub-cultured repeatedly to obtain pure cultures. All plating has been carried out on Luria Broth plates with 2% agar. The 16S rRNA gene has been amplified using universal primers to confirm the eubacterial nature of the isolates. The primers used to amplify a 1466-bp product were 27F forward primer 5′-AGAGTTTGATCMTGGCTCAG-3′ and 1492 reverse primer 5′-TACGGYTAC-CTTGTTACGACTT-Hence, in defined conditions two genome samples could be differentiated from each other. These features are applicable to DNA fingerprinting, marker assisted selection, genotyping, and high throughput laboratory screening methods for culturable microbes from any environmental niche. | 04-14-2011 |
| 20110020814 | METHODS AND COMPOSITIONS FOR SELECTION OF STEM CELLS - Described herein are methods and compositions for selection of pluripotent stem cells from a population of mammalian cells (e.g., human) undergoing a process that induces some cells within the population to become pluripotent. | 01-27-2011 |
| 20110003284 | Aberrantly Methylated Genes in Pancreatic Cancer - The present invention provides a method for detecting pancreatic carcinoma in a subject. The method includes contacting a nucleic acid-containing specimen from the subject with an agent that provides a determination of the methylation state of at least one gene or associated regulatory region of the gene and identifying aberrant methylation of regions of the gene or regulatory region, wherein aberrant methylation is identified as being different when compared to the same regions of the gene or associated regulatory region in a subject not having the pancreatic carcinoma, thereby detecting pancreatic carcinoma in the subject. | 01-06-2011 |
| 20110111403 | MULTI-PRIMER ASSAY FOR MYCOPLASMA DETECTION - Disclosed is a multi-primer amplification assay, method and kits for detecting | 05-12-2011 |
| 20110053160 | HCV NS3/4A REPLICON SHUTTLE VECTORS - The present invention provides for novel HCV NS3/4A replicon shuttle vectors useful for cloning in HCV polynucleotide sequences from samples of HCV-infected patients and testing the resulting replicons for drug susceptibility. | 03-03-2011 |
| 20110053154 | 2'-nitrobenzyl-modified ribonucleotides - This disclosure provides novel reversibly terminated ribonucleotides which can be used as a reagent for DNA sequencing reactions. Methods of sequencing nucleic acids using the disclosed nucleotides are also provided. | 03-03-2011 |
| 20110065113 | RECURRENT GENE FUSIONS IN PROSTATE CANCER - The present invention relates to compositions and methods for cancer diagnosis, research and therapy, including but not limited to, cancer markers. In particular, the present invention relates to recurrent gene fusions as diagnostic markers and clinical targets for prostate cancer. | 03-17-2011 |
| 20110033843 | METHOD FOR IN VITRO TESTING OF COMPOUNDS FOR ASSESSING THERAPEUTIC VALUE IN THE TREATMENT OF MULTIPLE SCLEROSIS AND OTHER DISEASES WHEREIN FOAMY CELLS ARE INVOLVED IN THE DISEASE ETIOLOGY - The invention provides a method for assessing or determining activity of a test Compound on modulation of gene product levels comprising culturing cells, contacting at least one of the cultured cells with a lipid-rich fraction, contacting at least one of the cultured cells with the test Compound, determining the presence of a gene product of at least one cell of the cultured cells and, optionally, determining the presence of the gene product of at least one cultured cell not contacted with the test Compound. To assess human conditions most fully, it is preferred that the cell is of human origin, for example, a peripheral blood monocyte taken from a healthy donor. | 02-10-2011 |
| 20110020803 | MARKERS FOR THE PROGNOSIS OF LUNG FUNCTION AND COLONIZATION WITH AN INFECTIOUS AGENT - The present invention provides a method and kit for determining the risk for impaired lung function and/or the susceptibility for colonization with an infectious agent. The method and kit comprise determining the presence or absence of one or more nucleic acid variants in a gene or a combination of genes. | 01-27-2011 |
| 20110111419 | Copy Number Variations Predictive of Risk of Schizophrenia - The present invention relates to genomic copy number variations as risk factors for schizophrenia. The invention provides methods and kits for risk management of schizophrenia, by assessing such copy number variations in the genome of individuals. | 05-12-2011 |
| 20090305286 | Method for the Identification of Suitable Fragmentation Sites in a Reporter Protein - The invention concerns a combinatorial method for the generation of new split-protein sensors, and its application towards the (β/α) | 12-10-2009 |
| 20090305240 | METHOD FOR DETECTION OF MICROORGANISM AND KIT FOR DETECTION OF MICROORGANISM - Live cells of a microorganism in a test sample are detected by the following steps:
| 12-10-2009 |
| 20110086346 | Novel haplotype tagging single nucleotide polymorphisms and use of same to predict childhood lymphoblastic leukemia - The present invention is directed to novel haplotype tagging single nucleotide polymorphisms (SNPs) in specific regions outside the HFE gene that serve as a reliable biomarker for a decreased risk for childhood lymphoblastic leukemia (ALL) in a child. There is provided herein methods and reagents for assessing the haplotype tagging SNPs selected from the group consisting of rs807212, rs198853, rs9467664, rs2213284, rs2230655 and rs12346. The method useful in applying these SNPs in predicting a decreased risk of childhood lymphoblastic leukemia (ALL) is also disclosed. | 04-14-2011 |
| 20100120026 | Particulate Substrates for Improved Recovery of Microbes - Specially modified microbial growth surfaces improve bacterial recovery or counts when testing for the presence or absence of microbial cells or performing microbial enumerations. | 05-13-2010 |
| 20100120031 | SYNTHESIS OF TRANS-TERT-BUTYL-2-AMINOCYCLOPENTYLCARBAMATE - The present invention concerns methods of synthesis of trans-tert-butyl-2-aminocylcopentylcarbamate comprising contacting 6-tosyl-6-azabicyclo[3.1.0]hexane with TMSN | 05-13-2010 |
| 20100120037 | METHOD FOR ISOLATING AND CULTURING UNCULTURABLE MICROORGANISMS - The invention provides a method for isolating and culturing a previously unculturable microorganism, which comprises: (i) collecting a sample from an environmental source; (ii) counting/estimating the number of microorganisms in the sample; (iii) diluting the sample in an appropriate medium; (iv) adding a gelating agent such as to entrap one or more microorganisms within a sphere of the gelating agent; (v) coating the spheres containing the entrapped microorganism(s) with a natural or synthetic polymer to form a polymeric membrane; (vi) incubating the coated spheres in the original environment for an appropriate time; (vii) cutting the spheres and scanning for microorganisms colonies; and (viii) isolating the microorganisms, and repeating steps (iii) to (vii) until a pure clone of said previously unculturable microorganism is obtained. | 05-13-2010 |
| 20100120027 | PROGNOSTIC TEST FOR EARLY STAGE NON SMALL CELL LUNG CANCER (NSCLC) - The invention provides methods for identifying early stage non-small cell lung cancer (NSCLC) patients who will have a favorable prognosis for the recurrence of lung cancer after surgical resection. The invention is based on the discovery that assessment of chromosomal copy number abnormalities at chromosome 10q23.3 and centromere 10 can be used for prognostic classification. The invention preferably uses fluorescence in situ hybridization with fluorescently labeled nucleic acid probes to hybridize to patient samples to quantify the chromosomal copy number of the these genetic loci. The chromosome copy number can also be determined using, for example, PCR or array CGH. Assessment of the copy number abnormality patterns with a classifier based on the relative loss of 10q23.3 signals compared to the centromere 10 signals produced statistically significant prognostic classification for NSCLC. The ratio of PTEN/CEP 10 signals, using a cutoff of 0.80, was capable of dividing patients into a group of 41 (≧0.80) in which 33 (80.5%) had the favorable prognosis, and a group of 18 (<0.80) in which 6 (33.3%) had the favorable prognosis (p=0.0008). Median times to recurrence in the former and latter groups were 83.0 and 13.0 months, respectively (p<0.0001). | 05-13-2010 |
| 20100120023 | Detection of macromolecular complexes with harmonic cantilevers - Method and apparatus which uses harmonic cantilevers, such as used in atomic force microscopy, to detect variations in the attractive and repulsive forces on a solid surface as a result of macromolecular binding, for example, hybridization of a single stranded DNA molecule attached to the surface with another DNA molecule. The complexed macromolecule is less flexible than an uncomplexed molecule. It will typically have more negative charge due to amino acids or DNA monomers. Both stiffness of the surface and the attractive capillary forces will change after binding and may be detected. By scanning the harmonic cantilever across a surface with macromolecules attached in tapping-mode and by recording the signals at the high frequency vibrations provided by harmonic cantilever, complexed molecules on a surface may be identified and quantified. | 05-13-2010 |
| 20100184046 | Methods and systems of using exosomes for determining phenotypes - Exosomes can be used for detecting biomarkers for diagnostic, therapy-related or prognostic methods to identify phenotypes, such as a condition or disease, for example, the stage or progression of a disease. Cell-of-origin exosomes can be used in profiling of physiological states or determining phenotypes. Biomarkers or markers from cell-of-origin specific exosomes can be used to determine treatment regimens for diseases, conditions, disease stages, and stages of a condition, and can also be used to determine treatment efficacy. Markers from cell-of-origin specific exosomes can also be used to identify conditions of diseases of unknown origin. | 07-22-2010 |
| 20110117570 | METHODOLOGIES, PROCESSES AND AUTOMATED DEVICES FOR THE ORIENTATION, SAMPLING AND COLLECTION OF SEED TISSUES FROM INDIVIDUAL SEED - Apparatus, methods, and systems for high throughput, useful sampling of seed, wherein viability is optionally maintained, are disclosed. Seed from one generation in a plant advancement experiment is individually sampled by removal and collection of tissue from the seed. The tissue is then processed to derive one or more biochemical, genetic, or phenotypic characteristic of the seed before a decision is made whether to utilize that seed further in a plant advancement experiment or other plant research and development. In some embodiments of the method, the sampling is controlled to remove a useful amount of tissue for analytical purposes without significant effect on viability potential of the sampled seed. In some embodiments, the sampling is controlled to deter contamination of the sample. In some embodiments, the seed is automatically positioned and oriented to facilitate efficient and accurate sampling. | 05-19-2011 |
| 20110117569 | POLYMIDE NUCLEIC ACID DERIVATIVES, AND AGENTS AND PROCESSES FOR PREPARING THEM - The present invention relates to PNA derivatives which carry, at the C terminus, or at both the C and N termini of the PNA backbone, one or more phosphoryl radicals. The phosphoryl radicals carry, where appropriate, one or more labeling groups, groups for crosslinking, groups which promote intracellular uptake, or groups which increase the binding affinity of the PNA derivative for nucleic acids. The invention furthermore relates to a process for preparing the above-mentioned PNA derivatives and to their use as pharmaceuticals or diagnostic agents. | 05-19-2011 |
| 20110117564 | COMPOSITIONS, KITS AND RELATED METHODS FOR THE DETECTION AND/OR MONITORING OF SALMONELLA - Provided are compositions, kits, and methods for the identification of | 05-19-2011 |
| 20110117556 | HIGH-SENSITIVE FLUORESCENT ENERGY TRANSFER ASSAY USING FLUORESCENT AMINO ACIDS AND FLUORESENT PROTEINS - The disclosure provides method and composition utilizing fluorescent amino acids and endogenous fluorescent proteins comprising a moiety capable of undergoing FRET. The methods and compositions of the disclosure are useful in analyzing protein structure and function, and screening molecular inhibitors. | 05-19-2011 |
| 20110117555 | CD38 as a prognostic indicator in chronic lymphocytic leukemia - The subject invention discloses a method for determining the prognosis and probable clinical course of a subject diagnosed with B-CLL. Specifically, the invention involves comparing CD38 expression in a biological sample from the subject containing B-CLL cells to a baseline level of CD38 expression, wherein an elevated level of CD38 expression in relation to the baseline level of CD38 expression may indicate poor prognosis or aggressive course of disease in the subject. Also disclosed is a method for determining whether the Ig V genes of the B-CLL cells of a B-CLL patient are mutated, comprising comparing CD38 expression in a biological sample from the subject containing B-CLL cells to a baseline level of CD38 expression, wherein a lower level of CD38 expression in relation to the baseline level indicates IG V gene mutation. | 05-19-2011 |
| 20110117554 | Formamide-containing mixtures for detecting nucleic acids - Specific sequences of DNA are often detected by a process that comprises a step where the sequence to be detected (the “analyte”) binds to give a duplex with a DNA molecule or analog that is complementary in the Watson-Crick sense to some portion of the analyte in an aqueous “assay environment” that may contain buffer, salt, and/or detergent. Such purely aqueous systems cannot be exposed indefinitely to the environment, however, as the water in the system will evaporate. Further, such systems often support the growth of bacteria and other organisms, destroying their effectiveness. This invention provides for compositions of matter and processes that use them that comprise assay mixtures containing more than 40% formamide. This mixture remains a liquid at equilibrium with water in environments normally inhabited by humans. This invention also provides for mixtures containing formamides that include detergents. Formamide is usually regarded as a denaturant for duplex formation, destabilizing the binding that is key to detection. This invention therefore also provides for materials that form duplexes in formamide-water mixtures. | 05-19-2011 |
| 20110117551 | DETECTION AND PROGNOSIS OF LUNG CANCER - Methods and tools are provided for detecting and predicting lung cancer. The methods and tools are based on epigenetic modification due to methylation of genes in lung cancer or pre-lung cancer. The tools can be assembled into kits or can be used seperately. Genes found to be epigentically silenced in association with lung cancer include ACSL6, ALS2CL, APC2, ART-S1, BEX1, BMP7, BNIP3, CBR3, CD248, CD44, CHD5, DLK1, DPYSL4, DSC2, EDNRB, EPB41L3, EPHB6, ERBB3, FBLN2, FBN2, FOXL2, GNAS, GSTP1, HS3ST2, HPN, IGFBP7, IRF7, JAM3, LOX, LY6D, LY6K, MACF1, MCAM, NCBP1, NEFH, NID2, PCDHB15, PCDHGA12, PFKP, PGRMC1, PHACTR3, PHKA2, POMC, PRKCA, PSEN1, RASSF1A, RASSF2, RBP1, RRAD, SFRP1, SGK, SOD3, SOX17, SULF2, TIMP3, TJP2, TRPV2, UCHL1, WDR69, ZFP42, ZNF442, and ZNF655. | 05-19-2011 |
| 20110117550 | METHOD OF DETERMINING ANTI-HYPERTENSIVE DRUG THERAPY BY GENETIC PROFILING - The present invention comprises a method for determining an anti-hypertension therapy for an individual based upon the presence or absence of specific alleles affecting baseline blood pressure and sensititivity to different therapeutic formulations. | 05-19-2011 |
| 20110117548 | Detecting Fetal Chromosomal Abnormalities Using Tandem Single Nucleotide Polymorphisms - The invention provides tandem single nucleotide polymorphisms and methods for their use, for example, in diagnosing Down Syndrome. | 05-19-2011 |
| 20110117547 | TARGET DNA DETECTION METHOD AND TARGET DNA DETECTION KIT - The present invention provides a method for detecting a target DNA easily and highly accurately through simultaneous analysis of a sense strand and an antisense strand of the target DNA, and a kit therefor. The target DNA detection method of the present invention is a method for detecting a target DNA composed of a sense strand having a target nucleotide sequence and an antisense strand complementary to the sense strand, wherein: a first oligonucleotide which hybridizes with the sense strand, and a second oligonucleotide which hybridizes with the antisense strand are used; at least a part of a region, of the antisense strand, which hybridizes with the second oligonucleotide is complementary to at least a part of a region, of the sense strand, which hybridizes with the first oligonucleotide; and the first oligonucleotide and the second oligonucleotide are simultaneously added into one reaction solution to effect respective hybridizations with the target DNA, followed by ligation reactions and/or PCR, thereby detecting resultant products. | 05-19-2011 |
| 20110117546 | INCREASE OF SIGNAL SENSITIVITY USING DUAL PROBES IN PCR REACTIONS - A method increases the signal strength generated when performing real-time PCR on a target nucleic acid sequence. The method performs real-time PCR using forward primers, forward probes, reverse primers, reverse probes, nucleotides for strand/antistrand extension, and nucleic acid polymerase. Two different types of probes are used, a forward probe configured to anneal to a sense strand of a target nucleic acid sequence and a reverse probe configured to anneal to an antisense strand of the target nucleic acid sequence. The forward probe is complementary to an inner sequence of the target sense strand, and the reverse probe is complementary to an inner sequence of the target antisense strand. The forward probe and the reverse probe each include the same detectable element, that when released from the probe during strand extension results in an additive detectable signal. | 05-19-2011 |
| 20110117544 | METHOD FOR PRODUCING AN AMPLIFIED POLYNUCLEOTIDE SEQUENCE - There is a method for converting at least a part of a target polynucleotide sequence into a different sequence, comprising the steps of: (i) hybridising two or more first polynucleotides to adjacent positions on the target and linking first polynucleotides together, wherein at least one of the first polynucleotides comprises at least one nucleotide that is not complementary to the target; and (ii) dissociating the hybrid of step (i) and forming a second polynucleotide hybridised to the first polynucleotide, the second polynucleotide comprising at least one portion complementary to a portion on the first polynucleotide and comprising the complement to the at least one nucleotide of step (i). | 05-19-2011 |
| 20110117543 | DIAGNOSTIC METHOD AND PRODUCTS USEFUL THEREIN - A method for simultaneous detection and identification of | 05-19-2011 |
| 20100086921 | GENETIC SUSCEPTIBILITY VARIANTS OF TYPE 2 DIABETES MELLITUS - Association analysis has shown that certain genetic variants are susceptibility variants for Type 2 diabetes. The invention relates to diagnostic applications of such susceptibility variants, including methods of determining increased susceptibility to Type 2 diabetes, as well as methods of determining decreased susceptibility to Type 2 diabetes in an individual. The invention further relates to kits for determining a susceptibility to Type 2 diabetes based on the variants described herein. | 04-08-2010 |
| 20110070577 | Method for Detecting Target Nucleic Acids Using Template Catalyzed Transfer Reactions - The present invention relates to the detection and quantification of nucleic acid sequences and to the sequence determination of nucleic acids using template catalyzed transfer reactions. The invention also relates to methods, reagents, and kits for detecting and quantifying nucleic acid sequences and for determining the sequence of nucleic acids. | 03-24-2011 |
| 20090305245 | Method of Examining Zinc-Deficient Taste Disturbance - The present invention provides: a method for testing zinc deficiency dysgeusia, which is characterized in that it comprises correlating the expression levels of a gene encoding a gustatory receptor belonging to the THTR family and a gene encoding a gustatory receptor belonging to the T2R family obtained from a sample derived from the oral cavity of a subject, with a serum zinc level obtained from the sample of the subject; and a kit used for the aforementioned test. | 12-10-2009 |
| 20110076685 | METHOD FOR IN VITRO DETECTION AND DIFFERENTIATION OF PATHOPHYSIOLOGICAL CONDITIONS - The present invention relates to the use of defined polynucleotides to form at least one multi-gene biomarker for producing a multiplex assay as a tool for in vitro detection and/or early detection and/or differentiation and/or progress monitoring and/or evaluation of pathophysiological conditions of a patient, the pathophysiological condition selected from the group consisting of: SIRS, sepsis and its degrees of severity; sepsis-like conditions, septic shock, bacteremia, infective/non-infectious multiorgan failure, early detection of these conditions; focus control, control of surgical rehabilitation of the infection focus; responders/non-responders for a specific therapy, treatment monitoring; distinction between infectious and non-infectious etiology of systemic reactions of the organism, such as SIRS, sepsis, postoperative complications, chronic and/or acute organ dysfunction, shock response, inflammatory response and/or trauma. | 03-31-2011 |
| 20100081144 | POINT-OF-CARE FLUIDIC SYSTEMS AND USES THEREOF - This invention is in the field of medical devices. Specifically, the present invention provides portable medical devices that allow real-time detection of analytes from a biological fluid. The methods and devices are particularly useful for providing point-of-care testing for a variety of medical applications. | 04-01-2010 |
| 20100086930 | IMPROVED HOMOGENEOUS LUMINESCENCE BIOASSAY - A homogenous bioassay including i) a first group containing a short lifetime fluorescent acceptor capable of energy transfer, and ii) a second group containing a quencher capable of energy transfer from an acceptor, with the first and second groups linked by at least a first linkage. The bioassay measures the acceptor's fluorescence increase resulting from cleavage of the first linkage. The bioassay also includes iii) a third group containing a donor for energy transfer to the acceptor, where the donor is an up-conversion fluorescent compound, a long-lifetime fluorescent compound or an electrogenerated luminescent compound. A conformational or terminal epitope is created on the first group through cleavage of the linkage, and the third group includes a binder with affinity for this conformational or terminal epitope. The acceptor's fluorescence is brought about by exciting the donor. Also disclosed are kits for homogenous bioassays according to the method of the invention. | 04-08-2010 |
| 20100086913 | Methods of Identification Using Methylation of CPG - The present invention relates to the materials and methods for the identification of methylated nucleotides in samples of genomic DNA. The present invention also relates to methods of diagnosis of specific conditions by identification of specific methylated nucleotides. | 04-08-2010 |
| 20090263797 | REVERSIBLE DI-NUCLEOTIDE TERMINATOR SEQUENCING - The present teachings provide methods, compositions, and kits for synthesizing and sequencing nucleic acids. In some embodiments, reversible di-nucleotide compounds are employed along with cleaving reactions that remove a label and a blocking moiety. Improved sequencing efficiency is achieved by the rapid polymerase-mediated incorporation of reversible di-nucleotide compounds. In some embodiments, the di-nucleotides do not contain conventional nucleotide triphosphates, but rather employ amino acid phosphoramidate nucleotides (AAPNs). | 10-22-2009 |
| 20090263795 | DIAGNOSTIC METHODS INVOLVING DETERMINING GENE COPY NUMBERS AND SNPs IN THE FcyRII/FcyRIII GENE CLUSTER, AND PROBES FOR USE IN SUCH METHODS TO DETECT SUSCEPTIBILITY TO AND TREATMENT EFFICACY IN AUTOIMMUNE DISEASES - The invention relates to diagnostic methods to predict whether a subject is predisposed for acquiring a disease or to predict the therapy responsiveness of an individual patient. Provided is a method for determining whether a subject is predisposed for developing an autoimmune disease, comprising determining in a sample isolated from said subject the amount of intact genes, or gene products thereof, of the FcγRII/FcγRIII gene cluster, said gene cluster comprising the FCGR2C, FCGR3A, FCGR2A and FCGR3B genes encoding an activating FcγR, and FCGR2B encoding an inhibitory Fcγ R; and correlating said amount to the amount observed in a healthy population. Also provided is a method to predict the responsiveness of a subject to therapy with intravenous immunoglobulin (IVIg) therapy or a monospecific biological, such as a humanized or human monoclonal antibody or a chimeric molecule, comprising the C-terminal Fc-tail of IgG. | 10-22-2009 |
| 20110033850 | COMPOSITIONS AND METHODS FOR THE IDENTIFICATION OF INHIBITORS OF RETROVIRAL INFECTION - Methods of identifying inhibitors of retroviral propagation, tRNA used in the methods, and kits, including the tRNA, which can be used in the methods, are disclosed. Methods of treating or preventing retroviral infections by administering an effective amount of the inhibitors, and pharmaceutical compositions including the inhibitors, are also disclosed. The methods involve forming a mixture comprising a linear sequence of a tRNA anticodon stem loop fragment that is not capable of forming a stem-loop, a target nucleic acid molecule capable of binding to the tRNA anticodon stem loop fragment, and a test compound. The mixture is incubated under conditions that allow binding of the tRNA anticodon stem loop fragment and the target nucleic acid molecule in the absence of the test compound. Assays can then be performed that detect whether or not the test compound inhibits the binding of the tRNA anticodon stem loop fragment and the target nucleic acid molecule. | 02-10-2011 |
| 20110033847 | Methods for the characterization of microorganisms on solid or semi-solid media - The present invention relates to methods and systems for scanning, detecting, and monitoring microorganisms on solid or semi-solid media using intrinsic fluorescence (IF) measurements. The methods are further directed to detection, characterization and/or identification of microorganisms on a solid or semi-solid media using intrinsic fluorescence (IF) measurements that are characteristic of said microorganisms. | 02-10-2011 |
| 20100021902 | Method for methylation-selective amplification - Aspects of the invention relate to a method for methylation selective amplification. The method comprising a DNA treatment, wherein cytosine is converted to uracil, uracil sulfonate or another base having a different binding behavior than cytosine, while methylated cytosine remains unchanged, and the amplification of treated DNA in the presence of at least one restriction enzyme, said enzyme digesting the amplification product derived either from converted methylated DNA or from converted unmethylated DNA during amplification. Aspects of the invention relate to a kit for performing the inventive method. Aspects of the invention relate also to the use of the inventive methods and kits. | 01-28-2010 |
| 20110039273 | METHOD FOR MEASURING DNA METHYLATION - The present invention relates to a method of measuring the content of methylated DNA in a DNA region of interest in a genomic DNA contained in a biological specimen, and so on. | 02-17-2011 |
| 20110039266 | FLOWCELL SYSTEMS FOR SINGLE MOLECULE DETECTION - The present invention provides compounds, methods and systems for sequencing nucleic acid using single molecule detection. Using labeled NPs that exhibit charge-switching behavior, single-molecule DNA sequencing in a microchannel sorting system is realized. In operation, sequencing products are detected enabling real-time sequencing as successive detectable moieties flow through a detection channel. By electrically sorting charged molecules, the cleaved product molecules are detected in isolation without interference from unincorporated NPs and without illuminating the polymerase-DNA complex. | 02-17-2011 |
| 20110039272 | Gene Expression Markers for Colorectal Cancer Prognosis - A method of predicting clinical outcome in a subject diagnosed with colorectal cancer comprising determining evidence of the expression of one or more predictive RNA transcripts or their expression products in a biological sample of cancer cells obtained from the subject. | 02-17-2011 |
| 20110039268 | CYTOKINE PROTEIN FAMILY - The present invention relates to polynucleotide and polypeptide molecules for zcyto20, zcyto21, zcyto22, zycto24, and zcyto25 proteins which are most closely related to interferon-α at the amino acid sequence level. The receptor for this protein family is a class II cytokine receptor. The present invention includes methods of reducing viral infections and increasing monocyte counts. The present invention also includes antibodies to the zcyto20 polypeptides, and methods of producing the polynucleotides and polypeptides. | 02-17-2011 |
| 20110039271 | Gene Expression Markers for Colorectal Cancer Prognosis - A method of predicting clinical outcome in a subject diagnosed with colorectal cancer comprising determining evidence of the expression of one or more predictive RNA transcripts or their expression products in a biological sample of cancer cells obtained from the subject. | 02-17-2011 |
| 20110039264 | Format of Probes to Detect Nucleic Acid Differences - The invention provides, inter alia, novel probes, methods, reaction mixtures, and kits for detecting the presence or absence of a target nucleic acid sequence. | 02-17-2011 |
| 20110039269 | Gene Expression Markers for Colorectal Cancer Prognosis - A method of predicting clinical outcome in a subject diagnosed with colorectal cancer comprising determining evidence of the expression of one or more predictive RNA transcripts or their expression products in a biological sample of cancer cells obtained from the subject. | 02-17-2011 |
| 20110039267 | Sample Preparation And Detection Of Analytes Using Silica Beads - This invention provides methods for concentration of analyte from biological sample, or various liquid samples and methods for identification of the analyte. The method includes providing silica beads conjugated with analyte recognition element for concentration of analyte from sample, packaging the beads into a cartridge, and attaching the cartridge to a sample holder. After the analyte concentration, additional steps can be implemented to identify the analyte to provide visual positive/negative, qualitative or quantitative results. Another exemplary embodiment of the present invention provides a system for concentration of analyte from biological sample or other various liquid samples using silica beads. According to an exemplary implementation, the system includes a cartridge comprising silica beads conjugated with analyte recognition element to concentrate at least one analyte from the sample, and a sample holder having the cartridge attached thereto. A sample is passed through the cartridge. | 02-17-2011 |
| 20110045485 | ANALYTICAL METHOD AND KIT - RNA-containing probes and kits comprising RNA-containing probes for the detection and analysis of nucleic acid sequences are described. These probes are contacted with a sample suspected of containing the nucleic acid sequence and if they form duplexes, they are hydrolysed. This may be done, for example during an amplification reaction. AMP generated as a result of the hydrolysis is converted to ATP. The ATP may then be detected using bioluminescent reagents. Inclusion of modified adenosine in at least one probe means that the signal arising from one probe will give rise to a different and distinguishable bioluminescent signal thus enabling the use of for example an internal control in bioluminescently-reported nucleic acid tests. | 02-24-2011 |
| 20100075327 | INTERMITTENT DETECTION DURING ANALYTICAL REACTIONS - Methods, devices, and systems for performing intermittent detection during analytical reactions are provided. Such methods facilitate collection of reaction data from disparate reaction times. Further, such methods are useful for reducing photo-induced damage of one or more reactants in an illuminated analytical reaction at a given reaction time. In preferred embodiments, the reaction mixture is subjected to at least one illuminated and non-illuminated period and allowed to proceed such that the time in which the reaction mixture is illuminated is less than a photo-induced damage threshold period. | 03-25-2010 |
| 20110027790 | METHODS OF EQUALIZING REPRESENTATION LEVELS OF NUCLEIC ACID TARGETS - The disclosure provides methods of reducing the range of representation levels of nucleic acid targets. The methods are particularly useful for multi-target analyses benefiting from a low variance of target representations, such as, e.g., single molecule sequencing and/or heterozygous genotyping, and pathogen diagnosis. Two general methods are provided. In Method 1, starting concentrations of probes are adjusted. In Method 2, target-specific probes are “binned,” i.e., several subsets of probes are selected based on similar representation levels. Thereafter, each subset of corresponding targets is extracted, with or without amplification, using a separate portion of the sample (i.e., separate vessels). | 02-03-2011 |
| 20110027782 | PROBES AND METHODS FOR DETECTION OF PATHOGENS AND ANTIBIOTIC RESISTANCE - Described are probes and methods for detecting pathogens and antibiotic resistance of a specimen. The method comprises contacting the specimen with a growth medium; and lysing the specimen to release nucleic acid molecules from the specimen. The lysate of the specimen is contacted with a capture probe immobilized on a substrate, wherein the capture probe comprises an oligonucleotide that specifically hybridizes with a first target nucleic acid sequence region of ribosomal RNA. The lysate is in contact with a detector probe that comprises a detectably labeled oligonucleotide that specifically hybridizes with a second target nucleic acid sequence region of ribosomal RNA. The presence or absence of labeled oligonucleotide complexed with the substrate is determined. Detection of labeled oligonucleotide complexed with the substrate is indicative of the presence of pathogen. Performing the method in the presence and absence of an antibiotic permits detection of antibiotic resistance. | 02-03-2011 |
| 20110027784 | Novel Primers for Identification of Astrocytoma, Its Grades and Glioblastoma Prognosis - The present invention relates to novel primers for identification of astrocytoma, it's grades and glioblastoma prognosis. Further, disclosed is a method of diagnosing the presence of different grades of diffuse astrocytoma and glioblastoma, in a human subject, which involves detection of the expression levels of said genes in tumor tissue samples in comparison to normal brain. Also disclosed is a method of distinguishing between the two types of Glioblastoma—the progressive and de novo types. Also disclosed is a method of prognosis of glioblastoma based on the expression of the gene PBEF1, wherein the higher level of expression of the gene in the tumor sample, indicates poorer survival of the human subject. The disclosed compositions are useful, for example, in the diagnosis, prevention, treatment and/or prognosis of astrocytoma. The invention further provides kits for the detection and prognosis of the said diseases. | 02-03-2011 |
| 20110027780 | AMPLIFICATION METHODS - Methods are provided for amplification and monitoring of oligonucleotide amplification in which a primer has an overlap with one or more bases of a detection probe. | 02-03-2011 |
| 20110027785 | METHOD FOR DETERMINING SUSCEPTIBILITY OF INDIVIDUALS TO POLYPHENOLS - Consumption of high energy diets, lack of physical activity and sleep curtailment have all been linked to the development of type II diabetes and cardiovascular disease. Studies have also shown how powerful diet and lifestyle modification can be for preventing disease. However not everyone responds to lifestyle change in the same way. This is because genetic factors can modify biological response to environmental challenge. | 02-03-2011 |
| 20110027781 | System for Autonomous Monitoring of Bioagents - An autonomous monitoring system for monitoring for bioagents. A collector gathers the air, water, soil, or substance being monitored. A sample preparation means for preparing a sample is operatively connected to the collector. A detector for detecting the bioagents in the sample is operatively connected to the sample preparation means. One embodiment of the present invention includes confirmation means for confirming the bioagents in the sample. | 02-03-2011 |
| 20110027777 | METHOD FOR PERFORMING PROGNOSIS FOR HIGH-RISK BREAST CANCER PATIENTS USING TOP2A GENE ABERRATIONS - A first exemplary method for performing a prognosis for a breast cancer patient, comprises the steps of determining the status of an aberration of the TOP2A gene in a tissue sample taken from the patient; and estimating the probability of either recurrence-free survival or of overall survival of the patient at a later time based upon a pre determined Hazard Ratio corresponding to the determined status. A second such exemplary method comprises the steps of determining the status of an aberration of the TOP2A gene in a tissue sample taken from the patient; and estimating the probability of either recurrence-free survival or of overall survival of the patient at a later time based upon a pre-determined Kaplan-Meier plot corresponding to the determined status. | 02-03-2011 |
| 20090280479 | USE OF FREE CIRCULATING DNA FOR DIAGNOSIS, PROGNOSIS, AND TREATMENT OF CANCER FUNDING - A method of detecting circulating DNA in a body fluid. The method comprises identifying a subject suffering from or at risk for developing cancer, obtaining a body fluid sample from the subject, and determining the sequence integrity of circulating DNA in the sample, wherein the circulating DNA is not purified from the sample. | 11-12-2009 |
| 20110059462 | AUTOMATED PARTICULATE CONCENTRATION SYSTEM - An automated system for concentrating potentially harmful substances from various water types or other non-viscous liquids to facilitate detection of those substances is disclosed herein. The automated system comprises a water pressure driven or pump driven concentration unit that filters the test fluid through a hollow-fiber filter. Material collected on the filter is backflushed into a collection vessel by passing a small volume of sterile solution through the filter in the reverse direction. The automated system can be configured to be portable or to be integrated into a continuous liquid stream for online monitoring of test fluids. Optionally, an electronic signal at the end of the backflush sequence triggers a detector, such as an automated array biosensor, to begin processing and analyzing the sample. | 03-10-2011 |
| 20110059446 | METHOD FOR DETERMINING METHYLATION AT CYTOSINE RESIDUES - The present invention refers to a method and reagent kits for determining methylation at cytosine (dC) residues in nucleic acids, such as DNA. | 03-10-2011 |
| 20110059443 | FLUORESCENT GFP VARIANT DISPLAYING HIGHLY INCREASED FLUORESCENCE INTENSITY WITHOUT A SPECTRAL SHIFT - The present invention relates to a nucleic acid molecule encoding a polypeptide having a fluorescence emission activity with a maximum emission at 505 to 515 nm, wherein said nucleic acid molecule is selected from the group consisting of (a) a nucleic acid molecule encoding a polypeptide having the amino acid sequence of SEQ ID NO: 2; (b) a nucleic acid molecule having the DNA sequence of SEQ ID NO: 1; (c) a nucleic acid molecule hybridizing under stringent conditions to the complementary strand of (i.) a nucleic acid molecule of (a), wherein said nucleic acid molecule of (c) encodes a polypeptide having at the position corresponding to position 146 of SEQ NO:2 a phenylalanine and at the position corresponding to position 203 of SEQ NO:2 a threonine; or (ii) a nucleic acid molecule of (b), wherein said nucleic acid molecule of (c) has at the positions corresponding to positions 438 to 440 of SEQ ID NO: 1 a nucleotide triplet selected from the group consisting of TTT and TTC; and at the positions corresponding to positions 609 to 611 of SEQ ID NO: 1 a nucleotide triplet selected from the group consisting of ACT, ACC, ACA, ACG; wherein the polypeptide encoded by the nucleic acid molecule of (c) has a fluorescence enhanced by at least the factor of 2.5 as compared to the polypeptide having the amino acid sequence of SEQ ID NO: 10; or (d) a nucleic acid molecule degenerate with respect to the nucleic acid molecule of (b). The present invention furthermore relates to a polypeptide encoded by the nucleic acid molecule of the invention, a vector and a host cell comprising the nucleic acid molecule of the invention, a method of producing said polypeptide, a fusion protein comprising the polypeptide of the invention and methods of detecting the presence and/or localization of a protein of interest and methods of detecting the activity of a promoter. | 03-10-2011 |
| 20110059437 | PCR-BASED GENOTYPING | 03-10-2011 |
| 20110059432 | METHOD FOR PROVIDING DNA FRAGMENTS DERIVED FROM A REMOTE SAMPLE - Aspects of the present invention relate to compositions and methods for providing DNA fragments from a remote sample. In particular aspects a remote sample comprising DNA is provided, DNA is isolated from the remote sample, and the isolated DNA is treated in a way which allows differentiation of methylated and unmethylated cytosine. Additional, particular embodiments provide compositions and methods for methylation analysis of DNA derived from a remote sample. Other aspects provide for compositions and methods of whole genome amplification of bisulfite treated DNA. | 03-10-2011 |
| 20110059433 | Method for the detection and characterization of microorganisms on a filter - The present invention relates to a method for the specific detection on a filter of one or more microorganisms present in a fluid, characterized in that it comprises the following steps: a) contacting the microorganisms present in the fluid or on the surface with the filter; b) amplifying specifically the nucleic acids from the microorganism or microorganisms present on the filter, in an isothermal manner, in order to obtain amplification products, c) detecting the amplification products. The invention also relates to a device, a kit and oligonucleotides suitable for the implementation of this method. | 03-10-2011 |
| 20110059461 | METHODS OF DIAGNOSING MYELODYSPLASTIC SYNDROME (MDS) OR LEUKEMIA USING NUCLEIC ACIDS OR FRAGMENTS ENCODING FLT3 KINASE - To provide a nucleic acid encoding a receptor protein kinase, wherein the nucleic acid has tandem duplication in a nucleotide sequence of a juxtamembrane and is useful for diagnosis of leukemia; a polypeptide encoded by the nucleic acid; an antibody capable of specifically binding to a region encoded by the nucleic acid having tandem duplication occurring in a nucleotide sequence of a juxtamembrane; a nucleic acid capable of specifically binding to the nucleic acid having tandem duplication occurring in a nucleotide sequence of a juxtamembrane; a method for detection of the nucleic acid encoding a receptor protein kinase; and a kit therefor. A nucleic acid encoding a receptor protein kinase, wherein the nucleic acid has tandem duplication in a nucleotide sequence of a juxtamembrane; a polypeptide encoded by the nucleic acid; an antibody capable of specifically binding to the portion of the polypeptide; a nucleic acid capable of specifically binding to the nucleic acid; a method for detection of the nucleic acid; and a kit for detection. | 03-10-2011 |
| 20110059442 | Multiplex detection of nucleic acids - Methods of detecting nucleic acids, including methods of detecting two or more nucleic acids in multiplex branched-chain DNA assays, are provided. Nucleic acids captured on a solid support are detected, for example, through cooperative hybridization events that result in specific association of a label with the nucleic acids. Compositions, kits, and systems related to the methods are also described. | 03-10-2011 |
| 20110033852 | PRESENT INVENTION RELATES TO METHODS FOR PREDICTION OF THE THERAPEUTIC SUCCESS OF BREAST CANCER THERAPY - The present invention relates to a method for predicting a clinical response of a patient suffering from or at risk of developing gynecologic cancer towards a given mode of treatment, said method comprising the steps of: a) obtaining a biological sample from said patient; b) determining the expression level of at least one gene selected from the group comprising ALCAM, Osteopontin, Her-2/neu, EGFR, uPA/PAI-1 and/or ESR1, in particular of ALCAM and/or Osteopontin, in said sample; c) comparing the pattern of expression level (s) determined in (b) with one or several reference pattern (s) of expression levels; and d) predicting therapeutic success for said given mode of treatment in said patient or implementing therapeutic regimen in said patient from the outcome of the comparison in step (c). | 02-10-2011 |
| 20110039258 | METHODS AND COMPOSITIONS FOR DIFFERENTIAL EXPANSION OF FETAL CELLS IN MATERNAL BLOOD AND THEIR USE - Disclosed is a method and compositions for the differential expansion of fetal cells over maternal cells. In the method, cells from a sample of maternal blood containing CD34+ cells of both maternal and fetal origin are incubated in the presence of Stem Cell Factor in serum free media. It has been discovered that incubation of fetal cells in the presence of SCF will preferentially expand the fetal cells relative to adult cells. Fetal cells can also be identified, enriched or obtained by differential expansion of the fetal cells during colony formation. It has been discovered that differential expansion of fetal cells can result in colonies of fetal cells that are larger than colonies of adult cells. The fetal CD34+ cells can be expanded without generation of significant clonal genetic artifacts during expansion. Also disclosed is a method and compositions for producing differentiated fetal cells. It has been discovered that differentiated fetal cells have markers that distinguish the fetal cells from adult cells. Also disclosed are fetal cells made or obtained using the disclosed methods. For example, disclosed are expanded and/or differentiated fetal cells. The disclosed fetal cells can be used for any purpose and in any way that fetal cells can be used. The disclosed fetal cells are particularly useful for prenatal analysis of a gestating fetus. | 02-17-2011 |
| 20110039262 | METHODS FOR DETECTING VIRULENT PLASMODIUM, FOR EVALUATING PLASMODIUM VIRULENCE, AND FOR SCREENING NEW DRUGS EMPLOYING THE 3'UTR OF PLASMODIUM SUB2 AND THE PLASMODIUM SUB2 SERINE PROTEASE - Methods for regulating the serine protease of | 02-17-2011 |
| 20110039259 | DNA SEQUENCE WITH NON-FLUORESCENT NUCLEOTIDE REVERSIBLE TERMINATORS AND CLEAVABLE LABEL MODIFIED NUCLEOTIDE TERMINATORS - This invention provides a process for sequencing nucleic acids using 3′ modified deoxynucleotide analogues or 3′ modified deoxyinosine triphosphate analogues, and 3′ modified dideoxynucleotide analogues having a detectable marker attached to a base thereof. | 02-17-2011 |
| 20110045480 | METHODS FOR PREDICTING THE EFFICACY OF TREATMENT - Clinical tests for testing therapeutic sensitivity of cancerous breast tissue and methods and kits for performing the same are described herein. Embodiments of the present invention are directed to methods for predicting the efficacy of treatment of breast cancer. In addition, certain embodiments are directed to a kit for testing therapeutic sensitivity of breast cancer tissue. | 02-24-2011 |
| 20110045467 | PERIPHERAL NEUROPATHY DIAGNOSIS - Genes whose expression is correlated with the presence of CIDP or vasculitic neuropathy are disclosed. Probes and sets of nucleic acid and proteins specific for these genes are described, as are molecular and immunological methods for aiding in the diagnosis of these disease conditions in a subject. | 02-24-2011 |
| 20110045459 | Molecular determinants of EGFR kinase inhibitor response in glioblastoma - The invention disclosed herein provides methods for the examination and/or quantification of biochemical pathways that are disregulated in pathologies such as cancer and to reagents and kits adapted for performing such methods. | 02-24-2011 |
| 20110045466 | Field-effect transistor type biosensor and bio-signal amplification method thereof - The present invention discloses a field-effect transistor (FET) type biosensor and a bio-signal amplification method. The biosensor comprises a field-effect transistor chip, a biomolecular immobilization layer and at least one primer. The biomolecular immobilization layer is formed on a gate surface of the FET chip or a surface of an external device connected to a gate. The primer used for performing a nucleic acid amplification is immobilized onto the gate surface or the external device surface by binding with the biomolecular immobilization layer, such that an analyte can have a nucleic acid amplification reaction with the primer at room temperature or a constant temperature environment. With an extension of a nucleic acid sequence, the inducing electricity of the FET gate surface can be increased so as to amplify an inspection signal, thereby enhancing the sensitivity of the FET type biosensor effectively. | 02-24-2011 |
| 20110070582 | Gene Expression Profiling for Predicting the Response to Immunotherapy and/or the Survivability of Melanoma Subjects - A method is provided in various embodiments for determining a profile data set for predicting the response top immunotherapy and or survivability of a subject with melanoma based on a sample from the subject, wherein the sample provides a source of RNAs. The method includes using amplification under measurement conditions that are substantially repeatable for measuring the amount of RNA corresponding to at least 2, 3 or 4 constituents according to the gene models shown in Tables 2-3, 4-6 and 9. | 03-24-2011 |
| 20110070589 | MAGNETIC LYSIS METHOD AND DEVICE - A method for lysing cells is disclosed. The method includes stirring cells with a magnetic stir element in the presence of a plurality of cell lysis beads at a speed sufficient to lyse the cells. Also disclosed is a device for lysing cells. The device includes a container having a magnetic stir element and a plurality of cell lysis beads disposed therein. The container is dimensioned to allow rotation of the magnetic stir element inside the container. | 03-24-2011 |
| 20110081649 | DIAGNOSIS, STAGING AND MONITORING OF INFLAMMATORY BOWEL DISEASE - A method of differentiating between active and inactive IBD in a gastrointestinal mucosa sample or a sample from a sentinel lymph node draining gastrointestinal mucosa comprises preparing a suspension of single cells from the sample, analyzing the suspension for expression of the inflammation activation marker CD69 on CD4+ T helper cells using directly labelled fluorescent DC69 antibody; comparing the number of T helper cells expressing DC69 in the sample with that obtained from a corresponding sample of a healthy person, a significantly increased level of T helper cells expressing CDD69 signifying the presence of active IBD and a less than significantly increased level of T helper cells signifying the presence of inactive IBD. Also disclosed are methods of differentiating between ulcerative colitis (UC) and Crohn's disease (CD), of detecting UC and CD, and of determining the susceptibility of an IBD patient to steroid treatment. | 04-07-2011 |
| 20110081647 | NUCLEOTIDE ANALOGS - The invention generally relates to nucleotide analogs and methods of their use in sequencing-by-synthesis reactions. In certain embodiments, the invention provides a nucleotide analog including a detectable label attached to a nitrogenous base portion of a nucleotide analog by a cleavable linker, in which contact of the analog with at least one activating agent results in cleavage of the label and elimination of the linker, thereby producing a natural nucleotide, a 9-deaza-G, 9-deaza-A, or ψ-uridine. | 04-07-2011 |
| 20110097730 | Recombinant Sars-Cov nsp12 and the Use of Thereof and the Method for Producing it - The present invention relates to a recombinant severe acute respiratory syndrome coronavirus (SARS-CoV) non-structural protein (nsp) 12 with an RNA polymerase activity, its expression vector, its preparation method, and its use. According to the present invention, a soluble recombinant SARS-CoV nsp12 with an RdRp activity of initiating SARS-CoV genome synthesis can be over-expressed in the transformed host cells, and conveniently purified with high purity. An in vitro replication system important for studying SARS-CoV replication can be established with the purified recombinant SARS-CoV nsp12. SARS-CoV nsp12 produced by the present invention can also be used as a target for the development of anti-viral agents against SARS-CoV. In addition, materials inhibiting RNA-dependent RNA polymerase (RdRp) activity of nsp12 can be screened efficiently according to the present invention as the optimal conditions for the RdRp assay with SARS-CoV nsp12 were found. | 04-28-2011 |
| 20110097722 | Cold Shock Protein Compositions and Methods and Kits for the Use Thereof - The present invention provides cold shock protein-containing compositions for improved DNA synthesis reactions with improved reactivity, methods for synthesizing DNA using such compositions, kits for use in such methods, and DNA compositions yielded by such methods. The present invention further provides cold shock protein-containing compositions for the identification of endoribonuclease cleavage sites, methods for identifying endoribonuclease cleavage sites using such compositions, and kits for use in such methods. | 04-28-2011 |
| 20110097719 | Neprilysin Gene Polymorphism and Amyloid Beta Plaques in Traumatic Brain Injury - The invention relates to methods of diagnosing risk of amyloid β deposition following traumatic brain injury. More particularly, the invention relates to the discovery of a specific single nucleotide polymorphism in the neprilysin gene that is linked to an increased risk of amyloid β deposition after traumatic brain injury | 04-28-2011 |
| 20110097716 | Methods for Detecting Oligonucleotides - The invention provides methods and compositions for detecting and/or quantifying nucleic acid oligonucleotides. These methods and compositions are useful for detecting and quantifying diagnostic and/or therapeutic synthetic target oligonucleotides, such as aptamers, RNAi, siRNA, antisense oligonucleotides or ribozymes in a biological sample. | 04-28-2011 |
| 20110097714 | AMPLIFICATION METHOD OF METHYLATED OR UNMETHYLATED NUCLEIC ACID - The object of the present invention is to provide a gene amplification method, wherein the method can amplify both methylated and unmethylated nucleic acids present in a biological sample, and further regulate the amplification ratio of the methylated and/or unmethylated nucleic acid as needed. Such objects can be solved by an amplification method using a nonspecific primer which can hybridize both with methylated and unmethylated nucleic acids and a specific primer which specifically hybridizes with either methylated or unmethylated nucleic acid, and further by an amplification method which can change the amplification ratio of methylated or unmethylated nucleic acid by changing the mixing rate of these primers. | 04-28-2011 |
| 20110097712 | METHOD FOR DETECTING AND QUANTIFYING RARE MUTATIONS/POLYMORPHISMS - The present invention is directed to a method for detecting and quantifying rare mutations in a nucleic acid sample. The nucleic acid molecules under investigation can be either DNA or RNA. The rare mutation can be any type of functional or non-functional nucleic acid change or mutation, such as deletion, insertion, translocation, inversion, one or more base substitution or polymorphism. Therefore, the methods of the present invention are useful in detection of rare mutations in, for example, diagnostic, prognostic and follow-up applications, when the targets are rare known nucleic acid variants mixed in with the wildtype or the more common nucleic acid variant(s). | 04-28-2011 |
| 20110097713 | Compositions and methods for pharmacogenomic screening of CYP2C9 and VKORC1 - Compositions and methods for determining an optimal dose of a medication for a subject are described that include determining the subject's genotype for the CYP2C9 and VKORC1 genes and determining the dose of the medication based on the genotype. Articles of manufacture also are provided that include polynucleotides for genotyping. | 04-28-2011 |
| 20110097731 | NOVEL MITOCHONDRIAL DYE - The present invention relates to the use of single-barrel genetically encoded GFP-based calcium indicator as an intramitochondrial dye and to nucleic acid molecules coding for said indicators, as well as to methods using said indicators. Examples of single-barrel genetically encoded GFP-based calcium indicator is a GCaMP, Case16 and/or Case12. In a particular embodiment, the single-barrel genetically encoded GFP-based calcium indicator is GCaMP2 or Case16. | 04-28-2011 |
| 20110097721 | IN VIVO GENE SENSORS - Described are methods and compositions for the detection of target genes. The inventors have developed a synthetic nucleic acid sensor-effector gene circuit. In cells without a target gene, the circuit suppresses e.g., effector production, but in the presence of the target gene the suppression is subject to competition, such that the synthetic sensor is de-repressed and permits expression of the effector gene. The methods and compositions described further permit the selective expression of an effector gene in those cells expressing the target gene. In this manner, cells expressing a target gene can be selectively targeted for treatment or elimination. In certain aspects, the methods and compositions described permit the selective expression of an agent such as a therapeutic gene product, in a specifically targeted population of cells in an organism. | 04-28-2011 |
| 20110097729 | APPARATUS AND METHOD FOR SEQUENCING NUCLEIC ACID MOLECULES - The sequence of a target polynucleotide can be determined by:
| 04-28-2011 |
| 20110097717 | Gene Expression Profiling For Identification of Cancer - A method is provided for determining whether an individual has a particular cancer based on a sample from the subject, wherein the sample provides a source of RNAs. The method includes using amplification for measuring the amount of RNA corresponding to at least 1 constituent from Tables A-C. | 04-28-2011 |
| 20110097723 | Methods and reagents for analyte detection - The present invention relates to chemiluminescent method and regent to detect analyte. One aspect of the current invention relates to using chemiluminescent and fluorescent molecule/enzyme coupled with analyte binding molecules to detect specific analyte molecules. Another aspect of the current invention is to use gold nanoparticle triggered chemiluminescent reaction to detect analyte. | 04-28-2011 |
| 20110097711 | METHOD OF JUDGING INFLAMMATORY DISEASE BY USING SINGLE NUCLEOTDIE POLYMORPHISM - An object of the present invention is to identify a novel single nucleotide polymorphism (SNP) associated with the onset and the advancement of inflammatory diseases such as myocardial infarction. The present invention provides a method for judging an inflammatory disease which comprises detecting at least 1 type of genetic polymorphism existing in at least one gene selected from the group consisting of the LBP-32 gene, the TSBP gene, and the WAP gene. | 04-28-2011 |
| 20110097710 | Methods for detecting atrial fibrillation and related conditions - Methods for detecting disorders associated with atrial fibrillation, and, thus, at risk for stroke and/or heart failure) in a subject based on a monitoring plasma levels of apelin are provided. Diagnostic compositions for the detection of such disorders are additionally provided. | 04-28-2011 |
| 20090263801 | Phenotype-Genotype Relationship in Age-Related Macular Degeneration - Age-Related Macular Degeneration (AMD) cases possessing the LOC387715 (rs10490924) variant have a higher risk of neovascular AMD. Individuals with AMD who are homozygous for both variants might be at greater risk for earlier onset of neovascular AMD. Determining the presence of this variant indicates which path the disease may take and which nutritional, supplement, or medicaments are appropriate. | 10-22-2009 |
| 20110123990 | Methods To Predict Clinical Outcome Of Cancer - The present invention provides methods to determine the prognosis and appropriate treatment for patients diagnosed with cancer, based on the expression levels of one or more biomarkers. More particularly, the invention relates to the identification of genes, or sets of genes, able to distinguish breast cancer patients with a good clinical prognosis from those with a bad clinical prognosis. The invention further provides methods for providing a personalized genomics report for a cancer patient. The inventions also relates to computer systems and software for data analysis using the prognostic and statistical methods disclosed herein. | 05-26-2011 |
| 20110123989 | METHOD FOR THE DETECTION OF SCHIZOPHRENIA RELATED GENE TRANSCRIPTS IN BLOOD - The present invention is directed to detection and measurement of gene transcripts and their equivalent nucleic acid products in blood. Specifically provided is analysis performed on a drop of blood for detecting, diagnosing and monitoring diseases using gene-specific and/or tissue-specific primers. The present invention also describes methods by which delineation of the sequence and/or quantitation of the expression levels of disease-specific genes allows for an immediate and accurate diagnostic/prognostic test for disease or to assess the effect of a particular treatment regimen. | 05-26-2011 |
| 20090263813 | RIBONUCLEOTIDE TAG NUCLEIC ACID DETECTION - The present application provides polynucleotides comprising 5′-tails with sequence segments useful for the detection of target nucleic acid sequences, and methods for their use in detecting target nucleic acids. The polynucleotides are used to amplify a subsequence of a target nucleic acid in the presence of one or more ribonucleotides. The ribonucleotides are incorporated into amplification products at regular intervals complementary to the 5′-tail sequence segments. Cleavage of amplification products at the bond immediately 3′ to incorporated ribonucleotides produces detectably distinct fragments indicative of the presence or absence of a target nucleic acid. | 10-22-2009 |
| 20110059434 | P13k pathway mutations in cancer - Given the important role of protein kinases in pathways affecting cellular growth and invasion, we have analyzed 340 serine/threonine kinases for genetic mutations in colorectal cancers. Mutations in eight genes were identified, including three members of the phosphatidylinositol-3-kinase (PI3K) pathway; the alterations in the latter genes each occurred in different tumors and did not overlap with mutations in PIK3CA or other non-serine-threonine kinase (STK) members of the PI3K pathway, suggesting that mutations in any of these genes had equivalent tumorigenic effects. These data demonstrate that the PI3K pathway is a major target for mutational activation in colorectal cancers and provide new opportunities for therapeutic intervention. | 03-10-2011 |
| 20110014612 | POLYMERASE COMPOSITIONS & METHODS - Disclosed herein are modified polymerase compositions exhibiting altered polymerase activity, which can be useful in a variety of biological applications. Also disclosed herein are methods of making and using such compositions. In some embodiments, the compositions exhibit altered properties that can enhance their utility in a variety of biological applications. Such altered properties, can include, for example, altered nucleotide binding affinities, altered nucleotide incorporation kinetics, altered photostability and/or altered nanoparticle tolerance, as well as a range of other properties as disclosed herein. | 01-20-2011 |
| 20100285459 | Human Diabetes Susceptibility TNFRSF10A gene - The present invention relates to a diagnostic method of determining whether a subject is at risk of developing type 2 diabetes, which method comprises detecting the presence of an alteration in the TNFRSF10A gene locus in a biological sample of said subject. | 11-11-2010 |
| 20090246787 | METHOD AND APPARATUS FOR DETERMINING CHEMOSENSITIVITY - A method for determining chemosensitivity of a malignant tumor cell to anthracycline is described herein. According to this method, first tumor cell and second tumor sell are first prepared. The first tumor cell is not treated with anthracycline, and on the other the second tumor cell is treated with anthracycline. Secondly, first and second activity levels of CDK1 are measured. The first activity level is activity of CDK1 in the first tumor cell and the second activity level is that of CDK1 in the second tumor cell. Finally, chemosensitivity of the malignant tumor cell is determined. The determination is based on the first and second activity levels. | 10-01-2009 |
| 20090246783 | METHOD OF MEASURING PYROPHOSPHATE - Provided is a novel and useful method of measuring pyrophosphate in a sample. There may be provided a novel and useful method of measuring pyrophosphate in a sample using pyruvate orthophosphate dikinase, nicotinamide-nucleotide adenylyltransferase, and dehydrogenase. | 10-01-2009 |
| 20090246778 | IDENTIFICATION OF FAT AND LEAN PHENOTYPES IN CHICKENS USING MOLECULAR MARKERS - The present invention identifies genetic markers for lean and fat phenotypes in chickens and provides methods of screening chickens to determine those more likely to have a lean or fat phenotype. The invention also provides methods of screening chickens to identify a polymorphism in THRSPα associated with a fat or lean phenotype. | 10-01-2009 |
| 20090246775 | PROBE, PROBE SET, PROBE-IMMOBILIZED CARRIER, AND GENETIC TESTING METHOD - A nucleic acid probe for classification of pathogenic bacterial species is capable of collectively detecting bacterial strains of the same species and differentially detecting them from other bacterial species. Any one of the base sequences of SEQ ID NOS. 65 to 67 or a combination of at least two of them is used for detecting the gene of an infectious disease pathogenic bacterium. | 10-01-2009 |
| 20090246772 | NOVEL DIBENZO[c,h][1,5]NAPHTHYRIDINES AND THEIR USE AS DNA PROBES - The present invention concerns novel dibenzo[c,h][1,5]naphthyridine of formula (I) and their use as DNA probes, as well as the methods for marking DNA using the same. | 10-01-2009 |
| 20090246770 | GLYCEMIC CONTROL FOR REDUCTION OF CARDIOVASCULAR DISEASE RISK IN DIABETIC PATIENTS EXPRESSING HAPTOGLOBIN 2-2 - This invention relates to methods of reducing risk of developing cardiovascular complications in diabetic patients. Specifically, the invention relates to the use of haptoglobin genotyping for determining the importance of maintaining tight glycemic control in diabetic subjects expressing Hp 2-2 allele. | 10-01-2009 |
| 20090246766 | High throughput screening of genetically modified photosynthetic organisms - The present invention provides a method and compositions for high throughput screening of genetically modified photosynthetic organisms for plasmic state. The present invention provides methods of producing one or more proteins, including biomass degrading enzymes in a plant. Also provided are the methods of producing biomass degradation pathways in alga cells, particularly in the chloroplast. Single enzymes or multiple enzymes may be produced by the methods disclosed. The methods disclosed herein allow for the production of biofuel, including ethanol. | 10-01-2009 |
| 20090246769 | MOLECULAR DIAGNOSIS OF OVARIAN CANCERS - A molecular diagnosis system of ovarian cancers encompasses a detection device configured to obtain a detected value of an expression amount of an apolipoprotein A1 gene in ovarian tissue as a diagnosis subject, a storage device configured to store a normal value of the expression amount of the apolipoprotein A1 gene in normal ovarian tissue, and a determination mechanism configured to determine that the ovarian tissue as the diagnosis subject is clear cell adenocarcinoma when the detected value is lower than the normal value. | 10-01-2009 |
| 20090246767 | Compositions and methods for detecting Cryptococcus neoformans - Disclosed are oligonucleotides useful in methods for determining whether a sample contains | 10-01-2009 |
| 20090246765 | METHOD AND DEVICE FOR DETECTING TARGET SUBSTANCE USING PROBE CARRIER - A detecting device for detecting an enzyme present on a predetermined location on a substrate using a luminescence reaction, includes a mounting stage for mounting the substrate, a spotting means for locally applying a micro-droplet substance which contributes to a luminescence reaction with the enzyme onto a predetermined location on the substrate, and a detecting means for detecting a luminescence signal generated by applying the substance based on the timing of discharging a liquid droplet. | 10-01-2009 |
| 20090246763 | ELECTROCHEMICAL LABELS DERIVED FROM SIDEROPHORES - Disclosed are tri-nuclear metal complexes and salts thereof, such as tri-nuclear osmium or ruthenium complexes or salts thereof, suitable for use as electrochemical labels. Also disclosed are oligonucleotide probes with an attached electrochemical label, methods of nucleic acid amplification, methods of sequencing, and kits for nucleic acid amplification and sequencing having oligonucleotide probes including an electrochemical label. The electrochemical labels are synthesized from siderophores. | 10-01-2009 |
| 20110076682 | Over-production of secondary metabolites by over-expression of the VEA gene - The invention provides a general and facile method to obtain secondary metabolites from fungal sources. The invention is based on the discovery that the fungal gene veA and protein encoded thereby regulates the activity of multiple secondary metabolite gene clusters in fungi. Over expression of the gene veA provides increased production of secondary metabolites in engineered cells. In particular, such a method of increasing secondary metabolite production allows the production of improved yields of valuable secondary metabolite products. | 03-31-2011 |
| 20090246761 | DEVELOPMENT OF PROGNOSTIC MARKERS FROM THE SALIVA OF HEAD AND NECK CANCER PATIENTS - The present invention relates to biomarkers that are useful for the detection of cancer. The invention further relates to biomarkers and methods of using biomarkers for the early detection of head and neck cancer. | 10-01-2009 |
| 20090246759 | TEST AND MODEL FOR INFLAMMATORY DISEASE - The present invention relates to a means and methods for determining susceptibility to SEEK1 mediated diseases, such as psoriasis. In addition, there is provided polynucleotides encoding the SEEK1 protein having one or more nucleotide insertions, deletions or substitutions at one or novel positions, and the SEEK1 protein having one or more amino acid insertions, deletions and substitutions. Host cells and transgenics non-human animals comprising polynucleotides or proteins of the invention are also provided. Methods of screening for agents for use in treating SEEK1 mediated disease are also provided. | 10-01-2009 |
| 20090246757 | Method, Program, and System for Normalizing Gene Expression Amounts - The present invention aims at presenting novel means for analyzing and correcting gene expression amounts. There is provided a gene expression amount normalizing method in which the number of cells in a sample is obtained by measuring a repeated sequence present in a substantially fixed proportion in a genome contained in the sample, and the number of cells obtained is used as an index for normalizing gene expression amounts obtained from the same sample. For example, a DNA sample | 10-01-2009 |
| 20090246755 | Method of examining chemical using gene-disrupted strain - A method having higher sensitivity in a bioassay method utilizing cell response of a microorganism, for detecting the presence of a chemical in a test specimen is provided. The method of the present invention is characterized in that it uses specified gene-disrupted strains. | 10-01-2009 |
| 20110033845 | Methods For Amplification of Nucleic Acids Using Spanning Primers - The teachings relate to methods and kits for detecting whether target nucleic acid sequences are present and/or quantitating target nucleic acid sequences. | 02-10-2011 |
| 20110003305 | METHODS AND COMPOSITIONS FOR NUCLEIC ACID AMPLIFICATION - Compositions, reaction mixtures, and methods for performing an amplification reaction, including multiplex amplification reaction, wherein the method comprises using one or more amplification oligomer complexes comprising linked first and second amplification oligomer members. In one aspect, the amplification oligomer complex is hybridized to a target nucleic acid, the target nucleic acid with hybridized amplification oligomer complex is then captured, and other components are washed away. Target sequences of the target nucleic acids are pre-amplified to generate a first amplification product. The first amplification product is amplified in one or more secondary amplification reactions to generate second amplification products. | 01-06-2011 |
| 20110003303 | SHEATH FLOW DEVICES AND METHODS - The invention relates generally to fluid processing and, in particular aspects, processing fluids for detection, selection, trapping and/or sorting of particulate moieties. Sheath flow devices described allow isolation of target species from fluid samples while avoiding non-specific binding of unwanted species to the surfaces of the separation device. Biological fluid processing, detection, sorting or selection of cells, proteins, and nucleic acids is described. The invention finds particular use in diagnostic settings, analyzing a patient's medical condition, monitoring and/or adjusting a therapeutic regimen and producing cell based products. | 01-06-2011 |
| 20110003301 | METHODS FOR DETECTING GENETIC VARIATIONS IN DNA SAMPLES - The invention provides methods, compositions and kits for detecting genetic variation in a DNA sample at one or more polymorphic loci of interest. In some embodiments, the invention provides methods, compositions, and kits for determining the nucleotide present at a single nucleotide variant position of interest in a test sample. | 01-06-2011 |
| 20110003289 | METHOD FOR DETECTION OF PRE-NEOPLASTIC FIELDS AS A CANCER BIOMARKER IN ULCERATIVE COLITIS - Among other aspects, the present invention provides biomarkers and methods of identifying precancerous fields in a subject in need thereof. Methods of diagnosing and for providing a prognosis for a subject with an increased risk of developing cancer are also provided, along with methods of determining surgical margins for a tumor or tissue resection procedure. Additionally, reagents and kits are provided for the practice of the methods disclosed herein. | 01-06-2011 |
| 20100041050 | Disposable Reactor Module and Detection System - A disposable reactor module, monitoring/optical detection system and related hardware for, inter alia, chemical reactions including Polymerase Chain Reactions. | 02-18-2010 |
| 20110086357 | Methods for Evaluating a Disease Condition by Nucleic Acid Detection and Fractionation - This invention relates to the discovery that both non-particle and particle associated nucleic acids are present in blood plasma and serum and can be used to evaluate disease conditions. | 04-14-2011 |
| 20110086356 | METHOD FOR MEASURING DNA METHYLATION - The present invention relates to a method of measuring the content of methylated DNA in a DNA region of interest in a genomic DNA contained in a biological specimen, and so on. | 04-14-2011 |
| 20110086360 | METHOD FOR DETECTION OF IDIOPATHIC INTERSTITIAL PNEUMONIA - The present invention provides a method for detecting idiopathic interstitial pneumonia, which comprises measuring the expression level of a periostin gene or the amount of a periostin protein in a biological sample. Thereby, a method for detecting idiopathic interstitial pneumonia using a marker is provided. | 04-14-2011 |
| 20110086359 | LATERAL FLOW ASSAYS - Assays and methods including mobile tagged single stranded nucleic acid reagents pre-loaded on an analysis device, which are preferably tagged, but not labeled and are complementary to a strand (preferably the anti-sense strand in double stranded DNA targets) of the target nucleic acid. The assay also includes a running buffer that includes a dye or other detectable label that nonspecifically binds only to double stranded nucleic acids. In addition, the analysis device includes a detection zone including one or more test zones that have an immobilized tag that binds to the tag on the mobile nucleic acid reagent. | 04-14-2011 |
| 20110086355 | BRCA1 mRNA EXPRESSION LEVELS PREDICT SURVIVAL IN BREAST CANCER PATIENTS TREATED WITH NEOADJUVANT CHEMOTHERAPY - The invention relates to methods for predicting the clinical outcome of a patient which suffers from breast cancer based on the expression levels of BRCA1, wherein low BRCA1 expression levels are indicative of a good prognosis. Moreover, the invention relates to methods for predicting the response to a neoadjuvant therapy based on a combination of an anti-metabolite, an intercalating agent and an alkylating agent of a patient which suffers from breast cancer based on the expression levels of BRCA1. | 04-14-2011 |
| 20110086358 | PROBE, PROBE SET, PROBE CARRIER, AND TESTING METHOD - A probe, a set of probes, and a probe carrier on which the probe or the set of probes is immobilized, are provided for classification of fungus species. The probe or the set of probes is capable of collectively detecting fungus of the same species and distinguishingly detecting those fungus from fungus of other species. The probe is an oligonucleotide probe for detecting a pathogenic fungus DNA and includes at least one of base sequences of SEQ ID NOS. 1 to 4 and mutated sequences thereof. | 04-14-2011 |
| 20110086352 | Label Free Detection of Nucleic Acid Amplification - Provided are methods and devices for label-free detection of nucleic acids that are amplified by polymerase chain reaction. A solution containing the components necessary for a PCR is introduced to a microfluidic amplification chamber and an electric field applied to a confined region in which PCR occurs. PCR product generated in the confined region is detected by measuring an electrical parameter that is, for example, solution impedance. The devices and methods provided herein are used, for example, in assays to detect one or more pathogens or for point-of-care tests. In an aspect, the PCR product is confined to droplets and the assay relates to detecting an electrical parameter of a flowing droplet, thereby detecting PCR product without a label. In an aspect, the PCR occurs in the droplet. | 04-14-2011 |
| 20110086351 | ELIMINATION OF PATHOGENIC INFECTION IN FARMED ANIMAL POPULATIONS - Animal husbandry has always been susceptible to the ravages of pathogenic infections. Poultry flus and cattle diseases are but two examples that have dire consequences for animals and adversely affect the economic fortunes of farmers. A testing and culling methodology is presented that can eliminate pathogens from an infected herd. The sensitivity of PCR to detect very low levels of nucleic acid of an infecting pathogen is utilized to identify infected animals. In addition, it has been discovered that PCR analysis of manure samples can accurately identify infected animals and offspring for those species that consume placental remains after birth. Mink Aleutian Disease Virus (mADV) is one of several deadly DNA parvoviruses that can quickly reach epidemic proportions in a mink herd. PCR primers have been developed that generate amplicons to detect and identify the mADV. In addition, a previously unidentified strain of mADV has been discovered, genomically sequenced, and substantially detailed. | 04-14-2011 |
| 20110086350 | ELIMINATION OF PATHOGENIC INFECTION IN FARMED ANIMAL POPULATIONS - Animal husbandry has always been susceptible to the ravages of pathogenic infections. Poultry flus and cattle diseases are but two examples that have dire consequences for animals and adversely affect the economic fortunes of farmers. A testing and culling methodology is presented that can eliminate pathogens from an infected herd. The sensitivity of PCR to detect very low levels of nucleic acid of an infecting pathogen is utilized to identify infected animals. In addition, it has been discovered that PCR analysis of manure samples can accurately identify infected animals and offspring for those species that consume placental remains after birth. Mink Aleutian Disease Virus (mADV) is one of several deadly DNA parvoviruses that can quickly reach epidemic proportions in a mink herd. PCR primers have been developed that generate amplicons to detect and identify the mADV. In addition, a previously unidentified strain of mADV has been discovered, genomically sequenced, and substantially detailed. | 04-14-2011 |
| 20110086354 | METHODS AND COMPOSITIONS FOR MULTIPLEX PCR AMPLIFICATIONS - The present invention concerns in general PCR reaction mixtures comprising a mixture of hot-start primers and non-hot-start primers for a given target sequence, including multiplex PCR reaction mixtures; methods utilizing same for detection of one or more target polynucleotide sequences; and kits comprising same. | 04-14-2011 |
| 20110086349 | Proliferation Signatures and Prognosis for Gastrointestinal Cancer - This invention relates to methods and compositions for determining the prognosis of cancer in a patient, particularly for gastrointestinal cancer, such as gastric or colorectal cancer. Specifically, this invention relates to the use of genetic markers for the prediction of the prognosis of cancer, such as gastric or colorectal cancer, based on cell proliferation signatures. In various aspects, the invention relates to a method of predicting the likelihood of long-term survival of a cancer patient, a method of determining a treatment regime for a cancer patient, a method of preparing a personalized genomics profile for a cancer patient, among other methods as well as kits and devices for carrying out these methods. | 04-14-2011 |
| 20110086345 | ISOLATION AND USE OF RYANODINE RECEPTORS - The genes encoding ryanodine receptor homologs have been characterized from multiple insect families including lepidopteran tobacco budworm ( | 04-14-2011 |
| 20110086344 | METHODS OF CHARACTERIZING SMALL NUCLEIC ACID MOLECULES - The invention generally relates to methods of characterizing small nucleic acid molecules, such as plasmids or nucleic acid molecules obtained from a virus. In certain embodiments, the invention provides a method of characterizing a small circular nucleic acid molecule, the method including performing rolling circle amplification on a small circular nucleic acid molecule, thereby producing a concatamer, and generating an optical map of the concatamer, thereby characterizing the small circular nucleic acid molecule. | 04-14-2011 |
| 20110086348 | METHOD FOR ASSESSING HEART DISEASE - A method for assessing heart disease in a subject includes generating an expression profile of at least two or more miRNAs in a sample from the subject. The miRNAs can be selected from the group consisting of hsa-miRNA-1, hsa-miRNA-7, hsa-miRNA-29b, has-miRNA-125b, hsa-miRNA145, hsa-miRNA-181b, hsa-miRNA-214, hsa-miRNA-342, hsa-miRNA-378 and combinations thereof. | 04-14-2011 |
| 20110086347 | CELL DETECTION, MONITORING AND ISOLATION METHOD - The present invention relates generally to a method for identifying or distinguishing one type of cell from other cells within a population of cells. The present invention further provides the detection, monitoring and isolation of sub-populations cell types within a population of cells including a biological entity comprising such cell types. Kits, diagnostic agents and panels of nucleic acid probes for identifying and distinguishing cell types also form part of the present invention. The detection of particular cell types is based upon the use of a labelled probe that hybridizes to chromosomal DNA at the flanking sequences of a deletion. Alternatively two probes with distinguishable reporter molecules are used wherein only one probe is capable of hybridizing to chromosomal DNA in one cell type whereas both are capable of hybridizing to chromosomal DNA in another cell type. The methods are useful in the identification of cells with copy number variations, chromosomal deletions, additions or aberrations. | 04-14-2011 |
| 20110086342 | Hepatocellular Carcinoma-Associated Gene - The present invention provides a method for evaluating cancer, which comprises the following steps of:
| 04-14-2011 |
| 20100041046 | METHOD AND APPARATUS FOR THE DISCRETIZATION AND MANIPULATION OF SAMPLE VOLUMES - Embodiments of the present invention relate to methods and apparatuses for the discretization and manipulation of sample volumes that is simple, robust, and versatile. It is a fluidic device that partitions a sample by exploiting the interplay between fluidic forces, interfacial tension, channel geometry, and the final stability of the formed droplet and/or discretized volume. These compartmentalized volumes allow for isolation of samples and partitioning into a localized array that can subsequently be manipulated and analyzed. The isolation of the discretized volumes along with the device's inherent portability render our invention versatile for use in many areas, including but not limited to PCR, digital PCR, biological assays for diagnostics and prognostics, cancer diagnosis and prognosis, high throughput screening, single molecule and single cell reactions or assays, the study crystallization and other statistical processes, protein crystallization, drug screening, environmental testing, and the coupling to a wide range of analytical detection techniques for biomedical assays and measurements. The minimal fluid interconnects and simple flow geometry makes the device easy to use and implement, economical to fabricate and operate, and robust in its operations. | 02-18-2010 |
| 20100041031 | Optoelectronic detection system - The invention described herein provides methods for the detection of soluble antigens. In particular, the methods provide for the detection of soluble proteins and chemicals. In addition, the invention provides methods of detecting a nucleic acid sequence in a sample. Also described is an emittor cell comprising an Fc receptor and an emittor molecule for the detection of a target particle in a sample wherein the target particle to be detected is bound by one or more antibodies. Also provided is an optoelectronic sensor device for detecting a target particle in a plurality of samples. | 02-18-2010 |
| 20110053170 | Interleukin-33 (IL-33) for the Diagnosis and Prognosis of Cardiovascular Disease - The present invention includes methods for the use of interleukin-33 (IL-33) in the diagnosis of cardiovascular conditions including acute coronary syndrome (ACS), myocardial infarction, and/or heart failure, angina, cardiac hypertrophy, arteriosclerosis, myocarditis, pericarditis, endocarditis, stroke and/or pulmonary embolism and the determination of the severity of such conditions (prognosis). | 03-03-2011 |
| 20110014620 | METHODS FOR IDENTIFICATION OF BONE ANABOLIC AGENTS - The present invention is related to methods for identifying bone anabolic agents and factors, identifying pathways that promote proliferation of osteoblasts for bone growth and/or repair, and for identifying new therapeutic targets for treatments for osteoporosis and other bone degenerative disorders characterized by osteopenia. | 01-20-2011 |
| 20110014603 | TARGETS FOR USE IN DIAGNOSIS, PROGNOSIS AND THERAPY OF CANCER - Provided herein are targets that can be used for the diagnosis, prognosis and therapy of a variety of cancers. | 01-20-2011 |
| 20110014602 | Diagnostic composition for hepatocellular carcinoma, a diagnostic kit comprising it and diagnostic methods of hepatocellular carcinoma - In the present invention, it is confirmed that cystatin B (cystatin B, CSTB) can be used as a diagnostic marker for hepatocellular carcinoma. Accordingly, the invention relates to a method for early diagnosing hepatocellular carcinoma using the cystatin B as a diagnostic marker for hepatocellular carcinoma, a method for determining the progression or prognosis of hepatocellular carcinoma according to the CSTB expression level, and a method for applying to the prevention or treatment of hepatocellular carcinoma by adjusting the cystatin B expression. | 01-20-2011 |
| 20100143922 | METHODS FOR REDUCING OVER-REPRESENTATION OF FRAGMENT ENDS - Methods for preparing fragments for nucleic acids sequence analysis that demonstrates uniform coverage across the full fragment length. The methods disclosed herein are useful for candidate gene re-sequencing wherein the detailed analysis is performed on selected, amplified regions of the genome. | 06-10-2010 |
| 20100143902 | METHODS AND NUCLEIC ACIDS FOR ANALYSES OF CELLULAR PROLIFERATIVE DISORDERS - The invention provides methods, nucleic acids and kits for detecting colorectal cell proliferative disorders based on underexpression or methylation of a least one gene selected from RASSF2, TFAP2E, SND1, PCDHGC3, EDNRB, STOM, GLI3, RXFP3, LimK1, GPR73L1, PCDH1O, DOCKIO and MRPS21, and optionally Septin-9. The invention discloses genomic sequences the methylation patterns of which have utility for the improved detection of said class of disorders, thereby enabling the improved diagnosis and treatment of patients. | 06-10-2010 |
| 20100159456 | METHODS FOR DETECTING TCR-GAMMA GENE REARRANGEMENT - The invention provides methods for detection of TCR-γ nucleic acid in acellular body fluid. The methods can be used to detect the TCR-γ gene rearrangement in acellular body fluid. The detection of TCR-γ gene rearrangement is useful in determination of clonality of T-cell population. The invention is useful in the diagnosis of lymphoproliferative disorder. | 06-24-2010 |
| 20110091898 | DETECTION PROBE - A nucleotide probe permitting the detection of nucleic acids and constituted of a labeled nucleotide strand having three fragments: a first fragment having a first closing sequence, a second fragment, all or part of which has a recognition sequence for the molecular recognition of the target nucleic acid and a third fragment having a second closing sequence, and at least two markers, one of the ends of the strand of the detection probe being free of any marker, in which, when the two closing sequences are hybridized together, the detection probe has a completely circular shape, the closing sequences thus maintaining the probe in a conformation that cannot be detected in the absence of the target nucleic acid. | 04-21-2011 |
| 20110091897 | COMPOSITIONS COMPRISING NANOMATERIALS AND METHOD FOR USING SUCH COMPOSITIONS FOR HISTOCHEMICAL PROCESSES - Histochemical process compositions comprising at least one nanoparticle in an amount effective to reduce or substantially eliminate the average number of spots per slide that result from a sample staining protocol are disclosed. Various nanoparticles, or combinations thereof, including metals, metal alloys, metal oxides, ceramics, functionalized metals or metalloids, and other miscellaneous nanoparticles, such as carbon nanoparticles and diamond nanoparticles, can be used. The nanoparticle concentration typically is from about 2 parts per million to about 20 parts per million. One embodiment of a disclosed method concerns applying a histochemical process composition to a sample, followed by performing a staining protocol on the sample. Particular embodiments concern dispensing a nanosolution onto a sample using an automated system, heating the sample, and performing a sample staining process. | 04-21-2011 |
| 20110091896 | METHOD FOR ANALYSIS/IDENTIFICATION OF ANTIBODY GENE AT ONE-CELL LEVEL - Disclosed are: a method for identifying/analyzing a gene for an antibody in one cell derived from a human; a technique for producing an antibody derived from an identified one B cell; and others. A gene for an antibody specific to a melanoma antigen is analyzed/identified at a one-cell level by using an immortalized B cell produced from peripheral blood monocytes from a melanoma patient or a primary B cell included in the peripheral blood monocytes. It is found that B cells capable of producing a specific antibody can be separated on one cell by one cell basis by staining the B cells with a GST-labeled melanoma-specific cancer antigen MAGE1, an Alexa-labeled anti-GST antibody and a PE-labeled anti-human IgG antibody and carrying out the single cell sorting of the stained B cells. Further, a practical technique for extracting total RNA from the separated one B cell and cloning a gene for a specific antibody into the total RNA efficiently can be established. | 04-21-2011 |
| 20110091893 | BIOSENSORS FOR DETECTING MACROMOLECULES AND OTHER ANALYTES - The invention generally provides molecular biosensors. In particular, the invention provides molecular biosensors having one or more aptamers. The molecular biosensors are useful in several methods including in the identification and quantification of target molecules. | 04-21-2011 |
| 20110091888 | USE OF CATHEPSIN C - Present invention concerns the use of Cathepsin C. Other aspects of the invention concern methods for screening pharmaceuticals, for diagnosing pain susceptibility and for the treatment of pain. | 04-21-2011 |
| 20110091872 | DETECTING TRIAZOLE RESISTANCE IN ASPERGILLUS - Methods are provided for detecting triazole -resistant fungi in a sample. The methods comprise evaluating the sample for the presence of a gene encoding a mutant AzRF1 transcription factor, or the level of the transcription factor, to determine whether a fungus is triazole-resistant. Primers, probes and kits also are provided. | 04-21-2011 |
| 20110091874 | ULTRASENSITIVE DETECTION OF TARGET USING TARGET-READY PARTICLES - The invention relates to methods and reagents for detecting minute amounts of targets having affinity for nucleic acid. The present invention more particularly relates to target detection using aggregates of cationic polymer chains and nucleic acid capture probes linked to particles, such as controllable mobility particles. | 04-21-2011 |
| 20110020816 | Precursor miRNA loop-modulated target regulation - By modifying nucleotides from either or both the stem and loop of precursor-miRNA, greater specificity is achieved as to the mRNAs targeted. The improved efficiency in target regulation can be either mediated by direct base-pairings between targets and precursor miRNAs or indirectly by energy constraints on the availability of such base-pairings. It is found that pri- and pre-miRNA are active in the absence of functional mature miRNA, so pri- or pre-miRNA or truncated portion thereof, but not as mature miRNA, can be used as RNAi agents by themselves. Furthermore, besides the seed sequence of the stem of the pre-miRNA and 3′-extensions thereof to provide greater complementarity to the target mRNA, nucleotides in the loop can affect the activity and specificity of the precursor-miRNA and the processing and binding to target mRNA. By using mutated sequences in the natural pri- or pre-miRNA or modified mimetics, one can screen for target mRNA, target a unique mRNA or a group of mRNAs for regulation, and modulate cell properties with greater specificity and investigate cellular activity as to phenotype and response to external stimuli in the presence or absence of at least partial target protein expression. | 01-27-2011 |
| 20110020829 | RAPID ASSAY FOR DETECTING ATAXIA-TELANGIECTASIA HOMOZYGOTES AND HETEROZYGOTES - The present disclosure relates to methods for performing an assay to identify ataxia-telangiectasia homozygotes or heterozygotes. Some embodiments include the use of a rapid flow cytometry-based ataxiatelangiectasia (ATM) kinase assay that measures ATM-dependent phosphorylation of SMC1 following DNA damage. | 01-27-2011 |
| 20110020819 | ISOTHERMAL DETECTION METHODS AND USES THEREOF - The present disclosure relates to methods and probes for rapid, single temperature (isothermal) detection of specific nucleic acid sequences. The methods and probes provide a simple method for detecting bioagents including bacteria and viruses, and the detection of specific genetic markers on any nucleic sequence. | 01-27-2011 |
| 20110020818 | REACTOR FOR THE QUANTITATIVE ANALYSIS OF NECLEIC ACIDS - A reactor for the quantitative analysis of target nucleic acids using an evanescent wave detection technique and a method of use thereof is provided. The reactor includes a substrate with a cavity, a buffer layer arranged over the substrate; a cover plate arranged over the buffer layer, and inlet and outlet ports. The reactor is thermally and chemically stable for PCR processing and suitable for an evanescent wave detection technique. | 01-27-2011 |
| 20110020813 | ADVANCED PATHOGEN DETECTION AND SCREENING - Disclosed is a rapid, dual purpose, PCR-based method for identifying two or more pathogens, including | 01-27-2011 |
| 20110020810 | TRPC6 INVOLVED IN GLOMERULONEPHRITIS - Focal and segmental glomerulosclerosis (FSGS) is a kidney disorder of unknown etiology and up to 20% of patients on dialysis have this diagnosis. A large family with hereditary FSGS carries a missense mutation in the TRPC6 gene on chromosome 11q, encoding the ion channel protein Transient Receptor Potential Cation Channel 6. The missense mutation is a P112Q substitution, which occurs in a highly conserved region of the protein, enhances TRPC6-mediated calcium signals in response to agonists such as angiotensin II, and alters the intracellular distribution of TRPC6 protein. Previous work has emphasized the importance of cytoskeletal and structural proteins in proteinuric kidney diseases. Our findings suggest a novel mechanism for glomerular disease pathogenesis. | 01-27-2011 |
| 20110020801 | Carboxylesterase-1 Polymorphisms and Methods of Use Therefor - Methods and kits are provided for detecting polymorphisms in carboxylesterase-1 (CES1). Several single nucleotide polymorphisms (SNPs) in CES1 in humans, and methods for detecting the same, are provided (e.g., Gly143Glu, 12754T>del). Results indicate that the Gly143Glu (9486G>A) polymorphism has an allelic frequency of 1.5% in the Caucasian population. Polymorphisms of the present invention may alter the function of the carboxylesterase-1 enzyme (hCES1). Thus, the methods and kits of the present invention may be used to personalize a therapy and/or avoid adverse consequences of altered metabolism of a therapeutic or compound (e.g., enalapril, methylphenidate, etc.) which may result due to a CES1 polymorphism. In addition, recombinant cells lines overexpressing wild-type CES1 or expressing CES1 mutants are provided. Such cell lines may be used to assess the effects of candidate compounds on CES1, and the action of CES1 on these candidate compounds. | 01-27-2011 |
| 20110020793 | Molecular counting by color-coded micelles - The invention provides a method of determining ratios of target DNA molecules in a sample. A digital readout of the target DNA molecules is provided by converting ratios of target DNA molecules into equivalent ratios of amplifiable tags, which are, in turn, converted into ratios of color-coded micelles in an emulsion reaction. The micelles may be detected and counted by various methods, including by flow cytometers or slide-based imaging devices. The invention is useful for detection of relative expression levels of selected genes, gene copy number polymorphisms, allelic imbalance, relative levels of iRNAs, and related phenomena of scientific and medical interest. | 01-27-2011 |
| 20110020792 | DETECTION OF UTERINE LEIOMYOSARCOMA USING LMP2 - This invention provides a method for detecting the presence of uterine leiomyosarcoma using the transcription or expression level of LMP2 and/or cyclin E in uterine smooth muscle tissue as an indicator and a method for detecting uterine leiomyosarcoma using LMP2 and/or cyclin E as a marker. | 01-27-2011 |
| 20100143918 | TRANSLOCATION AND MUTANT ROS KINASE IN HUMAN NON-SMALL CELL LUNG CARCINOMA - In accordance with the invention, a novel gene translocation, (4p15, 6q22), in human non-small cell lung carcinoma (NSCLC) that results in fusion proteins combining part of Sodium-dependent Phosphate Transporter Isoform NaPi-3b protein (SLC34A2) with Proto-oncogene Tyrosine Protein Kinase ROS Precursor (ROS) kinase has now been identified. The SLC34A2-ROS fusion proteins are anticipated to drive the proliferation and survival of cancer cells, and particularly drive the proliferation and survival of a subgroup of NSCLC tumor cells. The invention therefore provides, in part, isolated polynucleotides and vectors encoding the disclosed mutant ROS kinase polypeptides, probes for detecting it, isolated mutant polypeptides, recombinant polypeptides, and reagents for detecting the fusion and truncated polypeptides. The disclosed identification of the new fusion protein enables new methods for determining the presence of these mutant ROS kinase polypeptides in a biological sample, methods for screening for compounds that inhibit the proteins, and methods for inhibiting the progression of a cancer characterized by the mutant polynucleotides or polypeptides, which are also provided by the invention. | 06-10-2010 |
| 20090298066 | Sex-Specific Marker for Shrimps and Prawns - The present invention relates to a sex-specific marker for shrimps and prawns. More specifically, it relates to a sex-specific PCR-based molecular marker, derived from | 12-03-2009 |
| 20110020807 | Methylated CpG Island Amplification (MCA) - The present invention provides a method for identifying a methylated CpG containing nucleic acid by contacting a nucleic acid with a methylation sensitive restriction endonuclease that cleaves unmethylated PcG sites and contacting the sample with an isoschizomer of the methylation sensitive restriction endonuclease, which cleaves both methylated and unmethylated CpG sites. The method also includes amplification of the CpG-containing nucleic acid using CpG-specific oligonucleotide primers. A method is also provided for detecting an age associated disorder by identification of a methylated CpG containing nucleic acid. A method is further provided for evaluating the responses of a cell to an agent. A kit is useful for detection of a CpG containing nucleic acid is also provided. Nucleic acid sequences encoding novel methylated clones. | 01-27-2011 |
| 20110020804 | PHOTOINDUCED ELECTRON TRANSFER (PET) PRIMER FOR NUCLEIC ACID AMPLIFICATION - This application provides photoinduced electron transfer (PET) nucleic acid molecules that can be used detect and amplify nucleic acid molecules, such as target nucleic acid molecules. These PET tags can be attached to the 5′-end of a target sequence-specific primer, thereby generating a PET primer. In particular examples, a PET tag includes a 5′-labeled nucleotide that can be quenched by at least two consecutive Gs within the tag sequence, and is unquenched when the PET tag hybridizes with its complementary nucleic acid molecule. Also disclosed are methods of using PET primers in nucleic acid amplification, such as real-time PCR. | 01-27-2011 |
| 20110020802 | NUCLEIC ACIDS, METHODS AND KITS FOR THE DIAGNOSIS OF DYT6 PRIMARY TORSION DYSTONIA - The invention relates generally to the THAP1 gene and mutations in this gene, as well as the THAP1 protein and mutations in this protein, that are associated with dystonia. The invention relates to the identification, isolation, cloning and characterization of the DNA sequence corresponding to the wild type and mutant THAP1 genes, as well as isolation and characterization of their transcripts and gene products. The invention further relates to methods and kits useful for detecting mutations in THAP1 that are associated with dystonia, as well as to methods and kits useful for diagnosing dystonia. The present invention also relates to therapies for treating dystonia, including gene therapeutics and protein/antibody based therapeutics. | 01-27-2011 |
| 20110020799 | Screening method for damaged DNA repairing substance - Provided are a novel screening method for a substance that potentiates damaged DNA repair capability, based on a test with DNA repair as an index with improved sensitivity as a simplified version of the currently available unscheduled DNA synthesis (UDS) assay based on | 01-27-2011 |
| 20110020798 | Novel italy, LOR-2, strife, trash, BDSF, LRSG, and STMST protein and nucleic acid molecules and uses therefor - Novel ITALY, LOR-2, STRIFE, TRASH, BDSF, LRSG, and STMST polypeptides, proteins, and nucleic acid molecules are disclosed. In addition to isolated, full-length ITALY, LOR-2, STRIFE, TRASH, BDSF, LRSG, and STMST proteins, the invention further provides isolated ITALY, LOR-2, STRIFE, TRASH, BDSF, LRSG, and STMST fusion proteins, antigenic peptides and anti-ITALY, LOR-2, STRIFE, TRASH, BDSF, LRSG, and STMST antibodies. The invention also provides ITALY, LOR-2, STRIFE, TRASH, BDSF, LRSG, and STMST nucleic acid molecules, recombinant expression vectors containing a nucleic acid molecule of the invention, host cells into which the expression vectors have been introduced and non-human transgenic animals in which an ITALY, LOR-2, STRIFE, TRASH, BDSF, LRSG, and STMST gene has been introduced or disrupted. Diagnostic, screening and therapeutic methods utilizing compositions of the invention are also provided. | 01-27-2011 |
| 20110020797 | Methods For Identifying Patients With An Increased Likelihood Of Responding To DPP-IV Inhibitors - The invention provides novel in vitro diagnostic methods for identifying patients who may have an increased likelihood of responding to DPP-IV inhibitor therapy. The invention also provides novel polynucleotides associated with increased responsiveness of a patient to DPP-IV inhibition. Polynucleotide fragments corresponding to the genomic and/or coding regions of these polynucleotides, which comprise at least one polymorphic locus per fragment, are also provided. Allele-specific primers and probes which hybridize to these polymorphic regions, and/or which comprise at least one polymorphic locus are also provided. The polynucleotides, primers, and probes of the present invention are useful in phenotype correlations, medicine, and genetic analysis. | 01-27-2011 |
| 20110020794 | METHOD FOR THE DETECTION OF DIAGNOSTIC RNA - Methods for the direct detection of diagnostic target RNA have been developed, which obviate the need for time consuming RNA purification and isolation procedures. | 01-27-2011 |
| 20100092953 | METHODS AND NUCLEIC ACIDS FOR ANALYSES FOR CELLULAR PROLIFERATIVE DISORDERS - The invention provides methods, nucleic acids and kits for detecting a cell proliferative disorder. The invention discloses genomic sequences of RASSF-2 the methylation patterns of which have utility for the improved detection of said disorder, thereby enabling the improved diagnosis and treatment of patients. | 04-15-2010 |
| 20110111408 | METHODS AND COMPOSITION FOR SECRETION OF HETEROLOGOUS POLYPEPTIDES - The present invention relates generally to the fields of molecular biology and protein technology. More specifically, the invention concerns signal sequences for the secretion of heterologous polypeptide from bacteria. The invention also concerns recombinant polypeptides and uses thereof. | 05-12-2011 |
| 20110111400 | METHOD FOR ENHANCING CHEMICAL SENSITIVITY OR RADIOSENSITIVITY OF CANCER CELLS BY INHIBITING EXPRESSION OF TSPYL5 - Disclosed herein is a method for enhancing sensitivity of cancer cells to compounds or radiation by inhibiting the expression of testis-specific protein, Y-encoded like 5 (TSPYL5). More specifically, because methylation of TSPYL5 protein expressed in lung cancer cell line was inhibited to increase the expression level of the gene, resistance to stress such as radiation or anticancer agents was increased. Because the sensitivity of cancer cells to stress such as radiation or anticancer agents was increased by inhibiting the expression of the TSPYL5 gene to promote the apoptosis of the cells, an anticancer supplement agent containing an inhibitor of the expression or activity of the TSPYL5 gene of the present invention inhibits the growth of cancer cells and enhances the sensitivity to various stresses to maximize the apoptosis. Thus, when used in combination with radiotherapy or chemotherapy, the anticancer supplement agent may be used very usefully for anticancer treatment. | 05-12-2011 |
| 20110111398 | NUCLEIC ACID PROBE-BASED DIAGNOSTIC ASSAYS TARGETING SSRA GENES OF PROKARYOTIC AND EUKARYOTIC ORGANISMS - Use of the ssrA gene or tmRNA, an RNA transcript of the ssrA gene, or fragments thereof as target regions in a nucleic acid probe assay for the detection and identification of prokaryotic and/or eukaryotic organisms is described. Nucleotide sequence alignment of tmRNA sequences from various organisms can be used to identify regions of homology and non-homology within the sequences which in turn can be used to design both genus specific and species specific oligonucleotide probes. These newly identified regions of homology and non-homology provide the basis of identifying and detecting organisms at the molecular level. Oligonucleotide probes identified in this way can be used to detect tmRNA in samples thereby giving an indication of the viability of non-viral organisms present in various sample types. | 05-12-2011 |
| 20110111397 | CONNEXIN ALLELE DETECTION ASSAYS - The present invention provides compositions and methods for the detection and characterization of mutations associated with non-syndromic hearing impairment. More particularly, the present invention provides compositions, methods and kits for using invasive cleavage structure assays (e.g. the INVADER assay) to screen nucleic acid samples, e.g., from patients, for the presence of any one of a collection of mutations in the Connexin 26, or gap junction beta 2, gene associated with non-syndromic hearing loss. | 05-12-2011 |
| 20100151476 | PHENYLTHIOCARBAMIDE (PTC) TASTE RECEPTOR - The invention provides isolated nucleic and amino acid sequences of a taste cell receptor that serves as a sensor for the bitter taste of phenylthiocarbamide (PTC), antibodies to such PTC taste receptor, methods of detecting such nucleic and amino acid sequences, and methods of screening for modulators of such PTC taste receptor. | 06-17-2010 |
| 20110003309 | Non-Competitive Internal Controls for Use in Nucleic Acid Tests - Provided are non-competitive internal controls for use in nucleic acid tests (NATs), which are obtained from the organisms | 01-06-2011 |
| 20110003307 | METHODS FOR PRODUCING INTERFERING RNA MOLECULES IN MAMMALIAN CELLS AND THERAPEUTIC USES FOR SUCH MOLECULES - Methods for producing interfering RNA molecules in mammalian cells are provided. Therapeutic uses for the expressed molecules, including inhibiting expression of HIV, are also provided. | 01-06-2011 |
| 20110003306 | IDENTIFICATION OF ANTIBIOTIC RESISTANCE USING LABELLED ANTIBIOTICS - Subject of the present invention is a method for detection of an antibiotic resistance in a micro-organism comprising the steps of exposing suspected micro-organism to a labelled (fluorescent) antibiotic and observing the differences between it and a non-resistant micro-organism of the same type. | 01-06-2011 |
| 20110003300 | RAPID STERILITY MICROASSAY - The present invention relates to a method for detecting a viable microorganism in a pharmaceutical composition comprising the steps of providing a filterable pharmaceutical composition; filtering the pharmaceutical composition to provide at least three membranes upon which the pharmaceutical composition is deposited, placing the three membranes onto solid culture media to produce at least three filtrand cultures, culturing under aerobic and anaerobic conditions and detecting a viable microorganism cell, micro-colony or colony, wherein the presence of a viable cell, micro-colony or colony on the membrane indicates the presence of a viable microorganism in the pharmaceutical composition. | 01-06-2011 |
| 20110003296 | Method for the detection of gene transcripts in blood and uses thereof - The present invention is directed to detection and measurement of gene transcripts in blood. Specifically provided is a RT-PCR analysis performed on a drop of blood for detecting, diagnosing and monitoring diseases using tissue-specific primers. The present invention also describes methods by which delineation of the sequence and/or quantitation of the expression levels of disease-associated genes allows for an immediate and accurate diagnostic/prognostic test for disease or to assess the effect of a particular treatment regimen. | 01-06-2011 |
| 20110003294 | Method of profiling gene expression in a healthy subject - The present invention is directed to detection and measurement of gene transcripts in blood. Specifically provided is a RT-PCR analysis performed on a drop of blood for detecting, diagnosing and monitoring diseases using tissue-specific primers. The present invention also describes methods by which delineation of the sequence and/or quantitation of the expression levels of disease-associated genes allows for an immediate and accurate diagnostic/prognostic test for disease or to assess the effect of a particular treatment regimen. | 01-06-2011 |
| 20110003293 | FETAL ANEUPLOIDY DETECTION BY SEQUENCING - The present invention provides apparatus and methods for enriching components or cells from a sample and conducting genetic analysis, such as SNP genotyping to provide diagnostic results for fetal disorders or conditions. | 01-06-2011 |
| 20110003292 | METHODS AND NUCLEIC ACIDS FOR ANALYSES OF CELL PROLIFERATIVE DISORDERS - The invention provides methods, nucleic acids and kits for detecting lung carcinoma. The invention discloses genomic (FOXL2, ONECUT1, TFAP2E, EN2-2, EN2-3, SHOX2-2 and BARHL2) sequences the methylation patterns of which have utility for the improved detection of said disorder, thereby enabling the improved diagnosis and treatment of patients. | 01-06-2011 |
| 20110003291 | METHOD FOR STUDYING V(D)J COMBINATORY DIVERSITY - The invention relates to a method for analysing the diversity of the catalogue of T and/or B lymphocytes in an individual, based on the amplification, from a sample, of genomic DNA fragments by PCR multi-n-plexes, with n≧2, carried out with a combination of at least 3 primers defining at least 2 primer couples, each of which includes a primer specifically hybridising upstream and/or in a given V or D gene and a primer specifically hybridising downstream and/or in a given J gene, in order to obtain the amplification of at least two fragments characteristic of two distinct V-J or D-J rearrangements from each primer couple. The invention also relates to the applications of this method, in particular in the treatment follow-up or in the diagnosis and/or prognosis of certain diseases. | 01-06-2011 |
| 20110003290 | Oligonucleotides and Uses Thereof - A method for determining the number of tandem repeats in a target polynucleotide, the method comprising (a) providing a sample containing the target polynucleotide, wherein one or more of the tandem repeats in the target polynucleotide is in single stranded form, (b) hybridising a labelled probe oligonucleotide to the single stranded portion of the target polynucleotide, wherein the probe oligonucleotide is complementary to at least one of the tandem repeats, and at least 5 nucleotides of the probe oligonucleotide are complementary to the tandem repeats, in the single stranded portion of the target polynucleotide, and (c) determining the number of tandem repeats in the target polynucleotide based on the hybridisation of the probe oligonucleotide to the single stranded portion of the target polynucleotide. | 01-06-2011 |
| 20110003286 | REACTOR PLATE AND REACTION PROCESSING METHOD - Disclosed herein is a reactor plate which prevents the entry of foreign matter from the outside and the pollution of a surrounding environment. A reactor plate ( | 01-06-2011 |
| 20110008769 | DOPAMINERGIC NEURON PROGENITOR CELL MARKER 187A5 - An object of the present invention is to provide a probe, a primer, a primer set and an antibody for use in the detection or selection of a dopaminergic neuron progenitor cell. The present invention provides a probe, a primer and a primer set for use in the detection or selection of a mesencephalon dopaminergic neuron progenitor cell, and preferably a dopaminergic neuron proliferative progenitor cell, which can hybridize with a nucleotide sequence of a 187A5 gene, or a complementary sequence thereto, and an antibody for use in the detection or selection of a mesencephalon dopaminergic neuron progenitor cell, and preferably a dopaminergic neuron progenitor cell, which is capable of binding to a 187A5 protein. | 01-13-2011 |
| 20090258350 | Diagnostic methods for determining prognosis of non-small cell lung cancer - The invention provides methods for identifying early stage non-small cell lung cancer (NSCLC) patients who will have a favorable prognosis for the recurrence of lung cancer after surgical resection. The invention is based on the discovery that assessment of chromosomal copy number abnormalities at two or more of chromosome 5p15, 7p12, 8q24 and centromere 6 can be used for prognostic classification. The invention preferably uses fluorescence in situ hybridization with fluorescently labeled nucleic acid probes to hybridize to patient samples to quantify the chromosomal copy number of the these genetic loci. Assessment of the copy number abnormality patterns using four classifiers produced statistically significant prognostic classification for NSCLC: (i) the Range3 pattern of cells showing a difference on a cell by cell basis, of at least three FISH probe signals between the FISH signals at the chromosomal locus with the largest number of FISH signals minus the FISH signals at the chromosomal locus with the lowest number of FISH signals; (ii) the MYC/EGFR % loss pattern assessing the percentage of cells showing fewer MYC FISH probe signals than EGFR FISH probe signals; (iii) a combination of the Range3 pattern and the MYC/CEP6 ratio pattern of a percentage of cells showing a relative loss of MYC FISH probe signals to the FISH probe signal for CEP6; (iv) the combination of the MYC/5p15 ratio pattern showing the relative ratio of MYC and 5p15 locus signals of ≧0.80 and the 5p15/CEP6 ratio pattern assessing percentage of cells having a relative ratio of 5p15 FISH probe signals to CEP6 FISH probe signals ≧1.1 versus MYC/5p15 ratio of <0.80 or 5p15/CEP6<1.1; and (v) a combination of the average range of probe signal differences of equal to or greater than about 2.5 with the Range3 pattern in a percentage of the cells. The invention can be used to identify those early stage NSCLC patients at higher risk of recurrence who should be treated with neoadjuvant chemotherapy before surgery or with adjuvant chemotherapy after surgery. | 10-15-2009 |
| 20090246791 | ENGINEERED FLUORESCENT DYE LABELED NUCLEOTIDE ANALOGS FOR DNA SEQUENCING - Engineered nucleotide compositions, having polymerase interacting components that improve the interactivity of the polymerase and the nucleotide, particularly for nucleic acid sequencing applications. Compositions include the interactive polymerases along with the nucleotide analogs. Kits, methods and systems are provided for analysis of nucleic acid synthesis reactions. | 10-01-2009 |
| 20090246792 | METHODS FOR DETECTING NUCLEIC ACID SEQUENCE VARIATIONS - The invention employs an unlabeled signal primer comprising a 5′ adapter sequence for detection of variations in nucleic acid target sequences. The detection system further comprises a reporter probe, the 3′ end of which hybridizes to the complement of the 5′ adapter sequence of the signal primer to produce a 5′ overhang. Polymerase is used to fill in the overhang and synthesize the complement of the 5′ overhang of the reporter probe. Synthesis of the reporter probe complement is detected, either directly or indirectly, as an indication of the presence of the target. | 10-01-2009 |
| 20090246782 | BARRIERS FOR FACILITATING BIOLOGICAL REACTIONS - The present invention relates to systems, devices, and methods for performing biological reactions. In particular, the present invention relates to the use of lipophilic, water immiscible, or hydrophobic barriers in sample separation, purification, modification, and analysis processes. | 10-01-2009 |
| 20110020832 | METHOD FOR DETECTING CANCER CELL CAUSED BY HPV, METHOD FOR DETERMINING WHETHER OR NOT TISSUE IS AT STAGE OF HIGH-GRADE DYSPLASIA OR MORE SEVERE STAGE, AND PRIMER SET AND KIT USED THEREFOR - Provided are a primer set, a method and a kit therefor, which can easily perform with high accuracy the detection of a cancer cell caused by HPV and the determination of whether or not a tissue is a tissue with high-grade dysplasia or in a more severe phase. As a primer set, used is a primer set consisting of a first primer which hybridizes with a nucleic acid consisting of a nucleotide sequence in which cytosine present in a site other than a CpG site is converted into another base in a nucleotide sequence having a CpG site in L1 region or L2 region of HPV and a second primer which hybridizes with a nucleic acid consisting of a nucleotide sequence in which cytosine is converted into another base in a nucleotide sequence having a CpG site in LCR or E6 region of HPV. | 01-27-2011 |
| 20110020831 | GENETIC DETECTION OF HIV-1 STRAINS THAT USE THE CXCR4 CO-RECEPTOR - The invention relates to a method for obtaining clonal HIV-1 sequence information from a clinical isolate derived from an HIV-1 infected individual to guide highly active anti-retroviral therapy (HAART) comprising the following steps;
| 01-27-2011 |
| 20110020830 | DESIGN FOR RAPIDLY CLONING ONE OR MORE POLYPEPTIDE CHAINS INTO AN EXPRESSION SYSTEM - The present invention provides methods and compositions for the generation and identification of expression constructs that can be used to express sufficient levels of a polypeptide of interest. The compositions include a population of expression vectors, wherein members of the population have a type IIS restriction enzyme recognition site adjacent to a regulatory sequence, and wherein the regulatory element is distinct in at least two members of the population of expression vectors. In various embodiments, the expression vectors further comprise a polynucleotide sequence encoding a polypeptide of interest, wherein the polynucleotide encoding the polypeptide, the polynucleotide of the regulatory sequence, or both, are distinct in at least two members of the population. The compositions are useful for identifying a combination of coding sequences and/or regulatory elements useful for the heterologous expression of the polypeptide of interest. | 01-27-2011 |
| 20110020827 | MODIFIED NUCLEOSIDES AND NUCLEOTIDES AND USES THEREOF - The invention is directed to modified guanine-containing nucleosides and nucleotides and uses thereof. More specifically, the invention relates to modified fluorescently labelled guanine-containing nucleosides and nucleotides which exhibit enhanced fluorophore intensity by virtue of reduced quenching effects. | 01-27-2011 |
| 20110020826 | METHODS FOR ASSESSING EFFICACY OF CHEMOTHERAPEUTIC AGENTS - Methods are provided for accurately predicting efficacy of chemotherapeutic agents. Methods of the invention increase the positive predictive value of chemosensitivity assays by assessing both the ability of a chemotherapeutic to destroy cells and the genetic propensity of those cells for resistance. Results obtained using methods of the invention provide insight into the in vivo effectiveness of a therapeutic, and lead to more effective chemotherapeutic treatment. | 01-27-2011 |
| 20110020824 | METHODS AND COMPOSITIONS FOR QUANTITATIVE AMPLIFICATION AND DETECTION OVER A WIDE DYNAMIC RANGE - Disclosed are compositions and methods for making differentiable amplicon species at unequal ratios using a single amplification system in a single vessel. The number of differentiable amplicons and their ratios to one another are chosen to span the required linear dynamic range for the amplification reaction and to accommodate limitations of the measuring system used to determine the amount of amplicon generated. Unequal amounts of distinguishable amplicon species are generated by providing unequal amounts of one or more amplification reaction components (e.g., distinguishable amplification oligomers, natural and unnatural NTP in an NTP mix, or the like). The amount of target nucleic acid present in a test sample is determined using the linear detection range generated from detection of one or more amplicon species having an amount within the dynamic range of detection. | 01-27-2011 |
| 20110020822 | MOLECULAR DETECTION OF CHROMOSOME ABERRATIONS - The invention relates to the field of cytogenetics and the application of genetic diagnostic techniques in pathology and hematology. Specifically, the invention relates to nucleic acid probes that can be used in hybridization techniques for the detection of chromosomal aberrations and other gene rearrangements such as immunoglobulin and T-cell receptor gene rearrangements. The probes provided by the invention are a distinct and balanced set of probes of comparable size, each preferably being from 1 to 100 kb, or smaller, and flanking a potential breakpoint in a chromosome. | 01-27-2011 |
| 20110020821 | METHOD FOR DETECTION OF MICROORGANISM AND KIT FOR DETECTION OF MICROORGANISM - According to the following steps, live cells, injured cells, VNC cells and dead cells of a microorganism in a test sample are detected by flow cytometry:
| 01-27-2011 |
| 20110020820 | METHOD FOR DETECTION OF MICROORGANISM AND KIT FOR DETECTION OF MICROORGANISM - A kit is disclosed for preparing a measurement sample for detecting live cells, injured cells, VNC cells and dead microorganism cells in a test sample by the following steps:
| 01-27-2011 |
| 20110020817 | De novo synthesized plasmid, methods of making and use thereof - The invention relates to a de novo synthesized plasmid. The plasmid comprises relevant sequences for plasmid replication and plasmid selection. The methods of making and use of the plasmid are disclosed. The plasmid can be used to make other plasmids. These plasmids and their host cells can be used for biomedical applications. | 01-27-2011 |
| 20110020815 | METHODS FOR GENOMIC ANALYSIS - The present invention relates to methods for identifying variations that occur in the human genome and relating these variations to the genetic basis of disease and drug response. In particular, the present invention relates to identifying individual SNPs, determining SNP haplotype blocks and patterns, and, further, using the SNP haplotype blocks and patterns to dissect the genetic bases of disease and drug response. The methods of the present invention are useful in whole genome analysis. | 01-27-2011 |
| 20110020812 | METHODS OF USING FET LABELED OLIGONUCLEOTIDES THAT INCLUDE A 3'-5' EXONUCLEASE RESISTANT QUENCHER DOMAIN AND COMPOSITIONS FOR PRACTICING THE SAME - Methods and compositions are provided for detecting a primer extension product in a reaction mixture. In the subject methods, a primer extension reaction is conducted in the presence of a polymerase having 3′→5′ exonuclease activity and at least one FET labeled oligonucleotide probe that includes a 3′→5′ exonuclease resistant quencher domain. Also provided are systems and kits for practicing the subject methods. The subject invention finds use in a variety of different applications, and are particularly suited for use in high fidelity PCR based reactions, including SNP detection applications, allelic variation detection applications, and the like. | 01-27-2011 |
| 20110020808 | BIOMARKERS FOR DIAGNOSING SCHIZOPHRENIA AND BIPOLAR DISORDER - The invention relates to the identification and selection of novel biomarkers and the identification and selection of novel biomarker combinations which are differentially expressed in blood and useful in diagnosing schizophrenia and/or bipolar disorder as well as monitoring therapeutic efficacy of treatment for schizophrenia or bipolar disorder. The measurement of expression levels of the products of the biomarkers and combinations of biomarkers of the invention can be used to diagnose schizophrenia and/or bipolar disorder. Measurement of the expression level of products of biomarkers of the invention using polynucleotides and proteins which specifically and/or selectively hybridize to the products of the biomarkers of the invention are also encompassed within the scope of the invention as are compositions and kits containing said polynucleotides and proteins. Further encompassed by the invention is the use of the polynucleotides and proteins to monitor the efficacy of therapeutic regimens. The invention also provides for the identification of methods of using the products of the biomarkers of the invention in the identification of novel therapeutic targets of schizophrenia and/or bipolar disorder and a method of screening the genes of said biomarkers for additional markers of disease. | 01-27-2011 |
| 20090325169 | RNASE H-BASED ASSAYS UTILIZING MODIFIED RNA MONOMERS - The present invention pertains to novel oligonucleotide compounds for use in various biological assays, such as nucleic acid amplification, ligation and sequencing reactions. The novel oligonucleotides comprise a ribonucleic acid domain and a blocking group at or near the 3′ end of the oligonucleotide. These compounds offer an added level of specificity previously unseen. Methods for performing nucleic acid amplification, ligation and sequencing are also provided. Additionally, kits containing the oligonucleotides are also disclosed herein. | 12-31-2009 |
| 20090311691 | Nucleic acid analysis by random mixtures of non-overlapping fragments - The invention provides methods and kits for ordering sequence information derived from one or more target polynucleotides. In one aspect, one or more tiers or levels of fragmentation and aliquoting are generated, after which sequence information is obtained from fragments in a final level or tier. Each fragment in such final tier is from a particular aliquot, which, in turn, is from a particular aliquot of a prior tier, and so on. For every fragment of an aliquot in the final tier, the aliquots from which it was derived at every prior tier is known, or can be discerned. Thus, identical sequences from overlapping fragments from different aliquots can be distinguished and grouped as being derived from the same or different fragments from prior tiers. When the fragments in the final tier are sequenced, overlapping sequence regions of fragments in different aliquots are used to register the fragments so that non-overlapping regions are ordered. In one aspect, this process is carried out in a hierarchical fashion until the one or more target polynucleotides are characterized, e.g. by their nucleic acid sequences, or by an ordering of sequence segments, or by an ordering of single nucleotide polymorphisms (SNPs), or the like. | 12-17-2009 |
| 20090298071 | METHOD FOR TESTING DRUG SENSITIVITY IN SOLID TUMORS BY QUANTIFYING MRNA EXPRESSION IN THINLY-SLICED TUMOR TISSUE - A method is disclosed for assaying the sensitivity of neoplastic tissue to therapeutic agents, and in particular, for the quantification of pro-apoptotic marker mRNA expression in cells obtained from thinly-sliced living tumor tissue in such methods. The method may comprise ascertaining a particular apoptosis marker mRNA for an individual tumor or tumor type as well as exposure of thin-sliced live cancer tissues from the individual tumor to candidate chemotherapeutic drug regimes in vitro, followed by an assessment of the level of the marker mRNA in the tissue. | 12-03-2009 |
| 20090246781 | Method for early determination of recurrence after therapy for prostate cancer - This invention describes compositions and methods for use in PSA assays having low functional sensitivity which are useful, for example, in the detection of early stage recurrence of prostate disease following treatment and in the determination of whether patients have early stage biochemical reoccurrence (ES-BCR) or stable disease. | 10-01-2009 |
| 20090246780 | HIGH THROUGHPUT PHYSICAL MAPPING USING AFLP - The present invention relates to a high throughput method for the identification and detection of molecular markers wherein restriction fragments are generated and suitable adaptors comprising (sample-specific) identifiers are ligated. The adapter-ligated restriction fragments may be selectively amplified with adaptor compatible primers carrying selective nucleotides at their 3′ end. The amplified adapter-ligated restriction fragments are, at least partly, sequenced using high throughput sequencing methods and the sequence parts of the restriction fragments together with the sample-specific identifiers serve as molecular markers. | 10-01-2009 |
| 20100003677 | IDENTIFICATION OF TUMOR SUPPRESSOR GENES IN AN ACUTE MYELOID LEUKAEMIA MODEL - The present invention comprises a method method to identify tumor suppressor genes by detecting genes in a mouse retroviral insertion mutagenesis model which expression is inhibited by methylation of the viral insertion or the VIS-flanking gene. This is preferably accomplished by first randomly cutting the mouse genomic DNA, immunoprecipitating the methylated DNA and amplifying the VIS-flanking DNA by inverse PCR, optionally followed by cloning and sequencing of the amplicons. | 01-07-2010 |
| 20110104704 | ASSOCIATION OF EDG5 POLYMORPHISM V286A WITH TYPE II DIABETES MELLITUS AND VENOUS THROMBOSIS/PULMONARY EMBOLISM AND THE USE THEREOF - The present invention relates to a method of identifying an increase in risk for type II Diabetes mellitus, venous thrombosis, or pulmonary embolism in a subject, wherein the presence of an amino acid exchange at position 286 from valine (Val) to alanine (Ala) in the EDG5 protein in a biological sample taken from the subject. | 05-05-2011 |
| 20110104703 | NUCLEIC ACID ANALYZER, AUTOMATIC ANALYZER, AND ANALYSIS METHOD - This invention relates to a nucleic acid analyzer comprising: reaction containers capable of containing nucleic-acid-containing samples and reagents; an incubation mechanism capable of controlling temperatures of reaction containers set at different levels; an analysis mechanism for analyzing the samples contained in the reaction containers; and a transport mechanism for transporting a reaction container. In accordance with the assay technique to be performed on a nucleic-acid-containing sample, the transport mechanism transports a reaction container to a given incubation mechanism in a given order. The reaction container subjected to the process of sample preparation is transported to the analysis mechanism at a given time and the sample is analyzed. | 05-05-2011 |
| 20110104702 | Methods for Predicting Tumor Response to Chemotherapy and Selection of Tumor Treatment - Methods of selecting a treatment for further treatment of a tumor that has been exposed to chemotherapy and methods of predicting response of a tumor to chemotherapy are disclosed. Some of the methods involve performing gene expression analysis on a sample obtained from a patient having a tumor that has been exposed to chemotherapy so as to obtain a chemotherapy gene expression data set and analysing the chemotherapy gene expression data set to predict response of the tumor to the chemotherapy to which the tumor has been exposed. | 05-05-2011 |
| 20110104701 | PROTEIN DISULFIDE ISOMERASE ASSAY METHOD FOR THE IN VITRO DIAGNOSIS OF COLORECTAL CANCER - A method for the in vitro diagnosis of colorectal cancer by determining the presence of the protein disulfide isomerase tumor marker in a biological sample taken from a patient suspected of having colorectal cancer using at least one anti-PDI monoclonal antibody directed against a PDI epitope chosen from the epitopes of sequence SEQ ID NO: 1, SEQ ID NO: 2 with an aromatic amino acid having a three-dimensional structure similar to that of PDI, and SEQ ID NO: 3. | 05-05-2011 |
| 20110104700 | MOLECULAR SIGNATURE FOR FIBROSIS AND ATROPHY - Materials and Methods involved in assessing tissue fibrosis and atrophy in mammals. For example, materials and methods involved in detecting organ (e.g., kidney) fibrosis/atrophy due to organ rejection are provided, as are materials and methods for determining the extent of fibrosis/atrophy in mammals such as humans, for example. | 05-05-2011 |
| 20110104699 | Method for Detection of Paecilomyces Variotii - A method of detecting | 05-05-2011 |
| 20110104698 | MARKERS FOR DETERMINING DNA DAMAGE AND TELOMERE DYSFUNCTION FOR THE DETERMINATION OF THE BIOLOGICAL AGE, REGENERATIVE CAPACITY, CANCER RISK, THE RISK OF DEVELOPING AGE-RELATED DISEASES AND THE PROGNOSIS OF CHRONIC DISEASES IN HUMANS AND ANIMALS - Process for determining the presence and extent of DNA damage and telomere dysfunction in humans or animals, comprising the following steps: | 05-05-2011 |
| 20110104697 | METHODS AND COMPOSITIONS FOR DIAGNOSING AND MONITORING TRANSPLANT REJECTION - Methods of diagnosing or monitoring transplant rejection, particularly cardiac transplant rejection, in a patient by detecting the expression level of one or more genes in a patient, are described. Diagnostic oligonucleotides for diagnosing or monitoring transplant rejection, particularly cardiac transplant rejection and kits or systems containing the same are also described. | 05-05-2011 |
| 20110104696 | KIT FOR DETECTION OF BACTERIAL SPECIES BY MEANS OF DNA ANALYSIS - The present invention relates to the detection and identification of different bacterial species, all of which cause zoonosis, based on DNA analysis. More specifically, the invention provides the primers, probes, genes and genic regions required to apply a method for the simultaneous detection of bacteria and bacterial groups belonging to the genera | 05-05-2011 |
| 20110104695 | METHODS OF PREDICTING THERAPEUTIC EFFICACY OF CANCER THERAPY - The present invention relates to novel methods and kits for predicting, prognosing, and/or monitoring therapeutic efficacy of cancer therapy on a subject having malignant tumor or cell proliferative disorder. | 05-05-2011 |
| 20110104694 | COMPOSITIONS AND METHODS FOR DETECTING CANCER - The present invention provides methods and compositions involving detecting the presence of and/or assessing the risk of cancer in a subject. These methods include methods of detecting and diagnosing cancer in an individual; methods of identifying individuals at risk of developing a cancer; and methods of staging a cancer. The methods generally involve detecting a palladin gene nucleotide sequence alteration that has been found to be associated with cancer and/or detecting a level of a palladin mRNA and/or protein in a biological sample. The present invention further provides nucleic acid probes, nucleic acid primers, and antibodies, as well as kits comprising one or more of the same, for use in a subject method. | 05-05-2011 |
| 20110104693 | QUANTITATIVE NUCLEASE PROTECTION SEQUENCING (qNPS) - The present invention provides a new approach, quantitative Nuclease Protection Sequencing (qNPS™), for addressing several challenges that face sequencing and which provides improvements for research and diagnostic applications. The method uses a lysis-only nuclease protection assay to generate nucleic acid, e.g., DNA probes for sequencing, which can be coupled to gene-specific tags to permit the identification of the gene without necessitating the sequencing of the nuclease protection probe itself and/or can be coupled to experiment-specific tags whereby samples from different patients can be combined into a single run. The disclosed qNPS makes sequencing fixed or insoluble samples possible and affordable as a research and discovery tool and as a diagnostic test. | 05-05-2011 |
| 20110104692 | Oligonucleotide Primers - Disclosed herein is a method of amplifying a target nucleotide sequence in 16S rRNA or in 16S rDNA that includes (a) contacting a sample comprising a 16S rDNA and/or the reverse transcription product of a 16S rRNA with an oligonucleotide primer comprising the nucleotide sequence of TCC TAC GGG AGG CAG CAG (SEQ ID NO 1) or a nucleotide sequence capable of hybridising under high stringency conditions to the sequence complementary to SEQ ID NO 1 and an oligonucleotide primer comprising the nucleotide sequence of CGG TTA CCT TGT TAC GAC TT (SEQ ID NO 2) or a nucleotide sequence capable of hybridising under high stringency conditions to the nucleotide sequence complementary to SEQ ID NO 2; and (b) performing a primer-dependent nucleic acid amplification reaction to amplify the target nucleotide sequence in the 16S rRNA or the 16S rDNA. | 05-05-2011 |
| 20110104691 | ANDROGENETIC ALOPECIA - The present invention relates to methods for testing for a predisposition or presence of androgenetic alopecia comprising testing a sample obtained from a prospective patient or from a person suspected of carrying a predisposition for androgenetic alopecia. The invention also relates to a genetic marker for androgenetic alopecia characterised in that the genetic marker is located in a chromosomal region of human chromosome 20p11 and wherein the genetic marker is selected from the group consisting of a single nucleotide polymorphism (SNP), variable number of tandem repeat (VNTR), microsatellites or short tandem repeats (STR). Further, the invention relates to a diagnostic composition for the detection of androgenetic alopecia or a predisposition therefore as well as to a kit. | 05-05-2011 |
| 20110104689 | Single nucleotide polymorphisms and the identification of lactose intolerance - The present invention relates generally to methods, kits, genotyping and/or nucleic acid molecules associated with the identification of a predisposition for lactase persistence, lactase non-persistence, lactose tolerance and/or lactose intolerance. The methods of the present invention comprise in general determining the presence or absence of at least one variant allele having one or more single nucleotide polymorphisms within a gene associated with the expression of lactase-phlorizin hydrolase. The single nucleotide polymorphism is selected from the group consisting essentially of C-14010, G-13915 and G-13907, as measured from the start of the LCT gene. | 05-05-2011 |
| 20110104688 | MICROFLUIDIC FLOW CELL - A microfluidic flow cell having a body with a fluid transport channel disposed therein, the fluid transport channel having a proximal end and a distal end defining a fluid flow path, a fluid inlet port disposed at the proximal end of the fluid transport channel at a central portion of the body and an outlet port disposed at the distal end of the fluid transport channel at an outer portion of the body, and a plurality sample wells disposed in the fluid transport channel substantially perpendicular to the fluid flow path in the fluid transport channel. The microfluidic flow cell may have hundreds or thousands of individual, sub-microliter sample wells. The microfluidic flow cell can be filled by applying a flowable liquid to the inlet port and spinning the flow cell to cause fluid to flow into fluid transport channel. The microfluidic flow cells described herein can be used in a variety of applications where small sample size and/or a large number of replicates are desirable. | 05-05-2011 |
| 20110104687 | Methods and Kits for Detecting Congenital Stationary Night Blindness and Selecting Different Coat Patterns - The present application describes biomarkers and methods useful for screening for, diagnosing or detecting congenital stationary night blindness in a subject. The present application also provides methods for selecting or detecting horse coat patterns. | 05-05-2011 |
| 20110104686 | RAPID DETECTION OF MYCOPLASMA CONTAMINATION IN CELL CULTURE SAMPLES - The present invention provides for methods of detecting | 05-05-2011 |
| 20110104685 | METHOD FOR TESTING MICROORGANISM OR THE LIKE AND TESTING APPARATUS THEREFOR - A means for accurately counting desired cells or microorganisms (viable bacteria) in a sample fluid in which contaminants are included is provided. One or plural types of membrane-permeable fluorochromes whose fluorescence amount is amplified by binding to a nucleic acid and glycerin are added to a sample fluid containing cells or microorganisms to be counted and allowed to stand for a certain time. Glycerin is added before or after or simultaneously with the mixing of the sample fluid and the fluorochrome(s). The cells or microorganisms to be counted are counted by staining the cells or microorganisms to be counted, followed by irradiating with light having a specific wavelength to detect the fluorescence emitted from the cells or microorganisms. | 05-05-2011 |
| 20110104684 | Methods and Compositions for Identifying Sulfur and Iron Modifying Bacteria - The invention relates to methods and compositions for identifying specific bacterial species, which are sulfur and iron oxidizers and/or reducers, from wall board (e.g., dry wall) and/or a patient tissue or body fluid. The method comprises the steps of extracting and recovering DNA of the bacterial species from the wall board and/or the patient tissue or body fluid, amplifying the DNA, hybridizing a probe to the DNA to specifically identify the bacterial species, and specifically identifying the bacterial species. Kits and nucleic acids for use in the methods are also provided. Methods for eliminating the sulfur and iron oxidizing and/or reducing bacteria from wall board using a zeolite are also provided. | 05-05-2011 |
| 20110104683 | PLASMINOGEN ACTIVATOR INHIBITOR-1 (PAI-1) HAPLOTYPES USEFUL AS INDICATORS OF PATIENT OUTCOME - The invention provides methods and kits for obtaining a prognosis for a patient having or at risk of developing an inflammatory condition. The method generally comprises determining a Plasminogen Activator Inhibitor-1 (PAI-1) genotype of a patient for one or more polymorphisms in the PAI-1 gene of the patient, comparing the determined genotype with known genotypes for the polymorphism that correspond with the ability of the patient to recover from the inflammatory condition and identifying patients based on their prognosis. PAI-1 genotype screening may be useful in identifying patients who would benefit from increased monitoring by healthcare professionals, and/or possible therapeutic intervention, if the patient were to develop inflammation due to systemic inflammation response syndrome (SIRS), bacterial infection, bacteraemia, sepsis, septic shock, organ dysfunction, and trauma. The invention also provides for methods of identifying other polymorphisms that correspond with the ability of the patient to recover from the inflammatory condition. | 05-05-2011 |
| 20110104681 | NOVEL TRANSGENE ASSAY USING STABLE AGROBACTERIUM RHIZOGENES TRANSFORMATION - A novel method is described for the screening of gene elements of interest using hairy roots of chimeric plants transformed with | 05-05-2011 |
| 20110104680 | RECURRENT GENE FUSIONS IN LUNG CANCER - The present invention relates to compositions and methods for cancer diagnosis, research and therapy, including but not limited to, cancer markers. In particular, the present invention relates to recurrent gene fusions as diagnostic markers and clinical targets for lung cancer. | 05-05-2011 |
| 20110104679 | Methods and Compositions for the Diagnosis and Treatment of Angiogenic Disorders - The invention provides methods and compositions for determining whether an individual is at risk of developing, or has, one or more angiogenic disorders. The methods detect the presence and/or amount of one or more genes or gene products in a sample, including a RORA, CRIM1, CXCR4, C5orf26, IGHG3, NALP2, PLA2G4A, IGLJ3, SHQ1, UCHL1, TANC1, PKP2, DNAJC6, C6orf105, NALP1, RGS13, CXCL13, RPS6KA2, MMP7, IL1A, ABCA1, VCAN, KIAA0888, ENPP2, and FAM38B gene or gene product. In addition, the invention provides methods for using one or more of these genes or gene products as a target for preventing or delaying the onset of one or more angiogenic disorders or treating a patient with one or more such disorders. The angiogenic disorder can be, for example, an ocular angiogenic disorder, for example, a disorder associated with choroidal neovascularization, for example, age-related macular degeneration. | 05-05-2011 |
| 20110104678 | POLYMERASE INHIBITOR AND METHOD OF USING SAME - The present invention provides nucleic acid based polymerase inhibitors and methods for reducing non-specific polymerase extension and amplification in nucleic acid amplification reactions. The polymerase inhibitors provide a double stranded nucleic acid portion that is recognized by a polymerase enzyme as a template for extension but is incapable of being extended by the polymerase enzyme. The polymerase binds to the polymerase inhibitor which sequesters the enzyme until the temperature achieves a level that denatures the double stranded portion of the inhibitor after which the polymerase is released and can then catalyze nucleic acid extension. | 05-05-2011 |
| 20110104677 | SELECTIVE RESTRICTION FRAGMENT AMPLIFICATION: FINGERPRINTING - The invention relates to a process for the controlled amplification of at least one part of a starting DNA containing a plurality of restriction sites for a determined specific restriction endonuclease, and of which at least part of its nucleic acid is unknown. This technology can be applied to human, animal or plant DNA fingerprinting, to identify restriction fragment length polymorphisms. Also encompassed by the inventive technology are kits for the application of the process. | 05-05-2011 |
| 20110104676 | HYBRIDIZATION CHAIN REACTION AMPLIFICATION FOR IN SITU IMAGING - The present invention relates to the use of fluorescently labeled nucleic acid probes to identify and image analytes in a biological sample. In the preferred embodiments, a probe is provided that comprises a target region able to specifically bind an analyte of interest and an initiator region that is able to initiate polymerization of nucleic acid monomers. After contacting a sample with the probe, labeled monomers are provided that form a tethered polymer. Triggered probes and self-quenching monomers can be used to provide active background suppression. | 05-05-2011 |
| 20110104675 | Methods and Compositions for Diagnosing Carcinomas - The invention is directed to compositions and methods for the detection of a malignant condition, and relates to the discovery of soluble forms of mesothelin polypeptides, including mesothelin related antigen (MRA). In particular the invention provides a nucleic acid sequence encoding MRA and an MRA variant. The invention also provides a method of screening for the presence of a malignant condition in a subject by detecting reactivity of an antibody specific for a mesothelin polypeptide with a molecule naturally occurring in soluble form in a sample from such a subject, and by hybridization screening using an MRA nucleotide sequence, as well as other related advantages. | 05-05-2011 |
| 20110104674 | SNP DETECTION AND OTHER METHODS FOR CHARACTERIZING AND TREATING BIPOLAR DISORDER AND OTHER AILMENTS - The present application relates to the use of SNPs and differential exon expression to characterize, diagnose or treat bipolar disorder and other mental illnesses, such as major depressive disorder and schizophrenia. | 05-05-2011 |
| 20110104673 | NUCLEIC ACID SEQUENCES AND METHODS FOR IDENTIFYING COMPOUNDS THAT AFFECT RNA/RNA BINDING PROTEIN INTERACTIONS AND mRNA FUNCTIONALITY - Disclosed herein are nucleic acid sequences and their optimized subfragments which are located in the mRNA untranslated regions of therapeutically-relevant genes. These sequences specifically bind RNA binding proteins (RBPs) and/or regulate the mRNA functionality. Also disclosed are methods of optimizing a subfragment of a parent nucleic acid sequence such that the RBP binding activity or mRNA functionality of the parent nucleic acid sequence is preserved in the optimized subfragment. | 05-05-2011 |
| 20110104672 | Method For Detection And/Or Analysis Of Yeast And Mold In Filterable Liquids - This invention is an improved process for preparing a food or beverage sample containing yeast or mold cells for analytical testing. The food sample is prepared into the form of a filterable liquid, and then filtered using a glass microfiber filter. The filter containing the fungal cell retentate is then placed into a disruption vessel and bead beaten until the glass microfiber filter is completely disrupted into glass fibers in suspension. An aliquot can then be tested directly using melting curve analysis of PCR amplification product derived from the nucleic acids of the sample to detect the presence of the fungal cells from the sample. | 05-05-2011 |
| 20110104671 | METHODS AND COMPOSITIONS FOR ASSESSING RESPONSIVENESS OF B-CELL LYMPHOMA TO TREATMENT WITH ANTI-CD40 ANTIBODIES - The invention provides methods and kits useful for predicting or assessing responsiveness of B-cell lymphoma to treatment with anti-CD40 antibodies. | 05-05-2011 |
| 20110104670 | METHOD, DEVICE AND MOLECULAR BIOLOGY KIT FOR EXTRACTING AMPLIFIED GENETIC MATERIAL - A method for collecting cellular material from particular cells present in a liquid, that includes: a step ( | 05-05-2011 |
| 20110104669 | METHOD TO PREDICT IRIS COLOR - The invention comprises a method to predict iris color of a human from a nucleic acid/protein sample comprising assaying for one or more polymorphisms in the region 5′ proximal of the OCA2 gene up to and including the HERC2 gene on chromosome 15 between basepairs 26018062 and 26240890 according to NCBI build 36 or Ensemble | 05-05-2011 |
| 20110104667 | METHODS FOR IDENTIFYING NUCLEIC ACID LIGANDS - The present invention generally relates to methods for identifying nucleic acid ligands of a target molecule. In certain embodiments, the invention provides methods for identifying a nucleic acid ligand of a target molecule from a candidate mixture of nucleic acids, including contacting at least one target molecule with a candidate mixture of nucleic acids, in which the nucleic acids have different affinities for the target molecule, and separating in a single step nucleic acids that bind the target molecule with greatest affinity from nucleic acids that bind the target molecule with a lesser affinity and nucleic acids that do not bind the target molecule, thereby identifying the nucleic acid ligand of the target molecule. | 05-05-2011 |
| 20110104666 | INSULIN RESISTANCE MARKER - It is provided an insulin resistance marker, a method of evaluating insulin resistance, a method of screening a substance that improves insulin resistance, and a pharmaceutical composition for improving insulin resistance. An insulin resistance marker including a polypeptide comprising at least any 15 continuous amino acids in the specific amino acid sequence (sequence of a proepithelin protein). An insulin resistance marker including a polynucleotide selected from the group consisting of a polynucleotide comprising at least any 45 continuous bases in the base sequence encoding the above specific amino acid sequence, and a polynucleotide that is complementary to the polynucleotide. | 05-05-2011 |
| 20110104664 | BIOMARKERS AND METHODS FOR DETERMINING SENSITIVITY TO MICORTUBULE-STABILIZING AGENTS - Biomarkers that are useful for identifying a mammal that will respond therapeutically or is responding therapeutically to a method of treating cancer that comprises administering a microtubule-stabilizing agent. In one aspect, the cancer is breast cancer, and the microtubule-stabilizing agent is an epothilone or analog or derivative thereof, or ixabepilone. | 05-05-2011 |
| 20110104663 | Method for the Quantification of Methylated DNA - The method according to the invention concerns in particular a method for the quantification of methylated DNA. For this purpose, the DNA to be examined is first transformed such that unmethylated cytosine is converted to uracil while 5-methylcytosine remains unchanged. Subsequently, the transformed DNA is amplified in the presence of a pair of real-time probes. For this, a probe is constructed, which is specific for the methylated or for the unmethylated state of the DNA, and a probe, which binds methylation-unspecifically to the amplificate. The ratio of the signal intensities of the probes or the CT values allows for the calculation of the degree of methylation of the examined DNA. The method according to the invention is suited particularly for the diagnosis and prognosis of cancer and other diseases associated with a change in the methylation status, as well as, prediction of adverse for side-effects of pharmaceuticals. | 05-05-2011 |
| 20100003692 | GAMMA SECRETASE NOTCH BIOMARKERS - The present invention relates to the biomarker TFF-3 that measures γ-secretase mediated Notch processing. TFF-3 has utility in predicting and/or determining in vivo Notch-related toxicity associated with inhibition of Notch processing mediated by γ-secretase. The reagents and methods of the invention can be utilized before, after, or concurrently with, pre-clinical, clinical, and/or post-clinical testing. The reagents and methods of the invention can be used to identify and maintain preferred doses of test compounds and thereby prevent medical complications, such as gastrointestinal cellular damage. | 01-07-2010 |
| 20110111418 | USE OF IRON-RELATED PATHWAYS AND GENES FOR TREATMENT AND DIAGNOSIS OF PARKINSON'S DISEASE - A collection of genetic variants having susceptability to, or protection from, Parkinson's Disease is provided. The variants are useful in method of diagnosing, prognosing, and treating Parkinson's Disease and related conditions | 05-12-2011 |
| 20110111421 | Gene Expression Markers for Colorectal Cancer Prognosis - A method of predicting clinical outcome in a subject diagnosed with colorectal cancer comprising determining evidence of the expression of one or more predictive RNA transcripts or their expression products in a biological sample of cancer cells obtained from the subject. | 05-12-2011 |
| 20110111420 | Corn Event MIR604 - A novel transgenic corn event designated MIR604, is disclosed. The invention relates to DNA sequences of the recombinant constructs inserted into the corn genome and of genomic sequences flanking the insertion site that resulted in the MIR604 event. The invention further relates to assays for detecting the presence of the DNA sequences of MIR604, to corn plants and corn seeds comprising the genotype of MIR604 and to methods for producing a corn plant by crossing a corn plant comprising the MIR604 genotype with itself or another corn variety | 05-12-2011 |
| 20110111417 | METHODS AND KITS FOR MONITORING THE EFFECTS OF IMMUNOMODULATORS ON ADAPTIVE IMMUNITY - The invention provides for noninvasive assessment of immunocompetence in various situations, for example, when modified by disease or by immunomodulators. The assessment determines the functional activity of germinal centers via measuring levels of immunogolublin isotype class switching. The invention provides for assessment of therapeutic efficacy of immunomodulators and for selection of treatment regimens. The invention also provides for determining the risk or susceptibility to adverse events upon receipt of therapy. Compositions, kits and methods are described herein. | 05-12-2011 |
| 20110111416 | Peptide Nucleic Acid Probes, Kits and Methods for Expression Profiling of Micrornas - Disclosed are peptide nucleic acid (PNA) probes, a kit and a method for expression profiling of microRNAs (miRNAs), which play an important role in regulation of expression of genes encoding proteins. | 05-12-2011 |
| 20110111410 | STABILIZATION OF RNA IN INTACT CELLS WITHIN A BLOOD SAMPLE - A method for preserving and processing nucleic acids located within a blood sample is disclosed, wherein a blood sample containing nucleic acids is treated to reduce both blood cell lysis and nuclease activity within the blood sample. The treatment of the sample aids in increasing the integrity and amount of cellular nucleic acids that can be identified and tested while avoiding contamination of the isolated nucleic acids with cell-free nucleic acids. | 05-12-2011 |
| 20110111395 | CD4+CELLS WITH CYTOLYTIC PROPERTIES - The present invention relates to CD4+ T cells, more specifically cytolytic or cytotoxic CD4+ T-cells and methods of obtaining and identifying them. | 05-12-2011 |
| 20110111394 | CTGF AS A BIOMARKER, THERAPEUTIC AND DIAGNOSTIC TARGET - The invention provides CTGF which is associated with the cardiovascular diseases and hematological diseases. The invention also provides assays for the identification of compounds useful in the treatment or prevention of cardiovascular diseases and hematological diseases. The invention also features compounds which bind to and/or activate or inhibit the activity of CTGF as well as pharmaceutical compositions comprising such compounds. The invention also provides CTGF as a biomarker for diseases as cardiovascular diseases and hematological diseases | 05-12-2011 |
| 20110117545 | GENETIC VARIANTS ON CHR2 AND CHR16 AS MARKERS FOR USE IN BREAST CANCER RISK ASSESSMENT, DIAGNOSIS, PROGNOSIS AND TREATMENT - The invention pertains to certain genetic variants on Chr2q14, Chr2q35 and Chr16q12 as susceptibility variants of breast cancer. Methods of risk assessment and diagnosis of increased and/or decreased susceptibility to breast cancer, using such variants are described. The invention further relates to kits for diagnosing a susceptibility to breast cancer. | 05-19-2011 |
| 20090305287 | Method and System for Multiplex Genetic Analysis - A method for identifying nucleotides in a nucleic acid sequence is disclosed. A plurality of polymerization complexes are provided within a plurality of confined reaction environments. Each complex comprises a polymerase enzyme and a template nucleic acid. The plurality of complexes are contacted with a plurality of types of nucleotide analogs labeled with distinguishable fluorescent labels under conditions suitable for polymerization. Fluorescent signals associated with incorporation of a nucleotide analog are transmitted to a detector, wherein the location of the fluorescent signal on the detector is indicative of the individual confined reaction environment and the type of nucleotide incorporated. The nucleotide in a nucleic acid sequence is identified based upon the type of nucleotide incorporated and the confined reaction environment. | 12-10-2009 |
| 20090305269 | PCR SCREENING METHOD - A tooling system ( | 12-10-2009 |
| 20100216144 | ANALYSIS OF DNA SAMPLES - The invention provides an improved method for obtaining information about DNA analysis of samples of uncertain origin by establishing the likelihood that they arose in certain manners compared with other possible manners. In this way all of the analysis information is taken into account and likelihood ratios are provided to express the results. The invention is particularly useful in analysing small DNA samples or DNA samples where the contribution from one or more sources is small. | 08-26-2010 |
| 20090305261 | PROBE, PROBE SET, PROBE-IMMOBILIZED CARRIER, AND GENETIC TESTING METHOD - A nucleic acid probe for classification of pathogenic bacterial species is capable of collectively detecting bacterial strains of the same species and differentially detecting them from other bacterial species. Any one of the base sequences of SEQ ID NOS. 65 to 67 or a combination of at least two of them is used for detecting the gene of an infectious disease pathogenic bacterium. | 12-10-2009 |
| 20090305252 | Methods and species-specific primers for detection and quantification of Streptococcus mutans and Streptococcus sanguinis in mixed bacterial samples - Dental caries is a polymicrobial infectious disease. Of the hundreds of bacteria present in the biofilms coating teeth, the | 12-10-2009 |
| 20090305243 | Oligonucleotides, Use Thereof, Detecting Method and Kit for Diagnosing the Presence of H5 and N1 Genes of the Influenza a Virus - The present invention relates to a double pair of oligonucleotides for amplifying two target sequences located, respectively, in the H5 and N1 genes of the genome of the Influenza A virus, said oligonucleotides being of a length ranging between 10 and 50 nucleotides and comprising at least one fragment of 10 consecutive nucleotides derived from the following sequences: | 12-10-2009 |
| 20090305237 | QUANTIFICATION OF NUCLEIC ACIDS AND PROTEINS USING OLIGONUCLEOTIDE MASS TAGS - The invention provides a method for detecting and quantifying the amount of target molecules, such as nucleic acids or proteins in a sample. The target molecules are first recognized and bounded by target-specific probes, generally nucleic acids or proteins that bind specifically to the targets, each of which is labeled with a short single-stranded nucleic acid probe, either DNA or RNA, with distinct molecular weight. This label is called an oligonucleotide mass tag. One or several standard oligonucleotide sequences can be designed with similar sequence but distinct molecular weight to those oligonucleotide mass tags. Then the oligonucleotide mass tags associated with bounded probes and the standard sequences are co-amplified using a pair of common primers. The presence and/or amount of each oligonucleotide mass tag, which corresponds to the amount of corresponding target molecule, is determined by a primer extension reaction and quantification of the primer extension product. | 12-10-2009 |
| 20100216137 | Gene Expression Profiling for Identification, Monitoring and Treatment of Ovarian Cancer - A method is provided in various embodiments for determining a profile data set for a subject with ovarian cancer or conditions related to ovarian cancer based on a sample from the subject, wherein the sample provides a source of RNAs. The method includes using amplification for measuring the amount of RNA corresponding to at least 1 constituent from Tables 1-5. The profile data set comprises the measure of each constituent, and amplification is performed under measurement conditions that are substantially repeatable. | 08-26-2010 |
| 20090253136 | GENETIC RISK ASSESSMENT TECHNOLOGY FOR EPITHELIAL CANCER INVOLVING GENE-ENVIRONMENT INTERACTION BETWEEN ERCC5 AND TOBACCO USE - Methods and compositions for assessing ERCC5 gene expression in view of certain environmental exposures and determining the risk of an individual for developing one or more epithelial cancers are provided. | 10-08-2009 |
| 20090258346 | Method of selecting sunflower genotypes with high oleic acid content in seed oil - The present invention relates to the selection of sunflower genotypes with high oleic acid content in seed oil. The invention concerns more particularly molecular markers useful for a rapid and easy selection of sunflower lines and then sunflower hybrids capable of producing seeds having high oleic acid content. | 10-15-2009 |
| 20100317014 | COMPOSITIONS AND METHODS FOR THE ISOLATION OF NUCLEIC ACID - The present invention provides compositions and methods for the isolation of nucleic acids from a sample or subject. In particular, the present invention provides isolation, purification, and analysis of total DNA and RNA from a subject or sample. The compositions and methods find particular use in the isolation of nucleic acids associated with arthropods (e.g., ticks), including nucleic acid from pathogens carried by arthropods. | 12-16-2010 |
| 20090246793 | CUDR AS BIOMARKER FOR CANCER PROGRESSION AND THERAPEUTIC RESPONSE - Disclosed is a novel human gene designated CUDR. Provides is also a CUDR gene as a biomarker in the diagnosis of human cancers and a cancer therapy. | 10-01-2009 |
| 20090317821 | METHODS AND COMPOSITIONS FOR IDENTIFYING INDIVIDUALS AT REDUCED RISK OF SEPSIS - The present invention provides a method of identifying a subject having a reduced risk of developing sepsis, comprising detecting at least one APOE3 allele in nucleic acid from the subject. | 12-24-2009 |
| 20090253141 | METHODS AND APPARATUSES FOR ANALYZING POLYNUCLEOTIDE SEQUENCES - Methods for high speed, high throughput analysis of polynucleotide sequences, and apparatuses with which to carry out the methods are provided in the invention. | 10-08-2009 |
| 20090258349 | METHOD FOR DETECTING AND QUANTIFYING PERCHLORATE-REDUCING BACTERIA - The present invention provides methods, compositions, and kits for detecting and quantitating perchlorate-reducing bacteria in samples using reagents that hybridize to and allow amplification of the pcrA gene. The invention includes a quantitative real-time PCR assay for amplification of the pcrA gene which may be used to detect and quantitate perchlorate-reducing bacteria in samples. | 10-15-2009 |
| 20090258351 | Methods and Reagents for Combined PCR Amplification - An oligonucleotide probe is disclosed, the probe including an oligonucleotide, a fluorescer molecule attached to a first end of the oligonucleotide and a quencher molecule attached to the opposite end of the oligonucleotide. The probe is rendered impervious to digestion by the 5′→3′ exonuclease activity of a polymerase and the 5′→3′ extension of by a polymerase. The invention also includes methods for performing combined PCR amplification and hybridization probing, one such method including the steps of contacting a target nucleic acid sequence with PCR reagents and an oligonucleotide probe as described above, and subjecting these reagents to thermal cycling. One preferred refinement of the above method further includes the addition of a strand displacer to facilitate amplification. Additional similar combined PCR hybridization methods are disclosed, such methods not requiring probes having their 5′ ends protected, wherein (i) the polymerase lacks 5′→3′ exonuclease activity, (ii) a 5′→3′ exonuclease inhibitor is included, and (iii) an exonuclease deactivation step is performed. | 10-15-2009 |
| 20090258347 | METHOD FOR DIAGNOSING AND MONITORING CELLULAR RESERVOIRS OF DISEASE - The invention provides an assay for diagnosing and/or monitoring a viral infection or disease in a patient, the assay including the steps of mixing a sample of leucocytes with a fluorescent cell membrane-permeable dye which stains RNA or both DNA and RNA within the leucocytes; identifying from all the leucocytes at least two of the three major sub-populations of leucoytes selected from the group consisting of monocytes, granulocytes and lymphocytes; determining the fluorescence intensity for each of the identified sub-populations; and comparing the fluorescence intensity of at least two cell sub-populations to each other to obtain at least one of the following ratios: monocytes:granulocytes, monocytes:lymphocytes, and granulocytes lymphocytes. The viral infection may be HIV and the disease may be AIDS. The invention also provides a method of monitoring the cellular viral, parasitic or bacterial reservoir of a patient with a viral or bacterial infection by the steps described above. A, kit for performing the assay or method is also provided. | 10-15-2009 |
| 20100261193 | Valve Structure for Consistent Valve Operation of a Miniaturized Fluid Delivery and Analysis System - A valve structure of a fluid delivery and analysis system having an upper substrate, a lower substrate and an intermediate layer with at least one opening and at least one open cavity having a first touch point between the upper substrate and the intermediate layer and a second touch point between the lower substrate and the intermediate layer where the first touch point and the second touch point are offset to create a torque so that when intermediate layer is compressed between the upper substrate and the lower substrate that the torque deforms the intermediate rubber layer in the direction of the opening for better sealing. | 10-14-2010 |
| 20100261192 | CLONING OF CYTOCHROME P450 GENES FROM NICOTIANA - The present invention relates to p450 enzymes and nucleic acid sequences encoding p450 enzymes in | 10-14-2010 |
| 20100261191 | STABLE CELL LINES EXPRESSING HERG - A stable eukaryotic cell line that expresses hERG and exhibits a stable current under electrophysiological test conditions is provided. | 10-14-2010 |
| 20100261188 | NON-INVASIVE PRENATAL GENETIC SCREEN - The present invention provides methods and kits useful for genetic testing or screening of fetuses using nucleic acid samples isolated from cervical mucus samples of fetus hosts. | 10-14-2010 |
| 20100261179 | SAMPLE PREPARATION DEVICES AND ANALYZERS - The application provides sample preparation devices and analyses. The devices and analyzes allow for the rapid preparation and analysis of samples using a variety of techniques, including PCR, by even unskilled users. | 10-14-2010 |
| 20100261177 | INCREASING SPECIFICITY IN A scFV SCREEN USING DUAL BAIT REPORTERS - To increase the efficiency of the selection of antibodies of desired specificity, we create multi-bait strain(s) in which one bait is the target and one or more bait(s) are non-target. The non-target bait(s) may use one or more DNA-binding domain(s) that differ(s) from that of the target bait and thereby activate one or more different reporters from that activated by the target bait. Library hits that activate both sets of reporters are presumed to be inadequately specific and can be eliminated from further consideration. Alternatively, a non-target bait may be replaced with a second target bait, and hits selected that activate both sets of reporters. Other combinations of elements can be used. | 10-14-2010 |
| 20100261176 | Methods of Tissue-Based Diagnosis - The current invention provides methods, as well as compositions useful in such methods, involving application of energy to a tissue of interest to generate a liquefied sample comprising tissue constituents so as to provide for rapid tissue sampling, as well as qualitative and/or quantitative detection of analytes that may be part of tissue constituents (e.g., several types of biomolecules, drugs, and microbes). Determination of tissue composition can be used in a variety of applications, including diagnosis or prognosis of local as well as systemic diseases, evaluating bioavailability of therapeutics in different tissues following drug administration, forensic detection of drugs-of-abuse, evaluating changes in the tissue microenvironment following exposure to a harmful agent, and various other applications. | 10-14-2010 |
| 20100261175 | USE OF SHORT OLIGONUCLEOTIDES FOR REAGENT REDUNDANCY EXPERIMENTS IN RNA FUNCTIONAL ANALYSIS - The present invention relates to functional analysis of miRNAs or other short non-coding RNAs involving the use of two or more sequence distinct miRNAs antagonising oligomeric compounds, which enables the reagent redundancy experiments to reduce the risk of reporting false positive effects of miRNA/ncRNA antagonists. | 10-14-2010 |
| 20100261170 | SCREENING METHODS AND SEQUENCES RELATING THERETO - Disclosed are screening methods and sequences related thereto. Disclosed are methods for detecting mutations in the MYH gene of an individual. Also disclosed are methods of genotyping and methods of predicting for an individual the likelihood of developing certain cancers, such as colorectal cancer. | 10-14-2010 |
| 20100261169 | NOVEL NUCLEOTIDE AND AMINO ACID SEQUENCES, AND METHODS OF USE THEREOF FOR DIAGNOSIS - The present invention relates to diagnostic markers comprising novel splice variants of known proteins and polynucleotides encoding same, useful in the qualitative and/or quantitative detection of various diseases and/or pathological conditions in a subject, and to the use of known proteins and polynucleotides encoding same for diagnosis. Particularly, the invention relates to the diagnosis of a disease in a sample of body fluid or secretion obtained from the subject, and to the diagnosis of cancer. | 10-14-2010 |
| 20100261167 | In vivo screen using chemical inducers of dimerization - A method for identifying a molecule that binds a known target in a cell from a pool of candidate molecules, comprising: (a) covalently bonding each molecule in the pool of candidate molecules to a methotrexate moiety to form a screening molecule; (b) introducing the screening molecule into a cell which expresses a first fusion-protein comprising a binding domain capable of binding methotrexate, a second fusion protein comprising the known target, and a reporter gene wherein expression of the reporter gene is conditioned on the proximity of the first fusion protein to the second fusion protein; (c) permitting the screening molecule to bind to the first fusion protein and to the second fusion protein so as to activate the expression of the reporter gene; (d) selecting which cell expresses the reporter gene; and (e) identifying the small molecule that binds the known target. | 10-14-2010 |
| 20100261163 | Method for simultaneous detection of Mycobacterium tuberculosis complex and identification of mutations in mycobacterial DNA resulting in the resistance of microorganisms to rifampicin and isoniazid on biological microarrays, set of primers, biochip, and set of oligonucleotide probes used in the method - The present invention relates to molecular biology, microbiology, and medicine and provides the method for detection of | 10-14-2010 |
| 20100261162 | Methods of assaying for telomerase activity and compositions related to same - The present invention relates generally to the field of diagnostic and prognostic assays such as diagnostic assays for conditions associated with telomerase activity. More particularly, the present invention provides an assay for measuring telomerase activity as an indicator of cancer, an inflammatory disorder and/or a condition involving embryogenesis and/or requiring stem cell proliferation and agents and kits useful for same. Automated and partially automated assays permitting high throughput screening also form part of the present invention. The subject invention further contemplates methods of treatment using agents identified by the subject assay or where treatment protocols are monitored by the assay. | 10-14-2010 |
| 20100261161 | Method for determining the specific growth rate of a distinct cell population within a non-homogeneous system - The present invention provides a method for measuring the specific rate of ribosome synthesis for a distinct cell population, such as a distinct microbial population. For an actively growing (or non-growing) culture, the specific rate of ribosome synthesis is identical to the specific growth rate of the culture. With the method of the invention, researchers will be able to measure the specific growth rate of distinct cell populations in mixed cultures, such as biological reactor systems or environmental samples. In addition, the method of the invention provides the ability to identify members of a distinct cell population that are rapidly growing. | 10-14-2010 |
| 20100261160 | Methods of screening for modulators of cell proliferation and methods of diagnosing cell proliferation states - Described herein are methods that can be used for diagnosis and prognosis of cellular proliferation. Also described herein are methods that can be used to screen candidate bioactive agents for the ability to modulate cellular proliferation. Additionally, methods and molecular targets (genes and their products) for therapeutic intervention in cancers are described. | 10-14-2010 |
| 20100261159 | Apparatus for assay, synthesis and storage, and methods of manufacture, use, and manipulation thereof - The invention features methods of making devices, or “platens”, having a high-density array of through-holes, as well as methods of cleaning and refurbishing the surfaces of the platens. The invention further features methods of making high-density arrays of chemical, biochemical, and biological compounds, having many advantages over conventional, lower-density arrays. The invention includes methods by which many physical, chemical or biological transformations can be implemented in serial or in parallel within each addressable through-hole of the devices. Additionally, the invention includes methods of analyzing the contents of the array, including assaying of physical properties of the samples. | 10-14-2010 |
| 20110045464 | METHODS AND COMPOSITIONS FOR IDENTIFICATION OF PROSTATE CANCER MARKERS - In some embodiments, the invention comprises methods and compositions for the assessment of prostate cancer in humans by determining the level of certain markers indicative of prostate cancer in vivo, including but not limited to SEQ ID NO:1 and SEQ ID NO:5, in tissue, blood, urine, or other biological samples. | 02-24-2011 |
| 20110045488 | METHODS OF DIAGNOSING MYELODYSPLASTIC SYNDROME (MDS) OR LEUKEMIA USING NUCLEIC ACIDS OR FRAGMENTS ENCODING FLT3 KINASE - To provide a nucleic acid encoding a receptor protein kinase, wherein the nucleic acid has tandem duplication in a nucleotide sequence of a juxtamembrane and is useful for diagnosis of leukemia; a polypeptide encoded by the nucleic acid; an antibody capable of specifically binding to a region encoded by the nucleic acid having tandem duplication occurring in a nucleotide sequence of a juxtamembrane; a nucleic acid capable of specifically binding to the nucleic acid having tandem duplication occurring in a nucleotide sequence of a juxtamembrane; a method for detection of the nucleic acid encoding a receptor protein kinase; and a kit therefor. A nucleic acid encoding a receptor protein kinase, wherein the nucleic acid has tandem duplication in a nucleotide sequence of a juxtamembrane; a polypeptide encoded by the nucleic acid; an antibody capable of specifically binding to the portion of the polypeptide; a nucleic acid capable of specifically binding to the nucleic acid; a method for detection of the nucleic acid; and a kit for detection. | 02-24-2011 |
| 20100317004 | PROBES - The present invention relates to probes, methods and apparatus for the detection of the presence or absence of non-contiguous cis-located nucleic acid sequences which are characteristic of alleles including those relating to the human leukocyte antigen (HLA) which is of interest in the field of human transplantation and disease. | 12-16-2010 |
| 20100316999 | Nucleic Acid Sequence Analysis - The present invention relates to a method for determining the sequence of a polynucleotide, the method comprising the steps of: (i) reacting a target polynucleotide with a polymerase enzyme immobilised on a solid support, and the different nucleotides, under conditions sufficient for the polymerase reaction; and (ii) detecting the incorporation of a specific nucleotide complementary to the target polynucleotide, by measuring radiation. | 12-16-2010 |
| 20100015632 | METHOD FOR EXAMINING COLORECTAL CANCER AND COLORECTAL ADENOMA - The present invention provides a method for examining colorectal cancer and colorectal adenoma, which enables to detect colorectal cancer patients and patients at high risk of colorectal cancer at a high probability and is useful for diagnosis of colorectal cancer and colorectal adenoma, and provides the examination reagents thereof. There are significant differences in the distribution of GlcNAc-6-sulfotransferase isozymes, sulfation enzymes of sugar residues, among non-cancer colorectal tissues, colorectal cancer tissues and colorectal adenoma tissues. Furthermore, colorectal cancers and adenomas are detected specifically by assaying a definite range of GlcNAc-6-sulfated sugar residues in tissues from patients or feces samples. MECA-79 antibody (Pharmingen, catalog No. 09961D, Distributor: Becton Dickinson), reacting with GlcNAc-6-sulfated sugar residues, which are produced specifically by the enzyme present in colorectal cancer and colorectal adenoma tissues could be used for the examination of colorectal cancers and colorectal adenomas. | 01-21-2010 |
| 20100015600 | METHOD FOR DIAGNOSING AND TREATING CROHN'S DISEASE - The invention concerns an in vitro method for diagnosing Crohn's disease, or for determining predisposition in a person to develop Crohn's disease, by detecting an overexpression of the CD66c receptor in subjects suffering from said disease or at risk. The invention also concerns preventive or curative treatment of Crohn's disease. | 01-21-2010 |
| 20090275025 | HPV Detection and Quantification by Real-Time Multiplex Application - The present invention relates to amplification primers and detection probes, which are useful for the detection of human papillomaviruses (HPV), and more particularly of HPV, which can be oncogenic for the mucosal epithelia. The amplification and detection systems provided by the present invention are group-targeted systems, namely A5-, A6- A7-, and A9-targeted systems. The amplification and detection systems of the invention allow for an amplification of HPV in multiplex as well as for a real-time detection, whereby at least the thirteen HR HPV can be detected in a single-tube assay. The invention further allows for a reliable quantitation of HPV viral loads in real-time multiplex amplification. | 11-05-2009 |
| 20090275023 | Compositions and methods for detecting borrelia afzelii - Disclosed are oligonucleotides useful in methods for determining whether a sample contains | 11-05-2009 |
| 20100255471 | Single cell gene expression for diagnosis, prognosis and identification of drug targets - Methods are provided for diagnosis and prognosis of disease by analyzing expression of a set of genes obtained from single cell analysis. Classification allows optimization of treatment, and determination of whether on whether to proceed with a specific therapy, and how to optimize dose, choice of treatment, and the like. Single cell analysis also provides for the identification and development of therapies which target mutations and/or pathways in disease-state cells. | 10-07-2010 |
| 20100255466 | Method for the in vitro diagnosis of bronchopulmonary carcinoma by detection of major alternative transcripts of the klk8 gene encoding kallicrein 8 and use thereof for prognosticating survival - The present invention relates to a method for the in vitro diagnosis of bronchopulmonary carcinoma, in particular of non-small cell bronchial carcinoma, characterized in that it comprises the stage of detecting, in a biological sample derived from a patient suspected to be suffering from said bronchopulmonary carcinoma, at least one of the major alternative transcripts of the KLK8 gene encoding kallikrein 8. This method is particularly useful for the survival prognostication of patients suffering from bronchopulmonary carcinoma. | 10-07-2010 |
| 20100184034 | Gene Expression Profiling for Identification, Monitoring and Treatment of Lung Cancer - A method is provided in various embodiments for determining a profile data set for a subject with lung cancer or conditions related to lung cancer based on a sample from the subject, wherein the sample provides a source of RNAs. The method includes using amplification for measuring the amount of RNA corresponding to at least 1 constituent from Tables 1-5. The profile data set comprises the measure of each constituent, and amplification is performed under measurement conditions that arc substantially repeatable. | 07-22-2010 |
| 20100240058 | MicroRNA Antisense PNAs, Compositions Comprising the Same, and Methods for Using and Evaluating the Same - Disclosed are a microRNA antisense PNA capable of inhibiting the activity or function of microRNA, a composition for inhibiting the activity or function of microRNA containing the same, a method for inhibiting the activity or function of microRNA using the same, and a method for evaluating the effectiveness thereof. | 09-23-2010 |
| 20100190165 | Methods of screening compounds for bioactivity in organized tissue - The invention provides a method of screening a compound for bioactivity, comprising contacting a candidate bioactive compound with an organized tissue, and measuring in at least a cell of the organized tissue a biological parameter that is associated with bioactivity, wherein a change in the biological parameter that occurs as a result of the contacting step is indicative of bioactivity of the candidate compound. | 07-29-2010 |
| 20100173310 | MICROCHIP LARGE-VOLUME PCR WITH INTEGRATED REAL-TIME CE DETECTION - A microfluidic device is provided with appropriate integrated structures to conduct large volume PCR and end-point or real-time capillary electrophoresis detection The microfluidic device includes a substrate having an amplification chamber of a volume of nucleic acid, wells disposed on the substrate, flow channels connecting the wells and the chamber in the substrate to allow for solution flow through the chamber, and one or more separation channels provided in the substrate and connected to the chamber for separating and detecting a fraction of the amplified nucleic acid The chamber, the flow channels, and the one or more separation channels are configured such that the hydrodynamic flow resistance of the chambers and the flow channels combined is at least 10Λ3 times smaller than the hydrodynamic flow resistance in the one or more separation channels The microfluidic device can achieve a very high sensitivity in detection while being highly cost effective | 07-08-2010 |
| 20090298082 | BIOMARKER PANELS FOR PREDICTING PROSTATE CANCER OUTCOMES - This document provides methods and materials related to assessing male mammals (e.g., humans) with prostate cancer. For example, methods and materials for predicting (1) which patients, at the time of PSA reoccurrence, will later develop systemic disease, (2) which patients, at the time of retropubic radial prostatectomy, will later develop systemic disease, and (3) which patients, at the time of systemic disease, will later die from prostate cancer are provided. | 12-03-2009 |
| 20100330579 | DETECTION OF PCR PRODUCTS IN GEL ELECTROPHORESIS - Disclosed is a method for analyzing nucleic acids in a sample comprising the following steps: (i) adding a DNA binding dye containing a benzothiazolium or benzoxazolium group to the sample to be analyzed, (ii) carrying out a polymerase chain reaction, (iii) applying the sample to a gel matrix, (iv) separating the nucleic acid molecules according to their size by applying a voltage and (v) excitation with light of a suitable wavelength for the optical visualization of the nucleic acid/DNA binding dye complexes. | 12-30-2010 |
| 20100330580 | METHOD FOR THE IN VITRO DIAGNOSIS OR PROGNOSIS OF TESTICULAR CANCER - A method for in vitro diagnosis or prognosis of testicular cancer in a biological sample from a patient suspected of suffering from testicular cancer, having a step of detecting the presence or absence of methylation of CpG dinucleotides in at least one genomic DNA target sequence of the sample, the target sequence being selected from at least one of the sequences identified in SEQ ID NOS: 1 to 7 or from at least one sequence which exhibits at least 99% identity with one of the sequences identified in SEQ ID NOS: 1 to 7 and the sequences complementary thereto; to the DNA sequences and to the use thereof as a testicular cancer marker. | 12-30-2010 |
| 20100330572 | ORGANIC COMPOUNDS - The present invention relates to a novel selection system for use in a eukaryotic cell culture process and for expression of a recombinant product of interest. The selection system is based on the introduction of an exogenous functional membrane-bound folate receptor gene together with the polynucleotide or gene encoding the product of interest into a eukaryotic cell and can be widely utilized with eukaryotic cells for which cellular viability is dependent upon folic acid uptake. | 12-30-2010 |
| 20100330578 | THERMO-OPTICAL CHARACTERISATION OF NUCLEIC ACID MOLECULES - The present invention pertains to a method and a device for the determination of thermo-optical properties, particularly the size or size distribution, of fluorescently labeled biomolecules or biomolecule complexes, particularly nucleic acids, in a reaction solution. The method comprises the steps of: (i) providing a reaction solution with fluorescently labeled biomolecules or biomolecule complexes; (ii) irradiating a laser light beam into the solution to obtain a spatial temperature distribution in the solution around the irradiated laser light beam; (iii) exciting fluorescently said fluorescently labeled biomolecules and detecting the fluorescence at two or more defined regions representing different mean temperatures in said spatial temperature distribution, wherein said detection of fluorescence is performed at least once at a predetermined time after the start of the laser irradiation; and (iv) determining the thermo-optical properties, particularly the size or size distribution, of the fluorescently labeled biomolecules or biomolecule complexes from the detected fluorescence intensity or fluorescence intensity distribution. | 12-30-2010 |
| 20100330566 | GENETIC POLYMORPHISMS IN THE PROSTATE-SPECIFIC ANTIGEN GENE PROMOTER - The present invention includes methods of identifying a subject at risk for increased cellular PSA production and/or prostate cancer by detecting the presence or absence of a genetic polymorphism in the prostate specific antigen gene. | 12-30-2010 |
| 20100330577 | METHODS FOR IDENTIFICATION OF AN ANTIBODY OR A TARGET - This disclosure relates to methods for identifying an antibody, a target molecule, or an agent by analyzing the immunoglobulin repertoire sequence data in a sample and by determining the most dominant VH and VL chains present in said sample, as well as materials used therewith. | 12-30-2010 |
| 20100330576 | Method, Kits, and Reaction Mixtures For High Resolution Melt Genotyping - Various methods are described that provide for high resolution melt (HRM) genotyping. Some embodiments comprise providing a locus specific primer, and two allele specific primers each comprising at least one single nucleotide polymorphism (SNP) allele-hybridizable sequence, wherein at least one of the allele specific primers also comprises at least one nucleotide alteration. In some embodiments, a nucleic acid is provided comprising a SNP base located within 1-20 bases of its 3′ end. Some embodiments comprise hybridizing the locus specific primer and at least one of the allele specific primers to the nucleic acid, amplifying the hybridized nucleic acid using pyrophosphorolysis activated polymerization (PAP) PCR, and determining the melting temperature (Tm) of the resulting amplicons, for example, using HRM. In some embodiments, reaction mixtures and kits for HRM genotyping are provided. The reaction mixtures and kits can each comprise a locus specific primer, one or more allele specific primers each comprising at least one SNP allele-hybridizable sequence, and a PAP PCR enzyme, wherein at least one of the allele specific primers also comprises a nucleotide alteration, for example, a tail. | 12-30-2010 |
| 20100330565 | REAGENT KIT FOR SAMPLE ANALYSIS AND SAMPLE ANALYSIS METHOD - The present invention provides a reagent kit for analyzing a sample comprising a first reagent containing a cationic surfactant, a nonionic surfactant and an aromatic carboxylic acid and a second reagent containing a fluorescent dye capable of staining nucleic acid, and a method for analyzing a sample using the kit. | 12-30-2010 |
| 20100330575 | MOLECULAR DIAGNOSTICS REAGENTS AND METHODS - The present invention relates to automated devices and methods for the extraction of nucleic acids from cells, the amplification of segments of nucleic acid and the detection of nucleic acids, all in a convenient and portable manner. The invention is particularly suited for use in point-of-care medical diagnostics testing. | 12-30-2010 |
| 20100330574 | CHIMERIC PRIMERS WITH HAIRPIN CONFORMATIONS AND METHODS OF USING SAME - Methods and compositions for nucleic acid amplification, detection, and genotyping techniques are disclosed. In one embodiment, a nucleic acid molecule having a target-specific primer sequence; an anti-tag sequence 5′ of the target-specific primer sequence; a tag sequence 5′ of the anti-tag sequence; and a blocker between the anti-tag sequence and the tag sequence is disclosed. Compositions containing such a nucleic acid molecule and methods of using such a nucleic acid molecule are also disclosed. | 12-30-2010 |
| 20100330564 | NUCLEIC ACID DETECTION METHOD AND NUCLEIC ACID DETECTION KIT - In the present invention, an amplified DNA fragment having a first substance binding site to which a first substance is specifically bindable is prepared, which amplified DNA fragment amplified by a nucleic acid amplification method. The amplified DNA fragment is concentrated by binding the amplified DNA fragment to the first substance. The concentration makes it possible to detect the DNA highly sensitively. Therefore, with the arrangement, it is possible to detect the amplified DNA fragment amplified by the nucleic acid amplification method, easily and highly accurately without requiring any special device. | 12-30-2010 |
| 20100330554 | DIAGNOSTIC KIT FOR SOLID CANCER AND MEDICAMENT FOR SOLID CANCER THERAPY - The present invention provides novel solid cancer antigenic proteins, and diagnostic kits for solid cancer and therapeutic agents for solid cancer based on the antigenic proteins. Specifically, the present invention provides a human solid cancer antigenic polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NOS: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 48, 50, 52, 54, 56, 59, 61, 63, 65, 67, 69, 71, 73, and 75. | 12-30-2010 |
| 20100330563 | MEDICINAL AGENT FOR DISEASE ASSOCIATED WITH EPSTEIN-BARR VIRUS, AND METHOD FOR SCREENING OF THE MEDICINAL AGENT - 1-(2-Fluoro-4-thio-β-D-arabinofuranosyl)-5-methyluracil exhibits an anti-EB virus activity, and is therefore effective as a prophylactic or therapeutic agent for a disease associated with an EB virus. Each of a plasmid capable of expressing EB virus-TK and a plasmid capable of expressing human-TK is introduced into a TK-defect cell, thereby producing two types of cells respectively having the plasmids introduced therein. By using the two types of cells, it is possible to screen a medicinal agent which has cytotoxicity against the cell having the plasmid capable of expressing EB virus-TK introduced therein but has no toxicity against the cell having the plasmid capable of expressing human-TK introduced therein. In this manner, it becomes possible to screen a medicinal agent which specifically exhibits an anti-EB virus activity. | 12-30-2010 |
| 20100330559 | FORENSIC IDENTIFICATION - The invention provides allelic ladder mixtures and individual alleles suitable for use in such mixtures. The allelic ladder mixtures give improved identification and distinguishing capabilities, particularly suitable in forensic investigations. | 12-30-2010 |
| 20100330558 | Gene Expression Profiling for Identification, Monitoring and Treatment of Cervical Cancer - A method is provided in various embodiments for determining a profile data set for a subject with cervical cancer or conditions related to cervical cancer based on a sample from the subject, wherein the sample provides a source of RNAs. The method includes using amplification for measuring the amount of RNA corresponding to at least 1 constituent from Tables 1-5. The profile data set comprises the measure of each constituent, and amplification is performed under measurement conditions that are substantially repeatable. | 12-30-2010 |
| 20100330556 | GENOME ANALYSIS USING A NICKING ENDONUCLEASE - A method of genome analysis is provided. In certain embodiments, the method of comprises: a) contacting a genomic sample comprising a double-stranded DNA with a site-specific nicking endonuclease to provide a nicked double-stranded DNA comprising a plurality of nick sites, in which the nicking endonuclease nicks a site adjacent to a variable nucleotide; b) contacting the nicked double-stranded DNA with a polymerase in the presence of a nucleotide composition comprising a first labeled nucleotide comprising a first label, thereby producing a labeled double-stranded DNA that is not labeled at every nick site; c) stretching out the labeled double-stranded DNA to provide a stretched, labeled double-stranded DNA; and d) imaging the stretched, labeled double-stranded DNA to identify a labeling pattern on the stretched labeled double-stranded DNA. | 12-30-2010 |
| 20100184058 | PERIPHERICAL TISSUE SAMPLE CONTAINING CELLS EXPRESSING THE 5HTR2C AND/OR ADARS AS MARKERS OF THE ALTERATION OF THE MECHANISM OF THE 5HTR2C MRNA EDITING AND ITS APPLICATIONS - The present invention relates to an in vitro method for predicting a pathology related to an alteration of the mechanism of the mRNA editing of ADAR dependent A to I mRNA editing, particularly the serotonin 2C receptor (5HTR2C), in a patient from a peripherical tissue sample containing cells expressing said mRNA, such as the 5HTR2C mRNA, and/or adenosine deaminases acting on RNA (ADARs), such as skin and/or blood tissue sample. The present invention further comprises a method for identifying if an agent is capable of in vivo modifying the editing of the 5HTR2C mRNA in brain tissue or to control the efficiency of a drug intended to prevent or to treat a pathology related to an alteration of the mechanism of the 5HTR2C mRNA editing brain tissue, these methods comprising the implementation of said peripherical tissue markers. In a particular aspect, the present invention relates to such methods wherein the 5HTR2C mRNA editing rate or profile, when it is necessary, is determined by a single strand conformation polymorphism (SSCP) method after amplification by a PCR, preferably by a nested PCR, of the specific mRNA fragment containing the edition sites, making it possible, under given analytical conditions, to obtain the editing rate and/or profile of this edited 5HTR2C mRNA from said peripherical tissue. Finally the invention relates to particular nucleic acid primers implemented in said nested PCR. | 07-22-2010 |
| 20100261158 | Method and System for Multiplex Genetic Analysis - The present disclosure provides apparatus, systems and method for detecting separately and substantially simultaneously light emissions from a plurality of localized light-emitting analytes. A system according to exemplary embodiments of the present disclosure comprises a sample holder having structures formed thereon for spatially separating and constraining a plurality of light-emitting analytes each having a single nucleic acid molecule or a single nucleic acid polymerizing enzyme, a light source configured to illuminate the sample holder, an optical assembly configured to collect and detect separately and substantially simultaneously light emissions associated with the plurality of light emitting analytes. The system may further include a computer system configured to analyze the light emissions to determine the structures or properties of a target nucleic acid molecule associated with each analyte. | 10-14-2010 |
| 20110111404 | Novel genes and markers in type 2 diabetes and obesity - Genes, SNP markers and haplotypes of susceptibility or predisposition to T2D and subdiagnosis of T2D and related medical conditions are disclosed. Methods for diagnosis, prediction of clinical course and efficacy of treatments for T2D, obesity and related phenotypes using polymorphisms in the risk genes are also disclosed. The genes, gene products and agents of the invention are also useful for monitoring the effectiveness of prevention and treatment of T2D and related traits. Kits are also provided for the diagnosis, selecting treatment and assessing prognosis of T2D. Novel methods for prevention and treatment of metabolic diseases such as T2D based on the disclosed T2D genes, polypeptides and related pathways are also disclosed. | 05-12-2011 |
| 20100184035 | METHODS FOR RAPID FORENSIC DNA ANALYSIS - The present invention provides methods and primer pairs for rapid, high-resolution forensic analysis of DNA and STR-typing by using amplification and mass spectrometry, determining the molecular masses and calculating base compositions of amplification products and comparing the molecular masses with the molecular masses of theoretical amplicons indexed in a database. | 07-22-2010 |
| 20100190174 | ADAM12, A NOVEL MARKER FOR ABNORMAL CELL FUNCTION - The present invention provides a method, an assay and a kit for providing an indication of abnormal cell function. It was surprisingly found that the change in the serum ADAM12 concentration in individuals was useful as a prognostic tool to predict the clinical outcome, complications and mortality following an abnormal cell function. | 07-29-2010 |
| 20100190156 | Quality control of agricultural products based on gene expression - The invention relates to the field of quality testing of fresh plant-based and mushroom based products. Methods, carriers and kits for determining the quality stage are provided. | 07-29-2010 |
| 20100297640 | HAND HELD MICRO PCR DEVICE - Instant invention is about a hand held micro PCR device comprising a LTCC micro PCR chip comprising a heater, a reaction chamber to load a sample. It also comprises a heater control to regulate the heater on basis of input received from a temperature sensor. It further has an optical system having an optical fiber to detect a fluorescence signal from the sample, and at least one communication interface to interact with other device(s). | 11-25-2010 |
| 20100216154 | GENETIC POLYMORPHISMS ASSOCIATED WITH LIVER FIBROSIS, METHODS OF DETECTION AND USES THEREOF - The present invention is based on the discovery of genetic polymorphisms that are associated with liver fibrosis and related pathologies. In particular, the present invention relates to nucleic acid molecules containing the polymorphisms, including groups of nucleic acid molecules that may be used as a signature marker set, variant proteins encoded by such nucleic acid molecules, reagents for detecting the polymorphic nucleic acid molecules and proteins, and methods of using the nucleic acid and proteins as well as methods of using reagents for their detection. | 08-26-2010 |
| 20100216135 | POLYNUCLEOTIDES FOR USE AS TAGS AND TAG COMPLEMENTS, MANUFACTURE AND USE THEREOF - A family of minimally cross-hybridizing nucleotide sequences, methods of use, etc. A specific family of 210 24mers is described. | 08-26-2010 |
| 20100216122 | ENZYMATIC NUCLEIC ACID SYNTHESIS: METHODS FOR DIRECT DETECTION OF TAGGED MONOMERS - Nucleotide triphosphate probes containing a molecular and/or atomic tag on a γ and/or β phosphate group and/or a base moiety having a detectable property are disclosed, and kits and method for using the tagged nucleotides in sequencing reactions and various assay. Also, phosphate and polyphosphate molecular fidelity altering agents are disclosed. | 08-26-2010 |
| 20110117552 | METHODS OF USING A NOD2/CARD15 HAPLOTYPE TO DIAGNOSE CROHN'S DISEASE - The present invention provides a method of diagnosing or predicting susceptibility to Crohn's disease in an individual by determining the presence or absence in the individual of a disease-predisposing haplotype containing a JW1 variant allele at the NOD2/CARD15 locus, where the presence of the disease-predisposing haplotype is diagnostic of or predictive of susceptibility to Crohn's disease. | 05-19-2011 |
| 20100227330 | METHODS FOR DIAGNOSING EPISODIC MOVEMENT DISORDERS AND RELATED CONDITIONS - The present invention provides compositions and methods for research, diagnostic, drug screening, and therapeutic applications related to paroxysmal dystonic choreoathetosis and related conditions. In particular, the present invention provides mutations in the myofibrillogenesis regulator 1 (MR-1) gene associated with such conditions. | 09-09-2010 |
| 20100248244 | Characterization of ESM-1 as a Tumor Associated Marker of Colorectal Cancer - Disclosed herein is a colorectal cancer marker for diagnosing colorectal cancer based on ESM-I overexpression in tissues, cells or body fluids of colorectal cancer patients. Disclosed also is the use of the colorectal cancer marker in the development of therapeutic agents for cancer and in the diagnosis and treatment of colorectal cancer. | 09-30-2010 |
| 20100240037 | IDENTIFICATION OF MARKERS IN ESOPHAGEAL CANCER, COLON CANCER, HEAD AND NECK CANCER, AND MELANOMA - Methods for identifying expression of markers indicative of the presence of esophageal, a squamous cell cancer, a squamous cell cancer of the head and neck, colon cancer and melanoma are provided. Also provided are articles of manufacture useful in such methods and compositions containing primers and probes useful in such methods. | 09-23-2010 |
| 20110059460 | Infection Mediated Foam Dissolution Rate Measurement - The subject invention concerns methods and materials for determining the presence or absence of bacterial or fungal infection in a blood sample. In one embodiment, a method of the invention comprises exposing an anticoagulant treated blood sample to freezing the sample to a solid, followed by thawing of the sample and then agitation of the sample to develop foam and then observing the rate that foam dissolves. | 03-10-2011 |
| 20110059459 | BRCA1 mRNA EXPRESSION PREDICTS SURVIVAL IN PATIENTS WITH BLADDER CANCER TREATED WITH NEOADJUVANT CISPLATIN-BASED CHEMOTHERAPY - The invention relates to methods for predicting the clinical outcome of a patient which suffers from bladder cancer based on the expression levels of BRCA1 wherein high BRCA1 expression levels are indicative of a poor prognosis. Moreover, the invention relates to methods for predicting the response to chemotherapy of a patient which suffers from bladder cancer based on the expression levels of BRCA1, in particular, in patients which have been treated with chemotherapy prior to surgical removal of the tumor. | 03-10-2011 |
| 20110059458 | COMPOSITIONS AND METHODS FOR CATALYZING DNA-PROGRAMMED CHEMISTRY - The present invention relates compositions and methods that are useful in catalyzing DNA-Programmed Chemistry (or Nucleic Acid-templated chemistry) for use in therapeutic and diagnostic applications. | 03-10-2011 |
| 20110059455 | METHODS AND COMPOSITIONS FOR DIRECT CHEMICAL LYSIS - A direct chemical lysis composition includes an assay compatible buffer composition and an assay compatible surfactant. When combined with a specimen storage composition, such compositions prevent undesired modifications to nucleic acid and proteins lysed from cells in the biological sample. Assays of samples from such compositions do not require expensive and time-consuming steps such as centrifugation and prolonged high temperature processing. The direct chemical lysis composition of the present invention permits direct nucleic acid extraction from the cells in the biological sample without the need to decant off the transport media or otherwise exchange the transport media with assay compatible buffers. There is no need to combine the sample with proteinase K or another enzyme to extract nucleic acids from the cells. A method for lysing cells to obtain target nucleic acid for assay and a kit for combining the direct chemical lysis composition with a sample are also contemplated. | 03-10-2011 |
| 20110059454 | FLUORESCENCE ENERGY TRANSFER BY COMPETITIVE HYBRIDIZATION - A method is provided for detecting the presence of nucleotides or monitoring nucleotide amplification. It utilizes fluorescence energy transfer by competitive hybridization. Competitive hybridization is achieved by using unequal length complementary probes which have a fluorophore on one probe and a quencher on the other. The fluorophore and quencher are juxtaposed in a manner wherein the proximity of the quencher to the fluorophore produces quenching of the fluorescence of the fluorophore. | 03-10-2011 |
| 20110059453 | Poly(A) Tail Length Measurement by PCR - Methods and kits for measuring the length of the poly(A) tail of selected target mRNA are disclosed herein. In preferred aspects the mRNA population is modified by addition of a tail comprising guanosine and inosine (G/I tailing). The added tail is used as a priming site for reverse transcription. The resulting cDNA is then amplified using one or more target specific primers and a universal primer that recognizes the tailed region. The products are separated according to size and the size is used to estimate the polyA tail length. | 03-10-2011 |
| 20110059450 | LABELED NUCLEOTIDE ANALOGS AND USES THEREFOR - Labeled nucleotide analogs used in place of naturally occurring nucleoside triphosphates or other analogs in template directed nucleic acid synthesis reactions and other nucleic acid reactions, and various analyses based thereon, including DNA sequencing, single base identification, hybridization assays and others. | 03-10-2011 |
| 20110059449 | METHODS AND COMPOSITIONS FOR DIAGNOSING AND MONITORING TRANSPLANT REJECTION - Methods of diagnosing or monitoring transplant rejection or cytomegalovirus infection in a patient by detecting the expression level of one or more genes or surrogates derived therefrom in the patient are described. Diagnostic oligonucleotides for diagnosing or monitoring transplant rejection or cytomegalovirus infection and kits or systems containing the same are also described. | 03-10-2011 |
| 20110059447 | METHOD FOR THE DETECTION OF GENE TRANSCRIPTS IN BLOOD AND USES THEREOF - The present invention is directed to detection and measurement of gene transcripts in blood. Specifically provided is a RT-PCR analysis performed on a drop of blood for detecting, diagnosing and monitoring diseases using tissue-specific primers. The present invention also describes methods by which delineation of the sequence and/or quantitation of the expression levels of disease-associated genes allows for an immediate and accurate diagnostic/prognostic test for disease or to assess the effect of a particular treatment regimen. | 03-10-2011 |
| 20110059439 | COMPOSITION AND METHOD FOR IMAGING STEM CELLS - An expression vector, comprising a first reporter nucleic acid sequence operably linked to a first expression control sequence comprising a promoter; and a second reporter nucleic acid sequence operably linked to a second expression control sequence that comprises a response element that is activated or inactivated as one or more of the cells differentiate or dedifferentiate. Methods and kits for imaging and monitoring stem cells comprising the expression vector are also provided. | 03-10-2011 |
| 20110059436 | METHODS FOR SEQUENCE DETERMINATION - A sequencing methodology is disclosed that allows a single DNA or RNA molecule or portion thereof to be sequenced directly and in substantially real time. The methodology involves engineering a polymerase and/or dNTPs with atomic and/or molecular tags that have a detectable property that is monitored by a detection system. | 03-10-2011 |
| 20110059438 | Method of Preparing DNA Fragments and Applications Thereof - A method of preparing DNA fragments, which entails at least the following steps of:
| 03-10-2011 |
| 20100216132 | METHODS AND COMPOSITIONS FOR DIRECT DETECTION OF DNA DAMAGE - The present invention is a method for detecting the extent of DNA damage in a subject suspected of having DNA damage wherein the damage results in the formation of aldehyde moieties in DNA comprising, obtaining a DNA sample from the subject, combining the DNA sample with a fluorescent, chromogenic, pro-fluorescent or pro-chromogenic hydrazine compound to from a fluorescent DNA, detecting the presence of the fluorescent DNA by monitoring the fluorescent emission and quantitating the fluorescent emission thereby determining the extent of DNA damage in the subject. | 08-26-2010 |
| 20100304384 | METHOD OF IDENTIFYING COMPOUNDS THAT INDUCE OR INHIBIT ENDOPLASMIC RETICULUM STRESS OR OXIDATIVE STRESS - The present invention generally relates to a method for the identification of compounds for the treatment of neurodegenerative diseases. Said method is based on a cell model for neurodegeneration useful for the identification of potentially useful compounds for the treatment or the prevention of a neurodegenerative disease associated with deficient expression of the DDIT3 gene, also known as CHOP. | 12-02-2010 |
| 20100216151 | METHODS FOR DETECTING FETAL NUCLEIC ACIDS AND DIAGNOSING FETAL ABNORMALITIES - The invention generally relates to methods for detecting fetal nucleic acids and methods for diagnosing fetal abnormalities. In certain embodiments, the invention provides methods for determining whether fetal nucleic acid is present in a maternal sample including obtaining a maternal sample suspected to include fetal nucleic acids, and performing a sequencing reaction on the sample to determine presence of at least a portion of a Y chromosome in the sample, thereby determining that fetal nucleic acid is present in the sample. In other embodiments, the invention provides methods for quantitative or qualitative analysis to detect fetal nucleic acid in a maternal sample, regardless of the ability to detect the Y chromosome, particularly for samples including normal nucleic acids from a female fetus. | 08-26-2010 |
| 20110065115 | METHODS FOR IDENTIFYING AN INCREASED LIKELIHOOD OF RECURRENCE OF BREAST CANCER - Methods of identifying a mammal having an increased likelihood of recurrence of breast cancer includes identifying in a breast tissue sample of the mammal expression of at least two genes selected from the group consisting of Hs.125867 (EVL), Hs.591847 (NAT1), Hs.208124 (ESR1), Hs.26225 (GABRP), Hs.408614 (ST8SIA1), Hs.480819 (TBC1D9), Hs.504115 (TRIM29), Hs.523468 (SCUBE2), Hs.532082 (IL6ST), Hs.592121 (RABEP1), Hs.79136 (SLC39A6), Hs.82128 (TPBG), Hs.95243 (TCEAL1), Hs.95612 (DSC2), Hs.654961 (FUT8), Hs.1594 (CENPA), Hs.184339 (MELK), Hs.26010 (PFKP), Hs.592049 (PLK1), Hs.370834 (ATAD2), Hs.437638 (XBP1), Hs.444118 (MCM6), Hs.469649 (BUB1), Hs.470477 (PTP4A2), Hs.473583 (YBX1), Hs.480938 (LRBA), Hs.524134 (GATA3), Hs.531668 (CX3CL1), Hs.532824 (MAPRE2), Hs.591314 (GMPS), Hs.83758 (CKS2) and Hs.99962 (SLC43A3) and subsets of the genes. | 03-17-2011 |
| 20110065114 | STEROIDOGENESIS MODIFIED CELLS AND METHODS FOR SCREENING FOR ENDOCRINE DISRUPTING CHEMICALS - An isolated steroidogenesis modified cell comprising one or more steroid biosynthesis knock down nucleic acid operatively linked to a promoter, wherein the steroid biosynthesis knock down nucleic acid reduces the expression of a gene selected from the group CYP21A2, CYP11A1, CYP17A1, CYP19A1, 3-βHSD1, 3-βHSD2, 17-βHSD1, StAR, HMGR, CYP11B2, CYP11B1, 5α-Reductase 2, SULT1E1, CYP3A4 and UTG1A1, wherein the cell comprises reduced expression of one or more of said genes. The cells are useful for identifying endocrine disruptors. Accordingly, the disclosure includes in a further aspect a screening assay for identifying an endocrine disruptor comprising:
| 03-17-2011 |
| 20110065106 | Recombinase polymerase amplification - This disclosure describe three related novel methods for Recombinase-Polymerase Amplification (RPA) of a target DNA that exploit the properties of the bacterial RecA and related proteins, to invade double-stranded DNA with single stranded homologous DNA permitting sequence specific priming of DNA polymerase reactions. The disclosed methods has the advantage of not requiring thermocycling or thermophilic enzymes. Further, the improved processivity of the disclosed methods allow amplification of DNA up to hundreds of megabases in length. | 03-17-2011 |
| 20110065102 | OSTEOARTHRITIS-SENSITIVE GENE - It is an object of the present invention to provide a method and kit for diagnosing osteoarthritis which involves genetic diagnosis or hemodiagnosis. The present invention provides a method for diagnosing a genetic susceptibility of a subject to osteoarthritis, which comprises detecting at least one polymorphism selected from polymorphisms existing in a gene (Dual Intracellular on Willebrand factor A gene; DIVA gene), encoding the amino acid sequence of SEQ ID NO: 2 or an amino acid sequence substantially homologous thereto, in a DNA-containing sample collected from the subject, wherein an allele frequency of one of alleles is higher in arbitrary osteoarthritis group than in arbitrary non-osteoarthritis group. | 03-17-2011 |
| 20100311041 | PCR DIAGNOSTICS OF DERMATOPHYTES AND OTHER PATHOGENIC FUNGI - Dermatophytes which belong to one of the three genera | 12-09-2010 |
| 20100221735 | DIAGNOSTIC TEST FOR PARKINSON'S DISEASE - The present invention relates to molecular markers for detection, prognosis and follow up of Parkinson's disease (PD), wherein said molecular markers are one or more genes with altered expression pattern, or gene products thereof (RNA or protein). Genes which expression is upregulated or downregulated in PD patients are tools for early diagnosis od PD, for monitoring the progress of the disease and can serve as targets for screening new agents for treatment of PD. | 09-02-2010 |
| 20100221729 | Methods for assessing Calpain 2 Resistance, Disease Progression, and Treatment Efficacy in Ovarian Cancer - The invention provides methods for predicting whether an ovarian cancer patient's tumor will be resistant to chemotherapy. The invention also provides methods for monitoring the effectiveness of treatment, particularly a chemotherapeutic treatment, in a patient treated for ovarian cancer. The invention further provides methods for treating ovarian cancer, by reducing chemotherapeutic drug resistance in said cells. In addition, the invention provides methods of screening compounds to identify tumor cell growth inhibitors in tumor cells resistant to conventional chemotherapeutic treatment regimes. | 09-02-2010 |
| 20100221734 | SHOTGUN DNA MAPPING BY UNZIPPING - The present invention provides a method of mapping a nucleic acid molecule such as, for example, DNA. Generally, the method includes providing a nucleic acid molecule comprising an unzipping force; comparing the unzipping force of the nucleic acid molecule to unzipping forces of a plurality of reference nucleic acid molecules, thereby generating a match score for each comparison; and identifying the reference nucleic acid that produces the best match score when compared to the nucleic acid molecule. | 09-02-2010 |
| 20100221705 | IN SITU HYBRIDIZATION DETECTION METHOD - The invention provides compositions and methods for the detection of targets in a sample; in particular, an in situ hybridization (ISH) sample. Probes and detectable labels may be provided in multiple layers in order to increase the flexibility of a detection system, and to allow for amplification to enhance the signal from a target. The layers may be created by incorporating probes and detectable labels into larger molecular units that interact through nucleic acids base-pairing, including peptide-nucleic acid (PNA) base-pairing. Optional non-natural bases allow for degenerate base pairing schemes. The compositions and methods are also compatible with immunohistochemistry (IHC), immunocytochemistry (ICC), flow cytometry, enzyme immuno-assays (EIA), enzyme linked immuno-assays (ELISA), blotting methods (e.g. Western, Southern, and Northern), labeling inside electrophoresis systems or on surfaces or arrays, and precipitation, among other general detection assay formats. The invention is also compatible with many different types of targets, probes, and detectable labels. | 09-02-2010 |
| 20100221721 | System for genome selection - Systems, methods, compositions and apparatus relating to genome selection are disclosed. | 09-02-2010 |
| 20100221716 | Classification of Nucleic Acid Templates - Methods, compositions, and systems are provided for characterization of modified nucleic acids. In certain preferred embodiments, single molecule sequencing methods are provided for identification of modified nucleotides within nucleic acid sequences. Modifications detectable by the methods provided herein include chemically modified bases, enzymatically modified bases, abasic sites, non-natural bases, secondary structures, and agents bound to a template nucleic acid. | 09-02-2010 |
| 20100221724 | PATCHED POLYPEPTIDES AND USES RELATED THERETO - Methods for isolating patched genes, including the mouse and human patched genes, as well as invertebrate patched genes and sequences, are provided. Decreased expression of patched is associated with the occurrence of human cancers, particularly basal cell carcinomas of the skin. The patched and hedgehog genes are useful in creating transgenic animal models for these human cancers. The patched nucleic acid compositions find use in identifying homologous or related proteins and the DNA sequences encoding such proteins; in producing compositions that modulate the expression or function of the protein; and in studying associated physiological pathways. In addition, modulation of the gene activity in vivo is used for prophylactic and therapeutic purposes, such as treatment of cancer, identification of cell type based on expression, and the like. The DNA is further used as a diagnostic for a genetic predisposition to cancer, and to identify specific cancers having mutations in this gene. | 09-02-2010 |
| 20100221711 | Respiratory Syncytial Virus (RSV) Viral Load Detection Assay - The invention concerns a method for the extraction of nucleic acids from biological samples e.g. tissue material or sputum derived from human or animal species and the quantitative detection thereafter of said nucleic acids e.g. in terms of viral load, more specifically RSV viral load detection. | 09-02-2010 |
| 20100221717 | Methods, Compositions, and Kits for Detecting Allelic Variants - In some embodiments, the present inventions relates generally to compositions, methods and kits for use in discriminating sequence variation between different alleles. More specifically, in some embodiments, the present invention provides for compositions, methods and kits for quantitating rare (e.g., mutant) allelic variants, such as SNPs, or nucleotide (NT) insertions or deletions, in samples comprising abundant (e.g., wild type) allelic variants with high specificity and selectivity. In particular, in some embodiments, the invention relates to a highly selective method for mutation detection referred to as competitive allele-specific TaqMan PCR (“cast-PCR”). | 09-02-2010 |
| 20100221704 | Method of Dispensing Nonvolatile Liquid in Reaction Vessel and Reaction Vessel Processing Apparatus - It is intended to easily dispense a minute amount of nonvolatile liquid. In a preferred embodiment, in dispensing of mineral oil (nonvolatile liquid), dispensing is conducted in the condition that the amount of air contained in a tip ( | 09-02-2010 |
| 20100221702 | Methods for detection and typing of nucleic acids - Disclosed are methods and kits for identifying and characterizing polynucleotide sequences in a sample which may include a heterogeneous sample. Some of the methods and kits are directed to the identification and characterization of a virus in a sample, which may include HIV capable of cause AIDS or AIDS-like symptoms. The virus may be HIV-1, and may also include drug resistant mutations. The methods may include reacting a mixture that includes, in addition to nucleic acid isolated from the sample, at least one oligonucleotide capable of specifically hybridizing to HIV nucleic acid where the oligonucleotide includes at least one non-natural base. In addition, the methods may include detection of one or more mutations in HIV nucleic acid that are associated with drug resistance. | 09-02-2010 |
| 20100240056 | Methods And Systems For Screening Species-Specific Insecticidal Candidates - Disclosed are methods and systems for identifying compounds that act to modulate insect growth and/or development in a species-specific manner. Such systems and methods may provide for the identification of species-specific insecticides. The methods and systems of the invention may include at least one an isolated nucleic acid molecule that encodes a polypeptide comprising an ecdysone receptor (EcR) isoform from a first distinct species and a second isolated nucleic acid molecule comprising a DNA sequence that encodes a polypeptide comprising at least a portion of an Ultraspiracle (USP) protein from a second distinct species. | 09-23-2010 |
| 20100227327 | METHODS AND COMPOSITIONS FOR CONTINUOUS SINGLE-MOLECULE NUCLEIC ACID SEQUENCING BY SYNTHESIS WITH FLUOROGENIC NUCLEOTIDES - Disclosed herein are methods and compositions for continuous single-molecule nucleic acid sequencing by synthesis with fluorogenic nucleotides. | 09-09-2010 |
| 20100267020 | GENETIC RISK FACTOR FOR NEURODEGENERATIVE DISEASE - The present invention relates to single base polymorphisms in the glycogen synthase kinase 3 beta and risk for developing neurodegenerative disease. | 10-21-2010 |
| 20100267013 | METHODS TO INCREASE NUCLEOTIDE SIGNALS BY RAMAN SCATTERING - The methods and apparatus disclosed herein concern nucleic acid sequencing by enhanced Raman spectroscopy. In certain embodiments of the invention, nucleotides are covalently attached to Raman labels before incorporation into a nucleic acid. In other embodiments, unlabeled nucleic acids are used. Exonuclease treatment of the nucleic acid results in the release of labeled or unlabeled nucleotides that are detected by Raman spectroscopy. In alternative embodiments of the invention, nucleotides released from a nucleic acid by exonuclease treatment are covalently cross-linked to nanoparticles and detected by surface enhanced Raman spectroscopy (SERS), surface enhanced resonance Raman spectroscopy (SERRS) and/or coherent anti-Stokes Raman spectroscopy (CARS). Other embodiments of the invention concern apparatus for nucleic acid sequencing. | 10-21-2010 |
| 20100261178 | High Throughput Assays for Inhibitors and Activators of PAQR Receptors - The subject invention provides methods of screening compounds or ligands that interact with human and/or non-human PAQR receptors or fungal osmotin receptors. These methods utilize a colorimetric assay to ascertain whether a compound binds to and activates a PAQR receptor or the osmotin receptor. | 10-14-2010 |
| 20100216146 | Methods and Kits for Hybridizing Multiple PNA Probe Panels to Nucleic Acid Samples - Described herein are methods and kits that employ multiple probe sets in combination with sequential steps of hybridization analysis for multiplex analysis and/or detection of nucleic acids having one or more distinguishable target sequences. | 08-26-2010 |
| 20100151477 | REDUCING NON-TARGET NUCLEIC ACID DEPENDENT AMPLIFICATIONS: AMPLIFYING REPETITIVE NUCLEIC ACID SEQUENCES - The present invention provides for compositions and methods for amplifying target nucleic acids using nucleic acid primers designed to limit non-target nucleic acid dependent priming events. The present invention permits amplifying and quantitating the number of repetitive units in a repetitive region, such as the number of telomere repetitive units. | 06-17-2010 |
| 20100151461 | GENETIC MARKERS FOR SCHIZOPHRENIA AND BIPOLAR DISORDER - The invention provides haplotypes and SNPs of the HPCAL1 and SV2C genes which predict the risk for developing schizophrenia or bipolar disorder and predict which patients are likely to respond to a given treatment or are more likely to experience negative side effects. | 06-17-2010 |
| 20100184038 | System and Method For the Heterologous Expression of Polyketide Synthase Gene Clusters - A system and method for heterologous expression of polyketide biosynthetic pathways from streptomycetes hosts in | 07-22-2010 |
| 20100273173 | METHOD FOR AMPLIFYING TARGET NUCLEIC ACID SEQUENCE AND PROBE USED FOR THE SAME - The present invention provides a method for amplifying a target sequence while suppressing inhibition of an amplification reaction in nucleic acid amplification in the presence of the probe. At the time of amplifying the target sequence, as the probe caused to coexist in amplification of the target sequence, a probe having a base sequence in which a melting temperature of the double-stranded nucleic acid is equal to or lower than a reaction temperature of the elongation reaction is used. In the presence of such a probe, for example, annealing of a primer and an elongation reaction from the primer are hardly inhibited by the presence of the probe so that amplification of the target sequence can be conducted sufficiently. Therefore, when a polymorphism of a target site in the target sequence is analyzed by a Tm analysis or the like, high reliability can be achieved. | 10-28-2010 |
| 20100184040 | COMPOSITIONS AND METHODS FOR DETERMINING LIKELIHOOD OF TWINNING - Collections of polynucleotides useful for estimating breeding value or detecting likelihood of twinning are disclosed. The polynucleotides are used to detect genomic sequences quantitatively associated with the twinning trait. Also disclosed are methods and kits for using the collections to estimate breeding value or predict likelihood of twinning. | 07-22-2010 |
| 20100273149 | PHOTOSYNTHETIC HYDROGEN PRODUCTION FROM THE GREEN ALGA CHLAMYDOMONAS REINHARDTII - The present invention relates generally to hydrogen production for use in fuel cells, foodstuffs and chemical production, and more particularly, to biologically and photosynthetically produced hydrogen. Specifically, disclosed is a method for producing bacteria and green alga that can produce hydrogen in quantities that exceed four hundred percent of the hydrogen produced by green alga in nature; thus, producing organisms which can serve as hydrogen generators for fuel cells, chemical production and numerous other applications. | 10-28-2010 |
| 20100227329 | TOOLS AND METHODS FOR GENETIC TESTS USING NEXT GENERATION SEQUENCING - The present invention provides tools and methods for use in genetic tests involving high performant sequencing techniques. More particularly, the invention provides a robust multiplex PCR method wherein the respective primers for amplifying the different amplicons are physically isolated from one another. The invention further provides quality control methods allowing a stringent monitoring of genetic tests carried out according to the present invention. | 09-09-2010 |
| 20100273170 | METHOD AND DEVICE FOR PREPARING BIOLOGICAL SAMPLES FOR ANALYSIS - The invention relates to a method for preparing biological samples for analysis, comprising the following steps: (a) the biological sample is placed on a two-dimensional support; (b) application of a protein-precipitating or denaturing first solution L | 10-28-2010 |
| 20100209926 | METHODS FOR DETECTING NEUTRALIZING ANTIBODIES FOR BONE MORPHOGENETIC PROTEINS - The present invention relates to methods of detecting neutralizing antibodies for bone morphogenetic proteins (BMP). More particularly, it relates to a highly specific, robust, rapid and accurate cell-based assay for detecting the presence of anti-BMP neutralizing antibodies. | 08-19-2010 |
| 20100136533 | COMPOUND CONTAINING FARNESYL DIPHOSPHATE FOR MODULATING TRPV3 FUNCTION AND USE THEREOF - The present invention relates to a method for activating TRPV3 (transient receptor potential vanilloid 3) using FPP (farnesyl diphosphate) and a method for screening a TRPV3 activity inhibitor. FPP of the present invention has TRPV3 specific activity and therefore it can be effectively used for the study on TRPV3 mechanism and functions and for the development of a TRPV3 based pain reliever. | 06-03-2010 |
| 20100279285 | GENETIC MARKERS OF MENTAL ILLNESS - This invention relates to genetic markers of mental illness, e.g., schizophrenia (SZ), and methods of use thereof. | 11-04-2010 |
| 20090253138 | KIF20A DIRECTED DIAGNOSTICS FOR NEOPLASTIC DISEASE - Disclosed are methods for diagnosing cancer in a test cell sample or fluid sample by detecting an increase in the level of expression of KIF20A in the test cell sample or fluid sample as compared to the level of expression of KIF20A in a control cell sample or fluid sample isolated from a normal subject. | 10-08-2009 |
| 20090253132 | MUTATED ACVR1 FOR DIAGNOSIS AND TREATMENT OF FIBRODYPLASIA OSSIFICANS PROGRESSIVA (FOP) - This invention is directed to mutated Activin A type I receptor proteins (ACVR1) and isolated nucleic acids encoding same. The invention also relates to the use of mutated ACVR1 in the diagnosis and treatment of Fibrodysplasia Ossificans Progressiva (FOP). | 10-08-2009 |
| 20100285477 | Method for Predicting the Response to a Therapy - The invention concerns an in vitro method for selecting the therapy for a steroid resistant patient, wherein the method comprises isolating cells from a sample taken from said patient; cultivating said isolated cells in the presence of a steroid, an immunomodulatory oligonucleotide or a mixture thereof; determining an expression level of at least one marker gene in said isolated cells; and comparing said expression level of said at least one marker gene to a value obtained from the cultivation of cells from a healthy person in the presence of a steroid, an immunomodulatory oligonucleotide or a mixture thereof, or to a normalized value obtained from a healthy population. Examples of marker genes are CD163, Tsp1, IL1-R2, TLR2, TLR4, MKP-1 and TXK. | 11-11-2010 |
| 20100143926 | Classification of Patients Having Diffuse Large B-cell Lymphoma Based upon Gene Expression - Methods and kits for classifying patients having diffuse large B-cell lymphoma (DLBCL) based upon expression of a plurality of genes are disclosed. Real-time quantitative RT-PCR can be used to measure expression values. Correlating expression values of the plurality of genes in a tumor sample from the patient to reference expression values obtained from DLBCL patients can stratify patients in the classification groups. The methods and kits can be used to predict overall patient survival. | 06-10-2010 |
| 20100143901 | Nuclease-Free Real-Time Detection of Nucleic Acids - The invention is a method for amplification and detection of nucleic acids using primers and at least one hybridization probe labeled with a first fluorescent moiety and a second moiety, capable of changing the fluorescence of said first fluorescent moiety. The method comprises the steps of effecting denaturation of said target, formation of hybrids between said primers and probe and said target and detecting the change in fluorescence of said first fluorescent moiety, upon formation of said hybrids. Reaction mixtures and kits for practicing the method of the present invention are also disclosed. | 06-10-2010 |
| 20100143929 | DNA METHYLATION BASED TEST FOR MONITORING EFFICACY OF TREATMENT - A DNA methylation-based test for efficiency of treatments is based on a plurality of genes. The test is suitable for monitoring treatment of subjects with neurological diseases, e.g., multiple sclerosis (MS); with cancer, e.g., breast and ovarian cancer, and with other diseases for which methylation of biomarkers differs in the diseased compared to the non-diseased state. | 06-10-2010 |
| 20100136557 | Methods and Compositions for Isolating Nucleic Acid Sequence Variants - The invention is drawn to isolating sequence variants of a genetic locus of interest using a modified iterative primer extension method. The nucleic acids analyzed are generally single stranded and have a reference sequence which is used as a basis for performing iterative single nucleotide extension reactions from a hybridized polymerization primer. The iterative polymerization reactions are configured such that polymerization of the strand will continue if the sequence of the nucleic acid being analyzed matches the reference sequence, whereas polymerization will be terminated if the nucleic acid being analyzed does not match the reference sequence. Nucleic acid strands that have mutations can be isolated using a variety of methods and sequenced to determine the precise identity of the mutation/polymorphism. By performing the method on both strands of the nucleic acid being analyzed, virtually all possible mutations can be identified. | 06-03-2010 |
| 20100136548 | METHODS AND COMPOSITIONS FOR ORDERING RESTRICTION FRAGMENTS - The invention relates to methods and systems for sequencing and constructing a high resolution physical map of a polynucleotide. In accordance with the invention, nucleotide sequences are determined at the ends of restriction fragments produced by a plurality of digestions with a plurality of combinations of restriction endonucleases so that a pair of nucleotide sequences is obtained for each restriction fragment. A physical map of the polynucleotide is constructed by ordering the pairs of sequences by matching the identical sequences among the pairs. | 06-03-2010 |
| 20100136549 | REPRODUCIBLE QUANTIFICATION OF BIOMARKER EXPRESSION - A method is described for the reproducible quantification of biomarker expression, including biomarker expression in a tissue sample. Methods and systems are described whereby reproducible scores for biomarker expression are obtained independent of instrument, its location, or operator. | 06-03-2010 |
| 20100136544 | ASSAYS AND OTHER REACTIONS INVOLVING DROPLETS - The present invention generally relates to droplets and/or emulsions, such as multiple emulsions. In some cases, the droplets and/or emulsions may be used in assays, and in certain embodiments, the droplet or emulsion may be hardened to form a gel. In some aspects, a heterogeneous assay can be performed using a gel. For example, a droplet may be hardened to form a gel, where the droplet contains a cell, DNA, or other suitable species. The gel may be exposed to a reactant, and the reactant may interact with the gel and/or with the cell, DNA, etc., in some fashion. For example, the reactant may diffuse through the gel, or the hardened particle may liquefy to form a liquid state, allowing the reactant to interact with the cell. As a specific example, DNA contained within a gel particle may be subjected to PCR (polymerase chain reaction) amplification, e.g., by using PCR primers able to bind to the gel as it forms. As the DNA is amplified using PCR, some of the DNA will be bound to the gel via the PCR primer. After the PCR reaction, unbound DNA may be removed from the gel, e.g., via diffusion or washing. Thus, a gel particle having bound DNA may be formed in one embodiment of the invention. | 06-03-2010 |
| 20100273156 | SEQUENCES AND METHODS FOR DETECTING INFLUENZA A AND INFLUENZA B VIRUS - Nucleic acid amplification primers and methods for specific detection of influenza A and influenza B nucleic acid targets are disclosed. The primer-target binding sequences are useful for detection of influenza A and influenza B targets in a variety of amplification and hybridization reactions. The oligonucleotide sequences are able to differentiate between influenza A and influenza B strains through specific hybridization to one or the other virus strain, enabling specific detection of the presence of influenza A and/or influenza B in a specimen. | 10-28-2010 |
| 20100273154 | NOVEL GLYCOSYLTRANSFERASES AND POLYNUCLEOTIDES ENCODING THE SAME - The present invention provides novel glycosyltransferase proteins produced by ascomycetous filamentous fungi (preferably species belonging to the genus | 10-28-2010 |
| 20100015609 | Method for Determining the Ratio of Two Distinct Peptides or Polynucleic Acids - The invention relates to a method for determining the ratio of two distinct target-peptides or polynucleic acids comprising: a) obtaining a sample containing said two distinct target-peptides or polynucleic acids, b) providing a precursor-peptide or precursor-polynucleic acid, comprising the two distinct target-peptides or -polynucleic acids in a known ratio, wherein the two distinct target-peptides or -polynucleic acids are connected by a cleavage site, c) cleaving the precursor-peptide or precursor-polynucleic acid at the cleavage site to obtain a standard with the known ratio of the two distinct target-peptides or -polynucleic acids, d) detecting a signal of each distinct target-peptide or -polynucleic acid of the standard in an analyzer, comparing the signals with the known ratio and determining a correction factor, e) detecting the signal of each distinct target-peptide or -polynucleic acid of the sample in the analyzer and f) determining the ratio of the two distinct target-peptides or -polynucleic acids by means of the correction factor or by double ratio calculation (calculation of the ratio of two intensity ratios—namely of the peptide and isoform-peptide with their corresponding labelled standards) to eliminate the compound-specific correction factors. | 01-21-2010 |
| 20100261184 | Micro-Chamber Plate, Manufacturing Method Thereof - The present invention relates to a micro-chamber plate and a manufacturing method of the same, more precisely a micro-chamber plate facilitating real-time measurement and analysis of fluorescence obtained from the reaction of multiple reaction solutions containing primers or probes selectively binding to each corresponding gene without cross-contamination in order to analyze biological samples containing numbers of genes and a manufacturing method of the same. | 10-14-2010 |
| 20100196889 | Gene Expression Profiling for Identification, Monitoring and Treatment of Colorectal Cancer - A method is provided in various embodiments for determining a profile data set for a subject with colorectal cancer or conditions related to colorectal cancer based on a sample from the subject, wherein the sample provides a source of RNAs. The method includes using amplification for measuring the amount of RNA corresponding to at least 1 constituent from Tables 1-5. The profile data set comprises the measure of each constituent, and amplification is performed under measurement conditions that are substantially repeatable. | 08-05-2010 |
| 20100273175 | METHOD OF JUDGING RISK FOR ONSET OF DRUG-INDUCED GRANULOCYTOPENIA - Means for determining the presence of the risk of drug-induced granulocytopenia in a human is provided. | 10-28-2010 |
| 20100273167 | METHODS FOR DETERMINING PRENATAL ALCOHOL EXPOSURE - Provided herein are methods for determining ethanol exposure of a prenatal subject, including measuring whether or not amniotic fluid stem cells collected from amniotic fluid surrounding the prenatal subject have a upregulation or expression of one or more genes of a first predetermined combination and/or a downregulation of expression of one or more genes of a second predetermined combination. Also provided are methods for determining ethanol exposure of a prenatal subject which methods include measuring alkaline phosphatase activity and/or calcium deposition of amniotic fluid stem cells collected from amniotic fluid surrounding the prenatal subject. | 10-28-2010 |
| 20100273161 | DETECTION OF BACTERIA BELONGING TO THE GENUS CAMPYLOBACTER BY TARGETING CYTOLETHAL DISTENDING TOXIN - An objective of the present invention is to provide the cytolethal distending toxin (CDT) of | 10-28-2010 |
| 20090291449 | METHOD AND APPARATUS TO MINIMIZE DIAGNOSTIC AND OTHER ERRORS DUE TO TRANSPOSITION OF BIOLOGICAL SPECIMENS AMONG SUBJECTS - A method and apparatus for minimizing diagnostic errors due to transposition of biological specimens among subjects provides for independent biometric confirmation that a given specimen is from a given donor. In certain embodiments, a biological specimen confirmation kit comprises a portable and openable case housing components of the kit, at least one biological specimen container adapted to receive a biological testing specimen from a donor, and at least one reference sample device adapted to receive a biological reference specimen from the same donor, such that the testing and reference specimens can later be compared for donor match verification by a reference verification entity. | 11-26-2009 |
| 20090291448 | Prognostic and Predictive Gene Signature for Non-Small Cell Lung Cancer and Adjuvant Chemotherapy - The application provides methods of prognosing and classifying lung cancer patients into poor survival groups or good survival groups and for determining the benefit of adjuvant chemotherapy by way of a multigene signature. The application also includes kits and computer products for use in the methods of the application. | 11-26-2009 |
| 20090291447 | Method of detecting colon cancer marker - It is intended to provide a non-invasive and convenient method of detecting a tumor marker for diagnosing colon cancer which is superior in sensitivity and specificity to the existing fecal occult blood test. More specifically speaking, a method of detecting a tumor marker for diagnosing colon cancer which comprises collecting biological sample which is immediately frozen using liquid nitrogen in some cases, homogenizing the sample in the presence of an inhibitor of an RNA digesting enzyme to give a suspension, extracting RNA from the obtained suspension, subjecting the extracted RNA to reverse transcription to give cDNA, amplifying the obtained cDNA and then detecting the thus amplified cDNA. This method is characterized by involving no procedure of separating cell components from the biological sample. | 11-26-2009 |
| 20090291446 | METHOD FOR CONFIRMING THE PRESENCE OF AN ANALYTE - The invention provides methods and kits for the rapid confirmation of an initial analyte test result. In a preferred embodiment, the process confirms the presence of a given microbial target in a mixed culture, or a mixed enrichment media, even when the competing organisms in the mix belong to related species, or are various biotypes of the same species. | 11-26-2009 |
| 20090291440 | METHOD FOR SYNTHESIZING NUCLEIC ACID USING DNA POLYMERASE BETA AND SINGLE MOLECULE SEQUENCING METHOD - The present invention provides a nucleic acid synthesis method capable of continuously carrying out an extension reaction and a single molecule sequencing method capable of obtaining base information accurately at high speed. A method for synthesizing a nucleic acid, including the steps of: forming a complex of a target nucleic acid hybridized to a primer oligonucleotide and a DNA polymerase β; allowing the DNA polymerase β to incorporate a fluorescently-labeled dNTP so that the fluorescently-labeled dNTP is bound to the 3′ end of the primer oligonucleotide; and allowing the DNA polymerase β to continuously incorporate fluorescently-labeled dNTP to extend a nucleic acid complementary to the target nucleic acid from the 3′ end of the bound fluorescently-labeled dNTP. A method for sequencing a single nucleic acid molecule, including the steps of said method for synthesizing a nucleic acid, wherein fluorescence emitted from each of the fluorescently-labeled dNTP incorporated into the DNA polymerase β is sequentially detected to carry out the sequencing of the target nucleic acid. | 11-26-2009 |
| 20090291443 | USE OF HIGHLY PARALLEL SNP GENOTYPING FOR FETAL DIAGNOSIS - The present invention provides apparatus and methods for enriching components or cells from a sample and conducting genetic analysis, such as SNP genotyping to provide diagnostic results for fetal disorders or conditions. | 11-26-2009 |
| 20090291442 | HSPA1A AS A MARKER FOR SENSITIVITY TO KSP INHIBITORS - The present invention relates to methods for predicting a response to treatment with a kinesin spindle protein inhibitor using heat shock protein 70, isoform A1a, also known as HSPA1a, as a marker for sensitivity to the kinesin spindle protein (KSP) inhibitors. Method are provided for predicting a response to treatment with a kinesin spindle protein inhibitor of a first mammal in need thereof comprising determining an amount of HSPA1a mRNA transcript produced by said first mammal, wherein the amount of said HSPA1a mRNA transcript produced by said first mammal is indicative of said mammal's sensitivity to said kinesin spindle protein inhibitor | 11-26-2009 |
| 20090291441 | POLYPEPTIDE, NUCLEIC ACID MOLECULE ENCODING IT AND THEIR USES - A polypeptide containing epitope of the amino acid sequence shown in SEQ ID NO:3 is provided, which is selected from the amino acid sequence of SEQ ID NO:3 and amino acids at 16-32 positions, amino acids at 1-30 positions, amino acids at 50-80 positions and amino acids at 17-200 positions of the amino acid sequence shown in SEQ ID NO:3. The nucleic acid molecule encoding the polypeptide, recombinant vectors and host cells comprising the nucleic acid molecule are also provided. The polypeptide and the nucleic acid molecule encoding it can be used for preparing reagents, kits or devices for diagnosing the diseases characterized by EECP expression and pharmaceutical compositions for preventing or treating the diseases characterized by EECP expression by increasing or inhibiting EECP expression and/or activity. | 11-26-2009 |
| 20090291436 | METHODS FOR DETECTING NUCLEIC ACIDS INDICATIVE OF CANCER - The invention provides methods for screening tissue or body fluid samples for nucleic acid indicia of cancer or precancer. | 11-26-2009 |
| 20090291439 | PHOSPHATASES INVOLVED IN THE REGULATION OF CARDIOMYOCYTE DIFFERENTIATION - An object of the invention is to provide a dephosphorylation enzyme that regulates cardiomyocyte differentiation, dominant negative enzyme thereof, a gene encoding the enzyme protein and use thereof. A protein or the like consisting of any one of the following amino acid sequences (A) to (C) is used: | 11-26-2009 |
| 20090291437 | METHODS FOR TARGETING QUADRUPLEX SEQUENCES - Provided are quadruplex nucleotide sequences and methods for identifying interacting molecules. | 11-26-2009 |
| 20090291435 | THERMAL REACTION DEVICE AND METHOD FOR USING THE SAME - Devices and methods for performing the relative concentration of a target in a sample, the sample containing both target and non-target components, the method performed by partitioning the sample into a large number of reaction volumes such that the target is concentrated relative to the non-target, and performing a detection assay upon each reaction volume to detect the target. | 11-26-2009 |
| 20100291552 | DETECTION OF MUTATIONS IN A GENE ENCODING IkB KINASE-COMPLEX-ASSOCIATED PROTEIN TO DIAGNOSE FAMILIAL DYSAUTONOMIA - A method for detecting the presence in a subject of a polymorphism linked to a gene associated with familial dysautonomia, said method comprising detecting a disruptive mutation in a gene of said subject encoding the IκB kinase-complex-associated protein, and, preferably, detecting a T→C change in position 6 of the donor splice site of intron 20 and/or a G→C transversion of nucleotide 2390 in exon 19 of the gene encoding the IκB kinase-complex-associated protein which is present on chromosome 9q31. Also disclosed are oligonucleotide primers useful in the detection method. This abstract is provided to comply with the rules requiring an abstract that will allow a searcher or other reader to ascertain quickly the subject matter of the technical disclosure. It is submitted with the understanding that it will not be used to interpret or limit the scope or meaning of the claims. | 11-18-2010 |
| 20100291554 | COMPOSITIONS AND METHODS FOR DETERMINING GENOTYPES - The present invention provides methods for determining the genotype of a selected gene present in at least two alleles in a sample. The methods involve amplifying DNA from the sample with a first pair of flanking primers that hybridize to nucleic acid sequences flanking a variant-specific gene sequence, the presence of which indicates the presence of a first gene variant, and the absence of which indicates the presence of a second gene variant. The DNA is also amplified with a third primer that specifically binds to the variant-specific sequence and together with one of the flanking primers forms a second pair of primers. Detection of one or more nucleic acid products of the amplification reaction is indicative of the genotype present in the sample. | 11-18-2010 |
| 20100291550 | Methods and compositions for modulating hair growth - The invention relates, in part, to methods and compounds that are useful to modulate hair growth in mammals. The invention, in part, also includes nucleic acids, polypeptides, and genetic constructs that may be used to diagnose and treat hair growth disorders, for screening for compounds that modulate hair growth, and for selecting treatment regimens for subjects with hair loss disorders or hair growth conditions. The invention in some aspects also includes kits that may include polypeptides and/or nucleic acids for diagnosis of hair growth disorders and/or for the modulation of hair growth in subjects. | 11-18-2010 |
| 20100291551 | GENEMAP OF THE HUMAN ASSOCIATED WITH CROHN'S DISEASE - The present invention relates to the selection of a set of polymorphism markers for use in genome wide association studies based on linkage disequilibrium mapping. In particular, the invention relates to the fields of pharmacogenomics, diagnostics, patient therapy and the use of genetic haplotype information to predict an individual's susceptibility to IBD (e.g. Crohn's Disease) and/or their response to a particular drug or drugs. | 11-18-2010 |
| 20110027789 | METHODS FOR PRESERVATION OF GENOMIC DNA SEQUENCE COMPLEXITY - The present invention relates to methods and kits for preserving genomic DNA sequence complexity within chemically and/or enzymatically converted DNA by an enzyme or series of enzymes that adds a methyl group to a cytosine outside of CpG dinucleotide sequences of genomic DNA. Further, the present invention relates to methylation analysis of the genomic DNA. | 02-03-2011 |
| 20110027779 | POLYNUCLEOTIDE PRIMERS - A polynucleotide comprising at least the final six nucleotides of one of the following primer sequences, or a sequence complementary thereto: SEQ. ID NOS. 3 to 16, 18, 20 to 33, 35 or 37 to 39. A method of detecting the presence or absence of a mutation in the PIK3CA gene, wherein the mutation is one of H1047R, H1047L, E542K and E545K, and preferably ARMS primers are combined with Scorpion primers. | 02-03-2011 |
| 20110027776 | KITS AND METHODS FOR ASSESSING ANTIOXIDANT REQUIREMENT OF A HUMAN - The invention relates to kits and methods for assessing the desirability of supplementing the diet of a human with reduced coenzyme Q (CoQH | 02-03-2011 |
| 20100261171 | NUCLEIC ACID SEQUENCES FOR BIOSYNTHESIS OF NON-MCCJ25-RELATED LARIAT PEPTIDES - A nucleic acid sequence is provided, encoding at least one of a precursor of a lariat peptide, a processing factor of a lariat peptide, and an export factor of a lariat peptide, wherein the lariat peptide is a non-MccJ25 lariat peptide according to general structural formula (I) Also provided are biosynthesis systems useful for the synthesis of peptides according to formula (I), and methods of detecting and identifying nucleic acid sequences encoding the disclosed proteins. | 10-14-2010 |
| 20100261165 | Methods, Compositions and Kits for Use in Prognosis, Characterization and Treatment of Cancer - The present invention provides methods, compositions and kits for the prognosis, characterization and treatment of cancers. The methods, compositions and kits of the invention comprise a set of markers whose expression is correlated with estrogen receptor beta function. Therefore, the methods, compositions and kits of the invention find particular use in endocrine-related cancers such as breast cancers. | 10-14-2010 |
| 20100221736 | METHOD FOR PREDICTING SUSCEPTIBILITY TO A MENTAL DISORDER - This invention relates generally to the field of mental disorders and, in particular, to a method for predicting susceptibility to a mental disorder, or a mental associated disorder. | 09-02-2010 |
| 20100221723 | EARLY DETECTION OF CANCER BY METHYLATED DNA IN BLOOD - This invention relates to early detection of cancer by detecting methylated DNA in blood. In one embodiment, there is provided a method of predicting the occurrence of hepatocellular carcinoma in a subject, comprising the steps of preparing DNA samples from blood samples of the subject; and determining methylation status of a group of genes comprising RASSF1A, p16 and p15, wherein hypermethylation of these genes as compared to normal control samples indicates the subject is likely to develop hepatocellular carcinoma in the future. | 09-02-2010 |
| 20100221718 | METHOD AND RAPID TEST FOR DETECTION OF SPECIFIC NUCLEIC ACID SEQUENCES - A universally usable method for specific detection of target nucleic acid sequences, which method can be performed very rapidly and also simply and furthermore which does not need any expensive instrumental systems. The method is intended to be suitable as a molecular genetic rapid test and to respect the requirements of diagnostic specificity assurance. In this regard it is important that only one specific amplification product be detected and that amplification artifacts can be unambiguously discriminated. A nucleic acid amplification kit suitable for performing this method. | 09-02-2010 |
| 20100221706 | KIT FOR THE AMPLIFICATION OF NUCLEIC ACIDS - A ready-to-use kit for the PCR amplification of nucleic acids is described, comprising at least one vessel into which a master mix comprising the salts, the buffer and the deoxynucleotide triphosphates required for the PCR amplification is prealiquotted, the said master mix being mixed with an effective amount of an inert temperature controllable polymer such that the final mixture thus formed is in the liquid phase at a predetermined temperature and in the gel phase at a temperature lower than a second predetermined temperature. | 09-02-2010 |
| 20100273152 | METHOD OF IDENTIFYING INDIVIDUALS AT RISK OF THIOPURINE DRUG RESISTANCE AND INTOLERANCE - The present invention is directed to a method of screening individuals for the presence or absence of one or more polymorphisms associated with the risk of thiopurine resistance or intolerance. | 10-28-2010 |
| 20110033848 | EPIGENETIC METHODS - The present invention provides methods for obtaining epigenetic information for a polyploid subject, the method including the steps of obtaining a biological sample from the subject, the sample containing: (i) at least one paternally-derived DNA molecule and/or associated protein and/or, (ii) at least one maternally-derived DNA molecule and/or associated protein, analyzing any one or more of the paternally- or maternally-derived DNA molecules or associated proteins for the presence or absence of modifications, wherein the step of analyzing determines whether any two modifications are present in cis on one chromosome, or in trans across two sister chromosomes. | 02-10-2011 |
| 20100143894 | Quantitative Detection of Hdv by Real-Time Rt-Pcr - Specific reagents for quantitative assay of HDV and more specifically to follow HDV viral load in chronically infected patients and such a quantitative assay. | 06-10-2010 |
| 20100297648 | METHOD FOR DIAGNOSING SUSCEPTIBILITY TO POST-TRAUMATIC SCAR-TISSUE FORMATION - Disclosed is an in vitro method for diagnosing susceptibility to post-traumatic scar tissue formation, wherein from a biological sample of a patient the nucleotide of the -509 position of the TGF-β1 gene is determined and if said -509 position contains exclusively C, thus it is the homozygotic wild type allele, then said patient is considered to be susceptible to post-traumatic scar tissue formation. The invention relates furthermore to diagnostic kits for the detection of susceptibility to post-traumatic scar tissue formation, preferably for the detection of susceptibility to tracheal stenosis from a biological sample. | 11-25-2010 |
| 20100297656 | AMPLICON MELTING ANALYSIS WITH SATURATION DYES - Methods are provided for nucleic acid analysis wherein a target nucleic acid that is at least partially double stranded is mixed with a dsDNA binding dye having a percent saturation of at least 50% to form a mixture. In one embodiment, the nucleic acid is amplified in the presence of the dsDNA binding dye, and in another embodiment a melting curve is generated for the target nucleic acid by measuring fluorescence from the dsDNA binding dye as the mixture is heated. Dyes for use in nucleic acid analysis and methods for making dyes are also provided. | 11-25-2010 |
| 20100297636 | CC2D2A GENE MUTATIONS ASSOCIATED WITH JOUBERT SYNDROME AND DIAGNOSTIC METHODS FOR IDENTIFYING THE SAME - The present invention provides a method of screening a subject for mutations in the CC2D2A gene that are associated with Joubert syndrome, an autosomal recessive form of mental retardation. The present invention also provides proteins that are associated with Joubert syndrome including proteins comprising an amino acid sequence that terminates in DHEGGSGMES (SEQ ID NO: 1). Also provided are nucleotide sequences encoding such proteins and methods of screening subjects to identify nucleotide sequences or proteins associated with Joubert syndrome. | 11-25-2010 |
| 20100221738 | METHOD OF DIAGNOSIS OF A PREDISPOSITION TO DEVELOP THROMBOTIC DISEASE AND ITS USES - The present invention refers to a method of diagnosis of a predisposition to develop thrombotic disease, to test systems and their use for the diagnosis of a predisposition to develop thrombotic disease, to a P | 09-02-2010 |
| 20100221728 | METHOD FOR QUANTIFYING INITIAL CONCENTRATION OF NUCLEIC ACID FROM REAL-TIME NUCLEIC ACID AMPLIFICATION DATA - Provided is a method for quantifying an initial concentration of a nucleic acid from a real-time nucleic acid amplification data. Nucleic acid (DNA or RNA) extracted from organism or virus is amplified using an enzyme. Then, the initial concentration of the nucleic acid is found by calculating the characteristic amplification cycle number or the characteristic amplification time at which the fluorescence intensity of the nucleic acid subtracted by the background fluorescence intensity of the nucleic acid has half of its maximum value, or the characteristic amplification cycle number or the characteristic amplification time at which the amplification efficiency has the maximum or the minimum value, or the prior-to-amplification fluorescence intensity of the nucleic acid subtracted by the background fluorescence intensity of the nucleic acid. Accordingly, the initial concentration of the nucleic acid can be calculated without differentiation or integration. | 09-02-2010 |
| 20100221712 | CELL-MEDIATED IMMUNE RESPONSE ASSAY AND KITS THEREFOR - The present invention provides methods and kits for measuring a cell-mediated immune (CMI) in a small volume of whole undiluted blood collected from a subject. In particular, the methods are for measuring responses in undiluted whole blood samples having a volume of, for example, 50 μl to 500 μl. Thus, capillary sampling and rapid testing of subjects including pediatric, adult or geriatric human subjects are facilitated. | 09-02-2010 |
| 20100240063 | SYSTEMS AND METHODS FOR DETECTING MULTIPLE OPTICAL SIGNALS - To minimize cross talk in systems and methods for detecting two or more different optical signals emitted from each of a plurality of reaction receptacles, an excitation signal associated with each of the optical signals has a known excitation frequency, and any detected signal having a frequency that is inconsistent with the excitation frequency is discarded. The receptacles are moved relative to optical sensors configured to detect each unique optical signal from an associated receptacle, and to further minimize cross talk, the optical sensors are arranged so that only one reaction receptacle at a time is in a signal detecting position with respect to one of its associated optical sensors, and the optical sensors are grouped by the optical signal they are configured to detect so that a first optical signal is detected from each of the reaction receptacles before a second optical signal is detected from the reaction receptacles. | 09-23-2010 |
| 20100240061 | Soybean Polymorphisms and Methods of Genotyping - Polymorphic soybean DNA loci useful for genotyping between at least two varieties of soybean. Sequences of the loci are useful for designing primers and probe oligonucleotides for detecting polymorphisms in soybean DNA. Polymorphisms are useful for genotyping applications in soybean. The polymorphic markers are useful to establish marker/trait associations, e.g. in linkage disequilibrium mapping and association studies, positional cloning and transgenic applications, marker-aided breeding and marker-assisted selection, and identity by descent studies. The polymorphic markers are also useful in mapping libraries of DNA clones, e.g. for soybean QTLs and genes linked to polymorphisms. | 09-23-2010 |
| 20100240057 | METHODS AND COMPOSITIONS FOR THE DIAGNOSIS AND TREATMENT OF CHRONIC MYELOID LEUKEMIA AND ACUTE LYMPHOBLASTIC LEUKEMIA - Compositions and methods for the identification, prognosis, classification, treatment, and diagnosis of leukemia or a genetic predisposition to leukemia are provided. The present invention is based on the discovery of various genomic abnormalities of the IKZFl gene which are shown herein to be associated with acute lymphoblastic leukemia (ALL), more particularly, associated with BCR-ABL1 positive ALL and/or shown to be associated with chronic myeloid leukemia (CML), more particularly, associated with blast crisis chronic myeloid leukemia (BC-CML) and/or the likelihood of progression into blastic transformation of CML. These various genomic abnormalities of the IKZFl gene can further be used as prognostic markers to identify a subgroup of ALL having very poor outcomes. Such genomic abnormalities of IKZFl find use in methods and compositions useful in the identification and/or prognosis and/or predisposition and/or treatment of ALL, more particularly, BCR-ABL1 positive ALL and/or in the identification and/or prognosis and/or predisposition and/or treatment of CML, more particularly, of BC-CML and/or the likelihood of progression into blastic transformation of CML and/or as prognostic markers to identify a subgroup of ALL having very poor outcomes. | 09-23-2010 |
| 20100136568 | Compositions and Methods for Regulating RNA Translation via CD154 CA-Dinucleotide Repeat - Compositions and methods for regulating CD154 gene expression are provided that rely on the interaction of hnRNP L with the CA-dinucleotide rich sequence of the 3′-untranslated region of CD154. | 06-03-2010 |
| 20100136562 | Multivariate Analysis Involving Genetic Polymorphisms Related To Mediators Of Inflammatory Response For Prediction Of Outcome Of Critcally Ill Patients - A method of using genetic polymorphisms related to pro-inflammatory mediators to predict clinical outcome in critically ill patients admitted to an ICU is provided. | 06-03-2010 |
| 20100136555 | Burkholderia Pseudomallei Diagnostic Genetic Elements that Predict Mortality in Melioidosis - The present invention provides methods for predicting the likelihood of mortality from melioidosis and detecting the presence of | 06-03-2010 |
| 20100136532 | AQP5 Polymorphism - In order to predict disease risks, disease courses and the response of an individual patient to pharmacological and non-pharmacological therapies a polymorphism in the AQP5 gene has been investigated, in particular in the promoter region of said gene,on the human 12q13 chromosome, wherein the therapy can also be a cosmetic treatment. | 06-03-2010 |
| 20100203542 | METHOD FOR TREATING AUTOIMMUNE DISEASES AND SCREENING METHOD FOR PREVENTIVE OR THERAPEUTIC AGENT FOR THE SAME - A screening method for a preventive or therapeutic agent for an autoimmune disease and/or for an apoptosis inhibitor, comprising determining retinoblastoma associated protein (RBAp48) production suppressing effect or RBAp48 production inhibitory effect of a sample. | 08-12-2010 |
| 20110117563 | ANTIVIRAL THERAPY - The application relates to treatments for improving antiviral therapies and to method for determining whether or not antiviral therapies will be effective. In particular, the present application provides a method for determining the likelihood that a subject having a viral infection of the liver will be responsive to antiviral therapy that includes stimulation of Interferon (IFN) activity, and kits for the performance of said determination. | 05-19-2011 |
| 20110117562 | Diagnosis and Treatment of Chronic Lymphocytic Leukemia (CLL) - The present invention provides diagnostic methods and kits for diagnosis of chronic lymphocytic leukemia (CLL) by determining expression levels of isoforms of cyclic nucleotide phosphodiesterases (PDEs) associated with CLL, particularly, PDE7B and/or PDE3B, and a ratio of mRNA expression of PDE7B to PDE3B. The present invention provides that CLL lymphocytes uniformly expressed high levels of PDE7B and low levels of PDE3B relative to those of normal lymphocytes. A method of treatment and a pharmaceutical composition for CLL comprising one or more therapeutic agents capable of modulating expression or activity levels of isoforms of PDEs associated with CLL, and/or reversing the ratio of PDE7B/PDE3B mRNA expression levels are also provided. | 05-19-2011 |
| 20110117557 | Methods and Compositions For Diagnosis of Age-Related Macular Degeneration - The invention generally concerns methods and compositions for screening individuals for susceptibility to age-related macular degeneration (AMD). In particular, association with the various markers including complement factor H, LOC387717/ARMS2, C2/CFB, C3 and VEGF, indicates that a subject is at risk of AMD. | 05-19-2011 |
| 20100240059 | MAIZE EVENT DP-098140-6 AND COMPOSITIONS AND MEHTODS FOR THE IDENTIFICATION AND/OR DETECTION THEREOF - Compositions and methods related to transgenic glyphosate/ALS inhibitor-tolerant maize plants are provided. Specifically, the present invention provides maize plants having a DP-098140-6 event which imparts tolerance to glyphosate and at least one ALS-inhibiting herbicide. The maize plant harboring the DP-098140-6 event at the recited chromosomal location comprises genomic/transgene junctions having at least the polynucleotide sequence of SEQ ID NO:5 and/or 6. The characterization of the genomic insertion site of the DP-098140-6 event provides for an enhanced breeding efficiency and enables the use of molecular markers to track the transgene insert in the breeding populations and progeny thereof. Various methods and compositions for the identification, detection, and use of the maize DP-098140-6 events are provided. | 09-23-2010 |
| 20100240046 | Methods and Systems for Identifying PCR Primers Specific to One or More Target Genomes - Methods and systems for identifying a primer pair for polymerase chain reaction specific to one or more target genomes. Methods and systems of the present disclosure can be used to identify primers that can distinguish between target genomes and closely related non-target genomes. | 09-23-2010 |
| 20100240051 | Device and Method for Preparing and Performing Multiple Polymerase Chain Reactions - The present invention relates to methods, kits and devices with multiple open reaction chambers having multiple pre-deposited primer compositions, and a basic sample loading mechanism that utilizes an immiscible companion fluid for preparing and performing multiple Polymerase Chain Reactions | 09-23-2010 |
| 20100297631 | Compositions and Methods For Detecting Histamine Related Disorders - The present invention generally relates to methods and compositions (e.g., assay kit) for the diagnosis of histamine related disorders. The invention also relates to a novel molecular target of histamine related disorders and the uses thereof for detecting or diagnosing such diseases, as well as to develop adapted and efficient therapeutic treatment thereof. The invention may be used in any mammalian subject, particularly human subjects. | 11-25-2010 |
| 20100297645 | AUTOMATIC DETECTION OF INFECTIOUS DISEASES - The invention relates to the detection of infectious diseases. A system for automatic detection of infectious diseases is disclosed. The system comprises an input unit for receiving a blood sample, a lysis unit, a PCR unit, a sample unit and a detection unit. The systemmay based on an inputted blood sample generate an output signal that isindicative of the presence of pathogen DNA in the blood sample. | 11-25-2010 |
| 20100129797 | USE OF GENETIC MODIFICATIONS IN HUMAN GENE CHK1 WHICH CODES FOR CHECKPOINT KINASE 1 - The invention relates to an in vitro method for predicting disease risks, progression of diseases, drug risks, success of treatment and for finding drug targets by looking for one or more genetic modifications in the promoter region of the CHK1 (CHEK1) gene on human chromosome 11q23, the genetic modifications being a substitution thymine for guanine in position -1143 in the promoter of CHK1, of thymine for cytosine in position -1400, a substitution of cytosine for thymine in position -1453 or an insertion of one cytosine in position -1454 and the genetic modifications being detected individually or in any combinations by way of known methods. | 05-27-2010 |
| 20100279286 | METHOD OF DETECTING EQUINE POLYSACCHARIDE STORAGE MYOPATHY - The present invention relates to diagnosing Polysaccharide Storage Myopathy (PSSM) disease in equines. | 11-04-2010 |
| 20100240033 | CONSTITUTIVELY ACTIVE MUTANTS OF THE PROLACTIN RECEPTOR - The invention relates to constitutively active mutants of the prolactin receptor (PRLR), wherein an Ile residue at position 76 or at position 146 of the mature form of said receptor has been substituted by another amino acid residue. The invention also provides methods useful for the diagnosis, prognosis, or treatment of diseases involving the PRLR. | 09-23-2010 |
| 20100240062 | METHOD FOR PREPARING AND ANALYZING CELLS HAVING CHROMOSOMAL ABNORMALITIES - The present invention provides methods for preparing cells with highly condensed chromosomes, such as sperm, and methods for detecting and quantifying specific cellular target molecules in intact cells. Specifically, methods are provided for detecting chromosomes and chromosomal abnormalities, including aneuploidy, in intact cells using fluorescence in situ hybridization of cells in suspension, such as sperm cells. | 09-23-2010 |
| 20100240055 | Method and System for Analyzing a Blood Sample - Methods, systems, and computer program products for the analysis of a blood sample are disclosed. One embodiment is a method of detecting and enumerating hard-to-ghost cells in a blood sample. Another embodiments is a method of analyzing reticulocytes in a blood sample. Methods of using blood count parameters are also provided. | 09-23-2010 |
| 20100240038 | Method of screening a drug such as insulin secretagogue - The screening method of the present invention is useful for screening drugs such as insulin secretagogues having an insulin secretagogue activity with minimized side effects (hypoglycemia induction, etc.). The transformant in which a polynucleotide encoding the fusion protein used for the screening method is introduced, the screening kit comprising the transformant, etc. are also useful for screening excellent drugs. | 09-23-2010 |
| 20100311066 | METHODS AND COMPOSITIONS FOR GENERATION OF MULTIPLE COPIES OF NUCLEIC ACID SEQUENCES AND METHODS OF DETECTION THEREOF - The present invention provides novel isothermal methods of generating multiple copies of, detecting and/or quantifying nucleic acid sequences of interest based on limited primer extension or attachment of oligonucleotide pairs using composite RNA/DNA primers. Methods for generating multiple copies of and/or detecting and/or quantifying nucleic acid sequences, wherein products of primer extension or attachment of oligonucleotide pairs comprising a cleavable portion are generated, and wherein cleavage of the products results in dissociation of cleaved products from target polynucleotides, are provided. The invention further provides compositions, kits and systems for practicing these methods. | 12-09-2010 |
| 20100311044 | ASSAY KIT FOR IN-SITU HYBRIDIZATION OF RHOGDI2 GENE, METHOD THEREFOR AND USE THEREOF THE ASSAY KIT - An assay kit for in-situ hybridization (Rho GDP dissociation inhibitor beta, ISH) of RhoGDI2 gene, an assay method therefor and a use of the assay kit are provided. The assay kit includes: a hybridization probe, a marker, a hybridization solution, and an enhancement reagent. The hybridization probe has a sequence of SEQ ID NO. 1. The assay method includes steps of: (a) mixing the hybridization probe of the assay kit with a to-be-tested RNA on a substrate to form a hybridization complex; and (b) assaying the hybridization complex formed in the step (a). The use of the assay kit is applied the assay kit to prepare a therapeutic medicines for early metastasis of a carcinoma or a relapse disease. The assay kit of the present invention can enhance sensitivity and strengthen specificity. Meanwhile, the assay method of the present invention can increase operational convenience and simplify procedures, so that the assay method can be popularized in the medical institutions including local hospitals. | 12-09-2010 |
| 20100311053 | USE OF CLEC1B FOR THE DETERMINATION OF CARDIOVASCULAR AND THROMBOTIC RISK - The use of the single nucleotide polymorphism (SNP) of the CLEC1B gene for the identification of cardiovascular and/or thrombotic disorders or of an increased risk for developing cardiovascular and/or thrombotic disorders in a biological sample taken from an individual to be examined; the use of CLEC1B for identifying substances active in preventing and/or treating cardiovascular and/or thrombotic disorders and methods for doing so. | 12-09-2010 |
| 20100209921 | Digital Amplification - The identification of pre-defined mutations expected to be present in a minor fraction of a cell population is important for a variety of basic research and clinical applications. The exponential, analog nature of the polymerase chain reaction is transformed into a linear, digital signal suitable for this purpose. Single molecules can be isolated by dilution and individually amplified; each product is then separately analyzed for the presence of pre-defined mutations. The process provides a reliable and quantitative measure of the proportion of variant sequences within a DNA sample. | 08-19-2010 |
| 20100304393 | Genetic predictors of international normalized ratio (INR) fluctuation with warfarin therapy - There are disclosed methods and kits for identifying a subject having genetic predictors of predisposition to abnormal international normalized ratio (INR) fluctuation during warfarin therapy. In an embodiment, a method includes testing the subject to check for a presence of a predetermined genetic variation. The predetermined genetic variation is correlated with abnormal INR fluctuation during warfarin therapy. The subject is identified as having a predisposition to abnormal INR fluctuation during warfarin therapy when the testing indicates the presence of the predetermined genetic variation. In one embodiment, a kit includes a test to check the subject for a presence of a predetermined genetic variation. The predetermined genetic variation is correlated with abnormal INR fluctuation during warfarin therapy. The kit includes an indicator to identify the presence of the predetermined genetic variation so as to identify the subject as having a predisposition to abnormal INR fluctuation during warfarin therapy. | 12-02-2010 |
| 20100304389 | Preparation And Isolation of 5' Capped mRNA - The synthesis of capped/tagged RNA, methods of use and kits providing same are contemplated. Tagged RNA permits isolation of RNA transcripts in vitro. The ability to isolate and purify capped RNA results in improved transcription and translation and provides a tool for identifying RNA-protein interactions. Such capped RNA finds use in therapeutic applications, diagnosis and prognosis and in the treatment of cancers and HIV. | 12-02-2010 |
| 20100304386 | ENZYMES FOR AMPLIFICATION AND COPYING BISULPHITE MODIFIED NUCLEIC ACIDS - The invention relates to the use of enzymes for copying or amplifying bisulphite modified or treated nucleic acids, wherein the enzymes are more effective in copying or amplifying the nucleic acid compared with native Taq polymerase under substantially the same conditions. | 12-02-2010 |
| 20100304380 | Quantitative DNA Methylation Imaging of Cells and Tissues - The invention is a method using immunofluorescence, high-resolution imaging, and 3D image analysis to quantify spatial distribution of methylcytosine (MeC) in global DNA in individual cell nuclei, for the characterization of cells and tissues based on their nuclear MeC distribution patterns. The invented method is intended for basic research, clinical diagnostics and prognostics, pharmacology and toxicology, and molecular and cell-based therapy. | 12-02-2010 |
| 20100304381 | FLUORESCENT NUCLEOBASE CONJUGATES HAVING ANIONIC LINKERS - Provided are nucleotide-dye conjugates and related compounds in which a dye is linked to a nucleobase directly or indirectly by an anionic linker. The anionic character of the linker is provided by one or more anionic moieties which are present in the linker, such as phosphate, phosphonate, sulfonate, and carboxylate groups. When the dye is a provided as a donor/acceptor dye pair, the anionic linker can be located between the donor and the acceptor, or between the nucleobase and either the donor or acceptor, or both. In one embodiment, conjugates of the invention provide enhanced electrophoretic mobility characteristics to sequencing fragments, e.g., for dideoxy sequencing using labeled terminators. | 12-02-2010 |
| 20100304378 | Method for Detecting or Quantifying a Truncating Mutation - The present invention discloses a new method for detecting or quantifying a truncating mutation of a target gene in a subject, said method relying on the in vitro compartmentalization of single genetic constructs in aqueous droplets of a water-in-oil emulsion. | 12-02-2010 |
| 20100304379 | SPORES FOR THE STABILIZATION AND ON-SITE APPLICATION OF BACTERIAL WHOLE-CELL BIOSENSING SYSTEMS - The presently-disclosed subject matter is directed to biosensors comprising spore-forming bacterial cells and/or spores generated therefrom, a recognition unit within each spore-forming cell for binding an analyte of interest, and a reporter molecule within each spore-forming cell for detecting binding of the analyte of interest, wherein the reporter molecule generates a detectable signal upon binding of the analyte by the recognition element. The presently-disclosed subject matter further provides methods of using the biosensors and systems and kits including the biosensors. | 12-02-2010 |
| 20100304366 | Methods for Determining Virulence and Invasiveness Among Various Staphylococcus Aureus Strains - This invention describes quick diagnostic methods to distinguish CA-MRSA MW2 or CA-MRSA USA300 strains in clinical samples from various sources. Fluorescent labeled primers which amplify 1) two unique agr sequences from each strain, 2) a partial spa gene and 3) a partial pvl gene are packaged into a multiplex PCR kit. A real-time instrumentation to amplify and quantify the PCR amplification products, measured by the change of each of the labeled fluorescent reporter and their thermal melting curve, provides a simple and rapid identification of the most virulent and invasive MRSA strains in the United States. | 12-02-2010 |
| 20090286254 | GENE SILENCING - Methods are disclosed for screening for the occurrence of gene silencing (e.g., post transcriptional gene silencing) in an organism. Also provided are methods for isolating silencing agents so identified. | 11-19-2009 |
| 20090286255 | METHODS FOR ASSESSING EFFICACY OF CHEMOTHERAPEUTIC AGENTS - Methods are provided for accurately predicting efficacy of chemotherapeutic agents. Methods of the invention increase the positive predictive value of chemosensitivity assays by assessing both the ability of a chemotherapeutic to destroy cells and the genetic propensity of those cells for resistance. Results obtained using methods of the invention provide insight into the in vivo effectiveness of a therapeutic, and lead to more effective chemotherapeutic treatment. | 11-19-2009 |
| 20090286250 | INCORPORATING SOLUBLE SECURITY MARKERS INTO CYANOACRYLATE SOLUTIONS - Methods for authenticating an article with a cyanoacrylate solution comprising a water soluble security marker compound are described. The methods for producing a nucleophilic security marker/cyanoacrylate solution as well as methods for labeling an item and detecting the nucleophilic security marker/cyanoacrylate from an item being authenticated are also described. A method for using a nucleophilic cyanoacrylate security marker for antitheft purposes is also described. | 11-19-2009 |
| 20090286242 | MicroRNA Expression Profiling and Uses Thereof - Provided are methods and reagents for obtaining microRNA expression profiles in selected cell populations or sub-populations, such as stem cell or progenitor cell populations, and using such microRNA expression profiles for cell characterization, isolation/purification, and/or reinforcement of cell fate specification, both in research & development, and in therapeutic applications. Also provided are methods of identifying and isolating mammary progenitor cells using miRNA sensor constructs. | 11-19-2009 |
| 20090286233 | Method for Diagnosing Diabetic Retinopathy by Single Nucleotide Polymorphism, DNA Fragment Thereof, and Primer Thereof - Disclosed is a method for diagnosing diabetic retinopathy by a single nucleotide polymorphism of VEGF and its receptor. | 11-19-2009 |
| 20110111415 | MULTI-STAGE NUTRIGENOMIC DIAGNOSTIC FOOD SENSITIVITY TESTING IN ANIMALS - A multi-stage method for diagnosing an immunologic food sensitivity or intolerance in a companion animal. Firstly a saliva or blood spot or other non-serum bodily fluid sample is collected. The screening the saliva or blood spot or other non-serum bodily fluid sample detects the presence of at least one of IgA or IgM antibody to a particular food ingredient or composition. An immunologic food sensitivity or intolerance based on the presence of the antibody is diagnosed. Secondly a blood sample is collected and serum from the sample is screened to detect the semi-quantitative or quantitative presence of at least one of an IgA, IgM or IgG antibody or immune complex to a particular food ingredient or composition. An immunologic food sensitivity or intolerance based on the presence of the antibody or immune complex is diagnosed. Thirdly, a biologically active nutrient in relation to the animal from a molecular dietary signature is determined. The molecular dietary signature for the animal is a variation of expression of a set of genes, proteins or metabolites which may differ for the genotype of each animal. | 05-12-2011 |
| 20110111402 | KIFS as Modifiers of the RHO Pathway and Methods of Use - Human KIF23 genes are identified as modulators of the RHO pathway, and thus are therapeutic targets for disorders associated with defective RHO function. Methods for identifying modulators of RHO, comprising screening for agents that modulate the activity of KIF23 are provided. | 05-12-2011 |
| 20100227323 | MICROCHANNEL DETECTION DEVICE AND USE THEREOF - The present invention relates to a device and methods for detecting or quantifying an analyte in a test sample. The device includes a substrate defining one or more microchannels and having a reaction region in a first portion of the one or more microchannels, wherein the reaction region contains a first binding element selected to bind with a first portion of the analyte. The device also includes a detection region in fluid communication with the reaction region. The detection region includes a second binding element selected to immobilize the analyte within the detection region. Methods of detecting or quantifying an analyte in a test sample using the device of the present invention are also disclosed. A method for coating a polymer with a gold layer is also disclosed. | 09-09-2010 |
| 20100221733 | BIOMARKER OF ALLERGIC DISEASE AND USE OF THE SAME - A biomarker is provided for an allergic disease caused by an allergic reaction that is caused not exclusively by histamine release, such as pruritus, and use of the same. Use of Granzyme A as a biomarker makes it possible to provide an indication for chronic itching skin disease, for which existing antiallergic drugs have little effect, and easily and adequately allow diagnosis of the disease. It is possible to, for example, make a diagnosis of an allergic disease with an IV type allergy-like reaction not depending on the antigen-antibody reaction system. Screening with the use of Granzyme A enables the development of novel remedies for allergic diseases. Moreover, a drug capable of specifically controlling the action of a granzyme enables treatment of allergic disease with little side effect. | 09-02-2010 |
| 20100221703 | Chemiluminescence proximity nucleic acid assay - This invention relates to the detection and quantitation of target nucleic acids in a heterogeneous mixture in a Sample and the methods of use thereof. The detection system includes a chemiluminescent molecule, a chemiluminescent substrate, a dye that is light responsive when intercalated into nucleic acids and nucleic acids. This invention is useful in any application where detection of a specific nucleic acid sequence is desirable, or where the detection of enzymes that modify nucleic acids is desirable such as diagnostics, research uses and industrial applications. | 09-02-2010 |
| 20100279304 | METHODS FOR PRODUCING NUCLEIC ACID HYBRIDIZATION PROBES THAT AMPLIFY HYBRIDIZATION SIGNAL BY PROMOTING NETWORK FORMATION - This invention describes methods for the generation of nucleic acid probes that improve the sensitivity of hybridization assays. The sensitivity increase results from structural modifications of nucleic acids that promote network formation during hybridization with the result that a single target molecule becomes attached to a complex of many probe molecules. The structural modification involves fragmentation of the probe nucleic acid followed by joining the fragments together such that their order and orientation and number is altered from the original probe molecule. The result is the generation of permuted probe libraries. Various fragmentation and joining methods are described. Labeling can be done by standard methods before during or after formation of permuted probe libraries. Individual members of permuted probe libraries can be isolated and amplified and perpetuated. Fixed mixtures of such isolated library members can be used as permuted probe libraries of limited variability to control network complexity. Libraries can be prepared with additional sequences not present in the target and the fraction of the library made up by such sequences can be controlled. Such extra-target additions can be used as targets for detection by secondary probes. Since their number can be far greater than equimolar with the probe sequences represented in the target they can be detected with higher sensitivity in the networks. Probes for different targets can incorporate different non-target sequences in hyper-molar quantities permitting sensitive detection of multiple hybridization targets in the same sample. Probes made according to this invention can be used in many kinds of hybridization assay including Southern. blots, Northern blots, Dot blots, Nucleic acid Array hybridization, ‘in situ’ hybridization with fluorescent or other labels (FISH) and various kinds of sandwich hybridization assays. | 11-04-2010 |
| 20100221726 | RELATING TO DEVICES - A method of analysis, instrument for analysis and device for use in such an instrument are provided, which perform a number of processes need to reach a useful result in the context of a wide variety of samples. The sequence of those processes being optimised. A device, instrument using the device and method of use are also provided which offer reliable performance of a heating based process, with minimal condensation and/or sample loss issues. | 09-02-2010 |
| 20100221725 | REAL TIME GENE EXPRESSION PROFILING - The invention relates to methods of monitoring the amplification of one or more nucleic acid sequences of interest. More particularly, the invention relates to methods of monitoring the amplification of sequences of interest in real time. The methods disclosed herein provide methods for monitoring the amplification of one sequence or two or more sequences from a single sample, as well as methods for monitoring the amplification of one or more than one sequence from two or more samples. The monitoring methods of the invention permit improved determination of the abundance of one or more target nucleic acids, especially target RNA species, in one or more original samples. | 09-02-2010 |
| 20100221715 | DETECTION OF BORDETELLA - The invention provides methods to detect | 09-02-2010 |
| 20100221714 | ANALYSIS AND USE OF PAR1 POLYMORPHISMS FOR EVALUATING THE RISK OF CARDIOVASCULAR DISEASE - The invention relates to polynucleotide sequences comprising genetic variations of the PAR1 gene at positions 3090 and/or 3329. The occurrence of these variants in humans correlates with increased occurrence of particular cardiovascular disorders. The invention furthermore relates to methods for detecting said genetic variations for the purpose of patient diagnosis. | 09-02-2010 |
| 20100221713 | Droplet Actuator Devices, Systems, and Methods - The invention relates to certain novel approaches to reducing or eliminating the movement of contaminants from one droplet to another on a droplet actuator via liquid filler fluid. In one application, droplet actuators are used to conduct genetic analysis using polymerase chain reaction (PCR) techniques. The invention addresses the need for improved methods of performing PCR on a droplet actuator that provide for optimum amplification and detection of a sample target. | 09-02-2010 |
| 20110111399 | Methods And Compositions Including Diagnostic Kits For The Detection of Staphylococcus Aureus - Methods and compositions, including diagnostic kits, for the detection of | 05-12-2011 |
| 20100196916 | Drug Screening using Islet Cells and Islet Cell Progenitors from Human Embryonic Stem Cells - This disclosure provides a system for producing pancreatic islet cells from embryonic stem cells. Differentiation is initiated towards endoderm cells, and focused using reagents that promote emergence of islet precursors and mature insulin-secreting cells. High quality populations of islet cells can be produced in commercial quantities for use in research, drug screening, or regenerative medicine. | 08-05-2010 |
| 20110014607 | IMPRINTED GENES AND DISEASE - Methods for identifying imprinted genes. In some embodiments, the methods comprise (a) providing a first data set comprising a plurality of nucleic acid sequences, wherein the nucleic acid sequences comprise genomic DNA sequences corresponding to a plurality of genes known to be imprinted in the subject; (b) providing a second data set comprising a plurality of nucleic acid sequences, wherein the nucleic acid sequences comprise genomic DNA sequences corresponding to a plurality of genes known not to be imprinted in the subject; (c) identifying one or more features that by themselves or in combination are differentially present or absent from the first data set as compared to the second data set; and (d) applying the one or more features to a test data set comprising a plurality of genomic DNA sequences which correspond to one or more genes for which the imprinting status is unknown to thereby identify an imprinted gene in a subject. The presently disclosed subject matter also provides methods for identifying a feature in a subject with respect to an imprinted gene and methods for detecting a presence of or a susceptibility to a medical condition associated with parent-of-origin dependent monoallelic expression in a subject. | 01-20-2011 |
| 20100184060 | METHOD FOR THE IDENTIFICATION OF PROPANE-OXIDIZING BACTERIA - The invention relates to a method for the identification of propane-oxidizing bacteria which is based on the identification of at least one fragment of the prmA gene encoding the alpha subunit of the propane monooxygenase enzyme and/or the prmD gene encoding an ancillary protein involved in the oxidation reaction of propane by gene amplification in the presence of pairs of primers selected in correspondence of homologous portions, deduced from the alignment of the prmA and prmD sequences. | 07-22-2010 |
| 20100196897 | Method and Device for Non-Invasive Prenatal Diagnosis - Method for non-invasive prenatal diagnosis comprising the following steps: a. obtain a sample of an organic fluid having a high probability of containing foetal cells from a pregnant woman; b. enrich said sample of organic fluid in at least one population of cells comprising at least one type of foetal nucleated cells; c. isolate at least one cell from among said at least one type of foetal nucleated cells; d. perform a genetic analysis on said at least one cell isolated from among said at least one type of foetal nucleated cells in order to highlight at least one genetic characteristic of said at least one foetal nucleated cell suitable for permitting said diagnosis; wherein the step of isolating at least one cell from among said at least one type of foetal nucleated cells is performed by individually selecting single cells in a microfluidic device designed for said purpose. | 08-05-2010 |
| 20100184030 | METHOD, COMPOSITIONS AND KITS FOR INCREASING EFFICIENCY OR SPECIFICITY OF HYBRIDIZATION BETWEEN PNA PROBES IMMOBILIZED ON SUPPORT AND TARGET NUCLEIC ACIDS - Disclosed are a process for increasing efficiency or specificity of hybridization between peptide nucleic acid (PNA) probes immobilized on a support and target nucleic acids, which comprises the step of fragment the target nucleic acids to reduce the size of the target nucleic acids, or selectively degrading the target nucleic acids which mismatch with the PNA probes, in the hybridization reaction between the PNA probes supported on a support and the target nucleic acids; and a composition and a kit therefor. | 07-22-2010 |
| 20100203540 | DEVICE FOR SEPARATING AND/OR ANALYZING SEVERAL MOLECULAR TARGETS DISSOLVED IN A COMPLEX MIXTURE - The invention relates to a device for separating and/analyzing several molecular targets dissolved in a complex mixture which is characterized in that it comprises
| 08-12-2010 |
| 20100203537 | DUAL OLIGONUCLEOTIDE METHOD OF NUCLEIC ACID DETECTION - Methods for amplifying and detecting nucleic acids are described, as well as sets of 5′ labeled oligonucleotides. | 08-12-2010 |
| 20100291567 | GENES AND POLYPEPTIDES RELATING TO HEPATOCELLULAR OR COLORECTAL CARCINOMA - The present application provides novel human genes WDRPUH and KRZFPUH, and PPIL1 whose expression is markedly elevated in a great majority of HCCs and colorectal cancers, respectively, compared to corresponding non-cancerous tissues, as well as novel human gene APCDD1 whose expression is elevated in primary colon cancers and down-regulated in response to the transduction of wild-type APC1 into colon-cancer cells. The genes and polypeptides encoded by the genes can be used, for example, in the diagnosis of a cell proliferative disease, and as target molecules for developing drugs against the disease. | 11-18-2010 |
| 20100041040 | Internally Controlled Multiplex Detection and Quantification of Microbial Nucleic Acids - The present invention relates to new methods and uses for the detection and quantification of microbial nucleic acids employing an internal quantitative reference. Preferred methods are based on the amplification of nucleic acids, preferably the polymerase chain reaction. Further provided are kits comprising components for performing said methods and uses. Moreover, an analytical system for advantageously performing the method according to the invention is disclosed. | 02-18-2010 |
| 20100041035 | IDENTIFICATION OF CENTROMERE SEQUENCES AND USES THEREFOR - Provided herein are methods for identifying centromeres and centromeres identified by such methods. Centromeres of organisms such as algae, fungi, and protists can be used, for example, for constructing artificial chromosomes and cells containing such artificial chromosomes. | 02-18-2010 |
| 20100178653 | GENE EXPRESSION SIGNATURE FOR CLASSIFICATION OF CANCERS - The present invention provides a process for classification of cancers and tissues of origin through the analysis of the expression patterns of specific microRNAs and nucleic acid molecules relating thereto. Classification according to a microRNA tree-based expression framework allows optimization of treatment, and determination of specific therapy. | 07-15-2010 |
| 20100178650 | CAPILLARY-BASED CELL AND TISSUE ACQUISITION SYSTEM (CTAS) - The present invention relates to a capillary-based cell and tissue acquisition system that integrates the capillary approach with a microscope manipulator to collect and sort cells of interest. Cells of interest are determined by using a laser beam focus to identify the initial contact between the capillary and the cells. | 07-15-2010 |
| 20110033853 | CSNKS As Modifiers of the RAC Pathway and Methods of Use - Human CSNK genes are identified as modulators of the RAC pathway, and thus are therapeutic targets for disorders associated with defective RAC function. Methods for identifying modulators of RAC, comprising screening for agents that modulate the activity of CSNK are provided. | 02-10-2011 |
| 20100297628 | Methods Of Producing And Sequencing Modified Polynucleotides - The present invention encompasses methods for producing a modified polynucleotide sequence that comprises a (e.g., one or more) phosphorothiolate linkage, methods for determining a polynucleotide sequence comprising a (e.g., one or more) phosphorothiolate linkage, and methods for separating forward and reverse extension products that comprise a (e.g., one or more) phosphorothiolate linkage. The invention also encompasses kits for producing and/or determining the sequence of a modified polynucleotide that comprises a (e.g., one or more) phosphorothiolate linkage. | 11-25-2010 |
| 20100297639 | QUANTITATIVE/SEMI-QUANTITATIVE MEASUREMENT OF EPOR ON CANCER CELLS - The present invention provides for assays useful in predicting whether a cancer patient risks suffering erythropoietin-induced tumor progression if treated with erythropoietin. More specifically, one embodiment provides for a validated quantitative reverse transcriptase polymerase chain reaction assay that detects erythropoietin receptor expression, thus indicating whether a cancer patient risks suffering erythropoietin-induced tumor progression if treated with erythropoietin. | 11-25-2010 |
| 20100297642 | METHOD FOR DETERMINING FRAMESHIFT MUTATIONS IN CODING NUCLEIC ACIDS - The present invention relates to a method for identifying frameshift mutations in coding nucleic acid sequences. | 11-25-2010 |
| 20100297629 | NUCLEIC ACID SUPPORTED PROTEIN COMPLEMENTATION - The present invention is directed to novel methods for in vitro and in vivo detection of target nucleic acid molecules, including DNA and RNA targets, as well as nucleic acid analogues. The present invention is based on protein complementation, in which two individual polypeptides are inactive. When the two inactive polypeptide fragment are brought in close proximity during hybridization to a target nucleic acid, they re-associate into an active, detectable protein. | 11-25-2010 |
| 20100297649 | METHODS AND MATERIALS FOR DETECTING GENE AMPLIFICATION - This document relates to methods and materials involved in detecting gene amplification in a mammal. For example, methods and materials for detecting amplification at CPM and MDM2 loci to determine the presence or absence of a malignant lipomatous neoplasm in a mammal are provided. | 11-25-2010 |
| 20100297647 | POLYMERASE-BASED SINGLE-MOLECULE SEQUENCING - The invention relates to an assay method for determining the base sequence in a nucleic acid sample which comprises detection of a single base in said sequence using a polymerase modified to include at least one fluorophore and a dark quencher group; detecting and deducing the amount of energy transfer. | 11-25-2010 |
| 20100297660 | SINGLE NUCLEOTIDE POLYMORPHISMS ASSOCIATED WITH RENAL DISEASE - Methods for determining the genetic predisposition of a human subject to developing renal disease, such as focal segmental glomerulosclerosis (FSGS) or end-stage kidney disease are provided herein. These methods include methods for detecting renal disease, or determining the risk of developing renal disease in a human subject, such as a subject of African ancestry. The methods utilize the detection of one or more haplotype blocks comprising at least two tag single nucleotide polymorphisms (SNPs) in a non-coding region of a MYH9 gene or detecting the presence of at least one tag SNP in a non-coding region of a MYH9 gene. An array for detecting a genetic predisposition to renal disease using probes complementary to the tag SNPs in the non-coding region of the MYH9 gene are also disclosed. | 11-25-2010 |
| 20110111411 | Protein-Responsive RNA Control Devices and Uses Thereof - The invention described herein relates to an RNA-based control device that senses the presence and/or concentration of at least one protein ligand, preferably through its protein-binding aptamer domain, and regulates a target gene expression through alternative splicing of the target gene in which the RNA-based control device is integrated. The device has uses in therapeutic as well as diagnostic applications. | 05-12-2011 |
| 20110045472 | MONITORING ENZYMATIC PROCESS - Techniques, apparatus and systems are described for performing label-free monitoring of processes. In one aspect, a label-free monitoring system includes an array of label-free optical sensors to detect an optical signal in response to synthesis of one or more target genetic structures. Each label-free optical sensor is functionalized with a respective target genetic structure. The system also includes a fluid flow control module that includes fluid receiving units to provide paths for different fluids to flow into the fluid flow control module and at least one switch connected to the fluid receiving units to selectively switch among the fluid receiving units to receive a select sequence of the fluids through the fluid receiving units. The select sequence of the fluids includes at least a dNTP or base. A fluid channel is connected between the fluid flow control module and the array of sensors to allow the select sequence of the fluids to flow from the fluid flow control module to the array of label-free optical sensors. | 02-24-2011 |
| 20090298085 | Detection of Extracellular Tumor-Associated Nucleic Acid in Blood Plasma or Serum Using Nucleic Acid Amplification Assays - This invention relates to detection of specific extracellular nucleic acid in plasma or serum fractions of human or animal blood associated with neoplastic or proliferative disease. Specifically, the invention relates to detection of nucleic acid derived from mutant oncogenes or other tumor-associated DNA, and to those methods of detecting and monitoring extracellular mutant oncogenes or tumor-associated DNA found in the plasma or serum fraction of blood by using rapid DNA extraction followed by nucleic acid amplification with or without enrichment for mutant DNA. In particular, the invention relates to the detection, identification, or monitoring of the existence, progression or clinical status of benign, premalignant, or malignant neoplasms in humans or other animals that contain a mutation that is associated with the neoplasm through detection of the mutated nucleic acid of the neoplasm in plasma or serum fractions. The invention permits the detection of extracellular, tumor-associated nucleic acid in the serum or plasma of humans or other animals recognized as having a neoplastic or proliferative disease or in individuals without any prior history or diagnosis of neoplastic or proliferative disease. The invention provides the ability to detect extracellular nucleic acid derived from genetic sequences known to be associated with neoplasia, such as oncogenes, as well as genetic sequences previously unrecognized as being associated with neoplastic or proliferative disease. The invention thereby provides methods for early identification of colorectal, pancreatic, lung, breast, bladder, ovarian, lymphoma and all other malignancies carrying tumor-related mutations of DNA and methods for monitoring cancer and other neoplastic disorders in humans and other animals. | 12-03-2009 |
| 20090298084 | GENE AND PROTEIN EXPRESSION PROFILES ASSOCIATED WITH THE THERAPEUTIC EFFICACY OF IRINOTECAN - The present invention includes gene and protein expression profiles indicative of whether a cancer patient is likely to respond to treatment with irinotecan. By identifying such responsiveness, a treatment provider may determine in advance those patients who would benefit from such treatment, as well as identify alternative therapies for non-responders. The present invention further provide methods of using the gene and/or protein expression profiles and assays for identifying the presence of a gene and/or protein expression profile in a patient sample. | 12-03-2009 |
| 20090298068 | METHOD AND TEST KIT FOR THE DIAGNOSIS AND/OR MAKING PREDICTIONS ABOUT AND/OR FOR THE ASSESSMENT OF THE EFFICACY OF THERAPEUTIC AGENTS FOR THE TREATMENT OF OVARIAN CANCER AND METHOD OF PLANNING A REGIMEN FOR THE TREATMENT OF OVARIAN CANCER - The invention relates to a method and a test kit for diagnosing ovarian cancer and/or making predictions in case of ovarian cancer as well as a method for estimating the effectiveness of therapeutic agents during the treatment of ovarian cancer, the promoter hypermethylation of the TUSC3 marker in a biological sample that is to be analyzed, preferably in a tissue sample or biological liquid that is to be analyzed, being measured. The result of said method can be used for planning an ovarian cancer treatment. | 12-03-2009 |
| 20090298063 | IL-1 Gene Cluster and Associated Inflammatory Polymorphisms and Haplotypes - The invention provides methods and compositions relating to identification and use of genetic information from the IL-1 gene cluster—including the structure and organization of novel IL-1-like genes found within the IL-1 locus as well as polymorphisms and associated haplotypes within these genes. The invention thereby expands the repertoire of useful genetic information available from the IL-1 locus—which contains the previously-identified IL-1α, EL-1β and IL-1RN genes, for predicting IL-1 associated phenotypes (e.g. increased or decreased risks of inflammatory disease) and for treating IL-1 haplotype associated inflammatory phenotypes. | 12-03-2009 |
| 20090298053 | Use of novel biomarkers for detection of testicular carcinoma in situ and derived cancers in human samples - The present invention relates to methods and kits for identification of testicular carcinoma in situ (CIS), gonadoblastoma (a CIS-like pre-cancerous lesion found in dysgenetic gonads) and CIS-derived cancers based on at least one of the biomarkers included in the invention. It also relates to diagnosis of a subject's status of the testicular carcinoma in situ and the derived cancers based on the measurement of a relative abundance of one of the biomarkers. | 12-03-2009 |
| 20110020796 | Compositions, Methods, and Kits for the Detection of Chlamydia Trachomatis - Method for the detection of | 01-27-2011 |
| 20100311060 | Integrated Chip Carriers With Thermocycler Interfaces And Methods Of Using The Same - Methods and systems are provided for conducting a reaction at a selected temperature or range of temperatures over time. An array device is provided. The array device contains separate reaction chambers and is formed as an elastomeric block from multiple layers. At least one layer has at least one recess that recess has at least one deflectable membrane integral to the layer with the recess. The array device has a thermal transfer device proximal to at least one of the reaction chambers. The thermal transfer device is formed to contact a thermal control source. Reagents for carrying out a desired reaction are introduced into the array device. The array device is contacted with a thermal control device such that the thermal control device is in thermal communication with the thermal control source so that a temperature of the reaction in at least one of the reaction chamber is changed as a result of a change in temperature of the thermal control source. | 12-09-2010 |
| 20100311055 | COMPOSITIONS AND METHODS FOR TERMINATING A SEQUENCING REACTION AT A SPECIFIC LOCATION IN A TARGET DNA TEMPLATE - Compositions and methods for sequencing a template polynucleotide comprising a sequence of interest are provided herein. The compositions and methods employ at least one blocking probe that is designed to bind in a sequence-specific manner to a blocking sequence such that primer extension beyond the site where the blocking probe binds is reduced or prevented. | 12-09-2010 |
| 20100311040 | Dna Fragments, Primers, Kits, and Methods for Amplification the Detection and Identification of Clinically Relevant Candida Species - The present invention describes a novel molecular method based on the polymerase chain reaction (PCR) in a multiplex variant in order to detect and identify | 12-09-2010 |
| 20100021923 | METHOD FOR THE EFFICIENCY-CORRECTED REAL-TIME QUANTIFICATION OF NUCLEIC ACIDS - The present invention concerns a method for the quantification of a target nucleic acid in a sample comprising the following steps: (i) determination of the amplification efficiency of the target nucleic acid under defined amplification conditions, (ii) amplification of the target nucleic acid contained in the sample under the same defined reaction conditions, (iii) measuring the amplification in real-time, (iv) quantification of the original amount of target nucleic acid in the sample by correction of the original amount derived from step (iii) with the aid of the determined amplification efficiency. The efficiency correction of PCR reactions according to the invention for the quantification of nucleic acids can be used for absolute quantification with the aid of an external or internal standard as well as for relative quantification compared to the expression of housekeeping genes. | 01-28-2010 |
| 20090280495 | ACTIVATING MUTATIONS OF PLATELET DERIVED GROWTH FACTOR RECEPTOR ALPHA (PDGFRA) AS DIAGNOSTIC MARKERS AND THERAPEUTIC TARGETS - This disclosure provides tyrosine kinase protein and nucleic acid variants, particularly PDGFRA variants, which are activating forms of these molecules and are linked to neoplasms and/or the development or progression of cancer. The disclosure further provides methods of diagnosis and prognosis, and development of new therapeutic agents using these molecules and fragments thereof, and kits for employing these methods and compositions. | 11-12-2009 |
| 20090280493 | Methods and Compositions for the Prediction of Response to Trastuzumab Containing Chemotherapy Regimen in Malignant Neoplasia - The invention relates to methods and compositions for the prediction, diagnosis, prognosis, prevention and treatment of neoplastic disease. Neoplastic disease is often caused by chromosomal rearrangements which lead to over- or underexpression of the rearranged genes. The invention discloses genes which are overexpressed in neoplastic tissue and are useful as diagnostic markers and targets for treatment. Methods are disclosed for predicting, diagnosing and prognosing as well as preventing and treating neoplastic disease. | 11-12-2009 |
| 20090280488 | Prophylactic/therapeutic agent for neurodegenerative disease - To provide a prophylactic/therapeutic agent for neurodegenerative diseases (such as polyglutamine diseases), the agent containing an HMGB family protein or a derivative thereof, such as a protein according any one of (a) and (b) below:
| 11-12-2009 |
| 20090280484 | METHODS FOR GENE MAPPING AND HAPLOTYPING - The present invention is directed to methods for providing a definitive haplotype of a subject. The haplotype information generated by the methods described herein is more accurate than that provided by prior art methods that only give an inferred haplotype. Accordingly, in one aspect the present invention provides a method for determining a definitive haplotype of a subject the method including the steps of providing a substantially isolated haploid element from the subject, and obtaining nucleotide sequence information from the haploid element. Applicants propose that the use of a substantially isolated haploid element eliminates the problem of incorrect or misleading inferences concerning the phase of two or more loci within a haplotype, and allows for revelation of two or more participatory genes within a haplotype, uncomplicated by differences in modes of inheritance. The guarantee of strictly cis-phase associations is provided in the present methods by the use of a substantially isolated haploid element as starting material for sequence analysis. | 11-12-2009 |
| 20090280483 | Methods for Screening Interleukin-6 (IL-6) Signal Transduction Inhibitors - The present invention provides methods for screening compounds which inhibit activation of a member of the IL-6 signaling pathways, comprising: (a) a positive screening step using a cell capable of being killed by IL-6 stimulation to select compounds which inhibit death of the cell when it is stimulated by IL-6; and then (b) a biochemical screening step to further select compounds which inhibit activation of a member of the IL-6 signaling pathways by a biochemical means from the compounds selected in step (a). The present invention also provides compounds which inhibit activation of a member of the IL-6 signaling pathways identified using said methods. | 11-12-2009 |
| 20090280475 | Droplet-based pyrosequencing - The present invention relates to a droplet microactuator and to systems, apparatuses and methods employing the droplet microactuator for executing various protocols using droplets. The invention includes a droplet microactuator or droplet microactuator system having one or more input reservoirs loaded with reagents for conducting sequencing protocols, such as the reagents for conducting a pyrosequencing protocol. The invention also includes a droplet microactuator or droplet microactuator system, having one or more input reservoirs loaded with a sample for conducting a pyrosequencing protocol. | 11-12-2009 |
| 20100311042 | Amplifying bisulfite-treated template - Methods of amplifying nucleic acid are described. Primers on a solid support, e.g. a population of beads, are employed. A population of nucleic acid template molecules, wherein said nucleic acid template molecules have been treated with bisulfite, is amplified so as to create loaded beads comprising immobilized amplified nucleic acid. | 12-09-2010 |
| 20100311064 | MULTIPLEX NUCLEIC ACID REACTIONS - The invention is directed to a variety of multiplexing methods used to amplify and/or genotype a variety of samples simultaneously. | 12-09-2010 |
| 20100311062 | E. COLI O157:H7 SPECIFIC ASSAY - Disclosed are assays, methods and kits for the specific detection of | 12-09-2010 |
| 20100311056 | METHOD FOR HYBRIDIZING NUCLEIC ACIDS - The invention relates to a method for manipulating, isolating, detecting or amplifying a target nucleic acid in a sample by hybridization with an oligonucleotide-oligocation conjugate, comprising allowing said nucleic acid to react with an oligonucleotide-oligocation conjugate comprising at least A1 and Bj linked together directly or via a linker, wherein. A, is an i-mer oligonucleotides, with i=3 to 50, where Ai is an oligomer with naturally or non naturally occurring nucleobases and/or pentafuranosyl groups and/or native phosphodiester bonds, optionally comprising a marker group. Bj is a j-mer organic oligocation moiety, with j=1 to 50, where B is —HPO | 12-09-2010 |
| 20100311045 | CANCER - The invention provides methods of diagnosis, prognosis and treatment of cancer related to the OBCAM and NTM genes. The methods are particularly suited to ovarian and colorectal cancers. | 12-09-2010 |
| 20100311063 | METHODS AND COMPOSITIONS FOR LABELING NUCLEIC ACIDS - The present invention relates to methods for the labeling of nucleic acid polymers in vitro and in vivo. Certain methods are provided that include a [3+2] cycloaddition between a nucleotide analogue incorporated into a nucleic acid polymer and a reagent attached to a label. Other methods are provided that include a Staudinger ligation between a nucleotide analogue incorporated into a nucleic acid polymer and a reagent comprising a substituted triarylphosphine attached to a label. Such methods do not require fixation and denaturation and therefore can be applied to the labeling of nucleic acid polymers in living cells and in organisms. Also provided are methods for measuring cellular proliferation. In these methods, the amount of label incorporated into the DNA is measured as an indication of cellular proliferation. The methods of the invention can be used in a wide variety of applications including clinical diagnosis of diseases and disorders in which cellular proliferation is involved, toxicity assays, and as a tool for the study of chromosomes' ultrastructures. | 12-09-2010 |
| 20100311065 | GENETICALLY MODIFIED MICROBES PRODUCING ISOPRENOIDS - Provided herein are methods of generating genetically modified yeast cells, e.g., genetically modified diploid and haploid yeast cells, that comprise novel polypeptides, and genetically modified yeast cells that persistently produce isoprenoid compounds in industrial fermentation processes, produced thereby. | 12-09-2010 |
| 20090311708 | METHOD OF DETERMINING A CHEMOTHERAPEUTIC REGIMEN BASED ON ERCC1 AND TS EXPRESSION - The present invention relates to prognostic methods which are useful in medicine, particularly cancer chemotherapy. The object of the invention to provide a method for assessing TS and/or ERCC1 expression levels in fixed or fixed and paraffin embedded tissues and prognosticate the probable resistance of a patient's tumor to treatment with 5-FU and oxaliplatin-based therapies by examination of the amount of TS and/or ERCC1 mRNA in a patient's tumor cells and comparing it to a predetermined threshold expression level for those genes. More specifically, the invention provides to oligonucleotide primer pairs ERCC1 and TS and methods comprising their use for detecting levels of ERCC1 and TS mRNA, respectively. | 12-17-2009 |
| 20090311677 | Identification of contaminating bacteria in industrial ethanol fermentations - A method for determining the presence of a contaminating organism in a fermentation process includes initiating the fermentation process using a syngas and obtaining a first aliquot from the fermentation process. The method further includes subjecting said first aliquot to a polymerase chain reaction using at least one oligonucleotide primer capable of hybridizing to a target sequence of a genomic nucleic acid from a suspected contaminating organism, producing a first amplified product based on the polymerase chain reaction, separating the first amplified product based on size, and determining the presence of the suspected contaminating organism based on the first separated amplified product. | 12-17-2009 |
| 20090311712 | METHOD OF SCREENING MULTIPLE SINGLE NUCLEOTIDE POLYMORPHISMS ASSOCIATED WITH SUSCEPTIBILITY TO SPECIFIC DISEASE OR DRUG RESPONSE - Provided is a method of screening multiple single nucleotide polymorphisms (SNPs) having significance with a case group, the method comprising: selecting one or more SNPs from nucleic acid sequences of the case group and a control group; generating all combinable genotype patterns of multiple SNPs comprised of two or more of the selected SNPs; determining frequencies of the genotype patterns from the case group and the control group; and determining and choosing genotype patterns having statistical significance with the case group using the frequencies. According to the method of screening multiple SNPs, multiple SNPs associated with a specific disease or drug can be effectively selected from the entire genome of an individual. Methods of identifying susceptibility of an individual to development of Type II diabetes are also disclosed. | 12-17-2009 |
| 20100317006 | SCA RISK STRATIFICATION BY PREDICTING PATIENT RESPONSE TO ANTI-ARRHYTHMICS - Genetic tests and methods for treatment based on markers to identify patients suffering from life-threatening ventricular tachy-arrhythmias, such as Ventricular Tachycardias (“VT”) and Ventricular Fibrillation (“VF”) that might lead to Sudden Cardiac Arrest (“SCA”) or Sudden Cardiac Death (“SCD”) are provided. Patients who cannot be sufficiently protected by medication alone, such as those refractory to anti-arrhythmic medication, are identified based on their genotype. The resulting information is used in a diagnostic test to identify and treat those patients who would benefit from the implantation of an Implantable Cardio Defibrillator (“ICD”). | 12-16-2010 |
| 20100317018 | METHODS AND COMPOSITIONS FOR DIAGNOSING AND MONITORING TRANSPLANT REJECTION - Methods of diagnosing or monitoring transplant rejection, particularly cardiac transplant rejection, in a patient by detecting the expression level of one or more genes in a patient, are described. Diagnostic oligonucleotides for diagnosing or monitoring transplant rejection, particularly cardiac transplant rejection and kits or systems containing the same are also described. | 12-16-2010 |
| 20100317011 | Proteins having serine/threonine kinase domains, corresponding nucleic acid molecules, and their use - The invention relates to the molecule referred to as ALK-1, and its role as a type I receptor for members of the TGF-β family. The molecule has a role in the phosphorylation of Smad-5 and Smad1, which also act as activators of certain genes. Aspects of the invention relate to this interaction. | 12-16-2010 |
| 20100240035 | MULTIGENE PROGNOSTIC ASSAY FOR LUNG CANCER - The present invention provides methods for providing a prognosis for lung adenocarcinoma, using a panel of eight molecular markers that are differentially expressed in lung adenocarcinoma. | 09-23-2010 |
| 20100323350 | Methods And Devices For Sequencing Nucleic Acids In Smaller Batches - The invention provides methods and compositions, including, without limitation, algorithms, computer readable media, computer programs, apparatus, and systems for determining the identity of nucleic acids in nucleotide sequences using, for example, data obtained from sequencing by synthesis methods. A plurality of smaller flow cells is employed, each with a relatively small area to be imaged, in order to provide greater flexibility and efficiency. | 12-23-2010 |
| 20100304395 | Method, Program, and System for Normalizing Gene Expression Amounts - The present invention aims at presenting novel means for analyzing and correcting gene expression amounts. There is provided a gene expression amount normalizing method in which the number of cells in a sample is obtained by measuring a repeated sequence present in a substantially fixed proportion in a genome contained in the sample, and the number of cells obtained is used as an index for normalizing gene expression amounts obtained from the same sample. For example, a DNA sample | 12-02-2010 |
| 20100304392 | HEPATITIS B VIRAL VARIANTS WITH REDUCED SUSCEPTIBILITY TO NUCLEOSIDE ANALOGS AND USES THEREOF - The present invention relates generally to viral variants exhibiting reduced sensitivity to particular agents and/or reduced interactivity with immunological reagents. More particularly, the present invention is directed to hepatitis B virus (HBV) variants exhibiting complete or partial resistance to nucleoside or nucleotide analogs and/or reduced interactivity with antibodies to viral surface components including reduced sensitivity to these antibodies. The present invention further contemplates assays for detecting such viral variants, which assays are useful in monitoring anti-viral therapeutic regimens and in developing new or modified vaccines directed against viral agents and in particular HBV variants. The present invention also contemplates the use of the viral variants to screen for and/or develop or design agents capable of inhibiting infection, replication and/or release of the virus. | 12-02-2010 |
| 20100304388 | Biomarker For Successful Aging Without Cognitive Decline - Methods and compositions for determining whether a subject will age without developing cognitive decline are provided. An exemplary method includes detecting one or more allelic variants in a gene encoding low density lipoprotein-related protein 1B. In a preferred embodiment, the detecting step is accomplished by contacting a sample obtained from the subject with a probe that forms a detectable complex with a nucleic acid in the sample containing an allelic variant indicative of aging without developing cognitive decline, wherein detection of the allelic variant in the sample indicates that the subject will age without developing cognitive decline. | 12-02-2010 |
| 20100304383 | BIOMARKERS FOR PRENATAL DIAGNOSIS OF CONGENITAL CYTOMEGALOVIRUS - The invention provides compositions and methods useful for early detection of congenital CMV infection, predicting the likelihood and severity of congenital CMV disease, and monitoring the efficacy of therapeutic approaches. Compositions of the present invention include biomarkers that are differentially expressed in CMV-infected mothers and fetuses compared to uninfected individuals. | 12-02-2010 |
| 20100304375 | Influenza Virus Genome Replication and Transcription System in Yeast Cells - A system in which vRNP purified from influenza virus particles is introduced into yeast ( | 12-02-2010 |
| 20100304377 | METHOD OF DETECTING NOROVIRUS RNA - The amount of an RNA transcription product amplified in an RNA amplification process is measured using a nucleic acid probe labeled with an intercalating fluorescent dye. The RNA amplification process comprises the steps of using at least two sets of primer pairs comprising a first primer and a second primer (in which one of these primers carries a promoter sequence added to the 5′ end thereof), both of which have high hybridization efficiency to a nucleic acid sequence that is homologous to or complementary to each norovirus genotype RNA; forming a double-stranded DNA containing the promoter sequence with a reverse transcriptase; forming an RNA transcription product with an RNA polymerase by using the double-stranded DNA as a template; and forming the double-stranded DNA by successively using the RNA transcription product as a template in the DNA synthesis with the reverse transcriptase. | 12-02-2010 |
| 20100304372 | Liver Cancer Methods and Compositions - The present invention provides a novel method for detection of liver cancer. This method detects high-sensitively, high-specifically, simply and accurately liver cancer, especially that in early stage by identifying and/or quantifying methylation on particular genes and/or their DNA fragments in clinical specimens, and by combining said methylated DNA values with existing tumor marker values and/or DNA amounts in blood. This invention also detects a precancerous lesion, detects a risk of recurrence after treatment of liver cancer, detects malignancy of liver cancer and monitors progression of liver cancer with time by the same method. As for particular genes, BASP1 gene, SPINT2 gene, APC gene, CCND2 gene, CFTR gene, RASSF1 gene and SRD5A2 gene are mentioned. | 12-02-2010 |
| 20100304369 | METHOD AND APPARATUS FOR DIAGNOSING AGE-RELATED MACULAR DEGENERATION - Disclosed is a method for identifying an individual who has an altered risk for developing age-related macular degeneration comprising detecting an insertion/deletion polymorphism in the ARMS2 gene | 12-02-2010 |
| 20100304365 | MUTATION OF PRPS1 GENE CAUSING CMTX5 DISEASE AND THE USE THEREOF - Disclosed is a gene mutation associated with peripheral neuropathy associated with sensorineural hearing loss and optic neuropathy. More specifically, disclosed are: a polynucleotide comprising a mutation associated with peripheral neuropathy associated with sensorineural hearing loss and optic neuropathy, or a complementary polynucleotide thereof; a polynucleotide which hybridizes with said polynucleotide; a polypeptide which is encoded by said polynucleotide; an antibody which binds to said polypeptide; and a microarray chip and a kit, which comprise said polynucleotide. Also disclosed are a method for diagnosing a syndrome of peripheral neuropathy associated with sensorineural hearing loss and optic neuropathy, a method for detecting the mutation, and a method for screening drugs for treating these diseases. | 12-02-2010 |
| 20090311684 | ENHANCED FC RECEPTOR-MEDIATED TUMOR NECROSIS FACTOR SUPERFAMILY AND CHEMOKINE MRNA EXPRESSION IN PERIPHERAL BLOOD LEUKOCYTES IN PATIENTS WITH RHEUMATOID ARTHRITIS - A method for predicting patient responsiveness to rheumatoid arthritis treatments involving altering expression of TNFSF-3, TNFSF-4, TNFSF-7, TNFSF-11, or TNFSF-14 is disclosed. A method for monitoring the effectiveness of such therapy is also disclosed. Furthermore, a method of screening compounds for use in the treatment of rheumatoid arthritis is disclosed. A method of monitoring the disease state over time in rheumatoid arthritis patients is also disclosed. | 12-17-2009 |
| 20100112551 | Approaches to identifying mutations associated with hereditary nonpolyposis colorectal cancer - The present invention relates to the field of genetic screening. More specifically, the described embodiments concern methods to screen multiple samples, in a single assay, for the presence or absence of mutations or polymorphisms in a plurality of genes. Approaches to screen for the presence or absence of mutations that are associated with Hereditary Nonpolyposis Colorectal Cancer (HNPCC) and approaches to design primers that generate extension products that facilitate the resolution of multiple extension products in a single lane of a gel or in a single run on a column are also provided. | 05-06-2010 |
| 20100311054 | Compositions and Methods for the Detection of Human T Cell Receptor Variable Family Gene Expression - Compositions and methods for the assessment of T cell receptor variable subunits. The present invention provides nucleotide sequences for the evaluation of the expression of TCRV families. These nucleotides sequences were obtained through a bioinformatic investigation of the nucleotide sequences for TCRVaα and TCRVβ families. The nucleotide sequences of the present invention uniquely recognize each and every subfamily and allelic member of a particular TCRV family, while at the same time not recognizing the members of any other TCRV family. This unique expression recognition profile of the nucleotide sequences of the present invention provides great utility for the assessment of TCR families in a clinical setting, such as through polymerase chain reactions, gene chip technology, and direct electrophoretic measurement of DNA or RNA. | 12-09-2010 |
| 20100311043 | RNA complexes, method of their production and sensors and analytical methods involving same - The invention includes RNA complexes comprising at least three monomeric units of an RNA molecule, each monomeric unit comprising an RNA polymer having first and second helical domains that have respective first and second binding sites, wherein the first binding sites are adapted to binding to one another and are not adapted to bind to the second binding sites, and the second binding sites are adapted to binding to one another and are not adapted to bind to the first binding sites; such that the at least three monomeric units are adapted to self-assemble by forming pairs of cognate interactions and so as to form the RNA complex in a circular closed complex. The invention also includes derivatives of these complexes including aptamers, and analytical methods and devices using same. | 12-09-2010 |
| 20100311069 | MULTIPLEX CELL SIGNALLING ASSAYS - Disclosed are methods useful in multiplex cell-based assays for compound screening employing imaging instrumentation. The methods described herein offer high content information relating to the biological potency of test agents, off-target effects and cellular toxicity of potential drug candidates. | 12-09-2010 |
| 20100311046 | METHOD FOR THE DETECTION OF CHROMOSOMAL ANEUPLOIDIES - The non-invasive detection of fetal chromosomal aneuploidies is demonstrated. Alleles of fetal RNA-SNPs present in a biological sample (e.g. maternal blood) containing fetal RNA are detected and quantified in order to determine the ratio of the alleles. This ratio is compared to a standard control consisting of euploid fetuses. Deviation of allele ratio indicates the presence of chromosomal aneuploidy. | 12-09-2010 |
| 20110091870 | MULTISITE BIOSENSOR AND ASSOCIATED METHOD - A method of detecting a biomarker in one embodiment includes identifying a quantity of biomolecule types in a sample, exposing the sample to a plurality of test sites, wherein the number of test sites in the plurality of test sites is equal to or greater than the identified quantity of biomolecule types, establishing, for each of the plurality of test sites, a respective test environment, wherein the test environment for each of the plurality of test sites is different from the test environment for each of the other of the plurality of test sites, obtaining a detection signal associated with each of the plurality of test sites, and determining the concentration of one of the biomolecule types based upon the obtained detection signals. | 04-21-2011 |
| 20100311073 | SR-BI AS A PREDICTOR OF ELEVATED HIGH DENSITY LIPOPROTEIN AND CARDIOVASCULAR DISEASE - The present invention relates to the field of single nucleotide polymorphisms (SNPs) and uses therefore as a predictor of diseases and conditions. Specifically, the present invention provides methods and kits useful in determining whether a subject is at increased risk for developing a cardiovascular disease by screening for the presence of a SNP in the scavenger receptor class B type I (SR-BI) gene of a subject. | 12-09-2010 |
| 20100323347 | Method for Evaluating or Selecting Agent for Preventing or Curing Photodamage of Skin - A method for evaluating or selecting a substance capable of preventing or curing photodamage of skin is provided. Provided is a method for evaluating or selecting an agent for preventing or curing photodamage of skin, the method including: (A) contacting cells that are capable of expressing TIMP-1 gene or TIMP-1 protein, with a test substance; (B) measuring the expression level of the TIMP-1 gene or the TIMP-1 protein in the cells; (C) comparing the expression level obtained in (B), with the expression level of TIMP-1 gene or TIMP-1 protein in a control group in which the cells capable of expressing TIMP-1 gene or TIMP-1 protein have not been contacted with the test substance; and (D) evaluating or selecting the test substance which increases the expression level of TIMP-1 gene or TIMP-1 protein, as an agent for preventing or curing photodamage of skin, based on the results of (C). | 12-23-2010 |
| 20100323365 | PRIMER AND PROBE FOR DETECTING CHLAMYDOPHILA CAVIAE, AS WELL AS A CHLAMYDOPHILA CAVIAE DETECTION METHOD USING THE SAME - Provided are a novel primer and a probe for the detection of | 12-23-2010 |
| 20100323355 | MEANS AND METHODS FOR DETECTION OF NUCLEIC ACIDS - The present invention related to methods and tools for nuclease-dependent detection of nucleic acid hybridization. In these methods magnetic or magnetizable particles are used to discriminate between hybridized and non-hybridized DNA. | 12-23-2010 |
| 20090311678 | METHOD OF DISCRIMINATING AT LEAST TWO CELL POPULATIONS, AND APPLICATION - A subject of the invention is a method for discriminating between and counting at least two populations of biological elements carrying specific characteristics, optionally present in a sample. The invention allows the clear and unambiguous detection of at least three populations of biological elements by the use of only two detection means, which means that at least two populations of biological elements are detected by one and the same detection means. The invention can be carried out if three different probes are used, each recognizing and becoming fixed to one of the populations of biological elements to be detected, each of the probes being itself rendered detectable by a different marker, two of said markers having two emission spectra having at least one common part (overlapping emission spectra) and the third having an emission spectrum having essentially no part in common with the other two (non-overlapping spectrum). | 12-17-2009 |
| 20100311070 | POLYMERASE CHAIN REACTION (PCR) MODULE AND MULTIPLE PCR SYSTEM USING THE SAME - Provided are a PCR module and a multiple PCR system using the same. More particularly, provided are a PCR module with a combined PCR thermal cycler and PCR product detector, and a multiple PCR system using the same. | 12-09-2010 |
| 20100221731 | Methods for assessing MetAP2 Resistance, Disease Progression, and Treatment Efficacy in Ovarian Cancer - The invention provides methods for predicting whether an ovarian cancer patient's tumor will be resistant to chemotherapy. The invention also provides methods for monitoring the effectiveness of treatment, particularly a chemotherapeutic treatment, in a patient treated for ovarian cancer. The invention further provides methods for treating ovarian cancer, by reducing chemotherapeutic drug resistance in said cells. In addition, the invention provides methods of screening compounds to identify tumor cell growth inhibitors in tumor cells resistant to conventional chemotherapeutic treatment regimes. | 09-02-2010 |
| 20100233698 | APPARATUS AND METHOD FOR MULTIPLEX ANALYSIS - The present invention provides miniaturized instruments for conducting chemical reactions where control of the reaction temperature is desired or required. Specifically, this invention provides chips and optical systems for performing and monitoring temperature-dependent chemical reactions. The apparatus and methods embodied in the present invention are particularly useful for high-throughput and low-cost amplification of nucleic acids. | 09-16-2010 |
| 20100279301 | METHODS AND COMPOSITIONS FOR DIAGNOSING BLADDER CANCER - The present invention relates to compositions and methods for cancer diagnosis, research and therapy, including but not limited to, cancer markers. In particular, the present invention relates to genes and gene panels as diagnostic markers and clinical targets for bladder cancer. Methods, compositions, and kits for diagnosing, determining, and determining risk of tumor aggressiveness are disclosed. | 11-04-2010 |
| 20100009346 | Lafora's disease gene - A novel gene (EPMZA) that is deleted or mutated in people with Lafora's disease is described. The EPM2A gene encodes a protein having an active catalytic site of a protein tyrosine phosphatase. Many different sequence mutations as well as several microdeletions in EMP2A have been found that co-segregate with Lafora's disease. | 01-14-2010 |
| 20100323366 | Methods of Selecting a Dopaminergic Neuron Proliferative Progenitor Cells Using LRP4/CORIN Markers - In neuron transplantation therapy, in terms of safety, it is preferable to use a cell population consisting only of a desired type of cells, and to use postmitotic neurons in consideration to avoid the risk of tumorigenesis. Moreover, greater therapeutic effects would be expected through the use of earlier progenitor cells in consideration of post-transplantation viability, proper network formation ability, and such. | 12-23-2010 |
| 20100323367 | METHOD OF DETECTING COLON CANCER MARKER - It is intended to provide a non-invasive and convenient method of detecting a tumor marker for diagnosing colon cancer which is superior in sensitivity and specificity to the existing fecal occult blood test. More specifically speaking, a method of detecting a tumor marker for diagnosing colon cancer which comprises collecting biological sample which is immediately frozen using liquid nitrogen in some cases, homogenizing the sample in the presence of an inhibitor of an RNA digesting enzyme to give a suspension, extracting RNA from the obtained suspension, subjecting the extracted RNA to reverse transcription to give cDNA. amplifying the obtained cDNA and then detecting the thus amplified cDNA. This method is characterized by involving no procedure of separating cell components from the biological sample. | 12-23-2010 |
| 20100240064 | DIFFERENTIAL ENZYMATIC FRAGMENTATION - The present invention provides methods for detecting the presence of methylation at a locus within a population of nucleic acids. | 09-23-2010 |
| 20100273150 | SINGLE MOLECULE-FORMAT BIOLUMINESCENT PROBE - This application aims to provide a single molecule-format probe for detecting a target-specific ligand easily and accurately as an index of the presence or absence of a signal. | 10-28-2010 |
| 20100273148 | Urine markers for detection of bladder cancer - Early detection of tumors is a major determinant of survival of patients suffering from tumors, including bladder tumors. Members of the BTM or UBTM family can be highly and consistently accumulated in bladder tumor tissue and other tumor tissue, and/or can be accumulated in urine of patients, and thus are markers for bladder and other types of cancer. In certain embodiments, BTMs or UBTMs can accumulate in the urine, and detection of UBTM family members can be an effective diagnostic approach. In some embodiments, quantitative PCR methods have advantages over microarray methods. In other embodiments, detection and quantification of a plurality of BTMs or UBTMs can increase the sensitivity and specificity of detection of bladder cancer, and therefore provides methods for determining the stage and type of bladder cancer. Kits provide easy, convenient ways for carrying out the methods of this invention. | 10-28-2010 |
| 20100055703 | Organism-Specific Hybridizable Nucleic Acid Molecule - The present invention relates to a method for producing an organism-specific hybridizable nucleic acid molecule, a nucleic acid molecule produced by this method, a kit comprising at least any of the nucleic acid molecules, the use of a nucleotide sequence located between two elements on the genomic information of an organism for producing an organism-specific hybridizable nucleic acid molecule, and a method for detecting an organism in a biological sample. | 03-04-2010 |
| 20100055702 | Pathogenecity Islands of Pseudomonas Aeruginosa - Disclosed are | 03-04-2010 |
| 20110097718 | MS-COMPATIBLE NONIONIC OR ZWITTERIONIC SURFACTANTS IN FREE-FLOW ELECTROPHORESIS - The invention relates to the use of MS compatible surfactants in free-flow electrophoretic methods, which allow the separation of analytes with differentiated electrophoretic mobility. The surfactant is preferably a cleavable surfactant, such as PPS. | 04-28-2011 |
| 20100297659 | THIN-FILM LAYERED CENTRIFUGE DEVICE AND ANALYSIS METHOD USING THE SAME - Disclosed herein is a thin-film layered centrifuge device and an analysis method using the same. One example of an embodiment of the present invention is a thin film layered centrifuge device where a device, such as a lab on a chip, a protein chip and a DNA chip, for diagnosing and detecting a small amount of material in a fluid is integrated into a rotatable thin-film layered body, and to an analysis method using the thin-film layered centrifuge device. | 11-25-2010 |
| 20100291576 | IMPRINTED GENES AS EPIGENETIC MARKERS FOR USE IN CLONING AND REGENERATIVE CELL PROCEDURES - In general, the invention features methods of identifying and/or preparing a mammalian cell or a cell population (e.g., bovine or porcine cells) for use in cloning procedures or regenerative cell procedures using expression of one or more of the epigenetic markers, IGF2, p57, and NNAT. | 11-18-2010 |
| 20100297654 | THREE-COMPONENT BIOSENSORS FOR DETECTING MACROMOLECULES AND OTHER ANALYTES - The invention generally provides three-component molecular biosensors. The molecular biosensors are useful in several methods including in the identification and quantification of target molecules. | 11-25-2010 |
| 20100291573 | Methods of Predicting Cancer Risk Using Gene Expression in Premalignant Tissue - The present disclosure provides methods for assessing a patient's cancer risk and/or recurrence risk, which methods comprise assaying, in a biological sample obtained from the gastrointestinal (GI) tract of the patient, an expression level of a risk gene. The present disclosure also provides methods involving a cancer risk/recurrence risk sequence, i.e. the V600E mutation of the BRAF gene, which is useful for assessing cancer risk and/or recurrence risk in a patient. | 11-18-2010 |
| 20100291584 | MICROFLUIDIC IMAGING CYTOMETRY - A microfluidic system has a pipette system comprising a plurality of pipettes, a microfluidic chip arranged proximate the pipette system, an imaging optical detection system arranged proximate the microfluidic chip, and an image processing system in communication with the imaging optical detection system. The microfluidic chip has a plurality of cell culture chambers defined by a body of the microfluidic chip, each cell culture chamber being in fluid connection with an input channel and an output channel defined by the microfluidic chip. The pipette system is constructed and arranged to at least one of inject fluid through the plurality of pipettes into the plurality of input channels or extract fluid through the plurality of pipettes from the plurality of output channels while the microfluidic system is in operation. | 11-18-2010 |
| 20100291561 | METHODS FOR DETECTING A TARGET NUCLEOTIDE SEQUENCE IN A SAMPLE UTILISING A NUCLEASE-APTAMER COMPLEX - The present invention relates to methods for detecting a target nucleotide sequence in a sample. More particularly, the present invention relates to methods for detecting a target nucleotide sequence in a sample which utilise a nuclease-aptamer complex. The present invention also provides nuclease-binding aptamers, nuclease-aptamer complexes and linker molecules that may be used in accordance with the methods of the present invention. | 11-18-2010 |
| 20100291570 | MATERIALS AND METHODS FOR DETECTION OF NUCLEIC ACIDS - Assays using non-natural bases are described. In one embodiment, the method involves contacting a sample suspected of containing the target nucleic acid with a polymerase and first and second primers; amplifying the target nucleic acid by PCR using the first and second primers to generate an amplification product having a double-stranded region and a single-stranded region that comprises the non-natural base; contacting the sample with a reporter comprising a label and a non-natural base that is complementary to the non-natural base of the single-stranded region; annealing at least a portion of the reporter to the single-stranded region of the amplification product; and correlating a signal of the label with the presence of the target nucleic acid in the sample. The invention also provides corresponding kits for use in detecting target nucleic acids in a sample. | 11-18-2010 |
| 20100291568 | METHODS FOR GENETIC ANALYSIS OF DNA TO DETECT SEQUENCE VARIANCES - Methods for determining genotypes and haplotypes of genes are described. Also described are single nucleotide polymorphisms and haplotypes in the ApoE gene and methods of using that information. | 11-18-2010 |
| 20100291562 | METHOD FOR THE DETECTION OF AN ANALYTE IN BIOLOGICAL MATRIX - The present invention relates to a method for the highly sensitive Immuno-PCR detection of an analyte in a sample comprising the use of a nucleic acids containing sample dilution buffer for diluting the sample as well as methods for the preparation of the sample dilution buffer and the use thereof. | 11-18-2010 |
| 20100291560 | METHODS AND COMPOSITIONS FOR DIAGNOSIS AND TREATMENT OF DYSKERATOSIS CONGENITA AND RELATED DISORDERS - The present invention features methods of detection, diagnosing a presence or a predisposition to, or determining the risk for a subject to develop telomere-associated diseases or disorders. The methods include detecting the presence or absence of an alteration in a nucleic acid in a sample. The methods also include determining telomere length. In certain cases, average telomere length is a surrogate marker for a telomere-associated disease or disorder. | 11-18-2010 |
| 20100297650 | NUCLEIC ACID AND CORRESPONDING PROTEIN ENTITLED 193P1E1B USEFUL IN TREATMENT AND DETECTION OF CANCER - A novel gene 0193P1E1B (also designated 193P1E1B) and its encoded protein, and variants thereof, are described wherein 193P1E1B exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, 193P1E1B provides a diagnostic, prognostic, prophylactic and/or therapeutic target for cancer. The 193P1E1B gene or fragment thereof, or its encoded protein, or variants thereof, or a fragment thereof, can be used to elicit a humoral or cellular immune response; antibodies or T cells reactive with 193P1E1B can be used in active or passive immunization. | 11-25-2010 |
| 20100297635 | COLLECTION AND MEASUREMENT OF EXHALED PARTICLES - Particles are exhaled in the breath of animals. The nature and amounts of the particles can be indicative of certain medical conditions. They can therefore be collected, sorted according to size or mass and used in the diagnosis of one or more medical conditions. The invention provides a method and system for collecting and sorting exhaled particles and a method for diagnosis using said exhaled particles. | 11-25-2010 |
| 20100297638 | MOLECULAR ADAPTORS - The invention relates to transmembrane protein pore for use in detecting a analyte in a sample. The pore comprises a molecular adaptor that facilitates an interaction between the pore and the analyte. The adaptor is covalently attached to the pore in an orientation that allows the analyte to be detected using the pore. | 11-25-2010 |
| 20100297634 | GENE EXPRESSION SIGNATURES IN ENRICHED TUMOR CELL SAMPLES - The invention is embodied in methods for finding gene expression signatures of circulating melanoma cells, ovarian, breast, colorectal cancer cells, and circulating endothelial progenitor cells, which signatures are effective in distinguishing the circulating cancer cell from normal circulating cells and can also distinguish between different types of circulating cancer cells. | 11-25-2010 |
| 20100297637 | PRIMER FOR AMPLIFICATION OF RRNA OR BACTERIUM BELONGING TO THE GENUS LEGIONELLA, DETECTION METHOD, AND DETECTION KIT - To detect a bacterium belonging to the genus | 11-25-2010 |
| 20100297633 | METHOD OF AMPLIFYING NUCLEIC ACID - The present invention provides a method for detecting a polymorphism or mutation in nucleic acid comprising a first phase to amplify or enrich for a sequence comprising a polymorphism or mutation and a second phase for detecting the polymorphism or mutation, wherein both phases are performed in the same reaction vessel. | 11-25-2010 |
| 20100297613 | Nucleic acid, amino acid encoded by said nucleic acid, probe comprising said nucleic acid or said amino acid, and screening method using said probe - A nucleic acid involved in the control of the biological clock comprising following (a) or (b):
| 11-25-2010 |
| 20100297617 | PRIMER SET FOR AMPLIFYING NAT2 GENE, REAGENT FOR AMPLIFYING NAT2 GENE CONTAINING THE SAME, AND THE USES THEREOF - Primer sets for amplifying target regions containing sites to be detected in the NAT2 gene by a gene amplification method are provided, wherein the primer sets can amplify the regions specifically. Three pairs of primer sets are used including forward primers consisting of the base sequences of SEQ ID NOs: 7, 33, and 60 as well as reverse primers consisting of the base sequences of SEQ ID NOs: 18, 48 and 81, respectively. The use of these primer sets makes it possible to amplify three target regions including parts where three types of polymorphisms (NAT2*5, NAT2*6, and NAT2*7) of the NAT2 gene are generated, respectively, in the same reaction solution at the same time. | 11-25-2010 |
| 20100297621 | USE OF PRE-MRNA SPLICING IN PLATELET CELLS FOR THE DIAGNOSIS OF DISEASE - The invention relates to materials and procedures for identifying or using tissue factor (TF) pre-mRNA splicing, CIk 1 activity or TF-dependent coagulation in platelet cells for the diagnosis, prognosis, or prediction of a disease or disorder associated with disordered coagulation. Since activated platelets splice pre-mRNAs to generate inflammatory and thrombotic mediators that contribute to diseases such as sepsis and septic shock, (TF) pre-mRNA splicing in platelets is an indicator of inflammatory and thrombotic disease states. TF pre-mRNA splicing in platelets is correlated with sepsis, increased age (≧65), APACHE II score, and bacteremia. Thus, TF mRNA expression patterns in platelets may be used for the diagnosis, prognosis, or prediction of a disease or disorder associated with disordered coagulation, for example, patients that are at a higher risk for severe sepsis, organ failure, and death. | 11-25-2010 |
| 20100062435 | Methods for Stem Cell Production and Therapy - The present invention relates to methods for rapidly expanding a stem cell population with or without culture supplements in simulated microgravity conditions. The present invention relates to methods for rapidly increasing the life span of stem cell populations without culture supplements in simulated microgravity conditions. The present invention also relates to methods for increasing the sensitivity of cancer stem cells to chemotherapeutic agents by culturing the cancer stem cells under microgravity conditions and in the presence of omega-3 fatty acids. The methods of the present invention can also be used to proliferate cancer cells by culturing them in the presence of omega-3 fatty acids. The present invention also relates to methods for testing the sensitivity of cancer cells and cancer stem cells to chemotherapeutic agents by culturing the cancer cells and cancer stem cells under microgravity conditions. The methods of the present invention can also be used to produce tissue for use in transplantation by culturing stem cells or cancer stem cells under microgravity conditions. The methods of the present invention can also be used to produce cellular factors and growth factors by culturing stem cells or cancer stem cells under microgravity conditions. The methods of the present invention can also be used to produce cellular factors and growth factors to promote differentiation of cancer stem cells under microgravity conditions. | 03-11-2010 |
| 20100062429 | Fluorochromes for organelle tracing and multi-color imaging - Provided are compounds, methods and kits for identifying in cells of interest organelles including nuclei and a wide variety of organelles other than nuclei (non-nuclear organelles), as well as cell regions or cell domains. These compounds and methods can be used with other conventional detection reagents for identifying the location or position or quantity of organelles and even for distinguishing between organelles in cells of interest. | 03-11-2010 |
| 20100062431 | USE OF ADAMTS4 GENE AND PROTEIN POLYMORPHISMS - The use of the single nucleotide polymorphism (SNP) of the ADAMTS4 gene for the identification of cardiovascular and peripheral vascular disorders or of an increased risk for developing cardiovascular and peripheral vascular disorders in a biological sample taken from an individual to be examined; the use of ADAMTS4 for identifying substances active in preventing and/or treating cardiovascular and peripheral vascular disorders and methods for doing so. | 03-11-2010 |
| 20100255483 | LIQUID-FEEDING CHIP AND ANALYSIS METHOD - A liquid-feeding chip for feeding a liquid utilizing the action of centrifugal force and gravity by rotating the chip around an axis of rotation, includes a first storage tank ( | 10-07-2010 |
| 20100255475 | DIAGNOSTICS AND THERAPEUTICS FOR OSTEOPOROSIS - Diagnostics and therapeutics for osteoporosis, which are bases upon the identification of a subjects IL-1 haplotype and genotype pattern are described. | 10-07-2010 |
| 20100255474 | Method for Detecting Bacteria and Fungi - The present invention relates to methods and means for determining pathogenic fungi in a sample material, e.g. blood. In the method, the bacterial DNA is initially enriched from the total DNA of the sample material, and then the enriched DNA is amplified with specific primer pairs. Detection of the obtained amplicons allows the accurate identification of bacteria and fungi contained in the sample material and of their resistances. The methods and means of the invention allow an early diagnosis of inflammatory diseases, in particular involving non-detected infection (SIRS), and of infectious diseases such as sepsis, spontaneous bacterial peritonitis and endocarditis. | 10-07-2010 |
| 20100255492 | Non-Invasive Fetal Genetic Screening by Digital Analysis - The present methods are exemplified by a process in which maternal blood containing fetal DNA is diluted to a nominal value of approximately 0.5 genome equivalent of DNA per reaction sample. Digital PCR is then be used to detect aneuploidy, such as the trisomy that causes Down Syndrome. Since aneuploidies do not present a mutational change in sequence, and are merely a change in the number of chromosomes, it has not been possible to detect them in a fetus without resorting to invasive techniques such as amniocentesis or chorionic villi sampling. Digital amplification allows the detection of aneuploidy using massively parallel amplification and detection methods, examining, e.g., 10,000 genome equivalents. | 10-07-2010 |
| 20100255491 | MAMMALIAN SELENOPROTEIN DIFFERENTIALLY EXPRESSED IN TUMOR CELLS - A 15 kDa selenium-containing protein (“selenoprotein”) is disclosed. The protein is shown to be differentially expressed in cancer cells, such as prostate cancer cells. There is a correlation between the presence of a polymorphism at nucleotide positions 811 and 1125 of the 15 kDa selenoprotein gene, and the presence of cancer. This polymorphism is more prevalent in the African American population. The determination of an individual's genotype may be used as an indicator of the need for dietary selenium supplementation to inhibit tumor development. Compositions including the isolated protein, specific binding agents that recognize the protein, as well as underlying nucleic acid sequences are presented, as are methods of using such compositions. | 10-07-2010 |
| 20100255488 | FRET-LABELED COMPOUNDS AND USES THEREFOR - FRET-labeled compounds are provided for use in analytical reactions. In certain embodiments, FRET-labeled nucleotide analogs are used in place of naturally occurring nucleoside triphosphates or other analogs in analytical reactions comprising nucleic acids, for example, template-directed nucleic acid synthesis, DNA sequencing, RNA sequencing, single-base identification, hybridization, binding assays, and other analytical reactions. | 10-07-2010 |
| 20100255478 | TARGETS FOR USE IN DIAGNOSIS, PROGNOSIS AND THERAPY OF CANCER - The invention is directed to a method of diagnosing cancer, or susceptibility to cancer, in an individual in need thereof comprising detecting homozygosity at one or more loci of the individual's nucleic acid, wherein the one or more loci is selected from the group consisting of: D2S1790, D3S2427, D4S2394, D5S2505, D6S1959, D7S3046, D9S1871, D10S1222, D11S1993, D11S1986, D11S4463, D13S793, D15S822, GATA178F11, D18S1376, and D20S477, and homozygosity at the one or more loci is indicative of a diagnosis of cancer, or susceptibility to cancer, in the individual. Also provided herein are kits for use in diagnosing cancer or susceptibility to cancer in an individual comprising one or more regents for detecting the presence of a homozygosity at one or more loci selected from the group consisting of: D2S1790, D3S2427, D4S2394, D5S2505, D6S1959, D7S3046, D9S1871, D10S1222, D11S1993, D11S1986, D11S4463, D13S793, D15S822, GATA178F11, D18S1376, and D20S477 and instructions for use. | 10-07-2010 |
| 20100255476 | Composition For Increasing Microorganism Wall Permeability And Method For Detecting Said Microorganisms On A Membrane - The present invention relates to a composition for permeabilizing microorganism walls, comprising the combination of polyethyleneimine (PEI) with at least one alcohol, and also to a method using said composition for counting and detecting in a targeted manner the microorganisms on a membrane. The invention also relates to a kit and to probes that are suitable for carrying out said method. | 10-07-2010 |
| 20100255473 | Assays - A device comprising a rigid substrate, a flexible cover element at least partially covering the substrate, a first structure formed in the substrate, adapted for accommodating liquids and adapted for releasing contents of one or more cells, spores, or viruses, the contents including the target molecules, a second structure formed in the substrate, adapted for accommodating liquids and comprising at least one binding member adapted for capturing the target molecules and for determining a value indicative for the presence and/or amount of the target molecules, a microfluidic network interconnecting at least the first structure and the second structure, and an actuator member adapted for effecting a fluid flow between the first structure and the second structure by pressing the flexible cover element against the substrate to selectively close a portion of the microfluidic network. | 10-07-2010 |
| 20100255462 | FLUORESCENT MARKER FOR LIVING ORGANISM AND FLUORESCENT MARKING METHOD FOR THE SAME - A fluorescent marker comprising inorganic fluorescent nanoparticles having on a surface of the nanoparticles a modifying group containing a reactive portion, wherein the reactive portion is located at a most remote site of the modifying group from the surface of the nanoparticles; the reactive portion comprises at least one selected from the group consisting of bases consisting of DNA or RNA, nucleotides, polynucleotides and intercalators; and the reactive portion is capable of specifically binding to a living organism. | 10-07-2010 |
| 20100255470 | Gene Expression Profiling for Identification, Monitoring and Treatment of Breast Cancer - A method is provided in various embodiments for determining a profile data set for a subject with breast cancer or conditions related to breast cancer based on a sample from the subject, wherein the sample provides a source of RNAs. The method includes using amplification for measuring the amount of RNA corresponding to at least 1 constituent from Tables 1-5. The profile data set comprises the measure of each constituent, and amplification is performed under measurement conditions that are substantially repeatable. | 10-07-2010 |
| 20100255464 | Enzymatic nucleic acid synthesis: compositions and methods for inhibiting pyrophosphorolysis - Nucleotide triphosphate probes containing a molecular and/or atomic tag on a γ and/or β phosphate group and/or a base moiety having a detectable property are disclosed, and kits and method for using the tagged nucleotides in sequencing reactions and various assay. Also, phosphate and polyphosphate molecular fidelity altering agents are disclosed. | 10-07-2010 |
| 20100255463 | Compositions and methods for sequence determination - A sequencing methodology is disclosed that allows a single DNA or RNA molecule or portion thereof to be sequenced directly and in substantially real time. The methodology involves engineering a polymerase and/or dNTPs with atomic and/or molecular tags that have a detectable property that is monitored by a detection system. | 10-07-2010 |
| 20100248233 | ACETYL-COA PRODUCING ENZYMES IN YEAST - The present invention relates to a method of identifying a heterologous polypeptide having enzymatic activity for converting pyruvate, acetaldehyde or acetate into acetyl-CoA in (the cytosol of) a yeast cell comprising: a) providing a mutated yeast cell comprising a deletion of at least one gene of the (PDH) by-pass, selected from the genes encoding the enzymes pyruvate decarboxylase (PDC), acetaldehyde dehydrogenase (ALD), and acetyl-CoA synthetase (ACS); b) transforming said mutated yeast cell with an expression vector comprising a heterologous nucleotide sequence encoding a candidate polypeptide having potential enzymatic activity for converting pyruvate, acetaldehyde or acetate into acetyl-CoA; c) testing said recombinant mutated yeast cell for its ability to grow on minimal medium containing glucose as sole carbon source, and d) identifying said candidate polypeptide as a heterologous polypeptide having enzymatic activity for converting pyruvate, acetaldehyde or acetate into acetyl-CoA in (the cytosol of) said yeast cell when growth of said cell is observed. The invention further relates to a method of producing a fermentation production such as butanol. | 09-30-2010 |
| 20100227322 | Detection of Bordetella - The invention provides methods to detect | 09-09-2010 |
| 20100227321 | METHODS AND DEVICES FOR NUCLEIC ACID SEQUENCE DETERMINATION - Methods of the invention comprise methods and devices for nucleic acid sequence determination. Generally, the invention relates to preparing a substrate for sequencing a target nucleic acid | 09-09-2010 |
| 20100227319 | USE OF RUNX3 AND MIR-532-5P AS CANCER MARKERS AND THERAPEUTIC TARGETS - The invention relates to methods for cancer diagnosis, prognosis, and treatment based on the expression or activity levels of RUNX3 and miR-532-5p. Also disclosed is a method of reducing the inhibition of RUNX3 by miR-532-5p with an agent that interferes with the interaction between RUNX3 and miR-532-5p transcripts. | 09-09-2010 |
| 20100227317 | Method for the Molecular Diagnosis of Prostate Cancer and Kit for Implementing Same - The invention relates to a method for the molecular diagnosis of prostate cancer, comprising the in vitro analysis of the overexpression or underexpression of combinations of genes that can distinguish, with high statistical significance, tumorous prostate samples from non-tumorous prostate samples. The invention also relates to a kit for the molecular diagnosis of prostate cancer, which can perform the above-mentioned detection. | 09-09-2010 |
| 20100227315 | Biosensor Using Whispering Gallery Modes in Microspheres - A biosensor for detecting the presence of a target analyte is disclosed. The biosensor is formed from microspheroidal particles which have had a binding partner for the target analyte immobilized on their surfaces. The binding partners may be nucleotides; peptides, proteins, enzymes, antibodies and so on. When the analyte binds to its partner, the whispering gallery mode (WGM) profiles of the microspheroidal particles change such that the profile peaks undergo a red-or blue-shift. The immobilised binding partners may include fluorophores and the like so that they emit fluorescence, phosphorescence, incandescence and the like. These fluorophores may take the form of a nanocrystal or quantum dot. | 09-09-2010 |
| 20100227326 | Detection System - A method for detecting the presence of a target nucleic acid sequence in a sample, said method comprising: performing nucleic acid amplification on the sample in the presence of (a) a DNA duplex binding agent, (b) a nucleic acid polymerase and (c) a reagent comprising an amplification primer which can hybridise to said target sequence when in single stranded form and which is connected at its 5′ end to a probe which carries a label by way of a chemical linking group, said labelled probe being of a sequence which is similar to that of the said target nucleic acid sequence, such that it can hybridise to a complementary region in an amplification product, and wherein the label is able to absorb fluorescence from or donate fluorescent energy to the DNA duplex binding agent; and monitoring fluorescence of said sample. | 09-09-2010 |
| 20100227332 | Method for selecting antimicrobial agent and utilization thereof - The present invention provides for a method for selecting an antimicrobial agent, which comprises a microbe analyzing step in which microbes in the microbial biota of a sample are analyzed based on base sequence of DNA and an antimicrobial agent selecting step comprising performing search in a data base storing data for industrial antimicrobial agents applicable to the analyzed microbes recited at effective concentrations, picking up industrial antimicrobial agents effective for the microbial biota, dominant microbe or specific microbe(s) in the sample analyzed in the above microbe analyzing step and selecting among the picked up ones an industrial antimicrobial agent, which method permits to select an antimicrobial agent that is optimum for the treatment in a simple and assured manner within a brief time and to grasp whether the effect of the antimicrobial agent is revealed or not in a simple and assured manner within a brief time, by utilizing this selecting method for the selection of antimicrobial agent, for example, in an antimicrobial treating, in monitoring of the antimicrobial effect, in slime control in paper manufacturing process courses and in microbe inhibition in paper manufacturing process courses, whereby troubles caused by growth of microbes can be prevented beforehand. | 09-09-2010 |
| 20100227324 | MEASUREMENT OF ARYLESTERASE ENZYMATIC ACTIVITY AND ASSESSMENT OF GENETIC POLYMORPHISMS LOCATED IN THE PON1 GENE AS A DIAGNOSTIC TOOL IN AUTISM-SPECTRUM DISORDERS - The present invention concerns a method for detecting the presence of or predisposition to autism, an autism spectrum disorder, or an autism-associated disorder in a subject, the method comprising measuring an arylesterase enzymatic activity in a sample from the subject, optionally combined with the determination of alleles of PON1 polymorphisms. | 09-09-2010 |
| 20100227320 | NUCLEIC ACID DETECTION - This invention provides methods and kits for enriching and/or detecting a nucleic acid with at least one variant nucleotide from a nucleic acid population in a sample. Methods employ the use of enriching primers and bridge-probes for enriching and detecting target nucleic acids. Extension of the enriching primer permits amplification of the target nucleic acid having the variant nucleotide. | 09-09-2010 |
| 20100227316 | LUMINESCENSE MEASURING APPARATUS AND LUMINESCENSE MEASURING METHOD - There is provided a novel luminescence measuring apparatus that enables measuring a luminescence amount or a luminescence intensity from plural living biological samples, such as tissues, cells, and biological individuals, into which a gene expressing a luminescent protein has been introduced, individually for the respective biological samples. The inventive luminescence measuring apparatus comprises an image acquisition portion that acquires a luminescence image of biological samples; a measurement region determination portion that determines at least one measurement region in the luminescence image; and a luminescence measurement portion that measures the luminescence amount or luminescence intensity in the determined measurement region; thereby measuring the luminescence amount or luminescence intensity individually by the biological sample(s) included in the measurement region. Irrespective of an efficiency of transfer of a luminescent protein gene into a cell, etc., it becomes possible to execute a luminescence measurement successfully while observing only biological samples having a gene expression. | 09-09-2010 |
| 20110076684 | APPARATUS AND METHOD FOR ACQUIRING, DETECTING, AND ANALYZING CELLS IN A MICROFLUIDIC SYSTEM - An apparatus is disclosed for acquiring, detecting, and, optionally, analyzing cells in a biological liquid, which apparatus has a microfluidic system. In at least one embodiment, the apparatus includes at least one microfluidic channel having a small cross-section which is completely or partially coated with cell-specific binding molecules and which has no flow obstacles dividing the fluid flow; at least one apparatus for generating a steady and alterable liquid flow through the microfluidic channel, and optionally at least one apparatus for analyzing the genetic information of the cell. In at least one embodiment, the method includes a sample of a biological liquid being conducted through an apparatus defined above at a defined velocity V | 03-31-2011 |
| 20110076690 | TITER PLATE, READING DEVICE THEREFOR AND METHOD FOR DETECTING AN ANALYTE, AND USE THEREOF - A titer plate and a method for detecting an analyte, and the use thereof are disclosed. According to at least one embodiment of the invention, it is proposed that a plurality of depressions and a biochip of the titer plate sposed adjacent thereto be surrounded by a wall in order to effectively prevent sample contamination when there is a high degree of spatial integration. | 03-31-2011 |
| 20110070584 | METHODS AND COMPOSITIONS FOR DIAGNOSING AND MONITORING AUTOIMMUNE AND CHRONIC INFLAMMATORY DISEASES - Methods of diagnosing or monitoring autoimmune and chronic inflammatory diseases, particularly systemic lupus erythematosis and rheumatoid arthritis, in a patient by detecting the expression level of one or more genes in a patient, are described. Diagnostic oligonucleotides for diagnosing or monitoring autoimmune and chronic inflammatory diseases, particularly systemic lupus erythematosis and rheumatoid arthritis and kits or systems containing the same are also described. | 03-24-2011 |
| 20100129817 | IDENTIFYING GERMLINE COMPETENT EMBRYONIC STEM CELLS - Methods and compositions for selecting ES cells that are germline competent are provided, including gene expression arrays of from one to about 300 or more genes. Selecting ES cells that are competent for germline transmission by comparing the expression of one or more genes between an ES cell that is competent at germline transmission with an ES cell of interest is described. Selecting ES cells likely to be competent at germline transmission, based on their level of expression of gtl2, is also described. | 05-27-2010 |
| 20100240029 | Cholesterol-Regulating Complex of SIRT1 and LXR and Methods of Use - A cholesterol-regulating complex of SIRT1 and LXR and methods of use are disclosed. SIRT1 forms a complex with LXR bound to an LXR element. Methods of forming the complex, identifying an agent that modulates formation of the complex, increasing the ratio of cholesterol bound to high density lipoprotein (HDL) to total cholesterol in the plasma of a mammal, promoting ABCA1-mediated cholesterol efflux from a mammalian cell, treating a subject deemed to have a level of SIRT1 activity that is below normal, assessing whether a candidate substance modulates an LXR-dependent process, and assessing whether a candidate substance modulates an SIRT1-dependent effect of an LXR are disclosed. | 09-23-2010 |
| 20100297643 | Terminus-Specific DNA Modification Using Random-Sequence Template Oligonucleotides - A method is provided for analyzing DNA molecules having unknown 3′ terminal sequences. The method involves contacting a DNA molecule with a plurality of template oligonucleotides blocked at their 3′ termini such that the template oligonucleotides are not extendable by DNA polymerase. The 3′ proximal portions of each of the template oligonucleotides comprise a region of random sequence and the 5′ proximal portions of each of the template oligonucleotides comprise the complement of a tag sequence. The DNA molecule and the template oligonucleotides are combined under conditions wherein the 3′ terminus of the DNA molecule hybridizes to the 3′ proximal portion of a template oligonucleotide and is extended by a DNA polymerase to produce a DNA molecule comprising a 3′ terminal tag sequence, and wherein the template oligonucleotide is not extended. | 11-25-2010 |
| 20100311068 | ASSAY - The invention relates to process for in vitro prediction of a potentially allergenic substance wherein monocytes and/or macrophages and/or myelomonocytic cell lines are cultivated in the presence of the substance and interferon-γ, whereby productions of cytokines and/or neopterin are increased and measured. The allergic reaction may be estimated by measuring up regulated or down-regulated genes chosen from G1P2, OASL, IFIT1, TRIM22, IFI44L, MXI, RSAD2, IFIT3, IFITM1, IFIT2, C 33.28 HERV-H protein mRNA, IFITM3, XK, GPR15, MT1G, MT1B; MT1A, ADFP, IL8, MT1E, MT1F, MT1H, SLC30A1, SERPINB2, CD83, TncRNA or expression products from them are measured. The invention also relates to a reagent kit for use in the process comprising interferon-γ and reagents which recognise cytokines preferably each of IL-8 and neopterin and/or reagents such as probes recognising up-regulated or down-regulated genes. | 12-09-2010 |
| 20100311057 | Mitochondrial DNA Deletion Between About Residues 12317-16254 for Use in the Detection of Cancer - The present invention relates to methods for predicting, diagnosing and monitoring cancer. The methods comprise obtaining biological samples, extracting mitochondrial DNA (mtDNA) from the samples, quantifying mitochondrial DNA mutation in the sample and comparing the level of mtDNA mutation with a reference value. The methods of the invention may also be effective in screening for new therapeutic agents and treatment regimes, and may also be useful for monitoring the response of a subject to a preventative or therapeutic treatment. | 12-09-2010 |
| 20100311048 | Neural Crest Enhancers and Methods for Use - DNA enhancer sequences are provided for use in constructs to identify early stage embryonic cells. The enhancer sequences can be used in parallel with short-hairpin RNA in a vector construct for endogenously regulated gene knockdowns. The disclosed enhancer sequences can be used to isolate a selected population of early stage embryonic cells. | 12-09-2010 |
| 20110076678 | REPROGRAMMING OF SOMATIC CELLS - The disclosure relates to a method of reprogramming one or more somatic cells, e.g., partially differentiated or fully/terminally differentiated somatic cells, to a less differentiated state, e.g., a pluripotent or multipotent state. In further embodiments the invention also relates to reprogrammed somatic cells produced by methods of the invention, to uses of said cells, and to methods for identifying agents useful for reprogramming somatic cells. | 03-31-2011 |
| 20100317015 | SPINOCEREBELLAR ATAXIA TYPE 8 AND METHODS OF DETECTION - The present invention provides an isolated nucleic acid molecule containing a repeat region of an isolated spinocerebellar ataxia type 8 (SCA8) coding sequence, the coding sequence located within the long arm of chromosome 13, and the complement of the nucleic acid molecule. Diagnostic methods based on identification of this repeat region are also provided. | 12-16-2010 |
| 20100317007 | Methods and Systems to Identify Operational Reaction Pathways - The present invention provides a method for identifying an operational reaction pathway of a biosystem. The method includes (a) providing a set of systemic reaction pathways through a reaction network representing said biosystem; (b) providing a set of phenomenological reaction pathways of said biosystem, and (c) comparing said set of systemic reaction pathways with said set of phenomenological reaction pathways, wherein a pathway common to said sets is an operational reaction pathway of said biosystem. Also described is a method of refining a biosystem reaction network; a method of reconciling biosystem data sets; a method of determining the effect of a genetic polymorphism on whole cell function; and a method of diagnosing a genetic polymorphism-mediated pathology. | 12-16-2010 |
| 20100317008 | Nonseparation Assay Methods - Assay methods are disclosed involving specific binding reactions which are simplified compared to known methods. A compound capable of producing chemiluminescence is immobilized on a solid support as is a member of a specific binding pair for capturing an analyte from a sample. An activator compound that activates the chemiluminescent compound and is conjugated to a specific binding pair member is added in excess along with the sample to the solid support. Addition of a trigger solution causes a chemiluminescent reaction at the sites where the activator conjugate has been specifically bound. The assay methods are termed non-separation assays because they do not require removal or separation of excess detection label (activator conjugate) prior to the detection step. The methods are applicable to various types of assays including immunoassays, receptor-ligand assays and nucleic acid hybridization assays. | 12-16-2010 |
| 20100317010 | ELF3 gene compositions and methods - ELF3 gene compositions associated with cancer are provided, including ELF3 mRNA intron retention, a novel ELF3 5′ untranslated region, and a novel Alu, Alu | 12-16-2010 |
| 20100317005 | Modified Nucleotides and Methods for Making and Use Same - Labeled nucleotide triphosphates are disclosed having a label bonded to the gamma phosphate of the nucleotide triphosphate. Methods for using the gamma phosphate labeled nucleotide are also disclosed where the gamma phosphate labeled nucleotide are used to attach the labeled gamma phosphate in a catalyzed (enzyme or man-made catalyst) reaction to a target biomolecule or to exchange a phosphate on a target biomolecule with a labeled gamme phosphate. Preferred target biomolecules are DNAs, RNAs, DNA/RNAs, PNA, polypeptide (e.g., proteins enzymes, protein, assemblages, etc.), sugars and polysaccharides or mixed biomolecules having two or more of DNAs, RNAs, DNA/RNAs, polypeptide, sugars and polysaccharides moieties. | 12-16-2010 |
| 20100317003 | NOVEL COMPOSITIONS AND METHODS IN CANCER WITH ALTERED EXPRESSION OF KCNJ9 - The present invention relates to novel sequences for use in diagnosis and treatment of carcinomas, especially breast cancers. In addition, the present invention describes the use of novel compositions for use in screening methods. | 12-16-2010 |
| 20100317000 | METHOD FOR DIAGNOSING BLADDER CANCER BY ANALYZING DNA METHYLATION PROFILES IN URINE SEDIMENTS AND ITS KIT - The present invention provides a method for detecting bladder cancer in a subject, comprising the following steps: (a) providing urine sediment sample from said subject; (b) determining methylation pattern of a given sequence within the promoter CpG islands of one or more genes (known as “gene” infra) in the samples; (c) comparing the methylation pattern from said subject with that from normal subject, wherein the hypermethylation of one or more of genes indicates that said subject is suffering from bladder cancer. The present invention also provides a kit for diagnosing bladder cancer. | 12-16-2010 |
| 20100316996 | Nasopharyngeal cancer malignancy biomarker and method thereof - The present invention discloses a nasopharyngeal cancer malignancy biomarker and a method thereof, wherein relative hnRNP K expression is used to evaluate the malignancy of nasopharyngeal cancer. The biomarker of the present invention assists the currently-existing inspections to find out cancer in the early stage and realize early diagnosis and early therapy. The present invention also functions as an effective indicator to monitor the metastasis and relapse of nasopharyngeal cancer. | 12-16-2010 |
| 20100267045 | CUDR AS BIOMARKER FOR CANCER PROGRESSION AND THERAPEUTIC RESPONSE - Disclosed is a novel human gene designated CUDR. Provides is also a CUDR gene as a biomarker in the diagnosis of human cancers and a cancer therapy. | 10-21-2010 |
| 20100267043 | System and method for identification of individual samples from a multiplex mixture - An embodiment of an identifier element for identifying an origin of a template nucleic acid molecule is described that comprises a nucleic acid element comprising a sequence composition that enables detection of an introduced error in sequence data generated from the nucleic acid element and correction of the introduced error, where the nucleic acid element is constructed to couple with the end of a template nucleic acid molecule and identifies an origin of the template nucleic acid molecule. | 10-21-2010 |
| 20100267042 | Antigen-Presenting Cell Populations And Their Use As Reagents For Enhancing Or Reducing Immune Tolerance - The present invention is based on the discovery antigen-presenting cells (APCs) may be generated to have predetermined levels of expression of the intracellular enzyme, indoleamine 2,3-dioxygenase (IDO). Because expression of high levels of IDO is correlated with a reduced ability to stimulate T cell responses and an enhanced ability to induce immunologic tolerance, APCs having high levels of IDO may be used to increase tolerance in the immune system, as for example in transplant therapy or treatment of autoimmune disorders. For example, APCs having high levels of IDO, and expressing or loaded with at least one antigen from a donor tissue may be used to increase tolerance of the recipient to the donor's tissue. Alternatively, APCs having reduced levels of IDO expression and expressing or loaded with at least one antigen from a cancer or infectious pathogen may be used as vaccines to promote T cell responses and increase immunity. | 10-21-2010 |
| 20110070581 | Separation of Leukocytes - Leukocytes (e.g., neutrophils, monocytes and/or lymphocytes) can be captured and separated from blood by removing platelets using a spiral channel, followed by capturing individual leukocyte types in a series of cell capture channels having leukocyte binding moieties. Accordingly, various microfluidic-based cell affinity chromatography methods can be used to separate leukocytes from whole blood. | 03-24-2011 |
| 20110070583 | Lsamp gene associated with cardiovascular disease - The LSAMP gene can be used for cardiovascular disease risk assessment, in particular Left Main Disease. The genetic risk attributable to LSAMP adds to known cardiovascular disease risk factors. Assessment of risk attributable to LSAMP permits early initiation of preventive and therapeutic strategies. Given the pronounced clinical risk associated with Left Main Disease, such risk assessment should significantly reduce morbidity and mortality. | 03-24-2011 |
| 20100233690 | Use of genes identified to be involved in tumor development for the development of anti-cancer drugs and diagnosis of cancer - The invention relates to the use of inhibitors of the expressed proteins of the murine genes and/or their human homologues listed in Table 1 for the preparation of a therapeutical composition for the treatment of cancer, in particular for the treatment of solid tumors of lung, colon, breast, prostate, ovarian, pancreas and leukemia and the use of the genes listed in Table 1 for the diagnosis of cancer. The invention also relates to the therapeutical compositions comprising the inhibitors and to methods for development of the inhibitor compounds. | 09-16-2010 |
| 20100233689 | PYRAZOLOANTHRONE AND DERIVATIVES THEREOF FOR THE TREATMENT OF CANCER EXPRESSING 'MULLERIAN INHIBITING SUBSTANCE' TYPE II RECEPTOR (MISRII) AND OF EXCESS ANDROGEN STATES - The present invention relates to pyrazoloanthrones or functional derivatives or functional analogues thereof to activate MIS receptor-mediated downstream effects in a cell. In particular, the present invention relates to method to prevent and treat cancer that expresses MIS receptor type II (MISRII) by administering to a subject at least one pyrazoloanthrone or a functional derivative or a functional analogue thereof. Another aspect of the present invention relates to methods to lower plasma androgen levels in a subject, and/or for the treatment of a subject with a disease characterized by excess androgen, whereby the subject is administered at least one pyrazoloanthrone or a functional derivative or a functional analogue thereof. Another aspect provides pharmaceutical compositions comprising at least one pyrazoloanthrone or functional a derivative or a functional analogue thereof, and optionally with one or more additional agents such as chemotherapeutic agents. Another aspect of the present invention relates to methods to decrease the dose of a chemotherapeutic agent by administering the chemotherapeutic agent with a pyrazoloanthrone or a functional derivative or a functional analogue thereof that lowers the effective dose of the chemotherapeutic agent, such as for example, paclitaxel. | 09-16-2010 |
| 20100233687 | METHOD AND SYSTEM FOR TEMPERATURE CORRECTION IN THERMAL MELT ANALYSIS - The present invention relates to methods and systems for temperature correction in thermal melt analysis. More specifically, embodiments of the invention relate to the correction of the melting temperature (T | 09-16-2010 |
| 20100233686 | Multiplex Quantitative Nucleic Acid Amplification and Melting Assay - The invention is a single-tube multiplex assay, capable of simultaneously amplifying, detecting and quantifying multiple nucleic acid targets, using multiple hybridization probes, labeled with the same fluorescent reporter label, but each having a distinct melting temperature. The assay can be further multiplexed with the use of multiple sets of hybridization probes, each set labeled with a separate fluorescent reporter label. | 09-16-2010 |
| 20100273158 | HIN-1, A Tumor Suppressor Gene - The invention encompasses isolated DNAs encoding HIN-1 polypeptides, vectors containing such DNAs, cells containing the vectors, and isolated HIN-1 polypeptides. The invention also features methods of making and using HIN-1 polypeptides. | 10-28-2010 |
| 20100273147 | Medical diagnostic system and methods - A system and methods are provided for a medical diagnostic system that incorporates a genetically encoded digital signature to authenticate a patient. In an illustrative implementation, a platform is provided performing one or more functions including but not limited to patient authentication, diagnostics, transmission, and storage of data in a centralized secure database capable of being accessed by healthcare professionals. In the illustrative implementation, the exemplary medical diagnostic system can comprise a genetic material collector/analyzer. Responsive to inputting genetic material in the collector/analyzer, the collector/analyzer generates a unique genetic-based electronic signature representative of the genetic material. The unique genetic-base electronic signature can then be processed by cooperating parties to authenticate the person providing the genetic sample. In the illustrative operation, such comparison can be accomplished by comparing the generated unique genetic-based electronic signature with a stored genetic-based electronic signature as part of a patient authentication process. | 10-28-2010 |
| 20100273157 | System and Method for Authentication or Identification of Bio-Artifacts Related to President Abraham Lincoln - An invention for authenticating artifacts related to President Abraham Lincoln is presented. In an embodiment of the invention, an artifact is identified. The artifact has a biologically-derived component (“bio-component”). At least a portion of the bio-component is processed to yield matter that may be analyzed. This matter is analyzed and the analysis results interpreted. The interpretation is based on information related to a syndrome of marfanoid habitus and stable multiple lip dysmorphisms (an “MH/LD syndrome”). Two such syndromes are multiple endocrine neoplasia type 2B and pure mucosal neuroma syndrome. Other such syndromes may exist. Evidence of an MH/LD syndrome in the analysis results is evidence that the artifact is authentically associated with President Lincoln. A report is optionally produced. | 10-28-2010 |
| 20100291581 | Aldehyde Dehydrogenase 1 (ALDH1) as a Cancer Stem Cell Marker - The present invention relates to compositions and methods for treating, characterizing, and diagnosing cancer. In particular, the present invention provides a novel stem cell cancer marker, ALDH | 11-18-2010 |
| 20100081131 | IDENTIFICATION OF MICROBES USING OLIGONUCLEOTIDE BASED IN SITU HYBRIDIZATION - A method of sample analysis is provided. In certain embodiments, the method may comprise: a) contacting a sample comprising a microbe with a set of at least two labeled oligonucleotides under in situ hybridization conditions to produce a contacted sample, where the labeled oligonucleotides i. hybridize to different RNA molecules of the microbe at sites that are unique to the microbe, ii. provide a predetermined optically detectable signature that identifies the microbe when the labeled oligonucleotides are hybridized to the different RNA molecules of the microbe, and iii. do not hybridize to ribosomal RNA of the microbe; b) reading the contacted sample to detect hybridization of the labeled oligonucleotides; and c) determining the identity of the microbe on the basis of the predetermined optically detectable signal, where the predetermined optically detectable signal indicates the identity of the microbe in the sample. | 04-01-2010 |
| 20100081128 | Self-assembled single molecule arrays and uses thereof - The present invention provides methods of making and using self-assembled arrays of single polynucleotide molecules for carrying out a variety of large-scale genetic measurements, such as gene expression analysis, gene copy number assessment, and the like. Random arrays used in the invention are “self-assembled” in the sense that they are formed by deposition of polynucleotide molecules onto a surface where they become fixed at random locations. The polynucleotide molecules fixed on the surface are then identified by direct sequence determination of component nucleic acids, such as incorporated probe sequences, or by other decoding schemes. Such identification converts a random array of determinable polynucleotides, and their respective probes into an addressable array of probe sequences. | 04-01-2010 |
| 20100291580 | BIOMARKERS FOR TRICHOGENICITY - Biomarkers for identifying trichogenic cells have been identified. The biomarkers include microRNA as wells as mRNA and proteins. Certain biomarkers are upregulated in trichogenic cells compared to non-trichogenic cells; whereas, other biomarkers are down-regulated in trichogenic cells compared to non-trichogenic cells. The cells can be dermal cells, epidermal cells, or a combination thereof. Preferably the cells are mammalian, more preferably the cells are human. One embodiment provides a method for selecting trichogenic cells by assaying the cells for expression of one or more biomarkers for trichogenicity, and selecting the cells having increased expression of the one or more biomarkers relative to a control, wherein increased expression of the a biomarker in the cells is indicative of trichogenicity. Preferably, the one or more biomarkers are selected from the group consisting of hsa-miR-200c, hsa-miR-205, hsa-miR-200a*, hsa-miR-200a, hsa-miR-141, hsa-miR-182, DEPDC1, hFLEG1, ESM1, TOME-1, THBD and combinations thereof. | 11-18-2010 |
| 20100291563 | ASSESSING TISSUE REJECTION - This document relates to methods and materials involved in assessing tissue rejection (e.g., organ rejection) in mammals. For example, methods and materials involved in detecting tissue rejection (e.g., kidney rejection) are provided, as are methods and materials for determining the extent of rejection in mammals (e.g., humans). | 11-18-2010 |
| 20100291548 | Methods of Detecting Target Nucleic Acids - The present disclosure relates to methods of identifying target nucleic acids by using coded molecules and its analysis by translocation through a nanopore. Generally, coded molecules are subject to a target polynucleotide dependent modification. The modified coded molecule is detected by isolating the modified coded molecules from the unmodified coded molecules prior to analysis through the nanopore or by detecting a change in the signal pattern of the coded molecule when analyzed through the nanopore. | 11-18-2010 |
| 20110091894 | OLIGONUCLEOTIDES FOR AMPLIFYING CHLAMYDOPHILA PNEUMONIAE NUCLEIC ACID - Oligonucleotides for use in determining the presence of | 04-21-2011 |
| 20110076688 | METHOD FOR ENUMERATION OF MAMMALIAN MICRONUCLEATED ERYTHROCYTE POPULATIONS, WHILE DISTINGUISHING PLATELETS AND/OR PLATELET-ASSOCIATED AGGREGATES - A method for the enumeration of micronucleated erythrocyte populations while distinguishing platelet and platelet-associated aggregates involves the use of a first fluorescent labeled antibody having binding specificity for a surface marker for reticulocytes, a second fluorescent labeled antibody having binding specificity for a surface marker for platelets, and a nucleic acid staining dye that stains DNA (micronuclei) in erythrocyte populations. Because the fluorescent emission spectra of the first and second fluorescent labeled antibodies do not substantially overlap with one another or with the emission spectra of the nucleic acid staining dye, upon excitation of the labels and dye it is possible to detect the fluorescent emission and light scatter produced by the erythrocyte populations and platelets, and count the number of cells from one or more erythrocyte populations in said sample. In particular, the use of the second antibody prevents interference by platelet-associated aggregates in the scoring procedures. | 03-31-2011 |
| 20110151444 | METHOD FOR DETECTION OF AN RNA MOLECULE, A KIT AND USE RELATED THEREFOR - Described is a method for the detection of a RNA molecule, the method involving the steps of providing a sample containing the RNA molecule; hybridizing to the RNA molecule a first polynucleotide; extending the first polynucleotide to generate a first strand cDNA; hybridizing a second polynucleotide to the first strand cDNA; extending the first strand cDNA to generate an extension reaction product; amplifying the extension reaction product by means of polymerase chain reaction; and detecting the amplification product by means of real-time fluorescence readout. Also described is a kit containing a first and a second polynucleotide as defined in the present invention, a set of dNTPs, a reverse transcriptase enzyme, and a detection moiety. | 06-23-2011 |
| 20110065116 | Method for Detecting ATP - Methods are provided for detection of concentrations of less than 3.4 picomolar of adenosine triphosphate (ATP) using recombinant luciferase in the luciferin-luciferase reaction. Aspects include a low pH composition for use in detecting the presence of ATP. The low pH composition can include low concentrations of detergents and can be used in combination with methods for reading, calculating and interpreting luminescence generated by the ATP-luciferin-luciferase reaction. | 03-17-2011 |
| 20110065117 | Mesothelioma Specific Transferred Promoter And Use Thereof - Provided is a promoter showing transcriptional activity in a mesothelioma-specific manner and showing low transcriptional activity in other kinds of cancer cells and normal cells including mesothelium. Also provided are applications of the promoter, and more specifically, a gene therapy vector and a therapeutic agent for mesothelioma each including the promoter. The promoter includes a CRI1 gene-derived promoter, which is one kind of mesothelioma markers. The use of a vector including a cell death-inducing gene or a cell lysis-inducing gene as a transgene and carrying the CRI1 gene-derived promoter upstream of the transgene can induce a cell death or cell lysis action in a mesothelioma-specific manner. That is, the gene therapy vector and the therapeutic agent for mesothelioma each include a virus vector carrying the CRI1 gene-derived promoter. | 03-17-2011 |
| 20100297657 | EXPRESSION PROFILE OF PROSTATE CANCER - The present invention relates to compositions and methods for cancer diagnostics, including but not limited to, cancer markers. In particular, the present invention provides gene expression profiles associated with prostate cancers. Genes identified as cancer markers using the methods of the present invention find use in the diagnosis and characterization of prostate cancer. In addition, the genes provide targets for cancer drug screens and therapeutic applications. | 11-25-2010 |
| 20110033844 | USE OF LYSOSOMAL CARBOXYPEPTIDASE C (PRCP) AS A THERAPEUTIC OR DIAGNOSTIC TARGET - The invention provides a human PRCP which is associated with the cardiovascular diseases, hematological diseases, neurological diseases and cancer. The invention also provides assays for the identification of compounds useful in the treatment or prevention of cardiovascular diseases, hematological diseases, neurological diseases and cancer. The invention also features compounds which bind to and/or activate or inhibit the activity of PRCP as well as pharmaceutical compositions comprising such compounds. | 02-10-2011 |
| 20100304367 | COMPOSITIONS FOR REAL-TIME, SINGLE MOLECULE SEQUENCE DETERMINATION - A sequencing methodology is disclosed that allows a single DNA or RNA molecule or portion thereof to be sequenced directly and in substantially real time. The methodology involves engineering a polymerase and/or dNTPs with atomic and/or molecular tags that have a detectable property that is monitored by a detection system. | 12-02-2010 |
| 20110033857 | PEPTIDE SEQUENCE THAT PROMOTES TUMER INVASION - An isolated sequence SGSSEEKQNAVSSEET (OPNcPEP) SEQ ID NO: | 02-10-2011 |
| 20110033863 | RNA-SELECTIVE HYBRIDIZATION REAGENT AND USE OF THE SAME - Provided is a nucleoside derivative which has a high affinity for RNA. Use is made of a nucleoside derivative represented by either formula (1) or formula (2). (In formulae (1) and (2), Z represents a carbon atom or a nitrogen atom; R | 02-10-2011 |
| 20100304396 | ANIMAL HEALTH DIAGNOSTICS - A physical blood sample of animal is sent to a satellite laboratory facility. The blood sample is pre-processed into sub-samples of the sample and the sub-samples are coded. The coded blood sub-samples are physically carried to the main laboratory for analysis. The satellite facility electronically inputs a request for a laboratory analysis by a main laboratory. The request is electronically transmitted to the main laboratory, and the main laboratory coordinates the electronically received input from the satellite facility with the physical blood sub-samples. A computer report of the analysis from the laboratory is obtained for the satellite facility. A clinical pathologist with data of physical characteristics of the animal makes a diagnosis. A menu on a computer permits the generation of a supplemental report to support the diagnosis. An integrated computer report having the laboratory analysis, supplemental report, and a pathologist-enhanced report is electronically communicated to the client. | 12-02-2010 |
| 20100304391 | METHODS FOR ASSESSMENT AND TREATMENT OF DEPRESSION VIA UTILIZATION OF SINGLE NUCLEOTIDE POLYMORPHISMS ANALYSIS - Described herein are assays, kits and methods for treating depression, including the diagnosis and treatment of depression based on the determination of genetic predispositions towards inhibition or enhancement of Ca2+/calmodulin-dependent protein kinase II (CaMKII). For example, described herein are methods and kits (including assays) for determining if one or more gene in an excitatory or inhibitory pathway for modulating CaMKII activity or expression is likely to be inhibited or enhanced by an SNP. Also described are methods and kits (including assays) for prescribing treatment based on the identification of SNPs that may modulate CaMKII. | 12-02-2010 |
| 20100304387 | METHODS AND COMPOSITIONS FOR SIGNAL ENHANCEMENT USING MULTIVALENT INTERACTIONS - Methods and materials are disclosed relating to an improved method for amplifying a signal in a diagnostic assay for an analyte, using an amplification polymer that multivalently binds to one or more non-analyte-specific binding site of the multivalent bridge conjugate, if present on the solid support. | 12-02-2010 |
| 20100304373 | Methods for Assessing the Susceptibility of a Human to Diminished Health and Wellness - The present invention relates to methods for assessing the advisability that a human should employ a compensatory composition comprised of one or more antioxidant ingredients. The methods involve assessing occurrence in the human's genome of a plurality of certain polymorphisms. Methods for determining the composition of preferred compensatory compositions are also disclosed. | 12-02-2010 |
| 20100304368 | COMPONENTS AND METHOD FOR ENZYMATIC SYNTHESIS OF NUCLEIC ACIDS - Novel methods for enzymatic synthesis of nucleic acid chains and the substrates for the same are disclosed. The methods are based on a step-wise enzymatic reaction. The sequencing of nucleic acids is an example of the use of the claimed methods. | 12-02-2010 |
| 20110033859 | RNAi INHIBITION OF INFLUENZA VIRUS REPLICATION - The invention relates to compositions and methods for modulating the expression of influenza viral genes, and more particularly to the downregulation of influenza viral genes by chemically modified oligonucleotides. | 02-10-2011 |
| 20110033865 | NOVEL METHOD FOR DIAGNOSING PREGNANCY-RELATED COMPLICATIONS - A method for diagnosing pregnancy-related complications in a pregnant woman is provided. The method includes the following steps: (a) determining the level of Placental Protein 17 (PP17) in a bodily substance obtained from the pregnant woman; and (b) comparing the determined level of PP17 to a standard level of PP17, a significant modification in the level of PP17 indicating the existence of a pregnancy-related complication in the pregnant woman. A diagnostic kit is also described. | 02-10-2011 |
| 20100297630 | METHOD FOR THE SIMULTANEOUS DETECTION OF MULTIPLE NUCLEIC ACID SEQUENCES IN A SAMPLE - The invention is in the technical field of detecting nucleic acid sequences in a sample, such as the detection of pathogenic organisms in clinical samples. More specifically, the invention relates to the field of detecting an infection caused by a pathogenic organism such as a virus or a bacterium in a clinical specimen by means of amplifying and detecting specific nucleic acid sequences from said pathogenic organism. It provides a multiplex assay with the possibility to determine about 30 different target nucleic acid sequences in a single one-tube assay combined with real-time probe detection. The method employs multiplex ligation dependent Probe Amplification (MLPA) employing labelled primers in combination with labelled, probes and detection of the fluorescence. | 11-25-2010 |
| 20110045479 | Method For High Resolution Melt Genotyping - Various methods are described that provide for high resolution melt (HRM) genotyping. The embodiments include providing a locus specific primer and two allele specific primers each having a 5′ end with a short tail, providing a nucleic acid having a single nucleotide polymorphism (SNP) base located within 1-20 base pairs of the 3′ end of nucleic acid, hybridizing the locus specific primer and the allele specific primers to the nucleic acid, amplifying the sample using pyrophosphorolysis activated polymerization (PAP) PCR enzyme, and determining the Tm of the amplicons using HRM. In other embodiments, reactions mixtures and kits for HRM genotyping are provided and disclosed. These kits comprise a locus specific primer, one or more allele specific primers each having a 5′ end with a short tail, a nucleic acid, and a pyrophosphorolysis activate polymerization (PAP) PCR enzyme. | 02-24-2011 |
| 20110045484 | METHOD OF DETECTING TARGET MOLECULE BY USING APTAMER - An aptamer-probe complex for detecting the presence of a target molecule is disclosed. The complex of the present invention contains an aptamer moiety which is able to bind to an indicator protein and change the properties of the indicator protein, and a probe moiety which is able to bind to a target molecule, wherein the aptamer moiety and the probe moiety are combined in such a manner that the binding mode between the aptamer moiety and the indicator protein changes when the probe moiety binds to the target molecule. A target molecule can be detected with combination of an aptamer which binds to a certain protein, and a probe which binds to the target molecule, utilizing the properties of that protein as an indicator. | 02-24-2011 |
| 20110045478 | Genetic Fingerprinting And Identification Method - The present disclosure provides methods for molecular fingerprinting for the characterization and identification of organisms. More specifically, in one aspect the present invention provides a method of identifying an organism in a sample comprising: (a) providing a sample comprising said organism, said organism comprising at least one nucleic acid; (b) combining said sample or the at least one nucleic acid therefrom with an amplification mix comprising at least one labeled oligonucleotide primer; (c) generating at least one labeled amplification product from the at least one nucleic acid of said organism using a nucleotide amplification technique employing said at least one labeled oligonucleotide primer; (d) combining said at least one labeled amplification product with products of a DNA sequencing reaction to create a separation mix; and (e) separating said separation mix on the basis of oligonucleotide length in a fluorescent DNA sequencing instrument to generate a sequence embedded fingerprint pattern for said organism. | 02-24-2011 |
| 20110045482 | SCREENING METHODS FOR IDENTIFYING TARGET ANTIFUNGAL GENES AND COMPOUNDS BY DETECTING CELL SURFACE GLYCOPROTEINS - The present invention relates to an assay method that can be used for high-throughput detection of cell surface glycoproteins. Specifically, the secretion of a chimeric glycoprotein reporter signals disruption of GPI anchor-mediated attachment of the glycoprotein to the cell surface. This method provides a high signal-to-noise ratio and is particularly useful for screening compounds that affect GP1 anchor biosynthesis. The method of the present invention thus permits genome-wide screens for genes that are needed for GPI anchor-mediated attachment of a glycoprotein to the surface of a cell as well as chemical inhibitors of proteins that promote GP1 anchor-mediated attachment of a glycoprotein to the surface of a cell. Protein inhibitors identified by the present method could be useful in antifungal drug treatments as well. | 02-24-2011 |
| 20110045477 | HUMAN SKIN EXPLANT CULTURE SYSTEM AND USE THEREFOR - The present invention features a human skin explant culture system and uses thereof. | 02-24-2011 |
| 20110045473 | LIVER SCREENING METHOD - The invention features a method of identifying therapeutically relevant compositions that include a therapeutic agent and a delivery component by screening for an effect of the agent on the liver of a model subject. | 02-24-2011 |
| 20110045475 | UPREGULATION OF RACK-1 IN MELANOMA AND ITS USE AS A MARKER - The present invention concerns a method for diagnosing a melanoma in a mammal comprising the detection of the overexpression of RACK-1 protein in a melanocytic cell of said mammal, and the deduction of the presence of a melanoma from the overexpression of RACK-1 protein. The invention is also directed to a method for determining the tumoral status of a melanocytic cell of a mammal, comprising the detection of overexpression of RACK-1 protein in the melanocytic cell, and the deduction of the tumoral state of said cell from the overexpression of RACK-1 protein. | 02-24-2011 |
| 20110045469 | SNPs ASSOCIATED WITH FATTY ACID COMPOSITION OF BOVINE MEAT AND MILK - The present invention provides compositions and methods for genotyping bovines including dairy cows and beef cattle More particularly, the invention is directed to single nucleotide polymorphisms in Stearoyl-CoA-Desaturase 5 (SCD5) Sterol regulatory element-binding protein-1 (SREBP1). SREBP cleavage-activating protein (SCAP), Insulin induced protein 1 (INS1G1). Insulin induced protein 2 (INS1G2) and Signal recognition particle receptor (SRPR) associated with fatty acid composition of bovine meat and milk. | 02-24-2011 |
| 20110045468 | Polynucleotides for the identification and quantification of group a streptococcus nucleic acids - The present invention provides polynucleotides that can specifically hybridize to Group A | 02-24-2011 |
| 20110045471 | Methods for Assaying MC1R Variants and Mitochondrial Markers in Skin Samples - The present invention relates to methods for predicting, diagnosing and monitoring skin states and skin diseases. The methods combine the use of non-invasive skin collecting techniques with one or more assays for determining mitochondrial DNA (mtDNA) aberrations and Melanocortin 1 Receptor (MC1R) variants, thereby providing a comprehensive tool for identifying, predicting and/or monitoring photoageing, ultraviolet radiation (UVR) damage or skin disease. The methods of the invention may also be effective in screening for new therapeutic agents, skin care products and treatment regimes, and may also be useful for monitoring the response of a subject to a preventative or therapeutic treatment. | 02-24-2011 |
| 20100279303 | REACTION VESSEL, REACTION VESSEL LIQUID INTRODUCING DEVICE, LIQUID INTRODUCING AND REACTION MEASURING DEVICE, AND LIQUID INTRODUCING DEVICE - The invention relates to a reaction vessel, a reaction vessel liquid introducing device, a liquid introducing and reaction measuring device, and a liquid introducing device, and is directed to being able to perform temperature control of a liquid stored within the reaction vessel with a high accuracy and faithful responsiveness. The reaction vessel comprises: a storage chamber in which a liquid is storable, that has an opening part; a reaction chamber that is formed thinner or narrower than the storage chamber; and at least one flow passage that communicates between the storage chamber or the exterior and the reaction chamber. The reaction vessel is formed such that it is connectable to a liquid introducing section provided externally, and the liquid can be introduced into the reaction chamber by connecting to the liquid introducing section. | 11-04-2010 |
| 20100323352 | Marker for Prenatal Diagnosis and Monitoring - The present invention relates to new methods for diagnosing a pregnancy-associated disorder by analyzing fetal DNA present in the mother's blood. More specifically, this invention relies on the discovery that the maspin gene is differentially methylated in fetal DNA and in maternal DNA and provides these new diagnostic methods, which distinguish fetal DNA from maternal DNA and detect prenatal disorders based on abnormalities in fetal DNA level and methylation status. | 12-23-2010 |
| 20090258356 | Modulators of the transporter ABCD3 for treating acne or hyperseborrhea - An in vitro method for screening candidate compounds for the preventive or curative treatment of acne, includes the determination of the capacity of a compound to modulate the expression or the activity of the peroxisome membrane transporter 1 comprising a type 3 ATP-binding site of the sub-family D (ABCD3), and the use of modulators of the expression or activity of this transporter for the treatment of acne or skin disorders associated with a hyperseborrhea; methods for the in vitro diagnosis or prognosis of these pathologies are also described. | 10-15-2009 |
| 20100311051 | Calcium-binding photoprotein, gene encoding the same and use thereof - The invention provides calcium-binding photoproteins which can detect light emission with a higher sensitivity. The proteins of the invention comprising the amino acid sequence of SEQ ID NO: 2 can be used for the detection and measurement of calcium ions. The proteins of the invention are useful as reporter proteins, luminescent markers, etc. The polynucleotides of the invention are useful as reporter genes, etc. | 12-09-2010 |
| 20100255495 | METHODS FOR PREDICTING THE RISK OF DIABETIC NEPHROPATHY USING GENETIC MARKERS AND ARRAYS CONTAINING THE SAME - A method for detecting a Chinese diabetic subject suffering from, at risk for developing, or suspected of suffering from a nephropathy. The method includes determining whether a sample from the subject has at least one of the following polymorphic sequences: an I/D genotype of an ACE gene, an M235T genotype of an AGT gene, a (CA)n-5′(z−2) genotype of an ALR2 gene, an C106T genotype of an ALR2 gene in the promoter region, a G-308A genotype of a TNF-α gene, or a complement thereof, provided that the ALR2 gene cannot be used alone, in which the presence of the polymorphic sequence indicates the subject suffering from, at risk for suffering from a nephropathy. An array for detecting a Chinese diabetic subject suffering from, or at risk for suffering from, a nephropathy. | 10-07-2010 |
| 20100120039 | METHODS AND COMPOSITIONS IN BREAST CANCER THERAPY RESISTANCE - The present invention is directed to methods and/or compositions regarding a specific mutation in estrogen receptor alpha and their use for identifying resistance to breast cancer therapy and/or treatment therefor. More specifically, the present invention concerns presence or absence of an A908G mutation in an estrogen receptor alpha nucleic acid sequence, and/or the corresponding K303R mutation in the estrogen receptor alpha polypeptide sequence, for example, as a predictive marker for resistance to breast cancer therapy. Therapeutic embodiments for overcoming the resistance are also provided. | 05-13-2010 |
| 20100285464 | A CONSERVED REGION OF THE HIV-1 GENOME AND USES THEREOF - The present invention discloses sequences having a structure and sequence homology to lox-P recombinase target site corresponding to a highly conserved region within the Long Terminal Repeats (LTR) of HIV and to the use thereof for the identification of recombinase enzymes useful in treating HIV-1. | 11-11-2010 |
| 20100279300 | METHODS FOR DETERMINING THE PROGNOSIS FOR PATIENTS WITH A PROSTATE NEOPLASTIC CONDITION - The invention provide a method of identifying a biomarker that is diagnostic for survival of a patient with a prostate neoplastic condition. The method consists of (a) measuring the level of IAPs in a neoplastic prostate cell-containing sample from patients with a prostate neoplastic condition, and (b) identifying a correlation between the level of IAPs in a sample from a patient with the survival of that patient, where the correlation of an IAP with survival in patients indicates the IAP is a biomarker diagnostic of survival of a patient with a prostate neoplastic condition. Also provided is a method of determining a prognosis for survival for a patient with a prostate neoplastic condition. The method consists of (a) measuring the level of XIAP in a neoplastic prostate cell-containing sample from the patient, and (b) comparing the level of XIAP in the sample to a reference level of XIAP, where an increased level of XIAP in the sample correlates with increased survival of the patient. The invention further provides a method of determining a prognosis for survival for a patient with a prostate neoplastic condition. The method consists of (a) measuring the level of two or more IAPs selected from the group consisting of XIAP, cIAP1, and cIAP2 in a neoplastic prostate cell-containing sample from a patient, and (b)comparing the level of the two or more IAPs in the sample to a reference level of the IAPs, where an increased level of XIAP and decreased level of cIAP1 or cIAP2 in the sample correlates with increased survival of the patient. | 11-04-2010 |
| 20100279299 | Devices and Methods for Heating Biological Samples - This invention provides a systems and methods for regulating temperature and heat transfer in applications in which it is desirable to maintain temperature uniformity such as thermal cycling applications. A heat block is used to rapidly transfer heat to or from a set of one or more reaction vessels. | 11-04-2010 |
| 20100279298 | Methods and Compositions For Detecting Autoimmune Disorders - The invention provides methods and compositions useful for detecting autoimmune disorders. | 11-04-2010 |
| 20100279297 | Method for Identifying an Increased Susceptibility to Ulcerative Colitis - A method is provided for detecting an increased susceptibility to ulcerative colitis by determining the presence of a polymorphism at position 256 of the nucleotide sequence of rs3024505 in which C is substituted by T or the presence of a polymorphism at position 501 of the nucleotide sequence of rs12612347 in which G is substituted by A. | 11-04-2010 |
| 20100279296 | ENHANCED FC RECEPTOR-MEDIATED TUMOR NECROSIS FACTOR SUPERFAMILY MRNA EXPRESSION IN PERIPHERAL BLOOD LEUKOCYTES IN PATIENTS WITH RHEUMATOID ARTHRITIS - A method for predicting patient responsiveness to rheumatoid arthritis treatments involving altering expression of tumor necrosis factor superfamily (“TNFSF”)-2, TNFSF-8, or TNFSF-15 is disclosed. A method for monitoring the effectiveness of such therapy is also disclosed. Furthermore, a method of screening compounds for use in the treatment of rheumatoid arthritis is disclosed. A method of monitoring the disease state over time in rheumatoid arthritis patients is also disclosed. | 11-04-2010 |
| 20100279281 | METHOD OF IDENTIFYING LUNG CANCERS ASSOCIATED WITH ASBESTOS-EXPOSURE - The present invention is related to a method for assessing the presence of, or disposition to, an asbestos-related disorder in a subject. Particularly, the invention provides a method of identifying lung cancers associated with asbestos-exposure. The association is confirmed by the detection of allelic imbalance (AI) in at least one of the following chromosomal regions of lung cancer cells: 19p13.3-p13.1; 9q32-34.3; 2p21-p16.3; 16p13.3; 22q12.3-q13.1; and 5q35.3. | 11-04-2010 |
| 20100196913 | Mutant AOX1 Promoters | 08-05-2010 |
| 20100196910 | METHODS OF GENERATING HUMAN CARDIAC CELLS AND TISSUES AND USES THEREOF - A method of generating cells predominantly displaying at least one characteristic associated with a cardiac phenotype is disclosed. The method comprises (a) partially dispersing a confluent cultured population of human stem cells, thereby generating a cell population including cell aggregates; (b) subjecting the cell aggregates to culturing conditions suitable for generating embryoid bodies; (c) subjecting the embryoid bodies to culturing conditions suitable for inducing cardiac lineage differentiation in at least a portion of the cells of the embryoid bodies, the culturing conditions suitable for inducing cardiac lineage differentiation including adherence of the embryoid bodies to a surface, and culture, medium supplemented with serum, thereby generating cells predominantly displaying at least one characteristic associated with a cardiac phenotype. | 08-05-2010 |
| 20100196908 | SYSTEMS AND METHODS FOR DETECTING A SIGNAL AND APPLYING THERMAL ENERGY TO A SIGNAL TRANSMISSION ELEMENT - A signal detection system configured for detecting a signal emitted by the contents of a reaction receptacle is also configured to apply thermal energy to a portion of the reaction receptacle to affect a reaction occurring within the reaction receptacle. More particularly, a system for detecting electromagnetic radiation emitted by the contents of a reaction receptacle includes a transmission element configured for transmitting electromagnetic radiation from the contents of the receptacle, a thermal element associated with the transmission element and configured to apply thermal energy to at least a portion of the receptacle, and a detector configured to receive electromagnetic radiation from the transmission element and to generate a signal corresponding to a characteristic of the electromagnetic radiation received by the detector. | 08-05-2010 |
| 20100196917 | CELL ANALYSIS APPARATUS AND CELL ANALYSIS METHOD - A cell analysis apparatus that can accurately distinguish between an aggregating cell and a non-aggregating cell is provided. The cell analysis apparatus ( | 08-05-2010 |
| 20100196914 | RARE CELL DETECTION USING FLAT-PANEL IMAGER AND CHEMILUMINESCENT OR RADIOISOTOPIC TAGS - Disclosed is a method using a large area flat panel imager which is specifically adapted for rare cell detection methods. The method generally includes an imager having a sample receiving surface which can provide a digital or electronic image of a sample deposited on the surface. The method also includes a selectively positionable microscope and/or camera which are used to obtain high resolution images of the deposited samples. An electronic controller can also be used in conjunction with the imager, microscope, and/or camera to selectively position at least one of those components to focus on desired regions of the deposited sample. The noted method is particularly adapted for use with chemiluminescence or other tagging technologies. | 08-05-2010 |
| 20100196895 | METHOD FOR DETERMINATION OF ONSET RISK OF GLAUCOMA - A method of determining the presence or the absence of a glaucoma risk, including the steps of detecting in vitro an allele and/or a genotype of a single nucleotide polymorphism which is located on a 31st base of a base sequence, in a sample from a subject, wherein the base sequence is at least one base sequence selected from the group consisting of base sequences shown in SEQ ID NOs: 203 to 514 or a complementary sequence thereto (step A), and comparing the allele and/or the genotype detected in the step A with at least one of an allele and/or a genotype, containing a high-risk allele, in the base sequences shown in SEQ ID NOs: 203 to 514 (step B). According to the method of the present invention, the level of an onset risk of glaucoma in a sample donor can be determined by analyzing an allele or a genotype of a single nucleotide polymorphism in the present invention on the sample, so that the sample donor can take a preventive measure of glaucoma, or can receive appropriate treatments, on the basis of this risk. | 08-05-2010 |
| 20100196899 | Systems for genome selection - Systems, methods, compositions and apparatus relating to genome selection are disclosed. | 08-05-2010 |
| 20100196900 | METHOD OF DETECTING CANINE EXERCISE-INDUCED COLLAPSE - The present invention relates to diagnosing Canine Exercise-Induced Collapse (EIC). | 08-05-2010 |
| 20100196880 | COMPOSITIONS AND MULTIPLEX ASSAYS FOR MEASURING BIOLOGICAL MEDIATORS OF PHYSIOLOGICAL HEALTH - Multiplex assays are provided including panels of probes for development of multiplex assays capable of simultaneously measuring multiple biologically-relevant proteins using very small quantities of biological samples to rapidly assess the health status of animals, especially companion animals, as well as to formulate nutritional regimens for improving the health status of animals. The probes are provided as are methods for using them to assess the health status of animals, as well as their responses to therapeutic or nutritional interventions therein. | 08-05-2010 |
| 20100285489 | METHOD FOR DIAGNOSING RENAL DISEASES OR PREDISPOSITIONS - The invention provides a method of diagnosing a disease or a predisposition to contract a disease by assaying for mutations of uromodulin (UMOD) within a test subject or patient. The presence of a mutation in the UMOD supports a diagnosis of a disease or a predisposition to contract a disease within the patient. | 11-11-2010 |
| 20100285488 | T-STRUCTURE INVASIVE CLEAVAGE ASSAYS, CONSISTENT NUCLEIC ACID DISPENSING, AND LOW LEVEL TARGET NUCLEIC ACID DETECTION - The present invention relates to systems, methods and kits for low-level detection of nucleic acids, detecting at least two different viral sequences in a single reaction vessel, and increasing the dynamic range of detection of a viral target nucleic acid in a sample. The present invention also relates to T-structure invasive cleavage assays, as well as T-structure related target dependent non-target amplification methods and compositions. The present invention further relates to methods, compositions, devices and systems for consistent nucleic acid dispensing onto surfaces. | 11-11-2010 |
| 20100285487 | FLUORESCENT TWO-HYBRID (F2H) ASSAY FOR DIRECT VISUALIZATION OF PROTEIN INTERACTIONS IN LIVING CELLS - The present invention relates to an in vitro method for detecting protein-protein interactions comprising: (a) expressing in a eukaryotic cell a first fusion protein comprising (i) a (poly)peptide that, when expressed in a cell, accumulates at distinct sites in the nucleus of the cell or interacts with proteinaceous or non-proteinaceous structures accumulated at distinct sites in the nucleus of the cell; and (ii) a (poly)peptide specifically binding to GFP; (b) expressing in the same cell a second fusion protein comprising (i) GFP; and (ii) a bait (poly)peptide; (c) expressing in the same cell a third fusion protein comprising (i) a fluorescent (poly)peptide, the excitation and/or emission wavelength of which differs from that of GFP; and (ii) a prey (poly)peptide; and (d) detecting the fluorescence emission of the fluorescent parts of the second and the third fusion protein in the cell upon excitation, wherein a co-localization of the fluorescence emission of both fusion proteins in the cell nucleus is indicative of an interaction of the bait and the prey (poly)peptide. The invention also relates to an in vitro method for detecting protein-protein interactions comprising: (a) expressing in a eukaryotic cell a first fusion protein comprising (i) a fluorescent (poly)peptide; (ii) a (poly)peptide that, when expressed in a cell, accumulates at distinct sites in the nucleus of the cell; and (iii) a bait (poly)peptide (b) expressing in the same cell a second fusion protein comprising (i) a fluorescent (poly)peptide, the excitation and/or emission wavelength of which differs from that of the fluorescent (poly)peptide comprised in said first fusion protein; and (ii) a prey (poly)peptide and (c) detecting the fluorescence emission of the fluorescent parts of the first and the second fusion protein in the cell upon excitation, wherein a co-localization of the fluorescence emission of both fusion proteins in the cell nucleus is indicative of an interaction of the bait and the prey (poly)peptide. Furthermore, the present invention relates to methods for identifying a compound modulating the interaction of two (poly)peptides and methods of determining the relative strength of the interaction of two proteins with a third protein. | 11-11-2010 |
| 20100285466 | ESOPHAGEAL CANCER MARKERS - The present invention is directed to methods for diagnosing cancer in a subject. Morphologically normal epithelial cells of the esophagus are assayed for marker expression. Characteristic expression of the markers indicates the presence of cancer or the predisposition to cancer. A panel of eleven markers are particularly good at identifying cancer and the predisposition to cancer. | 11-11-2010 |
| 20100285465 | Molecular Typing of Neisseria Strains by Determining the Presence of Genes Involved in Lipooligosaccharide (LOS) Biosynthesis - The present invention relates to a method of LOS molecular typing of a | 11-11-2010 |
| 20100285463 | SELECTING NUCLEIC ACID SAMPLES SUITABLE FOR GENOTYPING - The present invention relates to a method for selecting a DNA sample comprising genomic DNA suitable for genotyping, comprising the steps of: i) pre-genotyping said genomic DNA using a set of polymorphic markers; ii) determining out of said set of polymorphic markers the percentage of polymorphic markers for which said genomic DNA is homozygous; and iii) selecting said DNA sample when said genomic DNA is homozygous for less than 70% of said set of polymorphic markers. Furthermore, a method of genotyping comprising a step of using a DNA sample selected by the method in accordance with the present invention and/or a step of applying the method provided herein is disclosed. The present invention also relates to a method for identifying a gene or a locus on a genome, said method comprising a step of using a DNA sample selected by the method provided herein and a step of applying the method described herein. Further, the present invention relates to a kit for carrying out the method in accordance with the present invention comprising primers for the amplification of the set of polymorphic markers employed herein. | 11-11-2010 |
| 20100285462 | METHODS AND MATERIALS RELATED TO HAIR PIGMENTATION AND CANCER - This document relates to methods and materials for determining whether or not a horse contains a Grey allele. For example, diagnostic methods such as nucleic acid-based detection methods and materials such as nucleic acid probes and primer pairs that can be used to determine whether or not a horse contains a duplication in intron 6 of STX17 nucleic acid are provided. This document also relates to methods and materials for treating a mammal having or being likely to develop cancer (e.g., benign, malignant, or metastatic cancer). For example, methods and materials for treating cancer in a mammal by administering an agent having the ability to reduce expression of an STX17 polypeptide and/or an NR4A polypeptide (e.g., an NR4A1, NR4A2, or NR4A3 polypeptide) in the mammal are provided. | 11-11-2010 |
| 20100285461 | Methods Of Producing And Sequencing Modified Polynucleotides - The present invention encompasses methods for producing a modified polynucleotide sequence that comprises a (e.g., one or more) phosphorothiolate linkage, methods for determining a polynucleotide sequence comprising a (e.g., one or more) phosphorothiolate linkage, and methods for separating forward and reverse extension products that comprise a (e.g., one or more) phosphorothiolate linkage. The invention also encompasses kits for producing and/or determining the sequence of a modified polynucleotide that comprises a (e.g., one or more) phosphorothiolate linkage. | 11-11-2010 |
| 20100285460 | Biological Detection System and Method - The present disclosure, according to some embodiments, relates to phage-based biological detection systems, compositions, and methods. In some embodiments, it relates to a detection system and method using phage binding and bacterial infection to detect the presence of a target molecule (e.g., a toxin). One detection system may include a genetically engineered phage that expresses a surface molecule able to bind a target molecule and/or target microorganism; a bacterium susceptible to infection by the phage; and a detection component able to determine whether the bacterium has been infected by the phage. Infection of a bacterium by a phage may be indicative of phage binding to the target molecule and/or target microorganism. One method may include placing a sample suspected of containing the target molecule and/or target microorganism with a binder; adding a genetically engineered phage having reporter genetic material and able to bind the target molecule and/or target microorganism; washing away unbound phage; releasing phage bound to the target molecule and/or target microorganism; infecting a bacterium with the released phage; and detecting the presence of any reporter genetic material in the bacterium. Reporter material in the bacterium may correlate with target molecule and/or target microorganism in the sample. In some embodiments, the disclosure relates to a detection system and method using phage comprising a reporter to infect a microorganism (e.g., | 11-11-2010 |
| 20100267023 | SELECTIVE RESTRICTION FRAGMENT AMPLIFICATION: FINGERPRINTING - The invention relates to a process for the controlled amplification of at least one part of a starting DNA containing a plurality of restriction sites for a determined specific restriction endonuclease, and of which at least part of its nucleic acid is unknown. Application of this process to human, animal or plant DNA fingerprinting, to identification of restriction fragment length polymorphisms. Kit for the application of the process. | 10-21-2010 |
| 20100291583 | METHODS FOR DETECTING NUCLEIC ACIDS USING MULTIPLE SIGNALS - Disclosed is are methods for identifying a nucleic acid in a sample. In one example, the method includes: (a) contacting the nucleic acid in the sample with an oligonucleotide that is specific for the nucleic acid in the sample and that is labeled with at least a first fluorescent dye; (b) contacting the nucleic acid in the sample with a second fluorescent dye that is different from the first fluorescent dye, such that the second fluorescent dye interacts with the nucleic acid; (c) amplifying the nucleic acid if present in the sample; and (d) detecting the nucleic acid if present in the sample by observing fluorescence from the first fluorescent dye after the oligonucleotide hybridizes to the amplified nucleic acid and determining the melting temperature of the amplified nucleic acid by measuring the fluorescence of the second fluorescent dye. The second fluorescent dye may include a fluorescent intercalating agent. | 11-18-2010 |
| 20100291565 | Detection of Methylation in Nucleic Acid Sequences - The present invention provides a method for detecting and/or quantifying the presence of, and relative abundance of, methylated nucleic acid bases within double-stranded nucleic acid by i) contacting a double-stranded nucleic acid sample with an intercalating fluorescent dye when bound to the nucleic acid sample fluoresces when exposed to light of a wavelength capable of causing the dye to fluoresce; 2) altering the hybridisation conditions of the solution containing the double-stranded nucleic acid-dye complex such that dissociation of the two strands of the said nucleic acid-dye complex occurs at a rate that permits progressive release of the dye 3) and monitoring the difference in fluorescence, and uses thereof. | 11-18-2010 |
| 20100273176 | METHOD OF JUDGING RISK FOR ONSET OF DRUG-INDUCED GRANULOCYTOPENIA - Means for determining the presence of the risk of drug-induced granulocytopenia in a human is provided. | 10-28-2010 |
| 20100297632 | UPREGULATION OF RACK-1 IN MELANOMA AND ITS USE AS A MARKER - The present invention concerns a method for diagnosing a melanoma in a mammal comprising the detection of the overexpression of RACK-1 protein in a melanocyte cell of said mammal, and the deduction of the presence of a melanoma from the overexpression of RACK-1 protein. The invention is also directed to a method for determining the tumoral status of a melanocyte cell of a mammal, comprising the detection of overexpression of RACK-1 protein in the melanocyte cell, and the deduction of the tumoral state of said cell from the overexpression of RACK-1 protein. | 11-25-2010 |
| 20100297619 | GENETIC PREDICTION OF SCHIZOPHRENIA SUSCEPTIBILITY - Provided are methods of determining the likelihood that a patient will be diagnosed with schizophrenia. | 11-25-2010 |
| 20100297614 | PROCESS FOR THE DETECTION OF CYTOSINE METHYLATIONS - The invention concerns a method for the detection of cytosine methylations in DNA and a kit for undertaking an assay according to the method of the invention. | 11-25-2010 |
| 20100297655 | SOCS-1 GENE METHYLATION IN CANCER - Methods are provided for identifying a cell exhibiting unregulated growth associated with methylation-silenced transcription of a suppressor of cytokine signaling (SOCS)/cytokine-inducible SH2 protein (CIS) family member (SOCS/CIS) gene such as the SOCS-1 gene. In addition, methods of treating a cancer patient, wherein cancer cells in the patient exhibit methylation-silenced transcription of SOCS/CIS gene such as a SOCS-1 gene, are provided, as are reagents for practicing such methods. | 11-25-2010 |
| 20100297625 | BIOMARKERS FOR PSYCHOSIS - The present invention relates generally to the diagnosis of psychosis, schizophrenia and bipolar disorder, including psychotic bipolar disorder. | 11-25-2010 |
| 20100297620 | ACTIVATED PROTEASE INDICATOR - It is an object of the invention to provide novel approaches capable of detecting activated protease and also detecting protease activation on real time at a high sensitivity in a noninvasive manner. By the method for detecting activated protease of the invention, an indicator in a circular form comprising the C-half fragment of luciferase (Luc-C) and the N-half fragment of luciferase (Luc-N) linked together through a substrate peptide for a protease is introduced in an in vitro assay system or in cells. Upon digestion of the substrate peptide by the protease, Luc-N and Luc-C together reconstructs active luciferase, so that the activated protease can be detected by assaying the luminescence signal from the luciferase. | 11-25-2010 |
| 20100297615 | EGFR MUTATIONS - The present invention relates to mutations in Epidermal Growth Factor Receptor (EGFR) and methods of detecting such mutations as well as prognostic methods method for identifying a tumors that are susceptible to anticancer therapy such as chemotherapy and/or kinase inhibitor treatment. The methods involve determining the presence of a mutated EGFR gene or mutated EGFR protein in a tumor sample whereby the presence of a mutated EGFR gene or protein indicates the tumor is susceptible to treatment. | 11-25-2010 |
| 20100304376 | Epigenetic Silencing of Cyclooxygenase-2 Affects Clinical Outcome in Gastric Cancer - The present invention discloses methods of using the methylation status of the COX-2 gene promoter region as a biomarker for a gastric cancer patient to determine a prognosis and a treatment regimen, and to monitor the progress of a treatment regimen. | 12-02-2010 |
| 20100304394 | Screening methods involving the detection of short-lived proteins - A method is provided for screening for agents that affect protein degradation rates, the method comprising: taking a library of cells, the cells expressing a fusion protein comprising a reporter protein and a protein encoded by a sequence from a cDNA library derived from a sample of cells, the sequence from the cDNA library varying within the cell library; contacting the library of cells with a plurality of agents which may affect protein degradation rates; for each agent, selecting cells in the library which express short-lived proteins based on whether the cells have different reporter signal intensities than other cells in the library, the difference being indicative of the selected cells expressing shorter lived fusion proteins than the fusion proteins expressed by the other cells in the library; and characterizing the fusion proteins expressed by the selected cells for each agent. | 12-02-2010 |
| 20100304371 | COMPOSITIONS AND METHODS FOR DETECTING MYCOBACTERIA - The present invention features compositions and methods that can be used to analyze samples for the presence of | 12-02-2010 |
| 20100291582 | Detection of Group B Streptococcus - The invention provides methods to detect group B | 11-18-2010 |
| 20100317016 | DYES AND LABELED MOLECULES - Dimeric and trimeric nucleic acid dyes, and associated systems and methods are provided. Such a dye may form a hairpin-like structure that enables it to stain nucleic acids via a release-on-demand mechanism, for example. Such a dye may have low background fluorescence in the absence of nucleic acids and high fluorescence in the presence of nucleic acids, upon binding therewith, for example. A dye provided herein may be useful in a variety of applications, such as in DNA quantitation in real-time PCR, for example. | 12-16-2010 |
| 20100291585 | METHODS AND COMPOSITIONS FOR DIAGNOSING COMPLICATIONS OF PREGNANCY - The present invention provides methods and compositions for identifying subjects at risk of developing a complication of pregnancy, such as preeclampsia or preterm labor. The compositions are microRNAs and associated nucleic acids. | 11-18-2010 |
| 20100184067 | PRIMER EVALUATION METHOD, PRIMER EVALUATION PROGRAM, AND REAL-TIME POLYMERASE CHAIN REACTION APPARATUS - A primer evaluation method includes: acquiring a signal indicating time change in an amplification amount obtained when sample sets prepared for the number of temperature conditions that should be made different from each other at an annealing stage in units of target nucleic acids diluted in a stepwise manner are so amplified that a temperature condition at a stage other than the annealing stage is fixed; acquiring a signal indicating initial amounts of the target nucleic acids diluted in a stepwise manner; obtaining amplification efficiency for each of the temperature conditions based on the time change in the amplification amount and the initial amount, and calculating a variation degree of the amplification efficiency; and submitting the variation degree and a reference value for quality evaluation of a primer, set with respect to the variation degree. | 07-22-2010 |
| 20100311071 | Compositions and Methods for Detecting Juvenile Renal Dysplasia or Calcium Oxalate Stones in Dogs - The application relates to Canine Cox2 allelic variants associated with Juvenile Renal Dysplasia, primer and probe compositions and methods and kits useful in detecting, monitoring and diagnosing Juvenile Renal Dysplasia or calcium oxalate stones. | 12-09-2010 |
| 20100323360 | Oligonucleotide arrangements, processes for their employment and their use - Oligonucleotide arrangements are disclosed which, in each case, have at least two oligonucleotide sequences linked via at least one spacer. A process is disclosed using the oligonucleotide arrangements for the amplification and/or detection of nucleic acid sequences with formation of crosslinked conglomerates. The process can be used, for example, for the sensitive, simple and inexpensive detection of nucleic acid sequences. | 12-23-2010 |
| 20100323359 | Methods for identifying analgesic agents - The present invention relates to the discovery that mutations in SCN9A are causative of Congenital Indifference to Pain (CIP) in humans. The invention also relates to methods of utilizing the SCN9A gene and expression products thereof for the screening and identification of therapeutic agents, including small organic compounds, which are selective for SCN9A, and are useful in the treatment of pain and other disorders. The invention also relates to methods of using these compounds to treat or otherwise ameliorate such disorders. | 12-23-2010 |
| 20100323362 | COMPOSITIONS AND METHODS FOR DETECTING NUCLEIC ACID FROM MOLLICUTES - Compositions, reaction mixtures, kits and methods used in amplifying and detecting nucleic acids from various species of the class Mollicutes. Particular regions of the 23S rRNA or its gene have been identified as preferred targets for nucleic acid amplification reactions of a sample suspected containing at least one species of Mollicutes. Some oligomers comprise tag regions, target closing regions, promoter sequences, and/or binding moieties. Samples can be from any source suspected of containing a species of the class Mollicutes. Preferred sample sources include bioreactors, cell lines, cell culture wares and pharmaceutical manufacturing wares. | 12-23-2010 |
| 20100323356 | SMALL RNA-DEPENDENT TRANSLATIONAL REGULATORY SYSTEM IN CELL OR ARTIFICIAL CELL MODEL - An object of the present invention is to construct an mRNA which specifically responds to a short RNA sequence and can activate, repress, and regulate the translation of the desired gene, and to construct an artificial cell model system using a liposome comprising the mRNA and a cell-free translational system encapsulated therein. The present invention provides: an mRNA comprising a target RNA-binding site located immediately 5′ to the ribosome-binding site, and a nucleotide sequence located 5′ to the target RNA-binding site, the nucleotide sequence being complementary to the ribosome-binding site; an mRNA comprising a small RNA-binding site located 3′ to the start codon, and a nucleotide sequence located 3′ to the small RNA-binding site, the nucleotide sequence encoding a protein; and a liposome comprising any of these mRNAs encapsulated therein. | 12-23-2010 |
| 20100323357 | MicroRNA Expression Profiling and Targeting in Peripheral Blood in Lung Cancer - A method for the diagnosis, prognosis and treatment of lung cancer by detecting at least one microRNA in peripheral blood is disclosed. | 12-23-2010 |
| 20100323353 | MARKER ASSISTED DIRECTED EVOLUTION - The present invention is directed at a novel method to enhance the genetic improvement of industrial microorganisms. More specifically, the present invention is directed at molecular methods for the identification of genetic variants that contribute to the genetic improvement of the microorganisms. The methods of the present invention comprise novel approaches for identifying genetic markers that linked to said genetic variants, and for using said genetic markers to select improved industrial microorganisms. In one of the embodiments, the genetic markers linked to said genetic variants are identified in microbial populations that are subjected to directed evolution. In another embodiment the genetic markers linked to said genetic variants are identified in microbial sub populations that have been prescreened for improved characteristics. The primary benefits of the use of the methods of the present invention include the speeding up of the directed evolution process for the genetic improvement of industrial microorganisms and the enhancement of the improvement itself. Indeed the improved industrial microorganisms obtained with the methods of the present invention are superior over those obtained by conventional methods because the methods allow more beneficial genetic variants to be combined together in a single genetic improvement step. Finally, it is anticipated that the methods of the present invention can be utilized on any industrial microorganism for which natural genetic diversity is available, including bacteria, yeasts, fungi and algae. | 12-23-2010 |
| 20100297646 | METHOD FOR DETECTION OF CANCER - A method for detecting a cancer(s) based on an expression of prescribed polypeptides is disclosed. These polypeptides were isolated, by the SEREX method using a cDNA library derived from canine testis and serum from a cancer-bearing dog, as a polypeptide which binds to an antibody existing in serum derived from cancer-bearing living body. Because these polypeptides react with antibodies specifically existing in serum of a cancer patient, cancers in a living body can be detected by measuring the antibody in a sample. Cancers in a living body can also be detected by measuring the antigen protein of the antibody per se or mRNA encoding it. | 11-25-2010 |
| 20090269774 | EVALUATION OF EOSINOPHILIC ESOPHAGITIS - A method to evaluate eosinophilic esophagitis based on information in an eosinophilic esophagitis transcriptome. | 10-29-2009 |
| 20100173317 | METHOD FOR DIAGNOSING NON-SMALL CELL LUNG CANCER - Disclosed are methods for detecting non-small cell lung cancer (NSCLC) using differentially expressed genes KIF11, GHSR1b, NTSR1, and FOXM1. Also disclosed are methods of identifying compounds for treating and preventing NSCLC, based on the interaction between KOC1 and KIF11, or NMU and GHSR1b or NTSR1. | 07-08-2010 |
| 20100173314 | DIAGNOSTIC METHODS USING TENASCIN-W COMPOSITIONS - Tenascin-W. an extracellular matrix molecule that is specifically expressed in metastatic tumours is provided. A system comprising a sample expressing tenascin-W is used as an in vitro method for screening possible anti-tumour agents or for agents that promote osteogenesis. | 07-08-2010 |
| 20100173312 | GENETIC LESION ASSOCIATED WITH CANCER - The invention comprises methods for identifying mutations within the 3′ UTRs of genes that lead to increased risk or probability of developing cancer. | 07-08-2010 |
| 20100173307 | NUCLEIC ACID MODULES FOR EXPRESSION AND TAGGING OF MEMBRANE PROTEINS AND METHODS OF USE - Described herein are nucleic acid modules for cloning, expression and tagging of eukaryotic membrane proteins. The nucleic acid modules include a receptor for advanced glycation end products (RAGE) signal sequence, a nucleic acid sequence encoding a tag and a multiple cloning sequence (MCS). Any membrane protein of interest can be cloned into the MCS for expression in cells. The nucleic acid modules can encode any type of tag, such as an epitope tag or affinity tag. The nucleic acid modules disclosed herein can be used to express any type of membrane protein and are particularly suited to the expression and tagging of Type I and Type III membrane proteins. | 07-08-2010 |
| 20100173304 | METHOD OF DNA SEQUENCING - The invention includes a method for sequencing DNA by partially sequencing the bases of complementary strands of double-stranded DNA and combining the partial information from both strands of the double strand DNA to fully sequence the DNA. The invention also includes DNA sequences sequenced by the methods, computer readable mediums including program instructions for such methods, and kits adapted to perform such methods. | 07-08-2010 |
| 20100173303 | MULTIBASE DELIVERY FOR LONG READS IN SEQUENCING BY SYNTHESIS PROTOCOLS - The present technology relates to molecular sciences, such as genomics. More particularly, the present technology relates to methods for obtaining long lengths of sequencing data. | 07-08-2010 |
| 20100173302 | POSITIVE CONTROL PROTEINS FOR GLUCOSE TRANSPORTER PROTEINS AND PROCESSES FOR THE GENERATION OF SUCH POSITIVE CONTROL PROTEINS - Positive controls for experimentation related to membrane-bound glucose transporter proteins and methods for preparing such positive controls, such proteins including GLUT1, GLUT4, GLUT5, and GLUT12. | 07-08-2010 |
| 20100173298 | HCV GENE - The present invention provides a hepatitis C virus gene, a replicon RNA derived from the gene, a replicon-replicating cell into which the replicon RNA is introduced, and a method for screening a drug using the replicon-replicating cell. By introducing a replicon RNA comprising (A) a polynucleotide having the nucleic acid sequence shown in SEQ ID NO: 5; (B) a polynucleotide having the nucleic acid sequence shown in SEQ ID NO: 7; (C) a polynucleotide coding for a polypeptide having the amino acid sequence shown in SEQ ID NO: 6; (D) a polynucleotide coding for a polypeptide having the amino acid sequence shown in SEQ ID NO: 8; or (E) a polynucleotide having a nucleic acid sequence having a homology of not less than 90% with the nucleic acid sequence shown in SEQ ID NO: 5 or SEQ ID NO: 7; or a replicon RNA of the genotype 1b comprising nucleotides coding for the 1804th amino acid leucine and the 1966th amino acid lysine in the amino acid sequence of a hepatitis C virus polyprotein and a polynucleotide coding for an NS4B protein, into a cell, the replicon-replicating cell can be prepared. By using the replicon-replicating cell, the screening for the drug can be carried out. | 07-08-2010 |
| 20100255482 | Hepatitis B Virus (HBV) Specific Oligonucleotide Sequences - The present invention relates to oligonucleotide sequences for amplification primers and detection probes and to their use in nucleic acid amplification methods for the detection of HBV in biological samples. In particular, oligonucleotide sequences are provided for the sensitive qualitative or quantitative detection of all eight HBV genotypes. The invention also provides oligonucleotide primer sets and primer/probe sets in the form of kits for the diagnosis of HBV infection. | 10-07-2010 |
| 20100015620 | CANCER-LINKED GENES AS BIOMARKERS TO MONITOR RESPONSE TO IMPDH INHIBITORS - Sets of biomarker genes useful for monitoring exposure and response to anti-tumor agents that inhibit IMPDH and related biomolecules are disclosed along with methods for identifying such sets of genes, methods of using such sets to identify additional therapeutic agents as well as methods for stratifying patients into groups that are sensitive or resistant to such therapeutic agents. Methods of screening patients for recurrence of disease by monitoring changes in gene expression associated with malignancy are also described. The nucleotide sequence of such biomarkers are presented. | 01-21-2010 |
| 20100330569 | Hydroxymethyl Linkers For Labeling Nucleotides - The invention provides methods and compositions, including, without limitation, algorithms, computer readable media, computer programs, apparatus, and systems for determining the identity of nucleic acids in nucleotide sequences using, for example, data obtained from sequencing by synthesis methods. The methods of the invention include correcting one or more phenomena that are encountered during nucleotide sequencing, such as using sequencing by synthesis methods. These phenomena include, without limitation, sequence lead, sequence lag, spectral crosstalk, and noise resulting from variations in illumination and/or filter responses. | 12-30-2010 |
| 20110014623 | TAGGED OLIGONUCLEOTIDES AND THEIR USE IN NUCLEIC ACID AMPLIFICATION METHODS - The present invention provides nucleic acid amplification methods that desirably reduce or eliminate false positive amplification signals resulting from contaminating biological material, e.g., nucleic acid, that may be present in one or more reagents used in an amplification reaction and/or that may be present in the environment in which an amplification reaction is performed. The invention offers the further advantage of requiring less stringent purification and/or sterility efforts than conventionally needed in order to ensure that enzymes and other reagents used in amplification reactions, and the environment in which an amplification reaction is performed, are free of bacterial or other nucleic acid contamination that may yield false positive results. | 01-20-2011 |
| 20100021888 | Screening for disease susceptibility by genotyping the CCR5 and CCR2 genes - Provided are compositions, methods and uses for identifying persons at an increased risk of infection by, transmission of, or accelerated progression of a disease caused by an HIV-1 virus. Diagnostic, prognostic and combined therapeutic kits are also provided. | 01-28-2010 |
| 20100021887 | PROBE FOR TAGGING VALUABLES BASED ON DNA-METAL COMPLEX - Methods are disclosed involving the formation of complex DNA-Metal and the detection of the complex, such as by employing several analytical methods, e.g., X-Ray Fluorescence, FT-IR and Raman spectroscopy. | 01-28-2010 |
| 20100021886 | Methods and Materials for Identifying the Origin of a Carcinoma of Unknown Primary Origin - The present invention provides a method of identifying origin of a metastasis of unknown origin by obtaining a sample containing metastatic cells; measuring Biomarkers associated with at least two different carcinomas; combining the data from the Biomarkers into a linear discrimination analysis where the linear discrimination analysis normalizes the Biomarkers against a reference; and imposes a cut-off which optimizes sensitivity and specificity of each Biomarker, weights the prevalence of the carcinomas and selects a tissue of origin determining origin based on highest probability determined by the linear discrimination analysis or determining that the carcinoma is not derived from a particular set of carcinomas; and optionally measuring Biomarkers specific for one or more additional different carcinoma, and repeating the steps for additional Biomarkers. | 01-28-2010 |
| 20110020825 | PROTEIN C POLYMORPHISMS USEFUL AS AN INDICATOR OF PATIENT OUTCOME - The invention provides methods and kits for obtaining a prognosis for a patient having or at risk of developing an inflammatory condition. The method generally comprises determining a protein C promoter genotype of a patient for a polymorphism in the protein C promoter region of the patient, comparing the determined genotype with known genotypes for the polymorphism that correspond with the ability of the patient to recover from the inflammatory condition and identifying patients based on their prognosis. The invention also provides for methods of identifying other polymorphisms that correspond with the ability of the patient to recover from the inflammatory condition. | 01-27-2011 |
| 20110020823 | SEQUENCES AND THEIR USE FOR DETECTION AND CHARACTERIZATION OF E. COLI O157:H7 - This invention relates to a rapid method for detection and characterization of | 01-27-2011 |
| 20110053169 | METHOD FOR CONTINUOUS MODE PROCESSING OF THE CONTENTS OF MULTIPLE REACTION RECEPTACLES IN A REAL-TIME AMPLIFICATION ASSAY - An automated analyzer for performing multiple diagnostic assays simultaneously includes multiple stations in which discrete aspects of the assay are performed on fluid samples contained in sample vessels. The analyzer includes stations for automatically preparing a sample, incubating the sample, preforming an analyte isolation procedure, ascertaining the presence of a target analyte, and analyzing the amount of a target analyte. An automated receptacle transporting system moves the sample vessels from one station to the next. A method for performing an automated diagnostic assay includes an automated process for isolating and amplifying a target analyte, and, in one embodiment, a method for real-time monitoring of the amplification process. | 03-03-2011 |
| 20110053167 | GENE SIGNATURES - The present invention relates generally to a new cluster of correlating molecules in a tissue or at least one cell of a tissue for instance a cell of a blood tissue, preferably such myeloid cells and of identifying the condition of the genes expression said correlating molecules or of the expression levels of said molecules in a method or system for identifying obesity and the risk at obesity-related metabolic diseases such as the obesity associated cardiovascular risk or obesity-related insulin resistance. This system of method provides information on how to modulate the correlating molecules to treat or prevent obesity and to prevent the obesity-related metabolic diseases. | 03-03-2011 |
| 20110053162 | REACTIVE CYANINE COMPOUNDS - The invention provides compounds and compositions of Formulas I-VII, and methods of using the compounds. The compounds can be used to prepare dye conjugates that are uniformly and substantially more fluorescent on proteins, nucleic acids or other biopolymers, than conjugates labeled with structurally similar known carbocyanine dyes. In addition to having more intense fluorescence emission than structurally similar dyes at virtually identical wavelengths, and decreased artifacts in their absorption spectra upon conjugation to biopolymers, the compounds can have greater photostability and/or higher absorbance (extinction coefficients) at the wavelength(s) of peak absorbance than such structurally similar dyes. | 03-03-2011 |
| 20110053161 | SEQUENTIAL SAMPLING FOR UNEXPECTED DAMAGE TO BT CORN FOR CORN ROOTWORM CONTROL - Methods are provided for the sequential sampling of pest resistant crop plants for determining resistance of a pest to a pesticidal activity of a pest resistant crop plant. The methods involve choosing a plant in a plot in an unbiased sampling manner. Trait expression is determined for each of the transgenic pest resistant plants to identify plants having pesticidal activity, and plants determined to have the pesticidal activity are a batch. Then the pest damage to the roots of the batch is rated with each batch having at least about five plants to determine the resistance of pests in the plot. | 03-03-2011 |
| 20110053157 | USE OF MICROVESICLES IN DIAGNOSIS, PROGNOSIS AND TREATMENT OF MEDICAL DISEASES AND CONDITIONS - The presently disclosed subject matter is directed to methods of aiding diagnosis, prognosis, monitoring and evaluation of a disease or other medical condition in a′ subject by detecting a biomarker in microvesicles isolated from a biological, sample from the subject. Moreover, disclosed subject matter is directed to methods of diagnosis, monitoring a disease by determining the concentration of microvesicles within a biological sample; methods of delivering a nucleic acid or protein to a target all by administering microvesicles that contain said nucleic acid or protein; methods for performing a body fluid transfusion by introducing a microvesicle-free or microvesicle enriched fluid fraction into a patient. | 03-03-2011 |
| 20110053158 | MIRNA BIOMARKERS OF LUNG DISEASE - This application describes miRNAs that may be used as serum or plasma biomarkers for characterizing lung disease in a patient. These miRNA biomarkers may be used alone or in combination with other markers for the diagnosis, prognosis, or monitoring of diseases such as lung cancer. | 03-03-2011 |
| 20110053156 | SMALL CELL LUNG CARCINOMA BIOMARKER PANEL - The invention relates generally to the field of cancer detection, diagnosis, subtyping, staging, prognosis, treatment and prevention. More particularly, the present invention relates to methods for the detection, and/or diagnosing and/or subtyping and/or staging of lung cancer in a patient. Based on a particular panel of biomarkers, the present invention provides methods to detect, diagnose at an early stage and/or differentiate small cell lung cancer (SCLC) from non-small cell lung cancer (NSCLC) and within NSCLC to differentiate between squamous cell carcinomas (SCC), adenocarcinomas (AC), within SCC to discriminate G2 and G3 stage and within lung cancer to differentiate for lung cancers with or without neuroendocrine origin. It further provides the use of said panel of biomarkers in monitoring disease progression in a patient, including both in vitro and in vivo imaging techniques. The in vitro imaging techniques typically include an immunoassay detecting protein or antibody of the biomarkers on a sample taken from said patient, e.g. serum or tissue sample. The in vivo imaging techniques typically include chest radiographs (X-rays), Computed Tomography (CT) imaging, spiral CT, Positron Emission Tomography (PET), PET-CT and scintigraphy for molecular imaging and diagnosis and to monitor disease progression and treatment response in patients. It is accordingly a further aspect to provide a kit to perform the aforementioned diagnosing and/or subtyping and/or staging assay and the imaging techniques, comprising reagents to determine the gene expression or protein level of the aforementioned panel of biomarkers for in vitro and in vivo applications. | 03-03-2011 |
| 20110053152 | METHOD FOR CANCER DETECTION, DIAGNOSIS AND PROGNOSIS - The present invention provides a method for diagnosing cancer, predicting a disease outcome or response to therapy in a patient sample. The method involves isolating a circulating tumor cell (CTC), for example, a viable CTC, from a sample using a parylene microfilter device comprising a membrane filter having or consisting of a parylene substrate, which has an array of holes with a predetermined shape and size; and detecting and quantifying telomerase activity in blood circulating tumor cells. The invention further provides methods of using cells live-captured in various applications. | 03-03-2011 |
| 20110027778 | COMPOSITION COMPRISING AN OLIGONUCLEOTIDE MIXTURE FOR IMPROVED DETECTION OF HUMAN PAPILLOMAVIRUS GENOTYPES - The present invention relates to a composition comprising an oligonucleotide mixture. Moreover, the present invention relates to the use of said oligonucleotide mixture for diagnosing different HPV genotypes in a sample of a subject. Further encompassed is a method for diagnosing different HPV genotypes in a sample of a subject and a kit carrying out said method. | 02-03-2011 |
| 20110027786 | PRIMERS FOR NUCLEIC ACID EXTENSION OR AMPLIFICATION REACTIONS - Disclosed are methods and compositions for use in nucleic acid amplification or extension reactions. | 02-03-2011 |
| 20100240053 | PROBE, PROBE SET, PROBE CARRIER, AND TESTING METHOD - A probe, a set of probes, and a probe carrier on which the probe or the set of probes is immobilized, are provided for classification of fungus species. The probe or the set of probes is capable of collectively detecting fungus of the same species and distinguishingly detecting those fungus from fungus of other species. The probe is an oligonucleotide probe for detecting a pathogenic fungus DNA and includes at least one of base sequences of SEQ ID NOS. 1 to 4 and mutated sequences thereof. | 09-23-2010 |
| 20100240052 | PROBE, PROBE SET, PROBE CARRIER, AND TESTING METHOD - A probe, a set of probes, and a probe carrier on which the probe or the set of probes is immobilized, are provided for classification of fungus species. The probe or the set of probes is capable of collectively detecting fungus of the same species and distinguishingly detecting those fungus from fungus of other species. The probe is an oligonucleotide probe for detecting a pathogenic fungus DNA and includes at least one of base sequences of SEQ ID NOS. 1 to 4 and mutated sequences thereof. | 09-23-2010 |
| 20100240050 | Methods and Products For In Vivo Enzyme Profiling - The present invention relates to methods and products associated with in vivo enzyme profiling. In particular, the invention relates to methods of in vivo processing of exogenous molecules followed by detection of signature molecules as representative of the presence of active enzymes associated with diseases or conditions. The invention also relates to products, kits, and databases for use in the methods of the invention. | 09-23-2010 |
| 20100240047 | METHODS AND COMPOUNDS FOR DETECTION OF MOLECULAR TARGETS - The present invention relates to methods and compounds for detection of molecular targets, such as biological or chemical molecules, or molecular structures, in samples using a host of experimental schemes for detecting and visualizing such targets, e.g. immunohistochemistry (IHC), in situ hybridization (ISH), ELISA, Southern, Northern, and Western blotting, etc. | 09-23-2010 |
| 20100240045 | NUCLEOTIDE COMPOSITIONS AND USES THEREOF - The present invention relates to preparation of nucleotide compositions and uses thereof for conducting nucleic acid analyses. The compositions and methods embodied in the present invention are particularly useful for nucleic acid analyses that require high-resolution detection of labeled nucleotides or labeled nucleic acid targets. | 09-23-2010 |
| 20100240043 | METHODS OF USING GENETIC VARIANTS TO DIAGNOSE AND PREDICT INFLAMMATORY BOWEL DISEASE - The present invention relates to methods of diagnosing susceptibility to Inflammatory Bowel Disease and subtypes of Inflammatory Bowel Disease. In one embodiment, the present invention provides a method of diagnosing susceptibility to Inflammatory Bowel Disease by determining the presence of one or more risk variants at the DR3 locus, GATA3 locus, SIN(EFS) locus, BTLA locus, LIGHT locus and MAGE locus. | 09-23-2010 |
| 20100240040 | METHOD FOR SCREENING FOR SELECTIVE MODULATOR OF THE NF-KB PATHWAY ACTIVATION - The invention relates to methods for screening for selective modulator of NF-κB pathway activation. The invention concerns methods for primary screening molecules that potentially modulate (activate or inhibit) the NF-κB pathway activation by identifying and selecting molecules modulate the interaction of NEMO with other proteins. The invention also concerns methods for secondary screening for modulator (activator or inhibitor) of the NF-κB pathway activation. | 09-23-2010 |
| 20100240036 | NUCLEIC ACID PROBES AND METHODS FOR DETECTING PLASMODIUM PARASITES - This invention relates to novel nucleic acid-based probes and methods for detecting | 09-23-2010 |
| 20100240034 | Gene defects and mutant ALK kinase in human solid tumors - In accordance with the invention, novel gene deletions and translocations involving chromosome 2 resulting in fusion proteins combining part of Anaplastic Lymphoma Kinase (ALK) kinase with part of a secondary protein have now been identified in human solid tumors, e.g. non-small cell lung carcinoma (NSCLC). Secondary proteins include Echinoderm Microtubule-Associated Protein-Like 4 (EML-4) and TRK-Fusion Gene (TFG). The EML4-ALK fusion protein, which retains ALK tyrosine kinase activity, was confirmed to drive the proliferation and survival of NSCLC characterized by this mutation. The invention therefore provides, in part, isolated polynucleotides and vectors encoding the disclosed mutant ALK kinase polypeptides, probes for detecting it, isolated mutant polypeptides, recombinant polypeptides, and reagents for detecting the fusion and truncated polypeptides. The disclosed identification of this new fusion protein enables new methods for determining the presence of these mutant ALK kinase polypeptides in a biological sample, methods for screening for compounds that inhibit the proteins, and methods for inhibiting the progression of a cancer characterized by the mutant polynucleotides or polypeptides, which are also provided by the invention. | 09-23-2010 |
| 20100240032 | METHOD FOR DETERMINING THE ALLERGIC POTENTIAL OF A COMPOUND - The present invention is related to a method for determining the sensitizing potential of a chemical (test) compound, comprising the steps of:
| 09-23-2010 |
| 20100240028 | METHOD TO IMPROVE QUALITY OF MICROARRAYS BY CONTROLLING EVAPORATION - Methods and compositions described here minimize loss due to evaporation during the process of preparing gel-element microarrays; maintain uniform gel density; minimize irregular spontaneous polymerization; and provide conditions to obtain reproducible and consistent gel-array elements. The materials and methods described herein present techniques for restoring the original composition of the droplets dispensed on the microarray substrates prior to and during the step of ultraviolet light polymerization. | 09-23-2010 |
| 20100285485 | PRIMER, PROBE, DNA CHIP CONTAINING THE SAME AND METHOD FOR DETECTING HUMAN PAPILLOMAVIRUS AND DETECTION KIT THEREOF - The present invention discloses a primer, a probe, a DNA chip, and a test kit for diagnosis and genotyping of Human Papilloma Virus (HPV) as well as a method for testing HPV genotype. According to the present invention, it is possible to screen HPV genotypes with high sensitivity and specificity, and to diagnose infection by multiple HPV types which was not possible in other conventional HPV testing methods | 11-11-2010 |
| 20100285455 | PREDICTION OF SCHIZOPHRENIA RISK USING HOMOZYGOUS GENETIC MARKERS - Provided are methods of identifying a genetic profile influencing the relative probability of a subject manifesting a phenotype that is at least partially heritable. Also provided are methods of determining the relative likelihood that a subject will manifest a phenotype that is at least partially heritable. Additionally, methods of determining the relative risk of a human subject for manifesting schizophrenia are provided. Further provided are methods of screening a human embryo in vitro for the risk of becoming a human manifesting schizophrenia. Also, methods of identifying a single nucleotide polymorphism (SNP) variant affecting the risk of a human subject for manifesting schizophrenia are provided. Methods of screening for a compound that may affect schizophrenia are additionally provided. | 11-11-2010 |
| 20110086361 | AMPLIFICATION OF NUCEIC ACIDS USING TEMPERATURE ZONES - The present invention relates to the amplification and detection of amplified nucleic acid sequences employing methods and devices with distinct temperature zones. The methods and devices of the present invention may be used for quantitative analysis of target nucleic acid sequences, for simultaneous quantitative analysis of multiple target nucleic acid sequences or for analyzing a sample for the presence of a target nucleic acid. | 04-14-2011 |
| 20100233722 | Methods for determining the biological effect and/or activity of r pharmaceutical compositions based on their effect on the methylation status of the DNA - This invention is related to methods, systems and computer program products for determining the biological effect and/or activity of drugs, chemical substances and/or pharmaceutical compositions using their effect on DNA methylation as a marker for their biological effect(s). The invention is further related to the use of the inventive methods, systems and computer program products in obtaining new biologically active compounds for new and effective medicaments and treatment strategies of, in particular, human diseases. | 09-16-2010 |
| 20100233721 | APPARATUS AND METHODS FOR DETECTING DNA IN BIOLOGICAL SAMPLES - Apparatus and methods are described for detecting target DNA in a biological sample using capture probes and electrically-assisted hybridization. The reaction cell is formed with an attachment surface of aluminum oxide for better thermal and physical properties, and the aluminum oxide surface is coated with anti-DIG antibody to provide a convenient attachment layer for the capture probes allowing their correct orientation, while the capture probes are formed with a DIG-label so that they attach to the surface of the cell through an anti-DIG/DIG linkage. | 09-16-2010 |
| 20100233720 | BIOLOGICAL REAGENTS AND METHODS TO VERIFY THE EFFICIENCY OF SAMPLE PREPARATION AND NUCLEIC ACID AMPLIFICATION AND/OR DETECTION - This invention relates to reagent comprising: any one of cells, viral particles, organelles, parasites, cells comprising organelles, cells comprising viral particles, cells comprising parasites, cells comprising bacterial cells and any combination thereof, the cells, viral particles, organelles or parasites comprising at least one nucleic acid sequence serving as an internal control (IC) target for nucleic acid testing (NAT) assay; wherein the reagent is suitable to be added to a test sample undergoing sample preparation to release, concentrate and/or purify nucleic acids and amplification and/or detection of nucleic acids so as to be used to verify: (i) the efficiency of sample preparation; and (ii) the efficiency of nucleic acid amplification and/or detection. The present invention also relates to a method to verify or validate the preparation and amplification and/or detection of a nucleic acid target sequence in a sample spiked with a reagent of the present invention. | 09-16-2010 |
| 20100233719 | Genetic Markers for Predicting Disease and Treatment Outcome - The present invention provides for a method for identifying patients that are suitably treated by a therapy, such as a therapy involving administration of a fluoropyrimidine drug and/or a platinum drug. The method includes determining the expression level of at least one gene selected from a phospholipase 2 (PLA2) gene, a thymidine phosphorylase (TP) gene, and a glutathione S-transferase P1 (GSTP-1) gene in suitable sample isolated from the patient. Overexpression of the gene or genes identifies the patient as not being suitable for the therapy. | 09-16-2010 |
| 20100233718 | NON-INVASIVE TECHNIQUE FOR CONDUCTING SKIN INFLAMMATORY DISEASE PHARMACO-GENOMIC STUDIES AND DIAGNOSES THEREOF - Non-invasive techniques to conduct skin inflammatory disease pharmaco-genomic studies and diagnoses thereof feature discriminating biomarkers and genes and in vitro diagnostic methods employing such biomarkers. | 09-16-2010 |
| 20100233717 | METHODS FOR DETECTING TOXIGENIC MICROBES - The present invention provides methods and oligonucleotides for detecting toxigenic microbes, such as toxigenic | 09-16-2010 |
| 20100233716 | TRANSPLANT REJECTION MARKERS - The invention relates to the analysis and identification of genes that are regulated simultaneously in chronic kidney transplant rejection. This simultaneous regulation of genes provides a molecular signature to accurately detect, and optionally classify, chronic kidney transplant rejection. | 09-16-2010 |
| 20100233715 | METHOD OF NUCLEIC ACID AMPLIFICATION AND MEASURING REAGENT AND REAGENT KIT THEREFOR - The object of the present invention is to provide a method that allows stable amplification of an internal standard material while maintaining an accurate assay value for a target nucleic acid in a nucleic acid detection system involving the use of an internal standard material and a reagent kit used therefor. The present invention relates to a method for nucleic acid amplification comprising preventing an internal standard amplification product from affecting amplification reaction of a target nucleic acid by performing amplification of an internal standard material prior to amplification of the target nucleic acid in the method for amplifying a target nucleic acid in a sample using an internal standard material and a reagent and reagent kit used therefor. | 09-16-2010 |
| 20100233714 | MULTISTATE AFFINITY LIGANDS FOR THE SEPARATION AND PURIFICATION OF ANTIBODIES, ANTIBODY FRAGMENTS AND CONJUGATES OF - Separation of antibodies, antibody fragments, and conjugates thereof using multistate affinity ligands rationally designed and selected to undergo analytically and functionally definable conformational transitions from a first affinity state under a first operator-defined environmental condition to a second affinity state under a second operator-defined environmental condition. | 09-16-2010 |
| 20100233713 | METHOD FOR TREATING A SOLUTION IN ORDER TO DESTROY ANY RIBONUCLEIC ACID AFTER AMPLIFICATION - The present invention provides a method for treating a solution containing among others, target nucleic acid to be amplified in order to destroy any ribonucleic acid that is present in the solution and that could possibly be amplified in another assay. The method is useful to avoid carry-over contamination between experiments. | 09-16-2010 |
| 20100233712 | Method for Early Detection of Cancers - The invention includes methods for detecting the presence of a neoplastic condition by comparing a sample level of a BIF-1 to a reference, wherein a low level of BIF-1 in the sample correlates with the presence of a neoplastic condition. Another method involves determining the risk of relapse, tumor recurrence and/or metastasis by determining a sample level of a Bif-1 to a reference level of Bif-1, wherein low sample levels correlate with a likelihood of relapse, recurrence and/or metastasis. Yet another method includes detecting the presence of a pre-neoplastic condition, such as prostatic intraepithelial neoplasia. The method involves measuring a level of a Bif-1 in a sample and comparing the level of Bif-1 in the sample to a reference level of Bif-1. High levels of Bif-1 in the sample correlate with the presence of the pre-neoplastic condition. | 09-16-2010 |
| 20100233711 | GENE ENCODING LABYRINTHIN, A MARKER FOR CANCER - A cDNA molecule that encodes a protein designated Labyrinthin (Lab) isolated and its nucleotide sequence is determined. The protein, or peptides derived from the protein, are markers useful to define novel classes of cancers. Diagnostic assays for these cancers use antibodies to Lab or nucleotide probes that hybridize with the lab gene or a fragment therefrom. Vaccines useful either to prevent recurrence of cancers in subjects who test positive for Lab (or lab), or to prevent initial occurrence of cancer, use proteins or peptides derived from Lab. Expression of Lab via immunogenic assays is used to monitor effects of cancer treatments. Antisense molecules against lab are used in treatments. Sense molecules of lab are used to restore lost lab function in diseased normal cells, for example, gland cells. | 09-16-2010 |
| 20100233710 | NUCLEIC ACID BINDING DYES AND USES THEREFOR - The invention provides novel compounds and compositions of Formulas I and II, as well as methods of using them. The compounds can be used, for example, to quantify an amount of double stranded DNA in a sample subjected to nucleic acid amplification, or for real time monitoring of a nucleic acid amplification reaction. The compounds can be provided in a kit, for example, with other reagents and instructions for using the compounds and reagents. | 09-16-2010 |
| 20100233709 | ABSCRIPTION BASED MOLECULAR DETECTION - The present invention provides methods for detecting biomarkers based on Abscription®, abortive transcription technology. Particularly, the present invention provides bisulfate free methods for detecting methylation of CpG islands from small samples of DNA. The methods are suitable for multiplexing and can be used to analyze multiple CpG islands from a single sample in a short time. | 09-16-2010 |
| 20100233708 | SPLIT FLOW DEVICE FOR ANALYSES OF SPECIFIC-BINDING PARTNERS - The present invention provides an analyte detection system for detecting a target analyte in a sample. In particular, the invention provides a detection system capable of one-step amplification of the detection signal by incorporating a secondary flow path that can deliver reagents to a reaction zone. Methods of using the detection system to detect analytes in samples, particularly biological samples, and kits comprising the detection system are also disclosed. | 09-16-2010 |
| 20100233707 | MATERIALS AND METHODS FOR PREDICTING RECURRENCE OF NON-SMALL CELL LUNG CANCER - Disclosed herein is a DNA methylation-based test for determining the recurrence or non-recurrence of a lung cancer such as NSCLC after treatment. The assays involve the detection of methylation of the BAX gene promoter alone or in combination with other genes. The test is suitable for monitoring treatment of subjects with lung cancer for which methylation differs by stage of the disease and by treatment regimen. | 09-16-2010 |
| 20100233706 | METHODS TO FIX AND DETECT NUCLEIC ACIDS - In one aspect, the invention relates to a method for fixing a short nucleic acid in a biological sample. In another aspect, the invention relates to a method for detecting a target short nucleic acid in a biological sample. The method includes contacting the biological sample with an aldehyde-containing fixative, and subsequently contacting the sample with a water-soluble carbodiimide. In a further aspect, the invention relates to a kit for fixing a short nucleic acid in a biological sample. The kit includes a support substrate for holding the sample; an aldehyde-containing fixative; and a water-soluble carbodiimide. | 09-16-2010 |
| 20100233705 | METHOD OR SYSTEM USING BIOMARKERS FOR THE MONITORING OF A TREATMENT - The present invention relates to biomarkers to monitor the activity of the compound 3-Z-[1-(4-(N-((4-methyl-piperazin-1-yl)-methylcarbonyl)-N-methyl-amino)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone or a pharmaceutically acceptable salt thereof, and especially its monoethanesulphonate salt form, when used alone or optionally in combination with further pharmaceutically active ingredients and/or further treatments, such as for example radiotherapy. | 09-16-2010 |
| 20100233704 | METHODS OF DETECTING LUNG CANCER - Methods of lung cancer in a sample from a patient are provided. Methods of detecting changes in expression of one or more target RNAs associated with lung cancer are also provided. Compositions and kits are also provided. | 09-16-2010 |
| 20100233703 | EMX2 IN CANCER DIAGNOSIS AND PROGNOSIS - The present invention provides methods for determining a prognosis of disease free or overall survival in a patient suffering from cancer. The methods generally involve determining a normalized expression level of an EMX2 gene product, which correlates with prognosis and likelihood of survival. | 09-16-2010 |
| 20100233702 | METHOD TO PREDICT RESPONSE TO TREATMENT FOR PSYCHIATRIC ILLNESSES - The disclosure provides methods and compositions useful for identifying a subject's predisposition to lithium treatment. | 09-16-2010 |
| 20100233701 | Use of non-clonal chromosomal aberrations for cancer research and clinical diagnosis - A diagnostic method of determining tumorigenicity of a tissue specimen includes the steps of determining the magnitude of genome diversity in the tissue specimen, and diagnosing a likelihood of cancer in response thereto. The magnitude of genome diversity includes the determination of karyotypic heterogeneity in tissue specimen, illustratively by detecting non-clonal chromosome aberrations (NCCAs). The detection of NCCAs includes the identification of various types and frequency of NCCAs, and diagnosis is responsive to the step of detecting the frequency of NCCAs. Detection of NCCAs includes the further step of screening lymphocytes. Also, the step of determining the presence of elevated genome diversity includes the step of applying Spectral Karyotyping to detect structural and numerical aberrations throughout the genome. The diagnostic method is useful to determine drug resistance in a patient and potential harmfulness, to evaluate the side effects of drugs, and to measure genome system stress. | 09-16-2010 |
| 20100233700 | UBIAD1 GENE AND HYPERLIPIDEMIA - The disclosure relates to genetic mutations in UBIAD1 gene that segregate with Schnyder's crystalline corneal dystrophy. The disclosure provides methods for detecting such mutations as a diagnostic for Schnyder's crystalline corneal dystrophy either before or after the onset of clinical symptoms. Also provided are screening methods for identifying medical conditions related to cholesterol metabolism, including atherosclerosis, risk of future loss of vision, and future need for corneal transplantation. | 09-16-2010 |
| 20100233699 | PRIMERS AND METHODS FOR THE DETECTION AND DISCRIMINATION OF NUCLEIC ACIDS - The present invention provides novel primers and methods for the detection of specific nucleic acid sequences. The primers and methods of the invention are useful in a wide variety of molecular biology applications and are particularly useful in allele specific PCR. | 09-16-2010 |
| 20100311049 | PCR-Based Kit For Detecting Chlamydia Trachomatis and Nelsseria Gonorrhoeae - The invention relates to a PCR based prototype kit for detecting | 12-09-2010 |
| 20100184064 | DNA MOLECULES ENCODING LIGAND GATED ION CHANNELS FROM DERMACENTOR VARIABILIS - The present invention relates in part to isolated nucleic acid molecules (polynucleotides) which encode | 07-22-2010 |
| 20110014610 | COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING NEUROPSYCHIATRIC DISORDERS - The present invention provides methods for diagnosing mental disorders (e.g., psychotic disorders such as schizophrenia and mood disorders such as major depression disorder and bipolar disorder). The invention also provides methods of identifying modulators of such mental disorders as well as methods of using these modulators to treat patients suffering from such mental disorders. | 01-20-2011 |
| 20100323363 | METHOD FOR THE TREATMENT OF A SAMPLE CONTAINING BIOMOLECULES - The invention generally provides a method for the sample preparation for a subsequent preparation, processing or analysis method of a sample containing an at least one species of nucleic acid and/or one species of protein, whereby the method comprises the following steps: A) providing a sample which contains at least one species of a nucleic acid and/or of a protein, B) contacting the sample with a fluid or solid composition to produce a fluid sample preparation, whereby the composition contains at least a nitrogenous compound, which is selected from the group consisting of a) polyamines, b) amino acids, and oligo- and polypeptides, c) nitrogenous heterocyclic compounds, including homo- oder heteropolymeres, which comprise these nitrogenous compounds, d) amines of the type R | 12-23-2010 |
| 20100323364 | MODIFIED tRNA CONTAINING UNNATURAL BASE AND USE THEREOF - In the method for introducing a noncanonical amino acid residue into a desired position in a protein, the structure of tRNA is so modified as to have improved affinity for aminoacyl-tRNA synthetase or improved specificity to aminoacyl-tRNA synthetase. An unnatural base is contained at any position in tRNA, whereby the efficiency of aminoacylation of the tRNA with a noncanonical amino acid can be improved. | 12-23-2010 |
| 20100323346 | Method of Examining Inflammatory Disease and Method of Screening Remedy for Inflammatory Disease - A single nucleotide polymorphism occurring on a leptin receptor gene is analyzed and an inflammatory disease is examined on the basis of the analytical data. Further, a substance capable of changing the interaction between the leptin receptor and galectin-2 is selected to thereby screen a remedy for an inflammatory disease. | 12-23-2010 |
| 20100323351 | TUMOR SUPPRESSOR GENE, P47ING3 - The invention provides isolated nucleic acid and amino acid sequences of novel human tumor suppressors, antibodies to such tumor suppressors, methods of detecting such nucleic acids and proteins, methods of screening for modulators of tumor suppressors, and methods of diagnosing and treating tumors with such nucleic acids and proteins. | 12-23-2010 |
| 20100323354 | MEANS AND METHODS FOR THE DETECTION AND ISOLATION OF FETAL AND EMBRYONIC CELLS AND NUCLEIC ACID FROM MATERNAL BODY FLUID - The present invention is related to the use of an interaction partner of a high mobility group protein of the HMGA family for the detection of fetal and embryonic cells in a maternal body fluid. | 12-23-2010 |
| 20100330570 | NUCLEOTIDE TRANSIENT BINDING FOR SEQUENCING METHODS - Provided herein are compositions and systems for use in polymerase-dependent, nucleotide transient-binding methods. The methods are useful for deducing the sequence of a template nucleic acid molecule and single nucleotide polymorphism (SNP) analyses. The methods rely on the fact that the polymerase transient-binding time for a complementary nucleotide is longer compared to that of a non-complementary nucleotide. The labeled nucleotides transiently-binds the polymerase in a template-dependent manner, but does not incorporate. The methods are conducted under any reaction condition that permits transient binding of a complementary or non-complementary nucleotide to a polymerase, and inhibits nucleotide incorporation. | 12-30-2010 |
| 20090253134 | Cellular Pyrogen Test - The invention concerns methods, agents and kits for qualitative and quantitative detection and identification of pathogens and pathogen spectra based on endotoxins and other pyrogens. | 10-08-2009 |
| 20100240041 | MICROFLUIDIC DEVICE FOR TRAPPING SINGLE CELL - It is to provide a microfluidic device which separates and captures with high efficiency a large amount of cells in a sample at one-cell level without damaging the cells by utilizing a microfabrication technology. The device sequentially comprises: an upper substrate consisting of a plastic plate provided with a groove for forming a microchannel communicating a sample-supply opening and a sample-discharge opening; a plastic upper flat plate forming the microchannel by cooperating with the upper substrate, the plate being provided with an aperture for a micromesh; a holding plate holding a plastic micromesh having a plurality of micro through-pores for capturing cells; a plastic lower flat plate provided with an aperture for suctioning; and a lower substrate consisting of a plastic flat plate provided with a groove for forming a suction channel, wherein the micro through-pores for capturing cells of the micromesh have an inverted mortar-like shape or a cylindrical shape, and wherein the upper flat plate is constituted by a softer plastic as compared to the upper substrate. | 09-23-2010 |
| 20100227331 | DETECTION OF IMMOBILIZED NUCLEIC ACID - The present invention provides methods for determining the presence of immobilized nucleic acid employing unsymmetrical cyanine dyes that are derivatives of thiazole orange, a staining solution and select fluorogenic compounds that are characterized as being essentially non-genotoxic. The methods comprise immobilizing nucleic acid, single or double stranded DNA, RNA or a combination thereof, on a solid or semi solid support, contacting the immobilized nucleic acid with an unsymmetrical cyanine dye compound and then illuminating the immobilized nucleic acid with an appropriate wavelength whereby the presence of the nucleic acid is determined. The cyanine dye compounds are typically present in an aqueous staining solution comprising the dye compound and a tris acetate or tris borate buffer wherein the solution facilitates the contact of the dye compound and the immobilized nucleic acid. Typically the solid or semi-solid support is selected from the group consisting of a polymeric gel, a membrane, an array, a glass bead, a glass slide, and a polymeric microparticle. Preferably, the polymeric gel is agarose or polyacrylamide. The methods employing the non-genotoxic compounds represent an improvement over commonly used methods employing ethidium bromide wherein the present methods retain the advantages of ethidium bromide, ease of use and low cost, but without the disadvantageous, known mutagen requiring special handling and waste procedures. | 09-09-2010 |
| 20090263815 | CELL CULTURE SYSTEM, PROCESS FOR THE PRODUCTION THEREOF, AND THE USE THEREOF IN PRECLINICAL INVESTIGATION - The invention relates to a cell culture system, in particular for the preclinical testing of active substances, comprising a first and a second compartment which are in communication with one another via a separating layer between the first and the second compartment, the separation layer being permeable for cellularly secreted substances, wherein the first compartment includes a syntopic culture with tissue cells and immune cells and the second compartment includes a culture with blood cells. The invention further relates to a method in this regard and to a kit and uses for the preclinical testing of active substances. | 10-22-2009 |
| 20090263791 | Chemically Cleavable 3'-O-Allyl-DNTP-Allyl-Fluorophore Fluorescent Nucleotide Analogues and Related Methods - This invention provides a nucleotide analogue comprising (i) a base selected from the group consisting of adenine, guanine, cytosine, thymine and uracil, (ii) a deoxyribose, (iii) an allyl moiety bound to the 3′-oxygen of the deoxyribose and (iv) a fluorophore bound to the base via an allyl linker, and methods of nucleic acid sequencing employing the nucleotide analogue. | 10-22-2009 |
| 20100285483 | Molecular diagnostic method and treatment in dementia with Lewy bodies - The invention describes methods of molecular diagnosis of a concrete form of α-synucleinopathy, the dementia with Lewy bodies (DLB), associated to the levels of ubiquitin carboxy-terminal hydrolase L1 (UCH-L1) or the alteration of its ubiquityl-ligase activity. It also refers to the use of compounds that permit the modification of the UCH-L1 levels or of the enzymatic activity of UCH-L1. This invention has application in the diagnosis and treatment of patients suffering from DLB. | 11-11-2010 |
| 20100105033 | METHOD FOR SINGLE NUCLEOTIDE POLYMORPHISM AND MUTATION DETECTION USING REAL TIME POLYMERASE CHAIN REACTION MICROARRAY - A method and apparatus for real-time, simultaneous, qualitative measurement of one or more single nucleotide polymorphisms in one or more target nucleic acids is provided. This method involves combining a polymerase chain reaction (PCR) technique with an evanescent wave technique. | 04-29-2010 |
| 20110091887 | METHOD FOR DETECTION OF METHYLCYTOSINE USING PHOTORESPONSIVE PROBE - The present invention provides a method for detecting methylcytosine in DNA rapidly, conveniently, and with high sensitivity. The present invention relates to a method for detecting methylcytosine by using a methylcytosine photocoupling agent (a photoresponsive probe) consisting of nucleic acids having a group represented by the Formula (I), (II), (III) or (IV) as a base moiety. | 04-21-2011 |
| 20110091885 | COMPOSITION COMPRISING AN OLIGONUCLEOTIDE MIXTURE FOR THE DETECTION OF CONTAMINATIONS IN CELL CULTURES - The present invention relates to a method for determining contaminations in a cell culture sample comprising the steps of: a) contacting a sample of a cell culture suspected to comprise contaminations with a composition comprising oligonucleotides under conditions which allow for amplification of polynucleotides, wherein said oligonucleotides comprise oligonucleotides of at least three different groups of oligonucleotides, and b) determining the contaminations based on the amplified polynucleotides obtained by using the oligonucleotide groups of step (a). Moreover, the invention relates to a composition comprising an oligonucleotide mixture. Further encompassed by the present invention is a composition comprising a probe oligonucleotide mixture. Finally, the present invention also relates to kits comprising said oligonucleotide mixtures. | 04-21-2011 |
| 20110091882 | DETERMINATION OF METHYLATION STATUS OF POLYNUCLEOTIDES - The present invention provides compositions and methods for detecting the methylation status of a nucleic acid. In particular, the present invention provides a mass spectrometry-based method of determining DNA methylation status without sequencing. | 04-21-2011 |
| 20110091877 | SYSTEMS AND METHODS FOR MINIMIZATION OR ELIMINATION OF DIFFUSION EFFECTS IN A MICROFLUIDIC SYSTEM - The present invention relates to systems and methods for minimizing or eliminating diffusion effects. Diffused regions of a segmented flow of multiple, miscible fluid species may be vented off to a waste channel, and non-diffused regions of fluid may be preferentially pulled off the channel that contains the segmented flow. Multiple fluid samples that are not contaminated via diffusion may be collected for analysis and measurement in a single channel. The systems and methods for minimizing or eliminating diffusion effects may be used to minimize or eliminate diffusion effects in a microfluidic system for monitoring the amplification of DNA molecules and the dissociation behavior of the DNA molecules. | 04-21-2011 |
| 20110091876 | ZCYTOR19 POLYNUCLEOTIDES, POLYPEPTIDES, ANTIBODIES AND METHODS OF USE - Novel polypeptides, polynucleotides encoding the polypeptides, and related compositions and methods are disclosed for zcytor19, a novel class II cytokine receptor. The polypeptides may be used within methods for detecting ligands that stimulate the proliferation and/or development of hematopoietic, lymphoid and myeloid cells in vitro and in vivo. Ligand-binding receptor polypeptides can also be used to block ligand activity in vitro and in vivo. The polynucleotides encoding zcytor19, are located on chromosome 1p36.11, and can be used to identify a region of the genome associated with human disease states. The present invention also includes methods for producing the protein, uses therefor and antibodies thereto. | 04-21-2011 |
| 20110091880 | SUSCEPTIBILITY VARIANTS FOR LUNG CANCER - The present invention discloses certain genetic variants as susceptibility variants for lung cancer. The invention relates to methods of risk assessment using such variants. The invention further relates to kits for use in risk assessment of lung cancer. | 04-21-2011 |
| 20100159463 | FAST RESULTS HYBRID CAPTURE ASSAY AND SYSTEM - The present invention comprises a method that provides fast and reliable results for detecting the presence of a target nucleic acid molecule in a sample. | 06-24-2010 |
| 20100159470 | SCDs As Modifiers of the p53 Pathway and Methods of Use - Human SCD genes are identified as modulators of the p53 pathway, and thus are therapeutic targets for disorders associated with defective p53 function. Methods for identifying modulators of p53, comprising screening for agents that modulate the activity of SCD are provided. | 06-24-2010 |
| 20100159467 | METHOD FOR REPLICATING THE HEPATITIS C VIRUS - A process for screening anti-HCV agents, including the steps of introducing a compound to be tested for its anti-HCV properties with transformed Vero/6418 cells, having a nucleic acid selected from the group consisting of a nucleic acid coding for the structural and non-structural proteins of the HCV, a nucleic acid coding for the non-structural proteins of the HCV, and a replicon containing a resistance gene to an antibiotic and a nucleotide sequence coding for the non-structural proteins of the HCV; extracting total RNA of the cells; and analyzing any reduction of the rate, of synthesis of the RNA of the HCV of the cells relative to a control value corresponding to the rates of synthesis of the RNAs of the HCV of the cells in the absence of the tested compound. | 06-24-2010 |
| 20100159459 | PRODUCTION OF REPROGRAMMED CELLS WITH RESTORED POTENTIAL - A method for treating cells and/or nuclear transfer units and/or stem cells in culture with such compounds, individually or in combinations, is described. The method results in a globally hypomethylated genome and a restoration of cell differentiation and/or developmental potential, or potentiality. In addition, a method for the in vitro production of reprogrammed cells which have had differentiation potential (totipotential, pluripotential, or multipotential) restored by demethylating the genome is described. | 06-24-2010 |
| 20100159469 | Compositions and Methods for Breast Cancer Prognosis - The present invention provides novel compositions and their use in classifying breast tumors. | 06-24-2010 |
| 20100196901 | Method for Obtaining Information on Biological Rhythm by Using Hair - To provide a simple and low-invasive method for obtaining information on a biorhythm of an individual organism. Provided is a method for obtaining information on a biorhythm of an individual organism based on variations over time in an expression level of a clock gene in a hair follicle cell of the individual organism. According to this method, a phase shift of the biorhythm of the individual organism can be detected by preparing a plurality of times about the individual organism and conducting a collation. Further, a phase shift of the biorhythm of the individual organism can also be detected by collating an expression level of the clock gene at a predetermined time with the molecular clock table. | 08-05-2010 |
| 20100311058 | METHOD FOR DETECTING NUCLEIC ACIDS BY SIMULTANEOUS ISOTHERMAL AMPLIFICATION OF NUCLEIC ACIDS AND SIGNAL PROBE - The present invention relates to a method for detecting target nucleic acids by simultaneous isothermal amplification of the target nucleic acids and a signal probe 5 using an external primer set, a DNA-RNA-DNA hybrid primer set and a DNA-RNA-DNA hybrid signal probe. The method according to the present invention can be used to amplify target nucleic acids in a sample, rapid and exact manner without the risk of contamination compared to the conventional methods such as PCR, and it can simultaneously amplify target nucleic acid and a signal probe, so that it can 0 be applied to various genome projects, detection and identification of a pathogen, detection of gene modification producing a predetermined phenotype, detection of hereditary diseases or determination of sensibility to diseases, and estimation of gene expression. Thus, it is useful for molecular biological studies and disease diagnosis. | 12-09-2010 |
| 20110097726 | REGENERATION AND NEOGENESIS OF RETINAL PHOTORECEPTOR CELL USING OTX2 GENE - The present invention provides a medicine, comprising (a) an Otx2 protein or its partial peptide, or a salt thereof, or (b) a DNA or an RNA encoding an Otx2 protein or its partial peptide. The present medicine is useful as an agent for preventing, treating or suppressing progression of a retinal disease including retinal degeneration. In addition, the present medicine is useful, for example, as an agent for inducing differentiation from a retinal stem cell into a retinal photoreceptor cell, in the transplantation of a cell into the retina of patients suffering from retinal diseases. | 04-28-2011 |
| 20110097725 | RAPID DETECTION OF MYCOBACTERIA - The invention provides a method for detecting a | 04-28-2011 |
| 20110097724 | Detection of Head and Neck Cancer Using Hypermethylated Gene Detection - Methods and kits for detection of a cell proliferative disorder, such as head and neck cancer are provided utilizing analysis of the methylation state of targeted genes or regulatory regions of genes in a saliva or serum sample are described. The presence of hypermethylation of the genes or their regulatory regions is indicative of the presence, or a stronger possibility of recurrence and or a poorer prognosis in subjects with cancer. | 04-28-2011 |
| 20110097720 | SCREENING METHOD FOR SELECTED AMINO LIPID-CONTAINING COMPOSITIONS - The invention features a method of identifying therapeutically relevant compositions which include a therapeutic agent and 2,2-Dilinoley 1-4-dimethylaminomethyl-[1,3]-dioxolane by screening for an effect of the agent on the liver of a model subject. | 04-28-2011 |
| 20110097715 | METHOD FOR PURIFYING OR DETECTING A TARGET PROTEIN - A method for purifying or detecting a target protein present in a solution, includes, before carrying out the actual detection or purification step, a step of contacting the solution with an aptamer binding specifically to the target protein, where the aptamer does not bind to a protein homologous to the target protein that could also be present in the solution. | 04-28-2011 |
| 20100068699 | Assay System For Monitoring The Effects Of Genetically Engineered Cells To Alter Function Of A Synctium - This invention provides methods for determining the ability of a gene construct to alter the rhythm and contractility of a syncytial cell. Furthermore, this invention provides methods for constructing a gene construct capable of altering the rhythm or contractility of a syncytial cell. Finally, this invention provides a method for constructing a gene construct capable of coupling to a syncytial cell. | 03-18-2010 |
| 20090258370 | Acute Myelogenous Leukemia Biomarkers - The present invention provides novel compositions and their use in classifying acute myelogenous leukemia. | 10-15-2009 |
| 20090258368 | PARAMAGNETIC NUCLEATION NANOPARTICLES - A nucleic acid binding substance which has affinity for nucleic acid polymers. The nucleic acid binding substance is comprised of a nucleic acid binding element capable of specific binding to nucleic acid molecules and connected to a nucleation nanoparticle having paramagnetic properties. | 10-15-2009 |
| 20090258367 | METHOD OF MAPPING OF mRNA DISTRIBUTION WITH ATOMIC FORCE MICROSCOPY - The present invention relates to a method of mapping of mRNA distribution, comprising the steps of a preparing a probe DNA attached to a apical liner region of the dendron on AFM cantilever where the probe DNA can specifically hybridize a target mRNA and measuring specific adhesive force between the probe DNA and the target mRNA on sectioned tissue at nanometer resolution. | 10-15-2009 |
| 20090258365 | METHOD FOR DETECTING IGF1R/Chr 15 in CIRCULATING TUMOR CELLS USING FISH - The present invention describes methods and probe composition for an automated FISH assay of a blood sample containing circulating tumor cells expressing the IGF-1R gene. The assay provides genetic analysis of suspect circulating tumor cells that have been identified after immunomagnetic selection and fluorescent labeling. Using unique, repeat-free probes to the IGF-1R locus and a chromosome 15 reference probe, cell lines expressing an aberrant number of IGF-1R and Chr 15 signals were detected, including one cell line with a low level of IGF-1R amplification. The ability to directly examine the genetic profile of IGF-1R on circulating tumor cells may provide an automated means for assessing disease and patient response to therapy. | 10-15-2009 |
| 20090258363 | Targeted integration and expression of exogenous nucleic acid sequences - Disclosed herein are methods and compositions for targeted integration of a exogenous sequence into a predetermined target site in a genome for use, for example, in protein expression and gene inactivation. | 10-15-2009 |
| 20090258359 | MODULAR COMPOSITING-MULTIPLE LOT SCREENING PROTOCOLS FOR DETECTION OF PATHOGENS, MICROBIAL CONTAMINANTS AND/OR CONSTITUENTS - Provided are methods for sampling, testing and validating test lots, comprising: assembling a plurality of product portions from each of a plurality of test lots and combining the portions to provide a corresponding set of test lot samples; enriching the test lot samples; removing portions of each enriched sample, and combining the removed portions to provide a modular composite sample; and testing of the modular composite sample, and individual testing of the enriched test lot samples, using at least one suitable detection assay for a target microbe or organism, wherein when such testing is negative all test lots are validated, and wherein when such testing is positive with respect to the modular composite sample, or with respect to an individual enriched test lot sample, individual test lots may nonetheless yet be validated by further testing of a portion of respective initially-negative enriched test lot samples and obtaining negative results. | 10-15-2009 |
| 20090258357 | CYTOKINE RECEPTOR COMMON GAMMA CHAIN LIKE - The present invention relates to a novel human gene encoding a polypeptide which is a member of the Cytokine Receptor family. More specifically, the present invention relates to a polynucleotide encoding a novel human polypeptide named Cytokine Receptor Common Gamma Chain Like, or “CRCGCL.” This invention also relates to CRCGCL polypeptides, as well as vectors, host cells, antibodies directed to CRCGCL polypeptides, and the recombinant methods for producing the same. Also provided are diagnostic methods for detecting disorders related to the immune system, and therapeutic methods for treating diagnosing, detecting, and/or preventing such disorders. The invention further relates to screening methods for identifying agonists and antagonists of CRCGCL activity. | 10-15-2009 |
| 20100190163 | CANCER ANTIGEN-SPECIFIC T-CELL RECEPTOR GENE, PEPTIDE ENCODED BY THE GENE, AND USE OF THEM - Disclosed are: a nucleotide sequence and an amino acid sequence for CDR3 region of T-cell receptor (TCR) gene of WT1-specific cytotoxic T-cell (CTL) for WT1 protein; a method for the detection or treatment of cancer using the nucleotide sequence or the amino acid sequence; and a chip, a primer set, a kit, an apparatus and the like for use in the detection of cancer, each of which comprises the nucleotide sequence or the amino acid sequence. | 07-29-2010 |
| 20100028868 | Responsiveness to Therapy for Liver Disorders - Sets of nucleic acids and methods for predicting a subject's responsiveness to therapy for liver disorders. | 02-04-2010 |
| 20100028865 | Method for Identifying Regulatory T Cells - The present invention relates to methods and kits for identifying, quantifying and isolating regulatory T cells, to methods and kits for diagnosing or monitoring autoimmune diseases, immunoinflammatory diseases, allergic diseases, predispositions thereto, infectious diseases, cancer, cancer treatment and/or organ transplantation based on regulatory T cell quantity, to methods and kits for predicting responses to therapy for autoimmune diseases, immunoinflammatory diseases, allergic diseases, predispositions thereto, infectious diseases, cancer and/or organ transplantation based on regulatory T cell quantity, and to methods and kits for therapy using isolated regulatory T cells. | 02-04-2010 |
| 20100028880 | METHOD FOR SUSTAINED EXPRESSION OF AN EXOGENOUS GENE - A method for sustained expression of an exogenous gene forms a circular episomal plasmid to solve the problem of transient expression of baculovirus in the transduced mammalian cells caused by the dilution and degradation when mammalian cells replicate and also prevents dysfunctional cell metabolism. | 02-04-2010 |
| 20100028863 | HIGH THROUGHPUT ASSAY FOR CANCER CELL GROWTH INHIBITION - A high-throughput, anchorage-independent assay is described, which screens compounds for inhibition of cancer cell growth. The assay utilizes a three-dimensional matrix or semi-solid media transfected with the subject compound, and enables live colony growth determination and imaging. | 02-04-2010 |
| 20100028877 | MOLECULE FOR PROVIDING A STANDARD FOR THE QUANTITATIVE ANALYSIS OF THE METHYLATIONS STATUS OF A NUCLEIC ACID - The invention refers to a nucleic acid for providing a standard in the quantitative bisulfite based analysis of the methylation status of a DNA molecule with a given sequence, wherein the given sequence comprises at least one CpG position that is to be analyzed for its methylation status. This nucleic acid comprises: a first and a second sequence portion, both of which comprise at least part of the given sequence with at least one CpG position, wherein in the first sequence portion, all of the CpG positions represent the methylated status, and in the second sequence portion, all of the CpG positions represent the unmethylated status. | 02-04-2010 |
| 20100028875 | METHOD FOR DIAGNOSING CANCER BY DETECTING THE METHYLATION OF TRANSITIONAL ZONES - The present invention relates to a method for diagnosing cancer and predicting metastasis or prognosis by measuring the methylation of transitional zones and a primer for detecting the methylation. According to the present invention, a novel transitional zone is understood and a primer for detecting the methylation of the zone is provided, indicating that the present invention contributes to increase accuracy and liability of cancer prediction by measuring the methylation of transitional zones and chromosomal loss at the same time. | 02-04-2010 |
| 20100028869 | METHOD TO ASSESS SUSCEPTIBILITY TO ANDROGENIC ALOPECIA - The present invention relates to a method to assess the susceptibility to androgenetic alopecia comprising detecting the presence of polymorphisms in the EDA2R gene. | 02-04-2010 |
| 20100221739 | SUPPRESSION OF TLA1 GENE EXPRESSION FOR IMPROVED PHOTOSYNTHETIC PRODUCTIVITY - The invention provides method and compositions to minimize the chlorophyll antenna size of photosynthesis by decreasing TLA1 gene expression, thereby improving solar conversion efficiencies and photosynthetic productivity in plants, e.g., green microalgae, under bright sunlight conditions. | 09-02-2010 |
| 20090305266 | TEST FOR OVARIAN CANCER BY DETECTING ABNORMALITY IN FANCD2 PATHWAY - Methods are provided for determining diagnosing ovarian and breast cancer in a subject, including diagnosing the predisposition of a subject's risk of developing breast or ovarian cancer. The methods include selecting a subject, for example a subject with one or more risk factors for developing ovarian cancer or breast cancer, and detecting a decrease in the activity of the Fanconi anemia (FA) non-nuclear core (NNC) component in the subject. Such a decrease is indicative of a predisposition to ovarian cancer and/or breast cancer in the subject. These methods can be used to monitor the response of a subject to agents designed to prevent breast and ovarian cancer, for example an anti-neoplastic agent. Methods also are provided for identifying agents of use in preventing breast and ovarian cancer. | 12-10-2009 |
| 20090291444 | METHODS AND MATERIALS FOR DETECTING AND TREATING DEMENTIA - This document relates to methods and materials involved in detecting mutations linked to dementia (e.g., frontotemporal lobar degeneration). For example, methods and materials for determining whether or not a mammal is homozygous for a mutant T allele of rs5848 are provided. This document also relates to methods and materials involved in treating mammals having or being susceptible to developing neurodegenerative disorders (e.g., frontotemporal lobar degeneration). For example, methods and materials for inhibiting the ability of miRNA to suppress GRN polypeptide expression in mammals are provided. | 11-26-2009 |
| 20100221722 | METHODS FOR EVALUATING BREAST CANCER PROGNOSIS - Methods for diagnosing and for evaluating the prognosis of a cancer patient, particularly a breast cancer patient, are provided. The methods include determining expression levels of at least five biomarkers in a body sample including a cancer cell from the patient, where expression levels of the biomarkers are indicative of cancer prognosis. Overexpression of the biomarkers of the invention is indicative of a poor prognosis. In some embodiments, the body sample is a breast tissue sample, particularly a primary breast tumor sample. The methods of the invention can be used in combination with assessment of conventional clinical factors and permit a more accurate evaluation of breast cancer prognosis. | 09-02-2010 |
| 20090298083 | Phospho-Specific Anti-Pax3 Antibodies - Pax3, a member of the paired class homeodomain family of transcription factors and an essential protein for early skeletal muscle development, was shown to be phosphorylated in proliferating mouse primary myoblasts. Furthermore, Ser205, Ser201 and Ser209 were identified as the only sites of phosphorylation on Pax3 in proliferating mouse primary myoblasts. Phosphorylation of Ser205 was shown to be required for the efficient phosphorylation of Ser201 and/or Ser209. Site-specific antibodies were made to each of these three sites when phosphorylated. These three sites are also present and phosphorylated in the Pax3-FOXO1 fusion protein, and phosphorylation of these sites may play a role in ARMS. Thus, these new antibodies may be used in studying the regulation of nerve and muscle development and differentiation and in finding therapeutic solutions for certain disorders, including Waardenburg syndrome and childhood solid muscle tumor alveolar rhabdomyosarcoma (ARMS). | 12-03-2009 |
| 20100304374 | METHODS AND TOOLS FOR DISCRIMINATING COLORECTAL ADENOMAS AND ADENOCARCINOMAS - The present invention relates to the differential expression of genes in colorectal adenoma and adenocarcinoma cells and their correlation with chromosomal aberrations. The present invention provides tools for detecting chromosomal aberrations linked to progression of adenomas into adenocarcinoma cells. The present invention discloses methods and tools for in vivo and in vitro diagnosis of colorectal tumours. | 12-02-2010 |
| 20100279282 | METHODS FOR GENOTYPING MATURE COTTON FIBERS AND TEXTILES - Methods for distinguishing between cotton cultivars of a specific species by analyzing a sample of mature cotton fibers from raw cotton materials or from textile goods are disclosed. DNA is extracted from the mature cotton fiber sample and subjected to PCR techniques which enable the identification of the cultivar of a particular cotton species utilized in the textile or cotton material of interest. | 11-04-2010 |
| 20100248254 | ASSESSMENT AND REDUCTION OF RISK OF GRAFT-VERSUS-HOST DISEASE - Methods of assessing and reducing risk of graft versus host disease (GVHD) based on gene expression profiling are described, as well as methods of selecting a suitable transplant donor. Corresponding reagents and kits are also described. | 09-30-2010 |
| 20100316995 | CONSENSUS CODING SEQUENCES OF HUMAN BREAST AND COLORECTAL CANCERS - Analysis of 13,023 genes in 11 breast and 11 colorectal cancers revealed that individual tumors accumulate an average of ˜90 mutant genes but that only a subset of these contribute to the neoplastic process. Using stringent criteria to delineate this subset, we identified 189 genes (average of 11 per tumor) that were mutated at significant frequency. The vast majority of these genes were not known to be genetically altered in tumors and are predicted to affect a wide range of cellular functions, including transcription, adhesion, and invasion. These data define the genetic landscape of two human cancer types, provide new targets for diagnostic and therapeutic intervention and monitoring. | 12-16-2010 |
| 20100291566 | SYSTEMS AND METHODS FOR DIAGNOSIS AND MONITORING OF BACTERIA-RELATED CONDITIONS - The presently-disclosed subject matter provides systems, methods, and kits for diagnosing and/or monitoring a bacteria-related condition of interest in a subject by providing a cell sensing system, each system containing a reporter molecule capable of detecting binding of a quorum sensing molecule and capable of generating a detectable signal. | 11-18-2010 |
| 20110008790 | CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR GENE MUTATIONS - The present invention provides novel mutations of the CFTR gene related to cystic fibrosis or to conditions associated with cystic fibrosis. Also provided are probes for detecting the mutant sequences. Methods of identifying if an individual has a genotype containing one or more mutations in the CFTR gene are further provided. | 01-13-2011 |
| 20100099080 | NUCLEIC ACID MEMORY DEVICE - This invention pertains to methods of imparting information onto nucleic acid sequences. In specific embodiments, the present invention provides site-specific recombinase systems and error-prone polymerase systems to alter nucleotide sequences such as DNA and mini-genomes, as well as for the production of microarrays. The present invention also provides methods of analyzing the modified nucleotides sequences provided herein. Methods of engineering and screening for novel modified polymerases that incorporate chain terminating nucleotides and/or labeled nucleotides more efficiently than wild-type polymerases are also provided. | 04-22-2010 |
| 20100304370 | INTRACELLULAR PH SENSOR USING NUCLEIC ACID ASSEMBLIES - Disclosed are nucleic acid-based sensors for measuring the pH of a sample, including cells, regions thereof, and whole organisms. The sensor includes an I-switch that is triggered by protons, and which functions as a FRET-based pH sensor inside living cells and organisms. Also disclosed are compositions and methods for measuring the pH of a specific region of a cell, such as vesicles, the nucleus, mitochondrial matrix, or the Golgi lumen. | 12-02-2010 |
| 20100233685 | Two-Color Fluorescent Reporter for Alternative Pre-MRNA Splicing - The present invention provides reporter constructs for in vivo or in vitro monitoring of alternative pre-mRNA splicing events. The reporter constructs described herein are also particularly useful for high-throughput screening of compounds that affect alternative pre-mRNA splicing. Kits comprising the reporter constructs of the present invention find utility in a wide range of applications including, for example, basic research, drug screening, and drug design. | 09-16-2010 |
| 20090298060 | METHODS FOR DIAGNOSING AND MONITORING THE STATUS OF SYSTEMIC LUPUS ERYTHEMATOSUS - The invention presents a method of diagnosing or monitoring the status of systemic lupus erythematosus (SLE) in a subject or patient comprising detecting the expression of all genes of a diagnostic set in the subject or patient wherein the diagnostic set comprises two or more genes having expression correlated with the classification or status of SLE; and diagnosing or monitoring the status of SLE in the subject or patient by applying at least one statistical method to the expression of the genes of the diagnostic set. | 12-03-2009 |
| 20100279283 | METHOD FOR MOLECULAR BIOLOGY APPLICATIONS - The invention provides a method of nucleic acid synthesis and/or amplification, and/or of improving the efficiency, activity and/or stability of at least one nucleic acid-modifying enzyme, comprising carrying out the method in the presence of (a) at least one organic-based macromolecule having a molecular weight of 50 kDa to 500 kDa and neutral surface charge; or (b) at least one organic-based macromolecule of radius 2 to 50 nm and neutral surface charge. There is also provided a method of determining the optimum crowding conditions of macromolecule(s) in solution. | 11-04-2010 |
| 20110020809 | MILD OSTEOARTHRITIS BIOMARKERS AND USES THEREOF - The invention relates to the identification and selection of novel biomarkers and the identification and selection of novel biomarker combinations which are differentially expressed in individuals with mild osteoarthritis as compared with individuals without osteoarthritis. Polynucleotides and proteins which specifically and/or selectively hybridize to the products of the biomarkers of the invention are also encompassed within the scope of the invention as are kits containing said polynucleotides and proteins for use in diagnosing mild osteoarthritis. Further encompassed by the invention is the use of the polynucleotides and proteins which specifically and/or selectively hybridize to the product of the biomarkers of the invention to monitor disease regression in an individual and to monitor the efficacy of therapeutic regimens. The invention also provides for methods of using the products of the biomarkers of the invention in the identification of novel therapeutic targets for osteoarthritis. | 01-27-2011 |
| 20100196885 | METHODS OF VALIDATING CANDIDATE COMPOUNDS FOR USE IN TREATING COPD AND OTHER DISEASES - The present invention relates to methods of diagnosing and treating elastin fiber injuries. In additional preferred embodiments, the present invention relates to methods of validating candidate compounds for use in treating chronic obstructive pulmonary disease (COPD), chronic bronchitis, emphysema, refractory asthma, and other related diseases. Examples of such methods include determining if the candidate compound decreases the degradation of elastic fiber in a patient administered the candidate compound by measuring, using mass spectrometry, a marker of elastic fiber degradation in a sample of a body fluid or a tissue of the patient. The invention provides that a decrease in the presence of the marker compared to a control validates that the candidate compound is effective to treat, prevent, or ameliorate the disease. | 08-05-2010 |
| 20100184021 | NOVEL NUCLEOTIDE AND AMINO ACID SEQUENCES, AND METHODS OF USE THEREOF FOR DIAGNOSIS - The present invention relates to diagnostic markers comprising novel splice variants of known proteins and polynucleotides encoding same, useful in the qualitative and/or quantitative detection of various diseases and/or pathological conditions in a subject, and to the use of known proteins and polynucleotides encoding same for diagnosis. Particularly, the invention relates to the diagnosis of a disease in a sample of body fluid or secretion obtained from the subject, and to the diagnosis of cancer. | 07-22-2010 |
| 20090258360 | METHOD OF DETECTING EQUINE POLYSACCHARIDE STORAGE MYOPATHY - The present invention relates to diagnosing Polysaccharide Storage Myopathy (PSSM) disease in equines. | 10-15-2009 |
| 20100323348 | Methods and Compositions for Using Error-Detecting and/or Error-Correcting Barcodes in Nucleic Acid Amplification Process - The present invention provides methods and compositions for detecting and correcting errors in nucleic acid amplification processes, and methods for using the same. In particular, barcode amplification errors are detected and corrected such that integrity in sample assignment is maintained. The methods are compatible with high throughput sequencing techniques as some of the barcodes are based upon Hamming codes, thereby allowing self-correction for single bit errors. Some methods and compositions of the invention allow characterization (e.g., sequencing) of a plurality of nucleic acid samples simultaneously within a single sequencing reaction. | 12-23-2010 |
| 20100221737 | Translocation and Mutant ROS Kinase in Human Non-Small Cell Lung Carcinoma - In accordance with the invention, a novel gene translocation, (5q32, 6q22), in human non-small cell lung carcinoma (NSCLC) that results in a fusion proteins combining part of CD74 with Proto-oncogene Tyrosine Protein Kinase ROS Precursor (ROS) kinase has now been identified. The CD74-ROS fusion protein is anticipated to drive the proliferation and survival of a subgroup of NSCLC tumors. The invention therefore provides, in part, isolated polynucleotides and vectors encoding the disclosed mutant ROS kinase polypeptides, probes for detecting it, isolated mutant polypeptides, recombinant polypeptides, and reagents for detecting the fusion and truncated polypeptides. The disclosed identification of the new fusion protein enables new methods for determining the presence of these mutant ROS kinase polypeptides in a biological sample, methods for screening for compounds that inhibit the proteins, and methods for inhibiting the progression of a cancer characterized by the mutant polynucleotides or polypeptides, which are also provided by the invention. | 09-02-2010 |
| 20100261181 | LABELING AND DETECTION OF NUCLEIC ACIDS - Provided in certain embodiments are new methods for forming azido modified nucleic acid conjugates of reporter molecules, carrier molecules or solid support. In other embodiments are provided methods for enzymatically labeling nucleic acids with an azide group. | 10-14-2010 |
| 20110014605 | METHODS AND SYSTEMS FOR DNA ISOLATION ON A MICROFLUIDIC DEVICE - The present invention relates to methods and systems for the isolation of DNA on a microfluidic device and the subsequent analysis of the DNA on the microfluidic device. More specifically, embodiments of the present invention relate to methods and systems for the isolation of DNA from patient samples on a microfluidic device and use of the DNA for performing amplification reactions, such as PCR, and detection, such as thermal melt analysis, on the microfluidic | 01-20-2011 |
| 20100143911 | METHOD FOR SCREENING ESSENTIAL METABOLITES IN GROWTH OF MICROORGANISMS - The present invention disclosed is a method for screening metabolites essential for the growth of microorganism using metabolic flux analysis. More specifically, the present invention relates to the method for screening metabolites essential for the growth of microorganism, by selecting a target microorganism, constructing a metabolic network model of the selected microorganism, inactivating the consumption reaction of each of metabolites in the constructed metabolic network model, analyzing the metabolic flux of the metabolites to select metabolites essential for the growth of the microorganism, and confirming the selected metabolites using the utilization of each of the metabolites, defined as flux sum (Φ). According to the present invention, metabolites essential for the growth of microorganism, and genes involved in the essential metabolites, can be screened in a convenient manner, and drug-target genes against pathogenic microorganisms can be predicted by deleting genes associated with the metabolites screened according to the method. | 06-10-2010 |
| 20100323349 | Identification of the Gene and Mutation Responsible for Progressive Rod-Cone Degeneration in Dog and a Method for Testing Same - Tools and methods are provided for determining whether or not a dog is genetically normal, is a carrier of, or is affected with or predisposed to progressive rod-cone degeneration. The method is based on the detection of a transversion from G to A at position corresponding to nucleotide position 1298 of SEQ ID NO: 1. | 12-23-2010 |
| 20100184032 | Stem-Progenitor Cell Specific Micro-Ribonucleic Acids and Uses Thereof - Provided herein are methods and compositions for modulating the differentiation of incompletely differentiated cells, such as stem-progenitor cells, e.g., hematopoietic stem-progenitor cells. A method may comprise contacting a cell with an agononist or an antagonist of a miRNA comprising a nucleotide sequence from SEQ ID NO: 1-34. | 07-22-2010 |
| 20100240030 | NEW METHOD FOR QUALITATIVE AND QUANTITATIVE DETECTION OF SHORT NUCLEIC ACID SEQUENCES OF ABOUT 8-50 NUCLEOTIDES IN LENGTH - The present invention concerns a new analytical method for qualitative and quantitative detection of short nucleic acid sequences, preferably a DNA oligonucleotide or a modified DNA oligonucleotide such as antisense oligonucleotides or fragmented nucleic acid sequences of about 8-50 nucleotides in length. The invention relates to the introduction of modified nucleic acids into an oligonucleotide probe that hybridizes to the target sequence such that amplification and quantitation of the short nucleic acid sequence is enabled and sensitivity and specificity of the reaction is increased. The invention also embraces test kits for performing nucleic acid amplification to detect and quantitate short nucleic acid sequences and processes for preparing such and the use of new analytical methods. | 09-23-2010 |
| 20090246784 | METHOD OF ANALYZING METHYLATED DNA - The present invention provides a method of analyzing methylated DNA, comprising steps of: (A) treating a DNA-containing sample with a restriction enzyme to obtain a sample containing a DNA fragment; (B) concentrating methylated DNA contained in the sample obtained in step (A) to obtain a methylated DNA concentrate; (C) subjecting the methylated DNA concentrate obtained in step (B) and a primer set to nucleic acid amplification reaction, wherein the primer set performs the nucleic acid amplification reaction in step (C) by using a template DNA which does not have a CpG site; (D) detecting an amplification product obtained in step (C); (E) judging whether the methylated DNA concentrate obtained in step (B) is appropriate as a sample for detection of methylated DNA, on the basis of the detection result of the amplification product in step (D); and(F) analyzing the methylated DNA contained in the methylated DNA concentrate. | 10-01-2009 |
| 20100304390 | METHODS FOR DETECTING GENE DYSREGULATIONS - Described herein are methods, compositions and kits directed to the detection of gene dysregulations such as those arising from gene fusions and/or chromosomal abnormalities, e.g. translocations, insertions, inversions and deletions. Samples containing dysregulated gene(s) of interest may show independent expression patterns for the 5′ and 3′ regions of the gene. The methods, compositions and kits are useful for detecting mutations that cause the differential expression of a 5′ portion of a target gene relative to the 3′ region of the target gene. | 12-02-2010 |
| 20100221707 | DIAGNOSTIC METHODS FOR DETECTING CONGENITAL BONE DEFECTS - The present disclosure is directed to compositions and methods for screening for patients at risk for autosomal recessive hypophosphatemic rickets. More particularly, diagnostic reagents and procedures are provided for analyzing samples to detect defective DMP1 expression. | 09-02-2010 |
| 20100015622 | MOLECULAR BEACON-BASED METHODS FOR DETECTION OF TARGETS USING ABSCRIPTION - The present invention provides methods for detecting targets using an Abscription assay that exploits molecular beacon-based detection technology. The methods of the invention are highly sensitive and can be performed on a NanoDrop scale and can be multiplexed for simultaneous detection of multiple targets. | 01-21-2010 |
| 20110070580 | Methods, Compositions, and Kits for Amplifying and Sequencing Polynucleotides - In one aspect, there are provided methods of amplifying and sequencing a polynucleotide. In some embodiments, the method includes (a) amplifying the polynucleotide with at least one amplification primer, a processive amplification polymerase, a sequencing primer, a sequencing polymerase, deoxynucleoside triphosphates suitable for template-dependent primer extension, and one or more terminating nucleotides, the incubation being carried out at a first temperature suitable for amplifying the polynucleotide with the processive amplification polymerase; (b) incubating the product of step (a) at a second temperature suitable for forming a plurality of differently-sized extended sequencing primers with the sequencing polymerase; (c) evaluating the extended sequencing primers in order to determine the sequence of the polynucleotide. The reactions at the first and second temperatures can be carried out in a single reaction vessel. In other aspects, compositions and kits for carrying out the methods are also provided. | 03-24-2011 |
| 20100233697 | METHOD FOR STANDARIZING SURFACE BINDING OF A NUCLEIC ACID SAMPLE FOR SEQUENCING ANALYSIS - Methods are described which enable nucleic acid sample standardization prior to anchoring to a surface, especially useful in single molecule nucleic acid sequencing applications when sample is limiting or unamplified. | 09-16-2010 |
| 20100323358 | Use of KIR genes for predicting response to therapy - The present invention relates to the use of at least one Killer cell immunoglobulin-like receptor gene for the identification of subjects likely to respond to tumour necrosis factor-based therapy. The invention also provides methods of identifying subjects likely to respond to tumour necrosis factor-based therapy, and finds utility in assisting with prospectively predicting the likely clinical response of patients to therapeutic agents used in TNF therapy, based on the genotype of the patient, in particular, by evaluating the status of at least one KIR gene. This predictive tool finds wide clinical utility in the management of autoimmune diseases, such as rheumatoid arthritis, and greatly assists clinicians in the prioritisation of patients for tumour necrosis factor-based therapy, possibly reducing the cost of treatment in terms of adverse side effects and health budgets. | 12-23-2010 |
| 20110053159 | GENETIC MARKERS FOR ASSESSING RISK OF PREMATURE BIRTH RESULTING FROM PRETERM PREMATURE RUPTURE MEMBRANES - A method to identify women who are at risk for preterm delivery due to premature rupture of membranes (PPROM) is provided. The method entails detecting the presence of SERPINH1 gene variants that express low levels of the gene product, heat shock protein Hsp47. The occurrence of a T (rather than C) at a single nucleotide polymorphism (SNP) site at position −656 of the SERPINH1 gene promoter, together with the absence of a 12 base pair deletion at positions −694 to −683 of the promoter, result in an increased risk of PPROM. The method enables medical professionals to identify those at risk, and to provide suitable therapeutic intervention. | 03-03-2011 |
| 20100261180 | RECOMBINANT PERFORIN, EXPRESSION AND USES THEREOF - The present invention relates to retroviral vectors capable of driving the expression of perforin in a cell and a method of expressing recombinant perforin in a cell. The present invention also relates to recombinant perforin polypeptides and nucleic acid molecules derived therefrom and uses thereof. Also encompassed are screening assays employing such recombinant perforin molecules, compounds identified by the screening assays and uses thereof. | 10-14-2010 |
| 20100041059 | METHOD OF PREDICTING A BENEFIT OF ANTIOXIDANT THERAPY FOR PREVENTION OF CARDIOVASCULAR DISEASE IN HYPERGLYCEMIC PATIENTS - A method of determining a potential of a diabetic patient to benefit from anti oxidant therapy for treatment of a vascular complication, the method comprising determining a haptoglobin phenotype of the diabetic patient and thereby determining the potential of the diabetic patient to benefit from said anti oxidant therapy, whereby a patient having a haptoglobin 2-2 phenotype benefits from anti oxidant therapy more than a patient having a haptoglobin 1-2 phenotype or a patient having a haptoglobin 1-1 phenotype. | 02-18-2010 |
| 20100311072 | FLUORESCENCE POLARIZATION BINDING ASSAY FOR CHARACTERIZING GLUCOKINASE LIGANDS - The subject matter disclosed and claimed herein concerns measuring the binding affinity of glucokinase (“GK”) using a fluorescence polarization (“FP”) assay. The FP method includes use of modified GK ligands bound to a fluorescent label. Binding affinity is determined by measuring displacement of fluorescent ligand by the known or suspected GK ligands. The subject matter disclosed and claimed herein provides a robust high-throughput FP assay for the determination of binding affinity of ligands to glucokinase. The FP binding assay displayed both glucose and nucleotide dependence, and a useful dynamic range. The binding IC | 12-09-2010 |
| 20100203529 | Methods and systems of using exosomes for determining phenotypes - Exosomes can be used for detecting biomarkers for diagnostic, therapy-related or prognostic methods to identify phenotypes, such as a condition or disease, for example, the stage or progression of a disease. Cell-of-origin exosomes can be used in profiling of physiological states or determining phenotypes. Biomarkers or markers from cell-of-origin specific exosomes can be used to determine treatment regimens for diseases, conditions, disease stages, and stages of a condition, and can also be used to determine treatment efficacy. Markers from cell-of-origin specific exosomes can also be used to identify conditions of diseases of unknown origin. | 08-12-2010 |
| 20100003674 | Adult stem cells, molecular signatures, and applications in the evaluation, diagnosis, and therapy of mammalian conditions - MicroRNA genes are associated with regulatory elements of living cells of all species. The perturbations of the expression of these genes and their gene products in the cell or genomic structure or chromosomal architecture of a cell provide specific signatures on the condition of the cell and even the organism. Evaluation of miR gene expression can therefore be used to indicate the presence and state of specific cell types and/or their state of differentiation relative to their surrounding tissue. The present invention relates to the identification of a stem cell-specific signature or signatures composed of protein and/or nucleic acid markers expressed by virtue of the position of a cell or cells in the time line of its/their development and the impact of the cells' environment on this signature as it relates to the cells' stem cell potential. The composition and combination of these signatures provides a means of identifying, manipulating and differentiating said adult stem cells and thus, their acquisition and utilization in research, diagnosis, and therapy of normal and pathological conditions. | 01-07-2010 |
| 20100330560 | Immunogenic polypeptide isolated from mycobacterium avium subspecies paratuberculosis and uses thereof - The present invention relates to an immunogenic polypeptide isolated from | 12-30-2010 |
| 20100086927 | DEPOSITION OF METAL OXIDES ONTO SURFACES AS AN IMMOBILIZATION VEHICLE FOR CARBOXYLATED OR PHOPHATED PARTICLES OR POLYMERS - Intermediates and methods for forming activated metal complexes bound to surfaces on oxide layers, immobilizing beads to the modified surface and articles produced thereby are described. Hydroxyl groups on the oxide surfaces are reacted with a metal reagent complex of the formula Y(L-Pol) | 04-08-2010 |
| 20110045470 | PATHOGEN DETECTION IN LARGE-VOLUME PARTICULATE SAMPLES - Methods and filter systems for detecting microorganisms in a sample, such as a food sample, are disclosed. The filter is configured to attract the microorganism, for example by electrostatic charge. The filter containing the microorganism is incubated to grow the microorganism so that it may be detected. The filter may be degradable and the detection may involve extracting the microorganism or the molecular marker of the microorganism from the filter for detection. The filter system may also include a porous microbead component selected to trap dirt and other contaminants from the sample while allowing the microorganisms to pass among the microbeads. Methods are disclosed for detecting microorganisms in samples using the filter systems described. The methods may also include adding a polymer and/or a microorganism detection reagent to the filter to localize microorganism growth and prevent evaporation of reagents. | 02-24-2011 |
| 20110039257 | Permuted and nonpermuted luciferase biosensors - A modified luciferase protein which is a sensor for molecules including cAMP, cGMP, calcium, chelators thereof, kinases, or phosphatases is provided. Also provided is a circularly permuted anthozoan luciferase protein and a decapod crustacean luciferase protein, optionally containing one or more heterologous amino acid sequences, at least one of which directly or indirectly interacts with a molecule of interest. Further provided is a modified anthozoan luciferase protein and a decapod crustacean luciferase protein containing an insertion of one or more heterologous amino acid sequences, at least one of which directly or indirectly interacts with a molecule of interest. | 02-17-2011 |
| 20110033851 | NUCLEIC ACID AMPLIFICATION - Provided herein is a method for the selective amplification of a target nucleotide sequence located within a nucleic acid molecule, the method comprising contacting the nucleic acid molecule (“template” molecule) with (i) at least one facilitator oligonucleotide, wherein the facilitator oligonucleotide includes at least one modification at or near its 3′ terminus such that 3′ extension from the facilitator oligonucleotide is blocked, and (ii) two or more oligonucleotide primers, at least one of which is an initiator primer modified such that the presence of the modification prematurely terminates complementary strand synthesis, wherein the facilitator oligonucleotide and the initiator primer bind to substantially the same or adjacent regions of the template nucleic acid molecule and the facilitator oligonucleotide further comprises sequences complementary to the target sequence 3′ to the binding location of the initiator primer; and carrying out thermocyclic, enzymatic amplification such that the specific target sequence is selectively amplified. | 02-10-2011 |
| 20100285471 | Methods and Compositions for the Diagnosis and Treatment of Esphageal Adenocarcinomas - Methods and compositions for the diagnosis, prognosis and/or treatment of esophageal adenocarcinoma and Barrett's esophagus associated adenocarcinoma are disclosed, along with more markers where a difference is indicative of esophageal adenocarcinoma and squamous cell carcinoma, and/or Barrett's esophagus associated adenocarcinomas or a predisposition thereto. The invention also provides methods and compositions of identifying anti-cancer agents therefor. | 11-11-2010 |
| 20100167286 | Pluripotent cell lines and methods of use thereof - Methods of generating cell lines with a sequence variation or copy number variation of a gene of interest, methods of use thereof, and cell lines with a sequence variation or copy number variation of a gene of interest are provided. | 07-01-2010 |
| 20100021915 | HIGH THROUGHPUT DNA SEQUENCING METHOD AND APPARATUS - The present invention relates to a method for high throughput nucleic acid sequencing using a multi-bead flow cell and pyrophosphate sequencing, a sequencer capable of performing this method, and a kit of the pyrophosphate sequencing reagents. | 01-28-2010 |
| 20090269763 | Reprogramming a cell by inducing a pluripotent gene through RNA interference - The invention relate to methods, compositions, and kits for reprogramming a cell. In one embodiment, the invention relates to a method for inducing the expression of at least one gene that contributes to a cell being pluripotent or multipotent. In yet another embodiment, the method comprises inhibiting the expression of a gene that codes for a protein involved in transcriptional repression. In yet another embodiment, the invention relates to a reprogrammed cell or an enriched population of reprogrammed cells that can have characteristics of an ES-like cell, which can be re- or trans-differentiated into a differentiated cell type. | 10-29-2009 |
| 20100055693 | LUCIFERASE SIGNAL ENHANCING COMPOSITIONS - Reagents and compositions for use in reactions catalysed by luciferase enzymes, and in particular for use in luciferase-based gene reporter assays are described. The invention also provides methods and compositions for, inter alia, increasing the sensitivity and/or improving the kinetics of luciferase-catalysed reactions. | 03-04-2010 |
| 20100190157 | METHOD FOR DETECTION OF MUTANT ALLELES COMBINING REAL TIME PCR AND REMS-PCR - The instant invention refers to a method for simultaneous selective amplification and detection of mutant DNA sequences, to oligonucleotides to be used for said method and to kit for the same. The invention refers aldo to a method for identifying a specific mutated DNA sequence, to oligonucleotides to be used for said method and to kit for the same. | 07-29-2010 |
| 20090275038 | METHOD AND APPARATUS FOR FORENSIC SCREENING - This invention relates to methods and system for forensic screening. More specifically, this invention relates to various methods to detect or screen for at least one designated genetic sequences in a plurality of biological sample | 11-05-2009 |
| 20090275026 | Primer and Probe for Detection of Mycobacterium Intracellulare, and Method for Detection of Mycobacterium Intracellulare by Using the Primer and Probe - The present invention discloses an oligonucleotide which comprises a part or the entire sequence of the nucleotide sequence shown in SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7 or SEQ ID NO: 8, or a part or the entire sequence of a sequence complementary to the nucleotide sequence shown in SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7 or SEQ ID NO: 8, wherein the oligonucleotide is capable of hybridizing with a nucleotide sequence of | 11-05-2009 |
| 20100209929 | MULTIPLE MECHANISMS FOR MODULATION OF JAK/STAT ACTIVITY - An embodiment of the present invention is a method for subjecting a hematopoetic cell to a JAK/STAT inhibitor, determining the activity of gain-of-function mutations of a Jak family kinase, determining the expression levels and activity of JAK/STAT regulatory proteins, correlating the expression levels and the activity of JAK/STAT regulatory proteins with the activity of gain-of-function mutations of a Jak family kinase and with a response to the JAK/STAT inhibitor, and then classifying the cells. A further embodiment of the invention includes determining the clinical outcome based on the cell classification, determining a method of treatment, determining dosing and scheduling of at least one of the JAK/STAT inhibitors or other compounds. | 08-19-2010 |
| 20100317002 | METHODS AND KITS FOR DIAGNOSING LUNG CANCER - Provided is a method of identifying a genetically abnormal cell in a sputum sample, the method comprising: (a) staining a sputum sample using a morphological stain so as to identify a lower airway tract cell or lung cell in the sputum sample; and (b) staining the sputum sample using fluorescent in situ hybridization (FISH) so as to identify in the lower airway tract cell or lung cell a genetic abnormality in at least one of human chromosome 3p22.1 and 10q22-23, thereby identifying the genetically abnormal cell in the sputum sample. Also provided are methods and kits of diagnosing lung cancer by detecting a presence of genetically abnormal cells above a predetermined threshold in a sputum sample. | 12-16-2010 |
| 20110076680 | FLUORESCENT MOLECULE - It is an object of the present invention to provide an on-off type fluorescent compound (a fluorescence-producing molecule system) used in gene analyses, which is highly stable (namely, being active for a long period of time) and highly sensitive, and which enables amplification of a trace amount of gene signal and observation thereof. The present invention provides a nonfluorescent molecule having a fluorescent substance skeleton such as fluorescein skeleton and having a group represented by —O—C(Y1)(Y2)-N | 03-31-2011 |
| 20100136552 | Methods and compositions for DMXL-associated mental retardation - The present invention provides a method of identifying a human subject as having an increased likelihood of having DMXL-associated mental retardation, comprising detecting, in a nucleic acid sample from the subject, a mutation in a nucleotide sequence encoding DMXL1 and/or a mutation in a nucleotide sequence encoding DMXL2. The present invention further provides a method of identifying a human subject as having an increased likelihood of having DMXL-associated mental retardation, comprising detecting, in a sample from the subject, a mutation in a DMXL1 protein and/or a mutation in a DMXL2 protein. | 06-03-2010 |
| 20100129798 | DETECTING GENETIC PREDISPOSITION TO OSTEOARTHRITIS ASSOCIATED CONDITIONS - This application relates to methods and kits for detecting predisposition to increased risk for osteoarthritis associated conditions. | 05-27-2010 |
| 20100190167 | Methods, Reagents and Kits for Detection of Nucleic Acid Molecules - Methods, reagents and kits are provided for the production and use in detection assays of labeled nucleic acid molecules wherein a labeling molecule is attached directly to the 3′ end of the nucleic acid molecules. | 07-29-2010 |
| 20100068705 | GENETIC SUSCEPTIBILITY VARIANTS ASSOCIATED WITH CARDIOVASCULAR DISEASE - The invention relates to methods of diagnosing susceptibility to cardiovascular disease, including coronary artery disease. MI, abdominal aorta aneurysm, intracranial aneurysm restenosis and peripheral arterial disease, by assessing the presence or absence of alleles of certain polymorphic markers found to be associates with cardiovascular disease. The invention further relates to kits encompassing reagents for assessing such markers, and methods for assessing the probability of response to therapeutic agents and methods using such markers. | 03-18-2010 |
| 20110091889 | CENTROSOME-ASSAY - The present invention provides a centrosome assay for the identification of preferably, Eg | 04-21-2011 |
| 20100112585 | Method for Enriching Methylated CpG Sequences - Compositions and methods are provided for facilitating the enrichment of single-stranded DNA containing methylated CpG in a mixture containing methylated and unmethylated DNA. The compositions relate to methylation-binding protein domains that selectively bind to methylated single strand DNA. In embodiments of the invention, the methylated DNA is eluted in 0.4M-0.6M NaCl while the unmethylated single strand DNA is eluted in less than 0.4M salt. The ability to readily enrich for methylated DNA permits high throughput sequencing of the methylated DNA and identification of abnormal methylation patterns associated with disease. | 05-06-2010 |
| 20100112567 | RANDOM ACCESS SYSTEM AND METHOD FOR POLYMERASE CHAIN REACTION TESTING - A random access, high-throughput system and method for preparing a biological sample for polymerase chain reaction (PCR) testing are disclosed. The system includes a nucleic acid isolation/purification apparatus and a PCR apparatus. The nucleic acid isolation/purification apparatus magnetically captures nucleic acid (NA) solids from the biological sample and then suspends the NA in elution buffer solution. The PCR testing apparatus provides multiple cycles of the denaturing, annealing, and elongating thermal cycles. More particularly, the PCR testing apparatus includes a multi-vessel thermal cycler array that has a plurality of single-vessel thermal cyclers that is each individually-thermally-controllable so that adjacent single-vessel thermal cyclers can be heated or cooled to different temperatures corresponding to the different thermal cycles of the respective PCR testing process. | 05-06-2010 |
| 20100112566 | VIPR1S as Modifiers of the E2F/RB Pathway and Methods of Use - Human VIPR1 genes are identified as modulators of the E2F/RB pathway, and thus are therapeutic targets for disorders associated with defective E2F/RB function. Methods for identifying modulators of E2F/RB, comprising screening for agents that modulate the activity of VIPR1 are provided. | 05-06-2010 |
| 20100112556 | METHOD FOR SAMPLE ANALYSIS USING Q PROBES - A method of sample analysis is provided. In certain embodiments, the method may comprise: a) contacting a plurality of Q probes with a nucleic acid sample comprising a target polynucleotide under hybridization conditions to form a plurality of flap endonuclease substrates each comprising a Q probe and a site in the target polynucleotide; b) contacting the plurality of flap endonuclease substrates with a flap endonuclease under cleavage conditions to produce cleavage products, in which each of the Q probes of the flap endonuclease substrates is cleaved to produce cleavage products that include at least a first fragment that is hybridized with a site in the target polynucleotide and a second fragment that is linear and free in solution; and c) detecting at least one of the cleavage products. | 05-06-2010 |
| 20100112558 | Probe Bead Synthesis and Use - The present invention relates to the field of methods and devices of miniaturized synthesis. More specifically, the present invention relates to the parallel synthesis of large number of different types of molecules and oligomers, such as oligonucleotides (oligos), peptides, lipids, carbohydrates, small ligand molecules, and other organic and inorganic molecules as probes for multiplexing assays. The probes may be synthesized from and/or attached to nanobeads to microbeads. The present invention provides for assays of multiplexing large scale biology, such as analysis of genomic DNAs and RNAs and proteomic proteins or peptides performed simultaneously on the synthetic beads. | 05-06-2010 |
| 20100112562 | Mutation Implicated in Abnormality of Cardiac Sodium Channel Function - A novel mutation in the SCN5A gene is associated with loss of cardiac sodium channel function. Analysis of the novel mutation provides an early diagnosis of subjects with cardiac diseases or disorders caused by loss of cardiac sodium channel function, particularly Brugada syndrome. Diagnostic methods include analyzing the sequences of the SCN5A gene or protein of an individual to be tested and comparing them with the sequences of the native, nonvariant SCN5A gene or protein. Pre-symptomatic diagnosis of these syndromes will enable practitioners to treat these disorders using existing medical therapy, e.g., using sodium channel blockers or through electrical stimulation. | 05-06-2010 |
| 20100112553 | LUCIFERASE GENE OPTIMIZED FOR USE IN IMAGING OF INTRACELLULAR LUMINESCENCE - The present invention provides a gene construct encoding pH insensitive luciferase for visualizing intracellular information, wherein an intracellular expression activity is higher compared with a gene construct of luciferase derived from a firefly. | 05-06-2010 |
| 20100216141 | COMPOSITIONS AND METHODS TO DETECT LEGIONELLA PNEUMOPHILA NUCLEIC ACID - Compositions are disclosed as nucleic acid sequences that may be used as amplification oligomers, including primers, capture probes for sample preparation, and detection probes specific for | 08-26-2010 |
| 20100330571 | METHOD OF MEASURING ADAPTIVE IMMUNITY - A method of measuring immunocompetence is described. This method provides a means for assessing the effects of diseases or conditions that compromise the immune system and of therapies aimed to reconstitute it. This method is based on quantifying T-cell diversity by calculating the number of diverse T-cell receptor (TCR) beta chain variable regions from blood cells. | 12-30-2010 |
| 20100317009 | Method for DNA Double-Strand Break Repair in Vitro and Applications Thereof - A system and a method for DNA double-strand break repair in vitro are disclosed. Applications of the disclosed method in multiple areas are also disclosed. | 12-16-2010 |
| 20100221732 | METHODS AND COMPOSITIONS FOR EVALUATING CHRONIC IMMUNE DISEASES - Methods and compositions are provided for evaluating a subject for chronic immune disease, including predicting whether a subject is susceptible to a chronic immune disease, diagnosing whether a subject has a chronic immune disease and/or determining a treatment for a subject suffering from a chronic immune disease. Aspects of the methods include genotyping a subject to determine whether the subject has a least one polymorphism in at least one gene chosen from TLR4, Hsp60, IL-23R, IL-6 and IL-17F. In addition, reagents, devices and kits thereof that find use in practicing the subject methods are provided. | 09-02-2010 |
| 20110053153 | DNA Glycosylase/Lyase and AP Endonuclease substrates - A new class of nucleic acid substrates for AP endonucleases and members of the glycosylase/lyase family of enzymes is described. Representatives of each family, the enzymes Nfo and fpg, respectively, cleave nucleic acid backbones at positions in which a base has been replaced by a linker to which a variety of label moieties may be attached. The use of these synthetic substrates embedded within oligonucleotides is of utility in a number of applications. | 03-03-2011 |
| 20090246758 | Peptide nucleic acid probes for analysis of microorganisms - The instant invention provides PNA probes for detection, identification and/or quantitation of microorganisms, e.g., | 10-01-2009 |
| 20100136566 | LATERAL FLOW STRIP ASSAY WITH IMMOBILIZED CONJUGATE - The present invention discloses analyte detection devices for detecting one or more analytes present in test samples, especially biological samples. In particular, the devices of the invention are lateral flow assay devices comprising immobilized metal nanoparticle conjugates as the detection means. Methods of using the devices and kits comprising the devices are also described. | 06-03-2010 |
| 20100240042 | METHOD OF DETECTING METHYLATED CYTOSINE - The method for detecting a methylated cytosine of the present invention comprises the steps of: | 09-23-2010 |
| 20090275042 | Method of Detecting and/or Quantifying Expression of a Target Protein Candidate in a Cell, and a Method of Identifying a Target Protein of a Small Molecule Modulator - The present invention relates to a method of detecting and/or quantifying expression of a target protein candidate in a cell, and to a method of identifying a target protein of a small molecule modulator. | 11-05-2009 |
| 20100035253 | Methods And Compositions For Incorporating Nucleotides - The invention provides methods and compositions, including, without limitation, algorithms, computer readable media, computer programs, apparatus, and systems for determining the identity of nucleic acids in nucleotide sequences using, for example, data obtained from sequencing by synthesis methods. The methods of the invention include correcting one or more phenomena that are encountered during nucleotide sequencing, such as using sequencing by synthesis methods. These phenomena include, without limitation, sequence lead, sequence lag, spectral crosstalk, and noise resulting from variations in illumination and/or filter responses. | 02-11-2010 |
| 20100035239 | Compositions for use in identification of bacteria - The present invention provides oligonucleotide primers and compositions and kits containing the same for rapid identification of bacteria by amplification of a segment of bacterial nucleic acid followed by molecular mass analysis. | 02-11-2010 |
| 20110053166 | STEM CELL EXPRESSION CASSETTES - A stem cell expression cassette, comprising a nucleic acid comprising a pluripotent stem cell specific promoter, and a tag sequence, wherein the pluripotent stem cell specific promoter and tag sequences are operatively linked, is provided. Also provided are methods of identifying and methods of selecting a pluripotent cell, using the stem cell expression cassette. | 03-03-2011 |
| 20100196888 | Genotyping Using Multiple Variant-Specific Primer Pools - This invention relates to the identification of variants of an organism using variant-specific oligonucleotide primer pools to specifically hybridize to those polynucleotides in an sample comprising a plurality of polynucleotides that contain a target sequence that is unambiguously identifiable with a particular variant of the organism. | 08-05-2010 |
| 20100285478 | Methods, Compositions, and Kits for Detecting Allelic Variants - In some embodiments, the present inventions relates generally to compositions, methods and kits for use in discriminating sequence variation between different alleles. More specifically, in some embodiments, the present invention provides for compositions, methods and kits for quantitating rare (e.g., mutant) allelic variants, such as SNPs, or nucleotide (NT) insertions or deletions, in samples comprising abundant (e.g., wild type) allelic variants with high specificity and selectivity. In particular, in some embodiments, the invention relates to a highly selective method for mutation detection referred to as competitive allele-specific TaqMan PCR (“cast-PCR”). | 11-11-2010 |
| 20100285476 | METHODS OF IDENTIFYING HISTONE DEACETYLASE INHIBITORS USEFUL FOR NEUROLOGICAL DISORDERS - A method of identifying a candidate compound for treatment of a neurological condition includes obtaining a test compound; assaying a first activity of the test compound to inhibit histone deacetylase activity of a histone deacetylase 3 (HDAC3); assaying a second activity of the test compound to inhibit histone deacetylase activity of a histone deacetylase other than a HDAC3; and identifying the test compound as a candidate compound for treatment of a neurological condition if the first activity of the test compound is greater than the second activity of the test compound. | 11-11-2010 |
| 20100112588 | METHODS FOR SANGER SEQUENCING USING PARTICLE ASSOCIATED CLONAL AMPLICONS AND HIGHLY PARALLEL ELECTROPHORETIC SIZE-BASED SEPARATION - Methods for highly parallel Sanger sequencing are discussed. In particular, provided herein are methods using particles to clonally amplify templates and to introduce the amplified nucleic acids into many parallel channels with a single template per channel. Once in the channels, the nucleic acids are separated by size using electrophoresis to produce long read length sequencing information. Methods involving optical detection of the size-separated nucleic acids and analysis of the resulting electropherograms to yield the sequences are disclosed. | 05-06-2010 |
| 20100021903 | Use of Genetic Determinants in Cardiovascular Risk Assessment - The invention generally provides compositions and methods of using a subject's genetic information for the selection of prophylactic or therapeutic agents and treatment regimens, and related methods for assaying the risk of an adverse cardiovascular event in the patient. | 01-28-2010 |
| 20100184048 | EPIDERMAL GROWTH FACTOR (EGF) EXPRESSION AND/OR POLYMORPHISMS THEREOF FOR PREDICTING THE RISK OF DEVELOPING CANCER - The present invention relates to diagnostic and prognostic methods to determine the likelihood of a subject who has a inflammatory disease or liver disease of developing cancer. In particular, the present invention relates to methods for identifying subjects with increased susceptibility to developing cancer, such as hepatocellular carcinoma (HCC) where the subject has an inflammatory disease, such as, but not limited to cirrhosis, by identifying a variance or polymorphism in the human EGF gene. In particular, the methods of the present invention relate to identifying subjects with increased susceptibility to developing cancer such as HCC, where the subject has an inflammatory disease, such as but not limited to cirrhosis, and the subject is identified to have a single nucleotide polymorphism 61A>G in the 5′UTR of the EGF gene. Alternatively, the methods of the present invention relate to identifying subjects with increased susceptibility to developing cancer such as HCC, where the subject has an inflammatory disease, such as but not limited to cirrhosis, and the subject is identified to have increased expression of EGF as compared to a reference level of EGF expression. The present invention also relates to administering an effective amount of an anti-cancer therapy to subjects identified to have an increased susceptibility of developing cancer such as HCC by the methods as disclosed herein, and kits to identify a subject with a 61A>G polymorphism in the 5′UTR of the EGF gene or kits to determine increased EGF expression in subjects with chronic inflammatory disease. | 07-22-2010 |
| 20100190176 | TUMOR SUPPRESSOR DESIGNATED TS10Q23.3 - A specific region of chromosome 10 (10q23.3) has been implicated by series of studies to contain a tumor suppressor gene involved in gliomas, as well as a number of other human cancers. One gene within this region was identified, and the corresponding coding region of the gene represents a novel 47 kD protein. A domain of this product has an exact match to the conserved catalytic domain of protein tyrosine phosphatases, indicating a possible functional role in phosphorylation events. Sequence analyses demonstrated the a number of exons of the gene were deleted in tumor cell lines used to define the 10q23.3 region, leading to the classification of this gene as a tumor suppressor. Further analyses have demonstrated the presence of a number of mutations in the gene in both glioma and prostate carcinoma cells. Methods for diagnosing and treating cancers related to this tumor suppressor, designated as TS10q23.3, also are disclosed. | 07-29-2010 |
| 20100190173 | Gene Expression Markers For Colorectal Cancer Prognosis - A method of predicting clinical outcome in a subject diagnosed with colorectal cancer comprising determining evidence of the expression of one or more predictive RNA transcripts or their expression products in a biological sample of cancer cells obtained from the subject. | 07-29-2010 |
| 20100190155 | METHODS AND KITS FOR MEASUREMENT OF LYMPHOCYTE FUNCTION - The present invention provides simple and rapid methods for measuring the function of a desired subset of lymphocytes, for example, T cells, B cells or NK cells. In addition, the present invention provides an all-in-one kit that contains reagents which permit a rapid and reliable analysis of the functions of T cells, B cells and NK cells obtained directly from whole blood or cord blood. | 07-29-2010 |
| 20100028899 | CELL CYCLE PHASE MARKERS - The present invention relates to polypeptide and nucleic acids constructs which are useful for determining the cell cycle status of a mammalian cell. Host cells transfected with these nucleic acid constructs can be used to determine the effects that test agents have upon the mammalian cell cycle. | 02-04-2010 |
| 20100028898 | METHOD OF IDENTIFYING A TARGET ANALYTE USING PHOTONIC CRYSTAL RESONATORS, AND RELATED DEVICE - A method of identifying target analytes in a sample, particularly a biological sample, comprising the steps of putting a plurality of target analytes, bound to a common luminescent marker, in contact with a plurality of molecular probes immobilized on a support, each of said molecular probes being capable of complementary binding to a respective target analyte, if said target analyte is present in the sample, providing to said support an excitation radiation and detecting an emission radiation coming from said support as a result of at least one complementary binding event, characterized by the fact that:
| 02-04-2010 |
| 20100028897 | APPARATUS AND METHOD FOR EXAMINING BIOPOLYMER - A biopolymer examining apparatus includes a capsule-forming unit configured to form a capsule by sealing a target biopolymer and a reagent with a capsule film, a transferring unit configured to transfer the capsule, an amplification reaction unit configured to amplify the target biopolymer while having the target biopolymer enclosed in the capsule, and a detecting unit configured to detect the amplified target biopolymer while having the target biopolymer enclosed in the capsule. | 02-04-2010 |
| 20100028887 | METHOD, KIT AND SYSTEM FOR COLLECTING AND PROCESSING SAMPLES FOR DNA AND RNA DETECTION - This invention relates to a method, kit and system for collecting and processing of samples to release and treat DNA and RNA for gene sequence detection. The method described here in provides for rapid and convenient release, and recovery of DNA and RNA from tissues and cellular materials. | 02-04-2010 |
| 20100028871 | Light-inducible and rhythmically expressed genes and method for screening substances that affect an internal clock system - A method for screening a substance that affect an internal clock system in an organism, comprising the detection of the expression level of a gene exhibiting a light-inducible and rhythmic expression in a circadian manner, which is typically expressed in the suprachiasmatic nucleus of mammalian, such as for example, Dusp4, Snk, Slc39a6 or Nnat. | 02-04-2010 |
| 20100028870 | DESIGN OF SYNTHETIC NUCLEIC ACIDS FOR EXPRESSION OF ENCODED PROTEINS - Methods for determining a property that affects expression of polynucleotides are provided. A plurality of polynucleotides each encoding a polypeptide sequence is constructed. A frequency that a sequence element is used in a first polynucleotide is different than in a second polynucleotide. Each polynucleotide is expressed in an expression system to obtain an expression property value thereby constructing a dataset that contains, for each respective polynucleotide, sequence element occurrence in the respective polynucleotide and the measured expression property value of the respective polynucleotide. A model is computed that describes variation in the measured expression property values as a function of a plurality of variables and weights. From the model, a property that affects expression of polynucleotides in the expression system is determined, where the property is an effect that the frequency of occurrence of one or more sequence elements has on the expression property of polynucleotides in the expression system. | 02-04-2010 |
| 20090258344 | METHODS FOR IDENTIFYING RISK OF BREAST CANCER AND TREATMENTS THEREOF - Provided herein are methods for identifying risk of breast cancer in a subject and/or a subject at risk of breast cancer, reagents and kits for carrying out the methods, methods for identifying candidate therapeutics for treating breast cancer, and therapeutic methods for treating breast cancer in a subject. These embodiments are based upon an analysis of polymorphic variations in nucleotide sequences within the human genome. | 10-15-2009 |
| 20100297641 | METHYLATION ALTERED DNA SEQUENCES AS MARKERS ASSOCIATED WITH HUMAN CANCER - There is disclosed 103 novel methylation-altered DNA sequences (“marker sequences”) that have distinct methylation patterns in cancer, compared to normal tissue. In many instances, these marker sequences represent novel sequences not found in the GenBank data base, and none of these marker sequences have previously been characterized with respect to their methylation pattern in human cancers including, but not limited to those of bladder and prostate. These 103 sequences have utility as diagnostic, prognostic and therapeutic markers in the treatment of human cancer, and as reagents in kits for detecting methylated CpG-containing nucleic acids. | 11-25-2010 |
| 20100151462 | HUMAN DIABETES SUSCEPTIBILITY SHANK2 GENE - The present invention relates to a diagnostic method of determining whether a subject is at risk of developing type 2 diabetes, which method comprises detecting the presence of an alteration in the SHANK2 gene locus in a biological sample of said subject. | 06-17-2010 |
| 20100159452 | Method For Detecting a Target Nucleic Acid in a Sample - The invention relates to a method for detecting a target nucleic acid in a sample using fluorescent probe pairs which include fluorescent reporter and quencher molecules which may be used in hybridization assays and in nucleic acid amplification reactions, especially polymerase chain reactions (PCR). | 06-24-2010 |
| 20100159448 | METHOD FOR DETECTION AND MULTIPLE, SIMULTANEOUS QUANTIFICATION OF PATHOGENS BY MEANS OF REAL-TIME POLYMERASE CHAIN REACTION - A method for the detection and multiple, simultaneous quantification of any combination of | 06-24-2010 |
| 20100159445 | METHOD FOR THE INDIVIDUAL STAGING OF TUMOR DISEASES - The present invention concerns a method for the individual staging of the tumor disease of an individual cancer patient, a method for the individual decision on the method of treatment as well as a method for treating a cancer patient as well as their use in the treatment of various cancer diseases like colorectal tumor, prostate tumor, breast tumor, lung tumor, as primary tumors, tumor relapse and/or metastases. The present invention further provides a new prognosis factor in cancer treatment. This inventive method includes the step of analyzing at least one disseminated tumor cell present in a sample taken from a patient for the expression of at least one mRNA of at least one of growth factors, growth factor receptors and tumor associated transcripts. | 06-24-2010 |
| 20100081136 | CRTAC AS A BIOMARKER, THERAPEUTIC AND DIAGNOSTIC TARGET - The invention provides CRTAC, which is associated with cardiovascular diseases, hematological diseases, neurological diseases, cancer, endocrinological diseases, and urological diseases. The invention also provides assays for the identification of compounds useful in the treatment or prevention of cardiovascular diseases, hematological diseases, neurological diseases, cancer, endocrinological diseases, and urological diseases. The invention also features compounds which bind to and/or activate or inhibit the activity of CRTAC as well as pharmaceutical compositions comprising such compounds. The invention also provides CRTAC as a biomarker for diseases such as cardiovascular diseases, hematological diseases, neurological diseases, cancer, endocrinological diseases, and urological diseases. | 04-01-2010 |
| 20100015631 | CONCATAMERIC LIGATION PRODUCTS: COMPOSITIONS METHODS AND KITS FOR SAME - The present teachings relate to methods, compositions, and kits for detecting one or more target polynucleotide sequences in a sample, and methods compositions and kits for forming concatameric ligation products. In some embodiments of the present teachings, oligonucleotides are hybridized to complementary target polynucleotides and are ligated together to form a concatameric ligation product. In some embodiments of the present teachings, the concatameric ligation product can be amplified, and the identity and quantity of the target polynucleotides determined based on sequence introduced in the ligation reaction. Some embodiments of the present teachings provide methods for removing unligated probes from the reaction mixture. Some embodiments of the present teachings provide for highly multiplexed detection, identification, and quantification of a plurality of target polynucleotides using a variety of analytical procedures. | 01-21-2010 |
| 20100311067 | DETECTION OF MATERNAL ALCOHOL EXPOSURE - The present invention provides methods, compositions, and systems for detecting in utero alcohol exposure by detecting expression level changes in certain biomarkers (e.g., in placental tissue). In certain embodiments, the biomarkers are selected from glucocorticoid receptor (GR), thyroid hormone receptor alpha (TRα), iodothyronine deiodinase III (Dio3) and G-protein α-subunit (Gsα). | 12-09-2010 |
| 20100015626 | MULTIPLEX NUCLEIC ACID REACTIONS - The invention is directed to a variety of multiplexing methods used to amplify and/or genotype a variety of samples simultaneously. | 01-21-2010 |
| 20100015616 | High Speed, High Fidelity, High Sensitivity Nucleic Acid Detection - The present invention provides methods, compositions, and kits for nucleic acid detection. | 01-21-2010 |
| 20100015614 | Chip-Based Device for Parallel Sorting, Amplification, Detection, and Identification of Nucleic Acid Subsequences - An apparatus for chip-based sorting, amplification, detection, and identification of a sample having a planar substrate. The planar substrate is divided into cells. The cells are arranged on the planar substrate in rows and columns. Electrodes are located in the cells. A micro-reactor maker produces micro-reactors containing the sample. The micro-reactor maker is positioned to deliver the micro-reactors to the planar substrate. A microprocessor is connected to the electrodes for manipulating the micro-reactors on the planar substrate. A detector is positioned to interrogate the sample contained in the micro-reactors. | 01-21-2010 |
| 20100015613 | Systems and Methods for Improving Protein and Milk Production of Dairy Herds - The present invention provides for a direct correlation between milk production in livestock animals and the presence of alleles of a gene encoding an adipocyte-specific polypeptide, termed leptin, which gene is hereinafter referred to as ob. The invention also provides novel compositions consisting essentially of specific oligonucleotides that are useful as primers to amplify particular regions of the genome during enzymatic nucleic acid amplification, thus providing a rapid, sensitive and specific method for the detection of the ob-gene polymorphism which may be present in a specimen. The invention further provides for methods of screening bovine to determine those having predictably more milk productivity and advantageously selecting those livestock for future breeding and management purposes based on the ob polymorphisms. | 01-21-2010 |
| 20100015623 | GENETIC LOCI ASSOCIATED WITH MECHANICAL STALK STRENGTH IN MAIZE - The invention relates to methods and compositions for identifying and for selecting maize plants with mechanical stalk strength characteristics. The methods use molecular markers to identify and select plants with increased mechanical stalk strength or to identify and counter-select plants with decreased mechanical stalk strength. Maize plants generated by the methods of the invention are also a feature of the invention. | 01-21-2010 |
| 20100015624 | PEPTIDE HAVING ABILITY TO ACTIVATE CANCER-RELATED GENE - To provide a cancer diagnostic reagent for determining malignancy of a cancer patient or a cancer cell and a tendency of canceration of a healthy subject, the reagent including a peptide having an ability to activate a cancer-related gene and extracted from cell membrane surfaces of human squamous-cell carcinoma cells or including a synthetic polynucleotide encoding the peptide or a partial amino acid sequence of the peptide. | 01-21-2010 |
| 20100015599 | ISOLATED REDUCTIVE DEHALOGENASE GENES - The invention is directed to novel reductive dehalogenase genes encoding for reductive dehalogenases which are capable of dehalogenating halogenated organic compounds and may be useful in the bioremediation of pollutants. In particular, the invention provides an isolated polynucleotide of a novel vinyl chloride dehalogenase gene (bvcA). The novel vinyl chloride dehalogenase gene encodes a reductive dehalogenase that is capable of the complete reduction of vinyl chloride to ethene. | 01-21-2010 |
| 20100015603 | Chimeric proteins for measuring atp concentrations in pericellular space and related screening method - The invention relates to luminescent chimeric proteins comprising a first N-terminal protein sequence, a second protein sequence and a third C-terminal protein sequence wherein:
| 01-21-2010 |
| 20100015612 | METHODS AND SYSTEMS FOR EVALUATION OF HYDROCARBON RESERVOIRS AND ASSOCIATED FLUIDS USING BIOLOGICAL TAGS AND REAL-TIME PCR - This invention relates in general to characterizing hydrocarbon reservoirs and/or determining flow properties of fluids associated with the reservoir-including fluids introduced into the reservoir to provide for hydrocarbon extraction-using biological tags and real-time polymerase chain reactions for tag detection. In embodiments of the present invention, one or more biological tags may be added to one or more liquids associated with the hydrocarbon reservoir and subsequently one or more liquid samples may be taken from locations associated with the hydrocarbon and the presence of the one or more biological tag may be qualitatively and/or quantitatively tested for in the samples using real-time PCR. | 01-21-2010 |
| 20100015605 | HEPATOCELLULAR CARCINOMA CLASSIFICATION AND PROGNOSIS - Methodology for the in vitro classification and/or prognosis of hepatocellular carcinoma (HCC) from a HCC sample is based on the determination of the expression profile of particular gene combinations. | 01-21-2010 |
| 20100240049 | Methods of Detecting Cervical Cancer - Methods of detecting cervical dysplasia, such as cervical dysplasia likely to progress to carcinoma in a sample of human cervical cells, are provided. Methods of detecting changes in expression of one or more microRNAs or mRNAs associated with cervical dysplasia or cervical cancer are also provided. Compositions and kits are also provided. | 09-23-2010 |
| 20100248249 | Methods for Assessing Cancer for Increased Sensitivity to 10-Propargyl-10-Deazaaminopterin by Assessing Egfr Levels - The present invention relates to a method for assessing the sensitivity of a patient's cancer to treatment with 10-propargyl-10-deazaminopterin and a method for selecting a patient for treatment of cancer with 10-propargyl-10-deazaminopterin, by determining the amount of a EGFR or other growth factor expressed by the cancer and comparing the amount with the amount of EGFR or other growth factor expressed by a reference cancer. | 09-30-2010 |
| 20100261168 | Screening for Environmental DNAs Encoding Enzymes for Synthesizing Terpenoid-Based Therapeutic Compounds Using Genetically Modified E. Coli Strains - A screening method for identifying microbial genes involved in biosynthesis of therapeutic terpenoid-based compounds using genetically modified | 10-14-2010 |
| 20110111414 | Detecting Agent and Therapeutic Agent for Highly Malignant Breast Cancer - A detection agent for high malignancy breast cancer includes an antibody against collagen XIV, or a variant or derivative or fragment of the antibody. A therapeutic agent for high malignancy breast cancer includes a conjugate of an anticancer drug and an antibody against that protein, or a variant or derivative or fragment thereof. Accordingly, it is possible to easily and accurately detect and diagnose high malignancy breast cancer. | 05-12-2011 |
| 20110111413 | METHOD OF OPTIMIZING CODON USAGE THROUGH DNA SHUFFLING - The present invention relates to codon optimization utilizing DNA shuffling. A method of producing gene sequences optimized for a desired functional property is described involving synthesizing a library of parental codon variant genes encoding some or all codon choices at some or all amino acid positions of a gene, reassorting the variant codons among the parental codon variant genes using DNA shuffling thereby forming progeny codon variant genes, expressing the progeny codon variant genes in a host; and screening or selecting for progeny codon variant genes encoding a desired functional property. | 05-12-2011 |
| 20110111407 | METHOD FOR ANALYSING THE EPIGENETIC STATUS OF THE HTRA 1 GENE IN A BIOLOGICAL SAMPLE - The invention relates to a method for analysing a biological sample, wherein the epigenetic status of at least one section of the HtrA 1 gene is analysed. Furthermore, diagnostic kits as well as a screening method for identifying a molecule which inhibits the binding of an epigenetic factor to at least one section of the HtrA1 gene are provided. | 05-12-2011 |
| 20110111406 | ANTIGEN-BINDING MOLECULE CAPABLE OF BINDING TO TWO OR MORE ANTIGEN MOLECULES REPEATEDLY - The present inventors discovered that antibodies having weaker antigen-binding activity at the early endosomal pH in comparison with that at the pH of plasma are capable of binding to multiple antigen molecules with a single antibody molecule, have long half-lives in plasma, and have improved durations of time in which they can bind to antigen. | 05-12-2011 |
| 20110111405 | Novel genes and markers in type 2 diabetes and obesity - Genes, SNP markers and haplotypes of susceptibility or predisposition to T2D and subdiagnosis of T2D and related medical conditions are disclosed. Methods for diagnosis, prediction of clinical course and efficacy of treatments for T2D, obesity and related phenotypes using polymorphisms in the risk genes are also disclosed. The genes, gene products and agents of the invention are also useful for monitoring the effectiveness of prevention and treatment of T2D and related traits. Kits are also provided for the diagnosis, selecting treatment and assessing prognosis of T2D. Novel methods for prevention and treatment of metabolic diseases such as T2D based on the disclosed T2D genes, polypeptides and related pathways are also disclosed. | 05-12-2011 |
| 20110111401 | METHOD FOR SEQUENCING NUCLEIC ACID MOLECULES - The present invention is directed to a method of sequencing a target nucleic acid molecule having a plurality of bases. In its principle, the temporal order of base additions during the polymerization reaction is measured on a molecule of nucleic acid, i.e. the activity of a nucleic acid polymerizing enzyme on the template nucleic acid molecule to be sequenced is followed in real time. The sequence is deduced by identifying which base is being incorporated into the growing complementary strand of the target nucleic acid by the catalytic activity of the nucleic acid polymerizing enzyme at each step in the sequence of base additions. A polymerase on the target nucleic acid molecule complex is provided in a position suitable to move along the target nucleic acid molecule and extend the oligonucleotide primer at an active site. A plurality of labelled types of nucleotide analogs are provided proximate to the active site, with each distinguishable type of nucleotide analog being complementary to a different nucleotide in the target nucleic acid sequence. The growing nucleic acid strand is extended by using the polymerase to add a nucleotide analog to the nucleic acid strand at the active site, where the nucleotide analog being added is complementary to the nucleotide of the target nucleic acid at the active site. The nucleotide analog added to the oligonucleotide primer as a result of the polymerizing step is identified. The steps of providing labelled nucleotide analogs, polymerizing the growing nucleic acid strand, and identifying the added nucleotide analog are repeated so that the nucleic acid strand is further extended and the sequence of the target nucleic acid is determined. | 05-12-2011 |
| 20110111393 | PNA Probes, Mixtures, Methods And Kits Pertaining To The Determination Of Mycoplasma and related Mollicutes - This invention is related to PNA probes, probe sets, mixtures, methods and kits pertaining to the determination of | 05-12-2011 |
| 20100120048 | ASSAYS FOR SHORT SEQUENCE VARIANTS - The invention provides assays that can detect multiple genetic variants of a gene (e.g., a mycobacterium gene) in a sample using a pool (using 2, 3, 4, or more) of oligonucletide hybridization probes. | 05-13-2010 |
| 20100120051 | CYANINE DYE COMPOUNDS - Cyanine dye compounds having a negatively charged substituent that are nucleic acid stains, particularly for fluorescent staining of DNA, including compounds having the formula | 05-13-2010 |
| 20100120046 | Genetic Markers for Assessing Risk of Developing Bipolar Disorder - This document provides methods and materials related to genetic markers of Bipolar Disorder (BD) and Schizophrenia (SZ). For example, methods for using such genetic markers to assess risk of developing BD and/or SZ are provided, as are methods for making a differential diagnosis between BD and SZ. | 05-13-2010 |
| 20100120042 | METHOD OF SCREENING MATERIAL FOR IMPROVING SKIN FUNCTIONS - A method of screening a material for improving skin functions includes: (a) treating a skin cell with a candidate material; (b) detecting a change in a relative expression level of membrane-associated protein 17 (MAP17) gene; and (c) selecting a candidate material inducing the change in the expression level of the gene as a material for improving skin functions. That is to say, a material for improving skin functions is screened using MAP17 gene as a marker, on the basis of the change in the expression level of the MAP17 gene. A material for improving skin functions, which is useful in improving skin barrier function, promoting skin moisturization, preventing skin aging, or ameliorating skin troubles, may be effectively screened. | 05-13-2010 |
| 20100120036 | METHOD FOR AMPLIFYING DNA FRAGMENT - To measure the methylation degree of a genomic DNA simply and correctly as well as exhaustively, there is provided a method for amplifying a DNA fragment, characterized by comprising the following steps (1) to (5):
| 05-13-2010 |
| 20100120038 | ASSAY METHODS FOR INCREASED THROUGHPUT OF SAMPLES AND/OR TARGETS - The present invention provides assay methods that increase the number of samples and/or target nucleic acids that can be analyzed in a single assay. | 05-13-2010 |
| 20100120032 | TRANSGENIC PLANT EVENT DETECTION - The present invention relates to detection of materials derived from transgenic plant events. In particular, the invention provides methods, reagents, kits and reference materials for detecting the presence or absence in a sample of genetic material derived from and attributable to select transgenic plant events. | 05-13-2010 |
| 20100120040 | GENETIC POLYMORPHISMS ASSOCIATED WITH CORONARY EVENTS AND DRUG RESPONSE, METHODS OF DETECTION AND USES THEREOF - The present invention provides compositions and methods based on genetic polymorphisms that are associated with coronary heart disease (particularly myocardial infarction), aneurysm/dissection, and/or response to drug treatment, particularly statin treatment. For example, the present invention relates to nucleic acid molecules containing the polymorphisms, variant proteins encoded by these nucleic acid molecules, reagents for detecting the polymorphic nucleic acid molecules and variant proteins, and methods of using the nucleic acid molecules and proteins as well as methods of using reagents for their detection. | 05-13-2010 |
| 20100120045 | GENETIC VARIANTS USEFUL FOR RISK ASSESSMENTS OF CORONARY ARTERY DISEASE AND MYOCARDIAL INFARCTION - The invention relates to methods of risk assessment and diagnosis of susceptibility to coronary artery disease and myocardial infarction, by assessing the presence or absence of alleles of certain polymorphic markers found to be associated with coronary artery disease and myocardial infarction. The invention also relates to methods for use of such polymorphic markers for predicting drug response to drugs for treating cardiovascular disease, or for monitoring the effectiveness of such drugs. The invention further relates to kits encompassing reagents for use in these methods. | 05-13-2010 |
| 20100112595 | Bisulfite Conversion Reagent - Disclosed, among other things, are packaged bisulfite solutions comprising bisulfite reagent in an oxygen-impermeable container and methods. | 05-06-2010 |
| 20100112592 | METHODS FOR IDENTIFYING AN INCREASED LIKELIHOOD OF RECURRENCE OF BREAST CANCER - Methods of identifying a mammal having an increased likelihood of recurrence of breast cancer includes identifying in a breast tissue sample of the mammal expression of at least two genes selected from the group consisting of Hs.125867 (EVL), Hs.591847 (NAT1), Hs.208124 (ESR1), Hs.26225 (GABRP), Hs.408614 (ST8SIA1), Hs.480819 (TBC1D9), Hs.504115 (TRIM29), Hs.523468 (SCUBE2), Hs.532082 (IL6ST), Hs.592121 (RABEP1), Hs.79136 (SLC39A6), Hs.82128 (TPBG), Hs.95243 (TCEAL1), Hs.95612 (DSC2), Hs.654961 (FUT8), Hs.1594 (CENPA), Hs.184339 (MELK), Hs.26010 (PFKP), Hs.592049 (PLK1), Hs.370834 (ATAD2), Hs.437638 (XBP1), Hs.444118 (MCM6), Hs.469649 (BUB1), Hs.470477 (PTP4A2), Hs.473583 (YBX1), Hs.480938 (LRBA), Hs.524134 (GATA3), Hs.531668 (CX3CL1), Hs.532824 (MAPRE2), Hs.591314 (GMPS), Hs.83758 (CKS2) and Hs.99962 (SLC43A3) and subsets of the genes. | 05-06-2010 |
| 20100112564 | Methods for detecting therapeutic effects of anti-cancer drugs - precancerous lesions, and subject having precancerous lesions and being treated with an anti-cancer agent; (2) isolating total microbial genomic DNA from the fecal samples to provide total microbial genomic DNA; (3) comparing the total microbial genomic DNA using fingerprint spectrum analysis; (4) identifying key fingerprint bands correlated with the effect of the anti-cancer agent; (5) identifying key microorganisms associated with the key fingerprint bands; (6) designing microbial sequence-specific primers and probes; and (7) determining the quantitative differences of the key microorganisms in fecal samples to identify an indicator microorganism for monitoring the effect of the anti-cancer agent. | 05-06-2010 |
| 20100112587 | TRANSCRIPTOMIC BIOMARKERS FOR INDIVIDUAL RISK ASSESSMENT IN NEW ONSET HEART FAILURE - A novel transcriptomic biomarker for prognosis in heart failure has a direct clinical application in prediction of prognosis in new onset heart failure, heart disease, heart disorders and associated heart conditions. This approach should improve individualization of cardiac care and help identify patients at highest risk for circulatory collapse within the first years of presentation with heart failure. | 05-06-2010 |
| 20100112581 | METHODS FOR NORMALIZING AND FOR IDENTIFYING SMALL NUCLEIC ACIDS - The present teachings are generally directed to methods for normalizing at least one species of small nucleic acid that is present in a population of small nucleic acid species, wherein the relative concentration of at least one small nucleic acid species is substantially greater than the relative concentration of at least one other small nucleic acid species in the population. At least one small nucleic acid species is normalized using a multiplicity of primers comprising degenerate sequences. In some embodiments, a small nucleic acid species is identified by inserting at least part of an extension product from a normalized population into a vector and subsequently sequencing the insert. In some embodiments, a small nucleic acid species is identified by determining the sequence of at least part of an extension product. | 05-06-2010 |
| 20100112561 | FLUORESCENT NUCLEOSIDE ANALOGUES - Briefly described, embodiments of the present disclosure include novel fluorescent nucleoside analogs (fNAs) including a fluorescent nucleobase, selected from a purine and a pyrimidine base or analog thereof, and a modified sugar moiety that differs in structure from a sugar moiety of a naturally occurring nucleoside. In embodiments, the fNAs of the present disclosure are analogues of NA prodrugs used to treat viral disorders. Embodiments of the present disclosure also include methods of making the novel fNAs of the present disclosure. | 05-06-2010 |
| 20100112570 | Genetic Markers for Weight Management and Methods of Use Thereof - This application relates to methods and tests that allow for the establishment of personalized weight-loss programs for a subject based upon the subject's metabolic genotype in key metabolic genes. Kits and methods are disclosed for determining a subject's metabolic genotype, which may be used to select an appropriate therapeutic/dietary regimen or lifestyle recommendation based upon the likelihood of a subject's responsiveness to certain diets and activity levels. Such a personalized weight-loss program will have obvious benefits (e.g., yield better results in terms of weight loss and weight maintenance) over traditional weight-loss programs that do not take into account genetic information. | 05-06-2010 |
| 20100112563 | MULTIPLEX ANALYSIS OF NUCLEIC ACIDS - A method for identifying target nucleic acids includes the steps of contacting a sample containing a plurality of target nucleic acids with at least one series of nucleotide primers under conditions that allow binding of said primers to at least one of said target nucleic acids and labeling of said bound primers with a detectable signal, wherein one member within each series has a lower level of specificity than other members of the series; and measuring said detectable signal of each labeled primer to determine the identity of said target nucleic acids. | 05-06-2010 |
| 20100112568 | METHODS AND KITS FOR DIAGNOSIS OF MULTIPLE SCLEROSIS IN PROBABLE MULTIPLE SCLEROSIS SUBJECTS - Provided are methods and kits for determining the probability of a subject diagnosed with probable multiple sclerosis to develop definite diagnosis of multiple sclerosis by determining the expression level of polynucleotides which are differentially expressed between subjects diagnosed with probable multiple sclerosis and which further develop definite multiple sclerosis and unaffected subjects. Also provided are methods and kits for selecting a treatment regimen of a subject diagnosed with probable multiple sclerosis. | 05-06-2010 |
| 20100112557 | METHOD FOR HIGH RESOLUTION MELT GENOTYPING - Various methods are described that provide for high resolution melt (HRM) genotyping. The embodiments include providing a locus specific primer and two allele specific primers each having a 5′ end with a short tail, providing a nucleic acid having a single nucleotide polymorphism (SNP) base located within 1-20 base pairs of the 3′ end of nucleic acid, hybridizing the locus specific primer and the allele specific primers to the nucleic acid, amplifying the sample using pyrophosphorolysis activated polymerization (PAP) PCR enzyme, and determining the Tm of the amplicons using HRM. In other embodiments, reactions mixtures and kits for HRM genotyping are provided and disclosed. These kits comprise a locus specific primer, one or more allele specific primers each having a 5′ end with a short tail, a nucleic acid, and a pyrophosphorolysis activate polymerization (PAP) PCR enzyme. | 05-06-2010 |
| 20090291450 | CATERPILLER GENE FAMILY - The present invention relates to a new family of structurally and functionally related nucleic acids and proteins, designed the CATERPILLER family, which is characterized by landmark structural motifs including a nucleotide binding domain and leucine-rich repeat domains. | 11-26-2009 |
| 20100021905 | COMPOSITIONS AND METHODS OF SELECTIVE NUCLEIC ACID ISOLATION - The invention relates to methods for isolating and/or identifying nucleic acids. The invention also provides kits for isolating and/or identifying nucleic acids. | 01-28-2010 |
| 20100003687 | System and method for detection of HIV tropism variants - An embodiment of a method for detecting low frequency occurrence of one or more HIV sequence variants associated with drug resistance is described that comprises the steps of: generating cDNA species from each RNA molecule in an HIV sample population; amplifying at least one first amplicon from the cDNA species, wherein each first amplicon comprises a plurality of amplified copies and is amplified with a pair of nucleic acid primers that define a locus of the first amplicon; clonally amplifying the amplified copies of the first amplicons to produce a plurality of second amplicons wherein a plurality of the second amplicons comprise an immobilized population of substantially identical copies from one of the amplified copies of first amplicons; determining a nucleic acid sequence composition of the substantially identical copies from at least 100 of the immobilized populations in parallel on a single substrate; and detecting one or more sequence variants that occur at a frequency of 5% or less in the nucleic acid sequence composition of the at least 100 immobilized populations; and correlating the detected sequence variants with variation associated with HIV tropism. | 01-07-2010 |
| 20100003673 | Gene and methods for diagnosing neuropsychiatric disorders and treating such disorders - A mammalian 22444 gene and gene products which are predictive of a susceptibility or predisposition to various neuropsychiatric disorders are provided. Methods of predicting an individual's susceptibility to developing or having a neuropsychiatric disorder via detection of these diagnostic markers are also provided. In addition, compositions and methods for identifying compositions for use in the treatment of neuropsychiatric disorders via these genes and gene products are described. | 01-07-2010 |
| 20100003693 | Compositions and Methods For Detecting The Presence Of Cryptosporidium Organisms In A Test Sample - The present invention describes novel oligonucleotides targeted to nucleic acid sequences derived from | 01-07-2010 |
| 20100003672 | CDNA FOR HUMAN METHYLENETETRAHYDROFOLATE REDUCTASE AND USES THEREOF - The invention features methods for diagnosing subjects at risk for or suffering from a disease or disorder, such as a psychosis. Methods are also provided for selecting a preferred therapy for a particular subject or group of subjects. | 01-07-2010 |
| 20100035262 | METHOD FOR DETECTING THYROID CARCINOMA - It is an object of the present invention to identify a gene that exhibits behavior which is characteristic of carcinomas such as thyroid carcinoma, so as to provide a method for detecting carcinoma and a cell growth suppressing agent. The present invention provides a method for detecting carcinoma, which comprises detecting malignant transformation by detecting at least one alteration of gene existing in chromosomal regions 1q41, 3q28, 7q31.2, 8p12, 8q22.2, 8q24.21, 11q4.1, 17q12, 20q11, 9p21.3, 16q13.2, and 16q23.1 in a specimen. | 02-11-2010 |
| 20100035250 | USE OF PHENANTHRIDIUM DERIVATIVES FOR DISTINGUISHING BETWEEN INTACT AND MEMBRANE COMPROMISED CELLS USING MOLECULAR NUCLEIC ACID-BASED TECHNIQUES - The present invention provides novel chemicals and methods for selectively excluding DNA of dead cells from a mixture containing live and dead cells from molecular detection. | 02-11-2010 |
| 20100221710 | ASSAYS FOR FUNGAL INFECTION - Methods and kits are described for testing for the presence or absence of any fungus in a sample. Examples of fungi that can be detected include, but are not limited to, those belonging to the genera | 09-02-2010 |
| 20100279293 | METHODS AND COMPOSITIONS FOR IDENTIFYING INCREASED RISK OF DEVELOPING FRAGILE X-ASSOCIATED DISORDERS - The present invention provides compositions and methods of identifying a subject as having an increased risk of developing fragile X-associated tremor and ataxia syndrome (FXTAS) or identifying a subject having an increased risk of developing fragile X syndrome (FXS), comprising analyzing messenger RNA (mRNA) transcripts and/or translation products of the antisense gene ASFMR1. | 11-04-2010 |
| 20090280478 | GENE METHYLATION AND EXPRESSION - The invention provides a method of analyzing the methylation status of all or part of an entire genome. Moreover, the invention features methods of and reagents for characterizing biological cells containing DNA that is susceptible to methylation. Such methods include methods of diagnosing cancer, e.g., breast cancer. | 11-12-2009 |
| 20100136559 | CHROMATIN STRUCTURE DETECTION - The present application provides methods and compositions for determining accessibility of a DNA modifying agent in genomic DNA. | 06-03-2010 |
| 20100009370 | GENE ASSAYING METHOD, GENE ASSAYING PROGRAM, AND GENE ASSAYING DEVICE - A gene assaying method includes the steps of: acquiring two or more data which should be compared and represents expression levels of a plurality of target genes; converting the expression levels represented by the acquired two or more data into ratios based on the expression level of one of the two or more data; extracting a minimum ratio and a maximum ratio of each target gene; and classifying the plurality of target genes using as a classification border at least one of a first ratio with the peak in a frequency distribution of the minimum ratios and a second ratio with the peak in a frequency distribution of reciprocals of the maximum ratios. | 01-14-2010 |
| 20100009359 | Methods and compositions for detecting colon cancers - This application describes methods and compositions for detecting and treating vimentin-associated neoplasia. Differential methylation of the vimentin nucleotide sequences has been observed in vimentin-associated neoplasia such as colon neoplasia. | 01-14-2010 |
| 20100009369 | GENE EXPRESSION LEVEL ANALYZING METHOD, GENE EXPRESSION LEVEL ANALYZING PROGRAM, AND GENE EXPRESSION LEVEL ANALYZING DEVICE - A gene expression level analyzing method includes the steps of: acquiring expression levels of a plurality of target genes in a target cell every measurement time; extracting a maximum expression level and a minimum expression level from the expression levels of the target genes every measurement time; calculating a correlation coefficient of a frequency distribution of the gene having the maximum expression level at each measurement time and a frequency distribution of the gene having the minimum expression level at each measurement time; and comparing the correlation coefficient with a threshold value of the correlation coefficient. | 01-14-2010 |
| 20100009363 | RBP4 In Insulin sensitivity/resistance, diabetes, and obesity - Methods for screening molecules that modulate the activity of Retinol Binding Protein 4 (RBP4) and their use in treatment of insulin resistance are described. Also described are methods of diagnosing insulin resistance and related conditions by detecting modulation of RBP4 activity. | 01-14-2010 |
| 20100009367 | MICRO RNAS AND THEIR METHODS OF USE FOR THE TREATMENT AND DIAGNOSIS OF SCHIZOPHRENIA AND SCHIZOPHRENIA SPECTRUM DISORDERS - A method of diagnosing, assessing susceptibility, and/or treating schizophrenia involving the identification and/or observation of microRNAs (miRNA) and variant miRNA are provided. Micro RNAs alleles associated with schizophrenia and schizophrenia spectrum disorders were identified and ultra-rare variants in the precursor or mature miRNA were identified. Functional analyses of ectopically expressed copies of the variant miRNA precursors demonstrate loss of function, gain of function and altered expression levels. The present invention also provides methods for selecting a preferred therapy for a particular subject or group of subjects or individuals at risk for or suffering from schizophrenia or psychosis by use of miRNAs. | 01-14-2010 |
| 20100009355 | SELECTIVE AMPLIFICATION OF MINORITY MUTATIONS USING PRIMER BLOCKING HIGH-AFFINITY OLIGONUCLEOTIDES - In certain embodiments this invention pertains to methods of detecting and/or quantifying rare mutant nucleic acids in populations of nucleic acids in which the wild-type nucleic acids are in substantially greater abundance than the rare mutants. In various embodiments the methods utilize short high affinity oligonucleotides targeted to the wild type rather than the minority or mutant sequence. Rather than directly detecting mutant DNA, these probes block detection of wild type DNA. These “blocker” probes can be used in combination with longer “detection” probes or PCR primers to amplify and/or identify the minority mutation in, e.g., clinical specimens. The combination of short high affinity blocker probes and longer, lower affinity detection probes eliminates the single base specificity/complexity tradeoff in the design of nucleic acid probes. | 01-14-2010 |
| 20100009354 | METHOD FOR DETERMINING BASE SEQUENCE OF DNA - The present invention provides a method for determining the base sequence of a DNA. According to the method for determining the base sequence of a DNA of the present invention, a probe is used, which is a probe having a protruding end and identification-labeled according to the species of the base at the protruding end, containing a recognition sequence of a class IIS restriction enzyme, to carry out simultaneously in a chain reaction, for a plurality of DNAs to be analyzed, ligation of the end base of a DNA to be analyzed and a probe and cleavage of the end base of the DNA to be analyzed, allowing the base sequence to be determined sequentially by a single molecule spectrofluorimetry method, such that an effective determination of the base sequence of a DNA becomes possible. | 01-14-2010 |
| 20100009352 | Method for Modeling a Disease - The invention described herein provides for methods of profiling cellular models of disease. Cellular systems biology is the investigation of the integrated and interacting networks of genes, proteins, and metabolites that are responsible for normal and abnormal cell functions. Methods and reagents for the profiling a disease state, the treatment of a disease state and assaying of treatments of a disease state are provided. | 01-14-2010 |
| 20100009351 | Polynucleotide Capture Materials, and Method of Using Same - Methods for processing polynucleotide-containing biological samples, and materials for capturing polynucleotide molecules such as DNA from such samples. The DNA is captured by polyethyeleneimine (PEI) bound to a surface, such as the surface of magnetic particles. The methods and materials have high efficiency of binding DNA and of release, and thereby permit quantitative determinations. | 01-14-2010 |
| 20100009345 | Compositions and methods comprising a ligand of chemerin R - The present invention relates to a G-protein coupled receptor and a novel ligand therefor. The invention provides screeing assays for the identification of candidate compounds which modulate the activity of the G-protein coupled receptor, as well as assays useful for the diagnosis and treatment of a disease or disorder related to the dysregulation of G-protein coupled receptor signaling. | 01-14-2010 |
| 20100041025 | Compositons, methods and kits for real-time nucleic acid analysis in live cells - The present invention includes compositions, methods and kits for the real-time detection of transcription and translation in live cells, tissues and organisms. The present invention further provides method for the rapid sequencing of nucleic acids without using conventional sequencing techniques or reactions. | 02-18-2010 |
| 20100068717 | CANCER THERAPY PROGNOSIS - Methods and compositions based on FOXA1 expression to predict long-term disease-free survival in patients with breast cancer are disclosed. In ER+ positive patients, expression of FOXA1 is useful in identifying a subgroup of patients with a better prognosis. FOXA1 expression correlates with luminal subtype breast cancer, and serves as a clinical marker for luminal subtype breast cancer. Expression of FOXA1 is useful as a prognostic marker for an effective response tumors and as a predictive marker for a greater likelihood of response to an anti-hormonal therapy. Prognostic ability of FOXA1 in low-risk breast cancers is useful in treatment decision making. | 03-18-2010 |
| 20100028876 | DIAGNOSTIC TESTS USING GENE EXPRESSION RATIOS - The invention provides methods for diagnosing biological states or conditions based on ratios of gene expression data from cell or tissue samples, such as cancer cell or tissue samples. The invention also provides sets of genes that are expressed differentially in normal and cancer lung cells and tissues. These sets of genes can be used to discriminate between normal and malignant cells or tissues, and between classes of malignant cells or tissues. Accordingly, diagnostic assays for classification of tumors, prediction of tumor outcome, selecting and monitoring treatment regimens and monitoring tumour progression/regression also are provided. | 02-04-2010 |
| 20100028864 | REAGENTS AND METHODS FOR DETECTING NEISSERIA GONORRHOEAE - This invention provides compositions and methods for detecting | 02-04-2010 |
| 20100105047 | Method for the Simultaneous Determination of Blood Group and Platelet Antigen Genotypes - RBC and platelet (Plt) alloimmunization requires antigen-matched blood to avoid adverse transfusion reactions. Some blood collection facilities use unregulated Abs to reduce the cost of mass screening, and later confirm the phenotype with government approved reagents. Alternatively, RBC and Plt antigens can be screened by virtue of their associated single nucleotide polymorphisms (SNPs). We developed a multiplex PCR-oligonucleotide extension assay using the GenomeLab SNPStream platform to genotype blood for a plurality of blood group antigen-associated SNPs, including but not limited to: RhD (2), RhC/c, RhE/e, S/s, K/k, Kp | 04-29-2010 |
| 20090305235 | Novel Targets For The Identification Of Antibiotics That Are Not Susceptible To Antibiotic Resistance - To identify conserved and variable regions of the 16 S rRNA, an instant evolution experiment was performed on the entire 16 S rRNA. Analysis of these mutants identified regions that are required for function. These conserved sequences may be used as targets for pharmaceuticals that are taxonomically specific and which are refractory to the development of drug resistance. | 12-10-2009 |
| 20100092948 | BIOLOGICAL BAR CODE - The invention provides compositions and methods useful for identifying, verifying or authenticating any type of sample, whether the sample, is biological or non-biological. | 04-15-2010 |
| 20100015627 | SELECTION METHOD - The current invention comprises a method for the selection of a mammalian cell by transfecting a mammalian cell with a nucleic acid comprising a part of a nucleic acid encoding a polypeptide that catalyzes an α1,6-glycosidic bond formation between fucose and an asparagine-linked N-acetylglucosamine and cultivating the transfected mammalian cell in the presence of Lens culinaris agglutinin (LCA) and selecting a mammalian cell viable under these conditions. | 01-21-2010 |
| 20100062430 | METHOD AND KIT FOR MOLECULAR CHROMOSOMAL QUANTIFICATION - Diagnosis of chromosomal abnormalities or genetic disorders is performed using at least two marker sequences, wherein one marker sequence is a sequence known to be present on the chromosome or in the gene of interest, another marker sequence is a sequence known to be present on an autosomal chromosome, and the marker sequences are partially homologous. A kit for performing this diagnosis is also claimed. | 03-11-2010 |
| 20100003679 | ASSESSMENT OF CELLULAR COMPOSITION AND FRACTIONAL VIABILITY AND USES THEREOF - A method of assessing cellular composition and fractional viability that can be predictive of post-transplant cell potency and transplantation outcome, comprises identifying cellular composition and assessing cellular viability. This has particular importance in the field of tissue and cell transplantation, cell therapy and regenerative medicine, providing a method for tissue and cell characterization, viability and potency testing, that could be useful for the definition of product release criteria for research and clinical applications. | 01-07-2010 |
| 20100055704 | EXPRESSION PROFILE OF THYROID CANCER - The present invention relates to compositions and methods for cancer diagnostics, including but not limited to, cancer markers. In particular, the present invention provides gene expression profiles associated with thyroid cancers. Genes identified as cancer markers using the methods of the present invention find use in the diagnosis and characterization of thyroid cancer. In addition, the genes provide targets for cancer drug screens and therapeutic applications. | 03-04-2010 |
| 20100159453 | GENES INVOLVED IN INTESTINAL INFLAMMATORY DISEASES AND USE THEREOF - The invention concerns genes involved in inflammatory and/or immune diseases and some cancers, in particular intestinal cryptogenic inflammatory diseases, and proteins coded by said genes. The invention also concerns methods for diagnosing inflammatory diseases. | 06-24-2010 |
| 20100035254 | COMPOSITION AND METHOD FOR NUCLEIC ACID SEQUENCING - The present invention provides compositions and methods for detecting incorporation of a labeled nucleotide triphosphate onto the growing end of a primer nucleic acid molecule. The method is used, for example, to genotype and sequence a nucleic acid. In a preferred embodiment, the method described herein detects individual NTP molecules. | 02-11-2010 |
| 20100035245 | Analyte test system using non-enzymatic analyte recognition elements - An analyte test element for the qualitative and/or quantitative determination of at least one analyte in a physiological or aqueous sample fluid having a first surface ( | 02-11-2010 |
| 20100143912 | SPECIFIC N-TERMINAL LABELING OF PEPTIDES AND PROTEINS IN COMPLEX MIXTURES - This invention provides general methods for selective labeling of proteins on their N-termini with synthetic peptides. The methods of this invention can be applied to the global proteomic profiling of complex mixtures of proteins and polypeptides. | 06-10-2010 |
| 20100003671 | NUCLEOTIDE PRIMER SET AND NUCLEOTIDE PROBE FOR DETECTING GENOTYPE OF N-ACETYLTRANSFERASE-2 (NAT2) - There is provided a nucleotide primer set for LAMP amplification, used for detecting genotypes of single-nucleotide polymorphisms G590A, G857A and T341C of a NAT2 gene. There is also provided a nucleotide probe for detection of an amplification product amplified with the primer set according to the present invention. There is also provided a method of detecting the genotypes of NAT2 gene single-nucleotide polymorphisms G590A, G857A and T341C by using the primer set according to the present invention. | 01-07-2010 |
| 20110045474 | COPI MOLECULES AND USES THEREOF - The invention provides diagnostic, prognostic, and therapeutic uses for detecting COP1 overexpression in a variety of cancers. The methods and uses can further include detecting p53 expression. The invention also provides reagents and kits for use in screening for test compounds that interfere with COP1 and p53 binding. | 02-24-2011 |
| 20100047805 | Methods and compositions for targeted single-stranded cleavage and targeted integration - Disclosed herein are methods and compositions for generating a single-stranded break in a target sequence, which facilitates targeted integration of one or more exogenous sequences. | 02-25-2010 |
| 20100047786 | DNA-based test for detection of annual and intermediate ryegrass - We have developed a novel TaqMan quantitative PCR (Q-PCR) based DNA test for detecting annual and/or intermediate ryegrass types in perennial ryegrass. This DNA test was designed using an insertion/deletion (InDel) site in the LpVRN2_2 gene. The new DNA test is more reliable, accurate, and cost effective in detecting annual and intermediate type contamination in perennial ryegrass, having a sensitivity of 0.04% in a sample size of 5000 seeds. Use of a higher sample size (12.5-fold higher compared to the SRF test) provides additional accuracy in detecting the level of contamination A forward and reverse set of primers also identified an approximately 450 bp fragment in or near the LpVRN1 promoter, the fragment being present for all perennial, but not annual, varieties tested. | 02-25-2010 |
| 20100047772 | COMPOUNDS, COMPOSITIONS AND METHODS FOR THE TREATMENT OF DISEASES CHARACTERIZED BY A-33 RELATED ANTIGENS - The present invention relates to compositions and methods of treating and diagnosing disorders characterized the by the presence of antigens associated with inflammatory diseases and/or cancer, and nucleotide sequences, including expressed sequence tags (ESTs), oligonucleotide probes, polypeptides, vectors and host cells expressing such antigens PRO301, PRO362 or PRO245. | 02-25-2010 |
| 20100297627 | MicroRNA Diagnostics for Cancer - Disclosed are methods for detecting breast cancer or prostate cancer by measuring levels of miR-204 and miR-510 in samples. | 11-25-2010 |
| 20110117566 | Model System for Diagnosing Lipid Metabolism - The invention relates to a population model for the analysis of blood lipoprotein physiology in a test subject comprising: a. a submodel for the production of blood lipoproteins; b. a submodel for the lipolysis of blood lipoproteins; c. a submodel for the reabsorption of blood lipoproteins; and d. a submodel relating blood lipoprotein particle size to biochemical composition, more specifically triglyceride content, there-by providing an analysis of the physiological processes underlying a steady state particle population distribution. Each submodel is given as function, using the size of the lipoprotein particle as the independent variable. | 05-19-2011 |
| 20110117567 | Micro-RNA Associated With Rheumatoid Arthritis - An object of the present invention is to provide a novel marker for rheumatoid arthritis (RA), and more specifically, to provide a marker whose expression may be specifically increased or decreased in RA. Another object of the present invention is to confirm whether or not miRNA serving as the marker is involved as the etiology of RA, and to provide an inspection method for RA and a therapeutic agent for RA each using the miRNA involved. The marker includes miRNA (for example, miR124a) whose expression is specifically increased or decreased in RA synovial cells based on a small RNA expression profile in the RA synovial cells. In addition, the therapeutic agent for RA includes miRNA (for example, miR124a) as an active ingredient. | 05-19-2011 |
| 20110117565 | SERUM OR PLASMA MICRORNA AS BIOMARKERS FOR NON-SMALL CELL LUNG CANCER - The present invention provides non-small cell lung cancer markers and the use thereof. The non-small cell lung cancer markers in the present invention include at least one of the 26 selected detectable mature microRNAs existing stably in human serum or plasma. The invention also provides a probe combination, kit and biochip for detecting the non-small cell lung cancer markers. The invention further |
